{"data": [{"Element": "<div class=\"WordSection1\">\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>ANNEX I</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p class=\"Annex\">SUMMARY OF PRODUCT CHARACTERISTICS</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:green'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Kadcyla 100\u00a0mg powder for concentrate for solution for\ninfusion.</p>\n<p class=\"MsoNormal\">Kadcyla 160\u00a0mg powder for concentrate for solution for\ninfusion.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><u>Kadcyla 100 mg powder for concentrate for solution for\ninfusion</u></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">One vial of powder for\nconcentrate for solution for infusion contains 100 mg of trastuzumab emtansine.\nAfter reconstitution one vial of 5 mL solution contains 20 mg/mL of trastuzumab\nemtansine (see section 6.6).</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><u>Kadcyla 160 mg powder for\nconcentrate for solution for infusion</u></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">One vial of powder for\nconcentrate for solution for infusion contains 160 mg of trastuzumab emtansine.\nAfter reconstitution one vial of 8 mL solution contains 20 mg/mL of trastuzumab\nemtansine (see section 6.6).</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Trastuzumab emtansine is an\nantibody\u2011drug conjugate that contains trastuzumab, a humanised IgG1\nmonoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension\nculture, covalently linked to DM1, a microtubule inhibitor, via the stable\nthioether linker MCC (4\u2011[N\u2011maleimidomethyl]\u00a0cyclohexane\u20111\u2011carboxylate).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">For the full list of excipients, see section\u00a06.1.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Powder for concentrate for solution for infusion.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">White to off\u2011white lyophilised powder.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b><span style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></b><b>CLINICAL\nPARTICULARS</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><u>Early Breast Cancer (EBC)</u></p>\n<p class=\"MsoNormal\">Kadcyla, as a single agent, is indicated for the adjuvant\ntreatment of adult patients with HER2-positive early breast cancer who have\nresidual invasive disease, in the breast and/or lymph nodes, after neoadjuvant\ntaxane-based and HER2-targeted therapy.</p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\"><u>Metastatic Breast Cancer (MBC)</u></p>\n<p class=\"MsoNormal\">Kadcyla, as a single agent, is indicated for the treatment\nof adult patients with HER2-positive, </p>\n<p class=\"MsoNormal\">unresectable locally advanced or metastatic breast cancer\nwho previously received trastuzumab and a taxane, separately or in combination.\nPatients should have either:</p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Received\nprior therapy for locally advanced or metastatic disease, or</p>\n<p class=\"MsoNormal\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Developed\ndisease recurrence during or within six months of completing adjuvant therapy.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.2\u00a0\u00a0\u00a0\u00a0 Posology\nand method of administration</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Kadcyla should only be prescribed by a physician and\nadministered as an intravenous infusion under the supervision of a healthcare\nprofessional who is experienced in the treatment of cancer patients (i.e. <span lang=\"EN-GB\">prepared to manage allergic/anaphylactic infusion reactions and </span><span lang=\"EN-GB\">in an environment where full resuscitation facilities are\nimmediately available (see section 4.4))</span>.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Patients treated with trastuzumab emtansine should have HER2\npositive tumour status, defined as a score of 3\u00a0+ by immunohistochemistry\n(IHC) or a ratio of\u00a0\u2265\u00a02.0 by in situ hybridization (ISH) or by\nfluorescence in situ hybridization (FISH) assessed by a CE-marked In Vitro Diagnostic\n(IVD) medical device. If a CE-marked IVD is not available, the HER2-status\nshould be assessed by an alternate validated test. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">In order to prevent medicinal\nproduct errors it is important to check the vial labels to ensure that the\nmedicinal product being prepared and administered is Kadcyla (trastuzumab\nemtansine) and not Herceptin (trastuzumab).</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Posology</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The recommended dose of\ntrastuzumab emtansine is 3.6\u00a0mg/kg bodyweight administered as an\nintravenous infusion every\u00a03\u00a0weeks (21\u2011day cycle). </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The initial dose should be administered as a 90\u00a0minute\nintravenous infusion. Patients should be observed during the infusion and for\nat least 90\u00a0minutes following the initial infusion for fever, chills, or\nother infusion\u2011related reactions. The infusion site should be closely\nmonitored for possible subcutaneous infiltration during administration (see\nsection\u00a04.8).</p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\">If the prior infusion was well tolerated, subsequent doses\nof trastuzumab emtansine may be administered as 30\u00a0minute infusions.\nPatients should be observed during the infusion and for at least\n30\u00a0minutes after infusion.</p>\n<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\">The infusion rate of trastuzumab emtansine should be slowed\nor interrupted if the patient develops infusion\u2011related symptoms (see\nsections\u00a04.4 and 4.8). Trastuzumab emtansine should be discontinued in\ncase of life\u2011threatening infusion reactions.</p>\n<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\"><u>Duration of treatment</u></p>\n<p class=\"MsoNormal\"><i><u><span style=\"text-decoration:none\">\u00a0</span></u></i></p>\n<p class=\"MsoNormal\"><i>Early Breast Cancer (EBC)</i></p>\n<p class=\"MsoNormal\">Patients should receive treatment for a total of 14 cycles unless\nthere is disease recurrence or unmanageable toxicity.</p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\"><i>Metastatic Breast Cancer (MBC)</i></p>\n<p class=\"MsoNormal\">Patients should receive treatment until disease progression\nor unmanageable toxicity.</p>\n<p class=\"MsoNormal\"><i>Dose modification</i></p>\n<p class=\"MsoNormal\">Management of symptomatic adverse reactions may require\ntemporary interruption, dose reduction, or treatment discontinuation of\ntrastuzumab emtansine as per guidelines provided in text and\nTables\u00a01\u00a0and 2\u00a0.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Trastuzumab emtansine dose should not be re\u2011escalated\nafter a dose reduction is made.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Table\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dose\nreduction schedule</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"background:white;border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">reduction schedule</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">(Starting dose is 3.6 mg/kg)</span></b></p>\n</td>\n<td style=\"width:156.8pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"209\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">Dose\u00a0 to be administered</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">First\n  dose reduction</span></p>\n</td>\n<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">3\u00a0mg/kg</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Second\n  dose reduction</span></p>\n</td>\n<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">2.4\u00a0mg/kg</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Requirement\n  for further dose reduction</span></p>\n</td>\n<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Discontinue\n  treatment</span></p>\n</td>\n</tr>\n</table>\n<p class=\"TextTi12\" style=\"line-height:14.0pt\"><b><i><span lang=\"FR-CH\" style='font-family:\"Times New Roman\",serif'>\u00a0</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Table\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dose\nModification Guidelines</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:452.8pt;border-collapse:collapse\" width=\"604\">\n<tr style=\"height:15.75pt\">\n<td colspan=\"3\" style=\"border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">Modifications for Patients with EBC</span></b></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Adverse reaction</b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Treatment modification</b></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"2\" style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Thrombocytopenia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3 on day of scheduled\n  treatment<br/>\n  (25,000 to &lt; 75,000/mm<sup>3</sup>)</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to</span><span style=\"font-family:Symbol\"> \u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then treat at the same dose level. If a\n  patient requires 2 delays due to thrombocytopenia, consider reducing dose by\n  one level.</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 at any time<br/>\n  &lt; 25,000/mm<sup>3</sup></span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then reduce one dose level.</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Alanine Transaminase (ALT)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3<br/>\n  (&gt; 3.0 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment)</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until ALT recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4<br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time)</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Aspartate Transaminase (AST)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 <br/>\n  (&gt; 3.0 to \u2264 5</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> 1, and then\n  treat at the same dose level</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3 <br/>\n  (&gt; 5 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 <br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time) </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Hyperbilirubinemia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 1.0 to \u2264 2.0</span><span style=\"font-family:Symbol\">\u00b4 </span><span lang=\"EN-CARRIBEAN\">the ULN on day of scheduled treatment </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until total bilirubin recovers to \u2264\n  1.0\u00d7 ULN, and then reduce one dose level</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 2</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Nodular Regenerative Hyperplasia (NRH)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">All Grades</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Peripheral Neuropathy</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3-4</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until resolution <span style=\"font-family:Symbol\">\u00a3 </span>Grade 2</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"4\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &lt; 45%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> .<br/>\n  Repeat LVEF assessment within 3 weeks. </span>If LVEF &lt; 45% is confirmed,\n  discontinue trastuzumab emtansine.</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is \u2265 10% points from baseline*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine.<span lang=\"EN-CARRIBEAN\"><br/>\n  Repeat LVEF assessment within 3 weeks. If the LVEF remains &lt; 50% and has\n  not recovered to &lt; 10% points from baseline, discontinue </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">.</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is &lt; 10% points from baseline*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">. <br/>\n  Repeat LVEF assessment within 3 weeks. </span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF \u2265 50%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine</p>\n</td>\n</tr>\n<tr style=\"height:97.5pt\">\n<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:97.5pt\" valign=\"top\">\n<p class=\"MsoNormal\">Heart Failure</p>\n</td>\n<td style=\"border:none;border-right:solid windowtext 1.0pt;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:97.5pt\" valign=\"bottom\">\n<p class=\"MsoNormal\">Symptomatic CHF,</p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3-4 LVSD or Grade 3-4 heart\n  failure, or</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 heart failure <br/>\n  accompanied by LVEF &lt;45% </span></p>\n</td>\n<td style=\"border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:97.5pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:35.35pt\">\n<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Pulmonary Toxicity</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Interstitial lung disease (ILD) or pneumonitis</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:35.35pt\">\n<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;border-bottom:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Radiotherapy-Related Pneumonitis</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine if not resolving with\n  standard treatment</p>\n</td>\n</tr>\n<tr style=\"height:35.35pt\">\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3-4</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td colspan=\"3\" style=\"border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"color:black\">Dose Modifications for Patients with MBC</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><b>Adverse reaction</b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Treatment\n  modification</b></p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td rowspan=\"2\" style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Thrombocytopenia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3 </p>\n<p class=\"MsoNormal\">(25,000 to <span style=\"font-family:Symbol\">&lt;</span>\u00a050,000/mm<sup>3</sup>)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then treat at the same dose level</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4</p>\n<p class=\"MsoNormal\"><span style=\"font-family:Symbol\">(&lt;</span>\u00a025,000/mm<sup>3</sup>)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then reduce one dose level</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Transaminase (AST/ALT)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a02.5 to \u2264 5<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Treat at\n  the same dose level</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a05 to \u2264 20<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until AST/ALT\n  recovers to Grade \u2264 2, and then reduce one dose level</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a020<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Hyperbilirubinemia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a01.5 to \u2264 3<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1, and then treat at the same dose level.</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a03 to \u2264 10<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1 and then reduce one dose level.</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a010<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td rowspan=\"5\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Symptomatic CHF</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Discontinue\n  trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &lt;40%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Repeat\n  LVEF assessment within 3 weeks. If LVEF &lt;40% is confirmed, discontinue trastuzumab\n  emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is \u2265 10% points\n  from baseline</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>\n<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks. If the LVEF has not\n  recovered to within 10% points from baseline, discontinue trastuzumab\n  emtansine.</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is &lt; 10% points\n  from baseline</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Continue\n  treatment with<span style=\"color:#0000CC\"> </span>trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>\n<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks.</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &gt; 45%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Continue treatment with trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-top:12.0pt\"><span style=\"font-size:9.0pt\">ALT\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0alanine\ntransaminase; AST\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0aspartate transaminase, CHF = congestive heart\nfailure, LVEF\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0left ventricular ejection fraction, LVSD\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0left\nventricular systolic dysfunction, TBILI = Total Bilirubin, ULN\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0upper\nlimit of normal</span></p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:9.0pt\">* Prior to starting trastuzumab emtansine treatment. </span></p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\"><i>Delayed or missed dose</i></p>\n<p class=\"MsoNormal\">If a planned dose is missed, it should be administered as\nsoon as possible; without waiting until the next planned cycle. The schedule of\nadministration should be adjusted to maintain a 3\u2011week interval between\ndoses. The next dose should be administered in accordance with the dosing\nrecommendations above.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Peripheral neuropathy</i></p>\n<p class=\"MsoNormal\">Trastuzumab emtansine should be temporarily discontinued in\npatients experiencing Grade 3 or 4 peripheral neuropathy until resolution to\n\u2264 Grade 2. At retreatment a dose reduction may be considered according to\nthe dose reduction schedule (see Table 1).</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Special populations</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Elderly patients </i></p>\n<p class=\"MsoNormal\">No dose adjustment is required in patients aged\n\u2265\u00a065 years. There are insufficient data to establish the safety and\nefficacy in patients \u2265\u00a075 years due to limited data in this\nsubgroup.<span style='font-size:10.0pt;font-family:\"Arial\",sans-serif;\ncolor:#222222;background:white'> </span>Population pharmacokinetic analysis\nindicates that age does not have a clinically meaningful effect on the\npharmacokinetics of trastuzumab emtansine (see sections 5.1 and 5.2).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Renal impairment</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">No adjustment to the starting\ndose is needed in patients with mild or moderate renal impairment (see section\n5.2). The potential need for dose adjustment in patients with severe renal\nimpairment cannot be determined due to insufficient data and therefore patients\nwith severe renal impairment should be monitored carefully.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Hepatic impairment</i></p>\n<p class=\"MsoNormal\">No adjustment to the starting dose is required for patients\nwith mild or moderate hepatic impairment.\u00a0 Trastuzumab emtansine has not\nbeen studied in patients with severe hepatic impairment.\u00a0 Treatment of\npatients with hepatic impairment should be undertaken with caution due to known\nhepatotoxicity observed with trastuzumab emtansine (see section 4.4 and 5.2).</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Paediatric </span></i><i>population</i></p>\n<p class=\"MsoNormal\">The safety and efficacy in children and adolescents below\n18\u00a0years of age have not been established as there is no relevant use in\nthe <span lang=\"EN-GB\">paediatric </span>population for the indication of breast\ncancer . </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Method of administration</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">Kadcyla is for intravenous use. Trastuzumab emtansine must\nbe reconstituted and diluted by a healthcare professional and administered as\nan intravenous infusion. It must not be administered as an intravenous push or\nbolus.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">For instructions on reconstitution and dilution of the\nmedicinal product before administration, see section\u00a06.6.</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Hypersensitivity to the active substance or to any of the\nexcipients listed in section\u00a06.1.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.4\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In order to improve traceability of biological medicinal\nproducts, the tradename and the batch number of the administered product should\nbe clearly recorded (or stated) in the patient file.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In order to prevent medicinal product errors it is important\nto check the vial labels to ensure that the medicinal product being prepared\nand administered is Kadcyla (trastuzumab emtansine) and not Herceptin\n(trastuzumab).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><i>Thrombocytopenia</i></p>\n<p class=\"MsoNormal\">Thrombocytopenia, or decreased platelet counts, was commonly\nreported with trastuzumab emtansine and was the most common adverse reaction\nleading to treatment discontinuation, dose reduction, and dose interruption\n(see section\u00a04.8). In clinical studies, the incidence and severity of\nthrombocytopenia were higher in Asian patients (see section 4.8).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">It is recommended that platelet counts are monitored prior\nto each trastuzumab emtansine dose. Patients with thrombocytopenia\n(\u2264\u00a0100,000/mm<sup>3</sup>) and patients on anti\u2011coagulant\ntreatment (e.g. warfarin, heparin, low molecular weight heparins) should be\nmonitored closely while on trastuzumab emtansine treatment. Trastuzumab\nemtansine has not been studied in patients with platelet counts\n\u2264\u00a0100,000/mm<sup>3</sup> prior to initiation of treatment. In the\nevent of decreased platelet count to Grade\u00a03 or greater\n(&lt;\u00a050,000/mm<sup>3</sup>), do not administer trastuzumab emtansine\nuntil platelet counts recover to Grade\u00a01 (\u2265\u00a075,000/mm<sup>3</sup>)\n(see section\u00a04.2). </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><i>Haemorrhage</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Cases of haemorrhagic events,\nincluding central nervous system, respiratory and gastrointestinal haemorrhage,\nhave been reported with trastuzumab emtansine treatment. Some of these bleeding\nevents resulted in fatal outcomes. In some of the observed cases the patients\nhad thrombocytopenia, or were also receiving anti-coagulant therapy or\nantiplatelet therapy; in others there were no known additional risk factors.\nUse caution with these agents and consider additional monitoring when\nconcomitant use is medically necessary.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Hepatotoxicity</i></p>\n<p class=\"MsoNormal\">Hepatotoxicity, predominantly in the form of asymptomatic\nincreases in the concentrations of serum transaminases (Grade\u00a01\u20114\u00a0transaminitis),\nhas been observed during treatment with trastuzumab emtansine in clinical\nstudies (see section\u00a04.8). Transaminase elevations were generally\ntransient with peak elevation at day 8 after administration of therapy and\nsubsequent recovery to Grade 1 or less prior to the next cycle. A cumulative\neffect on transaminases has also been observed (the proportion of patients with\nGrade 1-2 ALT/AST abnormalities increases with successive cycles). </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Patients with elevated transaminases improved to Grade 1 or\nnormal within 30 days of the last dose of trastuzumab emtansine in the majority\nof the cases (see section 4.8). </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Serious hepatobiliary disorders, including nodular\nregenerative hyperplasia (NRH) of the liver and some with a fatal outcome due\nto drug-induced liver injury have been observed in patients treated with\ntrastuzumab emtansine. Observed cases may have been confounded by comorbidities\nand/or concomitant medicinal products with known hepatotoxic potential.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Liver function should be monitored prior to initiation of\ntreatment and each dose. Patients with baseline elevation of ALT (e.g. due to\nliver metastases)\u00a0may be predisposed to liver injury with a higher risk of\na Grade 3-5 hepatic event or liver function test increase. Dose reductions or\ndiscontinuation for increased serum transaminases and total bilirubin are\nspecified in section 4.2.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Cases of nodular regenerative hyperplasia (NRH) of the liver\nhave been identified from liver biopsies in patients treated with trastuzumab\nemtansine. NRH is a rare liver condition characterised by widespread benign\ntransformation of hepatic parenchyma into small regenerative nodules; NRH may\nlead to non\u2011cirrhotic portal hypertension. Diagnosis of NRH can be\nconfirmed only by histopathology. NRH should be considered in all patients with\nclinical symptoms of portal hypertension and/or cirrhosis-like pattern seen on\nthe computed tomography (CT) scan of the liver but with normal transaminases\nand no other manifestations of cirrhosis. Upon diagnosis of NRH, trastuzumab\nemtansine treatment must be permanently discontinued. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Trastuzumab emtansine has not been studied in patients with\nserum transaminases\u00a0&gt;\u00a02.5<b>\u00a0</b><span style=\"font-family:\nSymbol\">\u00b4</span>\u00a0ULN or total bilirubin\u00a0&gt;\u00a01.5<b>\u00a0</b><span style=\"font-family:Symbol\">\u00b4</span>\u00a0ULN prior to initiation of\ntreatment. Treatment in patients with serum transaminases\u00a0&gt;\u00a03<b>\u00a0</b><span style=\"font-family:Symbol\">\u00b4</span>\u00a0ULN and concomitant total\nbilirubin\u00a0&gt;\u00a02<b>\u00a0</b><span style=\"font-family:Symbol\">\u00b4</span>\u00a0ULN\nshould be permanently discontinued. Treatment of patients with hepatic\nimpairment should be undertaken with caution (see sections 4.2 and 5.2).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Neurotoxicity</i></p>\n<p class=\"MsoNormal\">Peripheral neuropathy, mainly Grade\u00a01 and predominantly\nsensory, has been reported in clinical studies with trastuzumab emtansine. MBC\npatients with Grade \u00a0<span style=\"font-family:Symbol\">\u00b3</span>\u00a03\nand EBC patients with Grade \u00a0<span style=\"font-family:Symbol\">\u00b3</span>\u00a02</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">peripheral neuropathy at\nbaseline were excluded from clinical studies. Treatment with trastuzumab emtansine\nshould be temporarily discontinued in patients experiencing Grade\u00a03 or 4\nperipheral neuropathy until symptoms resolve or improve to\n\u2264\u00a0Grade\u00a02. Patients should be clinically monitored on an\nongoing basis for signs/symptoms of neurotoxicity<i>. </i></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Left ventricular\ndysfunction</i> </p>\n<p class=\"MsoNormal\">Patients treated with trastuzumab emtansine are at increased\nrisk of developing left ventricular dysfunction. Left ventricular ejection\nfraction (LVEF)\u00a0&lt;\u00a040% has been observed in patients treated with\ntrastuzumab emtansine, and therefore symptomatic congestive heart failure (CHF)\nis a potential risk (see section\u00a04.8). General risk factors for a cardiac\nevent and those identified in adjuvant breast cancer studies with trastuzumab\ntherapy include advancing age (&gt; 50 years), low baseline LVEF values\n(&lt;\u00a055%), low LVEF levels prior to or following the use of paclitaxel in\nthe adjuvant setting, prior or concomitant use of antihypertensive medicinal\nproducts, previous therapy with an anthracycline and high BMI (&gt; 25 kg/m<sup>2</sup>).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Standard cardiac function testing (echocardiogram or\nmultigated acquisition (MUGA) scanning) should be performed prior to initiation\nand at regular intervals (e.g. every three months) during treatment. In\nclinical studies, patients had a LVEF\u00a0<span style=\"font-family:Symbol\">\u00b3</span>\u00a050%\nat baseline. Patients with a history of congestive heart failure (CHF), serious\ncardiac arrhythmia requiring treatment, history of myocardial infarction or\nunstable angina within 6 months of randomization, or current dyspnoea at rest\ndue to advanced malignancy were excluded from clinical studies. The dose should\nbe delayed or treatment discontinued as necessary in cases of left ventricular\ndysfunction (see section\u00a04.2).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><i>Pulmonary toxicity</i></p>\n<p class=\"MsoNormal\">Cases of interstitial lung disease (ILD), including\npneumonitis, some leading to acute respiratory distress syndrome or a fatal\noutcome, have been reported in clinical studies with trastuzumab emtansine (see\nsection\u00a04.8). Signs and symptoms include dyspnoea, cough, fatigue, and\npulmonary infiltrates. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">It\nis recommended that treatment with trastuzumab emtansine be permanently\ndiscontinued in patients who are diagnosed with ILD or pneumonitis,<b><span style=\"font-size:8.0pt\"> </span></b>except for radiation pneumonitis in the\nadjuvant setting, where trastuzumab emtansine should be permanently\ndiscontinued for <span style=\"font-family:Symbol\">\u00b3</span> Grade 3 or for\nGrade 2 not responding to standard treatment. (see section 4.2).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Patients with dyspnoea at rest due to complications of\nadvanced malignancy, co\u2011morbidities, and receiving concurrent pulmonary\nradiation therapy may be at increased risk of pulmonary events.</p>\n<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Infusion-related reactions</i></p>\n<p class=\"MsoNormal\">Trastuzumab emtansine treatment has not been studied in\npatients who had trastuzumab permanently discontinued due to infusion-related\nreactions (IRR); treatment is not recommended for these patients. Patients\nshould be observed closely for infusion-related reactions, especially during\nthe first infusion.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Infusion-related reactions (due to cytokine release),\ncharacterized by one or more of the following symptoms have been reported:\nflushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and\ntachycardia. In general, these symptoms were not severe (see section 4.8). In\nmost patients, these reactions resolved over the course of several hours to a\nday after the infusion was terminated. Treatment should be interrupted in\npatients with a severe IRR until signs and symptoms resolve. Consideration for\nre-treatment should be based on clinical assessment of the severity of the\nreaction. Treatment must be permanently discontinued in the event of a life\nthreatening infusion-related reaction (see section\u00a04.2). </p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Hypersensitivity reactions</i></p>\n<p class=\"MsoNormal\">Trastuzumab emtansine treatment has not been studied in\npatients who had trastuzumab permanently discontinued due to hypersensitivity;\ntreatment with trastuzumab emtansine is not recommended for these patients. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Patients should be observed closely for\nhypersensitivity/allergic reactions, which may have the same clinical\npresentation as an IRR. Serious, anaphylactic reactions have been observed in\nclinical studies with trastuzumab emtansine. Medicinal products to treat such\nreactions, as well as emergency equipment, should be available for immediate\nuse. In the event of a true hypersensitivity reaction (in which severity of\nreaction increases with subsequent infusions), trastuzumab emtansine treatment\nmust be permanently discontinued. </p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Sodium content in\nexcipients</i></p>\n<p class=\"MsoNormal\">This medicinal product contains less than 1 mmol sodium (23\nmg) per dose, i.e. essentially \u2018sodium- free\u2019.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.5\u00a0\u00a0\u00a0\u00a0 Interaction\nwith other medicinal products and other forms of interaction</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">No formal interaction studies have been performed. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><i>In vitro</i> metabolism studies in human liver microsomes\nsuggest that DM1, a component of trastuzumab emtansine, is metabolised mainly\nby CYP3A4 and, to a lesser extent, by CYP3A5.\u00a0\u00a0 Concomitant use of\nstrong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin,\natazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,\ntelithromycin, and voriconazole) with trastuzumab emtansine should be avoided\ndue to the potential for an increase in DM1 exposure and toxicity.\u00a0\nConsider an alternate medicinal product with no or minimal potential to inhibit\nCYP3A4.\u00a0 If concomitant use of strong CYP3A4 inhibitors is unavoidable,\nconsider delaying trastuzumab emtansine treatment until the strong CYP3A4\ninhibitors have cleared from the circulation (approximately 3 elimination\nhalf-lives of the inhibitors) when possible.\u00a0 If a strong CYP3A4 inhibitor\nis coadministered and trastuzumab emtansine treatment cannot be delayed,\npatients should be closely monitored for adverse reactions. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.6\u00a0\u00a0\u00a0\u00a0 Fertility,\npregnancy and lactation</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><u>Contraception in males and females</u></p>\n<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">Women of childbearing potential should use effective\ncontraception while receiving trastuzumab emtansine and for 7\u00a0months\nfollowing the last dose of trastuzumab emtansine. Male patients or their female\npartners should also use effective contraception.</p>\n<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Pregnancy</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">There are no data from the use of trastuzumab emtansine in\npregnant women. Trastuzumab, a component of trastuzumab emtansine, can cause\nfoetal harm or death when administered to a pregnant woman. In the post\u2011marketing\nsetting, cases of oligohydramnios, some associated with fatal pulmonary\nhypoplasia, have been reported in pregnant women receiving trastuzumab. Animal\nstudies of maytansine, a closely related chemical entity of the same\nmaytansinoid class as DM1, suggest that DM1, the microtubule inhibiting\ncytotoxic component of trastuzumab emtansine, is expected to be teratogenic and\npotentially embryotoxic (see section 5.3).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Administration<i> </i>of trastuzumab emtansine to pregnant\nwomen is not recommended and women should be informed of the possibility of\nharm to the foetus before they become pregnant. Women who become pregnant must\nimmediately contact their doctor. If a pregnant woman is treated with\ntrastuzumab emtansine, close monitoring by a multidisciplinary team is\nrecommended.</p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Breast\u2011feeding</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">It is not known whether trastuzumab emtansine is excreted in\nhuman milk. Since many medicinal products are excreted in human milk and\nbecause of the potential for serious adverse reactions in breast\u2011feeding\ninfants, women should discontinue breast\u2011feeding prior to initiating\ntreatment with trastuzumab emtansine. Women may begin breast\u2011feeding 7\u00a0months\nafter concluding treatment. </p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Fertility</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">No reproductive and developmental toxicology studies have\nbeen conducted with trastuzumab emtansine. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use\nmachines</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\">Trastuzumab emtansine has minor influence on the ability to\ndrive and use machines. </p>\n<p class=\"MsoNormal\">The significance of reported adverse reactions such as\nfatigue, headache, dizziness and blurred vision on the ability to drive or use\nmachines is unknown. Patients experiencing infusion\u2011related reactions (flushing,\nchills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and tachycardia)\nshould be advised not to drive and use machines until symptoms abate.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Summary of the safety\nprofile</u><u> </u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The safety of trastuzumab\nemtansine has been evaluated in 2,611\u00a0breast cancer patients in clinical\nstudies. In this patient population: </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 the most\ncommon serious ADRs (&gt; 0.5% of patients) were haemorrhage, pyrexia, thrombocytopenia,\ndyspnoea, abdominal pain, musculoskeletal pain, and vomiting.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span style=\"color:black\">the most common adverse drug reactions (ADRs) (\u226525%)\nwith trastuzumab emtansine were nausea, fatigue, musculoskeletal pain,\nhaemorrhage, headache, transaminases increased, thrombocytopenia, and peripheral\nneuropathy. The majority of ADRs reported were of Grade\u00a01 or 2 severity.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 the most\ncommon National Cancer Institute - Common Terminology Criteria for Adverse\nEvents (NCI-CTCAE) Grade \u2265\u00a03 ADRs (&gt;\u00a02%) were\nthrombocytopenia, increased transaminases, anaemia, neutropenia, fatigue and\nhypokalaemia.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Tabulated list of adverse\nreactions</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">The ADRs in 2,611\u00a0patients treated with trastuzumab\nemtansine are presented in Table\u00a03.\u00a0 The ADRs are listed below by\nMedDRA system organ class (SOC) and categories of frequency. Frequency\ncategories are defined as very common (\u2265\u00a01/10), common\n(\u2265\u00a01/100 to &lt;\u00a01/10), uncommon (\u2265\u00a01/1,000 to\n&lt;\u00a01/100), rare (\u2265\u00a01/10,000 to &lt;\u00a01/1,000), very rare\n(&lt;\u00a01/10,000) and not known (cannot be estimated from the available\ndata). Within each frequency grouping and SOC, adverse reactions are presented\nin order of decreasing seriousness.\u00a0 ADRs were reported using NCI-CTCAE\nfor assessment of toxicity.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Table\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tabulated\nlist of ADRs in patients treated with trastuzumab emtansine in clinical trials</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<thead>\n<tr style=\"height:15.8pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n   padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"181\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n   text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">System Organ Class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Very Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"127\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Uncommon</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"height:26.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Infections and infestations</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Urinary tract infection</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:26.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Blood and lymphatic system\n  disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Thrombocytopenia, Anaemia</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neutropenia, Leucopoenia</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:14.8pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Immune system disorders </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Drug hypersensitivity</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:17.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Metabolism and nutrition\n  disorders </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Hypokalaemia</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:6.7pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Psychiatric disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Insomnia</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:24.7pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Nervous system disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neuropathy peripheral,\n  Headache </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dizziness, Dysgeusia, Memory impairment</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:35.95pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Eye disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:8.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Cardiac disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Left ventricular dysfunction</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:3.5pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Vascular disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Haemorrhage</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hypertension</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Respiratory, thoracic and\n  mediastinal disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Epistaxis, Cough, Dyspnoea</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Pneumonitis (ILD)</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Gastrointestinal disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Stomatitis, Diarrhoea, Vomiting,\n  Nausea, Constipation, Dry mouth, Abdominal pain</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Dyspepsia, Gingival bleeding</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hepatobiliary disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Transaminases increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Blood alkaline phosphatase\n  increased, blood bilirubin increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.55pt;text-indent:-.55pt;page-break-after:\n  avoid\">Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia,\n  Portal hypertension</p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Skin and subcutaneous tissue\n  disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Rash, Pruritus, Alopecia, Nail\n  disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal and connective\n  tissue disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal pain, Arthralgia,\n  Myalgia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:28.3pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">General disorders and\n  administration site conditions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Fatigue, Pyrexia, Asthenia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Peripheral oedema, Chills</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Injection site extravasation</p>\n</td>\n</tr>\n<tr style=\"height:3.5pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Injury, poisoning and procedural\n  complications</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Infusion\u2011related reactions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Radiation pneumonitis</p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Table 3\nshows pooled data from the overall treatment period in the MBC studies (N=\n1871; median number of cycles of trastuzumab emtansine was 10) and in KATHERINE\n(N=740; median number of cycles was 14). </span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Description of selected\nadverse reactions</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Thrombocytopenia</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Thrombocytopenia or decreased\nplatelet counts were reported in 24.9% of patients in MBC clinical studies with\ntrastuzumab emtansine and was the most common adverse reaction leading to\ntreatment discontinuation (2.6%). Thrombocytopenia was reported in 28.5% of\npatients in EBC clinical studies with trastuzumab emtansine and was the most\ncommon reported adverse reaction for all grades and grades \u2265\u00a03, as\nwell as the most common adverse reaction leading to treatment discontinuation (4.2%),\ndose interruptions, and dose reductions. The majority of the patients had\nGrade\u00a01 or\u00a02\u00a0events (\u2265\u00a050,000/mm<sup>3</sup>), with\nthe nadir occurring by day\u00a08 and generally improving to Grade\u00a00\nor\u00a01 (\u2265\u00a075,000/mm<sup>3</sup>) by the next scheduled dose. In\nclinical studies, the incidence and severity of thrombocytopenia were higher in\nAsian patients. Independent of race, the incidence of Grade\u00a03 or\u00a04\nevents (&lt;\u00a050,000/mm<sup>3</sup>) was 8.7% in patients with MBC treated\nwith trastuzumab emtansine and <span style=\"color:black\">5.7</span>% in\npatients with EBC. For dose modifications for thrombocytopenia, see sections\n4.2 and 4.4.\u00a0 </p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\"><i>Haemorrhage</i></p>\n<p class=\"MsoNormal\">Haemorrhagic events were reported in 34.8% of patients in\nMBC clinical trials with trastuzumab emtansine and <span style=\"color:black\">t</span>he\nincidence of severe haemorrhagic events (Grade \u22653) occurred in 2.2%. Haemorrhagic\nevents were reported in 29% of patients with EBC and the incidence of severe\nhaemorrhagic events (Grade \u22653) was 0.4%, including one Grade 5 event. In\nsome of the observed cases the patients had thrombocytopenia, or were also\nreceiving anti-coagulant therapy or antiplatelet therapy; in others there were\nno known additional risk factors. Cases of bleeding events with a fatal outcome\nhave been observed in both MBC and EBC.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><i>Transaminases increased (AST/ALT)</i></p>\n<p class=\"MsoNormal\">Increase in serum transaminases (Grade\u00a01\u20114) has\nbeen observed during treatment with trastuzumab emtansine in clinical studies\n(see section\u00a04.4). Transaminase elevations were generally transient. A\ncumulative effect of trastuzumab emtansine on transaminases has been observed,\nand generally recovered when treatment was discontinued. Increased\ntransaminases were reported in 24.2% of patients in MBC clinical studies.\nGrade\u00a03 or\u00a04 increased AST and ALT were reported in 4.2% and 2.7% of\npatients with MBC respectively and usually occurred in the early treatment\ncycles (1\u20116). Increased transaminases were reported in 32.4% of patients\nwith EBC. Grade 3 and 4 increased transaminases were reported in 1.5% of\npatients with EBC. In general, the Grade\u00a0\u2265\u00a03 hepatic events\nwere not associated with poor clinical outcome; subsequent follow\u2011up\nvalues tended to show improvement to ranges allowing the patient to remain on\nstudy and continue to receive study treatment at the same or reduced dose. No\nrelationship was observed between trastuzumab emtansine exposure (AUC),\ntrastuzumab emtansine maximum serum concentration (C<sub>max</sub>), total\ntrastuzumab exposure (AUC), or C<sub>max</sub> of DM1 and increases in\ntransaminase. For dose modifications in the event of increased transaminases,\nsee sections 4.2 and 4.4. </p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\"><i>Left ventricular dysfunction</i></p>\n<p class=\"MsoNormal\">Left ventricular dysfunction was reported in 2.2% of\npatients in MBC clinical studies with trastuzumab emtansine. The majority of\nevents were asymptomatic Grade\u00a01 or\u00a02 decrease in LVEF. Grade\u00a03\nor\u00a04 events were reported in 0.4% of patients with MBC. Left ventricular\ndysfunction occurred in 3.0% of patients with EBC, with Grade 3 or 4 in 0.5% of\npatients. Additional LVEF monitoring is recommended for patients with\nLVEF\u00a0\u2264 45% (See Table\u00a05 in section 4.2 for specific dose\nmodifications). </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Peripheral neuropathy</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Peripheral neuropathy, mainly\nas Grade 1 and predominantly sensory, was reported in clinical trials of trastuzumab\nemtansine. In patients with MBC, the overall incidence of peripheral neuropathy\nwas 29.0% and 8.6% for Grade \u2265 2. In patients with EBC, the overall\nincidence was 32.3% and 10.3% for Grade \u2265 2. </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Infusion\u2011related\nreactions</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Infusion\u2011related\nreactions are characterised by one or more of the following symptoms: flushing,\nchills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm and tachycardia.\nInfusion\u2011related reactions were reported in 4.0% of patients in MBC clinical\nstudies with trastuzumab emtansine, with six Grade\u00a03 and no Grade\u00a04\nevents reported. Infusion-related reactions were reported in 1.6% of patients\nwith EBC, with no Grade 3 or 4 events reported. Infusion\u2011related\nreactions resolved over the course of several hours to a day after the infusion\nwas terminated. No dose relationship was observed in clinical studies. For dose\nmodifications in the event of infusion\u2011related reactions, see sections\n4.2 and 4.4. </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Hypersensitivity reactions</i></p>\n<p class=\"MsoNormal\">Hypersensitivity was reported in 2.6% of patients in MBC clinical\nstudies with trastuzumab emtansine, with one Grade\u00a03 and one Grade 4\nevents reported. Hypersensitivity was reported in 2.7% of patients with EBC,\nwith Grade 3 or 4 in 0.4% of patients. Overall, the majority of\nhypersensitivity reactions were mild or moderate in severity and resolved upon\ntreatment. For dose modifications in the event of hypersensitivity reactions,\nsee sections 4.2 and 4.4. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Immunogenicity</i></p>\n<p class=\"MsoNormal\">As with all therapeutic proteins, there is the potential for\nan immune response to trastuzumab emtansine. A total of 1243 patients from\nseven clinical studies were tested at multiple time points for anti-drug\nantibody (ADA) responses to trastuzumab emtansine. Following trastuzumab\nemtansine dosing, 5.1% (63/1243) of patients tested positive for anti-trastuzumab\nemtansine antibodies at one or more post-dose time points. In the Phase I and\nPhase II studies, 6.4% (24/376) of patients tested positive for anti- trastuzumab\nemtansine antibodies. In the EMILIA study (TDM4370g/BO21977), 5.2% (24/466) of\npatients tested positive for anti-trastuzumab emtansine antibodies, of which 13\nwere also positive for neutralizing antibodies. In the KATHERINE (BO27938)\nstudy, 3.7% (15/401) of patients tested positive for anti-trastuzumab emtansine\nantibodies, of which 5 were also positive for neutralizing antibodies. Due to\nthe low incidence of ADA, conclusions cannot be made on the impact of anti- trastuzumab\nemtansine antibodies on the pharmacokinetics, safety, and efficacy of trastuzumab\nemtansine. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Extravasation</i></p>\n<p class=\"MsoNormal\">Reactions secondary to extravasation have been observed in\nclinical studies with trastuzumab emtansine. These reactions were usually mild\nor moderate and comprised erythema, tenderness, skin irritation, pain, or\nswelling at the infusion site. These reactions have been observed more\nfrequently within 24\u00a0hours of infusion. Specific treatment for trastuzumab\nemtansine extravasation is unknown at this time. </p>\n<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\"><u>Laboratory abnormalities</u></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Tables\u00a04 and 5 displays laboratory abnormalities\nobserved in patients treated with trastuzumab emtansine in clinical study\nTDM4370g/BO21977/EMILIA and study BO27938/KATHERINE.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:49.65pt;text-indent:-49.65pt;page-break-after:\navoid\"><b>Table\u00a04\u00a0\u00a0\u00a0\u00a0 Laboratory abnormalities\nobserved in patients treated with trastuzumab emtansine in study\nTDM4370g/BO21977/EMILIA</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:49.65pt;text-indent:-49.65pt;page-break-after:\navoid\"><b>\u00a0</b></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:432.75pt;margin-left:4.65pt;border-collapse:collapse\" width=\"577\">\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" rowspan=\"2\" style=\"width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>\n</td>\n<td colspan=\"3\" nowrap=\"\" style=\"width:238.5pt;border:\n  solid windowtext 1.0pt;border-left:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"318\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab emtansine (N=490)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grades\u00a0(%)</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">21</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">98</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">8</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">82</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">85</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">14</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">63</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">41</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>\n</td>\n</tr>\n<tr style=\"height:2.9pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">35</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt; 1</p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>Table\u00a05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Laboratory\nabnormalities observed in patients treated with trastuzumab emtansine in study BO27938/KATHERINE</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:432.75pt;margin-left:4.65pt;border-collapse:collapse\" width=\"577\">\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" rowspan=\"2\" style=\"width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>\n</td>\n<td colspan=\"3\" nowrap=\"\" style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"318\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"DE\" style=\"font-size:\n  11.0pt;color:windowtext\">Trastuzumab emtansine (N=740)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grade %</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">11</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">79</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">55</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">51</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">31</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">24</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>\n</td>\n</tr>\n<tr style=\"height:2.9pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">26</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><u>Reporting of suspected adverse reactions</u></p>\n<p class=\"MsoNormal\">Reporting suspected adverse reactions after authorisation of\nthe medicinal product is important. It allows continued monitoring of the\nbenefit/risk balance of the medicinal product. Healthcare professionals are\nasked to report any suspected adverse reactions via <span style=\"background:\nlightgrey\">the national reporting system listed in </span><a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span style=\"background:lightgrey\">Appendix V</span></a><span style=\"background:lightgrey\">.</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>4.9\u00a0\u00a0\u00a0\u00a0 Overdose</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">There is no known antidote for trastuzumab emtansine overdose.\nIn case of overdose, the patient should be closely monitored for signs or\nsymptoms of adverse reactions and appropriate symptomatic treatment instituted.\nCases of overdose have been reported with trastuzumab emtansine treatment, most\nassociated with thrombocytopenia, and there was one death. In the fatal case,\nthe patient incorrectly received trastuzumab emtansine 6\u00a0mg/kg and died\napproximately 3\u00a0weeks following the overdose; a causal relationship to\ntrastuzumab emtansine was not established.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>5.1 \u00a0\u00a0\u00a0 Pharmacodynamic properties</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Pharmacotherapeutic group: Antineoplastic agents, other\nantineoplastic agents, monoclonal</p>\n<p class=\"MsoNormal\">antibodies, ATC code: L01XC14</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Mechanism of action</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Kadcyla, trastuzumab\nemtansine, is a HER2\u2011targeted antibody\u2011drug conjugate which\ncontains the humanised anti\u2011HER2 IgG1, trastuzumab, covalently linked to\nthe microtubule inhibitor DM1 (a maytansine derivative) via the stable\nthioether linker MCC\u00a0(4\u2011[N\u2011maleimidomethyl]\u00a0cyclohexane\u20111\u2011carboxylate).\nEmtansine refers to the MCC\u2011DM1 complex. An average of 3.5\u00a0DM1\nmolecules are conjugated to each molecule of trastuzumab. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Conjugation of DM1 to trastuzumab confers selectivity of the\ncytotoxic agent for HER2\u2011overexpressing tumour cells, thereby increasing\nintracellular delivery of DM1 directly to malignant cells. Upon binding to\nHER2, trastuzumab emtansine undergoes receptor\u2011mediated internalization\nand subsequent lysosomal degradation, resulting in release of DM1\u2011containing\ncytotoxic catabolites (primarily lysine\u2011MCC\u2011DM1).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Trastuzumab emtansine has the mechanisms of action of both\ntrastuzumab and DM1: </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Trastuzumab\nemtansine, like trastuzumab, binds to domain\u00a0IV of the HER2 extracellular\ndomain (ECD), as well as to Fc\u03b3 receptors and complement\u00a0C1q. In addition,\ntrastuzumab emtansine, like trastuzumab, inhibits shedding of the HER2 ECD,\ninhibits signalling through the phosphatidylinositol\u00a03\u2011kinase (PI3\u2011K)\npathway, and mediates antibody\u2011dependent cell\u2011mediated cytotoxicity\n(ADCC) in human breast cancer cells that overexpress HER2.\u00a0 </p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 DM1, the\ncytotoxic component of trastuzumab emtansine, binds to tubulin. By inhibiting\ntubulin polymerization, both DM1 and trastuzumab emtansine cause cells to\narrest in the G2/M phase of the cell cycle, ultimately leading to apoptotic\ncell death. Results from <i>in vitro</i> cytotoxicity assays show that DM1 is\n20\u2011200 times more potent than taxanes and vinca alkaloids. </p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The\nMCC\u00a0linker is designed to limit systemic release and increase targeted\ndelivery of DM1, as demonstrated by detection of very low levels of free DM1 in\nplasma. </p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Clinical efficacy </u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span style=\"text-decoration:\n none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><i><u>Early\nBreast Cancer</u></i></p>\n<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><i><u><span lang=\"EN-GB\">BO27938\n(KATHERINE) </span></u></i></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">BO27938 (KATHERINE)\u00a0was a\nrandomized, multicenter, open-label trial of 1486 patients with HER2-positive,\nearly breast cancer with residual invasive tumor\u00a0<span lang=\"EN-GB\">(patients\nwho had not achieved pathological complete response (pCR))</span>\u00a0in the\nbreast and/or axillary lymph nodes following completion of preoperative\nsystemic therapy that included chemotherapy and HER2-targeted therapy. Patients\nmay have received more than one HER2-targeted therapy. Patients received\nradiotherapy and/or hormonal therapy concurrent with study treatment as per\nlocal guidelines. Breast tumor samples were required to show HER2\noverexpression defined as 3+ IHC or ISH amplification ratio \u2265 2.0\ndetermined at a central laboratory. Patients were randomized (1:1) to receive\ntrastuzumab or trastuzumab emtansine. Randomization was stratified by clinical\nstage at presentation (operable vs. inoperable), hormone receptor status, preoperative\nHER2-directed therapy (trastuzumab, trastuzumab plus additional HER2-directed\nagent[s]), and pathological nodal status evaluated after preoperative therapy.</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n<p align=\"left\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:left\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Trastuzumab\nemtansine was given intravenously at 3.6 mg/kg on Day 1 of a 21-day\ncycle.\u00a0 Trastuzumab was given intravenously at 6 mg/kg on Day 1 of a\n21-day cycle. Patients were treated with trastuzumab emtansine or trastuzumab\nfor a total of 14 cycles unless there was recurrence of disease, withdrawal of\nconsent, or unacceptable toxicity, whichever occurred first. Patients who\ndiscontinued trastuzumab emtansine could complete the duration of their\nintended study treatment up to 14 cycles of HER2-directed therapy with\ntrastuzumab if appropriate based on toxicity considerations and investigator\ndiscretion.</span></p>\n<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>\u00a0</span></p>\n<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>The primary efficacy endpoint of the study\nwas Invasive Disease-Free Survival (IDFS). IDFS was defined as the time from\nthe date of randomization to first occurrence of ipsilateral invasive breast\ntumor recurrence, ipsilateral local or regional invasive breast cancer\nrecurrence, distant recurrence, contralateral invasive breast cancer, or death\nfrom any cause. Additional endpoints included IDFS including second primary\nnon-breast cancer, disease-free survival (DFS), overall survival (OS), and\ndistant recurrence-free interval (DRFI).</span></p>\n<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>\u00a0</span></p>\n<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>Patient demographics and baseline tumor\ncharacteristics were balanced between treatment arms.\u00a0 The median age was\napproximately 49 years (range 23-80 years), 72.8% were White, 8.7% were Asian\nand 2.7% were Black or African American.\u00a0 All but 5 patients were women; 3\nmen were included in the trastuzumab arm and 2 in the trastuzumab emtansine arm.\n22.5 percent of patients were enrolled in North America, 54.2% in Europe and\n23.3% throughout the rest of the world.\u00a0 Tumor prognostic characteristics\nincluding hormone receptor status (positive: 72.3%, negative: 27.7%), clinical\nstage at presentation (inoperable: 25.3%, operable: 74.8%) and pathological\nnodal status after preoperative therapy (node positive: 46.4%, node negative or\nnot evaluated: 53.6%) were similar in the study arms.\u00a0\u00a0 </span></p>\n<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>\u00a0</span></p>\n<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>The majority of\nthe patients (76.9%) had received an anthracycline-containing neoadjuvant\nchemotherapy regimen.19.5% percent of patients received another HER2-targeted\nagent in addition to trastuzumab as a component of neoadjuvant therapy; 93.8%\nof these patients received pertuzumab. All of the patients had received taxanes\nas part of neoadjuvant chemotherapy.</span></p>\n<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>\n<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:black;\nbackground:white'>A clinically meaningful and statistically significant\nimprovement in IDFS was observed in patients who received trastuzumab emtansine\ncompared with trastuzumab (HR = 0.50, 95% CI [0.39, 0.64], p &lt;0.0001.\nEstimates of 3 years IDFS rates were 88.3% vs. 77.0%\u00a0in trastuzumab\nemtansine vs. trastuzumab\u00a0arms, respectively. See Table 6 and Figure 1.</span></p>\n<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;background:white'>\u00a0</span></p>\n<p class=\"TableTitle\" style=\"margin-top:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Table\u00a06\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Summary of </span><span lang=\"EN-CARRIBEAN\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>e</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>fficacy from </span><span lang=\"EN-CARRIBEAN\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>s</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>tudy </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>BO27938 (<span style=\"letter-spacing:.05pt\">KATHERINE</span>) </span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:437.7pt;border-collapse:collapse;border:none\" width=\"584\">\n<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n   line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>\n<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab\n   Emtansine</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Primary\n  Endpoint</span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Invasive\n  Disease-Free Survival (IDFS)<sup> \u00a0</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">165 (22.2%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">91 (12.2%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.50 [0.39, 0.64]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">77.02 [73.78, 80.26]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">88.27 [85.81, 90.72]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:6.1pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Overall\n  Survival (OS)</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;\n  line-height:8.6pt;page-break-after:avoid;punctuation-wrap:simple\"><span style='font-size:8.0pt;font-family:\"Courier New\"'>\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">56 (7.5%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">42 (5.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.70 [0.47,\n  1.05]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0848</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">5\n  year survival rate<sup>2</sup>,% [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">86.8 [80.95, 92.63]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">92.1 [89.44, 94.74]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">IDFS</span></b> <b><span style=\"font-size:10.0pt\">including\n  second primary non-breast cancer<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">95 (12.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.51 [0.40, 0.66]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.7 [85.18, 90.18]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Disease-Free\n  Survival (DFS)<sup>3</sup> </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">98 (13.2%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.53 [0.41,\n  0.68]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.41 [84.88, 89.93]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Distant\n  recurrence-free interval (DRFI)<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">121 (16.3%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">78 (10.5%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.60 [0.45, 0.79]</span><sup><span style=\"font-size:9.0pt\"> </span></sup></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0003</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">83.0 [80.10, 85.92 ]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">89.7 [87.37, 92.01 ]</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><b><span style=\"font-size:10.0pt\">Data from first interim\nanalysis 25 July 2018</span></b></p>\n<p class=\"MsoNormal\"><b><span style=\"font-size:10.0pt\">Key to abbreviations\n(Table6): </span></b><span style=\"font-size:10.0pt\">HR: Hazard Ratio; CI:\nConfidence Intervals, </span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\"><span style=\"font-size:10.0pt\">1. Hierarchical testing\napplied for IDFS and OS </span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\"><span style=\"font-size:10.0pt\">2. 3-year event-free rate\nand 5-year survival rate derived from Kaplan-Meier estimates</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\"><span style=\"font-size:10.0pt\">3. These secondary\nendpoints were not adjusted for multiplicity</span><span style=\"font-size:10.0pt\">\n</span></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\">\u00a0</p>\n<p class=\"FigureHolder\" style=\"text-align:justify;text-justify:inter-ideograph\"><b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Figure\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier\nCurve of Invasive Disease-Free Survival in KATHERINE</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><img border=\"0\" height=\"406\" id=\"Picture 3\" src=\"Kadcyla%20II-45%20EN%20PIclean_files/image001.gif\" width=\"605\"/></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\">In KATHERINE, consistent treatment benefit of trastuzumab\nemtansine for IDFS was seen in all the pre\u2011specified subgroups evaluated,\nsupporting the overall result. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;page-break-after:\navoid\"><i><u>Metastatic Breast Cancer</u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>TDM4370g/BO21977(EMILIA)</u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">A Phase\u00a0III, randomised,\nmulticentre, international, open\u2011label clinical study was conducted in\npatients with HER2\u2011positive unresectable locally advanced breast cancer\n(LABC) or MBC who had received prior taxane and trastuzumab\u2011based\ntherapy, including patients who received prior therapy with trastuzumab and a\ntaxane in the adjuvant setting and who relapsed during or within six months of\ncompleting adjuvant therapy. Only patients with Eastern Cooperative Oncology\nGroup (ECOG) Performance Status 0 or 1 were eligible.<i>\u00a0</i>Prior to\nenrolment, breast tumour samples were required to be centrally confirmed for\nHER2\u2011positive status defined as a score of 3\u00a0+ by IHC or gene\namplification by ISH. Baseline patient and tumour characteristics were well\nbalanced between treatment groups. Patients with treated brain metastases were\neligible for enrollment if they did not require therapy to control symptoms.\nFor patients randomised to trastuzumab emtansine, the median age was 53\u00a0years,\nmost patients were female (99.8%), the majority were Caucasian (72%), and 57%\nhad oestrogen\u2011receptor and/or progesterone\u2011receptor positive\ndisease. The study compared the safety and efficacy of trastuzumab emtansine\nwith that of lapatinib plus capecitabine. A total of 991\u00a0patients were\nrandomised to trastuzumab emtansine or lapatinib plus capecitabine as follows:</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Trastuzumab\nemtansine arm: trastuzumab emtansine 3.6\u00a0mg/kg intravenously over 30\u201190\u00a0minutes\non Day\u00a01 of a 21\u2011day cycle </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Control\narm (lapatinib plus capecitabine): lapatinib 1250\u00a0mg/day orally once per\nday of a 21\u2011day cycle plus capecitabine 1000\u00a0mg/m<sup>2</sup> orally\ntwice daily on Days\u00a01\u201114 of a 21\u2011day cycle</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The co\u2011primary efficacy\nendpoints of the study were progression\u2011free survival (PFS) as assessed\nby an independent review committee (IRC) and overall survival (OS)\n(see\u00a0Table\u00a07\u00a0and\u00a0Figures 2\u00a0to\u00a03). </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\">Time to symptom\u00a0progression, as defined by a 5\u2011point\ndecrease in the score derived from the Trials Outcome Index\u2011Breast (TOI\u2011B)\nsubscale of the Functional Assessment of Cancer Therapy\u2011Breast Quality of\nLife (FACT\u2011B\u00a0QoL) questionnaire was also assessed during the\nclinical study. A change of 5\u00a0points in the TOI\u2011B is considered\nclinically significant. Kadcyla delayed patient-reported time to symptom progression\nfor 7.1 months compared with 4.6 months for the control arm (Hazard Ratio 0.796\n(0.667, 0.951); p-value 0.0121). The data are from an open-label study and no\nfirm conclusions can be drawn.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Table\u00a07\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof efficacy from study TDM4370g/BO21977 (EMILIA) </b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:2.85pt;border-collapse:collapse;border:none\" width=\"586\">\n<thead>\n<tr style=\"page-break-inside:avoid;height:14.5pt\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"252\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></b></p>\n</td>\n<td style=\"width:139.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Lapatinib\n   + Capecitabine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0496</span></b></p>\n</td>\n<td style=\"width:110.95pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab\n   emtansine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0495</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" width=\"586\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Primary\n  endpoints</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>IRC-assessed\n  progression-free survival (PFS)</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">304 (61.3%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">265 (53.5%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.4</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.6</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.650</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.549, 0.771)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test, stratified*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;\u00a00.0001</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Overall\n  Survival (OS)** </b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients who died </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">182 (36.7%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">149 (30.1%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of survival (months)</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">25.1</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">30.9</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.682</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.548, 0.849)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:4.0pt\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:4.0pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:4.0pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0006</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" width=\"586\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Key\n  secondary endpoints</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Investigator-assessed\n  PFS</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">335 (67.5%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">287 (58.0%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">5.8</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.4</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (95% CI)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.658 (0.560, 0.774)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;0.0001</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Objective\n  response rate (ORR)</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><i>\u00a0\u00a0\u00a0\n  </i></b>Patients with measurable disease</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">389</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">397</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.35pt;line-height:12.0pt;page-break-after:avoid\">Number\n  of patients with OR (%)</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120 (30.8%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173 (43.6%)</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Difference (95% CI)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.7% (6.0, 19.4)</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">p-value (Mantel-Haenszel chi-squared test*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0002</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Duration\n  of objective response (months)</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-indent:8.8pt;line-height:12.0pt;page-break-after:\n  avoid\">Number of patients with OR</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Median 95% CI</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.5 (5.5, 7.2) </p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.6 (8.4, 20.8)</p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-left:11.35pt;page-break-after:avoid\">OS:\noverall survival; PFS: progression-free survival; ORR: objective response rate;\nOR: objective response; IRC: independent review committee; HR: hazard ratios;\nCI: confidence interval</p>\n<p class=\"MsoNormal\" style=\"margin-left:11.35pt;text-indent:-7.1pt\">* Stratified\nby: world region (United States, Western Europe, other), number of prior\nchemotherapeutic regimens for locally advanced or metastatic disease (0-1 <i>vs.</i>\n&gt;\u00a01), and visceral <i>vs.</i> non-visceral disease.</p>\n<p class=\"MsoNormal\" style=\"margin-left:11.35pt;text-indent:-11.35pt\">** The\ninterim analysis for OS was conducted when 331 events were observed. Since the\nefficacy boundary was crossed at this analysis, this is considered the\ndefinitive analysis.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">A treatment benefit was seen in the subgroup of patients who\nhad relapsed within 6 months of completing adjuvant treatment and had not\nreceived any prior systemic anti-cancer therapy in the metastatic setting\n(n=118); hazard ratios for PFS and OS were 0.51 (95% CI: 0.30, 0.85) and 0.61\n(95% CI: 0.32, 1.16), respectively. The median PFS and OS for the trastuzumab\nemtansine group were 10.8 months and not reached,\u00a0respectively, compared\nwith 5.7 months and 27.9 months, respectively, for the lapatinib plus capecitabine\ngroup. </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Figure\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-meier\ncurve of IRC-assessed progression-free survival</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><img border=\"0\" height=\"385\" id=\"Picture 1\" src=\"Kadcyla%20II-45%20EN%20PIclean_files/image002.gif\" width=\"605\"/></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Figure\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-meier\ncurve of overall survival</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><img border=\"0\" height=\"387\" id=\"Picture 2\" src=\"Kadcyla%20II-45%20EN%20PIclean_files/image003.gif\" width=\"604\"/></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>\n<p class=\"MsoNormal\">In study TDM4370g/BO21977, consistent treatment benefit of\ntrastuzumab emtansine was seen in the majority of pre\u2011specified subgroups\nevaluated, supporting the robustness of the overall result. In the subgroup of\npatients with hormone receptor-negative disease (n=426), the hazard ratios for\nPFS and OS were 0.56 (95% CI: 0.44, 0.72) and 0.75 (95% CI: 0.54, 1.03),\nrespectively.\u00a0 In the subgroup of patients with hormone receptor-positive\ndisease (n=545), the hazard ratios for PFS and OS were 0.72 (95% CI: 0.58,\n0.91) and 0.62 (95% CI: 0.46, 0.85), respectively.\u00a0 </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In the subgroup of patients with non-measurable disease\n(n=205), based on IRC assessments, the hazard ratios for PFS and OS were 0.91\n(95% CI: 0.59, 1.42) and 0.96 (95% CI: 0.54, 1.68), respectively. In patients\n\u2265 65 years old (n=138 across both treatment arms) the hazard ratios for\nprogression-free survival (PFS) and Overall Survival (OS) were 1.06 (95% CI:\n0.68, 1.66) and 1.05 (95% CI: 0.58, 1.91), respectively. In patients 65 to\n74\u00a0years old (n=113), based on IRC assessments, the hazard ratios for PFS\nand OS were 0.88 (95% CI: 0.53, 1.45) and 0.74 (95% CI: 0.37, 1.47),\nrespectively.\u00a0 For patients 75\u00a0years or above, based on IRC\nassessments, the hazard ratios for PFS and OS were 3.51 (95% CI: 1.22, 10.13)\nand 3.45 (95% CI: 0.94, 12.65), respectively. The subgroup of patients\n75\u00a0years or above did not demonstrate a benefit for PFS or OS, but was too\nsmall (n=25) to draw any definitive conclusions. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In the descriptive follow-up overall survival analysis, the\nhazard ratio was 0.75 (95% CI 0.64, 0.88). The median duration of overall\nsurvival was 29.9 months in the trastuzumab emtansine arm compared with 25.9\nmonths in the lapatinib plus capecitabine arm. At the time of the descriptive\nfollow-up overall survival analysis, a total of 27.4% of the patients had\ncrossed over from the lapatinib plus capecitabine arm to the trastuzumab\nemtansine arm. In a sensitivity analysis censoring patients at the time of\ncross-over, the hazard ratio was 0.69 (95% CI 0.59, 0.82). The results of this\ndescriptive follow-up analysis are consistent with the confirmatory OS analysis.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><i><u>TDM4450g</u></i></p>\n<p class=\"MsoNormal\">A randomised, multicentre, open\u2011label phase\u00a0II\nstudy evaluated the effects of trastuzumab emtansine versus trastuzumab plus\ndocetaxel in patients with HER2\u2011positive MBC who had not received prior\nchemotherapy for metastatic disease. Patients were randomised to receive\ntrastuzumab emtansine 3.6\u00a0mg/kg intravenously every 3 weeks\n(n\u00a0=\u00a067) or trastuzumab\u00a08\u00a0mg/kg intravenous loading dose\nfollowed by 6\u00a0mg/kg intravenously every 3\u00a0weeks plus docetaxel 75\u2011100\u00a0mg/m<sup>2</sup>\nintravenously every 3\u00a0weeks (n\u00a0=\u00a070).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The primary endpoint was investigator assessed Progression\u2011Free\nSurvival (PFS). The median PFS was 9.2\u00a0months in the trastuzumab plus\ndocetaxel arm and 14.2\u00a0months in the trastuzumab emtansine arm (hazard\nratio, 0.59; p\u00a0=\u00a00.035), with a median follow\u2011up of\napproximately 14\u00a0months in both arms. The objective response rate (ORR)\nwas 58.0% with trastuzumab plus docetaxel and 64.2% with trastuzumab emtansine.\nThe median duration of response was not reached with trastuzumab emtansine <i>vs.</i>\n9.5\u00a0months in the control arm.</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><i><u>TDM4374g </u></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">A Phase\u00a0II, single\u2011arm,\nopen\u2011label study evaluated the effects of trastuzumab emtansine in\npatients with HER2\u2011positive incurable, LABC or MBC. All patients were\npreviously treated with HER2\u2011directed therapies (trastuzumab and\nlapatinib), and chemotherapy (anthracycline, taxane, and capecitabine) in the\nneoadjuvant, adjuvant, locally advanced, or metastatic setting. The median\nnumber of anti\u2011cancer agents that patients had received in any setting\nwas 8.5 (range, 5\u201119) and in the metastatic setting was 7.0 (range, 3\u201117),\nincluding all agents intended for the treatment of breast cancer. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Patients (n\u00a0=\u00a0110) received 3.6\u00a0mg/kg of\ntrastuzumab emtansine intravenously every 3\u00a0weeks until disease\nprogression or unacceptable toxicity. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The key efficacy analyses were ORR based on independent\nradiologic review and duration of objective response. The ORR was 32.7% (95%\nCI: 24.1,\u00a042.1), n\u00a0=\u00a036 responders, by both IRC and investigator\nreview. The median duration of response by IRC was not reached (95% CI,\n4.6\u00a0months to not estimable).</p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Paediatric population</u></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">The European Medicines Agency has waived the obligation to\nsubmit the results of studies with trastuzumab emtansine in all subsets of the\npaediatric population in breast cancer (see section\u00a04.2 for information on\npaediatric use).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\">The population pharmacokinetic analysis suggested no\ndifference in trastuzumab emtansine exposure based on disease status (adjuvant\nvs. metastatic setting).</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Absorption </u></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\">Trastuzumab emtansine is administered intravenously.\nThere have been no studies performed with other routes of administration. </p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Distribution </u></p>\n<p class=\"MsoNormal\">Patients in Study TDM4370g/BO21977 and Study BO29738 who\nreceived 3.6\u00a0mg/kg of trastuzumab emtansine intravenously every\n3\u00a0weeks had a mean Cycle 1 maximum serum concentration (C<sub>max</sub>)\nof trastuzumab emtansine of 83.4\u00a0(\u00b1\u00a016.5)\u00a0<span style=\"font-family:Symbol\">m</span>g/mL and 72.6 (\u00b1 24.3) <span style=\"font-family:Symbol\">m</span>g/mL, respectively. Based on population PK\nanalysis, following intravenous administration, the central volume of\ndistribution of trastuzumab emtansine was (3.13\u00a0L) and approximated that\nof plasma volume. </p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span lang=\"DE\">Biotransformation (trastuzumab emtansine and DM1)</span></u></p>\n<p class=\"MsoNormal\">Trastuzumab emtansine is expected to undergo deconjugation\nand catabolism by means of proteolysis in cellular lysosomes. </p>\n<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\"><i>In vitro</i> metabolism studies in human liver microsomes\nsuggest that DM1, a small molecule component of trastuzumab emtansine, is\nmetabolised mainly by CYP3A4 and to a lesser extent by CYP3A5. DM1 did not\ninhibit major CYP450 enzymes in vitro.\u00a0 In human plasma, trastuzumab\nemtansine catabolites MCC-DM1, Lys-MCC-DM1, and DM1 were detected at low levels.<i>\u00a0\nIn vitro,</i> DM1 was a substrate of P-glycoprotein (P-gp).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Elimination</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Based on population\npharmacokinetic (PK) analysis, following intravenous administration of\ntrastuzumab emtansine in patients with HER2\u2011positive metastatic breast\ncancer, the clearance of trastuzumab emtansine was 0.68\u00a0L/day and the\nelimination half\u2011life\u00a0(t<sub>1/2</sub>) was\napproximately\u00a04\u00a0days. No accumulation of trastuzumab emtansine was\nobserved after repeated dosing of intravenous infusion every\u00a03\u00a0weeks.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Based on population PK analysis, body weight, albumin, sum\nof longest diameter of target lesions by Response Evaluation Criteria In Solid\nTumors<i> </i>(RECIST), HER2 shed extracellular domain (ECD), baseline\ntrastuzumab concentrations, and aspartate aminotransferase\u00a0(AST) were\nidentified as statistically significant covariates for trastuzumab emtansine PK\nparameters. However, the magnitude of effect of these covariates on trastuzumab\nemtansine exposure suggests that these covariates are unlikely to have any\nclinically meaningful effect on trastuzumab emtansine exposure. In addition,\nexploratory analysis showed that the impact of covariates (i.e., renal function,\nrace and age) on the pharmacokinetics of total trastuzumab and DM1 was limited\nand was not clinically relevant. In nonclinical studies, trastuzumab emtansine\ncatabolites including DM1, Lys\u2011MCC\u2011DM1, and MCC\u2011DM1 are\nmainly excreted in the bile with minimal elimination in urine.</p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\"><u>Linearity/non-linearity</u></p>\n<p class=\"MsoNormal\">Trastuzumab emtansine when administered intravenously every\n3\u00a0weeks exhibited linear PK across doses ranging from 2.4 to\n4.8\u00a0mg/kg; patients who received doses less than or equal to\n1.2\u00a0mg/kg had faster clearance.</p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\"><u>Elderly patients\u00a0 </u></p>\n<p class=\"MsoNormal\">The population PK analysis showed that age did not affect\nthe PK of trastuzumab emtansine. No significant difference was observed in the\nPK of trastuzumab emtansine among patients &lt;\u00a065 years\n(n\u00a0=\u00a0577), patients between 65\u201175 years (n\u00a0=\u00a078) and\npatients &gt;\u00a075\u00a0years (n\u00a0=\u00a016).</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Renal impairment </u></p>\n<p class=\"MsoNormal\">No formal PK study has been conducted in patients with renal\nimpairment. The population PK analysis showed that creatinine clearance does\nnot affect the PK of trastuzumab emtansine. Pharmacokinetics of trastuzumab\nemtansine in patients with mild (creatinine clearance CLcr\u00a060 to\n89\u00a0mL/min,\u00a0n\u00a0=\u00a0254) or moderate (CLcr\u00a030 to\n59\u00a0mL/min,\u00a0n\u00a0=\u00a053) renal impairment were similar to those\nin patients with normal renal function (CLcr\u00a0<span style=\"font-family:\nSymbol\">\u00b3</span>\u00a090\u00a0mL/min,\u00a0n\u00a0=\u00a0361).\nPharmacokinetic data in patients with severe renal impairment (CLcr\u00a015 to\n29\u00a0mL/min) are limited (n\u00a0=\u00a01), therefore no dosage\nrecommendations can be made.</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u>Hepatic\nimpairment </u></p>\n<p class=\"MsoNormal\">The liver is a primary organ for eliminating DM1 and\nDM1-containing catabolites. The pharmacokinetics of trastuzumab emtansine and\nDM1-containing catabolites were evaluated after the administration of 3.6 mg/kg\nof trastuzumab emtansine to metastatic HER2+ breast cancer patients with normal\nhepatic function (n=10), mild (Child-Pugh A; n=10) and moderate (Child-Pugh B;\nn=8) hepatic impairment. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">- Plasma concentrations of DM1 and DM1-containing\ncatabolites (Lys-MCC-DM1 and MCC-DM1) were low and comparable between patients\nwith and without hepatic impairment.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">- Systemic exposures (AUC) of trastuzumab emtansine at Cycle\n1 in patients with mild and moderate hepatic impairment were approximately 38%\nand 67% lower than that of patients with normal hepatic function, respectively.\nTrastuzumab emtansine exposure (AUC) at Cycle 3 after repeated dosing in\npatients with mild or moderate hepatic dysfunction was within the range\nobserved in patients with normal hepatic function.\u00a0 </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">No formal pharmacokinetic study has been conducted and no\npopulation PK data was collected in patients with severe hepatic impairment\n(Child-Pugh class C).</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Other special populations</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The population PK analysis\nshowed that race did not appear to influence the PK of trastuzumab emtansine.\nBecause most of the patients in trastuzumab emtansine clinical studies were\nfemales, the effect of gender on the PK of trastuzumab emtansine was not\nformally evaluated.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.3\u00a0\u00a0\u00a0\u00a0 Preclinical\nsafety data</b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u>Animal\ntoxicology and/or pharmacology</u></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">Administration of trastuzumab emtansine was well tolerated\nin rats and monkeys at doses up to 20 and 10\u00a0mg/kg, respectively,\ncorresponding to 2040\u00a0<span style=\"font-family:Symbol\">m</span>g DM1/m<sup>2</sup>\nin both species, which\u00a0is approximately equivalent to the clinical dose of\ntrastuzumab emtansine in patients.\u00a0 In the GLP toxicity studies, with the\nexception of irreversible peripheral axonal toxicity (observed only in monkeys\nat <span style=\"font-family:Symbol\">\u00b3</span>\u00a010 mg/kg) and\nreproductive organ toxicity (observed only in rats at 60\u00a0mg/kg), partially\nor completely reversible dose dependent toxicities were identified in both\nanimal models. Principal toxicities included liver (liver enzyme elevations) at\n<span style=\"font-family:Symbol\">\u00b3</span>\u00a020 mg/kg and <span style=\"font-family:Symbol\">\u00b3</span>\u00a010 mg/kg, bone marrow (reduced\nplatelet and white blood cell count)/hematologic at <span style=\"font-family:\nSymbol\">\u00b3</span>\u00a020 mg/kg and <span style=\"font-family:Symbol\">\u00b3</span>\u00a010\nmg/kg, and lymphoid organs at <span style=\"font-family:Symbol\">\u00b3</span>\u00a020\nmg/kg and\u00a0<span style=\"font-family:Symbol\">\u00b3</span>\u00a03\u00a0mg/kg,\u00a0\nin rat and monkey, respectively.</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u>Mutagenicity</u></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">DM1 was aneugenic or clastogenic in an <i>in vivo</i>\nsingle-dose rat bone marrow micronucleus assay at exposures that were\ncomparable to mean maximum concentrations of DM1 measured in humans\nadministered trastuzumab emtansine. DM1 was not mutagenic in an <i>in vitro</i>\nbacterial reverse mutation (Ames) assay.\u00a0 </p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Impairment of fertility and teratogenicity</u></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">No fertility studies in animals have been performed to\nevaluate the effect of trastuzumab emtansine. However, based on results from\ngeneral animal toxicity studies, adverse effects on fertility can be expected.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Dedicated embryo\u2011foetal development studies have not\nbeen conducted in animals with trastuzumab emtansine. Developmental toxicity of\ntrastuzumab has been identified in the clinical setting although it was not\npredicted in the non\u2011clinical program. In addition, developmental\ntoxicity of maytansine has been identified in non\u2011clinical studies which\nsuggests that DM1, the microtubule\u2011inhibiting cytotoxic maytansinoid\ncomponent of trastuzumab emtansine, will be similarly teratogenic and\npotentially embryotoxic.</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.1\u00a0\u00a0\u00a0\u00a0 List\nof excipients</b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">Succinic\nacid</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">Sodium\nhydroxide</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">Sucrose</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">Polysorbate\u00a020</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</b></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\">This medicinal product must not be mixed or diluted with\nother medicinal products except those mentioned in section\u00a06.6.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Glucose\u00a0(5%) solution should not be used for\nreconstitution or dilution since it causes aggregation of the protein.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Unopened vial</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">3\u00a0years.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Reconstituted solution</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>\u00a0</u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Chemical and physical in\u2011use\nstability of the reconstituted solution has been demonstrated for up to\n24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C. From a microbiological point of\nview, the product should be used immediately. If not used immediately, the\nreconstituted vials can be stored for up to 24\u00a0hours at\n2\u00b0C\u00a0to\u00a08\u00b0C, provided it was reconstituted under controlled\nand validated aseptic conditions, and must be discarded thereafter.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><u>Diluted solution </u></p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\">The reconstituted Kadcyla solution diluted in infusion bags\ncontaining sodium chloride 9\u00a0mg/mL (0.9%) solution for infusion, or sodium\nchloride 4.5\u00a0mg/mL (0.45%) solution for infusion, is stable for up to\n24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C, provided it was prepared under\ncontrolled and validated aseptic conditions. Particulates may be observed on\nstorage if diluted in 0.9% sodium chloride (see\u00a0section\u00a06.6).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.4\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for storage</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Store in a refrigerator (2<span style=\"font-family:Symbol\">\u00b0</span>C\u00a0\u2013\u00a08<span style=\"font-family:Symbol\">\u00b0</span>C).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">For storage conditions after reconstitution and dilution of\nthe medicinal product, see section\u00a06.3.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.5\u00a0\u00a0\u00a0\u00a0 Nature\nand contents of container </b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><u>Kadcyla 100 mg powder for concentrate for solution for\ninfusion</u></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Kadcyla is provided in 15\u00a0mL (100 mg) Type 1 glass vial\nclosed with a grey-butyl rubber stopper coated with fluoro\u2011resin laminate,\nand sealed with an aluminium seal with a white plastic flip-off cap. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Pack of 1\u00a0vial.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><u>Kadcyla 160 mg powder for concentrate for solution for\ninfusion</u></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Kadcyla is provided in 20 mL (160 mg) Type 1 glass vial\nclosed with a grey-butyl rubber stopper coated with fluoro resin laminate, and\nsealed with an aluminium seal with a purple plastic flip-off cap.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Pack of 1 vial.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.6\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for disposal and other handling</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\">Appropriate aseptic technique should be used. Appropriate\nprocedures for the preparation of chemotherapeutic medicinal products should be\nused.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The reconstituted Kadcyla solution should be diluted in\npolyvinyl chloride (PVC) or latex\u2011free PVC\u2011free polyolefin infusion\nbags.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The use of 0.20 or 0.22 micron in-line polyethersulfone\n(PES) filter is required for the infusion when the concentrate for infusion is\ndiluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. </p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\">In order to prevent medicinal product errors it is important\nto check the vial labels to ensure that the medicinal product being prepared is\nKadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Instructions for reconstitution</u></p>\n<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-align:justify;text-justify:\ninter-ideograph;text-indent:-17.85pt;page-break-after:avoid\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 100 mg trastuzumab\nemtansine vial: Using a sterile syringe, slowly inject 5\u00a0mL of sterile\nwater for injection into the vial. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-align:justify;text-justify:\ninter-ideograph;text-indent:-17.85pt;page-break-after:avoid\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 160 mg trastuzumab\nemtansine vial: Using a sterile syringe, slowly inject 8\u00a0mL of sterile\nwater for injection into the vial. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-align:justify;text-justify:\ninter-ideograph;text-indent:-17.85pt;page-break-after:avoid\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Swirl the vial\ngently until completely dissolved. Do not shake. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Reconstituted solution should be inspected visually for\nparticulate matter and discolouration prior to administration. The\nreconstituted solution should be free of visible particulates, clear to\nslightly opalescent. The colour of the reconstituted solution should be\ncolourless to pale brown. Do not use if the reconstituted solution contains\nvisible particulates, or is cloudy or discoloured.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><u>Instructions for dilution</u></p>\n<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">Determine the volume of the reconstituted solution required\nbased on a dose of 3.6\u00a0mg trastuzumab emtansine/kg body weight (see\nsection\u00a04.2):</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Volume</b>\n(mL)\u00a0=\u00a0<i><u>Total dose to be administered</u></i><u> (<b>body weight</b>\n(kg) x <b>dose</b> (mg/kg))</u> </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n<b>20</b> (mg/mL, concentration of reconstituted solution)</p>\n<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\">The appropriate amount of solution should be withdrawn from\nthe vial and added to an infusion bag containing 250\u00a0mL of sodium chloride\n4.5 mg/mL (0.45%) solution for infusion or sodium chloride 9\u00a0mg/mL (0.9%)\nsolution for infusion. Glucose\u00a0(5%) solution should not be used (see\nsection\u00a06.2). Sodium chloride 4.5 mg/mL (0.45%) solution for infusion may\nbe used without a polyethersulfone (PES) 0.20 or 0.22\u2011\u03bcm in\u2011line\nfilter. If sodium chloride 9 mg/mL (0.9%) solution for infusion is used for\ninfusion, a 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is\nrequired. Once the infusion is prepared it should be administered immediately.\nDo not freeze or shake the infusion during storage. </p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\"><u>Disposal</u></p>\n<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\">The reconstituted product contains no preservative and is\nintended for single use only. Discard any unused portion.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Any unused medicinal product or waste material should be\ndisposed of in accordance with local requirements.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Roche Registration GmbH </p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">79639 Grenzach-Wyhlen</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Germany</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span style=\"color:black\">EU/1/13/885/001</span></p>\n<p class=\"MsoNormal\"><span style=\"color:black\">EU/1/13/885/002</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\">Date of first authorisation: 15 November 2013</p>\n<p class=\"MsoNormal\">Date of latest renewal: 17 September 2018</p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\"><i>\u00a0</i></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>10.\u00a0\u00a0\u00a0\u00a0 DATE\nOF REVISION OF THE TEXT</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\">Detailed information on this\nmedicinal product is available on the website of the European Medicines Agency <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a><span style=\"color:blue\">.</span></p>\n<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:13.0pt\"><b>ANNEX\nII</b></p>\n<p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:\n13.0pt\"><b>A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE\nBIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\n13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt\"><b>B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS REGARDING SUPPLY AND USE</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\n13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:77.95pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt\"><b>C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS\nOF THE MARKETING AUTHORISATION</b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:77.95pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:77.95pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt\"><b>D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </b><b>CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT\u00a0\n</b></p>\n<p class=\"MsoNormal\" style=\"margin-right:77.9pt;line-height:13.0pt\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:13.0pt\"><b>\u00a0</b></p>\n<b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"AnnexHeading\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE\nBIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</p>\n<p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><u>Name and address of the\nmanufacturer of the biological active substance</u></p>\n<p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">Lonza Ltd.<br/>\nLonzastrasse<br/>\nCH-3930 Visp<br/>\nSwitzerland</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><u>Name and address of the\nmanufacturer responsible for batch release</u></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"DE\">Roche Pharma AG<br/>\nEmil-Barell-Strasse 1<br/>\nD-79639 Grenzach-Whylen<br/>\nGermany</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"DE\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">The printed package leaflet of\nthe medicinal product must state the name and address of the manufacturer\nresponsible for the release of the concerned batch.</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"AnnexHeading\"><a name=\"OLE_LINK2\">B.</a>\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE </p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">Medicinal product subject to\nrestricted medical prescription (see Annex I: Summary of Product\nCharacteristics, section 4.2).</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><b>\u00a0</b></p>\n<p class=\"AnnexHeading\">C. \u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING AUTHORISATION</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b>Periodic\nSafety Update Reports</b></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\">The\nrequirements for submission of periodic safety update reports for this\nmedicinal product are set out in the list of Union reference dates (EURD list)\nprovided for under Article 107c(7) of Directive 2001/83/EC and any subsequent\nupdates published on the European medicines web-portal.</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"AnnexHeading\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT\u00a0 </p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b>Risk\nManagement Plan (RMP)</b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.0pt\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\">The MAH\nshall perform the required pharmacovigilance activities and interventions\ndetailed in the agreed RMP presented in Module 1.8.2 of the Marketing\nAuthorisation and any agreed subsequent updates of the RMP.</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid\">An updated RMP should be submitted:</p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt;line-height:\n13.0pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0 At the\nrequest of the European Medicines Agency;</p>\n<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt;line-height:\n13.0pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0 Whenever\nthe risk management system is modified, especially as the result of new information\nbeing received that may lead to a significant change to the benefit/risk\nprofile or as the result of an important (pharmacovigilance or risk\nminimisation) milestone being reached.</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt;\npage-break-after:avoid\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b>Additional\nrisk minimisation measures </b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid\">\u00a0</p>\n<p class=\"MsoNormal\">The MAH shall agree the content and format of the Kadcyla (trastuzumab\nemtansine) educational material and a communication plan with the National\nCompetent Authority in the Member State before Kadcyla (trastuzumab emtansine)\nis launched in each Member State.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The MAH shall ensure that in parallel to the launch of Kadcyla\n(trastuzumab emtansine), all health care professionals who may prescribe,\ndispense or administer Kadcyla (trastuzumab emtansine) and/or Herceptin (trastuzumab)\nare provided with a health care professional (HCP) educational pack.\u00a0 This\nHCP educational pack shall consist of the following:</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:38.25pt;text-indent:-17.85pt;line-height:\n115%\"><span lang=\"ES\" style=\"line-height:115%;font-family:Symbol\">\u00b7</span><span style=\"line-height:115%\">\u00a0\u00a0\u00a0 </span><span style=\"line-height:\n115%\">Kadcyla (trastuzumab emtansine) SPC</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:38.25pt;text-indent:-17.85pt;line-height:\n115%\"><span lang=\"ES\" style=\"line-height:115%;font-family:Symbol\">\u00b7</span><span style=\"line-height:115%\">\u00a0\u00a0\u00a0 </span><span style=\"line-height:\n115%\">Health care professional information </span></p>\n<p class=\"MsoNormal\">The HCP information shall contain the following key\nmessages:</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">1.\u00a0\u00a0 Kadcyla (</span><span style=\"line-height:115%\">trastuzumab emtansine)</span><span style=\"line-height:\n115%\"> and Herceptin (trastuzumab) are two very different products with\ndifferent active substances never to be used interchangeably.\u00a0 </span><span style=\"line-height:115%\">Kadcyla (trastuzumab emtansine)</span><span style=\"line-height:115%\"> is NOT a generic version of Herceptin (trastuzumab) and\nhas different properties, indications and dose.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">2.\u00a0\u00a0 Trastuzumab emtansine is an\nantibody-drug conjugate containing humanized anti-HER2 IgG1 antibody\ntrastuzumab and DM1, a microtubule-inhibitory maytansinoid. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">3.\u00a0\u00a0 Do not substitute or\ncombine trastuzumab emtansine with or for trastuzumab</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">4.\u00a0\u00a0 Do not administer trastuzumab\nemtansine in combination with chemotherapy</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">5.\u00a0\u00a0 Do not administer </span><span style=\"line-height:115%\">trastuzumab emtansine</span><span style=\"line-height:\n115%\"> at doses greater than 3.6 mg/kg once every 3 weeks</span><span style=\"line-height:115%\"> </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">6.\u00a0\u00a0 If a prescription for\nKadcyla (trastuzumab emtansine) is written electronically, it is important to\nensure that the medicinal product prescribed is trastuzumab emtansine and not\ntrastuzumab. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">7.\u00a0\u00a0 Both the invented name\nKadcyla<b> </b>and its full non-proprietary name (trastuzumab emtansine) should\nbe used and confirmed when prescribing, preparing the infusion solution and administering\nKadcyla (trastuzumab emtansine) to patients. It must be verified that the\nnon-proprietary name is trastuzumab emtansine.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">8.\u00a0\u00a0 In order to prevent medicinal\nproduct errors it is important to review the Summary of Product Characteristics\nand to check the outer carton and vial labels to ensure that the medicinal\nproduct being prepared and administered is Kadcyla (trastuzumab emtansine) and\nnot trastuzumab. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">9.\u00a0\u00a0 Description of the key\ndifferences between trastuzumab emtansine and trastuzumab in relation to\nindication, dose, administration and packaging differences. </span></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>Obligation to conduct\npost-authorisation measures</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">The MAH shall complete, within\nthe stated timeframe, the below measures:</p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:339.95pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"453\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Description</p>\n</td>\n<td style=\"width:113.15pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Due date</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:339.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"453\">\n<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PAES:\n  In order to further investigate the efficacy of trastuzumab emtansine in the\n  adjuvant treatment of adult patients with HER2-positive early breast cancer\n  who have residual invasive disease, in the breast and/or lymph nodes, after\n  neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the\n  final analysis of OS from the phase 3, randomised, open-label study KATHERINE\n  (BO27938).</span></p>\n</td>\n<td style=\"width:113.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\">\n<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30\n  June 2024</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\">\u00a0</p>\n<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>ANNEX III</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>LABELLING AND\nPACKAGE LEAFLET</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"Annex\">A. LABELLING</p>\n<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>CARTON </b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Kadcyla 100\u00a0mg powder for concentrate for solution for\ninfusion </p>\n<p class=\"MsoNormal\">trastuzumab emtansine</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">One vial of powder for concentrate for solution for infusion\ncontains 100 mg of trastuzumab emtansine. After reconstitution one vial of 5 mL\nsolution contains 20 mg/mL of trastuzumab emtansine.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Excipients:</p>\n<p class=\"MsoNormal\">Succinic acid, sodium hydroxide, sucrose, polysorbate\u00a020.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Powder for concentrate for solution for infusion</p>\n<p class=\"MsoNormal\">1 vial of 100\u00a0mg</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\">For intravenous use after reconstitution and dilution</p>\n<p class=\"MsoNormal\">Read the package leaflet before use</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Keep out of the sight and reach of children</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Cytotoxic</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">To be administered under the supervision of a physician\nexperienced in the use of cytotoxic agents.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">EXP</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Store in a refrigerator\n(2\u00baC \u2013 8\u00baC)</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">79639 Grenzach-Wyhlen</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Germany</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span style=\"color:black\">EU/1/13/885/001</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Batch</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Medicinal product subject to medical prescription</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b>16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span style=\"background:lightgrey\">Justification for not\nincluding Braille accepted</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>17.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span style=\"background:lightgrey\">&lt;2D barcode carrying\nthe unique identifier included.&gt;</span></p>\n<p class=\"MsoNormal\"><span style=\"background:#CCCCCC\">\u00a0</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>18.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">PC: </p>\n<p class=\"MsoNormal\">SN: </p>\n<p class=\"MsoNormal\">NN: </p>\n<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>MINIMUM PARTICULARS TO\nAPPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>VIAL LABEL</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>\n<p class=\"MsoNormal\">Kadcyla 100\u00a0mg powder for concentrate for solution for\ninfusion</p>\n<p class=\"MsoNormal\">trastuzumab emtansine</p>\n<p class=\"MsoNormal\">Intravenous use</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">For intravenous use after reconstitution and dilution</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">EXP</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">Lot</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">100\u00a0mg</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</b></p>\n</div>\n<p class=\"MsoNormal\" style=\"background:white\"><b>\u00a0</b></p>\n<b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>CARTON </b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Kadcyla 160\u00a0mg powder for concentrate for solution for\ninfusion </p>\n<p class=\"MsoNormal\">trastuzumab emtansine</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">One vial of powder for concentrate for solution for infusion\ncontains 160 mg of trastuzumab emtansine. After reconstitution one vial of 8 mL\nsolution contains 20 mg/mL of trastuzumab emtansine.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Excipients:</p>\n<p class=\"MsoNormal\">Succinic acid, sodium hydroxide, sucrose, polysorbate 20.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Powder for concentrate for solution for infusion</p>\n<p class=\"MsoNormal\">1 vial of 160\u00a0mg</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\">For intravenous use after reconstitution and dilution</p>\n<p class=\"MsoNormal\">Read the package leaflet before use</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Keep out of the sight and reach of children</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Cytotoxic</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">To be administered under the supervision of a physician\nexperienced in the use of cytotoxic agents.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">EXP</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Store in a refrigerator (2\u00baC \u2013 8\u00baC)</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">79639 Grenzach-Wyhlen</span></p>\n<p class=\"MsoNormal\">Germany</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span style=\"color:black\">EU/1/13/885/002</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Batch</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Medicinal product subject to medical prescription</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b>16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span style=\"background:lightgrey\">Justification for not\nincluding Braille accepted</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>17.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><span style=\"background:lightgrey\">&lt;2D barcode carrying\nthe unique identifier included.&gt;</span></p>\n<p class=\"MsoNormal\"><span style=\"background:#CCCCCC\">\u00a0</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>18.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">PC: </p>\n<p class=\"MsoNormal\">SN: </p>\n<p class=\"MsoNormal\">NN: </p>\n<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>MINIMUM PARTICULARS TO\nAPPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>VIAL LABEL</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>\n<p class=\"MsoNormal\">Kadcyla 160\u00a0mg powder for concentrate for solution for\ninfusion</p>\n<p class=\"MsoNormal\">trastuzumab emtansine</p>\n<p class=\"MsoNormal\">Intravenous use</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">For intravenous use after reconstitution and dilution</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">EXP</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">Lot</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</b></p>\n</div>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">160\u00a0mg</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</b></p>\n</div>\n<p class=\"MsoNormal\">\u00a0</p>\n<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"Annex\">B. PACKAGE LEAFLET</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Package leaflet:\nInformation for the user</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Kadcyla100\u00a0mg\npowder for concentrate for solution for infusion</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Kadcyla\n160\u00a0mg powder for concentrate for solution for infusion</b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">trastuzumab emtansine</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>Read all of this leaflet carefully before you start being\ngiven this medicine because it contains important information for you.</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Keep this\nleaflet. You may need to read it again.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you\nhave any further questions, ask your doctor, pharmacist or nurse.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you get\nany side effects, talk to your doctor, pharmacist or nurse. This includes any\npossible side effects not listed in this leaflet. See section 4.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>What is in this leaflet</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">1.\u00a0\u00a0 What\nKadcyla is and what it is used for</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">2.\u00a0\u00a0 What\nyou need to know before you are given Kadcyla</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">3.\u00a0\u00a0 How\nyou are given Kadcyla </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">4.\u00a0\u00a0 Possible\nside effects</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">5.\u00a0\u00a0 How\nto store Kadcyla</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">6.\u00a0\u00a0 Contents\nof the pack and other information</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Kadcyla is\nand what it is used for</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>What Kadcyla is</b></p>\n<p class=\"MsoNormal\">Kadcyla contains the active substance trastuzumab emtansine,\nwhich is made up of two parts that are linked together:</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 trastuzumab\n- a monoclonal antibody that binds selectively to an antigen (a target protein)\ncalled human epidermal growth factor receptor 2 (HER2). HER2 is found in large\namounts on the surface of some cancer cells where it stimulates their growth.\nWhen trastuzumab binds to HER2 it can stop the cancer cells growth and cause\nthem to die.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 DM1\n\u2013 an anti-cancer substance that becomes active once Kadcyla enters the\ncancer cell. </p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\"><b>What Kadcyla is used for</b></p>\n<p class=\"MsoNormal\">Kadcyla is used to treat breast cancer in adults when:</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 the cancer\ncells have many HER2 proteins on them - your doctor will test your cancer cells\nfor this. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 you have\nalready received the medicine trastuzumab and a medicine known as a taxane.</p>\n<p class=\"MsoListParagraph\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>the cancer has spread to areas near the breast or to other parts\nof your body (metastasized)</p>\n<p class=\"MsoListParagraph\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>the cancer has not spread to other parts of the body and\ntreatment is going to be given after surgery (treatment after surgery is called\nadjuvant therapy).</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to\nknow before you are given Kadcyla</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>You must not be given Kadcyla</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 if you are\nallergic to trastuzumab emtansine or any of the other ingredients of this\nmedicine (listed in section 6). </p>\n<p class=\"MsoNormal\">You should not be given Kadcyla if the above applies to you.\nIf you are not sure, talk to your doctor or nurse before you are given Kadcyla.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Warnings and precautions</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Talk to your doctor or nurse\nbefore you are given Kadcyla if:</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 you have\never had a serious infusion-related reaction from using trastuzumab characterised\nby symptoms such as flushing, chills, fever, shortness of breath, difficulty\nbreathing, rapid heartbeat or a drop in blood pressure.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 you are\nreceiving treatment with blood thinning medicines (e.g. warfarin, heparin).</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 you have\nany history of liver problems. Your doctor will check your blood to test your\nliver function before and regularly during treatment</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">If any of the above apply to you (or you are not sure), talk\nto your doctor or pharmacist before you are given Kadcyla.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>Look out for side effects</b></p>\n<p class=\"MsoNormal\">Kadcyla can make some existing conditions worse, or cause\nside effects. See section\u00a04 for more details about what side effects to\nlook out for.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>Tell your doctor or nurse straight away if you notice any\nof the following serious side effects while you are given Kadcyla:</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Breathing\nproblems:</b> Kadcyla can cause serious breathing problems such as shortness of\nbreath (either at rest or while performing any type of activity) and\ncough.\u00a0 These may be signs of inflammation of your lung, which may be\nserious, and even fatal. If you develop lung disease your doctor may stop\ntreatment with this medicine.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Liver\nproblems: </b>Kadcyla can cause inflammation or damage to cells in the liver that\ncan stop the liver from functioning normally. Inflamed or injured liver cells\nmay leak higher than normal amounts of certain substances (liver enzymes) into\nthe bloodstream, resulting in elevated liver enzymes in blood tests. In most\ncases you will not have any symptoms. Some symptoms could be yellowing of your\nskin and whites of your eyes (jaundice). Your doctor will check your blood to\ntest your liver function before and regularly during treatment.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">Another rare abnormality that can\noccur in the liver is a condition known as nodular regenerative hyperplasia\n(NRH). This abnormality causes the structure of the liver to change and can\nchange how the liver functions. Over time, this may lead to symptoms such as a\nbloated sensation or swelling of the abdomen due to fluid accumulation or\nbleeding from abnormal blood vessels in the gullet or rectum.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Heart\nproblems: </b>Kadcyla can weaken the heart muscle. When the heart muscle is\nweak, patients may develop symptoms such as shortness of breath at rest or when\nsleeping, chest pain, swollen legs or arms, and a sensation of rapid or\nirregular heartbeats. Your doctor will check your heart function before and\nregularly during treatment. You should tell your doctor immediately if you\nnotice any of the above symptoms.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Infusion-related\nreactions or allergic reactions</b>: Kadcyla can cause flushing, shivering\nfits, fever, trouble breathing, low blood pressure, rapid heartbeat, sudden\nswelling of your face, tongue, or trouble swallowing during the infusion or\nafter the infusion on the first day of treatment. Your doctor or nurse will\ncheck to see whether you are having any of these side effects. If you develop a\nreaction, they will slow down or stop the infusion and may give you treatment\nto counteract the side effects. The infusion may be continued after the\nsymptoms improve.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Bleeding\nproblems:</b> Kadcyla can lower the number of platelets in your blood.\nPlatelets help your blood to clot so you might get unexpected bruising or\nbleeding (such as nose bleeds, bleeding from gums). Your doctor will check your\nblood regularly for decreased platelets. You should tell your doctor\nimmediately if you notice any unexpected bruising or bleeding.</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Neurological\nproblems:</b> Kadcyla can damage nerves. You may experience tingling, pain,\nnumbness, itching, crawling sensation, pins and needles in your hands and feet.\nYour doctor will monitor you for signs and symptoms of neurological problems.<i>\n</i></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">Tell your\ndoctor or nurse straight away if you notice any of the side effects above.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Children and adolescents</b></p>\n<p class=\"MsoNormal\">Kadcyla is not recommended for anyone under the age of\n18\u00a0years. This is because there is no information on how well it works in\nthis age group.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>Other medicines and Kadcyla</b></p>\n<p class=\"MsoNormal\">Tell your doctor or nurse if you are taking, have recently\ntaken or might take any other medicines. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In particular, tell your doctor or pharmacist if you are\ntaking:</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 any\nmedicines to thin your blood such as warfarin or decrease the ability to form\nblood clot such as aspirin</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 medicines\nfor fungal infections called ketoconazole, itraconazole or voriconazole</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 antibiotics\nfor infections called clarithromycin or telithromycin</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 medicines\nfor HIV called atazanavir, indinavir, nelfinavir, ritonavir or saquinavir.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 medicine\nfor depression called nefazodone</p>\n<p class=\"MsoNormal\">If any of the above apply to you (or you are not sure), talk\nto your doctor or pharmacist before you are given Kadcyla.\u00a0 </p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>Pregnancy</b></p>\n<p class=\"MsoNormal\">Kadcyla is not recommended if you are pregnant because this medicine\nmay cause harm to the unborn baby. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Tell your\ndoctor before using Kadcyla if you are pregnant, think you may be pregnant or\nare planning to have a baby.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Use\neffective contraception to avoid becoming pregnant while you are being treated\nwith Kadcyla. Talk to your doctor about the best contraception for you.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 You should\ncontinue to take your contraception for at least 7 months after your last dose\nof Kadcyla. Talk to your doctor before stopping your contraception. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Male\npatients or their female partners should also use effective contraception. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you do\nbecome pregnant during treatment with Kadcyla, tell your doctor straight away.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>Breast-feeding</b></p>\n<p class=\"MsoNormal\">You should not breast-feed during treatment with Kadcyla.\nAlso you should not breast-feed for\u00a07 months after your last infusion of\nKadcyla. It is not known whether the ingredients in Kadcyla pass into\nbreast-milk. Talk to your doctor about this.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>Driving and using machines</b></p>\n<p class=\"MsoNormal\">It is not expected that Kadcyla will affect your ability to\ndrive, cycle, use tools or machines. If you experience flushing, shivering\nfits, fever, trouble breathing, low blood pressure or a rapid heartbeat\n(infusion-related reaction), blurred vision, tiredness, headache, or dizziness,\ndo not drive, cycle, use tools or machines until these reactions stop.</p>\n<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\"><b>Important information about some of the ingredients of\nKadcyla</b></p>\n<p class=\"MsoNormal\">This medicine contains less than 1 mmol sodium (23 mg) per\ndose. It is essentially \u2018sodium- free\u2019.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How you are given\nKadcyla</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\">Kadcyla\nwill be given to you by a doctor or nurse in a hospital or clinic:</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 It is\ngiven by a drip into a vein (intravenous infusion).</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 You will\nbe given one infusion every\u00a03\u00a0weeks.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>How much you will be given</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 You will\nbe given 3.6\u00a0mg of Kadcyla for every kilogram of your body weight. Your\ndoctor will calculate the correct dose for you.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The first\ninfusion will be given to you over 90\u00a0minutes. You will be observed by a\ndoctor or nurse while it is being given and for at least 90\u00a0minutes\nfollowing the initial dose, in case you have any side effects. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If the\nfirst infusion is well tolerated, the infusion on your next visit may be given\nover 30\u00a0minutes. You will be observed by a doctor or nurse while it is\nbeing given and for at least 30\u00a0minutes following the dose, in case you\nhave any side effects.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The total\nnumber of infusions that you will be given depends on how you respond to the\ntreatment and which indication is treated.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you\nexperience side effects, your doctor may decide to continue your treatment but\nlower your dose, delay the next dose or stop the treatment.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>If you miss a Kadcyla treatment</b></p>\n<p class=\"MsoNormal\">If you forget or miss your Kadcyla appointment, make another\nappointment as soon as possible. Do not wait until your next planned visit. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>If you stop Kadcyla treatment</b></p>\n<p class=\"MsoNormal\">Do not stop treatment with this medicine without talking to\nyour doctor first.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">If you have any further questions on the use of this\nmedicine, ask your doctor or nurse. </p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Like all medicines, this medicine can cause side effects,\nalthough not everybody gets them.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>Tell your doctor or nurse straight away if you notice any\nof following serious side effects.</b></p>\n<p class=\"MsoNormal\" style=\"margin-top:6.0pt\"><b>Very common (may affect more\nthan 1 in 10 people):</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Kadcyla\nmay cause inflammation or damage to cells in the liver, resulting in elevated\nliver enzymes in blood tests. However, in most cases during Kadcyla treatment,\nliver enzyme levels are elevated mildly and temporarily, do not cause any\nsymptoms, and do not affect liver function.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Unexpected\nbruising and bleeding (such as nose bleeds).</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Tingling,\npain, numbness, itching, crawling sensation, pins and needles in your hands and\nfeet. These symptoms may indicate nerve damage.</p>\n<p class=\"MsoNormal\" style=\"margin-top:6.0pt\"><b>Common (may affect up to 1 in 10\npeople):</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Flushing,\nshivering fits, fever, trouble breathing, low blood pressure or a rapid\nheartbeat during the infusion or up to 24 hours after the infusion \u2013\nthese are so-called infusion-related reactions. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Heart\nproblems can occur. Most patients will not have symptoms from the heart\nproblems. If symptoms do occur, cough shortness of breath at rest or when\nsleeping flat, chest pain and swollen ankles or arms, a sensation of rapid or\nirregular heartbeats may be observed. </p>\n<p class=\"MsoNormal\" style=\"margin-top:6.0pt\"><b>Uncommon (may affect up to 1 in\n100 people):</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Inflammation\nof your lungs can cause breathing problems such as shortness of breath (either\nat rest or while performing any type of activity), coughing or coughing spells\nwith a dry cough \u2013 these are signs of inflammation of your lung tissue.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Your skin\nand whites of your eyes get yellow (jaundice) \u2013 these could be signs of\nsevere liver damage.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Allergic\nreactions can occur and most patients will have mild symptoms such as itching\nor tightness in the chest. In more severe cases, swelling of your face or\ntongue, trouble swallowing or difficulty breathing may occur. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Tell your doctor or nurse straight away if you notice any of\nthe serious side effects above.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Other side effects include</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>Very common:</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 decreased\nred blood cells (shown in a blood test)</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 being sick\n(vomiting)</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 diarrhoea </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 dry mouth</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 urinary\ntract infection</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 constipation</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 stomach\nache</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 cough</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 shortness\nof breath</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 inflammation\nof the mouth</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 difficulty\nsleeping</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 muscle or joint\npain</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 fever</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 headache</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 feeling\ntired</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 weakness</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>Common</b><b>:</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 chills or\nflu like symptoms </p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>decrease in your potassium levels (shown in a blood test)</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>skin rashes</p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>decreased white blood cells (shown in a blood test)</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 dry eyes,\nwatery eyes or blurred vision</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 eye\nredness or infection</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 indigestion</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 swelling\nof legs and/or arms</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 bleeding\nfrom the gums</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 increase\nin blood pressure </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 feeling\ndizzy</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 taste\ndisturbances</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 itching</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 difficulty\nin remembering</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 hair loss</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 hand-and-foot\nskin reaction (Palmar-plantar erythrodysaesthesia syndrome)</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 nail\ndisorder</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Uncommon:</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Another\nabnormality that can be caused by Kadcyla is a condition known as nodular\nregenerative hyperplasia of the liver. This abnormality causes the structure of\nthe liver to change. Patients develop multiple nodules in the liver that can\nchange how the liver functions. Over time, this may lead to symptoms such as a\nbloated sensation or swelling of the abdomen due to fluid accumulation or\nbleeding from abnormal blood vessels in the gullet or rectum.</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If\nthe Kadcyla infusion solution leaks into the area around the infusion site you\nmay develop tenderness or redness of your skin, or swelling at the infusion\nsite. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">If you get any of the side effects after your treatment with\nKadcyla has stopped, talk to your doctor or nurse and tell them that you have\nbeen treated with Kadcyla.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>Reporting of side effects</b></p>\n<p class=\"MsoNormal\">If you get any side effects, talk to your doctor or nurse.\nThis includes any possible side effects not listed in this leaflet. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">You can also report side effects directly via <span style=\"background:lightgrey\">the national reporting system listed in </span><a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span style=\"background:lightgrey\">Appendix V</span></a><span style=\"color:#3366FF\">.</span>\nBy reporting side effects you can help provide more information on the safety\nof this medicine.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Kadcyla</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Kadcyla will be stored by the\nhealth professionals at the hospital or clinic.</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep\nthis medicine out of the sight and reach of children.</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do\nnot use this medicine after the expiry date which is stated on the outer carton\nand vial after EXP. The expiry date refers to the last day of that month.</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Store\nin a refrigerator at (2\u00b0C \u2011 8\u00b0C). Do not freeze.</p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 When\nprepared as a solution for infusion Kadcyla is stable for up to 24 hours at\n2\u00b0C\u00a0to\u00a08\u00b0C, and must be discarded thereafter. </p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do\nnot throw away any medicines via wastewater or household waste. Ask your\npharmacist how to dispose of medicines you no longer use. These measures will\nhelp to protect the environment.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the\npack and other information</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>What Kadcyla contains</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The active\nsubstance is trastuzumab emtansine. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0  Kadcyla\n100mg: One vial of powder for concentrate for solution for infusion contains\n100 mg of trastuzumab emtansine. After reconstitution one vial of 5 mL solution\ncontains 20 mg/mL of trastuzumab emtansine.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Kadcyla\n160mg: One vial of powder for concentrate for solution for infusion contains\n160 mg of trastuzumab emtansine. After reconstitution one vial of 8 mL solution\ncontains 20 mg/mL of trastuzumab emtansine.</p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The other\ningredients are succinic acid, sodium hydroxide (see section 2 under\n\u2018Important information about some of the ingredients of Kadcyla\u2019),\nsucrose, and polysorbate\u00a020.</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>What Kadcyla looks like and contents of the pack</b></p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Kadcyla is\na white to off-white lyophilised powder for concentrate for solution for\ninfusion supplied in glass vials. </p>\n<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Kadcyla is\navailable in packs containing 1 vial.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><b>Marketing Authorisation Holder</b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Roche Registration GmbH </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">79639 Grenzach-Wyhlen</span></p>\n<p class=\"MsoNormal\">Germany</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Manufacturer</b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">Roche Pharma\nAG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">D-79639 Grenzach-Wyhlen</span></p>\n<p class=\"MsoNormal\">Germany</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">For any information about\nthis medicine, please contact the local representative of the Marketing\nAuthorisation Holder:</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"FR\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</b></p>\n<p class=\"MsoNormal\">\u0420\u043e\u0448 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</p>\n<p class=\"MsoNormal\">\u0422\u0435\u043b<span lang=\"FR\">: +359 2\u00a0818 44 44</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +370 5 2546799</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +36 - 23 446 800</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Danmark</b></p>\n<p class=\"MsoNormal\">Roche a/s</p>\n<p class=\"MsoNormal\">Tlf: +45 - 36 39 99 99</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Malta</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">(See Ireland)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\">Tel: +31 (<span style=\"layout-grid-mode:line\">0) 348\n  438050</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span style=\"layout-grid-mode:line\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Roche Norge AS</span></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Tlf: +47 - 22 78 90 00</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</b></p>\n<p class=\"MsoNormal\">Roche (Hellas) A.E. </p>\n<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +30 210 61 66 100</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\">Tel: +34 - 91 324 81 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Polska</b></p>\n<p class=\"MsoNormal\">Roche Polska Sp.z o.o.</p>\n<p class=\"MsoNormal\">Tel: +48 - 22 345 18 88</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>France</b></p>\n<p class=\"MsoNormal\">Roche</p>\n<p class=\"MsoNormal\">T\u00e9l: +33\u00a0(0)1 47 61 40 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica,\n  Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel:\u00a0 +385 1 4722 333</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\">Tel: +40 21 206 47 01</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Ireland</b></p>\n<p class=\"MsoNormal\">Roche Products (Ireland) Ltd.</p>\n<p class=\"MsoNormal\">Tel: +353 (0) 1 469 0700</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Slovenija</b></p>\n<p class=\"MsoNormal\">Roche farmacevtska dru\u017eba d.o.o.</p>\n<p class=\"MsoNormal\">Tel: +386 - 1 360 26 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi<span style=\"layout-grid-mode:\n  line\">: +354 540 8000</span></span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\">Tel: +421 - 2 52638201</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>\n<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Sverige</b></p>\n<p class=\"MsoNormal\">Roche AB</p>\n<p class=\"MsoNormal\">Tel: +46 (0) 8 726 1200</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>United Kingdom</b></p>\n<p class=\"MsoNormal\">Roche Products Ltd.</p>\n<p class=\"MsoNormal\">Tel: +44 (0) 1707 366000</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>This leaflet was last\nrevised in </b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b>Other\nsources of information</b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\">Detailed information on this\nmedicine is available on the European Medicines Agency web site: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a><span style=\"color:blue\">.</span> </p>\n<b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b>The\nfollowing information is intended for medical or healthcare professionals only:\n</b></p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">In order to prevent medicinal product errors it is important\nto check the vial labels to ensure that the medicinal product being prepared is\nKadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Kadcyla must be reconstituted and diluted by a healthcare\nprofessional and administered as an intravenous infusion. It must not be\nadministered as an intravenous push or bolus.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Always keep this medicine in the closed original pack at a\ntemperature of 2\u00baC \u2013 8 \u00baC in a refrigerator. A vial of Kadcyla\nreconstituted with water for injections (not supplied) is stable for 24 hours\nat </p>\n<p class=\"MsoNormal\">2\u00baC \u2013 8 \u00baC after reconstitution and must not\nbe frozen. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Appropriate aseptic technique should be used. Appropriate\nprocedures for the preparation of chemotherapeutic medicinal products should be\nused. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The reconstituted Kadcyla solution should be diluted in\npolyvinyl chloride (PVC) or latex\u2011free PVC\u2011free polyolefin infusion\nbags.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">The use of 0.20 or 0.22 micron in-line polyethersulfone\n(PES) filter is required for the infusion when the concentrate for infusion is\ndiluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><i>Instructions for reconstitution</i></p>\n<p class=\"MsoNormal\" style=\"margin-left:22.5pt;text-indent:-22.5pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 <u>Kadcyla\n100mg</u>: using a sterile syringe, slowly inject 5\u00a0mL of sterile water\nfor injection into the 100\u00a0mg trastuzumab emtansine vial. </p>\n<p class=\"MsoNormal\" style=\"margin-left:22.5pt;text-indent:-22.5pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 <u>Kadcyla\n160mg</u>: using a sterile syringe, slowly inject 8\u00a0mL of sterile water\nfor injection into the 160 mg trastuzumab emtansine vial.</p>\n<p class=\"MsoNormal\" style=\"margin-left:22.5pt;text-indent:-22.5pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 Swirl\nthe vial gently until completely dissolved. Do not shake. </p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Reconstituted solution should be inspected visually for\nparticulate matter and discolouration prior to administration. The\nreconstituted solution should be free of visible particulates, clear to\nslightly opalescent. The colour of the reconstituted solution should be\ncolourless to pale brown. Do not use if reconstituted solution is cloudy or\ndiscoloured.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\">Discard any unused portion. The reconstituted product contains\nno preservative and is intended for single use only.</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\"><i>Instructions for dilution</i></p>\n<p class=\"MsoNormal\">Determine the volume of the reconstituted solution required\nbased on a dose of 3.6\u00a0mg trastuzumab emtansine/kg body weight:</p>\n<p class=\"MsoNormal\">\u00a0</p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Volume</b>\n(mL)\u00a0=\u00a0<i><u>Total dose to be administered</u></i><u> =(<b>body\nweight</b> (kg) x <b>dose</b> (mg/kg))</u> </p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n<b>20</b> (mg/mL, concentration of reconstituted solution)</p>\n<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>\n<p class=\"MsoNormal\">The appropriate amount of solution should be withdrawn from\nthe vial and added to an infusion bag containing 250\u00a0mL of sodium chloride\n4.5 mg/mL (0.45%) solution for infusion or sodium chloride 9\u00a0mg/mL (0.9%)\nsolution for infusion. Glucose\u00a0(5%) solution should not be used Sodium\nchloride 4.5\u00a0mg/mL (0.45%) solution for infusion may be used without a\npolyethersulfone (PES) 0.20 or 0.22\u2011\u03bcm in\u2011line filter. If\nsodium chloride 9 mg/mL (0.9%) solution for infusion is used for infusion, a\n0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required. Once the\ninfusion is prepared it should be administered immediately. Do not freeze or\nshake the infusion during storage. If diluted aseptically, it may be stored for\nup to 24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C.</p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt\">\u00a0</p>\n</div>", "ID": "d38ed4b3-383b-4546-9be2-af8a0800ef72", "Styles": "None", "Classes": "['WordSection1']", "Text": "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ", "ParentId": "101a466c-a024-403a-9db7-cfb6187bd979"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "34c7b373-a335-4f70-92cf-9558136efb6f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "b0c08f9f-c559-476a-ac64-bd4a61f2f271", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "34c7b373-a335-4f70-92cf-9558136efb6f"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "dc968653-f4d5-484b-9f8e-400f016d6666", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c229eb36-2bd4-45ff-8012-5180b7dd6d51", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "441ee71f-63f3-4d10-a516-5391f7f32830", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5d70ebc9-b9d4-4882-8e05-4599da02e16a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f18155b7-ce79-4389-9485-2e991736b791", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7e2182e5-fdd0-4fb7-8821-4b55041be173", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4ae9ec4a-e6af-4a6e-a1b9-222b8c0b79f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0ba1d8b7-adfa-4d6c-90eb-a0db71f26945", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "16855cf6-5911-4664-b811-ba9a6a0bb4c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d2e69d42-1c12-4bdf-9057-e1c50f60b523", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "b75d08e4-a4ad-4464-b4be-53adf1d4d442", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "165345c0-cb22-472d-9748-8c94ddc66571", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b75d08e4-a4ad-4464-b4be-53adf1d4d442"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in\">\u00a0</p>", "ID": "e5a918d7-a2cc-41a5-9737-e7edca6e754d", "Styles": "margin-left:.5in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in\">\u00a0</p>", "ID": "0e873a84-97b5-4828-b276-4d9f8d5ec749", "Styles": "margin-left:.5in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in\">\u00a0</p>", "ID": "67aece81-4bbf-407d-b67b-d5ce0988e946", "Styles": "margin-left:.5in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e6cb001f-5cc9-4afe-bccd-29905c813512", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bc5bf87b-2679-418b-97ac-1626d3228125", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8ee45053-9927-490b-8eb7-44c37f440039", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c3d2d943-b7de-4e6f-970f-36445bf046ea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "17561691-cc77-41f1-bf9a-262335f74838", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d43c7ba4-e067-48de-9a20-be2802b14846", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b988ad5b-1a99-4577-a1dd-860d9c7e320b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "79edb243-8999-4915-80a3-0c9e0e79ff4a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "44abd395-faa8-440d-baed-8fda7e4bf01f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7ef3ac07-0b34-4369-88a5-5b97490d9ea6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "dd9e138e-30ad-480c-a96f-a2cdd795851b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>ANNEX I</b></p>", "ID": "f9abb45c-a815-4523-b271-a09f8fa74eb1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>ANNEX I</b>", "ID": "396e98bd-b49c-475f-badd-e13c1e1ca0bd", "Styles": "None", "Classes": "None", "Text": "ANNEX I", "ParentId": "f9abb45c-a815-4523-b271-a09f8fa74eb1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "3a972f27-a1ab-42dc-b6fd-aa687f4f8d31", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"Annex\">SUMMARY OF PRODUCT CHARACTERISTICS</p>", "ID": "b07bdf18-0a38-48cb-91a3-f8558a2e8336", "Styles": "None", "Classes": "['Annex']", "Text": "SUMMARY OF PRODUCT CHARACTERISTICS", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "21f35cdf-e30a-468f-9a08-c14f369d4f40", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:green'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2587f594-1833-493f-a631-63550e1fe584", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;color:green", "Classes": "None", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "9f1520ed-98b9-4fd8-b818-3c11f7f824c7", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2587f594-1833-493f-a631-63550e1fe584"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8f8a9e05-3442-4ef6-8a4b-b4222b11d042", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>", "ID": "871acb83-5c4f-4271-984b-9a375d4c593e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</b></p>", "ID": "0e31b82b-1e05-429f-b02e-376a9ae66c6d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</b>", "ID": "55e5c01f-3a24-415d-8cfa-b104e5df3d67", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "0e31b82b-1e05-429f-b02e-376a9ae66c6d"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b517f619-1d21-44f1-a980-fb63f7252b31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla 100\u00a0mg powder for concentrate for solution for\ninfusion.</p>", "ID": "84f0e1d4-43c1-4350-b6a3-28985feb6fe2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla 100\u00a0mg powder for concentrate for solution for infusion.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla 160\u00a0mg powder for concentrate for solution for\ninfusion.</p>", "ID": "0133f947-7917-4abe-94a4-b94b69943606", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla 160\u00a0mg powder for concentrate for solution for infusion.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d2e92036-679c-4d3d-8843-ffa5913125bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8dd4c24f-7457-4bb1-86ca-5febc3d4251a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</b></p>", "ID": "44f30f2c-9c3b-4cc0-8064-e33466d20202", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</b>", "ID": "0d3944ef-14ef-42a6-a431-e759345b6b19", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE COMPOSITION", "ParentId": "44f30f2c-9c3b-4cc0-8064-e33466d20202"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8d26755d-df71-443b-b90c-939f416c112d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><u>Kadcyla 100 mg powder for concentrate for solution for\ninfusion</u></p>", "ID": "e01b10ff-b9dd-4af6-a6d2-c98af1322319", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Kadcyla 100 mg powder for concentrate for solution for\ninfusion</u>", "ID": "5af66a96-b1db-4a80-88af-1be6951ace64", "Styles": "None", "Classes": "None", "Text": "Kadcyla 100 mg powder for concentrate for solution for infusion", "ParentId": "e01b10ff-b9dd-4af6-a6d2-c98af1322319"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">One vial of powder for\nconcentrate for solution for infusion contains 100 mg of trastuzumab emtansine.\nAfter reconstitution one vial of 5 mL solution contains 20 mg/mL of trastuzumab\nemtansine (see section 6.6).</p>", "ID": "d14e6cbf-52aa-410a-b6c2-1f14ed55dd1b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "One vial of powder for concentrate for solution for infusion contains 100 mg of trastuzumab emtansine. After reconstitution one vial of 5 mL solution contains 20 mg/mL of trastuzumab emtansine (see section 6.6).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>", "ID": "8ac801c1-546d-4b0c-8fdd-9e3b66f6430c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><u>Kadcyla 160 mg powder for\nconcentrate for solution for infusion</u></p>", "ID": "c1d50f90-0769-43f1-bed7-5df36f632af7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Kadcyla 160 mg powder for\nconcentrate for solution for infusion</u>", "ID": "764bd74a-744b-4ffd-95be-dd47e9999293", "Styles": "None", "Classes": "None", "Text": "Kadcyla 160 mg powder for concentrate for solution for infusion", "ParentId": "c1d50f90-0769-43f1-bed7-5df36f632af7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">One vial of powder for\nconcentrate for solution for infusion contains 160 mg of trastuzumab emtansine.\nAfter reconstitution one vial of 8 mL solution contains 20 mg/mL of trastuzumab\nemtansine (see section 6.6).</p>", "ID": "8894edff-2492-4ac3-a302-a2ec221fc4ca", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "One vial of powder for concentrate for solution for infusion contains 160 mg of trastuzumab emtansine. After reconstitution one vial of 8 mL solution contains 20 mg/mL of trastuzumab emtansine (see section 6.6).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>", "ID": "10d25da8-9335-4dbf-8ba8-eba6cf74c462", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">Trastuzumab emtansine is an\nantibody\u2011drug conjugate that contains trastuzumab, a humanised IgG1\nmonoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension\nculture, covalently linked to DM1, a microtubule inhibitor, via the stable\nthioether linker MCC (4\u2011[N\u2011maleimidomethyl]\u00a0cyclohexane\u20111\u2011carboxylate).</p>", "ID": "828be3ee-cbeb-4e8d-9b7e-35291dee4e51", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine is an antibody\u2011drug conjugate that contains trastuzumab, a humanised IgG1 monoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension culture, covalently linked to DM1, a microtubule inhibitor, via the stable thioether linker MCC (4\u2011[N\u2011maleimidomethyl]\u00a0cyclohexane\u20111\u2011carboxylate).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a8e07ec9-a1d2-402a-b60f-a026e1f04569", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">For the full list of excipients, see section\u00a06.1.</p>", "ID": "79d1f369-0179-4fcc-a417-773daaca61e8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "For the full list of excipients, see section\u00a06.1.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3abeee61-c45e-4f04-be5f-d93477258fa3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f1dab796-8ed4-41f1-9967-6150982864ae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</b></p>", "ID": "50d75731-6303-4bc3-a734-d239b52df6fb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</b>", "ID": "80df4e1b-3883-4efc-9825-a46399bea9a8", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM", "ParentId": "50d75731-6303-4bc3-a734-d239b52df6fb"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7870de40-c8a2-42ae-84da-633de5ec0fc9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Powder for concentrate for solution for infusion.</p>", "ID": "2ba2d8d7-fce8-4967-9ff3-b4da9434b42c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Powder for concentrate for solution for infusion.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f176ddb3-a950-419f-b745-b96486f9dd90", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">White to off\u2011white lyophilised powder.</p>", "ID": "04d966e1-24ed-47d3-9db0-2441a10a651e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "White to off\u2011white lyophilised powder.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "56320891-2a2b-4a18-afc1-4e033639540e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "64699bc3-34d6-478e-ad3c-d32a7c5f54e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b><span style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></b><b>CLINICAL\nPARTICULARS</b></p>", "ID": "305d024f-2166-4a4e-8f41-38ef1873a630", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><span style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span></b>", "ID": "2da4c86f-dc31-4521-b5f6-8b3691797004", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "305d024f-2166-4a4e-8f41-38ef1873a630"}, {"Element": "<span style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "c0df3bd8-ff60-4558-ac22-e84a451872d6", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2da4c86f-dc31-4521-b5f6-8b3691797004"}, {"Element": "<b>CLINICAL\nPARTICULARS</b>", "ID": "2f453d59-6d80-4944-ad96-d93df8a423e0", "Styles": "None", "Classes": "None", "Text": "CLINICAL PARTICULARS", "ParentId": "305d024f-2166-4a4e-8f41-38ef1873a630"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "dd97a904-7719-4e65-9179-2cbdccbff1c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</b></p>", "ID": "632a872d-845f-48d2-907d-3d3a834082c4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</b>", "ID": "8323c331-980f-4dac-afa3-43798725bdfb", "Styles": "None", "Classes": "None", "Text": "4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications", "ParentId": "632a872d-845f-48d2-907d-3d3a834082c4"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3f29be08-5df1-451d-91dd-2de26c0202fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><u>Early Breast Cancer (EBC)</u></p>", "ID": "ad2e1153-75b3-4216-b24a-2189842ae3c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Early Breast Cancer (EBC)</u>", "ID": "3a4318ec-f40b-42b7-9495-39e39384eb81", "Styles": "None", "Classes": "None", "Text": "Early Breast Cancer (EBC)", "ParentId": "ad2e1153-75b3-4216-b24a-2189842ae3c9"}, {"Element": "<p class=\"MsoNormal\">Kadcyla, as a single agent, is indicated for the adjuvant\ntreatment of adult patients with HER2-positive early breast cancer who have\nresidual invasive disease, in the breast and/or lymph nodes, after neoadjuvant\ntaxane-based and HER2-targeted therapy.</p>", "ID": "7a019709-1d9d-4a5b-b140-383e0d01b392", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "25751477-a313-4d5b-9f91-b1572509c43d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "ec9a13e5-7871-497c-9d48-ef194041410c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "25751477-a313-4d5b-9f91-b1572509c43d"}, {"Element": "<p class=\"MsoNormal\"><u>Metastatic Breast Cancer (MBC)</u></p>", "ID": "4826109a-c1ef-4651-8574-8519ee1840b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Metastatic Breast Cancer (MBC)</u>", "ID": "c9871168-f329-4e04-979d-aeaac89b5a6a", "Styles": "None", "Classes": "None", "Text": "Metastatic Breast Cancer (MBC)", "ParentId": "4826109a-c1ef-4651-8574-8519ee1840b4"}, {"Element": "<p class=\"MsoNormal\">Kadcyla, as a single agent, is indicated for the treatment\nof adult patients with HER2-positive, </p>", "ID": "64e11d23-fff3-4db8-afec-ba44abe3a559", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">unresectable locally advanced or metastatic breast cancer\nwho previously received trastuzumab and a taxane, separately or in combination.\nPatients should have either:</p>", "ID": "aa822b06-f141-47d3-84cd-e5c63f422c19", "Styles": "None", "Classes": "['MsoNormal']", "Text": "unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Received\nprior therapy for locally advanced or metastatic disease, or</p>", "ID": "a1ac9a93-322c-465d-bf62-fd4db4119c6a", "Styles": "margin-left:35.7pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Received prior therapy for locally advanced or metastatic disease, or", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "86a47d28-51a6-4a5b-b75b-feddfb2e6487", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a1ac9a93-322c-465d-bf62-fd4db4119c6a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Developed\ndisease recurrence during or within six months of completing adjuvant therapy.</p>", "ID": "63141d7a-f4c1-4e96-a936-f59763d8561a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Developed disease recurrence during or within six months of completing adjuvant therapy.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "cb8127c8-3a70-48e7-9548-9c838f6bda5a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "63141d7a-f4c1-4e96-a936-f59763d8561a"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6e73092c-88b2-4bd9-8cd0-2f859b88566d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.2\u00a0\u00a0\u00a0\u00a0 Posology\nand method of administration</b></p>", "ID": "fe94e2ab-f0dc-4217-afb0-66e9c4124ae8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.2\u00a0\u00a0\u00a0\u00a0 Posology\nand method of administration</b>", "ID": "67c2d1c8-b2e0-449d-9411-7934ce10f313", "Styles": "None", "Classes": "None", "Text": "4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration", "ParentId": "fe94e2ab-f0dc-4217-afb0-66e9c4124ae8"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "982f42a3-7c0f-4772-96f2-8bf5bd645a6e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla should only be prescribed by a physician and\nadministered as an intravenous infusion under the supervision of a healthcare\nprofessional who is experienced in the treatment of cancer patients (i.e. <span lang=\"EN-GB\">prepared to manage allergic/anaphylactic infusion reactions and </span><span lang=\"EN-GB\">in an environment where full resuscitation facilities are\nimmediately available (see section 4.4))</span>.</p>", "ID": "3ba18ba2-13db-4adb-ac8c-af1e4ca24ab5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla should only be prescribed by a physician and administered as an intravenous infusion under the supervision of a healthcare professional who is experienced in the treatment of cancer patients (i.e. .", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-GB\">prepared to manage allergic/anaphylactic infusion reactions and </span>", "ID": "8ab1978d-c625-495f-bdac-2f5d63758300", "Styles": "None", "Classes": "None", "Text": "prepared to manage allergic/anaphylactic infusion reactions and ", "ParentId": "3ba18ba2-13db-4adb-ac8c-af1e4ca24ab5"}, {"Element": "<span lang=\"EN-GB\">in an environment where full resuscitation facilities are\nimmediately available (see section 4.4))</span>", "ID": "7d1e210a-47ba-433f-82d5-30c14f8b0a26", "Styles": "None", "Classes": "None", "Text": "in an environment where full resuscitation facilities are immediately available (see section 4.4))", "ParentId": "3ba18ba2-13db-4adb-ac8c-af1e4ca24ab5"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "14487698-d610-42af-85bc-193e517ea71b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Patients treated with trastuzumab emtansine should have HER2\npositive tumour status, defined as a score of 3\u00a0+ by immunohistochemistry\n(IHC) or a ratio of\u00a0\u2265\u00a02.0 by in situ hybridization (ISH) or by\nfluorescence in situ hybridization (FISH) assessed by a CE-marked In Vitro Diagnostic\n(IVD) medical device. If a CE-marked IVD is not available, the HER2-status\nshould be assessed by an alternate validated test. </p>", "ID": "fe57cb34-352f-44e8-84a9-1a0288adc152", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Patients treated with trastuzumab emtansine should have HER2 positive tumour status, defined as a score of 3\u00a0+ by immunohistochemistry (IHC) or a ratio of\u00a0\u2265\u00a02.0 by in situ hybridization (ISH) or by fluorescence in situ hybridization (FISH) assessed by a CE-marked In Vitro Diagnostic (IVD) medical device. If a CE-marked IVD is not available, the HER2-status should be assessed by an alternate validated test. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c580e08c-ff00-4074-8034-3a210efe2930", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">In order to prevent medicinal\nproduct errors it is important to check the vial labels to ensure that the\nmedicinal product being prepared and administered is Kadcyla (trastuzumab\nemtansine) and not Herceptin (trastuzumab).</p>", "ID": "d87e1b7e-25d0-4b5f-b043-0d4aba414967", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "In order to prevent medicinal product errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "b380289e-abdc-4a8c-a725-d8918f645319", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "c8dabc47-4dfa-4c33-a818-ddeaefd4e126", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Posology</u></p>", "ID": "85e6346f-e347-404f-b03f-9db86ddc2201", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Posology</u>", "ID": "6b44af4d-8752-458e-b29f-69cb1e380dd8", "Styles": "None", "Classes": "None", "Text": "Posology", "ParentId": "85e6346f-e347-404f-b03f-9db86ddc2201"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "0dfe4cfd-815c-40b4-9dd4-5e374ac176dc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The recommended dose of\ntrastuzumab emtansine is 3.6\u00a0mg/kg bodyweight administered as an\nintravenous infusion every\u00a03\u00a0weeks (21\u2011day cycle). </p>", "ID": "ffd419fd-e32c-4f82-9fdc-53981c892f9e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The recommended dose of trastuzumab emtansine is 3.6\u00a0mg/kg bodyweight administered as an intravenous infusion every\u00a03\u00a0weeks (21\u2011day cycle). ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5016c2b6-3fbb-4a0d-9655-12ef3eb9a2c7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The initial dose should be administered as a 90\u00a0minute\nintravenous infusion. Patients should be observed during the infusion and for\nat least 90\u00a0minutes following the initial infusion for fever, chills, or\nother infusion\u2011related reactions. The infusion site should be closely\nmonitored for possible subcutaneous infiltration during administration (see\nsection\u00a04.8).</p>", "ID": "be0f17fc-5a51-4de2-a879-d1013bf9c48d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The initial dose should be administered as a 90\u00a0minute intravenous infusion. Patients should be observed during the infusion and for at least 90\u00a0minutes following the initial infusion for fever, chills, or other infusion\u2011related reactions. The infusion site should be closely monitored for possible subcutaneous infiltration during administration (see section\u00a04.8).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "a0a59a11-f9bb-450f-8d8a-3c66a08523c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "d3469d31-e1df-489f-b906-0bc1d783bc3b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a0a59a11-f9bb-450f-8d8a-3c66a08523c3"}, {"Element": "<p class=\"MsoNormal\">If the prior infusion was well tolerated, subsequent doses\nof trastuzumab emtansine may be administered as 30\u00a0minute infusions.\nPatients should be observed during the infusion and for at least\n30\u00a0minutes after infusion.</p>", "ID": "e3b3ce56-3d6c-4afd-a370-66b2d4f9b859", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If the prior infusion was well tolerated, subsequent doses of trastuzumab emtansine may be administered as 30\u00a0minute infusions. Patients should be observed during the infusion and for at least 30\u00a0minutes after infusion.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "ad940bce-6592-472c-90df-a9252df3a588", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "c09df005-d3db-4c3d-ba4d-2d72af7f190f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ad940bce-6592-472c-90df-a9252df3a588"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "050398d7-4fad-4870-b73c-f6a10ac5b0aa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c09df005-d3db-4c3d-ba4d-2d72af7f190f"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b505a963-42df-4278-bfef-3ab8da10b079", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "050398d7-4fad-4870-b73c-f6a10ac5b0aa"}, {"Element": "<p class=\"MsoNormal\">The infusion rate of trastuzumab emtansine should be slowed\nor interrupted if the patient develops infusion\u2011related symptoms (see\nsections\u00a04.4 and 4.8). Trastuzumab emtansine should be discontinued in\ncase of life\u2011threatening infusion reactions.</p>", "ID": "975c654e-dee8-43f6-880e-7722ae3ffd4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The infusion rate of trastuzumab emtansine should be slowed or interrupted if the patient develops infusion\u2011related symptoms (see sections\u00a04.4 and 4.8). Trastuzumab emtansine should be discontinued in case of life\u2011threatening infusion reactions.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "17fd1d4a-027f-4364-b35d-0bc241f928ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "f2d7ba13-270e-47d9-9803-8b6b74aac23d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "17fd1d4a-027f-4364-b35d-0bc241f928ef"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "e98326ef-7dc5-499b-b329-489f6aa8f6af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f2d7ba13-270e-47d9-9803-8b6b74aac23d"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "26b99487-4c7e-4a10-b2e9-34bdfafaf4b5", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "e98326ef-7dc5-499b-b329-489f6aa8f6af"}, {"Element": "<p class=\"MsoNormal\"><u>Duration of treatment</u></p>", "ID": "c58c724b-b953-47d2-ac2f-ab2e9f6ae4d9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Duration of treatment</u>", "ID": "ba471839-f535-45a6-9d2d-3b12733a83ec", "Styles": "None", "Classes": "None", "Text": "Duration of treatment", "ParentId": "c58c724b-b953-47d2-ac2f-ab2e9f6ae4d9"}, {"Element": "<p class=\"MsoNormal\"><i><u><span style=\"text-decoration:none\">\u00a0</span></u></i></p>", "ID": "bdbec311-834a-47ac-9cc2-5ddd9315e90f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i><u><span style=\"text-decoration:none\">\u00a0</span></u></i>", "ID": "ec465922-9c4c-4056-966e-d628c5ab8ae5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bdbec311-834a-47ac-9cc2-5ddd9315e90f"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "23a75eee-4451-4f4e-b850-b2965d228052", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ec465922-9c4c-4056-966e-d628c5ab8ae5"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e5e759fb-de0e-4b12-8992-02cd41ae70aa", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "23a75eee-4451-4f4e-b850-b2965d228052"}, {"Element": "<p class=\"MsoNormal\"><i>Early Breast Cancer (EBC)</i></p>", "ID": "b0df0d0e-4796-4cf0-b096-74eee9c9ab33", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Early Breast Cancer (EBC)</i>", "ID": "bfed52ae-ee43-4cd7-97ba-894351f397eb", "Styles": "None", "Classes": "None", "Text": "Early Breast Cancer (EBC)", "ParentId": "b0df0d0e-4796-4cf0-b096-74eee9c9ab33"}, {"Element": "<p class=\"MsoNormal\">Patients should receive treatment for a total of 14 cycles unless\nthere is disease recurrence or unmanageable toxicity.</p>", "ID": "fac19225-9459-4508-bd25-5d8ab67929bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Patients should receive treatment for a total of 14 cycles unless there is disease recurrence or unmanageable toxicity.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "a9ba1de1-2359-49cb-b422-32184ae1d646", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "fc3be679-2cc2-4980-bf1e-ba12801e9f88", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a9ba1de1-2359-49cb-b422-32184ae1d646"}, {"Element": "<p class=\"MsoNormal\"><i>Metastatic Breast Cancer (MBC)</i></p>", "ID": "05de6c42-7abf-453c-83e8-cd36d137e003", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Metastatic Breast Cancer (MBC)</i>", "ID": "578f068b-d4f8-47b8-8b5b-77c138504e88", "Styles": "None", "Classes": "None", "Text": "Metastatic Breast Cancer (MBC)", "ParentId": "05de6c42-7abf-453c-83e8-cd36d137e003"}, {"Element": "<p class=\"MsoNormal\">Patients should receive treatment until disease progression\nor unmanageable toxicity.</p>", "ID": "6317fd46-0774-421d-aef8-91e3cc31d1aa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Patients should receive treatment until disease progression or unmanageable toxicity.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>Dose modification</i></p>", "ID": "0669839d-235b-45b2-94ce-d56ba7392152", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Dose modification</i>", "ID": "3f42cc27-2b76-4204-b40a-0af10556122d", "Styles": "None", "Classes": "None", "Text": "Dose modification", "ParentId": "0669839d-235b-45b2-94ce-d56ba7392152"}, {"Element": "<p class=\"MsoNormal\">Management of symptomatic adverse reactions may require\ntemporary interruption, dose reduction, or treatment discontinuation of\ntrastuzumab emtansine as per guidelines provided in text and\nTables\u00a01\u00a0and 2\u00a0.</p>", "ID": "fd8ad995-fb89-49a7-a6d7-3a731dd205c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Management of symptomatic adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of trastuzumab emtansine as per guidelines provided in text and Tables\u00a01\u00a0and 2\u00a0.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "66488980-bd44-4bcc-8046-81141f6b878c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Trastuzumab emtansine dose should not be re\u2011escalated\nafter a dose reduction is made.</p>", "ID": "9d13568e-d0cd-4a4f-be08-3c5fd8e9924c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine dose should not be re\u2011escalated after a dose reduction is made.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1dda7ae6-9900-4df2-b305-b7284d39bcff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Table\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dose\nreduction schedule</b></p>", "ID": "9cccd764-8e85-4cde-8522-08280201b96f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Table\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dose\nreduction schedule</b>", "ID": "96d91b26-7bc0-4244-8d85-206cf596ee15", "Styles": "None", "Classes": "None", "Text": "Table\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dose reduction schedule", "ParentId": "9cccd764-8e85-4cde-8522-08280201b96f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "05cfd301-265b-4581-a5b7-dec20f94d39c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "9ac5f7d1-b656-4f34-87aa-1e076c5e4c8d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "05cfd301-265b-4581-a5b7-dec20f94d39c"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"background:white;border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">reduction schedule</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">(Starting dose is 3.6 mg/kg)</span></b></p>\n</td>\n<td style=\"width:156.8pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"209\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">Dose\u00a0 to be administered</span></b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">First\n  dose reduction</span></p>\n</td>\n<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">3\u00a0mg/kg</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Second\n  dose reduction</span></p>\n</td>\n<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">2.4\u00a0mg/kg</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Requirement\n  for further dose reduction</span></p>\n</td>\n<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Discontinue\n  treatment</span></p>\n</td>\n</tr>\n</table>", "ID": "fa17c582-aa36-47e0-9ec7-7dd704cce7f0", "Styles": "background:white;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "     ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">reduction schedule</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">(Starting dose is 3.6 mg/kg)</span></b></p>\n</td>\n<td style=\"width:156.8pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"209\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">Dose\u00a0 to be administered</span></b></p>\n</td>\n</tr>", "ID": "865cc939-5f90-402f-90bc-e8145aff4923", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "fa17c582-aa36-47e0-9ec7-7dd704cce7f0"}, {"Element": "<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">reduction schedule</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">(Starting dose is 3.6 mg/kg)</span></b></p>\n</td>", "ID": "c49fefd0-cf1e-4693-96b5-fc8360f1cde3", "Styles": "width:204.1pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "865cc939-5f90-402f-90bc-e8145aff4923"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">reduction schedule</span></b></p>", "ID": "5728cc5b-885a-4b04-ad80-7dd1ff16a628", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c49fefd0-cf1e-4693-96b5-fc8360f1cde3"}, {"Element": "<b>Dose <span style=\"color:black\">reduction schedule</span></b>", "ID": "c4a28230-bb1f-4bf0-bf7b-48b86c0fef37", "Styles": "None", "Classes": "None", "Text": "Dose ", "ParentId": "5728cc5b-885a-4b04-ad80-7dd1ff16a628"}, {"Element": "<span style=\"color:black\">reduction schedule</span>", "ID": "b8d49ed2-ea1d-410d-834f-59518e5d89e6", "Styles": "color:black", "Classes": "None", "Text": "reduction schedule", "ParentId": "c4a28230-bb1f-4bf0-bf7b-48b86c0fef37"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">(Starting dose is 3.6 mg/kg)</span></b></p>", "ID": "46e26c5a-de1e-484e-9a6e-18e8161c5ca4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c49fefd0-cf1e-4693-96b5-fc8360f1cde3"}, {"Element": "<b><span style=\"color:black\">(Starting dose is 3.6 mg/kg)</span></b>", "ID": "1089a8e6-3879-4ea6-98e1-a29edcce9424", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "46e26c5a-de1e-484e-9a6e-18e8161c5ca4"}, {"Element": "<span style=\"color:black\">(Starting dose is 3.6 mg/kg)</span>", "ID": "094a549b-5359-4899-8403-70bd6865a208", "Styles": "color:black", "Classes": "None", "Text": "(Starting dose is 3.6 mg/kg)", "ParentId": "1089a8e6-3879-4ea6-98e1-a29edcce9424"}, {"Element": "<td style=\"width:156.8pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"209\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">Dose\u00a0 to be administered</span></b></p>\n</td>", "ID": "af115b92-aa6e-4742-a146-a1096ef9999e", "Styles": "width:156.8pt;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "865cc939-5f90-402f-90bc-e8145aff4923"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span style=\"color:black\">Dose\u00a0 to be administered</span></b></p>", "ID": "650d7f7a-f7dc-49e1-8fcf-ead7b734687e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "af115b92-aa6e-4742-a146-a1096ef9999e"}, {"Element": "<b><span style=\"color:black\">Dose\u00a0 to be administered</span></b>", "ID": "9b20eaad-e3c0-4708-9264-a19181d4fe9e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "650d7f7a-f7dc-49e1-8fcf-ead7b734687e"}, {"Element": "<span style=\"color:black\">Dose\u00a0 to be administered</span>", "ID": "1d11d669-6f55-46d2-ab20-275d6b588768", "Styles": "color:black", "Classes": "None", "Text": "Dose\u00a0 to be administered", "ParentId": "9b20eaad-e3c0-4708-9264-a19181d4fe9e"}, {"Element": "<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">First\n  dose reduction</span></p>\n</td>\n<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">3\u00a0mg/kg</span></p>\n</td>\n</tr>", "ID": "d702684e-e0ca-44f4-a09e-52886f61c22e", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "fa17c582-aa36-47e0-9ec7-7dd704cce7f0"}, {"Element": "<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">First\n  dose reduction</span></p>\n</td>", "ID": "5de6ce9e-27d8-4b9a-9399-9749e77c0153", "Styles": "width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d702684e-e0ca-44f4-a09e-52886f61c22e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">First\n  dose reduction</span></p>", "ID": "b6ce4c32-92e6-4cff-b137-cf2da9276c93", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5de6ce9e-27d8-4b9a-9399-9749e77c0153"}, {"Element": "<span style=\"color:black\">First\n  dose reduction</span>", "ID": "194474b2-0271-438c-9496-c78ba3bb94c0", "Styles": "color:black", "Classes": "None", "Text": "First   dose reduction", "ParentId": "b6ce4c32-92e6-4cff-b137-cf2da9276c93"}, {"Element": "<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">3\u00a0mg/kg</span></p>\n</td>", "ID": "551783a6-2d7a-4d8d-bd57-bab755b8687f", "Styles": "width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d702684e-e0ca-44f4-a09e-52886f61c22e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">3\u00a0mg/kg</span></p>", "ID": "0b177c75-95a9-47c1-ab65-4851c137fc39", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "551783a6-2d7a-4d8d-bd57-bab755b8687f"}, {"Element": "<span style=\"color:black\">3\u00a0mg/kg</span>", "ID": "cff0f4d8-58f9-43ff-9ca7-0c93bacf377c", "Styles": "color:black", "Classes": "None", "Text": "3\u00a0mg/kg", "ParentId": "0b177c75-95a9-47c1-ab65-4851c137fc39"}, {"Element": "<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Second\n  dose reduction</span></p>\n</td>\n<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">2.4\u00a0mg/kg</span></p>\n</td>\n</tr>", "ID": "d80ce6e8-64da-47ae-aa4b-278004c07d2a", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "fa17c582-aa36-47e0-9ec7-7dd704cce7f0"}, {"Element": "<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Second\n  dose reduction</span></p>\n</td>", "ID": "0d09fbea-c622-4322-83c9-30739b8a6eee", "Styles": "width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d80ce6e8-64da-47ae-aa4b-278004c07d2a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Second\n  dose reduction</span></p>", "ID": "91417363-cc53-461e-b3d4-a304d89e7778", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0d09fbea-c622-4322-83c9-30739b8a6eee"}, {"Element": "<span style=\"color:black\">Second\n  dose reduction</span>", "ID": "f875b330-0d29-4ecc-ad9f-ebc8bfc65790", "Styles": "color:black", "Classes": "None", "Text": "Second   dose reduction", "ParentId": "91417363-cc53-461e-b3d4-a304d89e7778"}, {"Element": "<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">2.4\u00a0mg/kg</span></p>\n</td>", "ID": "59d80789-13b2-49b2-b503-13443e2737b6", "Styles": "width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d80ce6e8-64da-47ae-aa4b-278004c07d2a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">2.4\u00a0mg/kg</span></p>", "ID": "3ab3993d-faff-4f9c-8eb7-a99c43612d32", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "59d80789-13b2-49b2-b503-13443e2737b6"}, {"Element": "<span style=\"color:black\">2.4\u00a0mg/kg</span>", "ID": "da9c0e4b-71b0-43ba-923c-d787a561627b", "Styles": "color:black", "Classes": "None", "Text": "2.4\u00a0mg/kg", "ParentId": "3ab3993d-faff-4f9c-8eb7-a99c43612d32"}, {"Element": "<tr>\n<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Requirement\n  for further dose reduction</span></p>\n</td>\n<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Discontinue\n  treatment</span></p>\n</td>\n</tr>", "ID": "02916509-a94f-4fee-9f26-acf1c1e14b0a", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "fa17c582-aa36-47e0-9ec7-7dd704cce7f0"}, {"Element": "<td style=\"width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"272\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Requirement\n  for further dose reduction</span></p>\n</td>", "ID": "7b585911-3d20-46dd-8ecc-64a7326a4de3", "Styles": "width:204.1pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02916509-a94f-4fee-9f26-acf1c1e14b0a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Requirement\n  for further dose reduction</span></p>", "ID": "6c98e8a1-5b50-4722-bf33-c83974b4076f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b585911-3d20-46dd-8ecc-64a7326a4de3"}, {"Element": "<span style=\"color:black\">Requirement\n  for further dose reduction</span>", "ID": "519d0573-1d99-45fd-b937-c9a1a028d36a", "Styles": "color:black", "Classes": "None", "Text": "Requirement   for further dose reduction", "ParentId": "6c98e8a1-5b50-4722-bf33-c83974b4076f"}, {"Element": "<td style=\"width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"209\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Discontinue\n  treatment</span></p>\n</td>", "ID": "499301da-56f8-4a4b-9bac-dd7a001e386d", "Styles": "width:156.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02916509-a94f-4fee-9f26-acf1c1e14b0a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span style=\"color:black\">Discontinue\n  treatment</span></p>", "ID": "5dcf3fbe-df02-4863-ad5d-52efaa27437e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "499301da-56f8-4a4b-9bac-dd7a001e386d"}, {"Element": "<span style=\"color:black\">Discontinue\n  treatment</span>", "ID": "695694c0-e0ce-4cbf-8723-6fc28a0abac3", "Styles": "color:black", "Classes": "None", "Text": "Discontinue   treatment", "ParentId": "5dcf3fbe-df02-4863-ad5d-52efaa27437e"}, {"Element": "<p class=\"TextTi12\" style=\"line-height:14.0pt\"><b><i><span lang=\"FR-CH\" style='font-family:\"Times New Roman\",serif'>\u00a0</span></i></b></p>", "ID": "c676569c-2587-4d10-977f-d42bc47758f5", "Styles": "line-height:14.0pt", "Classes": "['TextTi12']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><i><span lang=\"FR-CH\" style='font-family:\"Times New Roman\",serif'>\u00a0</span></i></b>", "ID": "2727cea5-aca2-44f2-a1ca-5ca55ef4a8a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c676569c-2587-4d10-977f-d42bc47758f5"}, {"Element": "<i><span lang=\"FR-CH\" style='font-family:\"Times New Roman\",serif'>\u00a0</span></i>", "ID": "6c6524ce-5319-4106-bf08-a534facf2e24", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2727cea5-aca2-44f2-a1ca-5ca55ef4a8a1"}, {"Element": "<span lang=\"FR-CH\" style='font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "60b3e1b2-b43b-476d-9298-863c2a91084c", "Styles": "font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "6c6524ce-5319-4106-bf08-a534facf2e24"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Table\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dose\nModification Guidelines</b></p>", "ID": "b9c276b4-71ee-4766-aa4d-4b5ce7ad3b72", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Table\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dose\nModification Guidelines</b>", "ID": "a3ee6770-41a6-45bc-8305-5758ec6a65fb", "Styles": "None", "Classes": "None", "Text": "Table\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dose Modification Guidelines", "ParentId": "b9c276b4-71ee-4766-aa4d-4b5ce7ad3b72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "620f20c9-467f-4a05-80f4-75d5faf6da47", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:452.8pt;border-collapse:collapse\" width=\"604\">\n<tr style=\"height:15.75pt\">\n<td colspan=\"3\" style=\"border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">Modifications for Patients with EBC</span></b></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Adverse reaction</b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Treatment modification</b></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"2\" style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Thrombocytopenia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3 on day of scheduled\n  treatment<br/>\n  (25,000 to &lt; 75,000/mm<sup>3</sup>)</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to</span><span style=\"font-family:Symbol\"> \u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then treat at the same dose level. If a\n  patient requires 2 delays due to thrombocytopenia, consider reducing dose by\n  one level.</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 at any time<br/>\n  &lt; 25,000/mm<sup>3</sup></span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then reduce one dose level.</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Alanine Transaminase (ALT)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3<br/>\n  (&gt; 3.0 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment)</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until ALT recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4<br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time)</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Aspartate Transaminase (AST)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 <br/>\n  (&gt; 3.0 to \u2264 5</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> 1, and then\n  treat at the same dose level</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3 <br/>\n  (&gt; 5 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 <br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time) </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Hyperbilirubinemia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 1.0 to \u2264 2.0</span><span style=\"font-family:Symbol\">\u00b4 </span><span lang=\"EN-CARRIBEAN\">the ULN on day of scheduled treatment </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until total bilirubin recovers to \u2264\n  1.0\u00d7 ULN, and then reduce one dose level</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 2</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Nodular Regenerative Hyperplasia (NRH)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">All Grades</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Peripheral Neuropathy</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3-4</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until resolution <span style=\"font-family:Symbol\">\u00a3 </span>Grade 2</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td rowspan=\"4\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &lt; 45%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> .<br/>\n  Repeat LVEF assessment within 3 weeks. </span>If LVEF &lt; 45% is confirmed,\n  discontinue trastuzumab emtansine.</p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is \u2265 10% points from baseline*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine.<span lang=\"EN-CARRIBEAN\"><br/>\n  Repeat LVEF assessment within 3 weeks. If the LVEF remains &lt; 50% and has\n  not recovered to &lt; 10% points from baseline, discontinue </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">.</span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is &lt; 10% points from baseline*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">. <br/>\n  Repeat LVEF assessment within 3 weeks. </span></p>\n</td>\n</tr>\n<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF \u2265 50%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine</p>\n</td>\n</tr>\n<tr style=\"height:97.5pt\">\n<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:97.5pt\" valign=\"top\">\n<p class=\"MsoNormal\">Heart Failure</p>\n</td>\n<td style=\"border:none;border-right:solid windowtext 1.0pt;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:97.5pt\" valign=\"bottom\">\n<p class=\"MsoNormal\">Symptomatic CHF,</p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3-4 LVSD or Grade 3-4 heart\n  failure, or</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 heart failure <br/>\n  accompanied by LVEF &lt;45% </span></p>\n</td>\n<td style=\"border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:97.5pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:35.35pt\">\n<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Pulmonary Toxicity</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Interstitial lung disease (ILD) or pneumonitis</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:35.35pt\">\n<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;border-bottom:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Radiotherapy-Related Pneumonitis</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine if not resolving with\n  standard treatment</p>\n</td>\n</tr>\n<tr style=\"height:35.35pt\">\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3-4</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td colspan=\"3\" style=\"border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"color:black\">Dose Modifications for Patients with MBC</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><b>Adverse reaction</b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Treatment\n  modification</b></p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td rowspan=\"2\" style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Thrombocytopenia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3 </p>\n<p class=\"MsoNormal\">(25,000 to <span style=\"font-family:Symbol\">&lt;</span>\u00a050,000/mm<sup>3</sup>)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then treat at the same dose level</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4</p>\n<p class=\"MsoNormal\"><span style=\"font-family:Symbol\">(&lt;</span>\u00a025,000/mm<sup>3</sup>)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then reduce one dose level</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Transaminase (AST/ALT)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a02.5 to \u2264 5<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Treat at\n  the same dose level</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a05 to \u2264 20<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until AST/ALT\n  recovers to Grade \u2264 2, and then reduce one dose level</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a020<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Hyperbilirubinemia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a01.5 to \u2264 3<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1, and then treat at the same dose level.</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a03 to \u2264 10<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1 and then reduce one dose level.</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a010<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td rowspan=\"5\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Symptomatic CHF</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Discontinue\n  trastuzumab emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &lt;40%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Repeat\n  LVEF assessment within 3 weeks. If LVEF &lt;40% is confirmed, discontinue trastuzumab\n  emtansine</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is \u2265 10% points\n  from baseline</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>\n<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks. If the LVEF has not\n  recovered to within 10% points from baseline, discontinue trastuzumab\n  emtansine.</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is &lt; 10% points\n  from baseline</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Continue\n  treatment with<span style=\"color:#0000CC\"> </span>trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>\n<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks.</p>\n</td>\n</tr>\n<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &gt; 45%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Continue treatment with trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>\n</td>\n</tr>\n</table>", "ID": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3", "Styles": "width:452.8pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                                       ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr style=\"height:15.75pt\">\n<td colspan=\"3\" style=\"border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">Modifications for Patients with EBC</span></b></p>\n</td>\n</tr>", "ID": "3166492f-2e82-4b45-83fe-99728d8bfe73", "Styles": "height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td colspan=\"3\" style=\"border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">Modifications for Patients with EBC</span></b></p>\n</td>", "ID": "a216ba2a-936e-42e5-87cd-f73d918141b0", "Styles": "border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "3166492f-2e82-4b45-83fe-99728d8bfe73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b>Dose <span style=\"color:black\">Modifications for Patients with EBC</span></b></p>", "ID": "2565595b-62ba-4e0c-be04-0d8f46b97d9a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a216ba2a-936e-42e5-87cd-f73d918141b0"}, {"Element": "<b>Dose <span style=\"color:black\">Modifications for Patients with EBC</span></b>", "ID": "43db944a-f874-4022-92ff-07679c23796b", "Styles": "None", "Classes": "None", "Text": "Dose ", "ParentId": "2565595b-62ba-4e0c-be04-0d8f46b97d9a"}, {"Element": "<span style=\"color:black\">Modifications for Patients with EBC</span>", "ID": "067aca57-0fc8-4ab5-9dca-e523bc2d5a09", "Styles": "color:black", "Classes": "None", "Text": "Modifications for Patients with EBC", "ParentId": "43db944a-f874-4022-92ff-07679c23796b"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Adverse reaction</b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Treatment modification</b></p>\n</td>\n</tr>", "ID": "33cab76a-9ccf-4a29-bc49-a76f15768814", "Styles": "height:7.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Adverse reaction</b></p>\n</td>", "ID": "66eece32-e792-4e73-ab64-51c67d9c81b5", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "33cab76a-9ccf-4a29-bc49-a76f15768814"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Adverse reaction</b></p>", "ID": "8984e3ba-cf0e-41a7-b3f9-bb23b5d69efc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "66eece32-e792-4e73-ab64-51c67d9c81b5"}, {"Element": "<b>Adverse reaction</b>", "ID": "5bc9671e-15db-4082-995b-8faa3bb7f21a", "Styles": "None", "Classes": "None", "Text": "Adverse reaction", "ParentId": "8984e3ba-cf0e-41a7-b3f9-bb23b5d69efc"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>\n</td>", "ID": "dfbccdaa-f9f6-4d92-affb-65c9b29535ad", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "33cab76a-9ccf-4a29-bc49-a76f15768814"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>", "ID": "0e17eaa2-656d-4713-9032-8397aa17dad4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfbccdaa-f9f6-4d92-affb-65c9b29535ad"}, {"Element": "<b><span lang=\"EN-CARRIBEAN\">Severity</span></b>", "ID": "7dcb6efd-e540-4338-944b-2ce4da9a857a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e17eaa2-656d-4713-9032-8397aa17dad4"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Severity</span>", "ID": "19c96df8-6b6d-44d4-ae83-471f13c2e421", "Styles": "None", "Classes": "None", "Text": "Severity", "ParentId": "7dcb6efd-e540-4338-944b-2ce4da9a857a"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Treatment modification</b></p>\n</td>", "ID": "0a90195b-19e8-4b59-b152-3e149254a721", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "33cab76a-9ccf-4a29-bc49-a76f15768814"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Treatment modification</b></p>", "ID": "050019bb-1d88-44a3-8fce-eea05b67e997", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a90195b-19e8-4b59-b152-3e149254a721"}, {"Element": "<b>Treatment modification</b>", "ID": "62137773-1598-48ef-a09a-6e0f9d507945", "Styles": "None", "Classes": "None", "Text": "Treatment modification", "ParentId": "050019bb-1d88-44a3-8fce-eea05b67e997"}, {"Element": "<tr style=\"height:7.75pt\">\n<td rowspan=\"2\" style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Thrombocytopenia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3 on day of scheduled\n  treatment<br/>\n  (25,000 to &lt; 75,000/mm<sup>3</sup>)</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to</span><span style=\"font-family:Symbol\"> \u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then treat at the same dose level. If a\n  patient requires 2 delays due to thrombocytopenia, consider reducing dose by\n  one level.</span></p>\n</td>\n</tr>", "ID": "aa9e5dd8-8b6d-480d-b59c-96260aa1530d", "Styles": "height:7.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"2\" style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Thrombocytopenia</p>\n</td>", "ID": "bb535a32-1a46-4ddd-98c6-9ef8e31e8e79", "Styles": "border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "aa9e5dd8-8b6d-480d-b59c-96260aa1530d"}, {"Element": "<p class=\"MsoNormal\">Thrombocytopenia</p>", "ID": "3ebb05c8-9552-4379-bf32-cc6c5d97ea31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Thrombocytopenia", "ParentId": "bb535a32-1a46-4ddd-98c6-9ef8e31e8e79"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3 on day of scheduled\n  treatment<br/>\n  (25,000 to &lt; 75,000/mm<sup>3</sup>)</span></p>\n</td>", "ID": "2cd34edf-9256-4fab-a98d-12d67721c65f", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "aa9e5dd8-8b6d-480d-b59c-96260aa1530d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3 on day of scheduled\n  treatment<br/>\n  (25,000 to &lt; 75,000/mm<sup>3</sup>)</span></p>", "ID": "13f9cf25-cb4d-4cfa-a945-ee01d76df6c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2cd34edf-9256-4fab-a98d-12d67721c65f"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Grade 2-3 on day of scheduled\n  treatment<br/>\n  (25,000 to &lt; 75,000/mm<sup>3</sup>)</span>", "ID": "8687a7ae-a0f8-47f5-8c02-fd39897088c8", "Styles": "None", "Classes": "None", "Text": "Grade 2-3 on day of scheduled   treatment   (25,000 to < 75,000/mm)", "ParentId": "13f9cf25-cb4d-4cfa-a945-ee01d76df6c3"}, {"Element": "<br/>", "ID": "b4c00dd2-18ef-452c-ab3e-2f6830847dd2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8687a7ae-a0f8-47f5-8c02-fd39897088c8"}, {"Element": "<sup>3</sup>", "ID": "f42b73e9-6701-401b-9f4f-4cd7d7b0862d", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "8687a7ae-a0f8-47f5-8c02-fd39897088c8"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to</span><span style=\"font-family:Symbol\"> \u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then treat at the same dose level. If a\n  patient requires 2 delays due to thrombocytopenia, consider reducing dose by\n  one level.</span></p>\n</td>", "ID": "71055310-2ba2-4425-8198-28a61bc019ce", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "aa9e5dd8-8b6d-480d-b59c-96260aa1530d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to</span><span style=\"font-family:Symbol\"> \u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then treat at the same dose level. If a\n  patient requires 2 delays due to thrombocytopenia, consider reducing dose by\n  one level.</span></p>", "ID": "67343937-5c60-4070-b2fe-50b0d9a86cce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansine", "ParentId": "71055310-2ba2-4425-8198-28a61bc019ce"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Do not administer </span>", "ID": "6f1040c1-6055-435c-9781-777070430166", "Styles": "None", "Classes": "None", "Text": "Do not administer ", "ParentId": "67343937-5c60-4070-b2fe-50b0d9a86cce"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to</span>", "ID": "e0c63aa7-4fa7-43c4-8000-8cdffc79bb0a", "Styles": "None", "Classes": "None", "Text": " until platelet count recovers to", "ParentId": "67343937-5c60-4070-b2fe-50b0d9a86cce"}, {"Element": "<span style=\"font-family:Symbol\"> \u00a3</span>", "ID": "27327b38-b1d5-4512-b719-baab327e1833", "Styles": "font-family:Symbol", "Classes": "None", "Text": " \u00a3", "ParentId": "67343937-5c60-4070-b2fe-50b0d9a86cce"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then treat at the same dose level. If a\n  patient requires 2 delays due to thrombocytopenia, consider reducing dose by\n  one level.</span>", "ID": "985cdb9a-5361-4a54-abcf-2f5f05c698d2", "Styles": "None", "Classes": "None", "Text": " Grade 1   (\u2265 75,000/mm), and then treat at the same dose level. If a   patient requires 2 delays due to thrombocytopenia, consider reducing dose by   one level.", "ParentId": "67343937-5c60-4070-b2fe-50b0d9a86cce"}, {"Element": "<sup>3</sup>", "ID": "60a6bf41-654f-4d7c-801c-3c1c4f90495e", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "985cdb9a-5361-4a54-abcf-2f5f05c698d2"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 at any time<br/>\n  &lt; 25,000/mm<sup>3</sup></span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then reduce one dose level.</span></p>\n</td>\n</tr>", "ID": "60029933-b69a-49ff-b57b-7f1b146f6a7d", "Styles": "height:7.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 at any time<br/>\n  &lt; 25,000/mm<sup>3</sup></span></p>\n</td>", "ID": "4cf83bde-471a-4782-a801-5fdae89767f6", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "60029933-b69a-49ff-b57b-7f1b146f6a7d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 at any time<br/>\n  &lt; 25,000/mm<sup>3</sup></span></p>", "ID": "205c7457-1b23-49ba-b691-9a6e2f71f11c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4cf83bde-471a-4782-a801-5fdae89767f6"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Grade 4 at any time<br/>\n  &lt; 25,000/mm<sup>3</sup></span>", "ID": "75eb1202-a2a2-467b-9586-df9e44a8ad9f", "Styles": "None", "Classes": "None", "Text": "Grade 4 at any time   < 25,000/mm", "ParentId": "205c7457-1b23-49ba-b691-9a6e2f71f11c"}, {"Element": "<br/>", "ID": "43c13088-9842-4485-b453-cb7dade51cc3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "75eb1202-a2a2-467b-9586-df9e44a8ad9f"}, {"Element": "<sup>3</sup>", "ID": "170f086f-8579-41b6-a1f4-7ac59359ff78", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "75eb1202-a2a2-467b-9586-df9e44a8ad9f"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then reduce one dose level.</span></p>\n</td>", "ID": "8ee24654-184c-438f-b15a-a7cc480bc965", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "60029933-b69a-49ff-b57b-7f1b146f6a7d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then reduce one dose level.</span></p>", "ID": "562604ec-f192-475b-a1a0-775aaf52cd2d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansine", "ParentId": "8ee24654-184c-438f-b15a-a7cc480bc965"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Do not administer </span>", "ID": "8a74f4b0-5aa9-4030-bf8e-c1135d35b5a1", "Styles": "None", "Classes": "None", "Text": "Do not administer ", "ParentId": "562604ec-f192-475b-a1a0-775aaf52cd2d"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> until platelet count recovers to </span>", "ID": "9eedcb52-e5b0-429e-84d3-c312afedc273", "Styles": "None", "Classes": "None", "Text": " until platelet count recovers to ", "ParentId": "562604ec-f192-475b-a1a0-775aaf52cd2d"}, {"Element": "<span style=\"font-family:Symbol\">\u00a3</span>", "ID": "cb6c8cac-5cec-419e-af32-f978c4200838", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00a3", "ParentId": "562604ec-f192-475b-a1a0-775aaf52cd2d"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> Grade 1\n  (\u2265 75,000/mm<sup>3</sup>), and then reduce one dose level.</span>", "ID": "1ddd4167-47d5-4234-b31e-42bb22e67d84", "Styles": "None", "Classes": "None", "Text": " Grade 1   (\u2265 75,000/mm), and then reduce one dose level.", "ParentId": "562604ec-f192-475b-a1a0-775aaf52cd2d"}, {"Element": "<sup>3</sup>", "ID": "a99a4dd7-8570-4a28-ba71-c2ccc10b0441", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "1ddd4167-47d5-4234-b31e-42bb22e67d84"}, {"Element": "<tr style=\"height:7.75pt\">\n<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Alanine Transaminase (ALT)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3<br/>\n  (&gt; 3.0 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment)</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until ALT recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>\n</td>\n</tr>", "ID": "0bd66754-c96d-44b5-a8a8-7c79ed187d51", "Styles": "height:7.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Alanine Transaminase (ALT)</p>\n</td>", "ID": "0978dc52-55ac-49cc-97c5-1d8aa9c44688", "Styles": "border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "0bd66754-c96d-44b5-a8a8-7c79ed187d51"}, {"Element": "<p class=\"MsoNormal\">Increased Alanine Transaminase (ALT)</p>", "ID": "8046c046-456f-4dbd-b5b9-cb31cb17ca85", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Increased Alanine Transaminase (ALT)", "ParentId": "0978dc52-55ac-49cc-97c5-1d8aa9c44688"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3<br/>\n  (&gt; 3.0 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment)</span></p>\n</td>", "ID": "d736147a-9add-4e10-9383-070cfe3ae4c5", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "0bd66754-c96d-44b5-a8a8-7c79ed187d51"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2-3<br/>\n  (&gt; 3.0 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment)</span></p>", "ID": "8bc43966-9a60-4578-9d03-aaebaef0ee2c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d736147a-9add-4e10-9383-070cfe3ae4c5"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Grade 2-3<br/>\n  (&gt; 3.0 to \u2264 20</span>", "ID": "7efd28c8-64c7-4b31-9a15-fae70b4a4f5b", "Styles": "None", "Classes": "None", "Text": "Grade 2-3   (> 3.0 to \u2264 20", "ParentId": "8bc43966-9a60-4578-9d03-aaebaef0ee2c"}, {"Element": "<br/>", "ID": "c20ace82-a207-490b-b275-6c1eb066f3ee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7efd28c8-64c7-4b31-9a15-fae70b4a4f5b"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "d65d57a2-e5b2-49ed-ae6d-10feecaf5010", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "8bc43966-9a60-4578-9d03-aaebaef0ee2c"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment)</span>", "ID": "7118bf51-45d5-4549-a7d4-d5074a745943", "Styles": "None", "Classes": "None", "Text": " ULN on day of scheduled treatment)", "ParentId": "8bc43966-9a60-4578-9d03-aaebaef0ee2c"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until ALT recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>\n</td>", "ID": "8084e2fd-1a14-4b8d-8fba-d9ed14cb4d54", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "0bd66754-c96d-44b5-a8a8-7c79ed187d51"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until ALT recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>", "ID": "dbfd3bd8-cf81-41d4-98ab-620c5547ffe5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansine", "ParentId": "8084e2fd-1a14-4b8d-8fba-d9ed14cb4d54"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Do not administer </span>", "ID": "0fddc8d9-6704-44e6-b0c2-2895e08b489a", "Styles": "None", "Classes": "None", "Text": "Do not administer ", "ParentId": "dbfd3bd8-cf81-41d4-98ab-620c5547ffe5"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> until ALT recovers to Grade \u2264 1, and\n  then reduce one dose level</span>", "ID": "10448c2c-6530-49d6-8773-c22bab2de727", "Styles": "None", "Classes": "None", "Text": " until ALT recovers to Grade \u2264 1, and   then reduce one dose level", "ParentId": "dbfd3bd8-cf81-41d4-98ab-620c5547ffe5"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4<br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time)</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "5d80691b-8f72-4b7e-94a2-71573f7ba3c9", "Styles": "height:7.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4<br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time)</span></p>\n</td>", "ID": "b311ba0f-2a5b-4863-9cc7-f20a04cd6129", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "5d80691b-8f72-4b7e-94a2-71573f7ba3c9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4<br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time)</span></p>", "ID": "06179485-ed90-4090-8dc0-311c1ac741ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b311ba0f-2a5b-4863-9cc7-f20a04cd6129"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Grade 4<br/>\n  (&gt; 20 </span>", "ID": "cc0dc344-ca19-451c-93e2-d2278f435376", "Styles": "None", "Classes": "None", "Text": "Grade 4   (> 20 ", "ParentId": "06179485-ed90-4090-8dc0-311c1ac741ff"}, {"Element": "<br/>", "ID": "912090c9-a34e-4073-b43e-69c1fc20363b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc0dc344-ca19-451c-93e2-d2278f435376"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "3fcf5c11-180e-4446-944d-f056c9c84950", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "06179485-ed90-4090-8dc0-311c1ac741ff"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> ULN at any time)</span>", "ID": "18dd55b5-3aa3-45ff-9aa5-45627e8d1e4d", "Styles": "None", "Classes": "None", "Text": " ULN at any time)", "ParentId": "06179485-ed90-4090-8dc0-311c1ac741ff"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>", "ID": "9c692a27-57d4-4a79-a1f5-8c3381cf50a2", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "5d80691b-8f72-4b7e-94a2-71573f7ba3c9"}, {"Element": "<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>", "ID": "8ab2c0bb-d658-4d59-8c7c-4ccb07c6257c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Discontinue trastuzumab emtansine", "ParentId": "9c692a27-57d4-4a79-a1f5-8c3381cf50a2"}, {"Element": "<tr style=\"height:7.75pt\">\n<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Aspartate Transaminase (AST)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 <br/>\n  (&gt; 3.0 to \u2264 5</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> 1, and then\n  treat at the same dose level</span></p>\n</td>\n</tr>", "ID": "98e3e72e-6894-4621-a1fb-8e9bb737e516", "Styles": "height:7.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Aspartate Transaminase (AST)</p>\n</td>", "ID": "e8c8f6fe-9b49-48c6-ab95-d7b76cdd15c3", "Styles": "border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "98e3e72e-6894-4621-a1fb-8e9bb737e516"}, {"Element": "<p class=\"MsoNormal\">Increased Aspartate Transaminase (AST)</p>", "ID": "2f470836-0b72-4e4b-9942-414f9cd6585e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Increased Aspartate Transaminase (AST)", "ParentId": "e8c8f6fe-9b49-48c6-ab95-d7b76cdd15c3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 <br/>\n  (&gt; 3.0 to \u2264 5</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>\n</td>", "ID": "72eaa787-5607-4b26-8bc0-feec36bef2e5", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "98e3e72e-6894-4621-a1fb-8e9bb737e516"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 <br/>\n  (&gt; 3.0 to \u2264 5</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>", "ID": "6497df4c-907e-4993-8d7a-e577240b9109", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "72eaa787-5607-4b26-8bc0-feec36bef2e5"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Grade 2 <br/>\n  (&gt; 3.0 to \u2264 5</span>", "ID": "d9f04f2c-eee7-4851-992d-a3eb4cb34186", "Styles": "None", "Classes": "None", "Text": "Grade 2    (> 3.0 to \u2264 5", "ParentId": "6497df4c-907e-4993-8d7a-e577240b9109"}, {"Element": "<br/>", "ID": "2f77f34d-c546-4023-ae37-effbe4a1a47d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d9f04f2c-eee7-4851-992d-a3eb4cb34186"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "0208114a-5622-4544-a2a7-cb7f79383304", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "6497df4c-907e-4993-8d7a-e577240b9109"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span>", "ID": "c9c5ba39-4c51-4672-9031-707ddec9e453", "Styles": "None", "Classes": "None", "Text": " ULN on day of scheduled treatment) ", "ParentId": "6497df4c-907e-4993-8d7a-e577240b9109"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> 1, and then\n  treat at the same dose level</span></p>\n</td>", "ID": "3ee50ef1-ef86-4de9-afcb-a4defcd080a1", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "98e3e72e-6894-4621-a1fb-8e9bb737e516"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade </span><span style=\"font-family:Symbol\">\u00a3</span><span lang=\"EN-CARRIBEAN\"> 1, and then\n  treat at the same dose level</span></p>", "ID": "01decbe6-f2e0-4b01-9a31-771ad3e862d5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansine", "ParentId": "3ee50ef1-ef86-4de9-afcb-a4defcd080a1"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Do not administer </span>", "ID": "88dabec2-90f2-4da0-8b42-8c260383abca", "Styles": "None", "Classes": "None", "Text": "Do not administer ", "ParentId": "01decbe6-f2e0-4b01-9a31-771ad3e862d5"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade </span>", "ID": "70a8ee4a-22af-450f-ab95-2f2968f92f89", "Styles": "None", "Classes": "None", "Text": " until AST recovers to Grade ", "ParentId": "01decbe6-f2e0-4b01-9a31-771ad3e862d5"}, {"Element": "<span style=\"font-family:Symbol\">\u00a3</span>", "ID": "ae7c2f8d-e3a2-455b-b5f1-be5a42fd5c1b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00a3", "ParentId": "01decbe6-f2e0-4b01-9a31-771ad3e862d5"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> 1, and then\n  treat at the same dose level</span>", "ID": "db26388e-af49-4caf-905e-f6dd61acafc2", "Styles": "None", "Classes": "None", "Text": " 1, and then   treat at the same dose level", "ParentId": "01decbe6-f2e0-4b01-9a31-771ad3e862d5"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3 <br/>\n  (&gt; 5 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>\n</td>\n</tr>", "ID": "e2a72f39-6b0e-41dc-9e5b-189d611f34d9", "Styles": "height:7.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3 <br/>\n  (&gt; 5 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>\n</td>", "ID": "17b963c5-e78f-4edf-8beb-4c4788886912", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "e2a72f39-6b0e-41dc-9e5b-189d611f34d9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3 <br/>\n  (&gt; 5 to \u2264 20</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span></p>", "ID": "81e085b0-658d-408b-951c-ec8d9cce9951", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "17b963c5-e78f-4edf-8beb-4c4788886912"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Grade 3 <br/>\n  (&gt; 5 to \u2264 20</span>", "ID": "e34bbe0a-fe06-4c7f-82b7-04829ddf3acc", "Styles": "None", "Classes": "None", "Text": "Grade 3    (> 5 to \u2264 20", "ParentId": "81e085b0-658d-408b-951c-ec8d9cce9951"}, {"Element": "<br/>", "ID": "848cc2f3-8625-4d3f-a14f-e9d5bca46ceb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e34bbe0a-fe06-4c7f-82b7-04829ddf3acc"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "d41ae14c-8b3d-4f18-a988-278cda7317de", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "81e085b0-658d-408b-951c-ec8d9cce9951"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> ULN on day of scheduled treatment) </span>", "ID": "9fbc117f-0d7a-4f5c-9a82-2fc7ed8a2044", "Styles": "None", "Classes": "None", "Text": " ULN on day of scheduled treatment) ", "ParentId": "81e085b0-658d-408b-951c-ec8d9cce9951"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>\n</td>", "ID": "ba28c68b-7775-47f6-bca0-e9df9995088e", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "e2a72f39-6b0e-41dc-9e5b-189d611f34d9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade \u2264 1, and\n  then reduce one dose level</span></p>", "ID": "ce521a5c-a509-4021-99a7-78e5fdfc160b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansine", "ParentId": "ba28c68b-7775-47f6-bca0-e9df9995088e"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Do not administer </span>", "ID": "b35632a2-7925-41a0-ac93-24127b3203a4", "Styles": "None", "Classes": "None", "Text": "Do not administer ", "ParentId": "ce521a5c-a509-4021-99a7-78e5fdfc160b"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> until AST recovers to Grade \u2264 1, and\n  then reduce one dose level</span>", "ID": "4bd6ade5-6da7-4c24-9721-51a77d793476", "Styles": "None", "Classes": "None", "Text": " until AST recovers to Grade \u2264 1, and   then reduce one dose level", "ParentId": "ce521a5c-a509-4021-99a7-78e5fdfc160b"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 <br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time) </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "b7abc346-3af3-438e-a804-0adeb070f251", "Styles": "height:7.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 <br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time) </span></p>\n</td>", "ID": "aee2e9aa-3f65-4499-9845-bee49febbb2d", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "b7abc346-3af3-438e-a804-0adeb070f251"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 4 <br/>\n  (&gt; 20 </span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time) </span></p>", "ID": "3c943b91-bf55-4e2a-a7c4-6c30cf462cbf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aee2e9aa-3f65-4499-9845-bee49febbb2d"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Grade 4 <br/>\n  (&gt; 20 </span>", "ID": "b0a9ee5c-a1af-4774-a378-a494573334f5", "Styles": "None", "Classes": "None", "Text": "Grade 4    (> 20 ", "ParentId": "3c943b91-bf55-4e2a-a7c4-6c30cf462cbf"}, {"Element": "<br/>", "ID": "0c738886-416e-4e8d-ae75-75fdc3892317", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b0a9ee5c-a1af-4774-a378-a494573334f5"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "81ba44f1-8fd1-4bcf-ad92-4b49624fd90d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "3c943b91-bf55-4e2a-a7c4-6c30cf462cbf"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> ULN at any time) </span>", "ID": "7b948c09-85a1-4bb2-8256-72533b36a741", "Styles": "None", "Classes": "None", "Text": " ULN at any time) ", "ParentId": "3c943b91-bf55-4e2a-a7c4-6c30cf462cbf"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>", "ID": "808ed886-763c-4f02-900b-1eda8e8bb4e1", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "b7abc346-3af3-438e-a804-0adeb070f251"}, {"Element": "<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>", "ID": "3292522f-d1d5-4125-8562-cb11569991b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Discontinue trastuzumab emtansine", "ParentId": "808ed886-763c-4f02-900b-1eda8e8bb4e1"}, {"Element": "<tr style=\"height:7.75pt\">\n<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Hyperbilirubinemia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 1.0 to \u2264 2.0</span><span style=\"font-family:Symbol\">\u00b4 </span><span lang=\"EN-CARRIBEAN\">the ULN on day of scheduled treatment </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until total bilirubin recovers to \u2264\n  1.0\u00d7 ULN, and then reduce one dose level</span></p>\n</td>\n</tr>", "ID": "8d81b171-aa9b-417f-b12a-2a810d382f7a", "Styles": "height:7.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Hyperbilirubinemia</p>\n</td>", "ID": "fa6df0ed-e840-4e3d-aa72-fe7e776be908", "Styles": "border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "8d81b171-aa9b-417f-b12a-2a810d382f7a"}, {"Element": "<p class=\"MsoNormal\">Hyperbilirubinemia</p>", "ID": "c45bf020-aa95-4d5c-a450-c9100af28b51", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Hyperbilirubinemia", "ParentId": "fa6df0ed-e840-4e3d-aa72-fe7e776be908"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 1.0 to \u2264 2.0</span><span style=\"font-family:Symbol\">\u00b4 </span><span lang=\"EN-CARRIBEAN\">the ULN on day of scheduled treatment </span></p>\n</td>", "ID": "130c1326-21a4-4981-875f-80c9e6b7e1fb", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "8d81b171-aa9b-417f-b12a-2a810d382f7a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 1.0 to \u2264 2.0</span><span style=\"font-family:Symbol\">\u00b4 </span><span lang=\"EN-CARRIBEAN\">the ULN on day of scheduled treatment </span></p>", "ID": "0418577b-55e2-4c43-96ba-a0191b61019e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "130c1326-21a4-4981-875f-80c9e6b7e1fb"}, {"Element": "<span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 1.0 to \u2264 2.0</span>", "ID": "b82050e6-fda6-499b-be9c-59a578503366", "Styles": "None", "Classes": "None", "Text": "TBILI    > 1.0 to \u2264 2.0", "ParentId": "0418577b-55e2-4c43-96ba-a0191b61019e"}, {"Element": "<br/>", "ID": "82f5223e-8ffd-481a-811e-0ced7c5193dc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b82050e6-fda6-499b-be9c-59a578503366"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4 </span>", "ID": "ed9abfc3-38cd-4131-9ba8-bf79d86e8ba1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4 ", "ParentId": "0418577b-55e2-4c43-96ba-a0191b61019e"}, {"Element": "<span lang=\"EN-CARRIBEAN\">the ULN on day of scheduled treatment </span>", "ID": "47b45467-2b28-44c6-aaad-b65f64175f21", "Styles": "None", "Classes": "None", "Text": "the ULN on day of scheduled treatment ", "ParentId": "0418577b-55e2-4c43-96ba-a0191b61019e"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until total bilirubin recovers to \u2264\n  1.0\u00d7 ULN, and then reduce one dose level</span></p>\n</td>", "ID": "b55066c2-1776-455c-bc94-c2dc21160788", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "8d81b171-aa9b-417f-b12a-2a810d382f7a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> until total bilirubin recovers to \u2264\n  1.0\u00d7 ULN, and then reduce one dose level</span></p>", "ID": "bb940b74-2a59-4562-bac7-a8c40bbc274a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansine", "ParentId": "b55066c2-1776-455c-bc94-c2dc21160788"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Do not administer </span>", "ID": "83e3e553-6c05-4f11-a2c8-91d0c5cf2359", "Styles": "None", "Classes": "None", "Text": "Do not administer ", "ParentId": "bb940b74-2a59-4562-bac7-a8c40bbc274a"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> until total bilirubin recovers to \u2264\n  1.0\u00d7 ULN, and then reduce one dose level</span>", "ID": "6a26dbe0-4dae-4b60-a22c-0387b7f3297d", "Styles": "None", "Classes": "None", "Text": " until total bilirubin recovers to \u2264   1.0\u00d7 ULN, and then reduce one dose level", "ParentId": "bb940b74-2a59-4562-bac7-a8c40bbc274a"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 2</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time </span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "d3f71e8e-7549-47fb-a358-bba5a326262c", "Styles": "height:7.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 2</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time </span></p>\n</td>", "ID": "092a5329-c582-4e91-ae2c-c9e7005426f5", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "d3f71e8e-7549-47fb-a358-bba5a326262c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 2</span><span style=\"font-family:Symbol\">\u00b4</span><span lang=\"EN-CARRIBEAN\"> ULN at any time </span></p>", "ID": "213bad2b-c29d-424c-a0de-6e4206a0185a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "092a5329-c582-4e91-ae2c-c9e7005426f5"}, {"Element": "<span lang=\"EN-CARRIBEAN\">TBILI <br/>\n  &gt; 2</span>", "ID": "cb3f8132-f086-454b-a6d8-fbb7008b26b0", "Styles": "None", "Classes": "None", "Text": "TBILI    > 2", "ParentId": "213bad2b-c29d-424c-a0de-6e4206a0185a"}, {"Element": "<br/>", "ID": "d76f475e-9e49-4a3b-ae26-cc43f48ea16f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cb3f8132-f086-454b-a6d8-fbb7008b26b0"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "ebec1325-f4d4-427a-9921-5f69863e7b7d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "213bad2b-c29d-424c-a0de-6e4206a0185a"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> ULN at any time </span>", "ID": "45f84ca8-8ee5-45a2-8501-667faa6a066b", "Styles": "None", "Classes": "None", "Text": " ULN at any time ", "ParentId": "213bad2b-c29d-424c-a0de-6e4206a0185a"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>", "ID": "9ec7647e-c813-4c3c-ad3b-bab0ca1f8a7f", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "d3f71e8e-7549-47fb-a358-bba5a326262c"}, {"Element": "<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>", "ID": "b7b4d96e-8e51-4a3c-b533-2e358f929b0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Discontinue trastuzumab emtansine", "ParentId": "9ec7647e-c813-4c3c-ad3b-bab0ca1f8a7f"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>\n</td>\n</tr>", "ID": "6d0f133f-9e04-4098-8f89-3790aff21968", "Styles": "height:7.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>\n</td>", "ID": "6f8ba3ad-78f0-4b15-aab2-a36d93ae2a32", "Styles": "border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "6d0f133f-9e04-4098-8f89-3790aff21968"}, {"Element": "<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>", "ID": "5e53c0b0-6dd0-4291-bb94-f0fcf7efb845", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Drug Induced Liver Injury (DILI)", "ParentId": "6f8ba3ad-78f0-4b15-aab2-a36d93ae2a32"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>\n</td>", "ID": "e486414c-1990-453e-a624-04ee9e8e19c8", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "6d0f133f-9e04-4098-8f89-3790aff21968"}, {"Element": "<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>", "ID": "5b4f47a6-ecd8-4593-a655-22be598c4869", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Serum transaminases > 3 x ULN and concomitant total   bilirubin > 2 ULN", "ParentId": "e486414c-1990-453e-a624-04ee9e8e19c8"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "8991b6c9-1ec0-44c9-9f58-9e63ae6042fa", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "5b4f47a6-ecd8-4593-a655-22be598c4869"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>\n</td>", "ID": "004c3f67-f0d4-46bc-acda-1c553314ebe4", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "6d0f133f-9e04-4098-8f89-3790aff21968"}, {"Element": "<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>", "ID": "03115a3a-fd74-4f17-93db-33c518918364", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Permanently discontinue trastuzumab emtansinein the absence of another   likely cause for the elevation of liver enzymes and bilirubin, e.g. liver   metastasis or concomitant medication", "ParentId": "004c3f67-f0d4-46bc-acda-1c553314ebe4"}, {"Element": "<span style='font-family:\"Calibri\",sans-serif'> </span>", "ID": "c4ab6df6-d5e0-49d9-814a-62f2161fefd6", "Styles": "font-family:\"Calibri\",sans-serif", "Classes": "None", "Text": " ", "ParentId": "03115a3a-fd74-4f17-93db-33c518918364"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Nodular Regenerative Hyperplasia (NRH)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">All Grades</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "b6647cdf-e910-49f2-b015-65c1bbb217ba", "Styles": "height:7.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Nodular Regenerative Hyperplasia (NRH)</p>\n</td>", "ID": "518ad826-3a04-4ee9-95b1-58a3415c12ae", "Styles": "border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "b6647cdf-e910-49f2-b015-65c1bbb217ba"}, {"Element": "<p class=\"MsoNormal\">Nodular Regenerative Hyperplasia (NRH)</p>", "ID": "939c1e2e-79d3-4c39-81cc-1ff8d393a0c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Nodular Regenerative Hyperplasia (NRH)", "ParentId": "518ad826-3a04-4ee9-95b1-58a3415c12ae"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">All Grades</p>\n</td>", "ID": "8b41e951-02c5-4ca7-8066-f734805569f1", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "b6647cdf-e910-49f2-b015-65c1bbb217ba"}, {"Element": "<p class=\"MsoNormal\">All Grades</p>", "ID": "0354d12a-25e0-492d-b992-a4dbf8085af1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "All Grades", "ParentId": "8b41e951-02c5-4ca7-8066-f734805569f1"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>\n</td>", "ID": "610f9b4c-024f-42b4-9b1c-f89c72c1fcf6", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "b6647cdf-e910-49f2-b015-65c1bbb217ba"}, {"Element": "<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>", "ID": "428f9959-5588-4232-b370-105e875d3261", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Permanently discontinue trastuzumab emtansine", "ParentId": "610f9b4c-024f-42b4-9b1c-f89c72c1fcf6"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Peripheral Neuropathy</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3-4</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until resolution <span style=\"font-family:Symbol\">\u00a3 </span>Grade 2</p>\n</td>\n</tr>", "ID": "df273a8c-fe42-4fa3-86c1-49acdc191e55", "Styles": "height:7.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Peripheral Neuropathy</p>\n</td>", "ID": "c4c84403-179f-418d-8965-fe0623e6e8b5", "Styles": "border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "df273a8c-fe42-4fa3-86c1-49acdc191e55"}, {"Element": "<p class=\"MsoNormal\">Peripheral Neuropathy</p>", "ID": "0fc148d6-c77a-4ad7-adec-9468cb1c8b2d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Peripheral Neuropathy", "ParentId": "c4c84403-179f-418d-8965-fe0623e6e8b5"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3-4</p>\n</td>", "ID": "2ca0167f-3fff-4294-8e0f-79227e1d4181", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "df273a8c-fe42-4fa3-86c1-49acdc191e55"}, {"Element": "<p class=\"MsoNormal\">Grade 3-4</p>", "ID": "315da6d7-690a-4835-8431-cd255fb2264a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 3-4", "ParentId": "2ca0167f-3fff-4294-8e0f-79227e1d4181"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until resolution <span style=\"font-family:Symbol\">\u00a3 </span>Grade 2</p>\n</td>", "ID": "cf6969d6-14c3-480e-a4fd-830e1160be08", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "df273a8c-fe42-4fa3-86c1-49acdc191e55"}, {"Element": "<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until resolution <span style=\"font-family:Symbol\">\u00a3 </span>Grade 2</p>", "ID": "bad7821e-2db3-4488-9a91-8621f2130ab5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Do not administer trastuzumab emtansine until resolution Grade 2", "ParentId": "cf6969d6-14c3-480e-a4fd-830e1160be08"}, {"Element": "<span style=\"font-family:Symbol\">\u00a3 </span>", "ID": "374ada3a-93cf-4093-b1c0-0da8ab171923", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00a3 ", "ParentId": "bad7821e-2db3-4488-9a91-8621f2130ab5"}, {"Element": "<tr style=\"height:7.75pt\">\n<td rowspan=\"4\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &lt; 45%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> .<br/>\n  Repeat LVEF assessment within 3 weeks. </span>If LVEF &lt; 45% is confirmed,\n  discontinue trastuzumab emtansine.</p>\n</td>\n</tr>", "ID": "b6c56435-af09-4d80-a560-b2d7fac995d0", "Styles": "height:7.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"4\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>\n</td>", "ID": "cda4033b-8256-4d54-88cd-9ed93c7730ff", "Styles": "border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "b6c56435-af09-4d80-a560-b2d7fac995d0"}, {"Element": "<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>", "ID": "070c611a-77a0-4e0f-83f4-1a40946d32f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Left Ventricular Dysfunction ", "ParentId": "cda4033b-8256-4d54-88cd-9ed93c7730ff"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &lt; 45%</p>\n</td>", "ID": "a914d545-72ee-4256-838e-4a3f0e854765", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "b6c56435-af09-4d80-a560-b2d7fac995d0"}, {"Element": "<p class=\"MsoNormal\">LVEF &lt; 45%</p>", "ID": "fc692200-1d63-4206-b397-b76533e9a50b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "LVEF < 45%", "ParentId": "a914d545-72ee-4256-838e-4a3f0e854765"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> .<br/>\n  Repeat LVEF assessment within 3 weeks. </span>If LVEF &lt; 45% is confirmed,\n  discontinue trastuzumab emtansine.</p>\n</td>", "ID": "c4c6cba9-f5fc-4ddf-9c27-065f3d071dd0", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "b6c56435-af09-4d80-a560-b2d7fac995d0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\"> .<br/>\n  Repeat LVEF assessment within 3 weeks. </span>If LVEF &lt; 45% is confirmed,\n  discontinue trastuzumab emtansine.</p>", "ID": "8ba92b46-3101-47a5-b935-f0dd0fdce8be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansineIf LVEF < 45% is confirmed,   discontinue trastuzumab emtansine.", "ParentId": "c4c6cba9-f5fc-4ddf-9c27-065f3d071dd0"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Do not administer </span>", "ID": "a4a39b1a-d9f9-4d88-83a6-c4d1c66602ec", "Styles": "None", "Classes": "None", "Text": "Do not administer ", "ParentId": "8ba92b46-3101-47a5-b935-f0dd0fdce8be"}, {"Element": "<span lang=\"EN-CARRIBEAN\"> .<br/>\n  Repeat LVEF assessment within 3 weeks. </span>", "ID": "d1eac4b8-ea49-4b18-8664-ae278a58a40a", "Styles": "None", "Classes": "None", "Text": " .   Repeat LVEF assessment within 3 weeks. ", "ParentId": "8ba92b46-3101-47a5-b935-f0dd0fdce8be"}, {"Element": "<br/>", "ID": "8796c9e1-1829-4b5c-a1c4-0e90b01682cb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d1eac4b8-ea49-4b18-8664-ae278a58a40a"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is \u2265 10% points from baseline*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine.<span lang=\"EN-CARRIBEAN\"><br/>\n  Repeat LVEF assessment within 3 weeks. If the LVEF remains &lt; 50% and has\n  not recovered to &lt; 10% points from baseline, discontinue </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">.</span></p>\n</td>\n</tr>", "ID": "5b95e3f5-2eb0-41ee-8252-16bae6e1f5b3", "Styles": "height:7.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is \u2265 10% points from baseline*</span></p>\n</td>", "ID": "9bdbc4a2-7412-407c-b80d-a4d50695b1d1", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "5b95e3f5-2eb0-41ee-8252-16bae6e1f5b3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is \u2265 10% points from baseline*</span></p>", "ID": "9aba0565-35f7-425b-9401-8844b9d2311d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9bdbc4a2-7412-407c-b80d-a4d50695b1d1"}, {"Element": "<span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is \u2265 10% points from baseline*</span>", "ID": "dd241ee7-0042-43f6-9358-c5a8f3736c54", "Styles": "None", "Classes": "None", "Text": "LVEF 45% to < 50% and decrease   is \u2265 10% points from baseline*", "ParentId": "9aba0565-35f7-425b-9401-8844b9d2311d"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine.<span lang=\"EN-CARRIBEAN\"><br/>\n  Repeat LVEF assessment within 3 weeks. If the LVEF remains &lt; 50% and has\n  not recovered to &lt; 10% points from baseline, discontinue </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">.</span></p>\n</td>", "ID": "fac728d8-18e3-4448-9600-2cb8d98713dc", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "5b95e3f5-2eb0-41ee-8252-16bae6e1f5b3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Do not administer </span>trastuzumab\n  emtansine.<span lang=\"EN-CARRIBEAN\"><br/>\n  Repeat LVEF assessment within 3 weeks. If the LVEF remains &lt; 50% and has\n  not recovered to &lt; 10% points from baseline, discontinue </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">.</span></p>", "ID": "a4ff45b7-fd8f-4722-9435-6cff2fd594d3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansine.trastuzumab   emtansine", "ParentId": "fac728d8-18e3-4448-9600-2cb8d98713dc"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Do not administer </span>", "ID": "0c22c828-f746-43ab-a8d0-bd5efc68a854", "Styles": "None", "Classes": "None", "Text": "Do not administer ", "ParentId": "a4ff45b7-fd8f-4722-9435-6cff2fd594d3"}, {"Element": "<span lang=\"EN-CARRIBEAN\"><br/>\n  Repeat LVEF assessment within 3 weeks. If the LVEF remains &lt; 50% and has\n  not recovered to &lt; 10% points from baseline, discontinue </span>", "ID": "caa7f006-54d0-4a7e-8767-f46d4c34680f", "Styles": "None", "Classes": "None", "Text": "   Repeat LVEF assessment within 3 weeks. If the LVEF remains < 50% and has   not recovered to < 10% points from baseline, discontinue ", "ParentId": "a4ff45b7-fd8f-4722-9435-6cff2fd594d3"}, {"Element": "<br/>", "ID": "1b41e42b-7bf5-4cb7-9054-18dac36d344a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "caa7f006-54d0-4a7e-8767-f46d4c34680f"}, {"Element": "<span lang=\"EN-CARRIBEAN\">.</span>", "ID": "61b9d54a-be1a-4a7c-84c2-b8ffc64479e4", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "a4ff45b7-fd8f-4722-9435-6cff2fd594d3"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is &lt; 10% points from baseline*</span></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">. <br/>\n  Repeat LVEF assessment within 3 weeks. </span></p>\n</td>\n</tr>", "ID": "67807fd4-097d-4a2e-ad68-12ace6d2aa6e", "Styles": "height:7.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is &lt; 10% points from baseline*</span></p>\n</td>", "ID": "c0f60f21-e83b-4614-965e-35f52a78348f", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "67807fd4-097d-4a2e-ad68-12ace6d2aa6e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is &lt; 10% points from baseline*</span></p>", "ID": "e5042558-dac6-43df-884a-9217aafa8686", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c0f60f21-e83b-4614-965e-35f52a78348f"}, {"Element": "<span lang=\"EN-CARRIBEAN\">LVEF 45% to &lt; 50% and decrease\n  is &lt; 10% points from baseline*</span>", "ID": "5bf28e49-e9c1-41fe-bcf5-8691d13ba8a0", "Styles": "None", "Classes": "None", "Text": "LVEF 45% to < 50% and decrease   is < 10% points from baseline*", "ParentId": "e5042558-dac6-43df-884a-9217aafa8686"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">. <br/>\n  Repeat LVEF assessment within 3 weeks. </span></p>\n</td>", "ID": "eca2eced-5a39-4594-9459-25fbd318995f", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "67807fd4-097d-4a2e-ad68-12ace6d2aa6e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine<span lang=\"EN-CARRIBEAN\">. <br/>\n  Repeat LVEF assessment within 3 weeks. </span></p>", "ID": "685122bc-868a-4c1e-ae7f-190f0abde2e7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansine", "ParentId": "eca2eced-5a39-4594-9459-25fbd318995f"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Continue treatment with </span>", "ID": "53901d6a-ad50-4f5a-b630-d55dc38d1976", "Styles": "None", "Classes": "None", "Text": "Continue treatment with ", "ParentId": "685122bc-868a-4c1e-ae7f-190f0abde2e7"}, {"Element": "<span lang=\"EN-CARRIBEAN\">. <br/>\n  Repeat LVEF assessment within 3 weeks. </span>", "ID": "97241a85-97a6-4e26-a8f7-1a7ed73601df", "Styles": "None", "Classes": "None", "Text": ".    Repeat LVEF assessment within 3 weeks. ", "ParentId": "685122bc-868a-4c1e-ae7f-190f0abde2e7"}, {"Element": "<br/>", "ID": "ee7632eb-44ef-4891-81d1-9f18c9a4c09e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "97241a85-97a6-4e26-a8f7-1a7ed73601df"}, {"Element": "<tr style=\"height:7.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF \u2265 50%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine</p>\n</td>\n</tr>", "ID": "ee41ea55-fe38-4640-8b1b-4f7565539e58", "Styles": "height:7.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF \u2265 50%</p>\n</td>", "ID": "00b77cc2-93c1-4b3f-9cc1-0227b1aa468d", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "ee41ea55-fe38-4640-8b1b-4f7565539e58"}, {"Element": "<p class=\"MsoNormal\">LVEF \u2265 50%</p>", "ID": "94dae69f-1c51-488e-88d7-a3ce2cd80d90", "Styles": "None", "Classes": "['MsoNormal']", "Text": "LVEF \u2265 50%", "ParentId": "00b77cc2-93c1-4b3f-9cc1-0227b1aa468d"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt\" valign=\"top\">\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine</p>\n</td>", "ID": "b19ea245-7fc9-4336-86bb-34f9246ac4a6", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt", "Classes": "None", "Text": "  ", "ParentId": "ee41ea55-fe38-4640-8b1b-4f7565539e58"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Continue treatment with </span>trastuzumab\n  emtansine</p>", "ID": "c16383b2-2d71-4bec-8975-d1c8a1a54a6c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab   emtansine", "ParentId": "b19ea245-7fc9-4336-86bb-34f9246ac4a6"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Continue treatment with </span>", "ID": "f2209b93-c551-414c-b24a-9f47a0ecbfa5", "Styles": "None", "Classes": "None", "Text": "Continue treatment with ", "ParentId": "c16383b2-2d71-4bec-8975-d1c8a1a54a6c"}, {"Element": "<tr style=\"height:97.5pt\">\n<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:97.5pt\" valign=\"top\">\n<p class=\"MsoNormal\">Heart Failure</p>\n</td>\n<td style=\"border:none;border-right:solid windowtext 1.0pt;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:97.5pt\" valign=\"bottom\">\n<p class=\"MsoNormal\">Symptomatic CHF,</p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3-4 LVSD or Grade 3-4 heart\n  failure, or</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 heart failure <br/>\n  accompanied by LVEF &lt;45% </span></p>\n</td>\n<td style=\"border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:97.5pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "9ca7662b-a4be-4b2b-bab8-d10edacda57f", "Styles": "height:97.5pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:97.5pt\" valign=\"top\">\n<p class=\"MsoNormal\">Heart Failure</p>\n</td>", "ID": "ab667294-1c24-411d-820f-c27bdfd15905", "Styles": "border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:97.5pt", "Classes": "None", "Text": "  ", "ParentId": "9ca7662b-a4be-4b2b-bab8-d10edacda57f"}, {"Element": "<p class=\"MsoNormal\">Heart Failure</p>", "ID": "1fbff4fe-b5e6-43cf-8d28-411c0b655164", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Heart Failure", "ParentId": "ab667294-1c24-411d-820f-c27bdfd15905"}, {"Element": "<td style=\"border:none;border-right:solid windowtext 1.0pt;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:97.5pt\" valign=\"bottom\">\n<p class=\"MsoNormal\">Symptomatic CHF,</p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3-4 LVSD or Grade 3-4 heart\n  failure, or</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 heart failure <br/>\n  accompanied by LVEF &lt;45% </span></p>\n</td>", "ID": "7fb33334-1c37-43b1-ab82-c4002b3c8755", "Styles": "border:none;border-right:solid windowtext 1.0pt;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:97.5pt", "Classes": "None", "Text": "    ", "ParentId": "9ca7662b-a4be-4b2b-bab8-d10edacda57f"}, {"Element": "<p class=\"MsoNormal\">Symptomatic CHF,</p>", "ID": "714f58f9-ab37-43c6-a923-9461cb10e693", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Symptomatic CHF,", "ParentId": "7fb33334-1c37-43b1-ab82-c4002b3c8755"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 3-4 LVSD or Grade 3-4 heart\n  failure, or</span></p>", "ID": "e8020ebd-d85a-4888-9cb2-017d61f44e04", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7fb33334-1c37-43b1-ab82-c4002b3c8755"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Grade 3-4 LVSD or Grade 3-4 heart\n  failure, or</span>", "ID": "8e046664-3e06-49f3-bb58-b48a4fda80e6", "Styles": "None", "Classes": "None", "Text": "Grade 3-4 LVSD or Grade 3-4 heart   failure, or", "ParentId": "e8020ebd-d85a-4888-9cb2-017d61f44e04"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Grade 2 heart failure <br/>\n  accompanied by LVEF &lt;45% </span></p>", "ID": "c278afad-64ab-436b-a82d-c4cf05f8cd7b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7fb33334-1c37-43b1-ab82-c4002b3c8755"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Grade 2 heart failure <br/>\n  accompanied by LVEF &lt;45% </span>", "ID": "56e84f0c-60ea-4445-af00-eb0a7f5321c9", "Styles": "None", "Classes": "None", "Text": "Grade 2 heart failure    accompanied by LVEF <45% ", "ParentId": "c278afad-64ab-436b-a82d-c4cf05f8cd7b"}, {"Element": "<br/>", "ID": "b94d330a-e50e-491c-b1dd-cac0b61ab14e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "56e84f0c-60ea-4445-af00-eb0a7f5321c9"}, {"Element": "<td style=\"border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:97.5pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>", "ID": "9b5598c5-0e5a-4539-8179-a61ca71bf43a", "Styles": "border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 0in 0in 0in;height:97.5pt", "Classes": "None", "Text": "  ", "ParentId": "9ca7662b-a4be-4b2b-bab8-d10edacda57f"}, {"Element": "<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>", "ID": "257eeb80-3c68-49c8-8843-4bce21dc3960", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Discontinue trastuzumab emtansine", "ParentId": "9b5598c5-0e5a-4539-8179-a61ca71bf43a"}, {"Element": "<tr style=\"height:35.35pt\">\n<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Pulmonary Toxicity</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Interstitial lung disease (ILD) or pneumonitis</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "08ac1f1e-a05e-4a8c-a86a-d9e6e49f0b20", "Styles": "height:35.35pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Pulmonary Toxicity</p>\n</td>", "ID": "2164c30f-5dd4-46d3-bbe9-a667988e382d", "Styles": "border:solid windowtext 1.0pt;border-bottom:none;\n  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt", "Classes": "None", "Text": "  ", "ParentId": "08ac1f1e-a05e-4a8c-a86a-d9e6e49f0b20"}, {"Element": "<p class=\"MsoNormal\">Pulmonary Toxicity</p>", "ID": "55d9efe7-dd77-4c80-ba0b-3d852e01154b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Pulmonary Toxicity", "ParentId": "2164c30f-5dd4-46d3-bbe9-a667988e382d"}, {"Element": "<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Interstitial lung disease (ILD) or pneumonitis</p>\n</td>", "ID": "01c6fa8b-1921-4d3d-938c-d9bd61e35e9f", "Styles": "border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt", "Classes": "None", "Text": "  ", "ParentId": "08ac1f1e-a05e-4a8c-a86a-d9e6e49f0b20"}, {"Element": "<p class=\"MsoNormal\">Interstitial lung disease (ILD) or pneumonitis</p>", "ID": "c0f1f3db-f2f1-48d8-86cd-2c05f3c5c0da", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Interstitial lung disease (ILD) or pneumonitis", "ParentId": "01c6fa8b-1921-4d3d-938c-d9bd61e35e9f"}, {"Element": "<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>\n</td>", "ID": "032cb5ec-a957-4ecc-a4e3-f4478f1fb614", "Styles": "border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt", "Classes": "None", "Text": "  ", "ParentId": "08ac1f1e-a05e-4a8c-a86a-d9e6e49f0b20"}, {"Element": "<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine</p>", "ID": "99aaf597-1f4b-4593-856d-06a1a6f6f6eb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Permanently discontinue trastuzumab emtansine", "ParentId": "032cb5ec-a957-4ecc-a4e3-f4478f1fb614"}, {"Element": "<tr style=\"height:35.35pt\">\n<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;border-bottom:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Radiotherapy-Related Pneumonitis</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine if not resolving with\n  standard treatment</p>\n</td>\n</tr>", "ID": "f5069824-1b00-477d-a961-d560a80e0160", "Styles": "height:35.35pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"2\" style=\"border:solid windowtext 1.0pt;border-bottom:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Radiotherapy-Related Pneumonitis</p>\n</td>", "ID": "d8a1db8f-eeb2-48a4-a3f4-011313358ddf", "Styles": "border:solid windowtext 1.0pt;border-bottom:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt", "Classes": "None", "Text": "  ", "ParentId": "f5069824-1b00-477d-a961-d560a80e0160"}, {"Element": "<p class=\"MsoNormal\">Radiotherapy-Related Pneumonitis</p>", "ID": "3b2de01f-f2d2-4755-a548-6bcdc0d986f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Radiotherapy-Related Pneumonitis", "ParentId": "d8a1db8f-eeb2-48a4-a3f4-011313358ddf"}, {"Element": "<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2</p>\n</td>", "ID": "e17796f5-c3e1-4833-a25f-9d8daad7be16", "Styles": "border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt", "Classes": "None", "Text": "  ", "ParentId": "f5069824-1b00-477d-a961-d560a80e0160"}, {"Element": "<p class=\"MsoNormal\">Grade 2</p>", "ID": "4d3e2f64-6c2d-4e31-9565-1857a2fe4704", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 2", "ParentId": "e17796f5-c3e1-4833-a25f-9d8daad7be16"}, {"Element": "<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine if not resolving with\n  standard treatment</p>\n</td>", "ID": "bccc8fb9-905d-44c5-9b1c-e602b3033bea", "Styles": "border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt", "Classes": "None", "Text": "  ", "ParentId": "f5069824-1b00-477d-a961-d560a80e0160"}, {"Element": "<p class=\"MsoNormal\">Discontinue trastuzumab emtansine if not resolving with\n  standard treatment</p>", "ID": "8cb14388-8373-4692-b3a8-73208f653f00", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Discontinue trastuzumab emtansine if not resolving with   standard treatment", "ParentId": "bccc8fb9-905d-44c5-9b1c-e602b3033bea"}, {"Element": "<tr style=\"height:35.35pt\">\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3-4</p>\n</td>\n<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "30f1a836-ccf5-4ef4-a1cf-a783c1a780fc", "Styles": "height:35.35pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3-4</p>\n</td>", "ID": "7f0cf6ae-ef83-4330-b077-12948b12aa3a", "Styles": "border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:35.35pt", "Classes": "None", "Text": "  ", "ParentId": "30f1a836-ccf5-4ef4-a1cf-a783c1a780fc"}, {"Element": "<p class=\"MsoNormal\">Grade 3-4</p>", "ID": "c4cc4b3a-7af9-4b34-9348-c711da091141", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 3-4", "ParentId": "7f0cf6ae-ef83-4330-b077-12948b12aa3a"}, {"Element": "<td style=\"border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>", "ID": "4fea2e08-c2a6-4d77-9933-8d21811ea454", "Styles": "border-top:solid windowtext 1.0pt;border-left:none;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\n  height:35.35pt", "Classes": "None", "Text": "  ", "ParentId": "30f1a836-ccf5-4ef4-a1cf-a783c1a780fc"}, {"Element": "<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>", "ID": "822b0d6d-16b4-42ca-81cf-d8197f6677f0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Discontinue trastuzumab emtansine", "ParentId": "4fea2e08-c2a6-4d77-9933-8d21811ea454"}, {"Element": "<tr style=\"height:15.75pt\">\n<td colspan=\"3\" style=\"border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"color:black\">Dose Modifications for Patients with MBC</span></b></p>\n</td>\n</tr>", "ID": "6cf74322-958c-498e-8171-955309fefcd3", "Styles": "height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td colspan=\"3\" style=\"border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"color:black\">Dose Modifications for Patients with MBC</span></b></p>\n</td>", "ID": "4d466115-8bee-4ad8-af24-29c656fa89f5", "Styles": "border:solid windowtext 1.0pt;background:\n  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "6cf74322-958c-498e-8171-955309fefcd3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span style=\"color:black\">Dose Modifications for Patients with MBC</span></b></p>", "ID": "7860749d-f63d-4a91-8c42-2a2d09edd165", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d466115-8bee-4ad8-af24-29c656fa89f5"}, {"Element": "<b><span style=\"color:black\">Dose Modifications for Patients with MBC</span></b>", "ID": "64a6857d-793f-4339-9b4e-baeb1a9287e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7860749d-f63d-4a91-8c42-2a2d09edd165"}, {"Element": "<span style=\"color:black\">Dose Modifications for Patients with MBC</span>", "ID": "708ea446-514f-4201-9f21-9a815a3fdf6a", "Styles": "color:black", "Classes": "None", "Text": "Dose Modifications for Patients with MBC", "ParentId": "64a6857d-793f-4339-9b4e-baeb1a9287e3"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><b>Adverse reaction</b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Treatment\n  modification</b></p>\n</td>\n</tr>", "ID": "14be8ada-f627-41e9-8e78-c3aba9ee7ff5", "Styles": "height:15.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 0in 1.5pt 0in;height:15.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><b>Adverse reaction</b></p>\n</td>", "ID": "d299d57a-4106-4077-9549-aaace8f7e072", "Styles": "border:solid windowtext 1.0pt;border-top:none;\n  padding:1.5pt 0in 1.5pt 0in;height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "14be8ada-f627-41e9-8e78-c3aba9ee7ff5"}, {"Element": "<p class=\"MsoNormal\"><b>Adverse reaction</b></p>", "ID": "d7d156c8-b8a2-48b2-af72-9b70700de1bd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d299d57a-4106-4077-9549-aaace8f7e072"}, {"Element": "<b>Adverse reaction</b>", "ID": "7af45b65-b9c2-4f8f-ac0b-92cf354d4a64", "Styles": "None", "Classes": "None", "Text": "Adverse reaction", "ParentId": "d7d156c8-b8a2-48b2-af72-9b70700de1bd"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"bottom\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>\n</td>", "ID": "883bb8ce-76d9-4662-b93a-e5ea177474b2", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "14be8ada-f627-41e9-8e78-c3aba9ee7ff5"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-CARRIBEAN\">Severity</span></b></p>", "ID": "e229b3ae-101f-401e-87bb-30bb0dfb6685", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "883bb8ce-76d9-4662-b93a-e5ea177474b2"}, {"Element": "<b><span lang=\"EN-CARRIBEAN\">Severity</span></b>", "ID": "d01083bc-2d15-4e85-8a5b-2ed83d8733a9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e229b3ae-101f-401e-87bb-30bb0dfb6685"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Severity</span>", "ID": "926c8fa8-f500-4f04-97b8-cec9cd0a2d55", "Styles": "None", "Classes": "None", "Text": "Severity", "ParentId": "d01083bc-2d15-4e85-8a5b-2ed83d8733a9"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Treatment\n  modification</b></p>\n</td>", "ID": "8092ff76-0455-4db2-869d-4a4022d5a496", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "14be8ada-f627-41e9-8e78-c3aba9ee7ff5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Treatment\n  modification</b></p>", "ID": "d9bbd322-23d2-48e4-b137-14a805a6eee0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8092ff76-0455-4db2-869d-4a4022d5a496"}, {"Element": "<b>Treatment\n  modification</b>", "ID": "abebcf28-9504-4294-8959-a3a75774ee50", "Styles": "None", "Classes": "None", "Text": "Treatment   modification", "ParentId": "d9bbd322-23d2-48e4-b137-14a805a6eee0"}, {"Element": "<tr style=\"height:15.75pt\">\n<td rowspan=\"2\" style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Thrombocytopenia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3 </p>\n<p class=\"MsoNormal\">(25,000 to <span style=\"font-family:Symbol\">&lt;</span>\u00a050,000/mm<sup>3</sup>)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then treat at the same dose level</p>\n</td>\n</tr>", "ID": "51b8b393-499b-48a6-aca0-77576cedea7e", "Styles": "height:15.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"2\" style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Thrombocytopenia</p>\n</td>", "ID": "71e37083-9223-489b-ab60-49390e21b1d7", "Styles": "border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "51b8b393-499b-48a6-aca0-77576cedea7e"}, {"Element": "<p class=\"MsoNormal\">Thrombocytopenia</p>", "ID": "9a44febd-2d45-46cb-8055-4c60ceba06fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Thrombocytopenia", "ParentId": "71e37083-9223-489b-ab60-49390e21b1d7"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3 </p>\n<p class=\"MsoNormal\">(25,000 to <span style=\"font-family:Symbol\">&lt;</span>\u00a050,000/mm<sup>3</sup>)</p>\n</td>", "ID": "a6ab907f-0198-429e-be65-c64610bce720", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "51b8b393-499b-48a6-aca0-77576cedea7e"}, {"Element": "<p class=\"MsoNormal\">Grade 3 </p>", "ID": "2963ebda-f054-41fb-b6b0-feeb49578635", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 3 ", "ParentId": "a6ab907f-0198-429e-be65-c64610bce720"}, {"Element": "<p class=\"MsoNormal\">(25,000 to <span style=\"font-family:Symbol\">&lt;</span>\u00a050,000/mm<sup>3</sup>)</p>", "ID": "749b38ef-90f9-4076-86ea-7ab6959dce0b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "(25,000 to \u00a050,000/mm)", "ParentId": "a6ab907f-0198-429e-be65-c64610bce720"}, {"Element": "<span style=\"font-family:Symbol\">&lt;</span>", "ID": "95c3e0da-8060-4887-bfab-06b588f11b32", "Styles": "font-family:Symbol", "Classes": "None", "Text": "<", "ParentId": "749b38ef-90f9-4076-86ea-7ab6959dce0b"}, {"Element": "<sup>3</sup>", "ID": "7a0edd9a-51d2-495d-8dfa-6ecd29b50e98", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "749b38ef-90f9-4076-86ea-7ab6959dce0b"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then treat at the same dose level</p>\n</td>", "ID": "c4d7305c-b858-4254-a1f6-6ecc129a3ec2", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "51b8b393-499b-48a6-aca0-77576cedea7e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then treat at the same dose level</p>", "ID": "73ee14b3-42fa-42a2-9a7c-391641d7f69b", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Do not   administer trastuzumab emtansine until platelet count recovers to  Grade\u00a01 (\u2265 75,000/mm),   and then treat at the same dose level", "ParentId": "c4d7305c-b858-4254-a1f6-6ecc129a3ec2"}, {"Element": "<span style=\"font-family:Symbol\">\u00a3</span>", "ID": "f32e379a-a790-4a37-90d4-5fbcf985e4d7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00a3", "ParentId": "73ee14b3-42fa-42a2-9a7c-391641d7f69b"}, {"Element": "<sup>3</sup>", "ID": "c04fbe24-4402-42de-92e5-fc3f5468641a", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "73ee14b3-42fa-42a2-9a7c-391641d7f69b"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4</p>\n<p class=\"MsoNormal\"><span style=\"font-family:Symbol\">(&lt;</span>\u00a025,000/mm<sup>3</sup>)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then reduce one dose level</p>\n</td>\n</tr>", "ID": "48a19d17-13c6-453f-94c2-aa16f52aa3d9", "Styles": "height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4</p>\n<p class=\"MsoNormal\"><span style=\"font-family:Symbol\">(&lt;</span>\u00a025,000/mm<sup>3</sup>)</p>\n</td>", "ID": "f9761885-e1af-4df2-bf1f-ee9670f9f009", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "48a19d17-13c6-453f-94c2-aa16f52aa3d9"}, {"Element": "<p class=\"MsoNormal\">Grade 4</p>", "ID": "40017ee9-8faf-4c80-b412-c36fbd14b64f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 4", "ParentId": "f9761885-e1af-4df2-bf1f-ee9670f9f009"}, {"Element": "<p class=\"MsoNormal\"><span style=\"font-family:Symbol\">(&lt;</span>\u00a025,000/mm<sup>3</sup>)</p>", "ID": "efe1505c-f5a4-4dca-924b-c94b097d2089", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a025,000/mm)", "ParentId": "f9761885-e1af-4df2-bf1f-ee9670f9f009"}, {"Element": "<span style=\"font-family:Symbol\">(&lt;</span>", "ID": "002c6fc1-5885-4711-ac97-eab2239d5014", "Styles": "font-family:Symbol", "Classes": "None", "Text": "(<", "ParentId": "efe1505c-f5a4-4dca-924b-c94b097d2089"}, {"Element": "<sup>3</sup>", "ID": "1a5709d8-3662-4a8b-83ac-6bc823137898", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "efe1505c-f5a4-4dca-924b-c94b097d2089"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then reduce one dose level</p>\n</td>", "ID": "871795fb-1856-4a6e-8890-2a27fbceeb7e", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "48a19d17-13c6-453f-94c2-aa16f52aa3d9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine until platelet count recovers to <span style=\"font-family:Symbol\">\u00a3</span> Grade\u00a01 (\u2265 75,000/mm<sup>3</sup>),\n  and then reduce one dose level</p>", "ID": "d8dffcad-2a84-490b-8946-981af1098c1d", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Do not   administer trastuzumab emtansine until platelet count recovers to  Grade\u00a01 (\u2265 75,000/mm),   and then reduce one dose level", "ParentId": "871795fb-1856-4a6e-8890-2a27fbceeb7e"}, {"Element": "<span style=\"font-family:Symbol\">\u00a3</span>", "ID": "f6ec6559-9a7c-45d2-9b7f-9e2e187584fa", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00a3", "ParentId": "d8dffcad-2a84-490b-8946-981af1098c1d"}, {"Element": "<sup>3</sup>", "ID": "99b1006c-5c14-4e59-b7cb-0c5c73b3d989", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "d8dffcad-2a84-490b-8946-981af1098c1d"}, {"Element": "<tr style=\"height:15.75pt\">\n<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Transaminase (AST/ALT)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a02.5 to \u2264 5<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Treat at\n  the same dose level</p>\n</td>\n</tr>", "ID": "01fb5cbb-c26a-4868-adad-24bb3749166d", "Styles": "height:15.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Increased Transaminase (AST/ALT)</p>\n</td>", "ID": "c0d73d1e-97b3-4956-b602-f1d8310f8b10", "Styles": "border:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "01fb5cbb-c26a-4868-adad-24bb3749166d"}, {"Element": "<p class=\"MsoNormal\">Increased Transaminase (AST/ALT)</p>", "ID": "8afacc4b-c535-4813-bcbd-6213240e8623", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Increased Transaminase (AST/ALT)", "ParentId": "c0d73d1e-97b3-4956-b602-f1d8310f8b10"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a02.5 to \u2264 5<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>", "ID": "e1c8cf81-aca4-4314-8157-1b55d0b69668", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "01fb5cbb-c26a-4868-adad-24bb3749166d"}, {"Element": "<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a02.5 to \u2264 5<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>", "ID": "8e8badff-0ddd-43c6-b8b0-b5274b9860f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 2   (\u00a02.5 to \u2264 5 the ULN)", "ParentId": "e1c8cf81-aca4-4314-8157-1b55d0b69668"}, {"Element": "<br/>", "ID": "a7ebf6c3-6ef2-47f1-b729-4e6c1b698e48", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8e8badff-0ddd-43c6-b8b0-b5274b9860f6"}, {"Element": "<span style=\"font-family:Symbol\">&gt;</span>", "ID": "d333c7da-dafc-4302-8032-e0821f7ef51b", "Styles": "font-family:Symbol", "Classes": "None", "Text": ">", "ParentId": "8e8badff-0ddd-43c6-b8b0-b5274b9860f6"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "78b66a2d-083d-4559-ac66-f97d865af27a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "8e8badff-0ddd-43c6-b8b0-b5274b9860f6"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Treat at\n  the same dose level</p>\n</td>", "ID": "13e236ec-8bcf-43eb-bc23-6735a21d7f70", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "01fb5cbb-c26a-4868-adad-24bb3749166d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Treat at\n  the same dose level</p>", "ID": "11f7b034-8e6f-4598-b420-dbb79940f078", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Treat at   the same dose level", "ParentId": "13e236ec-8bcf-43eb-bc23-6735a21d7f70"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a05 to \u2264 20<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until AST/ALT\n  recovers to Grade \u2264 2, and then reduce one dose level</p>\n</td>\n</tr>", "ID": "bc877527-9ff3-4f56-b3c0-7abeddbd59a8", "Styles": "height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a05 to \u2264 20<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>", "ID": "f32b5715-eebb-4009-976d-2b01ef37d944", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "bc877527-9ff3-4f56-b3c0-7abeddbd59a8"}, {"Element": "<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a05 to \u2264 20<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>", "ID": "e2a91253-5250-4282-9d99-4e15efe4ed86", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 3   (\u00a05 to \u2264 20 the ULN)", "ParentId": "f32b5715-eebb-4009-976d-2b01ef37d944"}, {"Element": "<br/>", "ID": "b90b332a-1c60-4aff-b6bc-d9073ade7cea", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e2a91253-5250-4282-9d99-4e15efe4ed86"}, {"Element": "<span style=\"font-family:Symbol\">&gt;</span>", "ID": "0aa34be5-841f-497c-b0f4-3da0b717672a", "Styles": "font-family:Symbol", "Classes": "None", "Text": ">", "ParentId": "e2a91253-5250-4282-9d99-4e15efe4ed86"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "3a3d21ca-5884-48f9-b362-c2272155dcc7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "e2a91253-5250-4282-9d99-4e15efe4ed86"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until AST/ALT\n  recovers to Grade \u2264 2, and then reduce one dose level</p>\n</td>", "ID": "abdd8323-7241-4f41-b91a-6585d7e92e27", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "bc877527-9ff3-4f56-b3c0-7abeddbd59a8"}, {"Element": "<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until AST/ALT\n  recovers to Grade \u2264 2, and then reduce one dose level</p>", "ID": "0914ce34-c0b7-4cb4-b77b-fb0ab39db5be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Do not administer trastuzumab emtansine until AST/ALT   recovers to Grade \u2264 2, and then reduce one dose level", "ParentId": "abdd8323-7241-4f41-b91a-6585d7e92e27"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a020<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "427f73f1-4569-43a9-bc50-7a42726b5520", "Styles": "height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a020<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>\n</td>", "ID": "3cb6c7bb-d153-4aea-8c94-f22581117281", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "427f73f1-4569-43a9-bc50-7a42726b5520"}, {"Element": "<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a020<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>", "ID": "fd8ded05-175f-4c2a-ae82-47433643cb72", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 4   (\u00a020 the ULN)", "ParentId": "3cb6c7bb-d153-4aea-8c94-f22581117281"}, {"Element": "<br/>", "ID": "9c7d1f16-62de-45b1-9008-18b072560637", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fd8ded05-175f-4c2a-ae82-47433643cb72"}, {"Element": "<span style=\"font-family:Symbol\">&gt;</span>", "ID": "276e0492-d474-4c22-a0d2-8cf08eebce0d", "Styles": "font-family:Symbol", "Classes": "None", "Text": ">", "ParentId": "fd8ded05-175f-4c2a-ae82-47433643cb72"}, {"Element": "<span style=\"font-family:\n  Symbol\">\u00b4</span>", "ID": "b858e921-872f-455e-ba47-711a46db6c4a", "Styles": "font-family:\n  Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "fd8ded05-175f-4c2a-ae82-47433643cb72"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>", "ID": "e41930f8-0616-485f-8b0a-c769e0d774a9", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "427f73f1-4569-43a9-bc50-7a42726b5520"}, {"Element": "<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>", "ID": "b5dd4ff3-9329-4fa7-afd3-12a5ceb89ef2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Discontinue trastuzumab emtansine", "ParentId": "e41930f8-0616-485f-8b0a-c769e0d774a9"}, {"Element": "<tr style=\"height:15.75pt\">\n<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Hyperbilirubinemia</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a01.5 to \u2264 3<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1, and then treat at the same dose level.</p>\n</td>\n</tr>", "ID": "b76dff7b-d033-4243-aa6e-59d7604eae70", "Styles": "height:15.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"3\" style=\"border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Hyperbilirubinemia</p>\n</td>", "ID": "6474817d-1865-4b82-8eea-d8f59f99ae2e", "Styles": "border:solid windowtext 1.0pt;border-top:\n  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "b76dff7b-d033-4243-aa6e-59d7604eae70"}, {"Element": "<p class=\"MsoNormal\">Hyperbilirubinemia</p>", "ID": "e372743c-484c-4e9a-9047-c6f50ce217ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Hyperbilirubinemia", "ParentId": "6474817d-1865-4b82-8eea-d8f59f99ae2e"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a01.5 to \u2264 3<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>", "ID": "56e14828-de9b-4763-97e1-69b167fdd711", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "b76dff7b-d033-4243-aa6e-59d7604eae70"}, {"Element": "<p class=\"MsoNormal\">Grade 2<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a01.5 to \u2264 3<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>", "ID": "5af34903-3fbe-4154-935f-df2a443b772d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 2   (\u00a01.5 to \u2264 3 the ULN)", "ParentId": "56e14828-de9b-4763-97e1-69b167fdd711"}, {"Element": "<br/>", "ID": "2fdc6418-f84d-4f5b-86f4-6096bfee8c2c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5af34903-3fbe-4154-935f-df2a443b772d"}, {"Element": "<span style=\"font-family:Symbol\">&gt;</span>", "ID": "e8a654b5-9587-4bc7-8759-a6a58f49a10e", "Styles": "font-family:Symbol", "Classes": "None", "Text": ">", "ParentId": "5af34903-3fbe-4154-935f-df2a443b772d"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "c6ef73b5-e828-45d4-812e-3e3e446bbcd7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "5af34903-3fbe-4154-935f-df2a443b772d"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1, and then treat at the same dose level.</p>\n</td>", "ID": "16e62695-3f5f-4901-b0b0-0613e10dd55a", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "b76dff7b-d033-4243-aa6e-59d7604eae70"}, {"Element": "<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1, and then treat at the same dose level.</p>", "ID": "da740495-43b2-42db-a02a-449187808599", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Do not administer trastuzumab emtansine until total   bilirubin recovers to Grade \u2264 1, and then treat at the same dose level.", "ParentId": "16e62695-3f5f-4901-b0b0-0613e10dd55a"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a03 to \u2264 10<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1 and then reduce one dose level.</p>\n</td>\n</tr>", "ID": "b6e8190a-fa03-4848-84cf-37db77a20dff", "Styles": "height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a03 to \u2264 10<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>\n</td>", "ID": "c97929ce-eafa-473e-a964-5a2ab7394fb5", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "b6e8190a-fa03-4848-84cf-37db77a20dff"}, {"Element": "<p class=\"MsoNormal\">Grade 3<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a03 to \u2264 10<span style=\"font-family:Symbol\">\u00b4</span> the ULN)</p>", "ID": "18002ea8-8d5f-4b7e-b754-281cb0609467", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 3   (\u00a03 to \u2264 10 the ULN)", "ParentId": "c97929ce-eafa-473e-a964-5a2ab7394fb5"}, {"Element": "<br/>", "ID": "53e8eac2-9fd1-496e-bba7-d23d86806686", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "18002ea8-8d5f-4b7e-b754-281cb0609467"}, {"Element": "<span style=\"font-family:Symbol\">&gt;</span>", "ID": "6d64b8ab-e648-49e5-ba83-c2e9aca1205d", "Styles": "font-family:Symbol", "Classes": "None", "Text": ">", "ParentId": "18002ea8-8d5f-4b7e-b754-281cb0609467"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "923a69bd-bef2-4196-ad40-ee8ef5f7c7b4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "18002ea8-8d5f-4b7e-b754-281cb0609467"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1 and then reduce one dose level.</p>\n</td>", "ID": "0d5dd9d6-1ac8-4c0a-b4c7-975398f139a7", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "b6e8190a-fa03-4848-84cf-37db77a20dff"}, {"Element": "<p class=\"MsoNormal\">Do not administer trastuzumab emtansine until total\n  bilirubin recovers to Grade \u2264 1 and then reduce one dose level.</p>", "ID": "a1069cfc-a5eb-4b3d-ac24-732ccbabdb9c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Do not administer trastuzumab emtansine until total   bilirubin recovers to Grade \u2264 1 and then reduce one dose level.", "ParentId": "0d5dd9d6-1ac8-4c0a-b4c7-975398f139a7"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a010<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "bd517171-a585-4413-b027-daa6a22d7c71", "Styles": "height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a010<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>\n</td>", "ID": "6edeb747-96b3-4526-84f9-66f5afb0780e", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "bd517171-a585-4413-b027-daa6a22d7c71"}, {"Element": "<p class=\"MsoNormal\">Grade 4<br/>\n  (<span style=\"font-family:Symbol\">&gt;</span>\u00a010<span style=\"font-family:\n  Symbol\">\u00b4</span> the ULN)</p>", "ID": "6c4646ac-c3bc-4693-990f-d8e0d63e7c94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Grade 4   (\u00a010 the ULN)", "ParentId": "6edeb747-96b3-4526-84f9-66f5afb0780e"}, {"Element": "<br/>", "ID": "3dccbb0a-b95f-4734-b6c5-f5966a057f15", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6c4646ac-c3bc-4693-990f-d8e0d63e7c94"}, {"Element": "<span style=\"font-family:Symbol\">&gt;</span>", "ID": "5b44750e-51cc-4fe9-8e80-e65cd527cc42", "Styles": "font-family:Symbol", "Classes": "None", "Text": ">", "ParentId": "6c4646ac-c3bc-4693-990f-d8e0d63e7c94"}, {"Element": "<span style=\"font-family:\n  Symbol\">\u00b4</span>", "ID": "9435ab9f-2044-4aa4-873b-841a01d54f71", "Styles": "font-family:\n  Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "6c4646ac-c3bc-4693-990f-d8e0d63e7c94"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>\n</td>", "ID": "f072955c-0f52-4bb2-b876-b555435767b9", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "bd517171-a585-4413-b027-daa6a22d7c71"}, {"Element": "<p class=\"MsoNormal\">Discontinue trastuzumab emtansine</p>", "ID": "52c7c09d-64d5-47f5-acfd-b7c59c22bdf7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Discontinue trastuzumab emtansine", "ParentId": "f072955c-0f52-4bb2-b876-b555435767b9"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>\n</td>\n</tr>", "ID": "89b8a637-0e4c-4d6b-8fa3-de9166bddf97", "Styles": "height:15.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>\n</td>", "ID": "ee34a917-ac17-4614-b306-997adecd551d", "Styles": "border-top:none;border-left:solid windowtext 1.0pt;\n  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "89b8a637-0e4c-4d6b-8fa3-de9166bddf97"}, {"Element": "<p class=\"MsoNormal\">Drug Induced Liver Injury (DILI)</p>", "ID": "1575bb32-d213-4be5-98c5-82fc55be4a79", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Drug Induced Liver Injury (DILI)", "ParentId": "ee34a917-ac17-4614-b306-997adecd551d"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>\n</td>", "ID": "1dfa197f-d373-4c8a-87d5-16aa0765a16a", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "89b8a637-0e4c-4d6b-8fa3-de9166bddf97"}, {"Element": "<p class=\"MsoNormal\">Serum transaminases &gt; 3 x ULN and concomitant total\n  bilirubin &gt; 2<span style=\"font-family:Symbol\">\u00b4</span> ULN</p>", "ID": "ec7bbeab-bbff-4f11-a40b-1ff17336ba93", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Serum transaminases > 3 x ULN and concomitant total   bilirubin > 2 ULN", "ParentId": "1dfa197f-d373-4c8a-87d5-16aa0765a16a"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "6ad0580f-9b8f-4ddc-82a3-eb4a68c679d7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "ec7bbeab-bbff-4f11-a40b-1ff17336ba93"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>\n</td>", "ID": "5d336cba-a3b6-4c0b-848b-d3088d34dd2d", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "89b8a637-0e4c-4d6b-8fa3-de9166bddf97"}, {"Element": "<p class=\"MsoNormal\">Permanently discontinue trastuzumab emtansine<span style='font-family:\"Calibri\",sans-serif'> </span>in the absence of another\n  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver\n  metastasis or concomitant medication</p>", "ID": "7828b949-e4cb-413c-b611-068a4c1f2942", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Permanently discontinue trastuzumab emtansinein the absence of another   likely cause for the elevation of liver enzymes and bilirubin, e.g. liver   metastasis or concomitant medication", "ParentId": "5d336cba-a3b6-4c0b-848b-d3088d34dd2d"}, {"Element": "<span style='font-family:\"Calibri\",sans-serif'> </span>", "ID": "3d187c2c-b1e9-433d-a5cc-36f70945802b", "Styles": "font-family:\"Calibri\",sans-serif", "Classes": "None", "Text": " ", "ParentId": "7828b949-e4cb-413c-b611-068a4c1f2942"}, {"Element": "<tr style=\"height:15.75pt\">\n<td rowspan=\"5\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Symptomatic CHF</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Discontinue\n  trastuzumab emtansine</p>\n</td>\n</tr>", "ID": "d99bc746-f158-4a9d-8bf5-70df597ea79b", "Styles": "height:15.75pt", "Classes": "None", "Text": "    ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td rowspan=\"5\" style=\"border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>\n</td>", "ID": "146713ce-cc03-45fb-98a8-fea4325bfd80", "Styles": "border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "d99bc746-f158-4a9d-8bf5-70df597ea79b"}, {"Element": "<p class=\"MsoNormal\">Left Ventricular Dysfunction </p>", "ID": "75de2383-1d7e-433c-a332-cc1ca6278282", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Left Ventricular Dysfunction ", "ParentId": "146713ce-cc03-45fb-98a8-fea4325bfd80"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Symptomatic CHF</p>\n</td>", "ID": "b174f7ab-6d23-40b7-824e-7daf1eaa92b2", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "d99bc746-f158-4a9d-8bf5-70df597ea79b"}, {"Element": "<p class=\"MsoNormal\">Symptomatic CHF</p>", "ID": "b1dadcfe-a3c6-4831-947f-f6357d4a181f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Symptomatic CHF", "ParentId": "b174f7ab-6d23-40b7-824e-7daf1eaa92b2"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Discontinue\n  trastuzumab emtansine</p>\n</td>", "ID": "733b0c11-71f2-4383-aea7-b6e1c06416ac", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "d99bc746-f158-4a9d-8bf5-70df597ea79b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Discontinue\n  trastuzumab emtansine</p>", "ID": "ce544954-fcdf-493a-a336-3a174528884d", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Discontinue   trastuzumab emtansine", "ParentId": "733b0c11-71f2-4383-aea7-b6e1c06416ac"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &lt;40%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Repeat\n  LVEF assessment within 3 weeks. If LVEF &lt;40% is confirmed, discontinue trastuzumab\n  emtansine</p>\n</td>\n</tr>", "ID": "69babd22-230e-44a6-ae63-07eb1c42d9dd", "Styles": "height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &lt;40%</p>\n</td>", "ID": "7c295d13-d7e6-4742-bac3-047c37488526", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "69babd22-230e-44a6-ae63-07eb1c42d9dd"}, {"Element": "<p class=\"MsoNormal\">LVEF &lt;40%</p>", "ID": "8c20c28d-2f8b-45c6-8eca-0d2ba08b35c1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "LVEF <40%", "ParentId": "7c295d13-d7e6-4742-bac3-047c37488526"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Repeat\n  LVEF assessment within 3 weeks. If LVEF &lt;40% is confirmed, discontinue trastuzumab\n  emtansine</p>\n</td>", "ID": "ff5f853e-c7cc-456c-8fb5-b7ba690a0fec", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "69babd22-230e-44a6-ae63-07eb1c42d9dd"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>", "ID": "38c106b6-1a77-4b4c-abff-5fee8fd14e2d", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Do not   administer trastuzumab emtansine.", "ParentId": "ff5f853e-c7cc-456c-8fb5-b7ba690a0fec"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Repeat\n  LVEF assessment within 3 weeks. If LVEF &lt;40% is confirmed, discontinue trastuzumab\n  emtansine</p>", "ID": "739d03c0-c9ea-4cce-bea1-0c59d000947e", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Repeat   LVEF assessment within 3 weeks. If LVEF <40% is confirmed, discontinue trastuzumab   emtansine", "ParentId": "ff5f853e-c7cc-456c-8fb5-b7ba690a0fec"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is \u2265 10% points\n  from baseline</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>\n<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks. If the LVEF has not\n  recovered to within 10% points from baseline, discontinue trastuzumab\n  emtansine.</p>\n</td>\n</tr>", "ID": "eb8667df-b820-4c15-8a43-44625684ed8f", "Styles": "height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is \u2265 10% points\n  from baseline</p>\n</td>", "ID": "121ecc49-a883-4421-adaf-598ca362b7ec", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "eb8667df-b820-4c15-8a43-44625684ed8f"}, {"Element": "<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is \u2265 10% points\n  from baseline</p>", "ID": "1bbfc586-e47f-4a36-9fd3-100a9f86ade3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "LVEF 40% to \u2264 45% and decrease is \u2265 10% points   from baseline", "ParentId": "121ecc49-a883-4421-adaf-598ca362b7ec"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>\n<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks. If the LVEF has not\n  recovered to within 10% points from baseline, discontinue trastuzumab\n  emtansine.</p>\n</td>", "ID": "a5f6d676-3208-4f20-8abb-5e7a5b904b93", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "eb8667df-b820-4c15-8a43-44625684ed8f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Do not\n  administer trastuzumab emtansine.</p>", "ID": "7e4b110c-5bc3-43f3-b1a1-e99d3e027b27", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Do not   administer trastuzumab emtansine.", "ParentId": "a5f6d676-3208-4f20-8abb-5e7a5b904b93"}, {"Element": "<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks. If the LVEF has not\n  recovered to within 10% points from baseline, discontinue trastuzumab\n  emtansine.</p>", "ID": "474bfab4-ab46-4d7a-9520-86b783ed316f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Repeat LVEF assessment within 3 weeks. If the LVEF has not   recovered to within 10% points from baseline, discontinue trastuzumab   emtansine.", "ParentId": "a5f6d676-3208-4f20-8abb-5e7a5b904b93"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is &lt; 10% points\n  from baseline</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Continue\n  treatment with<span style=\"color:#0000CC\"> </span>trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>\n<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks.</p>\n</td>\n</tr>", "ID": "e16fb824-57c3-412e-9171-e86bf3e34241", "Styles": "height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is &lt; 10% points\n  from baseline</p>\n</td>", "ID": "d948decd-873f-4a04-a086-fc2a54c68cae", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "e16fb824-57c3-412e-9171-e86bf3e34241"}, {"Element": "<p class=\"MsoNormal\">LVEF 40% to \u2264 45% and decrease is &lt; 10% points\n  from baseline</p>", "ID": "e9248ac2-d6b2-4f55-868e-5b20f467b733", "Styles": "None", "Classes": "['MsoNormal']", "Text": "LVEF 40% to \u2264 45% and decrease is < 10% points   from baseline", "ParentId": "d948decd-873f-4a04-a086-fc2a54c68cae"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Continue\n  treatment with<span style=\"color:#0000CC\"> </span>trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>\n<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks.</p>\n</td>", "ID": "6998d297-a8d5-49db-ad7f-70368ca04d8b", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "e16fb824-57c3-412e-9171-e86bf3e34241"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\">Continue\n  treatment with<span style=\"color:#0000CC\"> </span>trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>", "ID": "a398477e-7f9f-41aa-957f-cad670cfc1f9", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Continue   treatment withtrastuzumab emtansine", "ParentId": "6998d297-a8d5-49db-ad7f-70368ca04d8b"}, {"Element": "<span style=\"color:#0000CC\"> </span>", "ID": "8dd63b06-218e-4c93-b48b-8ae75658c52d", "Styles": "color:#0000CC", "Classes": "None", "Text": " ", "ParentId": "a398477e-7f9f-41aa-957f-cad670cfc1f9"}, {"Element": "<i><span style=\"color:#002060\">.</span></i>", "ID": "7ff2569e-3396-48a0-a7c7-10a0a0eb98db", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a398477e-7f9f-41aa-957f-cad670cfc1f9"}, {"Element": "<span style=\"color:#002060\">.</span>", "ID": "22812328-f81a-4a2c-b28a-761affb8298f", "Styles": "color:#002060", "Classes": "None", "Text": ".", "ParentId": "7ff2569e-3396-48a0-a7c7-10a0a0eb98db"}, {"Element": "<p class=\"MsoNormal\">Repeat LVEF assessment within 3 weeks.</p>", "ID": "735641de-1075-488e-a9f9-fe08e359597c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Repeat LVEF assessment within 3 weeks.", "ParentId": "6998d297-a8d5-49db-ad7f-70368ca04d8b"}, {"Element": "<tr style=\"height:15.75pt\">\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &gt; 45%</p>\n</td>\n<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Continue treatment with trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>\n</td>\n</tr>", "ID": "45e6e9b3-a82a-43ed-a151-18bc26002855", "Styles": "height:15.75pt", "Classes": "None", "Text": "   ", "ParentId": "ccba2fff-9f5f-4577-8fd8-c0b80d6477b3"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">LVEF &gt; 45%</p>\n</td>", "ID": "17897b7c-8ba9-4022-87e0-adda2803b6e0", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "45e6e9b3-a82a-43ed-a151-18bc26002855"}, {"Element": "<p class=\"MsoNormal\">LVEF &gt; 45%</p>", "ID": "62bc167b-7f57-4809-822d-4c6814d132e7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "LVEF > 45%", "ParentId": "17897b7c-8ba9-4022-87e0-adda2803b6e0"}, {"Element": "<td style=\"border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt\" valign=\"top\">\n<p class=\"MsoNormal\">Continue treatment with trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>\n</td>", "ID": "879baf42-3aae-4e5d-8fa5-568bb7bdc419", "Styles": "border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;\n  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;\n  height:15.75pt", "Classes": "None", "Text": "  ", "ParentId": "45e6e9b3-a82a-43ed-a151-18bc26002855"}, {"Element": "<p class=\"MsoNormal\">Continue treatment with trastuzumab emtansine<i><span style=\"color:#002060\">.</span></i></p>", "ID": "342e9b3a-bf58-4807-9edc-0277ffd48020", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Continue treatment with trastuzumab emtansine", "ParentId": "879baf42-3aae-4e5d-8fa5-568bb7bdc419"}, {"Element": "<i><span style=\"color:#002060\">.</span></i>", "ID": "2f17773f-810c-4ab7-836c-7d24357525ef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "342e9b3a-bf58-4807-9edc-0277ffd48020"}, {"Element": "<span style=\"color:#002060\">.</span>", "ID": "4aeec481-f9e1-4a96-a80d-317a27c6caa2", "Styles": "color:#002060", "Classes": "None", "Text": ".", "ParentId": "2f17773f-810c-4ab7-836c-7d24357525ef"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:12.0pt\"><span style=\"font-size:9.0pt\">ALT\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0alanine\ntransaminase; AST\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0aspartate transaminase, CHF = congestive heart\nfailure, LVEF\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0left ventricular ejection fraction, LVSD\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0left\nventricular systolic dysfunction, TBILI = Total Bilirubin, ULN\u00a0</span><span style=\"font-size:9.0pt;font-family:Symbol\">=</span><span style=\"font-size:9.0pt\">\u00a0upper\nlimit of normal</span></p>", "ID": "b83e5407-3948-4a84-965e-984df2543a0d", "Styles": "margin-top:12.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-size:9.0pt\">ALT\u00a0</span>", "ID": "a65f34cd-c5d5-43ea-bba1-95a13d30cb60", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "ALT\u00a0", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt;font-family:Symbol\">=</span>", "ID": "d4225388-2adb-4ab0-bb7c-1db9b0371403", "Styles": "font-size:9.0pt;font-family:Symbol", "Classes": "None", "Text": "=", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt\">\u00a0alanine\ntransaminase; AST\u00a0</span>", "ID": "d0d7befb-87d5-4c98-9f07-d00b8b5e026e", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0alanine transaminase; AST\u00a0", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt;font-family:Symbol\">=</span>", "ID": "e576f211-235c-425b-9a43-136718cb14e0", "Styles": "font-size:9.0pt;font-family:Symbol", "Classes": "None", "Text": "=", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt\">\u00a0aspartate transaminase, CHF = congestive heart\nfailure, LVEF\u00a0</span>", "ID": "1940b0a5-117a-4c23-a9b1-441612d29478", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0aspartate transaminase, CHF = congestive heart failure, LVEF\u00a0", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt;font-family:Symbol\">=</span>", "ID": "860995e0-65d3-413a-be79-88e729f59ece", "Styles": "font-size:9.0pt;font-family:Symbol", "Classes": "None", "Text": "=", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt\">\u00a0left ventricular ejection fraction, LVSD\u00a0</span>", "ID": "3eafcc39-0710-45cd-a0bc-c73ab845bd28", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0left ventricular ejection fraction, LVSD\u00a0", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt;font-family:Symbol\">=</span>", "ID": "5280c7c0-a74c-4da9-9980-10440db4b953", "Styles": "font-size:9.0pt;font-family:Symbol", "Classes": "None", "Text": "=", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt\">\u00a0left\nventricular systolic dysfunction, TBILI = Total Bilirubin, ULN\u00a0</span>", "ID": "e86b853c-745a-4567-93c7-7429dcfcacf3", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0left ventricular systolic dysfunction, TBILI = Total Bilirubin, ULN\u00a0", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt;font-family:Symbol\">=</span>", "ID": "d1cf1911-438d-401c-bd1d-3c44cd1a4379", "Styles": "font-size:9.0pt;font-family:Symbol", "Classes": "None", "Text": "=", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<span style=\"font-size:9.0pt\">\u00a0upper\nlimit of normal</span>", "ID": "1c2fb188-00a6-42cb-b7ed-96b0194f6292", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0upper limit of normal", "ParentId": "b83e5407-3948-4a84-965e-984df2543a0d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:14.0pt;page-break-after:avoid\"><span style=\"font-size:9.0pt\">* Prior to starting trastuzumab emtansine treatment. </span></p>", "ID": "b5b0d343-3578-40bb-a1f1-6c7cdd468164", "Styles": "line-height:14.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-size:9.0pt\">* Prior to starting trastuzumab emtansine treatment. </span>", "ID": "8a92a73d-5dd5-4e0d-ab29-fc9a57b079e4", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "* Prior to starting trastuzumab emtansine treatment. ", "ParentId": "b5b0d343-3578-40bb-a1f1-6c7cdd468164"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "7fa9bf5f-75b9-452f-9dd4-1bcb494d5e7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "0c401c4a-37ea-41fe-be28-54ae5ff4f734", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fa9bf5f-75b9-452f-9dd4-1bcb494d5e7f"}, {"Element": "<p class=\"MsoNormal\"><i>Delayed or missed dose</i></p>", "ID": "e4981f9f-ff10-4060-a028-6356cfab87e9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Delayed or missed dose</i>", "ID": "2bf0dbb1-cc00-4956-bca3-f98f7eca3d15", "Styles": "None", "Classes": "None", "Text": "Delayed or missed dose", "ParentId": "e4981f9f-ff10-4060-a028-6356cfab87e9"}, {"Element": "<p class=\"MsoNormal\">If a planned dose is missed, it should be administered as\nsoon as possible; without waiting until the next planned cycle. The schedule of\nadministration should be adjusted to maintain a 3\u2011week interval between\ndoses. The next dose should be administered in accordance with the dosing\nrecommendations above.</p>", "ID": "f55d7be6-584c-4df2-a4ab-ed1c287c562e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If a planned dose is missed, it should be administered as soon as possible; without waiting until the next planned cycle. The schedule of administration should be adjusted to maintain a 3\u2011week interval between doses. The next dose should be administered in accordance with the dosing recommendations above.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>", "ID": "19e901f5-1e4b-46c9-8865-df75b1575f51", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "7bc1462c-53ea-403a-b286-813e22adf2d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "19e901f5-1e4b-46c9-8865-df75b1575f51"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Peripheral neuropathy</i></p>", "ID": "85a13d57-b9ec-40bc-bb2a-65983ba5c449", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Peripheral neuropathy</i>", "ID": "4cbf4460-588b-4f88-8591-0ac0a4367f21", "Styles": "None", "Classes": "None", "Text": "Peripheral neuropathy", "ParentId": "85a13d57-b9ec-40bc-bb2a-65983ba5c449"}, {"Element": "<p class=\"MsoNormal\">Trastuzumab emtansine should be temporarily discontinued in\npatients experiencing Grade 3 or 4 peripheral neuropathy until resolution to\n\u2264 Grade 2. At retreatment a dose reduction may be considered according to\nthe dose reduction schedule (see Table 1).</p>", "ID": "d5fb81b7-0347-494f-8043-d1a22037c15c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine should be temporarily discontinued in patients experiencing Grade 3 or 4 peripheral neuropathy until resolution to \u2264 Grade 2. At retreatment a dose reduction may be considered according to the dose reduction schedule (see Table 1).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>", "ID": "6e6e1790-c781-46f8-8997-e470133c89be", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "f4c1ec8a-8ccd-4da2-a438-2860ae8e2d5d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e6e1790-c781-46f8-8997-e470133c89be"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Special populations</i></p>", "ID": "6449edd6-8cb7-4ac2-87fb-b2db539f2802", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Special populations</i>", "ID": "0f1a4cb8-c411-4572-bf6a-15327b5eef30", "Styles": "None", "Classes": "None", "Text": "Special populations", "ParentId": "6449edd6-8cb7-4ac2-87fb-b2db539f2802"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>", "ID": "de304524-5c90-4f96-bddd-848cf07cabe2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "208c4625-b13b-492a-9759-8306e83f2a0b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de304524-5c90-4f96-bddd-848cf07cabe2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Elderly patients </i></p>", "ID": "5cf5e893-993c-4376-8227-2bcbd8e7db7b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Elderly patients </i>", "ID": "f529e01f-ff98-41df-9168-93bd871856c6", "Styles": "None", "Classes": "None", "Text": "Elderly patients ", "ParentId": "5cf5e893-993c-4376-8227-2bcbd8e7db7b"}, {"Element": "<p class=\"MsoNormal\">No dose adjustment is required in patients aged\n\u2265\u00a065 years. There are insufficient data to establish the safety and\nefficacy in patients \u2265\u00a075 years due to limited data in this\nsubgroup.<span style='font-size:10.0pt;font-family:\"Arial\",sans-serif;\ncolor:#222222;background:white'> </span>Population pharmacokinetic analysis\nindicates that age does not have a clinically meaningful effect on the\npharmacokinetics of trastuzumab emtansine (see sections 5.1 and 5.2).</p>", "ID": "49d181ba-90d8-47ac-8e5d-ca71746462e9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No dose adjustment is required in patients aged \u2265\u00a065 years. There are insufficient data to establish the safety and efficacy in patients \u2265\u00a075 years due to limited data in this subgroup.Population pharmacokinetic analysis indicates that age does not have a clinically meaningful effect on the pharmacokinetics of trastuzumab emtansine (see sections 5.1 and 5.2).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:10.0pt;font-family:\"Arial\",sans-serif;\ncolor:#222222;background:white'> </span>", "ID": "5d1a76f1-1593-4be8-8f21-ddae9a1d3bc8", "Styles": "font-size:10.0pt;font-family:\"Arial\",sans-serif;\ncolor:#222222;background:white", "Classes": "None", "Text": " ", "ParentId": "49d181ba-90d8-47ac-8e5d-ca71746462e9"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "dee3b4af-595d-40e6-af60-05f5a4b03480", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Renal impairment</i></p>", "ID": "c93ca7a6-6197-4dde-94b8-a8f1fea0e3f3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Renal impairment</i>", "ID": "368d0789-0677-41ee-a077-06b38dc8a4f1", "Styles": "None", "Classes": "None", "Text": "Renal impairment", "ParentId": "c93ca7a6-6197-4dde-94b8-a8f1fea0e3f3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">No adjustment to the starting\ndose is needed in patients with mild or moderate renal impairment (see section\n5.2). The potential need for dose adjustment in patients with severe renal\nimpairment cannot be determined due to insufficient data and therefore patients\nwith severe renal impairment should be monitored carefully.</p>", "ID": "bbe294b3-ae84-42d1-a296-b8336bd9751d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "No adjustment to the starting dose is needed in patients with mild or moderate renal impairment (see section 5.2). The potential need for dose adjustment in patients with severe renal impairment cannot be determined due to insufficient data and therefore patients with severe renal impairment should be monitored carefully.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "deebc9e8-3bbe-4d7d-a04b-d1703d6ff557", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Hepatic impairment</i></p>", "ID": "e34606d7-37e9-4633-b7d9-0fd17e8da137", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Hepatic impairment</i>", "ID": "d0ed98ec-64a5-41a9-9602-215732d3be8d", "Styles": "None", "Classes": "None", "Text": "Hepatic impairment", "ParentId": "e34606d7-37e9-4633-b7d9-0fd17e8da137"}, {"Element": "<p class=\"MsoNormal\">No adjustment to the starting dose is required for patients\nwith mild or moderate hepatic impairment.\u00a0 Trastuzumab emtansine has not\nbeen studied in patients with severe hepatic impairment.\u00a0 Treatment of\npatients with hepatic impairment should be undertaken with caution due to known\nhepatotoxicity observed with trastuzumab emtansine (see section 4.4 and 5.2).</p>", "ID": "b86f02ca-19f8-47c7-902d-3c9bddebc9e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No adjustment to the starting dose is required for patients with mild or moderate hepatic impairment.\u00a0 Trastuzumab emtansine has not been studied in patients with severe hepatic impairment.\u00a0 Treatment of patients with hepatic impairment should be undertaken with caution due to known hepatotoxicity observed with trastuzumab emtansine (see section 4.4 and 5.2).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c51320f3-0214-4b21-9a38-ea7db60673e9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f9c21ae5-a4a8-4b63-92db-e58b1b67d18a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c51320f3-0214-4b21-9a38-ea7db60673e9"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Paediatric </span></i><i>population</i></p>", "ID": "1e53cced-208f-4dbd-af57-d06104377055", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric </span></i>", "ID": "91be34dc-b07c-4bde-89f0-05b3bbfd46d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1e53cced-208f-4dbd-af57-d06104377055"}, {"Element": "<span lang=\"EN-GB\">Paediatric </span>", "ID": "1f0f7639-82e1-4cc7-abda-7d49de36216c", "Styles": "None", "Classes": "None", "Text": "Paediatric ", "ParentId": "91be34dc-b07c-4bde-89f0-05b3bbfd46d2"}, {"Element": "<i>population</i>", "ID": "39b66064-7fd0-4a01-895f-5b7fe0aea8ce", "Styles": "None", "Classes": "None", "Text": "population", "ParentId": "1e53cced-208f-4dbd-af57-d06104377055"}, {"Element": "<p class=\"MsoNormal\">The safety and efficacy in children and adolescents below\n18\u00a0years of age have not been established as there is no relevant use in\nthe <span lang=\"EN-GB\">paediatric </span>population for the indication of breast\ncancer . </p>", "ID": "4d782545-9794-4a96-aca2-458e432d4355", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The safety and efficacy in children and adolescents below 18\u00a0years of age have not been established as there is no relevant use in the population for the indication of breast cancer . ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-GB\">paediatric </span>", "ID": "2c6e4207-82e7-4b14-8a5d-139876226f2b", "Styles": "None", "Classes": "None", "Text": "paediatric ", "ParentId": "4d782545-9794-4a96-aca2-458e432d4355"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>", "ID": "a37a6f37-b59a-48ce-8563-1ef67dec8aa9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "7fcfdd83-bde8-49ad-ab18-15c87a0e230f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a37a6f37-b59a-48ce-8563-1ef67dec8aa9"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "3b3a65db-8d24-4ea8-a540-fdfb70054d6b", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "7fcfdd83-bde8-49ad-ab18-15c87a0e230f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Method of administration</u></p>", "ID": "c005ffa9-4501-4554-a297-fc17238775fc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Method of administration</u>", "ID": "76b99a78-c12b-4680-a5fe-d90c8a866d1e", "Styles": "None", "Classes": "None", "Text": "Method of administration", "ParentId": "c005ffa9-4501-4554-a297-fc17238775fc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>", "ID": "cd562ea5-4fa1-4456-9d49-79c21756f3de", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "449d1e4d-0621-4ed5-8a0f-aa7e5479788e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cd562ea5-4fa1-4456-9d49-79c21756f3de"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "f85cc1be-cdd2-4ffe-9e76-7b697c48a89e", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "449d1e4d-0621-4ed5-8a0f-aa7e5479788e"}, {"Element": "<p class=\"MsoNormal\">Kadcyla is for intravenous use. Trastuzumab emtansine must\nbe reconstituted and diluted by a healthcare professional and administered as\nan intravenous infusion. It must not be administered as an intravenous push or\nbolus.</p>", "ID": "ecd0d62e-5a84-4d60-9348-46a711a975d9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla is for intravenous use. Trastuzumab emtansine must be reconstituted and diluted by a healthcare professional and administered as an intravenous infusion. It must not be administered as an intravenous push or bolus.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8af47ee6-0d14-4274-8a91-2331f2f81b27", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">For instructions on reconstitution and dilution of the\nmedicinal product before administration, see section\u00a06.6.</p>", "ID": "12f956a7-796d-468d-ae56-e225c2212424", "Styles": "None", "Classes": "['MsoNormal']", "Text": "For instructions on reconstitution and dilution of the medicinal product before administration, see section\u00a06.6.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "338d868a-fb32-43b7-8e7f-24302cca10be", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "fc01a798-13c6-4382-98a5-ef686b3c87c8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "338d868a-fb32-43b7-8e7f-24302cca10be"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "9c224616-95b7-428e-8bbd-f6f3c05667e2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fc01a798-13c6-4382-98a5-ef686b3c87c8"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "c0e89a1d-0796-48ae-a646-a60754d8d5f4", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "9c224616-95b7-428e-8bbd-f6f3c05667e2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</b></p>", "ID": "47ad1a70-cf06-4a91-82be-9f2c4ba12dbc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</b>", "ID": "cbbe323c-18fa-45bc-8b2b-5b9887d28c40", "Styles": "None", "Classes": "None", "Text": "4.3\u00a0\u00a0\u00a0\u00a0 Contraindications", "ParentId": "47ad1a70-cf06-4a91-82be-9f2c4ba12dbc"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2bfe0d62-937f-4472-860b-10d84532bc2c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Hypersensitivity to the active substance or to any of the\nexcipients listed in section\u00a06.1.</p>", "ID": "9006626a-82cf-4601-ad72-8c77e1b018b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Hypersensitivity to the active substance or to any of the excipients listed in section\u00a06.1.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d7767bdd-4b99-4b36-91ad-0f5665400119", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.4\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</b></p>", "ID": "5309cc9b-c58d-4969-96c9-3e9299cf63b7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.4\u00a0\u00a0\u00a0\u00a0 Special\nwarnings and precautions for use</b>", "ID": "386d0981-d4a4-4bce-a88e-022e7c8cb34e", "Styles": "None", "Classes": "None", "Text": "4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use", "ParentId": "5309cc9b-c58d-4969-96c9-3e9299cf63b7"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bf930cb4-dbe0-4caa-b3bd-9e5a2bb81d90", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">In order to improve traceability of biological medicinal\nproducts, the tradename and the batch number of the administered product should\nbe clearly recorded (or stated) in the patient file.</p>", "ID": "165b3eee-11a8-423c-bbb7-4972d8a8b199", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In order to improve traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded (or stated) in the patient file.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6cd99cbe-0ea7-4cae-80c0-89778960592e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">In order to prevent medicinal product errors it is important\nto check the vial labels to ensure that the medicinal product being prepared\nand administered is Kadcyla (trastuzumab emtansine) and not Herceptin\n(trastuzumab).</p>", "ID": "526e543b-d39f-4c83-b7a7-c1ee5d4f4bf5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In order to prevent medicinal product errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "af088b24-bcbf-463c-bee0-d978cd57fc2b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>Thrombocytopenia</i></p>", "ID": "2ab04667-72e9-4621-8eb7-87d3821e55a6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Thrombocytopenia</i>", "ID": "1c9468b7-f1cc-4e57-a773-1bd5c1067123", "Styles": "None", "Classes": "None", "Text": "Thrombocytopenia", "ParentId": "2ab04667-72e9-4621-8eb7-87d3821e55a6"}, {"Element": "<p class=\"MsoNormal\">Thrombocytopenia, or decreased platelet counts, was commonly\nreported with trastuzumab emtansine and was the most common adverse reaction\nleading to treatment discontinuation, dose reduction, and dose interruption\n(see section\u00a04.8). In clinical studies, the incidence and severity of\nthrombocytopenia were higher in Asian patients (see section 4.8).</p>", "ID": "1a0b9b74-9f3e-497a-b16c-3071477b6c44", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Thrombocytopenia, or decreased platelet counts, was commonly reported with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation, dose reduction, and dose interruption (see section\u00a04.8). In clinical studies, the incidence and severity of thrombocytopenia were higher in Asian patients (see section 4.8).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "10011aa0-6194-49d9-9eaa-ef7f8480a0df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">It is recommended that platelet counts are monitored prior\nto each trastuzumab emtansine dose. Patients with thrombocytopenia\n(\u2264\u00a0100,000/mm<sup>3</sup>) and patients on anti\u2011coagulant\ntreatment (e.g. warfarin, heparin, low molecular weight heparins) should be\nmonitored closely while on trastuzumab emtansine treatment. Trastuzumab\nemtansine has not been studied in patients with platelet counts\n\u2264\u00a0100,000/mm<sup>3</sup> prior to initiation of treatment. In the\nevent of decreased platelet count to Grade\u00a03 or greater\n(&lt;\u00a050,000/mm<sup>3</sup>), do not administer trastuzumab emtansine\nuntil platelet counts recover to Grade\u00a01 (\u2265\u00a075,000/mm<sup>3</sup>)\n(see section\u00a04.2). </p>", "ID": "84d6c144-7bbd-4fbb-b0de-754e66a99287", "Styles": "None", "Classes": "['MsoNormal']", "Text": "It is recommended that platelet counts are monitored prior to each trastuzumab emtansine dose. Patients with thrombocytopenia (\u2264\u00a0100,000/mm) and patients on anti\u2011coagulant treatment (e.g. warfarin, heparin, low molecular weight heparins) should be monitored closely while on trastuzumab emtansine treatment. Trastuzumab emtansine has not been studied in patients with platelet counts \u2264\u00a0100,000/mm prior to initiation of treatment. In the event of decreased platelet count to Grade\u00a03 or greater (<\u00a050,000/mm), do not administer trastuzumab emtansine until platelet counts recover to Grade\u00a01 (\u2265\u00a075,000/mm) (see section\u00a04.2). ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<sup>3</sup>", "ID": "d3617fca-b0ce-4962-ba32-a76121ab04f6", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "84d6c144-7bbd-4fbb-b0de-754e66a99287"}, {"Element": "<sup>3</sup>", "ID": "27db4e3a-0ff1-47f2-809d-106ac2518d99", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "84d6c144-7bbd-4fbb-b0de-754e66a99287"}, {"Element": "<sup>3</sup>", "ID": "3b1c43a0-3a3a-4073-b5db-88922116936d", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "84d6c144-7bbd-4fbb-b0de-754e66a99287"}, {"Element": "<sup>3</sup>", "ID": "ab0fa154-179e-43d6-bc7d-e9ae67e26f4f", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "84d6c144-7bbd-4fbb-b0de-754e66a99287"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e6b5af52-0a8a-40ac-a082-b01aad78dde0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>Haemorrhage</i></p>", "ID": "ceee9806-519d-4fc5-933d-9c5b73427825", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Haemorrhage</i>", "ID": "b117895e-5ec5-4862-a25c-cf1582e6dfc5", "Styles": "None", "Classes": "None", "Text": "Haemorrhage", "ParentId": "ceee9806-519d-4fc5-933d-9c5b73427825"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Cases of haemorrhagic events,\nincluding central nervous system, respiratory and gastrointestinal haemorrhage,\nhave been reported with trastuzumab emtansine treatment. Some of these bleeding\nevents resulted in fatal outcomes. In some of the observed cases the patients\nhad thrombocytopenia, or were also receiving anti-coagulant therapy or\nantiplatelet therapy; in others there were no known additional risk factors.\nUse caution with these agents and consider additional monitoring when\nconcomitant use is medically necessary.</p>", "ID": "89510ad6-afe7-4563-b892-3e0cd6e9fdc4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Cases of haemorrhagic events, including central nervous system, respiratory and gastrointestinal haemorrhage, have been reported with trastuzumab emtansine treatment. Some of these bleeding events resulted in fatal outcomes. In some of the observed cases the patients had thrombocytopenia, or were also receiving anti-coagulant therapy or antiplatelet therapy; in others there were no known additional risk factors. Use caution with these agents and consider additional monitoring when concomitant use is medically necessary.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>", "ID": "c48ed3c6-31fb-4643-8309-a5240783f4cf", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "5bd6e25c-7597-40eb-8d07-5cba29655323", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c48ed3c6-31fb-4643-8309-a5240783f4cf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Hepatotoxicity</i></p>", "ID": "af0f1c92-118d-4cf8-bd96-1bb3a7a1f43f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Hepatotoxicity</i>", "ID": "44af62e0-d937-41c4-b0ba-466bbeacd7e8", "Styles": "None", "Classes": "None", "Text": "Hepatotoxicity", "ParentId": "af0f1c92-118d-4cf8-bd96-1bb3a7a1f43f"}, {"Element": "<p class=\"MsoNormal\">Hepatotoxicity, predominantly in the form of asymptomatic\nincreases in the concentrations of serum transaminases (Grade\u00a01\u20114\u00a0transaminitis),\nhas been observed during treatment with trastuzumab emtansine in clinical\nstudies (see section\u00a04.8). Transaminase elevations were generally\ntransient with peak elevation at day 8 after administration of therapy and\nsubsequent recovery to Grade 1 or less prior to the next cycle. A cumulative\neffect on transaminases has also been observed (the proportion of patients with\nGrade 1-2 ALT/AST abnormalities increases with successive cycles). </p>", "ID": "cfbbce57-3d1a-4894-bc89-9cf5b49abe8d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Hepatotoxicity, predominantly in the form of asymptomatic increases in the concentrations of serum transaminases (Grade\u00a01\u20114\u00a0transaminitis), has been observed during treatment with trastuzumab emtansine in clinical studies (see section\u00a04.8). Transaminase elevations were generally transient with peak elevation at day 8 after administration of therapy and subsequent recovery to Grade 1 or less prior to the next cycle. A cumulative effect on transaminases has also been observed (the proportion of patients with Grade 1-2 ALT/AST abnormalities increases with successive cycles). ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "93c79c0c-6ab6-44eb-8810-04dc52423294", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Patients with elevated transaminases improved to Grade 1 or\nnormal within 30 days of the last dose of trastuzumab emtansine in the majority\nof the cases (see section 4.8). </p>", "ID": "ce129a4f-5fff-4e0e-92af-a4f35663a9ab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Patients with elevated transaminases improved to Grade 1 or normal within 30 days of the last dose of trastuzumab emtansine in the majority of the cases (see section 4.8). ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "371d5891-3bf7-4325-a998-1f14538c9a13", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Serious hepatobiliary disorders, including nodular\nregenerative hyperplasia (NRH) of the liver and some with a fatal outcome due\nto drug-induced liver injury have been observed in patients treated with\ntrastuzumab emtansine. Observed cases may have been confounded by comorbidities\nand/or concomitant medicinal products with known hepatotoxic potential.</p>", "ID": "298ce653-3eca-46ce-9621-2c39f31a5131", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Serious hepatobiliary disorders, including nodular regenerative hyperplasia (NRH) of the liver and some with a fatal outcome due to drug-induced liver injury have been observed in patients treated with trastuzumab emtansine. Observed cases may have been confounded by comorbidities and/or concomitant medicinal products with known hepatotoxic potential.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "11fdc5a9-e19f-4dd3-a294-ea7d0853b5d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Liver function should be monitored prior to initiation of\ntreatment and each dose. Patients with baseline elevation of ALT (e.g. due to\nliver metastases)\u00a0may be predisposed to liver injury with a higher risk of\na Grade 3-5 hepatic event or liver function test increase. Dose reductions or\ndiscontinuation for increased serum transaminases and total bilirubin are\nspecified in section 4.2.</p>", "ID": "9866e5e0-1aed-457b-8555-1e8b7ad035c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Liver function should be monitored prior to initiation of treatment and each dose. Patients with baseline elevation of ALT (e.g. due to liver metastases)\u00a0may be predisposed to liver injury with a higher risk of a Grade 3-5 hepatic event or liver function test increase. Dose reductions or discontinuation for increased serum transaminases and total bilirubin are specified in section 4.2.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "21d395c6-7b7f-42b2-a6df-96d228f8830e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Cases of nodular regenerative hyperplasia (NRH) of the liver\nhave been identified from liver biopsies in patients treated with trastuzumab\nemtansine. NRH is a rare liver condition characterised by widespread benign\ntransformation of hepatic parenchyma into small regenerative nodules; NRH may\nlead to non\u2011cirrhotic portal hypertension. Diagnosis of NRH can be\nconfirmed only by histopathology. NRH should be considered in all patients with\nclinical symptoms of portal hypertension and/or cirrhosis-like pattern seen on\nthe computed tomography (CT) scan of the liver but with normal transaminases\nand no other manifestations of cirrhosis. Upon diagnosis of NRH, trastuzumab\nemtansine treatment must be permanently discontinued. </p>", "ID": "0f5c22f0-f75d-4a86-a728-a4f36ee7ebb7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Cases of nodular regenerative hyperplasia (NRH) of the liver have been identified from liver biopsies in patients treated with trastuzumab emtansine. NRH is a rare liver condition characterised by widespread benign transformation of hepatic parenchyma into small regenerative nodules; NRH may lead to non\u2011cirrhotic portal hypertension. Diagnosis of NRH can be confirmed only by histopathology. NRH should be considered in all patients with clinical symptoms of portal hypertension and/or cirrhosis-like pattern seen on the computed tomography (CT) scan of the liver but with normal transaminases and no other manifestations of cirrhosis. Upon diagnosis of NRH, trastuzumab emtansine treatment must be permanently discontinued. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "fdcb49d1-4604-4057-8dce-a836f1cea6e3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Trastuzumab emtansine has not been studied in patients with\nserum transaminases\u00a0&gt;\u00a02.5<b>\u00a0</b><span style=\"font-family:\nSymbol\">\u00b4</span>\u00a0ULN or total bilirubin\u00a0&gt;\u00a01.5<b>\u00a0</b><span style=\"font-family:Symbol\">\u00b4</span>\u00a0ULN prior to initiation of\ntreatment. Treatment in patients with serum transaminases\u00a0&gt;\u00a03<b>\u00a0</b><span style=\"font-family:Symbol\">\u00b4</span>\u00a0ULN and concomitant total\nbilirubin\u00a0&gt;\u00a02<b>\u00a0</b><span style=\"font-family:Symbol\">\u00b4</span>\u00a0ULN\nshould be permanently discontinued. Treatment of patients with hepatic\nimpairment should be undertaken with caution (see sections 4.2 and 5.2).</p>", "ID": "953c928e-71c0-4708-989d-e7847ac2f218", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine has not been studied in patients with serum transaminases\u00a0>\u00a02.5\u00a0ULN or total bilirubin\u00a0>\u00a01.5\u00a0ULN prior to initiation of treatment. Treatment in patients with serum transaminases\u00a0>\u00a03\u00a0ULN and concomitant total bilirubin\u00a0>\u00a02\u00a0ULN should be permanently discontinued. Treatment of patients with hepatic impairment should be undertaken with caution (see sections 4.2 and 5.2).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "ffd9a147-0ec1-4d89-ac57-59a799e8abf2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "953c928e-71c0-4708-989d-e7847ac2f218"}, {"Element": "<span style=\"font-family:\nSymbol\">\u00b4</span>", "ID": "e0a11e7a-6f4c-43bb-8dac-4bdfb829988c", "Styles": "font-family:\nSymbol", "Classes": "None", "Text": "\u00b4", "ParentId": "953c928e-71c0-4708-989d-e7847ac2f218"}, {"Element": "<b>\u00a0</b>", "ID": "615d1d12-7473-4b26-bb62-2d74b110a0b9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "953c928e-71c0-4708-989d-e7847ac2f218"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "148a6838-19bb-45a9-8695-2ad0e2af7498", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "953c928e-71c0-4708-989d-e7847ac2f218"}, {"Element": "<b>\u00a0</b>", "ID": "9763d1ed-a7a0-4eb7-9f26-54444c60f7db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "953c928e-71c0-4708-989d-e7847ac2f218"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "2c7ad0d4-827d-4f77-9dd2-06e21c14e0e3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "953c928e-71c0-4708-989d-e7847ac2f218"}, {"Element": "<b>\u00a0</b>", "ID": "8b4cca11-d62d-474f-a4ef-4bb88e81d701", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "953c928e-71c0-4708-989d-e7847ac2f218"}, {"Element": "<span style=\"font-family:Symbol\">\u00b4</span>", "ID": "4f860afe-bec9-4c66-9baa-a8fc59476c38", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b4", "ParentId": "953c928e-71c0-4708-989d-e7847ac2f218"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a79d400b-4ed8-4baf-abbd-17fcc9731c65", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Neurotoxicity</i></p>", "ID": "eef7cb97-b1cf-4bc9-81c8-94d36bda6493", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Neurotoxicity</i>", "ID": "4e4407d0-6bc6-4d6f-93b1-d528110d470d", "Styles": "None", "Classes": "None", "Text": "Neurotoxicity", "ParentId": "eef7cb97-b1cf-4bc9-81c8-94d36bda6493"}, {"Element": "<p class=\"MsoNormal\">Peripheral neuropathy, mainly Grade\u00a01 and predominantly\nsensory, has been reported in clinical studies with trastuzumab emtansine. MBC\npatients with Grade \u00a0<span style=\"font-family:Symbol\">\u00b3</span>\u00a03\nand EBC patients with Grade \u00a0<span style=\"font-family:Symbol\">\u00b3</span>\u00a02</p>", "ID": "60b81652-6321-4b12-9ddb-959d3e7ed5f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Peripheral neuropathy, mainly Grade\u00a01 and predominantly sensory, has been reported in clinical studies with trastuzumab emtansine. MBC patients with Grade \u00a0\u00a03 and EBC patients with Grade \u00a0\u00a02", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "6fb2da6c-b59e-448b-aa55-d690196984d0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "60b81652-6321-4b12-9ddb-959d3e7ed5f7"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "c2e3f2ca-860f-4172-91d3-43e271c193b1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "60b81652-6321-4b12-9ddb-959d3e7ed5f7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">peripheral neuropathy at\nbaseline were excluded from clinical studies. Treatment with trastuzumab emtansine\nshould be temporarily discontinued in patients experiencing Grade\u00a03 or 4\nperipheral neuropathy until symptoms resolve or improve to\n\u2264\u00a0Grade\u00a02. Patients should be clinically monitored on an\nongoing basis for signs/symptoms of neurotoxicity<i>. </i></p>", "ID": "339d3d09-08c2-4551-94ba-f1f1c7f20b53", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "peripheral neuropathy at baseline were excluded from clinical studies. Treatment with trastuzumab emtansine should be temporarily discontinued in patients experiencing Grade\u00a03 or 4 peripheral neuropathy until symptoms resolve or improve to \u2264\u00a0Grade\u00a02. Patients should be clinically monitored on an ongoing basis for signs/symptoms of neurotoxicity", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>. </i>", "ID": "86f302eb-a3ce-4ff5-92b3-a020461dfc9c", "Styles": "None", "Classes": "None", "Text": ". ", "ParentId": "339d3d09-08c2-4551-94ba-f1f1c7f20b53"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "21c84125-6386-4b6b-be7c-852369b97af4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Left ventricular\ndysfunction</i> </p>", "ID": "0c5d3feb-f702-4f46-a2ea-ae950fe7f8f0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Left ventricular\ndysfunction</i>", "ID": "1b63869d-4def-4df5-8ed7-13fced2f29bd", "Styles": "None", "Classes": "None", "Text": "Left ventricular dysfunction", "ParentId": "0c5d3feb-f702-4f46-a2ea-ae950fe7f8f0"}, {"Element": "<p class=\"MsoNormal\">Patients treated with trastuzumab emtansine are at increased\nrisk of developing left ventricular dysfunction. Left ventricular ejection\nfraction (LVEF)\u00a0&lt;\u00a040% has been observed in patients treated with\ntrastuzumab emtansine, and therefore symptomatic congestive heart failure (CHF)\nis a potential risk (see section\u00a04.8). General risk factors for a cardiac\nevent and those identified in adjuvant breast cancer studies with trastuzumab\ntherapy include advancing age (&gt; 50 years), low baseline LVEF values\n(&lt;\u00a055%), low LVEF levels prior to or following the use of paclitaxel in\nthe adjuvant setting, prior or concomitant use of antihypertensive medicinal\nproducts, previous therapy with an anthracycline and high BMI (&gt; 25 kg/m<sup>2</sup>).</p>", "ID": "8f809327-e9a9-4932-80a4-73d3d265be77", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Patients treated with trastuzumab emtansine are at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF)\u00a0<\u00a040% has been observed in patients treated with trastuzumab emtansine, and therefore symptomatic congestive heart failure (CHF) is a potential risk (see section\u00a04.8). General risk factors for a cardiac event and those identified in adjuvant breast cancer studies with trastuzumab therapy include advancing age (> 50 years), low baseline LVEF values (<\u00a055%), low LVEF levels prior to or following the use of paclitaxel in the adjuvant setting, prior or concomitant use of antihypertensive medicinal products, previous therapy with an anthracycline and high BMI (> 25 kg/m).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<sup>2</sup>", "ID": "2851b228-620b-493b-9ab4-538c9304e09d", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "8f809327-e9a9-4932-80a4-73d3d265be77"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a8eddbed-d9f9-4bb9-89c4-04a44c7c75b1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Standard cardiac function testing (echocardiogram or\nmultigated acquisition (MUGA) scanning) should be performed prior to initiation\nand at regular intervals (e.g. every three months) during treatment. In\nclinical studies, patients had a LVEF\u00a0<span style=\"font-family:Symbol\">\u00b3</span>\u00a050%\nat baseline. Patients with a history of congestive heart failure (CHF), serious\ncardiac arrhythmia requiring treatment, history of myocardial infarction or\nunstable angina within 6 months of randomization, or current dyspnoea at rest\ndue to advanced malignancy were excluded from clinical studies. The dose should\nbe delayed or treatment discontinued as necessary in cases of left ventricular\ndysfunction (see section\u00a04.2).</p>", "ID": "4c8b95a9-e3f3-477e-951d-920a008f936c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Standard cardiac function testing (echocardiogram or multigated acquisition (MUGA) scanning) should be performed prior to initiation and at regular intervals (e.g. every three months) during treatment. In clinical studies, patients had a LVEF\u00a0\u00a050% at baseline. Patients with a history of congestive heart failure (CHF), serious cardiac arrhythmia requiring treatment, history of myocardial infarction or unstable angina within 6 months of randomization, or current dyspnoea at rest due to advanced malignancy were excluded from clinical studies. The dose should be delayed or treatment discontinued as necessary in cases of left ventricular dysfunction (see section\u00a04.2).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "440903d4-0654-47fb-a22d-680e850e99b2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "4c8b95a9-e3f3-477e-951d-920a008f936c"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "fe40e4c6-391d-49d4-b30d-9756b947b44e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>Pulmonary toxicity</i></p>", "ID": "59efc274-875a-46d5-9775-68965a94cd63", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Pulmonary toxicity</i>", "ID": "fe1adeb4-0208-48cd-ac87-1980b5296f72", "Styles": "None", "Classes": "None", "Text": "Pulmonary toxicity", "ParentId": "59efc274-875a-46d5-9775-68965a94cd63"}, {"Element": "<p class=\"MsoNormal\">Cases of interstitial lung disease (ILD), including\npneumonitis, some leading to acute respiratory distress syndrome or a fatal\noutcome, have been reported in clinical studies with trastuzumab emtansine (see\nsection\u00a04.8). Signs and symptoms include dyspnoea, cough, fatigue, and\npulmonary infiltrates. </p>", "ID": "43bc41b5-03bd-4bcf-bcbc-322b4b7a8943", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Cases of interstitial lung disease (ILD), including pneumonitis, some leading to acute respiratory distress syndrome or a fatal outcome, have been reported in clinical studies with trastuzumab emtansine (see section\u00a04.8). Signs and symptoms include dyspnoea, cough, fatigue, and pulmonary infiltrates. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6369faca-6f5a-4611-81f6-90d4bc022280", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">It\nis recommended that treatment with trastuzumab emtansine be permanently\ndiscontinued in patients who are diagnosed with ILD or pneumonitis,<b><span style=\"font-size:8.0pt\"> </span></b>except for radiation pneumonitis in the\nadjuvant setting, where trastuzumab emtansine should be permanently\ndiscontinued for <span style=\"font-family:Symbol\">\u00b3</span> Grade 3 or for\nGrade 2 not responding to standard treatment. (see section 4.2).</p>", "ID": "8161a384-8164-4b83-96b0-92fbb430b63e", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "It is recommended that treatment with trastuzumab emtansine be permanently discontinued in patients who are diagnosed with ILD or pneumonitis,except for radiation pneumonitis in the adjuvant setting, where trastuzumab emtansine should be permanently discontinued for  Grade 3 or for Grade 2 not responding to standard treatment. (see section 4.2).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><span style=\"font-size:8.0pt\"> </span></b>", "ID": "4bcd914e-d980-48bd-aed1-a87c22430450", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8161a384-8164-4b83-96b0-92fbb430b63e"}, {"Element": "<span style=\"font-size:8.0pt\"> </span>", "ID": "86f89f16-02bd-4116-989b-b7e51db7c354", "Styles": "font-size:8.0pt", "Classes": "None", "Text": " ", "ParentId": "4bcd914e-d980-48bd-aed1-a87c22430450"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "a75e9c32-7ee4-431e-ab87-52588c1f5120", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "8161a384-8164-4b83-96b0-92fbb430b63e"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2cf2a746-7a02-4581-a89e-ba422f455d8c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Patients with dyspnoea at rest due to complications of\nadvanced malignancy, co\u2011morbidities, and receiving concurrent pulmonary\nradiation therapy may be at increased risk of pulmonary events.</p>", "ID": "d022ba8b-44e3-49dd-a0be-6918db9bce3d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Patients with dyspnoea at rest due to complications of advanced malignancy, co\u2011morbidities, and receiving concurrent pulmonary radiation therapy may be at increased risk of pulmonary events.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "996efd98-ad3c-44e8-ab9c-2edf2e636095", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "79c05cf5-81ce-4b04-96a8-b02d1a0c3b0b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "996efd98-ad3c-44e8-ab9c-2edf2e636095"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "57da6f15-70a7-4910-8635-c7830e0644fe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "79c05cf5-81ce-4b04-96a8-b02d1a0c3b0b"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "2665654b-eeb5-45b8-8830-2dfb93c7be75", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "57da6f15-70a7-4910-8635-c7830e0644fe"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Infusion-related reactions</i></p>", "ID": "c4cdbe74-9809-4450-952b-830211c84bf6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Infusion-related reactions</i>", "ID": "698e7435-deeb-48cb-b323-db1649725d61", "Styles": "None", "Classes": "None", "Text": "Infusion-related reactions", "ParentId": "c4cdbe74-9809-4450-952b-830211c84bf6"}, {"Element": "<p class=\"MsoNormal\">Trastuzumab emtansine treatment has not been studied in\npatients who had trastuzumab permanently discontinued due to infusion-related\nreactions (IRR); treatment is not recommended for these patients. Patients\nshould be observed closely for infusion-related reactions, especially during\nthe first infusion.</p>", "ID": "a8badf8a-c8fb-484e-89c8-a71e049ee47f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine treatment has not been studied in patients who had trastuzumab permanently discontinued due to infusion-related reactions (IRR); treatment is not recommended for these patients. Patients should be observed closely for infusion-related reactions, especially during the first infusion.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a8598c0a-c4d4-4321-bb8c-2aa7719c79df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Infusion-related reactions (due to cytokine release),\ncharacterized by one or more of the following symptoms have been reported:\nflushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and\ntachycardia. In general, these symptoms were not severe (see section 4.8). In\nmost patients, these reactions resolved over the course of several hours to a\nday after the infusion was terminated. Treatment should be interrupted in\npatients with a severe IRR until signs and symptoms resolve. Consideration for\nre-treatment should be based on clinical assessment of the severity of the\nreaction. Treatment must be permanently discontinued in the event of a life\nthreatening infusion-related reaction (see section\u00a04.2). </p>", "ID": "aeeec9a9-089a-4dfb-98b0-8638e0d59b1d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Infusion-related reactions (due to cytokine release), characterized by one or more of the following symptoms have been reported: flushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and tachycardia. In general, these symptoms were not severe (see section 4.8). In most patients, these reactions resolved over the course of several hours to a day after the infusion was terminated. Treatment should be interrupted in patients with a severe IRR until signs and symptoms resolve. Consideration for re-treatment should be based on clinical assessment of the severity of the reaction. Treatment must be permanently discontinued in the event of a life threatening infusion-related reaction (see section\u00a04.2). ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "8cdc25be-9ecb-41ad-bc47-9fcaf01be015", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "e2c8cbe3-6725-4479-a955-6d06cb61a832", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8cdc25be-9ecb-41ad-bc47-9fcaf01be015"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Hypersensitivity reactions</i></p>", "ID": "3d65c1eb-828d-4c4b-bb63-d372aa6f7af6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Hypersensitivity reactions</i>", "ID": "1f9a7f53-dcb1-4d6e-8c63-c4eb675f4164", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity reactions", "ParentId": "3d65c1eb-828d-4c4b-bb63-d372aa6f7af6"}, {"Element": "<p class=\"MsoNormal\">Trastuzumab emtansine treatment has not been studied in\npatients who had trastuzumab permanently discontinued due to hypersensitivity;\ntreatment with trastuzumab emtansine is not recommended for these patients. </p>", "ID": "b460cf1a-df9b-47d1-b4d2-674c05904af4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine treatment has not been studied in patients who had trastuzumab permanently discontinued due to hypersensitivity; treatment with trastuzumab emtansine is not recommended for these patients. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9e126f5d-3a89-4d24-bdd4-c85746a61e61", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Patients should be observed closely for\nhypersensitivity/allergic reactions, which may have the same clinical\npresentation as an IRR. Serious, anaphylactic reactions have been observed in\nclinical studies with trastuzumab emtansine. Medicinal products to treat such\nreactions, as well as emergency equipment, should be available for immediate\nuse. In the event of a true hypersensitivity reaction (in which severity of\nreaction increases with subsequent infusions), trastuzumab emtansine treatment\nmust be permanently discontinued. </p>", "ID": "104522ca-8f21-4017-b362-7b02424daee4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Patients should be observed closely for hypersensitivity/allergic reactions, which may have the same clinical presentation as an IRR. Serious, anaphylactic reactions have been observed in clinical studies with trastuzumab emtansine. Medicinal products to treat such reactions, as well as emergency equipment, should be available for immediate use. In the event of a true hypersensitivity reaction (in which severity of reaction increases with subsequent infusions), trastuzumab emtansine treatment must be permanently discontinued. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "acc07e32-d1d4-46db-87b6-367fa3b40ad9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "077f83eb-b129-492d-b2c0-7457bbefb01a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "acc07e32-d1d4-46db-87b6-367fa3b40ad9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Sodium content in\nexcipients</i></p>", "ID": "b6a20764-380c-4e2a-b0f2-439e0eeaf7c6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Sodium content in\nexcipients</i>", "ID": "f78ab4d2-df2e-4940-8e17-068a3334fec1", "Styles": "None", "Classes": "None", "Text": "Sodium content in excipients", "ParentId": "b6a20764-380c-4e2a-b0f2-439e0eeaf7c6"}, {"Element": "<p class=\"MsoNormal\">This medicinal product contains less than 1 mmol sodium (23\nmg) per dose, i.e. essentially \u2018sodium- free\u2019.</p>", "ID": "a41ada5e-e44e-4e88-aaae-2cc7812572bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially \u2018sodium- free\u2019.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "14445dd5-6bcb-4957-9b43-eaae86d29282", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.5\u00a0\u00a0\u00a0\u00a0 Interaction\nwith other medicinal products and other forms of interaction</b></p>", "ID": "39c4fff2-9b80-411a-a91e-32fbcb2434bc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.5\u00a0\u00a0\u00a0\u00a0 Interaction\nwith other medicinal products and other forms of interaction</b>", "ID": "94c6ef6e-c1e3-44ec-9194-e6c01a2fd846", "Styles": "None", "Classes": "None", "Text": "4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of interaction", "ParentId": "39c4fff2-9b80-411a-a91e-32fbcb2434bc"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "458246b8-6fac-4dba-a506-337f20d27844", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">No formal interaction studies have been performed. </p>", "ID": "e15a3a0b-0656-4ec0-9ff9-7b67424432c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No formal interaction studies have been performed. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9c8e4936-dd24-4af8-9ba9-4d3747bc6bd8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>In vitro</i> metabolism studies in human liver microsomes\nsuggest that DM1, a component of trastuzumab emtansine, is metabolised mainly\nby CYP3A4 and, to a lesser extent, by CYP3A5.\u00a0\u00a0 Concomitant use of\nstrong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin,\natazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,\ntelithromycin, and voriconazole) with trastuzumab emtansine should be avoided\ndue to the potential for an increase in DM1 exposure and toxicity.\u00a0\nConsider an alternate medicinal product with no or minimal potential to inhibit\nCYP3A4.\u00a0 If concomitant use of strong CYP3A4 inhibitors is unavoidable,\nconsider delaying trastuzumab emtansine treatment until the strong CYP3A4\ninhibitors have cleared from the circulation (approximately 3 elimination\nhalf-lives of the inhibitors) when possible.\u00a0 If a strong CYP3A4 inhibitor\nis coadministered and trastuzumab emtansine treatment cannot be delayed,\npatients should be closely monitored for adverse reactions. </p>", "ID": "f22360e4-6cd4-4b61-baa1-5c552e51e932", "Styles": "None", "Classes": "['MsoNormal']", "Text": " metabolism studies in human liver microsomes suggest that DM1, a component of trastuzumab emtansine, is metabolised mainly by CYP3A4 and, to a lesser extent, by CYP3A5.\u00a0\u00a0 Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) with trastuzumab emtansine should be avoided due to the potential for an increase in DM1 exposure and toxicity.\u00a0 Consider an alternate medicinal product with no or minimal potential to inhibit CYP3A4.\u00a0 If concomitant use of strong CYP3A4 inhibitors is unavoidable, consider delaying trastuzumab emtansine treatment until the strong CYP3A4 inhibitors have cleared from the circulation (approximately 3 elimination half-lives of the inhibitors) when possible.\u00a0 If a strong CYP3A4 inhibitor is coadministered and trastuzumab emtansine treatment cannot be delayed, patients should be closely monitored for adverse reactions. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>In vitro</i>", "ID": "fb1993d3-7c9f-42c8-ae51-6bac2574b9ea", "Styles": "None", "Classes": "None", "Text": "In vitro", "ParentId": "f22360e4-6cd4-4b61-baa1-5c552e51e932"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "83f9ae13-b93c-4a10-8491-e868bde78a0f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.6\u00a0\u00a0\u00a0\u00a0 Fertility,\npregnancy and lactation</b></p>", "ID": "5de2f7ff-dec0-4649-a665-4fea788229c5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.6\u00a0\u00a0\u00a0\u00a0 Fertility,\npregnancy and lactation</b>", "ID": "7f13a760-0a10-4cc2-8af2-30e76828d7d3", "Styles": "None", "Classes": "None", "Text": "4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and lactation", "ParentId": "5de2f7ff-dec0-4649-a665-4fea788229c5"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e5ea9fae-e98a-41f0-8cdf-2eb3ec6efe76", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><u>Contraception in males and females</u></p>", "ID": "6cebb710-0703-47d4-a35b-0e30e8e64981", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Contraception in males and females</u>", "ID": "6d1b1721-d884-4170-8983-4b5cce88bdd3", "Styles": "None", "Classes": "None", "Text": "Contraception in males and females", "ParentId": "6cebb710-0703-47d4-a35b-0e30e8e64981"}, {"Element": "<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "70f5914f-6768-443d-b479-fc307eee0e29", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "89bb2bbd-9f7e-47d9-8800-284b727d9439", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "70f5914f-6768-443d-b479-fc307eee0e29"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "3ee1d372-ebe1-441e-9bbf-9a39acd7dddf", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "89bb2bbd-9f7e-47d9-8800-284b727d9439"}, {"Element": "<p class=\"MsoNormal\">Women of childbearing potential should use effective\ncontraception while receiving trastuzumab emtansine and for 7\u00a0months\nfollowing the last dose of trastuzumab emtansine. Male patients or their female\npartners should also use effective contraception.</p>", "ID": "a955004b-a0f8-42dd-bf0c-0185fe0cb3cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Women of childbearing potential should use effective contraception while receiving trastuzumab emtansine and for 7\u00a0months following the last dose of trastuzumab emtansine. Male patients or their female partners should also use effective contraception.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "c3b9231c-ffc3-41b7-b8e8-acd5e0f0ce07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "bb6a6546-2ccb-4d99-9eef-3fa8dcd7ca08", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c3b9231c-ffc3-41b7-b8e8-acd5e0f0ce07"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "a1f3ef39-7e51-4064-a480-be66cec33555", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bb6a6546-2ccb-4d99-9eef-3fa8dcd7ca08"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "c1bfe1f6-1989-4885-8b48-c3932b837909", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "a1f3ef39-7e51-4064-a480-be66cec33555"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Pregnancy</u></p>", "ID": "b5d40530-2bcf-4026-bb31-09c17aec0c43", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Pregnancy</u>", "ID": "9be81fb2-090f-4f1c-9b13-c43ac39372ce", "Styles": "None", "Classes": "None", "Text": "Pregnancy", "ParentId": "b5d40530-2bcf-4026-bb31-09c17aec0c43"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>", "ID": "4520df73-624b-48ba-af54-ebfc42f6ed6a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "16bba20d-2e7d-4e74-ada9-4513de074f1a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4520df73-624b-48ba-af54-ebfc42f6ed6a"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "19b02f41-7556-4855-b85f-e891143d90f0", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "16bba20d-2e7d-4e74-ada9-4513de074f1a"}, {"Element": "<p class=\"MsoNormal\">There are no data from the use of trastuzumab emtansine in\npregnant women. Trastuzumab, a component of trastuzumab emtansine, can cause\nfoetal harm or death when administered to a pregnant woman. In the post\u2011marketing\nsetting, cases of oligohydramnios, some associated with fatal pulmonary\nhypoplasia, have been reported in pregnant women receiving trastuzumab. Animal\nstudies of maytansine, a closely related chemical entity of the same\nmaytansinoid class as DM1, suggest that DM1, the microtubule inhibiting\ncytotoxic component of trastuzumab emtansine, is expected to be teratogenic and\npotentially embryotoxic (see section 5.3).</p>", "ID": "452aa743-0bcd-4c3f-aa6a-899d48fbede8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "There are no data from the use of trastuzumab emtansine in pregnant women. Trastuzumab, a component of trastuzumab emtansine, can cause foetal harm or death when administered to a pregnant woman. In the post\u2011marketing setting, cases of oligohydramnios, some associated with fatal pulmonary hypoplasia, have been reported in pregnant women receiving trastuzumab. Animal studies of maytansine, a closely related chemical entity of the same maytansinoid class as DM1, suggest that DM1, the microtubule inhibiting cytotoxic component of trastuzumab emtansine, is expected to be teratogenic and potentially embryotoxic (see section 5.3).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "83bb5254-8ea9-407d-be9d-49e924303552", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Administration<i> </i>of trastuzumab emtansine to pregnant\nwomen is not recommended and women should be informed of the possibility of\nharm to the foetus before they become pregnant. Women who become pregnant must\nimmediately contact their doctor. If a pregnant woman is treated with\ntrastuzumab emtansine, close monitoring by a multidisciplinary team is\nrecommended.</p>", "ID": "75bf4013-6c61-4ece-9ee7-c58140f7e133", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Administrationof trastuzumab emtansine to pregnant women is not recommended and women should be informed of the possibility of harm to the foetus before they become pregnant. Women who become pregnant must immediately contact their doctor. If a pregnant woman is treated with trastuzumab emtansine, close monitoring by a multidisciplinary team is recommended.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i> </i>", "ID": "861ae7f7-97c4-413a-b768-3c1976ae07b3", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "75bf4013-6c61-4ece-9ee7-c58140f7e133"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "29145f36-24ea-4cf8-bde1-9bce57ba96ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "bcf621dc-d0ed-406a-a8aa-a9f4f10e3b6e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "29145f36-24ea-4cf8-bde1-9bce57ba96ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Breast\u2011feeding</u></p>", "ID": "d7b4f0b3-2db1-47d6-a2c7-f491f210dd16", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Breast\u2011feeding</u>", "ID": "27d5d738-1016-48c6-9cdc-d4c8f3fcb283", "Styles": "None", "Classes": "None", "Text": "Breast\u2011feeding", "ParentId": "d7b4f0b3-2db1-47d6-a2c7-f491f210dd16"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>", "ID": "95d32787-3112-404f-bcbc-77dbf803bbe5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "608806a4-801c-4482-b44f-4769fca9e22c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "95d32787-3112-404f-bcbc-77dbf803bbe5"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "3db2b174-bf1b-43a1-ac54-6243da6e6e04", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "608806a4-801c-4482-b44f-4769fca9e22c"}, {"Element": "<p class=\"MsoNormal\">It is not known whether trastuzumab emtansine is excreted in\nhuman milk. Since many medicinal products are excreted in human milk and\nbecause of the potential for serious adverse reactions in breast\u2011feeding\ninfants, women should discontinue breast\u2011feeding prior to initiating\ntreatment with trastuzumab emtansine. Women may begin breast\u2011feeding 7\u00a0months\nafter concluding treatment. </p>", "ID": "86ed48ec-92fa-435f-ab7e-e999b46af36f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "It is not known whether trastuzumab emtansine is excreted in human milk. Since many medicinal products are excreted in human milk and because of the potential for serious adverse reactions in breast\u2011feeding infants, women should discontinue breast\u2011feeding prior to initiating treatment with trastuzumab emtansine. Women may begin breast\u2011feeding 7\u00a0months after concluding treatment. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "429e2c0c-8f3c-4c82-8f9f-a1c1492b5f31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "b7c967ca-60ea-4401-a73b-ad4e0afcf3a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "429e2c0c-8f3c-4c82-8f9f-a1c1492b5f31"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Fertility</u></p>", "ID": "10d369a2-13c1-402b-8811-9e7bfeda0cd5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Fertility</u>", "ID": "afeee9bd-7162-4925-af34-c00465c63e77", "Styles": "None", "Classes": "None", "Text": "Fertility", "ParentId": "10d369a2-13c1-402b-8811-9e7bfeda0cd5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>", "ID": "41a761cf-c62b-43a8-a535-b52b99c61e91", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "9a051881-e831-421c-a089-969fbbb0e57a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "41a761cf-c62b-43a8-a535-b52b99c61e91"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "3957a92a-2820-4c61-bec0-62403c727ea7", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "9a051881-e831-421c-a089-969fbbb0e57a"}, {"Element": "<p class=\"MsoNormal\">No reproductive and developmental toxicology studies have\nbeen conducted with trastuzumab emtansine. </p>", "ID": "8e249d3f-0589-429e-a328-b45ebe261719", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No reproductive and developmental toxicology studies have been conducted with trastuzumab emtansine. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a7d5288d-edae-4cf1-ae96-46f07b486c82", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use\nmachines</b></p>", "ID": "433775e8-9134-4526-be79-0c95891d21d5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use\nmachines</b>", "ID": "940edc1f-0db5-41ab-982f-9be18f9fc754", "Styles": "None", "Classes": "None", "Text": "4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines", "ParentId": "433775e8-9134-4526-be79-0c95891d21d5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "2caf3a03-e34b-423c-80a0-c287a0b5db35", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Trastuzumab emtansine has minor influence on the ability to\ndrive and use machines. </p>", "ID": "d8b9c7e6-7250-4027-a2c9-5fa663306e96", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine has minor influence on the ability to drive and use machines. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The significance of reported adverse reactions such as\nfatigue, headache, dizziness and blurred vision on the ability to drive or use\nmachines is unknown. Patients experiencing infusion\u2011related reactions (flushing,\nchills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and tachycardia)\nshould be advised not to drive and use machines until symptoms abate.</p>", "ID": "2ea9f69e-47a7-4fd6-8da6-6ea6c37f857b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The significance of reported adverse reactions such as fatigue, headache, dizziness and blurred vision on the ability to drive or use machines is unknown. Patients experiencing infusion\u2011related reactions (flushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and tachycardia) should be advised not to drive and use machines until symptoms abate.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "eaefc6f3-1646-4a89-8c8d-9a9927d49871", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</b></p>", "ID": "89343763-5384-43d1-b3b5-233d5b931c67", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</b>", "ID": "1d005679-3608-4bb0-9896-74f636e4822a", "Styles": "None", "Classes": "None", "Text": "4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects", "ParentId": "89343763-5384-43d1-b3b5-233d5b931c67"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "90bddadc-e4c9-44dd-b0a6-886f6b5b7b18", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Summary of the safety\nprofile</u><u> </u></p>", "ID": "d1ed6d55-c023-4ed3-921e-a7d1f4ec22f5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Summary of the safety\nprofile</u>", "ID": "d52ebb17-15cb-48af-8726-9926cf0049e4", "Styles": "None", "Classes": "None", "Text": "Summary of the safety profile", "ParentId": "d1ed6d55-c023-4ed3-921e-a7d1f4ec22f5"}, {"Element": "<u> </u>", "ID": "8481f28b-8a2e-4576-a1ab-b925a33ec55b", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "d1ed6d55-c023-4ed3-921e-a7d1f4ec22f5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>", "ID": "79674fe7-f30f-45c4-8618-15849c0f5f61", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "ff83fdde-6b5e-4174-9dbc-7631277da457", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "79674fe7-f30f-45c4-8618-15849c0f5f61"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "62835de4-144e-4881-8a99-cc94bfc3f86e", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "ff83fdde-6b5e-4174-9dbc-7631277da457"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The safety of trastuzumab\nemtansine has been evaluated in 2,611\u00a0breast cancer patients in clinical\nstudies. In this patient population: </p>", "ID": "0eedfb14-227b-489f-9d6d-f704e27d553b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The safety of trastuzumab emtansine has been evaluated in 2,611\u00a0breast cancer patients in clinical studies. In this patient population: ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "fe4558b6-749a-473e-85d1-3b71feeff2e8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 the most\ncommon serious ADRs (&gt; 0.5% of patients) were haemorrhage, pyrexia, thrombocytopenia,\ndyspnoea, abdominal pain, musculoskeletal pain, and vomiting.</p>", "ID": "9d31e7c8-8536-4364-8948-1d9e9628ba24", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 the most common serious ADRs (> 0.5% of patients) were haemorrhage, pyrexia, thrombocytopenia, dyspnoea, abdominal pain, musculoskeletal pain, and vomiting.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "7413b34c-aa82-46d9-a74c-b5035b31895a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9d31e7c8-8536-4364-8948-1d9e9628ba24"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <span style=\"color:black\">the most common adverse drug reactions (ADRs) (\u226525%)\nwith trastuzumab emtansine were nausea, fatigue, musculoskeletal pain,\nhaemorrhage, headache, transaminases increased, thrombocytopenia, and peripheral\nneuropathy. The majority of ADRs reported were of Grade\u00a01 or 2 severity.</span></p>", "ID": "4dd369cc-9b5d-4bea-898e-7ef780eca84c", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "1ceb6533-727a-4c26-9153-2428f1e55f1e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4dd369cc-9b5d-4bea-898e-7ef780eca84c"}, {"Element": "<span style=\"color:black\">the most common adverse drug reactions (ADRs) (\u226525%)\nwith trastuzumab emtansine were nausea, fatigue, musculoskeletal pain,\nhaemorrhage, headache, transaminases increased, thrombocytopenia, and peripheral\nneuropathy. The majority of ADRs reported were of Grade\u00a01 or 2 severity.</span>", "ID": "7f46144f-aab3-4fbd-b352-50a49648936c", "Styles": "color:black", "Classes": "None", "Text": "the most common adverse drug reactions (ADRs) (\u226525%) with trastuzumab emtansine were nausea, fatigue, musculoskeletal pain, haemorrhage, headache, transaminases increased, thrombocytopenia, and peripheral neuropathy. The majority of ADRs reported were of Grade\u00a01 or 2 severity.", "ParentId": "4dd369cc-9b5d-4bea-898e-7ef780eca84c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 the most\ncommon National Cancer Institute - Common Terminology Criteria for Adverse\nEvents (NCI-CTCAE) Grade \u2265\u00a03 ADRs (&gt;\u00a02%) were\nthrombocytopenia, increased transaminases, anaemia, neutropenia, fatigue and\nhypokalaemia.</p>", "ID": "e9c405ad-8daa-4427-87f0-64a881d72f09", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 the most common National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade \u2265\u00a03 ADRs (>\u00a02%) were thrombocytopenia, increased transaminases, anaemia, neutropenia, fatigue and hypokalaemia.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "d6142c37-4984-4ced-9a78-6eb4b3d838c8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e9c405ad-8daa-4427-87f0-64a881d72f09"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>", "ID": "4e0d673b-209d-4758-a924-48c979872295", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "b618382d-ed5a-4be4-8d9a-6781a6d98cc1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4e0d673b-209d-4758-a924-48c979872295"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "688796af-6b2f-4942-b5f4-acdc27ab47c4", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "b618382d-ed5a-4be4-8d9a-6781a6d98cc1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Tabulated list of adverse\nreactions</u></p>", "ID": "18567d16-0435-4b20-af60-227242ab7dc6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Tabulated list of adverse\nreactions</u>", "ID": "083a8741-4f0e-434a-963e-d55704135f8a", "Styles": "None", "Classes": "None", "Text": "Tabulated list of adverse reactions", "ParentId": "18567d16-0435-4b20-af60-227242ab7dc6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>", "ID": "d8b6f098-ddb3-4345-bdaa-253029a976a4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "f0e3d72d-5458-4f40-b6f4-d034bc752cda", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d8b6f098-ddb3-4345-bdaa-253029a976a4"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "513b5236-f765-4f14-8aff-5a1dcee02ffe", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "f0e3d72d-5458-4f40-b6f4-d034bc752cda"}, {"Element": "<p class=\"MsoNormal\">The ADRs in 2,611\u00a0patients treated with trastuzumab\nemtansine are presented in Table\u00a03.\u00a0 The ADRs are listed below by\nMedDRA system organ class (SOC) and categories of frequency. Frequency\ncategories are defined as very common (\u2265\u00a01/10), common\n(\u2265\u00a01/100 to &lt;\u00a01/10), uncommon (\u2265\u00a01/1,000 to\n&lt;\u00a01/100), rare (\u2265\u00a01/10,000 to &lt;\u00a01/1,000), very rare\n(&lt;\u00a01/10,000) and not known (cannot be estimated from the available\ndata). Within each frequency grouping and SOC, adverse reactions are presented\nin order of decreasing seriousness.\u00a0 ADRs were reported using NCI-CTCAE\nfor assessment of toxicity.</p>", "ID": "8757317e-df60-43e5-92a6-04c67eb8e8f3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The ADRs in 2,611\u00a0patients treated with trastuzumab emtansine are presented in Table\u00a03.\u00a0 The ADRs are listed below by MedDRA system organ class (SOC) and categories of frequency. Frequency categories are defined as very common (\u2265\u00a01/10), common (\u2265\u00a01/100 to <\u00a01/10), uncommon (\u2265\u00a01/1,000 to <\u00a01/100), rare (\u2265\u00a01/10,000 to <\u00a01/1,000), very rare (<\u00a01/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping and SOC, adverse reactions are presented in order of decreasing seriousness.\u00a0 ADRs were reported using NCI-CTCAE for assessment of toxicity.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "9eb56202-1f78-40de-a90f-4a416671f7f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "2a6f7770-95de-4a3a-8511-9ac3cfd3316b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9eb56202-1f78-40de-a90f-4a416671f7f7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Table\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tabulated\nlist of ADRs in patients treated with trastuzumab emtansine in clinical trials</b></p>", "ID": "ad189c4f-5aca-4360-866f-128f8b84c7b8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Table\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tabulated\nlist of ADRs in patients treated with trastuzumab emtansine in clinical trials</b>", "ID": "7876ab61-2244-4c8e-9257-5e84af66f97f", "Styles": "None", "Classes": "None", "Text": "Table\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tabulated list of ADRs in patients treated with trastuzumab emtansine in clinical trials", "ParentId": "ad189c4f-5aca-4360-866f-128f8b84c7b8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "21038ec7-e8a6-4211-ae05-40d901916bb7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<thead>\n<tr style=\"height:15.8pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n   padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"181\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n   text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">System Organ Class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Very Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"127\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Uncommon</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"height:26.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Infections and infestations</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Urinary tract infection</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:26.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Blood and lymphatic system\n  disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Thrombocytopenia, Anaemia</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neutropenia, Leucopoenia</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:14.8pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Immune system disorders </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Drug hypersensitivity</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:17.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Metabolism and nutrition\n  disorders </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Hypokalaemia</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:6.7pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Psychiatric disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Insomnia</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:24.7pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Nervous system disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neuropathy peripheral,\n  Headache </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dizziness, Dysgeusia, Memory impairment</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:35.95pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Eye disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:8.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Cardiac disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Left ventricular dysfunction</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:3.5pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Vascular disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Haemorrhage</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hypertension</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Respiratory, thoracic and\n  mediastinal disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Epistaxis, Cough, Dyspnoea</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Pneumonitis (ILD)</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Gastrointestinal disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Stomatitis, Diarrhoea, Vomiting,\n  Nausea, Constipation, Dry mouth, Abdominal pain</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Dyspepsia, Gingival bleeding</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hepatobiliary disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Transaminases increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Blood alkaline phosphatase\n  increased, blood bilirubin increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.55pt;text-indent:-.55pt;page-break-after:\n  avoid\">Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia,\n  Portal hypertension</p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Skin and subcutaneous tissue\n  disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Rash, Pruritus, Alopecia, Nail\n  disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal and connective\n  tissue disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal pain, Arthralgia,\n  Myalgia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:28.3pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">General disorders and\n  administration site conditions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Fatigue, Pyrexia, Asthenia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Peripheral oedema, Chills</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Injection site extravasation</p>\n</td>\n</tr>\n<tr style=\"height:3.5pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Injury, poisoning and procedural\n  complications</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Infusion\u2011related reactions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Radiation pneumonitis</p>\n</td>\n</tr>\n</table>\n</div>", "ID": "0c1e89b0-c6b6-47b0-8574-b2fb2d15467d", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<thead>\n<tr style=\"height:15.8pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n   padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"181\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n   text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">System Organ Class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Very Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"127\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Uncommon</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"height:26.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Infections and infestations</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Urinary tract infection</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:26.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Blood and lymphatic system\n  disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Thrombocytopenia, Anaemia</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neutropenia, Leucopoenia</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:14.8pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Immune system disorders </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Drug hypersensitivity</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:17.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Metabolism and nutrition\n  disorders </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Hypokalaemia</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:6.7pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Psychiatric disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Insomnia</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:24.7pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Nervous system disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neuropathy peripheral,\n  Headache </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dizziness, Dysgeusia, Memory impairment</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:35.95pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Eye disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:8.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Cardiac disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Left ventricular dysfunction</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:3.5pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Vascular disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Haemorrhage</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hypertension</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Respiratory, thoracic and\n  mediastinal disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Epistaxis, Cough, Dyspnoea</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Pneumonitis (ILD)</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Gastrointestinal disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Stomatitis, Diarrhoea, Vomiting,\n  Nausea, Constipation, Dry mouth, Abdominal pain</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Dyspepsia, Gingival bleeding</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hepatobiliary disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Transaminases increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Blood alkaline phosphatase\n  increased, blood bilirubin increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.55pt;text-indent:-.55pt;page-break-after:\n  avoid\">Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia,\n  Portal hypertension</p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Skin and subcutaneous tissue\n  disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Rash, Pruritus, Alopecia, Nail\n  disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal and connective\n  tissue disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal pain, Arthralgia,\n  Myalgia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"height:28.3pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">General disorders and\n  administration site conditions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Fatigue, Pyrexia, Asthenia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Peripheral oedema, Chills</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Injection site extravasation</p>\n</td>\n</tr>\n<tr style=\"height:3.5pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Injury, poisoning and procedural\n  complications</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Infusion\u2011related reactions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Radiation pneumonitis</p>\n</td>\n</tr>\n</table>", "ID": "920eb9a5-ad19-4a48-af48-79cab38cfe38", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                  ", "ParentId": "0c1e89b0-c6b6-47b0-8574-b2fb2d15467d"}, {"Element": "<thead>\n<tr style=\"height:15.8pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n   padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"181\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n   text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">System Organ Class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Very Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"127\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Uncommon</span></b></p>\n</td>\n</tr>\n</thead>", "ID": "4dd9d102-2b0e-49f2-9659-0130529eda2d", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<tr style=\"height:15.8pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n   padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"181\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n   text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">System Organ Class</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Very Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Common</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"127\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Uncommon</span></b></p>\n</td>\n</tr>", "ID": "5e9dbf5c-83d2-4b0d-a41f-b6a647c235c0", "Styles": "height:15.8pt", "Classes": "None", "Text": "     ", "ParentId": "4dd9d102-2b0e-49f2-9659-0130529eda2d"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n   padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"181\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n   text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">System Organ Class</span></b></p>\n</td>", "ID": "18f0d182-9c38-4f3d-89b1-a8b283234515", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n   padding:0in 4.25pt 0in 4.25pt;height:15.8pt", "Classes": "None", "Text": "  ", "ParentId": "5e9dbf5c-83d2-4b0d-a41f-b6a647c235c0"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n   text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">System Organ Class</span></b></p>", "ID": "917f8719-a4eb-4b94-98ab-8b10c9713264", "Styles": "margin-left:-.05pt;text-align:center;\n   text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "18f0d182-9c38-4f3d-89b1-a8b283234515"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">System Organ Class</span></b>", "ID": "c449aa9e-8b5c-4ecc-be9b-5d43d45e71e6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "917f8719-a4eb-4b94-98ab-8b10c9713264"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">System Organ Class</span>", "ID": "9053b0e6-4049-4568-9662-b76244116690", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "System Organ Class", "ParentId": "c449aa9e-8b5c-4ecc-be9b-5d43d45e71e6"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Very Common</span></b></p>\n</td>", "ID": "b39c3eae-b539-43a4-ab9d-a9787f19eee9", "Styles": "width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt", "Classes": "None", "Text": "  ", "ParentId": "5e9dbf5c-83d2-4b0d-a41f-b6a647c235c0"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Very Common</span></b></p>", "ID": "54081d3d-1586-44f4-abd1-c578b9470cfa", "Styles": "text-align:center;page-break-after:\n   avoid", "Classes": "['Default']", "Text": "", "ParentId": "b39c3eae-b539-43a4-ab9d-a9787f19eee9"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Very Common</span></b>", "ID": "8065817e-a5b9-4354-9679-b874680a86f8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "54081d3d-1586-44f4-abd1-c578b9470cfa"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Very Common</span>", "ID": "851c16ce-94a5-4a43-8458-a415bff7cd28", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Very Common", "ParentId": "8065817e-a5b9-4354-9679-b874680a86f8"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"140\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Common</span></b></p>\n</td>", "ID": "1457d717-3d63-4317-8689-48cf7dddb092", "Styles": "width:104.9pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt", "Classes": "None", "Text": "  ", "ParentId": "5e9dbf5c-83d2-4b0d-a41f-b6a647c235c0"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Common</span></b></p>", "ID": "5c233fc4-adb4-40b7-9b88-81cae2191719", "Styles": "text-align:center;page-break-after:\n   avoid", "Classes": "['Default']", "Text": "", "ParentId": "1457d717-3d63-4317-8689-48cf7dddb092"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Common</span></b>", "ID": "44ef9626-3d69-4f7a-a3eb-37d6af2803a0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5c233fc4-adb4-40b7-9b88-81cae2191719"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Common</span>", "ID": "90a36ee5-6007-47b7-858d-46f753f6f905", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Common", "ParentId": "44ef9626-3d69-4f7a-a3eb-37d6af2803a0"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt\" width=\"127\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Uncommon</span></b></p>\n</td>", "ID": "7fdf0e12-1e7d-4ae2-a479-be1c79bb04b4", "Styles": "width:95.6pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt", "Classes": "None", "Text": "  ", "ParentId": "5e9dbf5c-83d2-4b0d-a41f-b6a647c235c0"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Uncommon</span></b></p>", "ID": "c3e1b2db-dc8e-4cf3-93c1-0cdca87cef83", "Styles": "text-align:center;page-break-after:\n   avoid", "Classes": "['Default']", "Text": "", "ParentId": "7fdf0e12-1e7d-4ae2-a479-be1c79bb04b4"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Uncommon</span></b>", "ID": "d6478282-10be-4f58-960d-0f3698fac44a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c3e1b2db-dc8e-4cf3-93c1-0cdca87cef83"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Uncommon</span>", "ID": "5973ceea-73ff-413b-9c88-9d97dceec871", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Uncommon", "ParentId": "d6478282-10be-4f58-960d-0f3698fac44a"}, {"Element": "<tr style=\"height:26.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Infections and infestations</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Urinary tract infection</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "95fbc5ba-d5c4-4458-9777-3b73458177db", "Styles": "height:26.05pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Infections and infestations</p>\n</td>", "ID": "7fbff1e0-1200-46ec-bf4b-dad230b4983d", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt", "Classes": "None", "Text": "  ", "ParentId": "95fbc5ba-d5c4-4458-9777-3b73458177db"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Infections and infestations</p>", "ID": "2e2171ca-13c4-4e64-a3c8-469bfdf2c8b4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Infections and infestations", "ParentId": "7fbff1e0-1200-46ec-bf4b-dad230b4983d"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Urinary tract infection</p>\n</td>", "ID": "997bb383-4405-495d-b627-1f0bf3e20005", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt", "Classes": "None", "Text": "  ", "ParentId": "95fbc5ba-d5c4-4458-9777-3b73458177db"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Urinary tract infection</p>", "ID": "2fde4366-6bee-4983-9431-61a0ed67cbb6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Urinary tract infection", "ParentId": "997bb383-4405-495d-b627-1f0bf3e20005"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "8009946b-b740-44df-a4ff-b82ae165e6df", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt", "Classes": "None", "Text": "  ", "ParentId": "95fbc5ba-d5c4-4458-9777-3b73458177db"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "26a13015-3acf-4f86-a705-e273959559d9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "8009946b-b740-44df-a4ff-b82ae165e6df"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "faffe27d-80ac-41ec-ba36-c9210b4d018e", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt", "Classes": "None", "Text": "  ", "ParentId": "95fbc5ba-d5c4-4458-9777-3b73458177db"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "2e1a7fb6-6439-4ba2-9cc2-88238fd4b94e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "faffe27d-80ac-41ec-ba36-c9210b4d018e"}, {"Element": "<tr style=\"height:26.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Blood and lymphatic system\n  disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Thrombocytopenia, Anaemia</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neutropenia, Leucopoenia</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "bd0d6bad-5b97-4de0-ae77-81ffbda61187", "Styles": "height:26.05pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Blood and lymphatic system\n  disorders</p>\n</td>", "ID": "92953de5-9b77-421b-8a7f-2d6d7e45e874", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt", "Classes": "None", "Text": "  ", "ParentId": "bd0d6bad-5b97-4de0-ae77-81ffbda61187"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Blood and lymphatic system\n  disorders</p>", "ID": "15832e49-5a69-4bea-a638-83c5db2fdb13", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Blood and lymphatic system   disorders", "ParentId": "92953de5-9b77-421b-8a7f-2d6d7e45e874"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Thrombocytopenia, Anaemia</p>\n</td>", "ID": "beb3b55b-fb67-400a-94cb-7981fb834e18", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt", "Classes": "None", "Text": "  ", "ParentId": "bd0d6bad-5b97-4de0-ae77-81ffbda61187"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Thrombocytopenia, Anaemia</p>", "ID": "19ce5a35-2e71-4b57-a083-851b080edc7e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Thrombocytopenia, Anaemia", "ParentId": "beb3b55b-fb67-400a-94cb-7981fb834e18"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neutropenia, Leucopoenia</p>\n</td>", "ID": "b7cd80d4-770e-46a8-8f68-1e1c57d6a247", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt", "Classes": "None", "Text": "  ", "ParentId": "bd0d6bad-5b97-4de0-ae77-81ffbda61187"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neutropenia, Leucopoenia</p>", "ID": "da5794ef-ce87-48b1-ab1c-6ebc9337e40d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Neutropenia, Leucopoenia", "ParentId": "b7cd80d4-770e-46a8-8f68-1e1c57d6a247"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "3eb1b31e-101a-4295-a574-e7e2b29f3df5", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:26.05pt", "Classes": "None", "Text": "  ", "ParentId": "bd0d6bad-5b97-4de0-ae77-81ffbda61187"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "91be53ea-0174-4ac6-b6b0-eeca714adf13", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "3eb1b31e-101a-4295-a574-e7e2b29f3df5"}, {"Element": "<tr style=\"height:14.8pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Immune system disorders </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Drug hypersensitivity</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "32558004-9828-460f-8673-b085006e051e", "Styles": "height:14.8pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Immune system disorders </p>\n</td>", "ID": "55314557-6396-4f3d-8cda-bd531d755de3", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:14.8pt", "Classes": "None", "Text": "  ", "ParentId": "32558004-9828-460f-8673-b085006e051e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Immune system disorders </p>", "ID": "fc15bf91-2a8c-40ae-84d6-3a729853fd71", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Immune system disorders ", "ParentId": "55314557-6396-4f3d-8cda-bd531d755de3"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "0cb0d7b5-5c46-4889-b1d7-ffc53a15bfcb", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt", "Classes": "None", "Text": "  ", "ParentId": "32558004-9828-460f-8673-b085006e051e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "9370830a-60f8-41b9-9836-f5778c099a17", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "0cb0d7b5-5c46-4889-b1d7-ffc53a15bfcb"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Drug hypersensitivity</p>\n</td>", "ID": "7116af16-d6af-46fc-be9d-b908b63a9444", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt", "Classes": "None", "Text": "  ", "ParentId": "32558004-9828-460f-8673-b085006e051e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Drug hypersensitivity</p>", "ID": "7e77bfc9-e6a4-44e5-8d46-8134cc95f3c9", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Drug hypersensitivity", "ParentId": "7116af16-d6af-46fc-be9d-b908b63a9444"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "1fd79271-dd7f-431b-a7bf-421edcdde0d5", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:14.8pt", "Classes": "None", "Text": "  ", "ParentId": "32558004-9828-460f-8673-b085006e051e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "4f615086-eb65-4a21-8cd7-f130442642db", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "1fd79271-dd7f-431b-a7bf-421edcdde0d5"}, {"Element": "<tr style=\"height:17.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Metabolism and nutrition\n  disorders </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Hypokalaemia</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "9a399847-ee26-4b5d-b0d8-2bee87fb21f0", "Styles": "height:17.05pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Metabolism and nutrition\n  disorders </p>\n</td>", "ID": "3d8c3d64-6f61-4c83-a7de-1f860632b073", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:17.05pt", "Classes": "None", "Text": "  ", "ParentId": "9a399847-ee26-4b5d-b0d8-2bee87fb21f0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Metabolism and nutrition\n  disorders </p>", "ID": "efd80baf-944a-4404-82b3-6dddf8303353", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Metabolism and nutrition   disorders ", "ParentId": "3d8c3d64-6f61-4c83-a7de-1f860632b073"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "ffd55e95-7c50-4d4d-a8e7-f4ccb34f0feb", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt", "Classes": "None", "Text": "  ", "ParentId": "9a399847-ee26-4b5d-b0d8-2bee87fb21f0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "9b311469-dfb5-4030-8ef3-32d8f1224f8a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "ffd55e95-7c50-4d4d-a8e7-f4ccb34f0feb"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Hypokalaemia</p>\n</td>", "ID": "1f52119c-bf4f-4653-990f-2cf8ff97313b", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt", "Classes": "None", "Text": "  ", "ParentId": "9a399847-ee26-4b5d-b0d8-2bee87fb21f0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Hypokalaemia</p>", "ID": "07b638ca-239f-4d0f-97f3-0247dd2844b3", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Hypokalaemia", "ParentId": "1f52119c-bf4f-4653-990f-2cf8ff97313b"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "3eed36b1-8ca0-4479-b3d8-b620c73281fa", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:17.05pt", "Classes": "None", "Text": "  ", "ParentId": "9a399847-ee26-4b5d-b0d8-2bee87fb21f0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "9f0b57fb-5c49-4671-913b-abc9c6217d39", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "3eed36b1-8ca0-4479-b3d8-b620c73281fa"}, {"Element": "<tr style=\"height:6.7pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Psychiatric disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Insomnia</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "6ab0f7f2-3f52-48d8-a3ba-481f5da2693a", "Styles": "height:6.7pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Psychiatric disorders</p>\n</td>", "ID": "21a59e79-c63e-44cf-85ee-786be938260d", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:6.7pt", "Classes": "None", "Text": "  ", "ParentId": "6ab0f7f2-3f52-48d8-a3ba-481f5da2693a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Psychiatric disorders</p>", "ID": "5c20567d-95e9-453e-9c22-e1122a570697", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Psychiatric disorders", "ParentId": "21a59e79-c63e-44cf-85ee-786be938260d"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Insomnia</p>\n</td>", "ID": "03853daf-02fc-4911-bb35-56d5d3ca30fa", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt", "Classes": "None", "Text": "  ", "ParentId": "6ab0f7f2-3f52-48d8-a3ba-481f5da2693a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Insomnia</p>", "ID": "e5caba05-d491-4f50-9be2-dc6963581464", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Insomnia", "ParentId": "03853daf-02fc-4911-bb35-56d5d3ca30fa"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>", "ID": "bda0d4c2-4457-487b-8c32-b6b425912435", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt", "Classes": "None", "Text": "  ", "ParentId": "6ab0f7f2-3f52-48d8-a3ba-481f5da2693a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>", "ID": "5d304165-1a59-4826-96f2-83e36d5d8a2b", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "bda0d4c2-4457-487b-8c32-b6b425912435"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "8b313174-598c-44b9-8ae4-69485109e63a", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:6.7pt", "Classes": "None", "Text": "  ", "ParentId": "6ab0f7f2-3f52-48d8-a3ba-481f5da2693a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "9624326f-4a74-4dea-92b3-6f27ae828e6e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "8b313174-598c-44b9-8ae4-69485109e63a"}, {"Element": "<tr style=\"height:24.7pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Nervous system disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neuropathy peripheral,\n  Headache </p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dizziness, Dysgeusia, Memory impairment</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "601e4fdc-135a-425f-af3a-c0b2881da781", "Styles": "height:24.7pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Nervous system disorders</p>\n</td>", "ID": "e547483b-5751-4b68-b5a4-802a87dafd30", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:24.7pt", "Classes": "None", "Text": "  ", "ParentId": "601e4fdc-135a-425f-af3a-c0b2881da781"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Nervous system disorders</p>", "ID": "d9ac5e68-cd42-4bfc-b330-aff1c07065d0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Nervous system disorders", "ParentId": "e547483b-5751-4b68-b5a4-802a87dafd30"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neuropathy peripheral,\n  Headache </p>\n</td>", "ID": "4425c104-d3dd-43ee-9fc5-0f7fe6013b3a", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt", "Classes": "None", "Text": "  ", "ParentId": "601e4fdc-135a-425f-af3a-c0b2881da781"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Neuropathy peripheral,\n  Headache </p>", "ID": "c7762b4b-9124-44d2-a9cc-a16102449627", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Neuropathy peripheral,   Headache ", "ParentId": "4425c104-d3dd-43ee-9fc5-0f7fe6013b3a"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dizziness, Dysgeusia, Memory impairment</p>\n</td>", "ID": "02128d6c-dc32-4624-a6e9-f87a6e9ea12d", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt", "Classes": "None", "Text": "  ", "ParentId": "601e4fdc-135a-425f-af3a-c0b2881da781"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dizziness, Dysgeusia, Memory impairment</p>", "ID": "deda6de2-394a-4cb2-a3f9-a007c5597b9a", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Dizziness, Dysgeusia, Memory impairment", "ParentId": "02128d6c-dc32-4624-a6e9-f87a6e9ea12d"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "00ef6960-3190-4227-b661-f61145fe8c17", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:24.7pt", "Classes": "None", "Text": "  ", "ParentId": "601e4fdc-135a-425f-af3a-c0b2881da781"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "f01b0de5-11bf-41ca-a195-fcf38f0346ba", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "00ef6960-3190-4227-b661-f61145fe8c17"}, {"Element": "<tr style=\"height:35.95pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Eye disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "37c4ebf4-25e5-470d-8e9c-58838632e733", "Styles": "height:35.95pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Eye disorders</p>\n</td>", "ID": "41d9899e-62a4-468f-ab1b-d694eb481e60", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:35.95pt", "Classes": "None", "Text": "  ", "ParentId": "37c4ebf4-25e5-470d-8e9c-58838632e733"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Eye disorders</p>", "ID": "9fe99b46-8f5f-4d92-9c51-a4f2361dfab8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Eye disorders", "ParentId": "41d9899e-62a4-468f-ab1b-d694eb481e60"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "005e4630-2367-4c4a-bd19-8db75bced6e1", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt", "Classes": "None", "Text": "  ", "ParentId": "37c4ebf4-25e5-470d-8e9c-58838632e733"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "cab07257-140a-4f72-8b71-478eeae6e9d2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "005e4630-2367-4c4a-bd19-8db75bced6e1"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased</p>\n</td>", "ID": "91a2eb3c-d140-4f1d-b9d1-779a1113f339", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt", "Classes": "None", "Text": "  ", "ParentId": "37c4ebf4-25e5-470d-8e9c-58838632e733"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased</p>", "ID": "eb4d11ce-01d6-42bb-b44f-1ddbe1899531", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased", "ParentId": "91a2eb3c-d140-4f1d-b9d1-779a1113f339"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "20d0bf43-a577-4a60-9e9b-8ef49899580d", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:35.95pt", "Classes": "None", "Text": "  ", "ParentId": "37c4ebf4-25e5-470d-8e9c-58838632e733"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "9aca52b8-1aca-45e7-aa83-75d28576e7ed", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "20d0bf43-a577-4a60-9e9b-8ef49899580d"}, {"Element": "<tr style=\"height:8.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Cardiac disorders</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Left ventricular dysfunction</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "6d9797eb-a7ed-4b30-b47b-d6d35d80dee2", "Styles": "height:8.05pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"181\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Cardiac disorders</p>\n</td>", "ID": "471686e5-a572-489e-ad22-dc8a31b3367c", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:8.05pt", "Classes": "None", "Text": "  ", "ParentId": "6d9797eb-a7ed-4b30-b47b-d6d35d80dee2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Cardiac disorders</p>", "ID": "12b8f98b-01ae-4892-add7-e2861ac91fed", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Cardiac disorders", "ParentId": "471686e5-a572-489e-ad22-dc8a31b3367c"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>\n</td>", "ID": "7406e04b-409c-4c8a-99b3-4f790e6930bc", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt", "Classes": "None", "Text": "  ", "ParentId": "6d9797eb-a7ed-4b30-b47b-d6d35d80dee2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "466418e8-69da-4ea9-b5a9-afef794b519b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "7406e04b-409c-4c8a-99b3-4f790e6930bc"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Left ventricular dysfunction</p>\n</td>", "ID": "301c8546-ba3a-42de-aa33-7b71a0ff0a8e", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt", "Classes": "None", "Text": "  ", "ParentId": "6d9797eb-a7ed-4b30-b47b-d6d35d80dee2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Left ventricular dysfunction</p>", "ID": "37e6574b-12d3-4b96-9080-825ba0f2ef4d", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Left ventricular dysfunction", "ParentId": "301c8546-ba3a-42de-aa33-7b71a0ff0a8e"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>", "ID": "2f85cc39-ff03-4659-a29e-355c77943bde", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:8.05pt", "Classes": "None", "Text": "  ", "ParentId": "6d9797eb-a7ed-4b30-b47b-d6d35d80dee2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>", "ID": "b3ae87cc-acc7-4067-b814-9d9071b46e9e", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "2f85cc39-ff03-4659-a29e-355c77943bde"}, {"Element": "<tr style=\"height:3.5pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Vascular disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Haemorrhage</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hypertension</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "f5a8f7b2-9da5-4a2f-a8fd-3d683d614ba1", "Styles": "height:3.5pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Vascular disorders</span></p>\n</td>", "ID": "a19523e1-a9ac-4c21-9ab0-68e6a0ee168e", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt", "Classes": "None", "Text": "  ", "ParentId": "f5a8f7b2-9da5-4a2f-a8fd-3d683d614ba1"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Vascular disorders</span></p>", "ID": "7cb48949-192f-445b-86fc-0f4b0476e35d", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "a19523e1-a9ac-4c21-9ab0-68e6a0ee168e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Vascular disorders</span>", "ID": "05a552f7-616f-463e-a800-8fa4d01fa3aa", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Vascular disorders", "ParentId": "7cb48949-192f-445b-86fc-0f4b0476e35d"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Haemorrhage</span></p>\n</td>", "ID": "27c3337e-733f-47fb-bcbd-a16849b6caab", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt", "Classes": "None", "Text": "  ", "ParentId": "f5a8f7b2-9da5-4a2f-a8fd-3d683d614ba1"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Haemorrhage</span></p>", "ID": "0871f4da-8d13-4b11-9860-30165e7099bb", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "27c3337e-733f-47fb-bcbd-a16849b6caab"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Haemorrhage</span>", "ID": "e15db4af-44ab-4fe7-998f-64a13e6423f6", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Haemorrhage", "ParentId": "0871f4da-8d13-4b11-9860-30165e7099bb"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hypertension</span></p>\n</td>", "ID": "06afe594-8b2a-4ac2-84f0-079bb1e0ac18", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt", "Classes": "None", "Text": "  ", "ParentId": "f5a8f7b2-9da5-4a2f-a8fd-3d683d614ba1"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hypertension</span></p>", "ID": "143e4075-4f82-4679-856d-5e507bf2fad2", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "06afe594-8b2a-4ac2-84f0-079bb1e0ac18"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hypertension</span>", "ID": "8d4a6c8e-a055-4228-b7e0-c44379007887", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Hypertension", "ParentId": "143e4075-4f82-4679-856d-5e507bf2fad2"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>", "ID": "de93bdf2-2e59-4355-8eb9-557f821b3cc7", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt", "Classes": "None", "Text": "  ", "ParentId": "f5a8f7b2-9da5-4a2f-a8fd-3d683d614ba1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>", "ID": "1ce6381f-e33f-424c-b717-ef727f63a00e", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "de93bdf2-2e59-4355-8eb9-557f821b3cc7"}, {"Element": "<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Respiratory, thoracic and\n  mediastinal disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Epistaxis, Cough, Dyspnoea</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Pneumonitis (ILD)</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "f3515a20-4694-4ec0-a1f3-17b523eff21f", "Styles": "height:13.05pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Respiratory, thoracic and\n  mediastinal disorders</span></p>\n</td>", "ID": "0171b011-2849-4be9-800f-c795c7f387e7", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "f3515a20-4694-4ec0-a1f3-17b523eff21f"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Respiratory, thoracic and\n  mediastinal disorders</span></p>", "ID": "ba145fa0-f47d-42a3-b308-bab3104a9883", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "0171b011-2849-4be9-800f-c795c7f387e7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Respiratory, thoracic and\n  mediastinal disorders</span>", "ID": "980cd1de-08d0-4feb-bfb8-3fb30a8367bf", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Respiratory, thoracic and   mediastinal disorders", "ParentId": "ba145fa0-f47d-42a3-b308-bab3104a9883"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Epistaxis, Cough, Dyspnoea</span></p>\n</td>", "ID": "d2cfd26b-70fa-4edf-8797-be781d4452fb", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "f3515a20-4694-4ec0-a1f3-17b523eff21f"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Epistaxis, Cough, Dyspnoea</span></p>", "ID": "2f3e8d07-cdcc-4386-8176-1075255763bc", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "d2cfd26b-70fa-4edf-8797-be781d4452fb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Epistaxis, Cough, Dyspnoea</span>", "ID": "11f6936f-79c5-4fab-aab7-6a3789f8d81c", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Epistaxis, Cough, Dyspnoea", "ParentId": "2f3e8d07-cdcc-4386-8176-1075255763bc"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>", "ID": "04922761-d53a-4deb-b23a-ee5eba549618", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "f3515a20-4694-4ec0-a1f3-17b523eff21f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>", "ID": "8800bd2b-7ba7-47ab-a65d-d7009889b37f", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "04922761-d53a-4deb-b23a-ee5eba549618"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Pneumonitis (ILD)</p>\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>", "ID": "f72b8e5c-2a65-414b-83f1-8b04e6682ff9", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "   ", "ParentId": "f3515a20-4694-4ec0-a1f3-17b523eff21f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Pneumonitis (ILD)</p>", "ID": "25bbe521-a4e3-4600-9b09-64ae80390c12", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Pneumonitis (ILD)", "ParentId": "f72b8e5c-2a65-414b-83f1-8b04e6682ff9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>", "ID": "ed98faf0-f316-48b4-b15e-34b2257cd3cb", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "f72b8e5c-2a65-414b-83f1-8b04e6682ff9"}, {"Element": "<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Gastrointestinal disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Stomatitis, Diarrhoea, Vomiting,\n  Nausea, Constipation, Dry mouth, Abdominal pain</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Dyspepsia, Gingival bleeding</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "eb0ccf38-6c20-4b7a-adfb-71be932c2c46", "Styles": "height:13.05pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Gastrointestinal disorders</span></p>\n</td>", "ID": "f8a62bd1-25ae-4a5f-a168-9fff0943decb", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "eb0ccf38-6c20-4b7a-adfb-71be932c2c46"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Gastrointestinal disorders</span></p>", "ID": "b50c0fb1-9801-4b8e-835a-7885b9ecee05", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "f8a62bd1-25ae-4a5f-a168-9fff0943decb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Gastrointestinal disorders</span>", "ID": "bcfd9e30-9401-4488-9553-d5ca0a18855a", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Gastrointestinal disorders", "ParentId": "b50c0fb1-9801-4b8e-835a-7885b9ecee05"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Stomatitis, Diarrhoea, Vomiting,\n  Nausea, Constipation, Dry mouth, Abdominal pain</span></p>\n</td>", "ID": "494e5a3c-a93c-4f11-baf7-8030c600265e", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "eb0ccf38-6c20-4b7a-adfb-71be932c2c46"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Stomatitis, Diarrhoea, Vomiting,\n  Nausea, Constipation, Dry mouth, Abdominal pain</span></p>", "ID": "d5234447-39aa-4ff0-bdf1-8e857085066e", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "494e5a3c-a93c-4f11-baf7-8030c600265e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Stomatitis, Diarrhoea, Vomiting,\n  Nausea, Constipation, Dry mouth, Abdominal pain</span>", "ID": "f125b397-b5a3-4607-8668-24e9649003bd", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Stomatitis, Diarrhoea, Vomiting,   Nausea, Constipation, Dry mouth, Abdominal pain", "ParentId": "d5234447-39aa-4ff0-bdf1-8e857085066e"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Dyspepsia, Gingival bleeding</span></p>\n</td>", "ID": "81df9001-bb9a-45ba-a39b-02928ad6b4ff", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "eb0ccf38-6c20-4b7a-adfb-71be932c2c46"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Dyspepsia, Gingival bleeding</span></p>", "ID": "1060931f-b3bd-4b4b-8a68-9919bf60a6a2", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "81df9001-bb9a-45ba-a39b-02928ad6b4ff"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Dyspepsia, Gingival bleeding</span>", "ID": "6571d855-f1e3-451c-8d21-379e8d95fe86", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Dyspepsia, Gingival bleeding", "ParentId": "1060931f-b3bd-4b4b-8a68-9919bf60a6a2"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>", "ID": "8ea66677-eece-4580-a6e6-ae28fc4996f5", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "eb0ccf38-6c20-4b7a-adfb-71be932c2c46"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>", "ID": "926194ea-aa89-48f2-93af-fc3f5e43615d", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "8ea66677-eece-4580-a6e6-ae28fc4996f5"}, {"Element": "<tr style=\"height:13.05pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hepatobiliary disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Transaminases increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Blood alkaline phosphatase\n  increased, blood bilirubin increased</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.55pt;text-indent:-.55pt;page-break-after:\n  avoid\">Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia,\n  Portal hypertension</p>\n</td>\n</tr>", "ID": "711521ad-2dc3-48b8-a854-6b6496e600f8", "Styles": "height:13.05pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hepatobiliary disorders</span></p>\n</td>", "ID": "47c2efea-79cc-420f-9e38-51ac9e7fc8d3", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "711521ad-2dc3-48b8-a854-6b6496e600f8"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hepatobiliary disorders</span></p>", "ID": "83402ebf-41ed-4f79-9cb0-de2b1ff89bc5", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "47c2efea-79cc-420f-9e38-51ac9e7fc8d3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Hepatobiliary disorders</span>", "ID": "c426985b-ff49-4de8-8fac-9584153b7f4c", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Hepatobiliary disorders", "ParentId": "83402ebf-41ed-4f79-9cb0-de2b1ff89bc5"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Transaminases increased</span></p>\n</td>", "ID": "a6c416a1-bedd-4203-80a4-c334fef7d3c2", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "711521ad-2dc3-48b8-a854-6b6496e600f8"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Transaminases increased</span></p>", "ID": "61af5bf5-f444-4654-b925-7c49947dbab1", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "a6c416a1-bedd-4203-80a4-c334fef7d3c2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Transaminases increased</span>", "ID": "8206810c-b6d6-4596-9b43-352418a216a8", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Transaminases increased", "ParentId": "61af5bf5-f444-4654-b925-7c49947dbab1"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Blood alkaline phosphatase\n  increased, blood bilirubin increased</span></p>\n</td>", "ID": "32ded27b-1de6-4b50-9792-9c3c190b867c", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "711521ad-2dc3-48b8-a854-6b6496e600f8"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Blood alkaline phosphatase\n  increased, blood bilirubin increased</span></p>", "ID": "3b3d240d-009c-4408-8e1a-0ae2fea8ceed", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "32ded27b-1de6-4b50-9792-9c3c190b867c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Blood alkaline phosphatase\n  increased, blood bilirubin increased</span>", "ID": "3f7cbe80-061a-42b5-92a4-c6f5f43be0f8", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Blood alkaline phosphatase   increased, blood bilirubin increased", "ParentId": "3b3d240d-009c-4408-8e1a-0ae2fea8ceed"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.55pt;text-indent:-.55pt;page-break-after:\n  avoid\">Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia,\n  Portal hypertension</p>\n</td>", "ID": "d734dda9-add9-4a2b-b1da-cf6fff307f91", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:13.05pt", "Classes": "None", "Text": "  ", "ParentId": "711521ad-2dc3-48b8-a854-6b6496e600f8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.55pt;text-indent:-.55pt;page-break-after:\n  avoid\">Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia,\n  Portal hypertension</p>", "ID": "e063fffc-f98e-48fc-8020-8bb2fa620a63", "Styles": "margin-left:.55pt;text-indent:-.55pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia,   Portal hypertension", "ParentId": "d734dda9-add9-4a2b-b1da-cf6fff307f91"}, {"Element": "<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Skin and subcutaneous tissue\n  disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Rash, Pruritus, Alopecia, Nail\n  disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "2cc86d7c-d07d-43f2-b22a-d0125659cd7a", "Styles": "height:18.2pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Skin and subcutaneous tissue\n  disorders</span></p>\n</td>", "ID": "eacddaa1-dbf4-4638-bdb8-ebc3a9fa01e4", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "2cc86d7c-d07d-43f2-b22a-d0125659cd7a"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Skin and subcutaneous tissue\n  disorders</span></p>", "ID": "c8044a9b-c500-4c59-990b-247769ee3324", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "eacddaa1-dbf4-4638-bdb8-ebc3a9fa01e4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Skin and subcutaneous tissue\n  disorders</span>", "ID": "467ac788-be91-41a3-910b-81d9cbf4aa29", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Skin and subcutaneous tissue   disorders", "ParentId": "c8044a9b-c500-4c59-990b-247769ee3324"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>", "ID": "cb411329-aab5-4bb9-b039-febe89983f76", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "2cc86d7c-d07d-43f2-b22a-d0125659cd7a"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>", "ID": "dba8677f-56b9-4d16-b634-e2cd7ca4ab67", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "cb411329-aab5-4bb9-b039-febe89983f76"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span>", "ID": "fd0367bf-009c-4cd3-94e4-e643ca9033cb", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "\u00a0", "ParentId": "dba8677f-56b9-4d16-b634-e2cd7ca4ab67"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Rash, Pruritus, Alopecia, Nail\n  disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria</span></p>\n</td>", "ID": "4424e29a-3ceb-40ea-a929-ad477f06efe2", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "2cc86d7c-d07d-43f2-b22a-d0125659cd7a"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Rash, Pruritus, Alopecia, Nail\n  disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria</span></p>", "ID": "db626f09-3e9d-44b8-aa09-b475b0e26642", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "4424e29a-3ceb-40ea-a929-ad477f06efe2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Rash, Pruritus, Alopecia, Nail\n  disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria</span>", "ID": "3a2412ba-a1af-4bc3-a933-6811440622a0", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Rash, Pruritus, Alopecia, Nail   disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria", "ParentId": "db626f09-3e9d-44b8-aa09-b475b0e26642"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "f29ae362-818e-42de-acaa-b3c518094c61", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "2cc86d7c-d07d-43f2-b22a-d0125659cd7a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1b9c4e2e-1d22-4fe9-8146-920fd2470834", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f29ae362-818e-42de-acaa-b3c518094c61"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "26dbada0-c8d3-4076-bb45-40a7bf662dc1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b9c4e2e-1d22-4fe9-8146-920fd2470834"}, {"Element": "<tr style=\"height:18.2pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal and connective\n  tissue disorders</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal pain, Arthralgia,\n  Myalgia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>\n</tr>", "ID": "26c7424d-f918-4766-815c-8ff6bc6d5893", "Styles": "height:18.2pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal and connective\n  tissue disorders</span></p>\n</td>", "ID": "6346b58c-a2e2-41a2-82f4-23519eb3ad7b", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "26c7424d-f918-4766-815c-8ff6bc6d5893"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal and connective\n  tissue disorders</span></p>", "ID": "61a3b3e6-2167-4515-9ea4-57accf4ad776", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "6346b58c-a2e2-41a2-82f4-23519eb3ad7b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal and connective\n  tissue disorders</span>", "ID": "d9cd490c-5bef-4f29-af76-fccc73180b90", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Musculoskeletal and connective   tissue disorders", "ParentId": "61a3b3e6-2167-4515-9ea4-57accf4ad776"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal pain, Arthralgia,\n  Myalgia</span></p>\n</td>", "ID": "e309e8e5-0bd3-4d80-983a-1e5a5249e0e5", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "26c7424d-f918-4766-815c-8ff6bc6d5893"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal pain, Arthralgia,\n  Myalgia</span></p>", "ID": "2b4eee99-f08e-4540-8aa0-e8f32ee7df7f", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "e309e8e5-0bd3-4d80-983a-1e5a5249e0e5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Musculoskeletal pain, Arthralgia,\n  Myalgia</span>", "ID": "3ae293ee-f56b-4c5f-8a16-d1568ce8b954", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Musculoskeletal pain, Arthralgia,   Myalgia", "ParentId": "2b4eee99-f08e-4540-8aa0-e8f32ee7df7f"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>", "ID": "1dde6148-57f4-4724-a79e-981d8f27905c", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "26c7424d-f918-4766-815c-8ff6bc6d5893"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>", "ID": "bd27255a-510f-4780-9f56-28b11504600e", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "1dde6148-57f4-4724-a79e-981d8f27905c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span>", "ID": "8f4dae19-5b62-4155-bdd1-93f845c3ec4c", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "\u00a0", "ParentId": "bd27255a-510f-4780-9f56-28b11504600e"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>\n</td>", "ID": "bc1f5e19-8ef0-4c3d-b446-00fc5b1bd86f", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:18.2pt", "Classes": "None", "Text": "  ", "ParentId": "26c7424d-f918-4766-815c-8ff6bc6d5893"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">\u00a0</p>", "ID": "6af34746-a119-4566-8362-672e7ea28383", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "bc1f5e19-8ef0-4c3d-b446-00fc5b1bd86f"}, {"Element": "<tr style=\"height:28.3pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">General disorders and\n  administration site conditions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Fatigue, Pyrexia, Asthenia</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Peripheral oedema, Chills</span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Injection site extravasation</p>\n</td>\n</tr>", "ID": "9b863e94-62c3-4e42-ba2a-e00e992aa387", "Styles": "height:28.3pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">General disorders and\n  administration site conditions </span></p>\n</td>", "ID": "58d910a6-7d2c-447d-80c3-85ecbaea7c5d", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:28.3pt", "Classes": "None", "Text": "  ", "ParentId": "9b863e94-62c3-4e42-ba2a-e00e992aa387"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">General disorders and\n  administration site conditions </span></p>", "ID": "051d5177-a08b-4cb3-8d6d-8d19ad12862d", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "58d910a6-7d2c-447d-80c3-85ecbaea7c5d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">General disorders and\n  administration site conditions </span>", "ID": "e8ef4811-a975-47bc-9993-d27a56bcaff0", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "General disorders and   administration site conditions ", "ParentId": "051d5177-a08b-4cb3-8d6d-8d19ad12862d"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Fatigue, Pyrexia, Asthenia</span></p>\n</td>", "ID": "fe408ca6-2238-418a-ba2b-447b0e70bb2e", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt", "Classes": "None", "Text": "  ", "ParentId": "9b863e94-62c3-4e42-ba2a-e00e992aa387"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Fatigue, Pyrexia, Asthenia</span></p>", "ID": "9b642c04-4990-4f40-b961-5bc8690a3e04", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "fe408ca6-2238-418a-ba2b-447b0e70bb2e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Fatigue, Pyrexia, Asthenia</span>", "ID": "69447219-cf65-4671-8424-2ce157f74979", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Fatigue, Pyrexia, Asthenia", "ParentId": "9b642c04-4990-4f40-b961-5bc8690a3e04"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Peripheral oedema, Chills</span></p>\n</td>", "ID": "d8842e0a-08b6-4266-a81d-2d9d9679a131", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt", "Classes": "None", "Text": "  ", "ParentId": "9b863e94-62c3-4e42-ba2a-e00e992aa387"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Peripheral oedema, Chills</span></p>", "ID": "4847d167-d5f5-4a2c-8822-eeafe760878a", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "d8842e0a-08b6-4266-a81d-2d9d9679a131"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Peripheral oedema, Chills</span>", "ID": "bbdbf83e-116e-41df-b693-e4d1c17fb9f5", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Peripheral oedema, Chills", "ParentId": "4847d167-d5f5-4a2c-8822-eeafe760878a"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Injection site extravasation</p>\n</td>", "ID": "4f6774ee-3760-453f-afbc-4f035df1ce93", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:28.3pt", "Classes": "None", "Text": "  ", "ParentId": "9b863e94-62c3-4e42-ba2a-e00e992aa387"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Injection site extravasation</p>", "ID": "06de775e-af51-4cd8-bb0d-6178a58c1391", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Injection site extravasation", "ParentId": "4f6774ee-3760-453f-afbc-4f035df1ce93"}, {"Element": "<tr style=\"height:3.5pt\">\n<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Injury, poisoning and procedural\n  complications</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>\n<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Infusion\u2011related reactions </span></p>\n</td>\n<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Radiation pneumonitis</p>\n</td>\n</tr>", "ID": "803c928e-b4ee-4c65-8033-600c25147b19", "Styles": "height:3.5pt", "Classes": "None", "Text": "     ", "ParentId": "920eb9a5-ad19-4a48-af48-79cab38cfe38"}, {"Element": "<td nowrap=\"\" style=\"width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"181\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Injury, poisoning and procedural\n  complications</span></p>\n</td>", "ID": "9570c604-cd8e-415b-b141-598070f7c576", "Styles": "width:135.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt", "Classes": "None", "Text": "  ", "ParentId": "803c928e-b4ee-4c65-8033-600c25147b19"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Injury, poisoning and procedural\n  complications</span></p>", "ID": "a19cb976-dac1-4084-a19f-ce96a147eb73", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "9570c604-cd8e-415b-b141-598070f7c576"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Injury, poisoning and procedural\n  complications</span>", "ID": "7c020cb4-20fc-4d37-9efc-6d66835e9fec", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Injury, poisoning and procedural   complications", "ParentId": "a19cb976-dac1-4084-a19f-ce96a147eb73"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>\n</td>", "ID": "d2b7ffc7-5233-48bb-ab1f-8ae256911b52", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt", "Classes": "None", "Text": "  ", "ParentId": "803c928e-b4ee-4c65-8033-600c25147b19"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></p>", "ID": "a15593f2-d9f3-4193-934a-75d7adb93745", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "d2b7ffc7-5233-48bb-ab1f-8ae256911b52"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span>", "ID": "59eab27e-1ecc-43bf-bcb8-65a353bd9e6a", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "\u00a0", "ParentId": "a15593f2-d9f3-4193-934a-75d7adb93745"}, {"Element": "<td nowrap=\"\" style=\"width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"140\">\n<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Infusion\u2011related reactions </span></p>\n</td>", "ID": "a0b06902-0251-442a-8265-2430cdb9e658", "Styles": "width:104.9pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt", "Classes": "None", "Text": "  ", "ParentId": "803c928e-b4ee-4c65-8033-600c25147b19"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Infusion\u2011related reactions </span></p>", "ID": "ebd64a91-83cc-425f-8a42-f46efa703aaa", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "a0b06902-0251-442a-8265-2430cdb9e658"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Infusion\u2011related reactions </span>", "ID": "6b69c7fc-76c9-4d52-bee1-fd5193f798ce", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Infusion\u2011related reactions ", "ParentId": "ebd64a91-83cc-425f-8a42-f46efa703aaa"}, {"Element": "<td nowrap=\"\" style=\"width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt\" valign=\"top\" width=\"127\">\n<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Radiation pneumonitis</p>\n</td>", "ID": "3bd6c907-2839-417f-8da3-c98345924e51", "Styles": "width:95.6pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 4.25pt 0in 4.25pt;height:3.5pt", "Classes": "None", "Text": "  ", "ParentId": "803c928e-b4ee-4c65-8033-600c25147b19"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid\">Radiation pneumonitis</p>", "ID": "519b55e9-c406-4814-afe2-f3cb81bd9cf8", "Styles": "margin-left:.5pt;text-indent:-.5pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Radiation pneumonitis", "ParentId": "3bd6c907-2839-417f-8da3-c98345924e51"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "824e5d2f-6570-4db1-9385-7c908fe3be0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "647702c9-7970-4131-b1d7-00f43619e373", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "824e5d2f-6570-4db1-9385-7c908fe3be0e"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "6ac72301-a4cc-40b0-a225-26ecff66f8e7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "647702c9-7970-4131-b1d7-00f43619e373"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "c3707e35-3f5e-4cc4-949f-48d985165e00", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "6ac72301-a4cc-40b0-a225-26ecff66f8e7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Table 3\nshows pooled data from the overall treatment period in the MBC studies (N=\n1871; median number of cycles of trastuzumab emtansine was 10) and in KATHERINE\n(N=740; median number of cycles was 14). </span></p>", "ID": "93d2fc87-2331-4fef-b474-552664874cf2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-GB\">Table 3\nshows pooled data from the overall treatment period in the MBC studies (N=\n1871; median number of cycles of trastuzumab emtansine was 10) and in KATHERINE\n(N=740; median number of cycles was 14). </span>", "ID": "f9fc175f-5f48-45ed-b87e-37d076154c74", "Styles": "None", "Classes": "None", "Text": "Table 3 shows pooled data from the overall treatment period in the MBC studies (N= 1871; median number of cycles of trastuzumab emtansine was 10) and in KATHERINE (N=740; median number of cycles was 14). ", "ParentId": "93d2fc87-2331-4fef-b474-552664874cf2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0b3a557b-86d1-433c-b180-1854e736be75", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b6cd9720-2690-43da-8a06-0e50bc3f3041", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0b3a557b-86d1-433c-b180-1854e736be75"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Description of selected\nadverse reactions</u></p>", "ID": "023d1bc0-928b-4de6-8ab0-917798fdb4f5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Description of selected\nadverse reactions</u>", "ID": "52d8e2f3-2712-40dd-8779-d851aa3151ba", "Styles": "None", "Classes": "None", "Text": "Description of selected adverse reactions", "ParentId": "023d1bc0-928b-4de6-8ab0-917798fdb4f5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>", "ID": "d93892ff-d5d1-4689-99b8-422a273b5448", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "e55d0e4c-bb6a-479c-af13-7a507abd4d3c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d93892ff-d5d1-4689-99b8-422a273b5448"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Thrombocytopenia</i></p>", "ID": "9db87bd2-2b7b-4266-9790-e68b59c1667c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Thrombocytopenia</i>", "ID": "4a87caab-c682-4273-b995-fb4feeae193b", "Styles": "None", "Classes": "None", "Text": "Thrombocytopenia", "ParentId": "9db87bd2-2b7b-4266-9790-e68b59c1667c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Thrombocytopenia or decreased\nplatelet counts were reported in 24.9% of patients in MBC clinical studies with\ntrastuzumab emtansine and was the most common adverse reaction leading to\ntreatment discontinuation (2.6%). Thrombocytopenia was reported in 28.5% of\npatients in EBC clinical studies with trastuzumab emtansine and was the most\ncommon reported adverse reaction for all grades and grades \u2265\u00a03, as\nwell as the most common adverse reaction leading to treatment discontinuation (4.2%),\ndose interruptions, and dose reductions. The majority of the patients had\nGrade\u00a01 or\u00a02\u00a0events (\u2265\u00a050,000/mm<sup>3</sup>), with\nthe nadir occurring by day\u00a08 and generally improving to Grade\u00a00\nor\u00a01 (\u2265\u00a075,000/mm<sup>3</sup>) by the next scheduled dose. In\nclinical studies, the incidence and severity of thrombocytopenia were higher in\nAsian patients. Independent of race, the incidence of Grade\u00a03 or\u00a04\nevents (&lt;\u00a050,000/mm<sup>3</sup>) was 8.7% in patients with MBC treated\nwith trastuzumab emtansine and <span style=\"color:black\">5.7</span>% in\npatients with EBC. For dose modifications for thrombocytopenia, see sections\n4.2 and 4.4.\u00a0 </p>", "ID": "962d77ce-d225-4c84-ab5f-146ad90076b4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Thrombocytopenia or decreased platelet counts were reported in 24.9% of patients in MBC clinical studies with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (2.6%). Thrombocytopenia was reported in 28.5% of patients in EBC clinical studies with trastuzumab emtansine and was the most common reported adverse reaction for all grades and grades \u2265\u00a03, as well as the most common adverse reaction leading to treatment discontinuation (4.2%), dose interruptions, and dose reductions. The majority of the patients had Grade\u00a01 or\u00a02\u00a0events (\u2265\u00a050,000/mm), with the nadir occurring by day\u00a08 and generally improving to Grade\u00a00 or\u00a01 (\u2265\u00a075,000/mm) by the next scheduled dose. In clinical studies, the incidence and severity of thrombocytopenia were higher in Asian patients. Independent of race, the incidence of Grade\u00a03 or\u00a04 events (<\u00a050,000/mm) was 8.7% in patients with MBC treated with trastuzumab emtansine and % in patients with EBC. For dose modifications for thrombocytopenia, see sections 4.2 and 4.4.\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<sup>3</sup>", "ID": "31086c28-fc4b-4130-b8df-20e308bd9eb6", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "962d77ce-d225-4c84-ab5f-146ad90076b4"}, {"Element": "<sup>3</sup>", "ID": "869e2a8f-cc5d-41cd-9e85-2fbaccaa516a", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "962d77ce-d225-4c84-ab5f-146ad90076b4"}, {"Element": "<sup>3</sup>", "ID": "c9d91e63-595a-435b-8f3f-f849a4dc3b04", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "962d77ce-d225-4c84-ab5f-146ad90076b4"}, {"Element": "<span style=\"color:black\">5.7</span>", "ID": "efa29bbf-b33c-475b-a9e8-dffb74c632dc", "Styles": "color:black", "Classes": "None", "Text": "5.7", "ParentId": "962d77ce-d225-4c84-ab5f-146ad90076b4"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "23c5ad61-fbe7-411a-a178-d932e442f321", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "a9fa9d6f-2df4-4432-af10-08e0b1949e13", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "23c5ad61-fbe7-411a-a178-d932e442f321"}, {"Element": "<p class=\"MsoNormal\"><i>Haemorrhage</i></p>", "ID": "6ced31d3-9262-4ca5-9e82-0df8a951b688", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Haemorrhage</i>", "ID": "ad9b6de7-8a79-4609-ba9b-4d8504dc9358", "Styles": "None", "Classes": "None", "Text": "Haemorrhage", "ParentId": "6ced31d3-9262-4ca5-9e82-0df8a951b688"}, {"Element": "<p class=\"MsoNormal\">Haemorrhagic events were reported in 34.8% of patients in\nMBC clinical trials with trastuzumab emtansine and <span style=\"color:black\">t</span>he\nincidence of severe haemorrhagic events (Grade \u22653) occurred in 2.2%. Haemorrhagic\nevents were reported in 29% of patients with EBC and the incidence of severe\nhaemorrhagic events (Grade \u22653) was 0.4%, including one Grade 5 event. In\nsome of the observed cases the patients had thrombocytopenia, or were also\nreceiving anti-coagulant therapy or antiplatelet therapy; in others there were\nno known additional risk factors. Cases of bleeding events with a fatal outcome\nhave been observed in both MBC and EBC.</p>", "ID": "c7775265-6cb4-41be-a176-0b2cdd530980", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Haemorrhagic events were reported in 34.8% of patients in MBC clinical trials with trastuzumab emtansine and he incidence of severe haemorrhagic events (Grade \u22653) occurred in 2.2%. Haemorrhagic events were reported in 29% of patients with EBC and the incidence of severe haemorrhagic events (Grade \u22653) was 0.4%, including one Grade 5 event. In some of the observed cases the patients had thrombocytopenia, or were also receiving anti-coagulant therapy or antiplatelet therapy; in others there were no known additional risk factors. Cases of bleeding events with a fatal outcome have been observed in both MBC and EBC.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"color:black\">t</span>", "ID": "815cbbf7-8360-4a85-9e72-6da58998c7d3", "Styles": "color:black", "Classes": "None", "Text": "t", "ParentId": "c7775265-6cb4-41be-a176-0b2cdd530980"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7d024ae0-0eec-4ec6-9d89-b1d1ab87eff1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>Transaminases increased (AST/ALT)</i></p>", "ID": "482f6764-672b-418f-b0da-1bacbb4e61e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Transaminases increased (AST/ALT)</i>", "ID": "99e4f4c0-76f2-45bd-aa54-def33dc49332", "Styles": "None", "Classes": "None", "Text": "Transaminases increased (AST/ALT)", "ParentId": "482f6764-672b-418f-b0da-1bacbb4e61e2"}, {"Element": "<p class=\"MsoNormal\">Increase in serum transaminases (Grade\u00a01\u20114) has\nbeen observed during treatment with trastuzumab emtansine in clinical studies\n(see section\u00a04.4). Transaminase elevations were generally transient. A\ncumulative effect of trastuzumab emtansine on transaminases has been observed,\nand generally recovered when treatment was discontinued. Increased\ntransaminases were reported in 24.2% of patients in MBC clinical studies.\nGrade\u00a03 or\u00a04 increased AST and ALT were reported in 4.2% and 2.7% of\npatients with MBC respectively and usually occurred in the early treatment\ncycles (1\u20116). Increased transaminases were reported in 32.4% of patients\nwith EBC. Grade 3 and 4 increased transaminases were reported in 1.5% of\npatients with EBC. In general, the Grade\u00a0\u2265\u00a03 hepatic events\nwere not associated with poor clinical outcome; subsequent follow\u2011up\nvalues tended to show improvement to ranges allowing the patient to remain on\nstudy and continue to receive study treatment at the same or reduced dose. No\nrelationship was observed between trastuzumab emtansine exposure (AUC),\ntrastuzumab emtansine maximum serum concentration (C<sub>max</sub>), total\ntrastuzumab exposure (AUC), or C<sub>max</sub> of DM1 and increases in\ntransaminase. For dose modifications in the event of increased transaminases,\nsee sections 4.2 and 4.4. </p>", "ID": "01cf8100-253e-400f-988a-7637ddc61b61", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Increase in serum transaminases (Grade\u00a01\u20114) has been observed during treatment with trastuzumab emtansine in clinical studies (see section\u00a04.4). Transaminase elevations were generally transient. A cumulative effect of trastuzumab emtansine on transaminases has been observed, and generally recovered when treatment was discontinued. Increased transaminases were reported in 24.2% of patients in MBC clinical studies. Grade\u00a03 or\u00a04 increased AST and ALT were reported in 4.2% and 2.7% of patients with MBC respectively and usually occurred in the early treatment cycles (1\u20116). Increased transaminases were reported in 32.4% of patients with EBC. Grade 3 and 4 increased transaminases were reported in 1.5% of patients with EBC. In general, the Grade\u00a0\u2265\u00a03 hepatic events were not associated with poor clinical outcome; subsequent follow\u2011up values tended to show improvement to ranges allowing the patient to remain on study and continue to receive study treatment at the same or reduced dose. No relationship was observed between trastuzumab emtansine exposure (AUC), trastuzumab emtansine maximum serum concentration (C), total trastuzumab exposure (AUC), or C of DM1 and increases in transaminase. For dose modifications in the event of increased transaminases, see sections 4.2 and 4.4. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<sub>max</sub>", "ID": "3e370af6-ea83-4966-8e5d-a31280caa971", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "01cf8100-253e-400f-988a-7637ddc61b61"}, {"Element": "<sub>max</sub>", "ID": "18431da4-07ac-4db4-bb93-27ce5c89fc8f", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "01cf8100-253e-400f-988a-7637ddc61b61"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "82c6cb0f-16f0-4668-a9c0-cdf2ed15adbe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "f933f357-13b4-45a5-858f-7d4e963c1fb8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82c6cb0f-16f0-4668-a9c0-cdf2ed15adbe"}, {"Element": "<p class=\"MsoNormal\"><i>Left ventricular dysfunction</i></p>", "ID": "54813650-99c8-455f-a073-f6ab7a8db843", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Left ventricular dysfunction</i>", "ID": "ea9fcfd8-2d1c-47b6-aa4b-bedf48a8f54d", "Styles": "None", "Classes": "None", "Text": "Left ventricular dysfunction", "ParentId": "54813650-99c8-455f-a073-f6ab7a8db843"}, {"Element": "<p class=\"MsoNormal\">Left ventricular dysfunction was reported in 2.2% of\npatients in MBC clinical studies with trastuzumab emtansine. The majority of\nevents were asymptomatic Grade\u00a01 or\u00a02 decrease in LVEF. Grade\u00a03\nor\u00a04 events were reported in 0.4% of patients with MBC. Left ventricular\ndysfunction occurred in 3.0% of patients with EBC, with Grade 3 or 4 in 0.5% of\npatients. Additional LVEF monitoring is recommended for patients with\nLVEF\u00a0\u2264 45% (See Table\u00a05 in section 4.2 for specific dose\nmodifications). </p>", "ID": "b38bd773-f075-41f4-bef7-68cfd48a4765", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Left ventricular dysfunction was reported in 2.2% of patients in MBC clinical studies with trastuzumab emtansine. The majority of events were asymptomatic Grade\u00a01 or\u00a02 decrease in LVEF. Grade\u00a03 or\u00a04 events were reported in 0.4% of patients with MBC. Left ventricular dysfunction occurred in 3.0% of patients with EBC, with Grade 3 or 4 in 0.5% of patients. Additional LVEF monitoring is recommended for patients with LVEF\u00a0\u2264 45% (See Table\u00a05 in section 4.2 for specific dose modifications). ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "234ff89e-f49b-4316-ba3d-5dc0cbc3998c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Peripheral neuropathy</i></p>", "ID": "b41bfd67-2c2f-43f0-a7db-4e23fbe48b43", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Peripheral neuropathy</i>", "ID": "f8eb5619-97b1-4755-ac5f-7f45f69d9de5", "Styles": "None", "Classes": "None", "Text": "Peripheral neuropathy", "ParentId": "b41bfd67-2c2f-43f0-a7db-4e23fbe48b43"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Peripheral neuropathy, mainly\nas Grade 1 and predominantly sensory, was reported in clinical trials of trastuzumab\nemtansine. In patients with MBC, the overall incidence of peripheral neuropathy\nwas 29.0% and 8.6% for Grade \u2265 2. In patients with EBC, the overall\nincidence was 32.3% and 10.3% for Grade \u2265 2. </p>", "ID": "70290bdd-7966-412c-abcb-de620181d894", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Peripheral neuropathy, mainly as Grade 1 and predominantly sensory, was reported in clinical trials of trastuzumab emtansine. In patients with MBC, the overall incidence of peripheral neuropathy was 29.0% and 8.6% for Grade \u2265 2. In patients with EBC, the overall incidence was 32.3% and 10.3% for Grade \u2265 2. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "5fa98515-eab9-455e-906a-ecffb1907413", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Infusion\u2011related\nreactions</i></p>", "ID": "aab00494-2913-486d-946e-a7cfebcad029", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Infusion\u2011related\nreactions</i>", "ID": "97a078b1-a700-4e69-b666-144b6270a3be", "Styles": "None", "Classes": "None", "Text": "Infusion\u2011related reactions", "ParentId": "aab00494-2913-486d-946e-a7cfebcad029"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Infusion\u2011related\nreactions are characterised by one or more of the following symptoms: flushing,\nchills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm and tachycardia.\nInfusion\u2011related reactions were reported in 4.0% of patients in MBC clinical\nstudies with trastuzumab emtansine, with six Grade\u00a03 and no Grade\u00a04\nevents reported. Infusion-related reactions were reported in 1.6% of patients\nwith EBC, with no Grade 3 or 4 events reported. Infusion\u2011related\nreactions resolved over the course of several hours to a day after the infusion\nwas terminated. No dose relationship was observed in clinical studies. For dose\nmodifications in the event of infusion\u2011related reactions, see sections\n4.2 and 4.4. </p>", "ID": "75302e65-030c-46df-b0e4-d682852e9a40", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Infusion\u2011related reactions are characterised by one or more of the following symptoms: flushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm and tachycardia. Infusion\u2011related reactions were reported in 4.0% of patients in MBC clinical studies with trastuzumab emtansine, with six Grade\u00a03 and no Grade\u00a04 events reported. Infusion-related reactions were reported in 1.6% of patients with EBC, with no Grade 3 or 4 events reported. Infusion\u2011related reactions resolved over the course of several hours to a day after the infusion was terminated. No dose relationship was observed in clinical studies. For dose modifications in the event of infusion\u2011related reactions, see sections 4.2 and 4.4. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>", "ID": "7912fad8-d106-4555-b86f-1de07abd6a11", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "9312e37d-297c-4d34-8488-40fdd18d1760", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7912fad8-d106-4555-b86f-1de07abd6a11"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Hypersensitivity reactions</i></p>", "ID": "d01df2cc-f7ae-43fb-8ef0-0781ea57f1f0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Hypersensitivity reactions</i>", "ID": "a94de53d-31bc-45f3-b48f-d86b6c4a2226", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity reactions", "ParentId": "d01df2cc-f7ae-43fb-8ef0-0781ea57f1f0"}, {"Element": "<p class=\"MsoNormal\">Hypersensitivity was reported in 2.6% of patients in MBC clinical\nstudies with trastuzumab emtansine, with one Grade\u00a03 and one Grade 4\nevents reported. Hypersensitivity was reported in 2.7% of patients with EBC,\nwith Grade 3 or 4 in 0.4% of patients. Overall, the majority of\nhypersensitivity reactions were mild or moderate in severity and resolved upon\ntreatment. For dose modifications in the event of hypersensitivity reactions,\nsee sections 4.2 and 4.4. </p>", "ID": "8bf658c3-1e9f-497a-a83e-9309a51b5dfe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Hypersensitivity was reported in 2.6% of patients in MBC clinical studies with trastuzumab emtansine, with one Grade\u00a03 and one Grade 4 events reported. Hypersensitivity was reported in 2.7% of patients with EBC, with Grade 3 or 4 in 0.4% of patients. Overall, the majority of hypersensitivity reactions were mild or moderate in severity and resolved upon treatment. For dose modifications in the event of hypersensitivity reactions, see sections 4.2 and 4.4. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "de9b0514-0ae8-4a3f-a560-5ef0ba9408dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Immunogenicity</i></p>", "ID": "85f9edb8-c504-40d0-bd57-e7cae2e7330d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Immunogenicity</i>", "ID": "a626ccd9-7ac7-431c-aa5e-16c6b1448bb1", "Styles": "None", "Classes": "None", "Text": "Immunogenicity", "ParentId": "85f9edb8-c504-40d0-bd57-e7cae2e7330d"}, {"Element": "<p class=\"MsoNormal\">As with all therapeutic proteins, there is the potential for\nan immune response to trastuzumab emtansine. A total of 1243 patients from\nseven clinical studies were tested at multiple time points for anti-drug\nantibody (ADA) responses to trastuzumab emtansine. Following trastuzumab\nemtansine dosing, 5.1% (63/1243) of patients tested positive for anti-trastuzumab\nemtansine antibodies at one or more post-dose time points. In the Phase I and\nPhase II studies, 6.4% (24/376) of patients tested positive for anti- trastuzumab\nemtansine antibodies. In the EMILIA study (TDM4370g/BO21977), 5.2% (24/466) of\npatients tested positive for anti-trastuzumab emtansine antibodies, of which 13\nwere also positive for neutralizing antibodies. In the KATHERINE (BO27938)\nstudy, 3.7% (15/401) of patients tested positive for anti-trastuzumab emtansine\nantibodies, of which 5 were also positive for neutralizing antibodies. Due to\nthe low incidence of ADA, conclusions cannot be made on the impact of anti- trastuzumab\nemtansine antibodies on the pharmacokinetics, safety, and efficacy of trastuzumab\nemtansine. </p>", "ID": "553c34c4-11c6-4731-87a6-2bab11d8767f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "As with all therapeutic proteins, there is the potential for an immune response to trastuzumab emtansine. A total of 1243 patients from seven clinical studies were tested at multiple time points for anti-drug antibody (ADA) responses to trastuzumab emtansine. Following trastuzumab emtansine dosing, 5.1% (63/1243) of patients tested positive for anti-trastuzumab emtansine antibodies at one or more post-dose time points. In the Phase I and Phase II studies, 6.4% (24/376) of patients tested positive for anti- trastuzumab emtansine antibodies. In the EMILIA study (TDM4370g/BO21977), 5.2% (24/466) of patients tested positive for anti-trastuzumab emtansine antibodies, of which 13 were also positive for neutralizing antibodies. In the KATHERINE (BO27938) study, 3.7% (15/401) of patients tested positive for anti-trastuzumab emtansine antibodies, of which 5 were also positive for neutralizing antibodies. Due to the low incidence of ADA, conclusions cannot be made on the impact of anti- trastuzumab emtansine antibodies on the pharmacokinetics, safety, and efficacy of trastuzumab emtansine. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2cee0fb5-55e3-417d-a512-1f2b2ee47457", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Extravasation</i></p>", "ID": "58e582c6-5e15-4b61-b5ce-793ad10c153a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Extravasation</i>", "ID": "d350861d-fc40-4d30-bd81-2ef78488095a", "Styles": "None", "Classes": "None", "Text": "Extravasation", "ParentId": "58e582c6-5e15-4b61-b5ce-793ad10c153a"}, {"Element": "<p class=\"MsoNormal\">Reactions secondary to extravasation have been observed in\nclinical studies with trastuzumab emtansine. These reactions were usually mild\nor moderate and comprised erythema, tenderness, skin irritation, pain, or\nswelling at the infusion site. These reactions have been observed more\nfrequently within 24\u00a0hours of infusion. Specific treatment for trastuzumab\nemtansine extravasation is unknown at this time. </p>", "ID": "8c345c83-95fa-4270-85c9-24b105a61cbf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Reactions secondary to extravasation have been observed in clinical studies with trastuzumab emtansine. These reactions were usually mild or moderate and comprised erythema, tenderness, skin irritation, pain, or swelling at the infusion site. These reactions have been observed more frequently within 24\u00a0hours of infusion. Specific treatment for trastuzumab emtansine extravasation is unknown at this time. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "dadc1d02-b2b0-4544-bceb-5762aa52b79b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "b6ee7f9e-e7c3-4ebf-ad53-43f15a2040d6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dadc1d02-b2b0-4544-bceb-5762aa52b79b"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e71a32a4-11fe-4c62-afeb-818aa81fb640", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "b6ee7f9e-e7c3-4ebf-ad53-43f15a2040d6"}, {"Element": "<p class=\"MsoNormal\"><u>Laboratory abnormalities</u></p>", "ID": "04b099de-bd82-42f3-a410-31241ae80c59", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Laboratory abnormalities</u>", "ID": "827b4087-577b-4a5d-948a-4129be0c3c73", "Styles": "None", "Classes": "None", "Text": "Laboratory abnormalities", "ParentId": "04b099de-bd82-42f3-a410-31241ae80c59"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e6833493-d679-4791-991a-6b8f4da7225c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Tables\u00a04 and 5 displays laboratory abnormalities\nobserved in patients treated with trastuzumab emtansine in clinical study\nTDM4370g/BO21977/EMILIA and study BO27938/KATHERINE.</p>", "ID": "d982e778-7fd6-46f6-a062-dc26cbe361ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tables\u00a04 and 5 displays laboratory abnormalities observed in patients treated with trastuzumab emtansine in clinical study TDM4370g/BO21977/EMILIA and study BO27938/KATHERINE.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "57005f8a-ba4e-4060-94a2-6882d57e38f3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:49.65pt;text-indent:-49.65pt;page-break-after:\navoid\"><b>Table\u00a04\u00a0\u00a0\u00a0\u00a0 Laboratory abnormalities\nobserved in patients treated with trastuzumab emtansine in study\nTDM4370g/BO21977/EMILIA</b></p>", "ID": "763fa583-a55e-40c3-85ab-b0d823bbc2b8", "Styles": "margin-left:49.65pt;text-indent:-49.65pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Table\u00a04\u00a0\u00a0\u00a0\u00a0 Laboratory abnormalities\nobserved in patients treated with trastuzumab emtansine in study\nTDM4370g/BO21977/EMILIA</b>", "ID": "c9885e35-2d36-427e-a9ef-be7e490ba0b2", "Styles": "None", "Classes": "None", "Text": "Table\u00a04\u00a0\u00a0\u00a0\u00a0 Laboratory abnormalities observed in patients treated with trastuzumab emtansine in study TDM4370g/BO21977/EMILIA", "ParentId": "763fa583-a55e-40c3-85ab-b0d823bbc2b8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:49.65pt;text-indent:-49.65pt;page-break-after:\navoid\"><b>\u00a0</b></p>", "ID": "1e86f23e-19ce-480a-a717-d2c6e17a74f8", "Styles": "margin-left:49.65pt;text-indent:-49.65pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "f02f3198-a898-4932-a164-327f79a3cc84", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1e86f23e-19ce-480a-a717-d2c6e17a74f8"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:432.75pt;margin-left:4.65pt;border-collapse:collapse\" width=\"577\">\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" rowspan=\"2\" style=\"width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>\n</td>\n<td colspan=\"3\" nowrap=\"\" style=\"width:238.5pt;border:\n  solid windowtext 1.0pt;border-left:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"318\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab emtansine (N=490)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grades\u00a0(%)</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">21</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">98</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">8</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">82</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">85</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">14</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">63</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">41</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>\n</td>\n</tr>\n<tr style=\"height:2.9pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">35</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt; 1</p>\n</td>\n</tr>\n</table>", "ID": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd", "Styles": "width:432.75pt;margin-left:4.65pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "             ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" rowspan=\"2\" style=\"width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>\n</td>\n<td colspan=\"3\" nowrap=\"\" style=\"width:238.5pt;border:\n  solid windowtext 1.0pt;border-left:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"318\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab emtansine (N=490)</span></b></p>\n</td>\n</tr>", "ID": "4f627228-b5fe-4efd-8548-e701d02b05b7", "Styles": "height:15.0pt", "Classes": "None", "Text": "   ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td nowrap=\"\" rowspan=\"2\" style=\"width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>\n</td>", "ID": "d247af2d-f482-43ea-93f6-afa9a7ec379d", "Styles": "width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4f627228-b5fe-4efd-8548-e701d02b05b7"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>", "ID": "3b2dc896-abe8-4cf0-9951-aa8541db9818", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "d247af2d-f482-43ea-93f6-afa9a7ec379d"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b>", "ID": "a023b9ec-6095-43a3-aca2-d1531e278b4b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3b2dc896-abe8-4cf0-9951-aa8541db9818"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span>", "ID": "71f4a878-d585-4651-b06f-a36dc141a961", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Parameter", "ParentId": "a023b9ec-6095-43a3-aca2-d1531e278b4b"}, {"Element": "<td colspan=\"3\" nowrap=\"\" style=\"width:238.5pt;border:\n  solid windowtext 1.0pt;border-left:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"318\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab emtansine (N=490)</span></b></p>\n</td>", "ID": "2a699f1c-e95c-47da-ae12-bdd3be3ebaa8", "Styles": "width:238.5pt;border:\n  solid windowtext 1.0pt;border-left:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4f627228-b5fe-4efd-8548-e701d02b05b7"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab emtansine (N=490)</span></b></p>", "ID": "ba8b4fae-2ce3-4956-9b7d-6b9ea18119db", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "2a699f1c-e95c-47da-ae12-bdd3be3ebaa8"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab emtansine (N=490)</span></b>", "ID": "15d68022-7d39-413d-a4ca-120a5119b18d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ba8b4fae-2ce3-4956-9b7d-6b9ea18119db"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab emtansine (N=490)</span>", "ID": "911e47cb-3f17-412d-bccb-565bde01a232", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Trastuzumab emtansine (N=490)", "ParentId": "15d68022-7d39-413d-a4ca-120a5119b18d"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grades\u00a0(%)</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>\n</td>\n</tr>", "ID": "a4a10316-3592-4714-b5b8-d2800640b64d", "Styles": "height:15.0pt", "Classes": "None", "Text": "    ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grades\u00a0(%)</span></b></p>\n</td>", "ID": "8c7ac71d-a44a-45d2-a424-aad1d8f68b88", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "a4a10316-3592-4714-b5b8-d2800640b64d"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grades\u00a0(%)</span></b></p>", "ID": "a3a85a61-226b-484e-915b-ea1206a3e5c3", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "8c7ac71d-a44a-45d2-a424-aad1d8f68b88"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grades\u00a0(%)</span></b>", "ID": "584ea099-db8a-4aad-96c2-4741c836fba8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a3a85a61-226b-484e-915b-ea1206a3e5c3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grades\u00a0(%)</span>", "ID": "3fdbb2c7-d67c-42e7-8e82-320f2e0005fc", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "All Grades\u00a0(%)", "ParentId": "584ea099-db8a-4aad-96c2-4741c836fba8"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>\n</td>", "ID": "bef43dea-5b2d-4a96-a9b8-1254616f09cb", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "a4a10316-3592-4714-b5b8-d2800640b64d"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>", "ID": "f49f9b44-5057-439a-a75c-f1a806612f29", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "bef43dea-5b2d-4a96-a9b8-1254616f09cb"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b>", "ID": "41dee47b-a43c-49a8-805c-5c0de9ed47ac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f49f9b44-5057-439a-a75c-f1a806612f29"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span>", "ID": "6b5b7a66-900e-4bd7-9fd5-dd4dad561807", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Grade\u00a03 (%)", "ParentId": "41dee47b-a43c-49a8-805c-5c0de9ed47ac"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>\n</td>", "ID": "77dba065-788c-4b19-a43b-9da11a29f2e3", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "a4a10316-3592-4714-b5b8-d2800640b64d"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>", "ID": "af21091a-2180-494c-9c88-f2ec3555d607", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "77dba065-788c-4b19-a43b-9da11a29f2e3"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b>", "ID": "c1e577ef-2739-4429-a938-c18b339dcaa8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "af21091a-2180-494c-9c88-f2ec3555d607"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span>", "ID": "18658b6b-939b-4c18-9737-553840bea356", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Grade\u00a04 (%)", "ParentId": "c1e577ef-2739-4429-a938-c18b339dcaa8"}, {"Element": "<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>\n</td>\n</tr>", "ID": "89f201a9-d7a3-47ba-9696-c3582ecf3c06", "Styles": "height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>\n</td>", "ID": "bd00f1a3-a4ea-46f8-9202-a459f10efa77", "Styles": "width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "89f201a9-d7a3-47ba-9696-c3582ecf3c06"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>", "ID": "6ce327a5-3fa2-47f8-baab-6ffff5ca19d2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd00f1a3-a4ea-46f8-9202-a459f10efa77"}, {"Element": "<b>Hepatic</b>", "ID": "d4dff671-f327-4563-bab7-9ff6fe60b2ad", "Styles": "None", "Classes": "None", "Text": "Hepatic", "ParentId": "6ce327a5-3fa2-47f8-baab-6ffff5ca19d2"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">21</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>", "ID": "4007f190-e045-420a-a7cb-db6d9fa28306", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>\n</td>", "ID": "a19f9baf-f1f4-4ad0-999d-ec6663d1d496", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4007f190-e045-420a-a7cb-db6d9fa28306"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>", "ID": "be27fe13-6373-4f78-9190-297027889b42", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Increased bilirubin", "ParentId": "a19f9baf-f1f4-4ad0-999d-ec6663d1d496"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">21</p>\n</td>", "ID": "604f63ea-7ab0-442a-9519-3572d74d66fb", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4007f190-e045-420a-a7cb-db6d9fa28306"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">21</p>", "ID": "b67041ac-4285-4587-b75b-9ce7cba7815e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "21", "ParentId": "604f63ea-7ab0-442a-9519-3572d74d66fb"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>", "ID": "8e80da25-0d8e-4d6d-8e3f-425f7261384a", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4007f190-e045-420a-a7cb-db6d9fa28306"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>", "ID": "315a73eb-ffa4-4e9d-8bee-af87a9e07789", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "<\u00a01", "ParentId": "8e80da25-0d8e-4d6d-8e3f-425f7261384a"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>", "ID": "a0542a75-2792-46f8-a521-d4869d81f912", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4007f190-e045-420a-a7cb-db6d9fa28306"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>", "ID": "8688d6a5-3ed7-407d-8745-efaa40240b9f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "0", "ParentId": "a0542a75-2792-46f8-a521-d4869d81f912"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">98</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">8</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n</tr>", "ID": "eddd2335-3ec8-474a-a1d4-9653ff3bebf2", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>\n</td>", "ID": "f7b0b881-469b-4fad-8eaa-370347ab12d4", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "eddd2335-3ec8-474a-a1d4-9653ff3bebf2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>", "ID": "3d2263e3-5344-42cc-b5ec-c1e3f0a3c524", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Increased AST", "ParentId": "f7b0b881-469b-4fad-8eaa-370347ab12d4"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">98</p>\n</td>", "ID": "952a4fb2-9191-434e-bd1a-ae3408e43bd6", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "eddd2335-3ec8-474a-a1d4-9653ff3bebf2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">98</p>", "ID": "860f12ec-6abb-47bc-959e-1e527b453e90", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "98", "ParentId": "952a4fb2-9191-434e-bd1a-ae3408e43bd6"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">8</p>\n</td>", "ID": "62b4ed92-c4ea-44bd-91c5-ee9f045a83d4", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "eddd2335-3ec8-474a-a1d4-9653ff3bebf2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">8</p>", "ID": "7aee450a-26e9-413a-92b0-d059e9a4e2d5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "8", "ParentId": "62b4ed92-c4ea-44bd-91c5-ee9f045a83d4"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>", "ID": "03983c2c-42f2-415e-9ef2-b5b9e84861d2", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "eddd2335-3ec8-474a-a1d4-9653ff3bebf2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>", "ID": "3b7a06b8-3251-4eef-bc4a-0a5cb2a73929", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "<\u00a01", "ParentId": "03983c2c-42f2-415e-9ef2-b5b9e84861d2"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">82</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n</tr>", "ID": "d88cac18-8ee5-4ed0-933a-486f68f4cecc", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>\n</td>", "ID": "828b2823-8ab0-4bb2-89f8-c58a16829009", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "d88cac18-8ee5-4ed0-933a-486f68f4cecc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>", "ID": "5353f4b7-dfeb-4ede-b951-aa266dda4714", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Increased ALT", "ParentId": "828b2823-8ab0-4bb2-89f8-c58a16829009"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">82</p>\n</td>", "ID": "ea129b69-83e5-44ef-851d-ed0b1d558fc2", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "d88cac18-8ee5-4ed0-933a-486f68f4cecc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">82</p>", "ID": "eacad399-8166-499d-a01f-69092126bd1b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "82", "ParentId": "ea129b69-83e5-44ef-851d-ed0b1d558fc2"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>\n</td>", "ID": "d8bfa830-b4e0-4f6f-b441-2a80c501714f", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "d88cac18-8ee5-4ed0-933a-486f68f4cecc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>", "ID": "161ff7c7-4b00-401f-a633-5330a4fc57c8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "5", "ParentId": "d8bfa830-b4e0-4f6f-b441-2a80c501714f"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>", "ID": "c61bb03c-1dca-46b0-8c56-a2a08372de87", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "d88cac18-8ee5-4ed0-933a-486f68f4cecc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>", "ID": "e9e8fd3a-22d2-406e-8326-55d431f84f74", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "<\u00a01", "ParentId": "c61bb03c-1dca-46b0-8c56-a2a08372de87"}, {"Element": "<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>\n</td>\n</tr>", "ID": "95050a06-23ee-4869-ac6b-ad33ac908de1", "Styles": "height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>\n</td>", "ID": "f0cac167-02e9-447b-ae17-ae08cd57c0d8", "Styles": "width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "95050a06-23ee-4869-ac6b-ad33ac908de1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>", "ID": "243f14f2-7b3f-4d6c-9569-3a01bd07b7a5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0cac167-02e9-447b-ae17-ae08cd57c0d8"}, {"Element": "<b>Haematologic</b>", "ID": "c55a42c6-a7d6-4ace-8fe9-d2f62bae90bf", "Styles": "None", "Classes": "None", "Text": "Haematologic", "ParentId": "243f14f2-7b3f-4d6c-9569-3a01bd07b7a5"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">85</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">14</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>\n</td>\n</tr>", "ID": "b9544b4c-49a9-4b13-b781-25879ce4abf4", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>\n</td>", "ID": "b5a93500-ca15-4523-b7c7-454931671f89", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "b9544b4c-49a9-4b13-b781-25879ce4abf4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>", "ID": "abdcf845-612d-42d7-a4d9-012d8cb0259a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Decreased platelet count", "ParentId": "b5a93500-ca15-4523-b7c7-454931671f89"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">85</p>\n</td>", "ID": "ec5b6aac-2530-47d4-a7d4-98b39a4c89bf", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "b9544b4c-49a9-4b13-b781-25879ce4abf4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">85</p>", "ID": "0bd253ab-6864-4978-8b14-f5fe57238ddc", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "85", "ParentId": "ec5b6aac-2530-47d4-a7d4-98b39a4c89bf"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">14</p>\n</td>", "ID": "fe21c339-da66-4f69-87f9-87e1fe0214e0", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "b9544b4c-49a9-4b13-b781-25879ce4abf4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">14</p>", "ID": "d56aef0d-7590-4514-aec9-d94fb45c2ac0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "14", "ParentId": "fe21c339-da66-4f69-87f9-87e1fe0214e0"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>\n</td>", "ID": "7739b320-dad5-4cb5-8fcc-71cb590c7315", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "b9544b4c-49a9-4b13-b781-25879ce4abf4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>", "ID": "5ad9c9b7-75d5-402f-849b-ce11e2729e58", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "3", "ParentId": "7739b320-dad5-4cb5-8fcc-71cb590c7315"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">63</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>\n</tr>", "ID": "2dbd6c70-293a-462f-bd02-aa6a6c926b03", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>\n</td>", "ID": "0fa05713-e17f-478f-9359-c6aee91f4a48", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "2dbd6c70-293a-462f-bd02-aa6a6c926b03"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>", "ID": "b47a640b-aded-4257-bc09-6860a93ce7ca", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Decreased haemoglobin", "ParentId": "0fa05713-e17f-478f-9359-c6aee91f4a48"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">63</p>\n</td>", "ID": "6a22b501-19bc-4f78-ba5a-7587cc39f197", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "2dbd6c70-293a-462f-bd02-aa6a6c926b03"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">63</p>", "ID": "1cedf093-e86f-4021-8d39-14b26ade6a3b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "63", "ParentId": "6a22b501-19bc-4f78-ba5a-7587cc39f197"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>\n</td>", "ID": "6715222c-1a49-462e-a6d7-7ccd8aa5a500", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "2dbd6c70-293a-462f-bd02-aa6a6c926b03"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">5</p>", "ID": "f06f1cc2-9d03-42ca-949e-2e17bb34fea5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "5", "ParentId": "6715222c-1a49-462e-a6d7-7ccd8aa5a500"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>", "ID": "d7bd5401-642d-4ecc-a6e9-a7d73748369c", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "2dbd6c70-293a-462f-bd02-aa6a6c926b03"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>", "ID": "cbf14b6d-a19d-46dc-a890-6e0693424970", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "1", "ParentId": "d7bd5401-642d-4ecc-a6e9-a7d73748369c"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">41</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>\n</tr>", "ID": "97f347c1-cd36-4310-a3dc-7d9a5c3bee85", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>\n</td>", "ID": "3207f264-0d64-4f34-882e-3c6b661a444d", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "97f347c1-cd36-4310-a3dc-7d9a5c3bee85"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>", "ID": "59309507-209d-4b6a-a2bb-933df695cd20", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Decreased neutrophils", "ParentId": "3207f264-0d64-4f34-882e-3c6b661a444d"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">41</p>\n</td>", "ID": "9870aca8-ff31-4f9c-9ed5-c14c342685d6", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "97f347c1-cd36-4310-a3dc-7d9a5c3bee85"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">41</p>", "ID": "83e72eab-498a-4a54-93cb-38adc9fbd6f8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "41", "ParentId": "9870aca8-ff31-4f9c-9ed5-c14c342685d6"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>\n</td>", "ID": "97cadbb1-3ffa-4c83-98bc-420667a82466", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "97f347c1-cd36-4310-a3dc-7d9a5c3bee85"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>", "ID": "c4ff1f75-8aef-4636-b538-bba67be1bc54", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "4", "ParentId": "97cadbb1-3ffa-4c83-98bc-420667a82466"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>\n</td>", "ID": "7c4864ed-b54f-4484-959f-f4875bb672dc", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "97f347c1-cd36-4310-a3dc-7d9a5c3bee85"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;\u00a01</p>", "ID": "8205603e-b234-4a0b-95d9-cdbecc341e59", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "<\u00a01", "ParentId": "7c4864ed-b54f-4484-959f-f4875bb672dc"}, {"Element": "<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>\n</td>\n</tr>", "ID": "e3ad7596-7b51-4a77-a620-1328e9e5920f", "Styles": "height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>\n</td>", "ID": "3be102a0-88a4-47c9-80eb-a48d3b95646c", "Styles": "width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "e3ad7596-7b51-4a77-a620-1328e9e5920f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>", "ID": "fe3c7176-6e66-471b-b320-6773c7f4ca37", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3be102a0-88a4-47c9-80eb-a48d3b95646c"}, {"Element": "<b>Potassium</b>", "ID": "3d84215b-260b-435f-87ec-1832142838f2", "Styles": "None", "Classes": "None", "Text": "Potassium", "ParentId": "fe3c7176-6e66-471b-b320-6773c7f4ca37"}, {"Element": "<tr style=\"height:2.9pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">35</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt; 1</p>\n</td>\n</tr>", "ID": "8d3a3976-bfec-426b-8da5-a471f2a104de", "Styles": "height:2.9pt", "Classes": "None", "Text": "     ", "ParentId": "1f0e0cac-39fd-4b1b-9307-e3e877f9c7bd"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>\n</td>", "ID": "57cb9f02-9400-497e-a57a-215384f7231a", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt", "Classes": "None", "Text": "  ", "ParentId": "8d3a3976-bfec-426b-8da5-a471f2a104de"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>", "ID": "527f0440-0323-43a8-a35a-59a0a684a9a4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Decreased potassium", "ParentId": "57cb9f02-9400-497e-a57a-215384f7231a"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">35</p>\n</td>", "ID": "cd996458-da0c-4268-83e3-6ab01f22cf0f", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt", "Classes": "None", "Text": "  ", "ParentId": "8d3a3976-bfec-426b-8da5-a471f2a104de"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">35</p>", "ID": "1a8a37e6-27b7-4208-bee5-1cb10cea9810", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "35", "ParentId": "cd996458-da0c-4268-83e3-6ab01f22cf0f"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>\n</td>", "ID": "130d8e5b-d812-4859-8201-f726f5c4277e", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt", "Classes": "None", "Text": "  ", "ParentId": "8d3a3976-bfec-426b-8da5-a471f2a104de"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">3</p>", "ID": "73454ea5-d350-49f2-b8dc-06406d82c5b7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "3", "ParentId": "130d8e5b-d812-4859-8201-f726f5c4277e"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt; 1</p>\n</td>", "ID": "c9b52cde-e024-4f21-b309-421f0cfcaf64", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt", "Classes": "None", "Text": "  ", "ParentId": "8d3a3976-bfec-426b-8da5-a471f2a104de"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt; 1</p>", "ID": "08c11168-7c5c-4a9c-9e8f-230484a615fa", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "< 1", "ParentId": "c9b52cde-e024-4f21-b309-421f0cfcaf64"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "67fbbaad-c31b-45f0-9c07-36ba5952024b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>Table\u00a05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Laboratory\nabnormalities observed in patients treated with trastuzumab emtansine in study BO27938/KATHERINE</b></p>", "ID": "d9b88689-7767-4bf3-b3b9-2d5aceea9827", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Table\u00a05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Laboratory\nabnormalities observed in patients treated with trastuzumab emtansine in study BO27938/KATHERINE</b>", "ID": "f696176a-413f-4649-a794-66b603547859", "Styles": "None", "Classes": "None", "Text": "Table\u00a05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Laboratory abnormalities observed in patients treated with trastuzumab emtansine in study BO27938/KATHERINE", "ParentId": "d9b88689-7767-4bf3-b3b9-2d5aceea9827"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "026493fd-43b5-4c22-b114-18d3a95acc9a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:432.75pt;margin-left:4.65pt;border-collapse:collapse\" width=\"577\">\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" rowspan=\"2\" style=\"width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>\n</td>\n<td colspan=\"3\" nowrap=\"\" style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"318\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"DE\" style=\"font-size:\n  11.0pt;color:windowtext\">Trastuzumab emtansine (N=740)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grade %</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">11</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">79</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">55</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">51</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">31</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">24</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>\n<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>\n</td>\n</tr>\n<tr style=\"height:2.9pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">26</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>\n</tr>\n</table>", "ID": "58703d15-3000-44c7-b56e-e5a511152241", "Styles": "width:432.75pt;margin-left:4.65pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "             ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" rowspan=\"2\" style=\"width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>\n</td>\n<td colspan=\"3\" nowrap=\"\" style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"318\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"DE\" style=\"font-size:\n  11.0pt;color:windowtext\">Trastuzumab emtansine (N=740)</span></b></p>\n</td>\n</tr>", "ID": "8fb500f6-9b0f-4661-a180-f9d35a9d2f94", "Styles": "height:15.0pt", "Classes": "None", "Text": "   ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td nowrap=\"\" rowspan=\"2\" style=\"width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"259\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>\n</td>", "ID": "51777e50-4a0f-4961-ab96-06d71ce7d810", "Styles": "width:194.25pt;\n  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "8fb500f6-9b0f-4661-a180-f9d35a9d2f94"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b></p>", "ID": "2eef6c90-74a1-45a3-96aa-0a87a2894686", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "51777e50-4a0f-4961-ab96-06d71ce7d810"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span></b>", "ID": "99cb6d3a-00a2-4339-8634-7851e3ad459b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2eef6c90-74a1-45a3-96aa-0a87a2894686"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Parameter</span>", "ID": "9a866d67-fae4-4909-9105-de41e50238e0", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Parameter", "ParentId": "99cb6d3a-00a2-4339-8634-7851e3ad459b"}, {"Element": "<td colspan=\"3\" nowrap=\"\" style=\"width:238.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"318\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"DE\" style=\"font-size:\n  11.0pt;color:windowtext\">Trastuzumab emtansine (N=740)</span></b></p>\n</td>", "ID": "33866182-b60d-4248-aee6-773875dcc5f3", "Styles": "width:238.5pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "8fb500f6-9b0f-4661-a180-f9d35a9d2f94"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"DE\" style=\"font-size:\n  11.0pt;color:windowtext\">Trastuzumab emtansine (N=740)</span></b></p>", "ID": "87046255-052c-45bc-83a8-aa90852eb745", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "33866182-b60d-4248-aee6-773875dcc5f3"}, {"Element": "<b><span lang=\"DE\" style=\"font-size:\n  11.0pt;color:windowtext\">Trastuzumab emtansine (N=740)</span></b>", "ID": "bd57fc9f-ff49-4999-85be-edd895215912", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "87046255-052c-45bc-83a8-aa90852eb745"}, {"Element": "<span lang=\"DE\" style=\"font-size:\n  11.0pt;color:windowtext\">Trastuzumab emtansine (N=740)</span>", "ID": "51919abf-3f3e-4dd4-9590-b400d56373de", "Styles": "font-size:\n  11.0pt;color:windowtext", "Classes": "None", "Text": "Trastuzumab emtansine (N=740)", "ParentId": "bd57fc9f-ff49-4999-85be-edd895215912"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grade %</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>\n</td>\n</tr>", "ID": "7e8f14eb-4b8e-4d2e-936c-d7d75b5e2890", "Styles": "height:15.0pt", "Classes": "None", "Text": "    ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grade %</span></b></p>\n</td>", "ID": "e56e6c59-c6d8-4dca-9825-5582e7ceaa1a", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "7e8f14eb-4b8e-4d2e-936c-d7d75b5e2890"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grade %</span></b></p>", "ID": "4417248b-4ff6-407f-9829-8a876a1d2b6a", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "e56e6c59-c6d8-4dca-9825-5582e7ceaa1a"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grade %</span></b>", "ID": "91438411-fbe0-4a38-9d81-ef7584fffbd0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4417248b-4ff6-407f-9829-8a876a1d2b6a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">All Grade %</span>", "ID": "e96f373f-f855-4843-a949-29af1c8ba813", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "All Grade %", "ParentId": "91438411-fbe0-4a38-9d81-ef7584fffbd0"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>\n</td>", "ID": "d6cb2798-0d80-4c6a-8db0-d21d6de82841", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "7e8f14eb-4b8e-4d2e-936c-d7d75b5e2890"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b></p>", "ID": "de63b7fa-f1d8-4af2-8187-99f1720f7758", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "d6cb2798-0d80-4c6a-8db0-d21d6de82841"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span></b>", "ID": "b8c9e0ac-63db-4c66-b76f-862fe4cac12d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "de63b7fa-f1d8-4af2-8187-99f1720f7758"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a03 (%)</span>", "ID": "775f2e98-b381-4dfc-afe3-31e3f392e71e", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Grade\u00a03 (%)", "ParentId": "b8c9e0ac-63db-4c66-b76f-862fe4cac12d"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>\n</td>", "ID": "02618d68-9deb-44be-8350-5af2ae221ac8", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "7e8f14eb-4b8e-4d2e-936c-d7d75b5e2890"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b></p>", "ID": "a9960fd1-5f8a-4b79-aa84-31e1abaa00b0", "Styles": "margin-left:-.05pt;text-align:center;\n  text-indent:.05pt;page-break-after:avoid", "Classes": "['Default']", "Text": "", "ParentId": "02618d68-9deb-44be-8350-5af2ae221ac8"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span></b>", "ID": "33728bb7-c5ed-40f5-a8f4-5e229d2cfbe0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a9960fd1-5f8a-4b79-aa84-31e1abaa00b0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Grade\u00a04 (%)</span>", "ID": "5e571c34-dcab-4bc2-ab33-58dd6c3f9e86", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Grade\u00a04 (%)", "ParentId": "33728bb7-c5ed-40f5-a8f4-5e229d2cfbe0"}, {"Element": "<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>\n</td>\n</tr>", "ID": "25dc0eb2-3b38-4b9e-8406-b467cc6238aa", "Styles": "height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>\n</td>", "ID": "712d2ddf-cf0c-44e4-8450-5828b359f687", "Styles": "width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "25dc0eb2-3b38-4b9e-8406-b467cc6238aa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Hepatic</b></p>", "ID": "974959cd-458c-49e6-982b-b7beaba9e9e1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "712d2ddf-cf0c-44e4-8450-5828b359f687"}, {"Element": "<b>Hepatic</b>", "ID": "c8220037-5a4f-478a-9d9b-805dcd6abe30", "Styles": "None", "Classes": "None", "Text": "Hepatic", "ParentId": "974959cd-458c-49e6-982b-b7beaba9e9e1"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">11</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>", "ID": "4bdaf67e-4251-4038-96bd-d6e49dc2639c", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>\n</td>", "ID": "bb28a714-c3eb-4e63-898b-87f324e72b7a", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4bdaf67e-4251-4038-96bd-d6e49dc2639c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased bilirubin</p>", "ID": "e574e77c-b0d2-45d2-b75f-8ed27b40147c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Increased bilirubin", "ParentId": "bb28a714-c3eb-4e63-898b-87f324e72b7a"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">11</p>\n</td>", "ID": "dc5ba5e1-18ba-4365-ac3a-0e846db35e99", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4bdaf67e-4251-4038-96bd-d6e49dc2639c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">11</p>", "ID": "b5973ae2-fad8-4033-b4d8-4e1466ff0702", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "11", "ParentId": "dc5ba5e1-18ba-4365-ac3a-0e846db35e99"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>", "ID": "f46177e8-dfe9-47f3-9b05-1b69ee9dab80", "Styles": "width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4bdaf67e-4251-4038-96bd-d6e49dc2639c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>", "ID": "36a30681-00cc-4314-b3ba-69d67e83685e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "0", "ParentId": "f46177e8-dfe9-47f3-9b05-1b69ee9dab80"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>", "ID": "c3798118-f076-42a8-a3d4-2d8e0a58418c", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4bdaf67e-4251-4038-96bd-d6e49dc2639c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>", "ID": "c75bf6f8-93ff-4d52-8d5b-eccc4ee988a7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "0", "ParentId": "c3798118-f076-42a8-a3d4-2d8e0a58418c"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">79</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>", "ID": "f4b53d25-975d-4e6c-9424-d3cd271f2e4a", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>\n</td>", "ID": "603dffa7-a272-4d25-a5a2-a827dd5b04e6", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "f4b53d25-975d-4e6c-9424-d3cd271f2e4a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased AST</p>", "ID": "be082017-a1b9-4300-a8ed-dab0075e49db", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Increased AST", "ParentId": "603dffa7-a272-4d25-a5a2-a827dd5b04e6"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">79</p>\n</td>", "ID": "fe3363a2-b3fa-4e0f-a98e-11e7375b944d", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "f4b53d25-975d-4e6c-9424-d3cd271f2e4a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">79</p>", "ID": "193bf242-ce9f-4531-8b52-ce3f706cdc42", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "79", "ParentId": "fe3363a2-b3fa-4e0f-a98e-11e7375b944d"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>", "ID": "3148b577-c23c-4df9-8981-086477706c6e", "Styles": "width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "f4b53d25-975d-4e6c-9424-d3cd271f2e4a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>", "ID": "c1e957f2-507d-481b-a952-de93aef76f08", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "<1", "ParentId": "3148b577-c23c-4df9-8981-086477706c6e"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>", "ID": "09d23517-2261-417e-b7cd-74ea9ca24ab1", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "f4b53d25-975d-4e6c-9424-d3cd271f2e4a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>", "ID": "f7179590-a622-4d21-bff7-332d67c8c2e3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "0", "ParentId": "09d23517-2261-417e-b7cd-74ea9ca24ab1"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">55</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>", "ID": "4b3c6a6c-753b-4d6a-b2f2-ef6b86a6d6a8", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>\n</td>", "ID": "b4274846-70ba-4501-b113-078a99e12d81", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4b3c6a6c-753b-4d6a-b2f2-ef6b86a6d6a8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Increased ALT</p>", "ID": "8a9b7b1e-e502-4ad4-946a-9a2a26ac9169", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Increased ALT", "ParentId": "b4274846-70ba-4501-b113-078a99e12d81"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">55</p>\n</td>", "ID": "aa414a10-7010-44a3-a6a1-13790647cb42", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4b3c6a6c-753b-4d6a-b2f2-ef6b86a6d6a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">55</p>", "ID": "844508a0-c3ef-4561-aab3-490181dabfae", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "55", "ParentId": "aa414a10-7010-44a3-a6a1-13790647cb42"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>", "ID": "8a850948-72ee-4a6c-baed-2fe1a1c45557", "Styles": "width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4b3c6a6c-753b-4d6a-b2f2-ef6b86a6d6a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>", "ID": "5969705a-1c93-4301-988d-a478324777ae", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "<1", "ParentId": "8a850948-72ee-4a6c-baed-2fe1a1c45557"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>", "ID": "ed826ca4-7d1f-4d37-b576-27927288d715", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "4b3c6a6c-753b-4d6a-b2f2-ef6b86a6d6a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>", "ID": "2d5dbb0d-f664-4f2e-ae95-f89ac840b7e8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "0", "ParentId": "ed826ca4-7d1f-4d37-b576-27927288d715"}, {"Element": "<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>\n</td>\n</tr>", "ID": "7e0375d4-d779-48bf-8593-66f4539c6783", "Styles": "height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>\n</td>", "ID": "46a2ede0-0de7-498f-94eb-dbb2016fca2b", "Styles": "width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "7e0375d4-d779-48bf-8593-66f4539c6783"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Haematologic</b></p>", "ID": "bccd6ca1-acee-4a60-a02b-d660c6c7c1c8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46a2ede0-0de7-498f-94eb-dbb2016fca2b"}, {"Element": "<b>Haematologic</b>", "ID": "1c0add0e-c461-4d37-b66e-ff4745b38262", "Styles": "None", "Classes": "None", "Text": "Haematologic", "ParentId": "bccd6ca1-acee-4a60-a02b-d660c6c7c1c8"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">51</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>\n</td>\n</tr>", "ID": "736eb738-f81b-4b37-84ba-e2dd6b910fce", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>\n</td>", "ID": "8789ec61-1310-4ba3-a826-7abf45c871d2", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "736eb738-f81b-4b37-84ba-e2dd6b910fce"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased platelet count</p>", "ID": "03342443-737b-4b75-a156-42450327de27", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Decreased platelet count", "ParentId": "8789ec61-1310-4ba3-a826-7abf45c871d2"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">51</p>\n</td>", "ID": "144616d5-17a9-4546-aea6-a64ad4e6088b", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "736eb738-f81b-4b37-84ba-e2dd6b910fce"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">51</p>", "ID": "12a7338a-c77d-4afd-954d-0bd23cbe8fa8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "51", "ParentId": "144616d5-17a9-4546-aea6-a64ad4e6088b"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>\n</td>", "ID": "463f9ea7-7491-4998-8747-b7831c3d32fd", "Styles": "width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "736eb738-f81b-4b37-84ba-e2dd6b910fce"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">4</p>", "ID": "ab97de77-67c7-4440-803c-4d692c6de07d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "4", "ParentId": "463f9ea7-7491-4998-8747-b7831c3d32fd"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>\n</td>", "ID": "45757dd5-7f85-4547-9187-93b1819efac3", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "736eb738-f81b-4b37-84ba-e2dd6b910fce"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>", "ID": "fb04cfd2-a7a8-470f-8974-e7ce26231239", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "2", "ParentId": "45757dd5-7f85-4547-9187-93b1819efac3"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">31</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>", "ID": "3433eab1-60b5-498f-85f0-7745503232c7", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>\n</td>", "ID": "ba49caf6-245d-444d-940e-3b5ac028ad42", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "3433eab1-60b5-498f-85f0-7745503232c7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased haemoglobin</p>", "ID": "337c40e8-dbce-4fff-83f3-e492317cab15", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Decreased haemoglobin", "ParentId": "ba49caf6-245d-444d-940e-3b5ac028ad42"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">31</p>\n</td>", "ID": "a070e487-df58-4941-bbd3-6202ccdc24a7", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "3433eab1-60b5-498f-85f0-7745503232c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">31</p>", "ID": "43cbeb52-c2a5-429c-a40b-80c44f758714", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "31", "ParentId": "a070e487-df58-4941-bbd3-6202ccdc24a7"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>", "ID": "cbc76a77-7fea-4d30-991d-5057ce4089aa", "Styles": "width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "3433eab1-60b5-498f-85f0-7745503232c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>", "ID": "cac6166a-0309-4a74-bf8e-40c5e61c7a21", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "1", "ParentId": "cbc76a77-7fea-4d30-991d-5057ce4089aa"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>", "ID": "2ae02a29-377c-44f1-9152-674fe62ece33", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "3433eab1-60b5-498f-85f0-7745503232c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>", "ID": "c7af4a74-fab6-4de5-8cf5-72d0d369f987", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "0", "ParentId": "2ae02a29-377c-44f1-9152-674fe62ece33"}, {"Element": "<tr style=\"height:15.0pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">24</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>\n</tr>", "ID": "0ea5b1a0-b687-445e-b1e1-4e3b0cacad4b", "Styles": "height:15.0pt", "Classes": "None", "Text": "     ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>\n</td>", "ID": "0114fedd-c5e1-48ce-bf6a-7d8a5a41e3fc", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "0ea5b1a0-b687-445e-b1e1-4e3b0cacad4b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased neutrophils</p>", "ID": "deeb3b79-8896-4f68-aed4-6395e8101f96", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Decreased neutrophils", "ParentId": "0114fedd-c5e1-48ce-bf6a-7d8a5a41e3fc"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">24</p>\n</td>", "ID": "7da2b1dd-d64f-43af-8480-7a928e1ff630", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "0ea5b1a0-b687-445e-b1e1-4e3b0cacad4b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">24</p>", "ID": "e3777dfd-6833-4e93-a845-1d2c2c58b2a9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "24", "ParentId": "7da2b1dd-d64f-43af-8480-7a928e1ff630"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>\n</td>", "ID": "17393696-4310-41c3-8d24-374ba3f96702", "Styles": "width:85.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "0ea5b1a0-b687-445e-b1e1-4e3b0cacad4b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">1</p>", "ID": "86fadc90-afd5-44ab-ba8b-7d85c36d011c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "1", "ParentId": "17393696-4310-41c3-8d24-374ba3f96702"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>\n</td>", "ID": "bc7264a5-7b8e-488b-83c2-852234786dc6", "Styles": "width:76.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "0ea5b1a0-b687-445e-b1e1-4e3b0cacad4b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">0</p>", "ID": "1e27f8e2-cd5e-4483-bf22-61ab3cb97684", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "0", "ParentId": "bc7264a5-7b8e-488b-83c2-852234786dc6"}, {"Element": "<tr style=\"height:15.0pt\">\n<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>\n</td>\n</tr>", "ID": "dbc74f54-ba79-4604-be35-f289493a7a98", "Styles": "height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td colspan=\"4\" nowrap=\"\" style=\"width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt\" valign=\"bottom\" width=\"577\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>\n</td>", "ID": "7fd6399e-a585-4614-b9fa-3b83c6f6cd0b", "Styles": "width:432.75pt;\n  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;\n  height:15.0pt", "Classes": "None", "Text": "  ", "ParentId": "dbc74f54-ba79-4604-be35-f289493a7a98"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Potassium</b></p>", "ID": "eeead7b7-b6aa-419d-8954-78911de0b5ba", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7fd6399e-a585-4614-b9fa-3b83c6f6cd0b"}, {"Element": "<b>Potassium</b>", "ID": "0674dfb5-605a-4e50-ae67-07590de154cf", "Styles": "None", "Classes": "None", "Text": "Potassium", "ParentId": "eeead7b7-b6aa-419d-8954-78911de0b5ba"}, {"Element": "<tr style=\"height:2.9pt\">\n<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">26</p>\n</td>\n<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>\n</td>\n<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>\n</tr>", "ID": "cef9d675-813a-4fd8-a9b3-29a3010b52fa", "Styles": "height:2.9pt", "Classes": "None", "Text": "     ", "ParentId": "58703d15-3000-44c7-b56e-e5a511152241"}, {"Element": "<td nowrap=\"\" style=\"width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"259\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>\n</td>", "ID": "7400b571-def7-4e58-bc2c-48ca4d72c62d", "Styles": "width:194.25pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt", "Classes": "None", "Text": "  ", "ParentId": "cef9d675-813a-4fd8-a9b3-29a3010b52fa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Decreased potassium</p>", "ID": "c9274c92-6a07-4ba3-b4e1-ed70773abd18", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Decreased potassium", "ParentId": "7400b571-def7-4e58-bc2c-48ca4d72c62d"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">26</p>\n</td>", "ID": "c97ae7d9-fcd5-4068-8704-78121d5c422f", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt", "Classes": "None", "Text": "  ", "ParentId": "cef9d675-813a-4fd8-a9b3-29a3010b52fa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">26</p>", "ID": "293bfcd2-5345-416c-98b6-cdbc710770d6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "26", "ParentId": "c97ae7d9-fcd5-4068-8704-78121d5c422f"}, {"Element": "<td nowrap=\"\" style=\"width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"114\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>\n</td>", "ID": "154250a8-8ab9-48ee-9333-99a17c548a47", "Styles": "width:85.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt", "Classes": "None", "Text": "  ", "ParentId": "cef9d675-813a-4fd8-a9b3-29a3010b52fa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">2</p>", "ID": "5305324c-9849-46e9-ac19-0416b94a5594", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "2", "ParentId": "154250a8-8ab9-48ee-9333-99a17c548a47"}, {"Element": "<td nowrap=\"\" style=\"width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt\" valign=\"bottom\" width=\"102\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>\n</td>", "ID": "a75e10ac-56be-4c3b-8fb1-15f211324a06", "Styles": "width:76.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:2.9pt", "Classes": "None", "Text": "  ", "ParentId": "cef9d675-813a-4fd8-a9b3-29a3010b52fa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\">&lt;1</p>", "ID": "e83da4d9-2719-4fd0-a8fb-2ed98ccbd8a5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "<1", "ParentId": "a75e10ac-56be-4c3b-8fb1-15f211324a06"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "fb2e2c49-e903-4118-be81-bbed34205986", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "cebeccab-e48b-4a2b-9888-69c6886b6b9e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><u>Reporting of suspected adverse reactions</u></p>", "ID": "69fae451-0f09-499e-ab40-627ef5060edb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Reporting of suspected adverse reactions</u>", "ID": "f2c99d8a-938b-4600-a391-788e77f15c4e", "Styles": "None", "Classes": "None", "Text": "Reporting of suspected adverse reactions", "ParentId": "69fae451-0f09-499e-ab40-627ef5060edb"}, {"Element": "<p class=\"MsoNormal\">Reporting suspected adverse reactions after authorisation of\nthe medicinal product is important. It allows continued monitoring of the\nbenefit/risk balance of the medicinal product. Healthcare professionals are\nasked to report any suspected adverse reactions via <span style=\"background:\nlightgrey\">the national reporting system listed in </span><a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span style=\"background:lightgrey\">Appendix V</span></a><span style=\"background:lightgrey\">.</span></p>", "ID": "313d791f-8a76-4bc8-a37c-11fb13e3d231", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"background:\nlightgrey\">the national reporting system listed in </span>", "ID": "4a94ceae-65a3-40c5-bc92-4178e263a8be", "Styles": "background:\nlightgrey", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "313d791f-8a76-4bc8-a37c-11fb13e3d231"}, {"Element": "<a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span style=\"background:lightgrey\">Appendix V</span></a>", "ID": "5ef45530-0338-4e76-a107-550d601a1234", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "313d791f-8a76-4bc8-a37c-11fb13e3d231"}, {"Element": "<span style=\"background:lightgrey\">Appendix V</span>", "ID": "d5d3d303-099b-42ad-9e95-89cc312e03c8", "Styles": "background:lightgrey", "Classes": "None", "Text": "Appendix V", "ParentId": "5ef45530-0338-4e76-a107-550d601a1234"}, {"Element": "<span style=\"background:lightgrey\">.</span>", "ID": "6298a792-89bc-4632-b0c4-209615484819", "Styles": "background:lightgrey", "Classes": "None", "Text": ".", "ParentId": "313d791f-8a76-4bc8-a37c-11fb13e3d231"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ccb9af5e-0564-4a97-8c65-154686dc9568", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>4.9\u00a0\u00a0\u00a0\u00a0 Overdose</b></p>", "ID": "7f97d231-1622-4546-bd6c-f3902e986166", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.9\u00a0\u00a0\u00a0\u00a0 Overdose</b>", "ID": "61b917ce-0f77-4fd3-8db7-7352f9b9f034", "Styles": "None", "Classes": "None", "Text": "4.9\u00a0\u00a0\u00a0\u00a0 Overdose", "ParentId": "7f97d231-1622-4546-bd6c-f3902e986166"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "513abbab-a442-4411-bd92-d7953200c5df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">There is no known antidote for trastuzumab emtansine overdose.\nIn case of overdose, the patient should be closely monitored for signs or\nsymptoms of adverse reactions and appropriate symptomatic treatment instituted.\nCases of overdose have been reported with trastuzumab emtansine treatment, most\nassociated with thrombocytopenia, and there was one death. In the fatal case,\nthe patient incorrectly received trastuzumab emtansine 6\u00a0mg/kg and died\napproximately 3\u00a0weeks following the overdose; a causal relationship to\ntrastuzumab emtansine was not established.</p>", "ID": "050508cf-028b-494e-a60b-b4cdcade4cc1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "There is no known antidote for trastuzumab emtansine overdose. In case of overdose, the patient should be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted. Cases of overdose have been reported with trastuzumab emtansine treatment, most associated with thrombocytopenia, and there was one death. In the fatal case, the patient incorrectly received trastuzumab emtansine 6\u00a0mg/kg and died approximately 3\u00a0weeks following the overdose; a causal relationship to trastuzumab emtansine was not established.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6bb1a116-f848-425e-8db1-095e1c4afadf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7e031d6c-4e0f-4305-9ded-4ef7689896de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</b></p>", "ID": "21c3f185-d41c-46a1-b0c8-237e206c14e7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</b>", "ID": "76afc734-d5b3-4a05-b138-00f42817f886", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES", "ParentId": "21c3f185-d41c-46a1-b0c8-237e206c14e7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "158c562e-078d-429e-8e2d-7c05e71ccc3c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>5.1 \u00a0\u00a0\u00a0 Pharmacodynamic properties</b></p>", "ID": "2990bc74-0c5e-4e19-9a81-30c24e84738f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>5.1 \u00a0\u00a0\u00a0 Pharmacodynamic properties</b>", "ID": "d3f2166f-0eea-4d65-a3f5-b484ced3ecf9", "Styles": "None", "Classes": "None", "Text": "5.1 \u00a0\u00a0\u00a0 Pharmacodynamic properties", "ParentId": "2990bc74-0c5e-4e19-9a81-30c24e84738f"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1ee26c5e-0b08-4b64-9fae-ba6b5fcbe4d6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Pharmacotherapeutic group: Antineoplastic agents, other\nantineoplastic agents, monoclonal</p>", "ID": "9cecb446-f702-4dd8-8fea-e1e0b0bfd868", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, monoclonal", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">antibodies, ATC code: L01XC14</p>", "ID": "485f6b0e-b480-4c20-b68d-275d13ee6eb9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "antibodies, ATC code: L01XC14", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ba9b082c-cf14-4a3c-8f1f-be0c2842483b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Mechanism of action</u></p>", "ID": "44a9f5a1-a907-41c2-8cdc-066b37240e92", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Mechanism of action</u>", "ID": "df166970-cb29-419b-a653-735a042ea3fc", "Styles": "None", "Classes": "None", "Text": "Mechanism of action", "ParentId": "44a9f5a1-a907-41c2-8cdc-066b37240e92"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:\n none\">\u00a0</span></u></p>", "ID": "c4fd7422-df9f-4e61-b1bc-0ef2438384e6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "aab0219f-5a9d-471a-b4c7-b6796e5a36fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c4fd7422-df9f-4e61-b1bc-0ef2438384e6"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "6681bdcf-d94e-4625-bff4-a546a23fbba8", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "aab0219f-5a9d-471a-b4c7-b6796e5a36fc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Kadcyla, trastuzumab\nemtansine, is a HER2\u2011targeted antibody\u2011drug conjugate which\ncontains the humanised anti\u2011HER2 IgG1, trastuzumab, covalently linked to\nthe microtubule inhibitor DM1 (a maytansine derivative) via the stable\nthioether linker MCC\u00a0(4\u2011[N\u2011maleimidomethyl]\u00a0cyclohexane\u20111\u2011carboxylate).\nEmtansine refers to the MCC\u2011DM1 complex. An average of 3.5\u00a0DM1\nmolecules are conjugated to each molecule of trastuzumab. </p>", "ID": "cdac6874-4ea8-4c30-9c07-93c3073bcea4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Kadcyla, trastuzumab emtansine, is a HER2\u2011targeted antibody\u2011drug conjugate which contains the humanised anti\u2011HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitor DM1 (a maytansine derivative) via the stable thioether linker MCC\u00a0(4\u2011[N\u2011maleimidomethyl]\u00a0cyclohexane\u20111\u2011carboxylate). Emtansine refers to the MCC\u2011DM1 complex. An average of 3.5\u00a0DM1 molecules are conjugated to each molecule of trastuzumab. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2d8b1a64-6a50-4b83-887e-68961ed1bf55", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Conjugation of DM1 to trastuzumab confers selectivity of the\ncytotoxic agent for HER2\u2011overexpressing tumour cells, thereby increasing\nintracellular delivery of DM1 directly to malignant cells. Upon binding to\nHER2, trastuzumab emtansine undergoes receptor\u2011mediated internalization\nand subsequent lysosomal degradation, resulting in release of DM1\u2011containing\ncytotoxic catabolites (primarily lysine\u2011MCC\u2011DM1).</p>", "ID": "1bfdbdcb-870c-4410-bdcd-da10cf6e3943", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Conjugation of DM1 to trastuzumab confers selectivity of the cytotoxic agent for HER2\u2011overexpressing tumour cells, thereby increasing intracellular delivery of DM1 directly to malignant cells. Upon binding to HER2, trastuzumab emtansine undergoes receptor\u2011mediated internalization and subsequent lysosomal degradation, resulting in release of DM1\u2011containing cytotoxic catabolites (primarily lysine\u2011MCC\u2011DM1).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a21ad5dc-075d-4a79-bfe6-e694eb27e7a6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Trastuzumab emtansine has the mechanisms of action of both\ntrastuzumab and DM1: </p>", "ID": "f48c4171-8005-4c95-9fcc-3f2755b86347", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine has the mechanisms of action of both trastuzumab and DM1: ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "fff8c689-26ea-4e56-a870-ce5cdc53e20a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Trastuzumab\nemtansine, like trastuzumab, binds to domain\u00a0IV of the HER2 extracellular\ndomain (ECD), as well as to Fc\u03b3 receptors and complement\u00a0C1q. In addition,\ntrastuzumab emtansine, like trastuzumab, inhibits shedding of the HER2 ECD,\ninhibits signalling through the phosphatidylinositol\u00a03\u2011kinase (PI3\u2011K)\npathway, and mediates antibody\u2011dependent cell\u2011mediated cytotoxicity\n(ADCC) in human breast cancer cells that overexpress HER2.\u00a0 </p>", "ID": "988417d5-134e-4a40-9d11-df1d1079841b", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Trastuzumab emtansine, like trastuzumab, binds to domain\u00a0IV of the HER2 extracellular domain (ECD), as well as to Fc\u03b3 receptors and complement\u00a0C1q. In addition, trastuzumab emtansine, like trastuzumab, inhibits shedding of the HER2 ECD, inhibits signalling through the phosphatidylinositol\u00a03\u2011kinase (PI3\u2011K) pathway, and mediates antibody\u2011dependent cell\u2011mediated cytotoxicity (ADCC) in human breast cancer cells that overexpress HER2.\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "d395f69b-ae81-4e5e-8b1c-27aac031dd8e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "988417d5-134e-4a40-9d11-df1d1079841b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "f83a4998-f136-43a3-84aa-adb6718485fc", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 DM1, the\ncytotoxic component of trastuzumab emtansine, binds to tubulin. By inhibiting\ntubulin polymerization, both DM1 and trastuzumab emtansine cause cells to\narrest in the G2/M phase of the cell cycle, ultimately leading to apoptotic\ncell death. Results from <i>in vitro</i> cytotoxicity assays show that DM1 is\n20\u2011200 times more potent than taxanes and vinca alkaloids. </p>", "ID": "11b2af90-6c1f-4a24-a283-77dd74343636", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 DM1, the cytotoxic component of trastuzumab emtansine, binds to tubulin. By inhibiting tubulin polymerization, both DM1 and trastuzumab emtansine cause cells to arrest in the G2/M phase of the cell cycle, ultimately leading to apoptotic cell death. Results from  cytotoxicity assays show that DM1 is 20\u2011200 times more potent than taxanes and vinca alkaloids. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "e8fb7969-bfeb-4cf3-a8ad-c3fa88195ddc", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "11b2af90-6c1f-4a24-a283-77dd74343636"}, {"Element": "<i>in vitro</i>", "ID": "2a801fab-5a02-4429-923a-a52e17867d5a", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "11b2af90-6c1f-4a24-a283-77dd74343636"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "a91084ff-3bd5-46ff-adf6-04faf3b70473", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The\nMCC\u00a0linker is designed to limit systemic release and increase targeted\ndelivery of DM1, as demonstrated by detection of very low levels of free DM1 in\nplasma. </p>", "ID": "e388cbd0-21e5-460a-96c6-8ea3cca01afa", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 The MCC\u00a0linker is designed to limit systemic release and increase targeted delivery of DM1, as demonstrated by detection of very low levels of free DM1 in plasma. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "0cee4839-b081-41fd-9693-2a37839042f7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e388cbd0-21e5-460a-96c6-8ea3cca01afa"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>", "ID": "77d826cb-ef70-4b61-96e0-8a3bcd41c4f2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Clinical efficacy </u></p>", "ID": "4320c2fe-f653-4732-a233-2d857dbc06d3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Clinical efficacy </u>", "ID": "89fa40be-eeb8-4174-9439-01c337111d72", "Styles": "None", "Classes": "None", "Text": "Clinical efficacy ", "ParentId": "4320c2fe-f653-4732-a233-2d857dbc06d3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span style=\"text-decoration:\n none\">\u00a0</span></u></b></p>", "ID": "86f4c493-d269-44a5-9528-f87bbce46142", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:\n none\">\u00a0</span></u></b>", "ID": "84ce056e-b747-4ee8-82dd-6646a90fe04b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "86f4c493-d269-44a5-9528-f87bbce46142"}, {"Element": "<u><span style=\"text-decoration:\n none\">\u00a0</span></u>", "ID": "078934bd-1d9a-474d-b706-aa23440352db", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "84ce056e-b747-4ee8-82dd-6646a90fe04b"}, {"Element": "<span style=\"text-decoration:\n none\">\u00a0</span>", "ID": "57115bc2-ff5f-4385-9389-3cdd9a1dfe8b", "Styles": "text-decoration:\n none", "Classes": "None", "Text": "\u00a0", "ParentId": "078934bd-1d9a-474d-b706-aa23440352db"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><i><u>Early\nBreast Cancer</u></i></p>", "ID": "d19e9d73-e7b4-4e8b-a509-06bea56afbc2", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i><u>Early\nBreast Cancer</u></i>", "ID": "f1da41c1-38c1-4df7-b046-dfa781b3a325", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d19e9d73-e7b4-4e8b-a509-06bea56afbc2"}, {"Element": "<u>Early\nBreast Cancer</u>", "ID": "f550a0e5-6e2e-4b3f-a166-0557b9341641", "Styles": "None", "Classes": "None", "Text": "Early Breast Cancer", "ParentId": "f1da41c1-38c1-4df7-b046-dfa781b3a325"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "c8772dbb-6340-4a5a-a588-52d86c483e8d", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['Paragraph']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "fe0cf566-8f7e-4260-b267-e5b240bcd36a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "c8772dbb-6340-4a5a-a588-52d86c483e8d"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><i><u><span lang=\"EN-GB\">BO27938\n(KATHERINE) </span></u></i></p>", "ID": "8a8ce325-0bfb-4c65-acba-85f8ebc64dbc", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i><u><span lang=\"EN-GB\">BO27938\n(KATHERINE) </span></u></i>", "ID": "8d6e001a-b4ab-4127-a839-953fde073f38", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8a8ce325-0bfb-4c65-acba-85f8ebc64dbc"}, {"Element": "<u><span lang=\"EN-GB\">BO27938\n(KATHERINE) </span></u>", "ID": "7bc2f389-f9a8-4b30-8603-ad9848dbb68e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8d6e001a-b4ab-4127-a839-953fde073f38"}, {"Element": "<span lang=\"EN-GB\">BO27938\n(KATHERINE) </span>", "ID": "5672d01b-d068-493a-8292-80ce9f8e2d70", "Styles": "None", "Classes": "None", "Text": "BO27938 (KATHERINE) ", "ParentId": "7bc2f389-f9a8-4b30-8603-ad9848dbb68e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i></p>", "ID": "b8672a03-6b75-41ad-8bde-02f0333a2f01", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></i>", "ID": "454b8e4c-ae4e-4eba-8bcc-15ca2da2d4a7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8672a03-6b75-41ad-8bde-02f0333a2f01"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "8adbacdc-3a86-423a-b6a7-62cf9eebd58e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "454b8e4c-ae4e-4eba-8bcc-15ca2da2d4a7"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "447c93e0-d88f-4ed0-bf54-c635fc4ee5fb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8adbacdc-3a86-423a-b6a7-62cf9eebd58e"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e27c8e5a-3382-486c-ba62-0f04456b0582", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "447c93e0-d88f-4ed0-bf54-c635fc4ee5fb"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">BO27938 (KATHERINE)\u00a0was a\nrandomized, multicenter, open-label trial of 1486 patients with HER2-positive,\nearly breast cancer with residual invasive tumor\u00a0<span lang=\"EN-GB\">(patients\nwho had not achieved pathological complete response (pCR))</span>\u00a0in the\nbreast and/or axillary lymph nodes following completion of preoperative\nsystemic therapy that included chemotherapy and HER2-targeted therapy. Patients\nmay have received more than one HER2-targeted therapy. Patients received\nradiotherapy and/or hormonal therapy concurrent with study treatment as per\nlocal guidelines. Breast tumor samples were required to show HER2\noverexpression defined as 3+ IHC or ISH amplification ratio \u2265 2.0\ndetermined at a central laboratory. Patients were randomized (1:1) to receive\ntrastuzumab or trastuzumab emtansine. Randomization was stratified by clinical\nstage at presentation (operable vs. inoperable), hormone receptor status, preoperative\nHER2-directed therapy (trastuzumab, trastuzumab plus additional HER2-directed\nagent[s]), and pathological nodal status evaluated after preoperative therapy.</p>", "ID": "43af0416-3a39-43bd-8aa9-0ea5f9db4607", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "BO27938 (KATHERINE)\u00a0was a randomized, multicenter, open-label trial of 1486 patients with HER2-positive, early breast cancer with residual invasive tumor\u00a0\u00a0in the breast and/or axillary lymph nodes following completion of preoperative systemic therapy that included chemotherapy and HER2-targeted therapy. Patients may have received more than one HER2-targeted therapy. Patients received radiotherapy and/or hormonal therapy concurrent with study treatment as per local guidelines. Breast tumor samples were required to show HER2 overexpression defined as 3+ IHC or ISH amplification ratio \u2265 2.0 determined at a central laboratory. Patients were randomized (1:1) to receive trastuzumab or trastuzumab emtansine. Randomization was stratified by clinical stage at presentation (operable vs. inoperable), hormone receptor status, preoperative HER2-directed therapy (trastuzumab, trastuzumab plus additional HER2-directed agent[s]), and pathological nodal status evaluated after preoperative therapy.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-GB\">(patients\nwho had not achieved pathological complete response (pCR))</span>", "ID": "560bc56a-c02d-4c78-941c-b403536f3951", "Styles": "None", "Classes": "None", "Text": "(patients who had not achieved pathological complete response (pCR))", "ParentId": "43af0416-3a39-43bd-8aa9-0ea5f9db4607"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>", "ID": "d56ba112-93e8-486c-8c95-2dcf821409e5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"left\" class=\"TextTi12\" style=\"margin-bottom:0in;text-align:left\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Trastuzumab\nemtansine was given intravenously at 3.6 mg/kg on Day 1 of a 21-day\ncycle.\u00a0 Trastuzumab was given intravenously at 6 mg/kg on Day 1 of a\n21-day cycle. Patients were treated with trastuzumab emtansine or trastuzumab\nfor a total of 14 cycles unless there was recurrence of disease, withdrawal of\nconsent, or unacceptable toxicity, whichever occurred first. Patients who\ndiscontinued trastuzumab emtansine could complete the duration of their\nintended study treatment up to 14 cycles of HER2-directed therapy with\ntrastuzumab if appropriate based on toxicity considerations and investigator\ndiscretion.</span></p>", "ID": "b3ddc2fb-2dd6-4f67-821a-7e2c156fe6bd", "Styles": "margin-bottom:0in;text-align:left", "Classes": "['TextTi12']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Trastuzumab\nemtansine was given intravenously at 3.6 mg/kg on Day 1 of a 21-day\ncycle.\u00a0 Trastuzumab was given intravenously at 6 mg/kg on Day 1 of a\n21-day cycle. Patients were treated with trastuzumab emtansine or trastuzumab\nfor a total of 14 cycles unless there was recurrence of disease, withdrawal of\nconsent, or unacceptable toxicity, whichever occurred first. Patients who\ndiscontinued trastuzumab emtansine could complete the duration of their\nintended study treatment up to 14 cycles of HER2-directed therapy with\ntrastuzumab if appropriate based on toxicity considerations and investigator\ndiscretion.</span>", "ID": "fa9a162b-1237-40c6-a238-6c220faca026", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Trastuzumab emtansine was given intravenously at 3.6 mg/kg on Day 1 of a 21-day cycle.\u00a0 Trastuzumab was given intravenously at 6 mg/kg on Day 1 of a 21-day cycle. Patients were treated with trastuzumab emtansine or trastuzumab for a total of 14 cycles unless there was recurrence of disease, withdrawal of consent, or unacceptable toxicity, whichever occurred first. Patients who discontinued trastuzumab emtansine could complete the duration of their intended study treatment up to 14 cycles of HER2-directed therapy with trastuzumab if appropriate based on toxicity considerations and investigator discretion.", "ParentId": "b3ddc2fb-2dd6-4f67-821a-7e2c156fe6bd"}, {"Element": "<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "78408f4c-8e56-4285-89b4-31ad2cd02057", "Styles": "margin-bottom:0in", "Classes": "['TextTi12']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "e25a0829-3828-4ac2-b67f-c31991f6cb0b", "Styles": "font-size:11.0pt;\nfont-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "78408f4c-8e56-4285-89b4-31ad2cd02057"}, {"Element": "<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>The primary efficacy endpoint of the study\nwas Invasive Disease-Free Survival (IDFS). IDFS was defined as the time from\nthe date of randomization to first occurrence of ipsilateral invasive breast\ntumor recurrence, ipsilateral local or regional invasive breast cancer\nrecurrence, distant recurrence, contralateral invasive breast cancer, or death\nfrom any cause. Additional endpoints included IDFS including second primary\nnon-breast cancer, disease-free survival (DFS), overall survival (OS), and\ndistant recurrence-free interval (DRFI).</span></p>", "ID": "f10a85a0-b1ad-4060-8af3-1b2c805b0e01", "Styles": "margin-bottom:0in", "Classes": "['TextTi12']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>The primary efficacy endpoint of the study\nwas Invasive Disease-Free Survival (IDFS). IDFS was defined as the time from\nthe date of randomization to first occurrence of ipsilateral invasive breast\ntumor recurrence, ipsilateral local or regional invasive breast cancer\nrecurrence, distant recurrence, contralateral invasive breast cancer, or death\nfrom any cause. Additional endpoints included IDFS including second primary\nnon-breast cancer, disease-free survival (DFS), overall survival (OS), and\ndistant recurrence-free interval (DRFI).</span>", "ID": "679605da-4cd8-40c1-b30b-ebe1302d3b4f", "Styles": "font-size:11.0pt;\nfont-family:\"Times New Roman\",serif", "Classes": "None", "Text": "The primary efficacy endpoint of the study was Invasive Disease-Free Survival (IDFS). IDFS was defined as the time from the date of randomization to first occurrence of ipsilateral invasive breast tumor recurrence, ipsilateral local or regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or death from any cause. Additional endpoints included IDFS including second primary non-breast cancer, disease-free survival (DFS), overall survival (OS), and distant recurrence-free interval (DRFI).", "ParentId": "f10a85a0-b1ad-4060-8af3-1b2c805b0e01"}, {"Element": "<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "95784ca4-d338-401c-b35b-8719c3da898d", "Styles": "margin-bottom:0in", "Classes": "['TextTi12']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "4ee3f08c-8895-4e8c-aebe-d50b0b020e4e", "Styles": "font-size:11.0pt;\nfont-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "95784ca4-d338-401c-b35b-8719c3da898d"}, {"Element": "<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>Patient demographics and baseline tumor\ncharacteristics were balanced between treatment arms.\u00a0 The median age was\napproximately 49 years (range 23-80 years), 72.8% were White, 8.7% were Asian\nand 2.7% were Black or African American.\u00a0 All but 5 patients were women; 3\nmen were included in the trastuzumab arm and 2 in the trastuzumab emtansine arm.\n22.5 percent of patients were enrolled in North America, 54.2% in Europe and\n23.3% throughout the rest of the world.\u00a0 Tumor prognostic characteristics\nincluding hormone receptor status (positive: 72.3%, negative: 27.7%), clinical\nstage at presentation (inoperable: 25.3%, operable: 74.8%) and pathological\nnodal status after preoperative therapy (node positive: 46.4%, node negative or\nnot evaluated: 53.6%) were similar in the study arms.\u00a0\u00a0 </span></p>", "ID": "2b2c943e-8be8-42fd-9ee3-88a5116174d1", "Styles": "margin-bottom:0in", "Classes": "['TextTi12']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>Patient demographics and baseline tumor\ncharacteristics were balanced between treatment arms.\u00a0 The median age was\napproximately 49 years (range 23-80 years), 72.8% were White, 8.7% were Asian\nand 2.7% were Black or African American.\u00a0 All but 5 patients were women; 3\nmen were included in the trastuzumab arm and 2 in the trastuzumab emtansine arm.\n22.5 percent of patients were enrolled in North America, 54.2% in Europe and\n23.3% throughout the rest of the world.\u00a0 Tumor prognostic characteristics\nincluding hormone receptor status (positive: 72.3%, negative: 27.7%), clinical\nstage at presentation (inoperable: 25.3%, operable: 74.8%) and pathological\nnodal status after preoperative therapy (node positive: 46.4%, node negative or\nnot evaluated: 53.6%) were similar in the study arms.\u00a0\u00a0 </span>", "ID": "0026fba0-69ed-4925-b0bc-8118413c2c94", "Styles": "font-size:11.0pt;\nfont-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Patient demographics and baseline tumor characteristics were balanced between treatment arms.\u00a0 The median age was approximately 49 years (range 23-80 years), 72.8% were White, 8.7% were Asian and 2.7% were Black or African American.\u00a0 All but 5 patients were women; 3 men were included in the trastuzumab arm and 2 in the trastuzumab emtansine arm. 22.5 percent of patients were enrolled in North America, 54.2% in Europe and 23.3% throughout the rest of the world.\u00a0 Tumor prognostic characteristics including hormone receptor status (positive: 72.3%, negative: 27.7%), clinical stage at presentation (inoperable: 25.3%, operable: 74.8%) and pathological nodal status after preoperative therapy (node positive: 46.4%, node negative or not evaluated: 53.6%) were similar in the study arms.\u00a0\u00a0 ", "ParentId": "2b2c943e-8be8-42fd-9ee3-88a5116174d1"}, {"Element": "<p class=\"TextTi12\" style=\"margin-bottom:0in\"><span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "2b35a8fe-d88a-4478-92d6-667051716358", "Styles": "margin-bottom:0in", "Classes": "['TextTi12']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;\nfont-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "b5174fa7-f484-4db9-9046-ac8d329f12a7", "Styles": "font-size:11.0pt;\nfont-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "2b35a8fe-d88a-4478-92d6-667051716358"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>The majority of\nthe patients (76.9%) had received an anthracycline-containing neoadjuvant\nchemotherapy regimen.19.5% percent of patients received another HER2-targeted\nagent in addition to trastuzumab as a component of neoadjuvant therapy; 93.8%\nof these patients received pertuzumab. All of the patients had received taxanes\nas part of neoadjuvant chemotherapy.</span></p>", "ID": "8c079768-352c-4d16-aef0-034dc7f8cfdb", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['Paragraph']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>The majority of\nthe patients (76.9%) had received an anthracycline-containing neoadjuvant\nchemotherapy regimen.19.5% percent of patients received another HER2-targeted\nagent in addition to trastuzumab as a component of neoadjuvant therapy; 93.8%\nof these patients received pertuzumab. All of the patients had received taxanes\nas part of neoadjuvant chemotherapy.</span>", "ID": "6e4c21ba-b74b-467c-b74f-47806c0b5a9a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "The majority of the patients (76.9%) had received an anthracycline-containing neoadjuvant chemotherapy regimen.19.5% percent of patients received another HER2-targeted agent in addition to trastuzumab as a component of neoadjuvant therapy; 93.8% of these patients received pertuzumab. All of the patients had received taxanes as part of neoadjuvant chemotherapy.", "ParentId": "8c079768-352c-4d16-aef0-034dc7f8cfdb"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span></p>", "ID": "e5ccff4b-7fe1-46a3-8ccf-b98e73f735c5", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['Paragraph']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\u00a0</span>", "ID": "642a9536-049c-4ada-bc4d-963d9de28d7a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "e5ccff4b-7fe1-46a3-8ccf-b98e73f735c5"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:black;\nbackground:white'>A clinically meaningful and statistically significant\nimprovement in IDFS was observed in patients who received trastuzumab emtansine\ncompared with trastuzumab (HR = 0.50, 95% CI [0.39, 0.64], p &lt;0.0001.\nEstimates of 3 years IDFS rates were 88.3% vs. 77.0%\u00a0in trastuzumab\nemtansine vs. trastuzumab\u00a0arms, respectively. See Table 6 and Figure 1.</span></p>", "ID": "4dff7043-a6a3-45ba-9057-ae4e2523227f", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['Paragraph']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:black;\nbackground:white'>A clinically meaningful and statistically significant\nimprovement in IDFS was observed in patients who received trastuzumab emtansine\ncompared with trastuzumab (HR = 0.50, 95% CI [0.39, 0.64], p &lt;0.0001.\nEstimates of 3 years IDFS rates were 88.3% vs. 77.0%\u00a0in trastuzumab\nemtansine vs. trastuzumab\u00a0arms, respectively. See Table 6 and Figure 1.</span>", "ID": "17744337-4b7a-42de-89e7-abfd90208ae4", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;color:black;\nbackground:white", "Classes": "None", "Text": "A clinically meaningful and statistically significant improvement in IDFS was observed in patients who received trastuzumab emtansine compared with trastuzumab (HR = 0.50, 95% CI [0.39, 0.64], p <0.0001. Estimates of 3 years IDFS rates were 88.3% vs. 77.0%\u00a0in trastuzumab emtansine vs. trastuzumab\u00a0arms, respectively. See Table 6 and Figure 1.", "ParentId": "4dff7043-a6a3-45ba-9057-ae4e2523227f"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;background:white'>\u00a0</span></p>", "ID": "7fe63989-aa6d-420a-9b62-ac51d1bc3753", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['Paragraph']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;background:white'>\u00a0</span>", "ID": "57a4c024-28fb-42a0-975e-e65fbfee1ddb", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;background:white", "Classes": "None", "Text": "\u00a0", "ParentId": "7fe63989-aa6d-420a-9b62-ac51d1bc3753"}, {"Element": "<p class=\"TableTitle\" style=\"margin-top:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Table\u00a06\u00a0\u00a0\u00a0\u00a0\u00a0 </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Summary of </span><span lang=\"EN-CARRIBEAN\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>e</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>fficacy from </span><span lang=\"EN-CARRIBEAN\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>s</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>tudy </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>BO27938 (<span style=\"letter-spacing:.05pt\">KATHERINE</span>) </span></p>", "ID": "f6cb39b6-7d42-458f-861d-a8a1cc958839", "Styles": "margin-top:0in;line-height:normal", "Classes": "['TableTitle']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Table\u00a06\u00a0\u00a0\u00a0\u00a0\u00a0 </span>", "ID": "96157d86-c47a-4ef4-9017-87a94ce1e34b", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Table\u00a06\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f6cb39b6-7d42-458f-861d-a8a1cc958839"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Summary of </span>", "ID": "676b13df-5528-4645-988a-2304ec25c37d", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Summary of ", "ParentId": "f6cb39b6-7d42-458f-861d-a8a1cc958839"}, {"Element": "<span lang=\"EN-CARRIBEAN\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>e</span>", "ID": "898f4584-2b6b-4628-b3b0-4b3711f71b0a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "e", "ParentId": "f6cb39b6-7d42-458f-861d-a8a1cc958839"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>fficacy from </span>", "ID": "f32ccd85-a9af-454d-90c5-74305515c7c6", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "fficacy from ", "ParentId": "f6cb39b6-7d42-458f-861d-a8a1cc958839"}, {"Element": "<span lang=\"EN-CARRIBEAN\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>s</span>", "ID": "216b649f-3d61-4460-ad7a-2ff4711600e0", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "s", "ParentId": "f6cb39b6-7d42-458f-861d-a8a1cc958839"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>tudy </span>", "ID": "ab0c9e41-ceb7-4553-a925-cd383d8cee62", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "tudy ", "ParentId": "f6cb39b6-7d42-458f-861d-a8a1cc958839"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>BO27938 (<span style=\"letter-spacing:.05pt\">KATHERINE</span>) </span>", "ID": "4a6a4d19-1cab-4825-bb02-277def206e75", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "BO27938 () ", "ParentId": "f6cb39b6-7d42-458f-861d-a8a1cc958839"}, {"Element": "<span style=\"letter-spacing:.05pt\">KATHERINE</span>", "ID": "1e3119a3-7b68-4feb-82bb-eb794b50585d", "Styles": "letter-spacing:.05pt", "Classes": "None", "Text": "KATHERINE", "ParentId": "4a6a4d19-1cab-4825-bb02-277def206e75"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:437.7pt;border-collapse:collapse;border:none\" width=\"584\">\n<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n   line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>\n<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab\n   Emtansine</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Primary\n  Endpoint</span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Invasive\n  Disease-Free Survival (IDFS)<sup> \u00a0</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">165 (22.2%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">91 (12.2%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.50 [0.39, 0.64]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">77.02 [73.78, 80.26]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">88.27 [85.81, 90.72]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:6.1pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Overall\n  Survival (OS)</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;\n  line-height:8.6pt;page-break-after:avoid;punctuation-wrap:simple\"><span style='font-size:8.0pt;font-family:\"Courier New\"'>\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">56 (7.5%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">42 (5.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.70 [0.47,\n  1.05]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0848</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">5\n  year survival rate<sup>2</sup>,% [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">86.8 [80.95, 92.63]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">92.1 [89.44, 94.74]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">IDFS</span></b> <b><span style=\"font-size:10.0pt\">including\n  second primary non-breast cancer<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">95 (12.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.51 [0.40, 0.66]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.7 [85.18, 90.18]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Disease-Free\n  Survival (DFS)<sup>3</sup> </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">98 (13.2%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.53 [0.41,\n  0.68]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.41 [84.88, 89.93]</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Distant\n  recurrence-free interval (DRFI)<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">121 (16.3%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">78 (10.5%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.60 [0.45, 0.79]</span><sup><span style=\"font-size:9.0pt\"> </span></sup></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0003</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">83.0 [80.10, 85.92 ]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">89.7 [87.37, 92.01 ]</span></p>\n</td>\n</tr>\n</table>", "ID": "5b33625f-fd3b-42b7-8f85-52cf050fa782", "Styles": "width:437.7pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                             ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<thead>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n   line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>\n<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab\n   Emtansine</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>\n</tr>\n</thead>", "ID": "a050bc6e-bf6d-49ac-8264-42c4f6e15e03", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n   line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>\n<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab\n   Emtansine</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>\n</tr>", "ID": "edb88954-d4a2-4e1a-9746-32e8ce88dd49", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "a050bc6e-bf6d-49ac-8264-42c4f6e15e03"}, {"Element": "<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n   line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "70069b25-a977-4a86-a6d0-8eb87d071df8", "Styles": "width:218.85pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "edb88954-d4a2-4e1a-9746-32e8ce88dd49"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n   line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "b0b43eea-53dd-4e26-83a9-1c2f6d2d846c", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n   2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n   line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "70069b25-a977-4a86-a6d0-8eb87d071df8"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a0</span>", "ID": "cb5a257e-afa6-4436-bb76-3c88ecf7bd71", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "b0b43eea-53dd-4e26-83a9-1c2f6d2d846c"}, {"Element": "<td style=\"width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab </span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>", "ID": "d3a7170d-db96-42b6-866b-13cee70b71d2", "Styles": "width:112.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "edb88954-d4a2-4e1a-9746-32e8ce88dd49"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab </span></b></p>", "ID": "570c1e38-ef2d-4dd0-9695-1050a4038e17", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d3a7170d-db96-42b6-866b-13cee70b71d2"}, {"Element": "<b><span style=\"font-size:10.0pt\">Trastuzumab </span></b>", "ID": "a86f7eaf-1ea7-4a93-a151-7e668cd2e88f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "570c1e38-ef2d-4dd0-9695-1050a4038e17"}, {"Element": "<span style=\"font-size:10.0pt\">Trastuzumab </span>", "ID": "5cf4f697-c7e1-4efa-a42c-a38d0fe399a1", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Trastuzumab ", "ParentId": "a86f7eaf-1ea7-4a93-a151-7e668cd2e88f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>", "ID": "0fc8a4d9-5815-4ed0-9a26-bec939fe0ffd", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d3a7170d-db96-42b6-866b-13cee70b71d2"}, {"Element": "<b><span style=\"font-size:10.0pt\">N = 743</span></b>", "ID": "16bf72d0-2001-4dcc-9fe2-64f5eae072cc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0fc8a4d9-5815-4ed0-9a26-bec939fe0ffd"}, {"Element": "<span style=\"font-size:10.0pt\">N = 743</span>", "ID": "6645a4b7-5cfc-4e11-a314-f866927e3703", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N = 743", "ParentId": "16bf72d0-2001-4dcc-9fe2-64f5eae072cc"}, {"Element": "<td style=\"width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab\n   Emtansine</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>\n</td>", "ID": "f3df04c9-98b6-4b2c-b399-0e593f914c99", "Styles": "width:106.35pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "edb88954-d4a2-4e1a-9746-32e8ce88dd49"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Trastuzumab\n   Emtansine</span></b></p>", "ID": "6c017b3b-f73e-400f-8304-f0fc845891da", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f3df04c9-98b6-4b2c-b399-0e593f914c99"}, {"Element": "<b><span style=\"font-size:10.0pt\">Trastuzumab\n   Emtansine</span></b>", "ID": "0813fd43-1a29-4d82-952b-8d36312a427f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6c017b3b-f73e-400f-8304-f0fc845891da"}, {"Element": "<span style=\"font-size:10.0pt\">Trastuzumab\n   Emtansine</span>", "ID": "cc1ce701-d158-42d3-b819-67dad954c09a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Trastuzumab    Emtansine", "ParentId": "0813fd43-1a29-4d82-952b-8d36312a427f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">N = 743</span></b></p>", "ID": "c0494ef6-c09f-4306-96e1-365102065499", "Styles": "margin-top:2.5pt;margin-right:0in;\n   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n   page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f3df04c9-98b6-4b2c-b399-0e593f914c99"}, {"Element": "<b><span style=\"font-size:10.0pt\">N = 743</span></b>", "ID": "e37f9941-b133-4feb-abb5-39b031090131", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c0494ef6-c09f-4306-96e1-365102065499"}, {"Element": "<span style=\"font-size:10.0pt\">N = 743</span>", "ID": "3bc98069-ae45-4f9d-9674-c9d8409a48ab", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N = 743", "ParentId": "e37f9941-b133-4feb-abb5-39b031090131"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Primary\n  Endpoint</span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>\n</td>\n</tr>", "ID": "e46842f3-7b21-49a5-a23d-b2844f0b1515", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Primary\n  Endpoint</span></i></b></p>\n</td>", "ID": "ba53e10e-9c0d-4bfa-b844-5c3a5987078a", "Styles": "width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "e46842f3-7b21-49a5-a23d-b2844f0b1515"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Primary\n  Endpoint</span></i></b></p>", "ID": "2e419ff3-6073-48b8-8f9a-a14789ad1e27", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ba53e10e-9c0d-4bfa-b844-5c3a5987078a"}, {"Element": "<b><i><span style=\"font-size:10.0pt\">Primary\n  Endpoint</span></i></b>", "ID": "1a2bee63-8358-4dcd-bc05-725b01528be5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2e419ff3-6073-48b8-8f9a-a14789ad1e27"}, {"Element": "<i><span style=\"font-size:10.0pt\">Primary\n  Endpoint</span></i>", "ID": "1716e069-6d7c-4881-aa57-9d706a445537", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1a2bee63-8358-4dcd-bc05-725b01528be5"}, {"Element": "<span style=\"font-size:10.0pt\">Primary\n  Endpoint</span>", "ID": "0363621c-1762-4b11-bb13-d47da22eae49", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Primary   Endpoint", "ParentId": "1716e069-6d7c-4881-aa57-9d706a445537"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>\n</td>", "ID": "862531de-0a38-48fc-a039-d88e4eabf3d8", "Styles": "width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "e46842f3-7b21-49a5-a23d-b2844f0b1515"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>", "ID": "c044e0c3-8b09-4927-b735-6a3eacb69ec9", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "862531de-0a38-48fc-a039-d88e4eabf3d8"}, {"Element": "<b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b>", "ID": "d7af81ac-cbee-45f1-809e-0aadd7cfd57f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c044e0c3-8b09-4927-b735-6a3eacb69ec9"}, {"Element": "<i><span style=\"font-size:10.0pt\">\u00a0</span></i>", "ID": "0b3c72ab-e5c0-4586-8845-54129bb18720", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7af81ac-cbee-45f1-809e-0aadd7cfd57f"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a0</span>", "ID": "05e4723f-cf82-42be-950a-2e84c405f070", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "0b3c72ab-e5c0-4586-8845-54129bb18720"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Invasive\n  Disease-Free Survival (IDFS)<sup> \u00a0</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "f9d29f60-904b-44e0-8fda-50d376d42cc1", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Invasive\n  Disease-Free Survival (IDFS)<sup> \u00a0</sup></span></b></p>\n</td>", "ID": "3a5fa2af-f1b1-4217-be5c-df5403cbe771", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "f9d29f60-904b-44e0-8fda-50d376d42cc1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Invasive\n  Disease-Free Survival (IDFS)<sup> \u00a0</sup></span></b></p>", "ID": "64cca7b1-fff5-4e03-82dc-116a9de22a75", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3a5fa2af-f1b1-4217-be5c-df5403cbe771"}, {"Element": "<b><span style=\"font-size:10.0pt\">Invasive\n  Disease-Free Survival (IDFS)<sup> \u00a0</sup></span></b>", "ID": "3dada52e-d0e6-4961-86db-72da3cf41466", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "64cca7b1-fff5-4e03-82dc-116a9de22a75"}, {"Element": "<span style=\"font-size:10.0pt\">Invasive\n  Disease-Free Survival (IDFS)<sup> \u00a0</sup></span>", "ID": "a3409192-cd24-4d97-b82f-fcc3586da981", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Invasive   Disease-Free Survival (IDFS)", "ParentId": "3dada52e-d0e6-4961-86db-72da3cf41466"}, {"Element": "<sup> \u00a0</sup>", "ID": "a56e5dfd-941b-4343-9062-ee2650f494bf", "Styles": "None", "Classes": "None", "Text": " \u00a0", "ParentId": "a3409192-cd24-4d97-b82f-fcc3586da981"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "1870b5f1-9677-4bcd-a200-a93da4d2c688", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "f9d29f60-904b-44e0-8fda-50d376d42cc1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "a10a407a-a49a-4f26-9936-72158eba553e", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1870b5f1-9677-4bcd-a200-a93da4d2c688"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a0</span>", "ID": "569db1dc-cf51-4ef1-8a0b-37fa743522a6", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "a10a407a-a49a-4f26-9936-72158eba553e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">165 (22.2%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">91 (12.2%)</span></p>\n</td>\n</tr>", "ID": "f60f842e-b0f9-4ba8-ad01-f15271cae89c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>\n</td>", "ID": "e328306a-0e96-453f-a5ee-14bde600dc9b", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "f60f842e-b0f9-4ba8-ad01-f15271cae89c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>", "ID": "5de0d79b-668c-4332-aca8-9c8b5a35eb82", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e328306a-0e96-453f-a5ee-14bde600dc9b"}, {"Element": "<span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span>", "ID": "5169dc9f-9070-453c-a4b1-abd5bf2a0e9d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Number   (%) of patients with event ", "ParentId": "5de0d79b-668c-4332-aca8-9c8b5a35eb82"}, {"Element": "<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">165 (22.2%)</span></p>\n</td>", "ID": "dd61dd3a-e453-44d6-af6e-ba71f3b23472", "Styles": "width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "f60f842e-b0f9-4ba8-ad01-f15271cae89c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">165 (22.2%)</span></p>", "ID": "849a09b6-b9ff-4b7e-a748-8d64cb231ce3", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dd61dd3a-e453-44d6-af6e-ba71f3b23472"}, {"Element": "<span style=\"font-size:10.0pt\">165 (22.2%)</span>", "ID": "c21a45b5-c84a-4f0f-bbbf-86288509dc92", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "165 (22.2%)", "ParentId": "849a09b6-b9ff-4b7e-a748-8d64cb231ce3"}, {"Element": "<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">91 (12.2%)</span></p>\n</td>", "ID": "4984f2d1-bdec-4128-8d19-37c4ed91a680", "Styles": "width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "f60f842e-b0f9-4ba8-ad01-f15271cae89c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">91 (12.2%)</span></p>", "ID": "95aa098d-4afe-40aa-83ed-80307063a8f1", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4984f2d1-bdec-4128-8d19-37c4ed91a680"}, {"Element": "<span style=\"font-size:10.0pt\">91 (12.2%)</span>", "ID": "a6db7477-fa2e-4a0c-b30b-dcf19600631d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "91 (12.2%)", "ParentId": "95aa098d-4afe-40aa-83ed-80307063a8f1"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.50 [0.39, 0.64]</span></p>\n</td>\n</tr>", "ID": "8f6f41a1-3962-4ed4-b455-392d75251762", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>", "ID": "6b5349f1-94ad-4a2f-970b-00679b2f83d6", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8f6f41a1-3962-4ed4-b455-392d75251762"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>", "ID": "70eb1bae-aecd-49eb-8371-b5469828b201", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6b5349f1-94ad-4a2f-970b-00679b2f83d6"}, {"Element": "<span style=\"font-size:10.0pt\">HR\n  [95% CI]</span>", "ID": "500e0cd2-083d-4aa3-a3db-fa02f933d8c6", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "HR   [95% CI]", "ParentId": "70eb1bae-aecd-49eb-8371-b5469828b201"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.50 [0.39, 0.64]</span></p>\n</td>", "ID": "8d132b42-5724-4ec2-aac9-d84671c2c641", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8f6f41a1-3962-4ed4-b455-392d75251762"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.50 [0.39, 0.64]</span></p>", "ID": "e9c12773-5a2b-4650-bd8b-e89b60ff7c4d", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8d132b42-5724-4ec2-aac9-d84671c2c641"}, {"Element": "<span style=\"font-size:10.0pt\">0.50 [0.39, 0.64]</span>", "ID": "4bc9aaac-e6a1-4b1d-b48f-8227e1518c39", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.50 [0.39, 0.64]", "ParentId": "e9c12773-5a2b-4650-bd8b-e89b60ff7c4d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>\n</tr>", "ID": "014a554b-a553-48b2-be73-21c30a6de679", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>", "ID": "06a59079-e4eb-4b81-bee6-e7053296f048", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "014a554b-a553-48b2-be73-21c30a6de679"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>", "ID": "88dcbb01-e530-4134-a678-8dcdac2dcf12", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "06a59079-e4eb-4b81-bee6-e7053296f048"}, {"Element": "<span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span>", "ID": "a5c5207b-88af-447a-bc96-393438d3eec0", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "p-value   (Log-Rank test, unstratified)", "ParentId": "88dcbb01-e530-4134-a678-8dcdac2dcf12"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>", "ID": "21504e9f-e5c4-4949-a4f1-d4567abfdb7e", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "014a554b-a553-48b2-be73-21c30a6de679"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>", "ID": "6f7e79fb-3810-4b3b-a98a-519303db9ccc", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "21504e9f-e5c4-4949-a4f1-d4567abfdb7e"}, {"Element": "<span style=\"font-size:10.0pt\">&lt;0.0001</span>", "ID": "a7b377c8-68ce-4b75-9360-4527e59e4c97", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "<0.0001", "ParentId": "6f7e79fb-3810-4b3b-a98a-519303db9ccc"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">77.02 [73.78, 80.26]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">88.27 [85.81, 90.72]</span></p>\n</td>\n</tr>", "ID": "3c1609cb-8c69-42e3-9a1b-a1034cac0576", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>\n</td>", "ID": "b1336345-c918-4087-93f9-d0f3c5728860", "Styles": "width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3c1609cb-8c69-42e3-9a1b-a1034cac0576"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>", "ID": "43154ff4-9e05-4485-9daa-f42ed128fc50", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1336345-c918-4087-93f9-d0f3c5728860"}, {"Element": "<span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span>", "ID": "e7b625c1-2888-48f3-a652-858b2a05c3fd", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3   year event-free rate,% [95% CI] ", "ParentId": "43154ff4-9e05-4485-9daa-f42ed128fc50"}, {"Element": "<sup>2</sup>", "ID": "0fdef239-7a2d-479c-8431-4a2afbedac7d", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "e7b625c1-2888-48f3-a652-858b2a05c3fd"}, {"Element": "<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">77.02 [73.78, 80.26]</span></p>\n</td>", "ID": "58881849-1a3e-4b8d-aa4f-87653841cd8d", "Styles": "width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3c1609cb-8c69-42e3-9a1b-a1034cac0576"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">77.02 [73.78, 80.26]</span></p>", "ID": "26bf6236-b550-4c67-9f82-214ae5332462", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "58881849-1a3e-4b8d-aa4f-87653841cd8d"}, {"Element": "<span style=\"font-size:10.0pt\">77.02 [73.78, 80.26]</span>", "ID": "2ce36e2a-d38b-4078-abf0-4316ecc520b7", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "77.02 [73.78, 80.26]", "ParentId": "26bf6236-b550-4c67-9f82-214ae5332462"}, {"Element": "<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">88.27 [85.81, 90.72]</span></p>\n</td>", "ID": "67ca868a-35d4-4d7b-826b-7ac717670e67", "Styles": "width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3c1609cb-8c69-42e3-9a1b-a1034cac0576"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">88.27 [85.81, 90.72]</span></p>", "ID": "a4dc7adf-09e2-4538-9404-9708580a2e6e", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "67ca868a-35d4-4d7b-826b-7ac717670e67"}, {"Element": "<span style=\"font-size:10.0pt\">88.27 [85.81, 90.72]</span>", "ID": "6f193092-9379-4853-a06d-8222ee02f6c1", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "88.27 [85.81, 90.72]", "ParentId": "a4dc7adf-09e2-4538-9404-9708580a2e6e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>\n</td>\n</tr>", "ID": "4098e385-2a5d-45ac-8ea8-a20acdc89dee", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>\n</td>", "ID": "39a9ac93-dd15-48be-9c46-3501a73f7572", "Styles": "width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "4098e385-2a5d-45ac-8ea8-a20acdc89dee"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">Secondary\n  Endpoints<sup>1</sup></span></i></b></p>", "ID": "16e53ccd-a982-4d3f-80e2-207edf40e131", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39a9ac93-dd15-48be-9c46-3501a73f7572"}, {"Element": "<b><i><span style=\"font-size:10.0pt\">Secondary\n  Endpoints<sup>1</sup></span></i></b>", "ID": "b042b0c5-f3bb-4c89-9384-2c18673a223d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "16e53ccd-a982-4d3f-80e2-207edf40e131"}, {"Element": "<i><span style=\"font-size:10.0pt\">Secondary\n  Endpoints<sup>1</sup></span></i>", "ID": "1d4170d2-0c1f-4991-adb4-cb2b4945990d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b042b0c5-f3bb-4c89-9384-2c18673a223d"}, {"Element": "<span style=\"font-size:10.0pt\">Secondary\n  Endpoints<sup>1</sup></span>", "ID": "2796fe88-7eb6-4f20-a040-6a2b7d8ab88d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Secondary   Endpoints", "ParentId": "1d4170d2-0c1f-4991-adb4-cb2b4945990d"}, {"Element": "<sup>1</sup>", "ID": "b873a4fc-7859-4fbd-a2a9-007d99dc5025", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "2796fe88-7eb6-4f20-a040-6a2b7d8ab88d"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>\n</td>", "ID": "87a5d5c2-d4be-47b9-b73b-f89280fde04d", "Styles": "width:218.85pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "4098e385-2a5d-45ac-8ea8-a20acdc89dee"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b></p>", "ID": "21c7485c-6cd6-41cd-a27c-5a7b823883d3", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "87a5d5c2-d4be-47b9-b73b-f89280fde04d"}, {"Element": "<b><i><span style=\"font-size:10.0pt\">\u00a0</span></i></b>", "ID": "9bba33b2-3fde-4d84-a2c1-cc9be82cb89e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "21c7485c-6cd6-41cd-a27c-5a7b823883d3"}, {"Element": "<i><span style=\"font-size:10.0pt\">\u00a0</span></i>", "ID": "6f82d6d4-21d9-4c46-a837-d2da2000b375", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9bba33b2-3fde-4d84-a2c1-cc9be82cb89e"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a0</span>", "ID": "b9c16ed5-4162-4418-815d-c5b39fc846a0", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "6f82d6d4-21d9-4c46-a837-d2da2000b375"}, {"Element": "<tr style=\"page-break-inside:avoid;height:6.1pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Overall\n  Survival (OS)</span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;\n  line-height:8.6pt;page-break-after:avoid;punctuation-wrap:simple\"><span style='font-size:8.0pt;font-family:\"Courier New\"'>\u00a0</span></p>\n</td>\n</tr>", "ID": "0e64115a-5169-4b49-9c8c-bb8b3f930750", "Styles": "page-break-inside:avoid;height:6.1pt", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Overall\n  Survival (OS)</span></b></p>\n</td>", "ID": "49b18d44-ae48-42f3-8352-a85344243d2a", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:6.1pt", "Classes": "None", "Text": "  ", "ParentId": "0e64115a-5169-4b49-9c8c-bb8b3f930750"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Overall\n  Survival (OS)</span></b></p>", "ID": "1939b2c2-f168-4cc2-b855-b052398b0c8b", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "49b18d44-ae48-42f3-8352-a85344243d2a"}, {"Element": "<b><span style=\"font-size:10.0pt\">Overall\n  Survival (OS)</span></b>", "ID": "4904aabf-2830-4b6f-ae63-7f00ab2e0658", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1939b2c2-f168-4cc2-b855-b052398b0c8b"}, {"Element": "<span style=\"font-size:10.0pt\">Overall\n  Survival (OS)</span>", "ID": "60b68d92-e369-49a5-abff-d07572b20011", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Overall   Survival (OS)", "ParentId": "4904aabf-2830-4b6f-ae63-7f00ab2e0658"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;\n  line-height:8.6pt;page-break-after:avoid;punctuation-wrap:simple\"><span style='font-size:8.0pt;font-family:\"Courier New\"'>\u00a0</span></p>\n</td>", "ID": "cceea071-48f2-4821-9e51-1a4ca1ad52a9", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  6.1pt", "Classes": "None", "Text": "  ", "ParentId": "0e64115a-5169-4b49-9c8c-bb8b3f930750"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;\n  line-height:8.6pt;page-break-after:avoid;punctuation-wrap:simple\"><span style='font-size:8.0pt;font-family:\"Courier New\"'>\u00a0</span></p>", "ID": "941f58ff-c268-4fec-93c4-c3746b38d8f8", "Styles": "margin-bottom:6.0pt;text-align:center;\n  line-height:8.6pt;page-break-after:avoid;punctuation-wrap:simple", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cceea071-48f2-4821-9e51-1a4ca1ad52a9"}, {"Element": "<span style='font-size:8.0pt;font-family:\"Courier New\"'>\u00a0</span>", "ID": "b3383444-83fa-4951-8288-64c1a9fc6e95", "Styles": "font-size:8.0pt;font-family:\"Courier New\"", "Classes": "None", "Text": "\u00a0", "ParentId": "941f58ff-c268-4fec-93c4-c3746b38d8f8"}, {"Element": "<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">56 (7.5%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">42 (5.7%)</span></p>\n</td>\n</tr>", "ID": "1b2de6fc-2840-49f4-bb03-2301b945a21b", "Styles": "page-break-inside:avoid;height:10.9pt", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>", "ID": "8b3b313b-161f-44ee-8cdf-a4f66656ac38", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "1b2de6fc-2840-49f4-bb03-2301b945a21b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>", "ID": "70beb822-b436-423b-919a-f3721a06b5c7", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b3b313b-161f-44ee-8cdf-a4f66656ac38"}, {"Element": "<span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span>", "ID": "a241b350-6510-478a-b546-e1dd65f4d9a1", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Number   (%) of patients with event", "ParentId": "70beb822-b436-423b-919a-f3721a06b5c7"}, {"Element": "<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">56 (7.5%)</span></p>\n</td>", "ID": "314c5499-4b0f-4ef9-a573-e25b85e11ab3", "Styles": "width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;\n  height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "1b2de6fc-2840-49f4-bb03-2301b945a21b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">56 (7.5%)</span></p>", "ID": "f4c9a813-ccb1-4ffe-a27e-0cba2bfeb802", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "314c5499-4b0f-4ef9-a573-e25b85e11ab3"}, {"Element": "<span style=\"font-size:10.0pt\">56 (7.5%)</span>", "ID": "d96c90d6-43a7-4e51-9e19-b26990d2b311", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "56 (7.5%)", "ParentId": "f4c9a813-ccb1-4ffe-a27e-0cba2bfeb802"}, {"Element": "<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">42 (5.7%)</span></p>\n</td>", "ID": "863fd61f-8fc0-46c8-bf78-131f5d0f21ed", "Styles": "width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "1b2de6fc-2840-49f4-bb03-2301b945a21b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">42 (5.7%)</span></p>", "ID": "ae3ebf0b-6e90-42b6-b960-5c8401150fd0", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "863fd61f-8fc0-46c8-bf78-131f5d0f21ed"}, {"Element": "<span style=\"font-size:10.0pt\">42 (5.7%)</span>", "ID": "0e0f56dd-f704-4ccd-a18b-777e8a83412b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "42 (5.7%)", "ParentId": "ae3ebf0b-6e90-42b6-b960-5c8401150fd0"}, {"Element": "<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.70 [0.47,\n  1.05]</span></p>\n</td>\n</tr>", "ID": "5e60fa53-46b6-44e0-a7a0-cb0fe2eb6331", "Styles": "page-break-inside:avoid;height:10.9pt", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>", "ID": "b588ee7e-ff09-48f6-a4a2-27ca8af2ded1", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "5e60fa53-46b6-44e0-a7a0-cb0fe2eb6331"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>", "ID": "7c2ed908-c6c8-47bd-83ec-6ffc9edb06de", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b588ee7e-ff09-48f6-a4a2-27ca8af2ded1"}, {"Element": "<span style=\"font-size:10.0pt\">HR\n  [95% CI]</span>", "ID": "a5c9825e-49d1-4add-b40e-ee36cb5e45fd", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "HR   [95% CI]", "ParentId": "7c2ed908-c6c8-47bd-83ec-6ffc9edb06de"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.70 [0.47,\n  1.05]</span></p>\n</td>", "ID": "6ff96259-aead-4f68-a011-91daaae152d3", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt", "Classes": "None", "Text": "  ", "ParentId": "5e60fa53-46b6-44e0-a7a0-cb0fe2eb6331"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.70 [0.47,\n  1.05]</span></p>", "ID": "f4a4e897-ded7-4b10-8265-504853c81566", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6ff96259-aead-4f68-a011-91daaae152d3"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a00.70 [0.47,\n  1.05]</span>", "ID": "5f5acc97-fa52-4551-a1dd-adcdc63654ea", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a00.70 [0.47,   1.05]", "ParentId": "f4a4e897-ded7-4b10-8265-504853c81566"}, {"Element": "<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0848</span></p>\n</td>\n</tr>", "ID": "93e27e3f-4deb-49d3-9168-1b7be33e7dcc", "Styles": "page-break-inside:avoid;height:10.9pt", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>", "ID": "c10cb67c-3416-4b3f-a3e3-b3aa8c37b9c5", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "93e27e3f-4deb-49d3-9168-1b7be33e7dcc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>", "ID": "b74bb826-d4ee-4af1-89bf-d291125452b8", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c10cb67c-3416-4b3f-a3e3-b3aa8c37b9c5"}, {"Element": "<span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span>", "ID": "4d0143bb-fe06-494e-bf7e-6136f89a54dc", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "p-value   (Log-Rank test, unstratified)", "ParentId": "b74bb826-d4ee-4af1-89bf-d291125452b8"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0848</span></p>\n</td>", "ID": "0af2d199-d064-44be-95f3-55923adb04ec", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:\n  10.9pt", "Classes": "None", "Text": "  ", "ParentId": "93e27e3f-4deb-49d3-9168-1b7be33e7dcc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0848</span></p>", "ID": "ff621187-22a3-4f3c-9cf6-bff580844118", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0af2d199-d064-44be-95f3-55923adb04ec"}, {"Element": "<span style=\"font-size:10.0pt\">0.0848</span>", "ID": "cc3d2ad6-1e77-4add-8228-ef87b372742d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0848", "ParentId": "ff621187-22a3-4f3c-9cf6-bff580844118"}, {"Element": "<tr style=\"page-break-inside:avoid;height:10.9pt\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">5\n  year survival rate<sup>2</sup>,% [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">86.8 [80.95, 92.63]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">92.1 [89.44, 94.74]</span></p>\n</td>\n</tr>", "ID": "da47e12c-8363-41dc-93b1-1e13f740fb70", "Styles": "page-break-inside:avoid;height:10.9pt", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">5\n  year survival rate<sup>2</sup>,% [95% CI]</span></p>\n</td>", "ID": "22ba9356-c6b4-4ac2-a281-82f0c6098166", "Styles": "width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "da47e12c-8363-41dc-93b1-1e13f740fb70"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">5\n  year survival rate<sup>2</sup>,% [95% CI]</span></p>", "ID": "d5010a56-f14e-4055-915b-40068ff14dc9", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22ba9356-c6b4-4ac2-a281-82f0c6098166"}, {"Element": "<span style=\"font-size:10.0pt\">5\n  year survival rate<sup>2</sup>,% [95% CI]</span>", "ID": "2f9fa3bb-9294-4a23-8a17-682909cc2fa0", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "5   year survival rate,% [95% CI]", "ParentId": "d5010a56-f14e-4055-915b-40068ff14dc9"}, {"Element": "<sup>2</sup>", "ID": "6ab9c88c-71e7-41bf-9b7f-0184058df4ff", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "2f9fa3bb-9294-4a23-8a17-682909cc2fa0"}, {"Element": "<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">86.8 [80.95, 92.63]</span></p>\n</td>", "ID": "0aa22e87-db74-4fc3-b1d8-572c7ba55795", "Styles": "width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "da47e12c-8363-41dc-93b1-1e13f740fb70"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">86.8 [80.95, 92.63]</span></p>", "ID": "215b070e-3330-4a4a-b988-3c7ed5bd2e9e", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0aa22e87-db74-4fc3-b1d8-572c7ba55795"}, {"Element": "<span style=\"font-size:10.0pt\">86.8 [80.95, 92.63]</span>", "ID": "1368ab10-3deb-4bb6-bb40-2a53f18635cb", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "86.8 [80.95, 92.63]", "ParentId": "215b070e-3330-4a4a-b988-3c7ed5bd2e9e"}, {"Element": "<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">92.1 [89.44, 94.74]</span></p>\n</td>", "ID": "b3309a02-c737-4cfe-935f-c89ce1ab3d64", "Styles": "width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:10.9pt", "Classes": "None", "Text": "  ", "ParentId": "da47e12c-8363-41dc-93b1-1e13f740fb70"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">92.1 [89.44, 94.74]</span></p>", "ID": "9bfc3fb7-0fee-4f12-9ba2-6d900d83aa77", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b3309a02-c737-4cfe-935f-c89ce1ab3d64"}, {"Element": "<span style=\"font-size:10.0pt\">92.1 [89.44, 94.74]</span>", "ID": "842eaacb-47fa-4350-a4c5-1bb90231b60c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "92.1 [89.44, 94.74]", "ParentId": "9bfc3fb7-0fee-4f12-9ba2-6d900d83aa77"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">IDFS</span></b> <b><span style=\"font-size:10.0pt\">including\n  second primary non-breast cancer<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>\n</td>\n</tr>", "ID": "49b490d0-6fd9-49fc-833e-e772799938fa", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">IDFS</span></b> <b><span style=\"font-size:10.0pt\">including\n  second primary non-breast cancer<sup>3</sup></span></b></p>\n</td>", "ID": "80e83219-f872-4b03-a03b-b4efc4066074", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "49b490d0-6fd9-49fc-833e-e772799938fa"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">IDFS</span></b> <b><span style=\"font-size:10.0pt\">including\n  second primary non-breast cancer<sup>3</sup></span></b></p>", "ID": "fce721b1-92e2-44d3-b2fc-fcf78e3201af", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": " ", "ParentId": "80e83219-f872-4b03-a03b-b4efc4066074"}, {"Element": "<b><span style=\"font-size:10.0pt\">IDFS</span></b>", "ID": "3d066c43-4792-45a9-abae-ee98a185cadc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fce721b1-92e2-44d3-b2fc-fcf78e3201af"}, {"Element": "<span style=\"font-size:10.0pt\">IDFS</span>", "ID": "c1f7de7d-6798-49f9-a765-85a3b845da66", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "IDFS", "ParentId": "3d066c43-4792-45a9-abae-ee98a185cadc"}, {"Element": "<b><span style=\"font-size:10.0pt\">including\n  second primary non-breast cancer<sup>3</sup></span></b>", "ID": "cda8f2c5-6282-4e8b-9eba-ca5ebf0fb677", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fce721b1-92e2-44d3-b2fc-fcf78e3201af"}, {"Element": "<span style=\"font-size:10.0pt\">including\n  second primary non-breast cancer<sup>3</sup></span>", "ID": "e4ac8bff-ec12-4687-bdaa-51548b7f73f7", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "including   second primary non-breast cancer", "ParentId": "cda8f2c5-6282-4e8b-9eba-ca5ebf0fb677"}, {"Element": "<sup>3</sup>", "ID": "ff073cc4-08eb-4555-8c47-a8cf1d2a7ffc", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "e4ac8bff-ec12-4687-bdaa-51548b7f73f7"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>\n</td>", "ID": "f81526fd-cd8b-4ace-9789-36853a8ad278", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "49b490d0-6fd9-49fc-833e-e772799938fa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>", "ID": "384c1fba-5e41-4b17-854b-ca282421efc4", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f81526fd-cd8b-4ace-9789-36853a8ad278"}, {"Element": "<span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span>", "ID": "87b44e45-0938-4481-b3e8-0b007b9fa403", "Styles": "font-size:8.0pt;font-family:\"CourierStd\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "384c1fba-5e41-4b17-854b-ca282421efc4"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">95 (12.8%)</span></p>\n</td>\n</tr>", "ID": "a669b0a3-e970-4cd7-a5f5-a4f00f9bed73", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>\n</td>", "ID": "0025ad37-078c-4312-a000-f69822304775", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a669b0a3-e970-4cd7-a5f5-a4f00f9bed73"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span></p>", "ID": "c9fb9281-7890-495c-b74a-169c3e29f820", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0025ad37-078c-4312-a000-f69822304775"}, {"Element": "<span style=\"font-size:10.0pt\">Number\n  (%) of patients with event </span>", "ID": "d2ddaca1-0feb-4b2e-9db2-cdb71e75c939", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Number   (%) of patients with event ", "ParentId": "c9fb9281-7890-495c-b74a-169c3e29f820"}, {"Element": "<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>\n</td>", "ID": "b754f0b6-db52-4319-ad49-93f7342307c5", "Styles": "width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a669b0a3-e970-4cd7-a5f5-a4f00f9bed73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>", "ID": "1dce955a-87c6-460e-99ef-d669d7a97e50", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b754f0b6-db52-4319-ad49-93f7342307c5"}, {"Element": "<span style=\"font-size:10.0pt\">167 (22.5%)</span>", "ID": "c3775452-8f34-44fd-9389-50b7bd55c6d4", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "167 (22.5%)", "ParentId": "1dce955a-87c6-460e-99ef-d669d7a97e50"}, {"Element": "<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">95 (12.8%)</span></p>\n</td>", "ID": "e38df5ec-fbfc-40a1-9c6c-ecd7b8e92377", "Styles": "width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a669b0a3-e970-4cd7-a5f5-a4f00f9bed73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">95 (12.8%)</span></p>", "ID": "c6f28f8b-3236-42c3-b7e9-40a7a623eb3e", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e38df5ec-fbfc-40a1-9c6c-ecd7b8e92377"}, {"Element": "<span style=\"font-size:10.0pt\">95 (12.8%)</span>", "ID": "28cf25ef-d53a-4cab-b530-f844fc676de2", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "95 (12.8%)", "ParentId": "c6f28f8b-3236-42c3-b7e9-40a7a623eb3e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.51 [0.40, 0.66]</span></p>\n</td>\n</tr>", "ID": "f8f16f73-eeb5-4bba-9ebc-dc863da6b341", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR [95% CI]</span></p>\n</td>", "ID": "05b068ba-9aa4-4032-a057-c307e93d19f4", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "f8f16f73-eeb5-4bba-9ebc-dc863da6b341"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR [95% CI]</span></p>", "ID": "8d8a6c8a-63e8-40e8-8201-d46a2d241a5f", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "05b068ba-9aa4-4032-a057-c307e93d19f4"}, {"Element": "<span style=\"font-size:10.0pt\">HR [95% CI]</span>", "ID": "e8586ab9-808c-4d72-a335-cd530243b4ec", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "HR [95% CI]", "ParentId": "8d8a6c8a-63e8-40e8-8201-d46a2d241a5f"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.51 [0.40, 0.66]</span></p>\n</td>", "ID": "4711f135-339d-42c1-98bc-f4eaf84e08bd", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "f8f16f73-eeb5-4bba-9ebc-dc863da6b341"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.51 [0.40, 0.66]</span></p>", "ID": "fd038768-96b3-4895-8c80-a68416c4a98b", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4711f135-339d-42c1-98bc-f4eaf84e08bd"}, {"Element": "<span style=\"font-size:10.0pt\">0.51 [0.40, 0.66]</span>", "ID": "97607f38-e1b6-4503-a849-d76d11c0d506", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.51 [0.40, 0.66]", "ParentId": "fd038768-96b3-4895-8c80-a68416c4a98b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>\n</tr>", "ID": "fdac604f-fbd9-49c3-8a54-8489adc5ae4d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>", "ID": "cc852f52-21ce-436b-ad3f-f60f2294de58", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fdac604f-fbd9-49c3-8a54-8489adc5ae4d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>", "ID": "10484722-d2db-42cf-9944-733347b5ea6c", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cc852f52-21ce-436b-ad3f-f60f2294de58"}, {"Element": "<span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span>", "ID": "7e92264a-8419-48bb-b1db-2775831af987", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "p-value   (Log-Rank test, unstratified)", "ParentId": "10484722-d2db-42cf-9944-733347b5ea6c"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>", "ID": "d7f2ff2b-0720-4af1-a70b-12780a6c8e01", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fdac604f-fbd9-49c3-8a54-8489adc5ae4d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>", "ID": "4ea7c1e9-c640-4179-8f85-aecab0cd8210", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7f2ff2b-0720-4af1-a70b-12780a6c8e01"}, {"Element": "<span style=\"font-size:10.0pt\">&lt;0.0001</span>", "ID": "5cde6d9b-b0c2-48a7-85ba-e70fd40b3fce", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "<0.0001", "ParentId": "4ea7c1e9-c640-4179-8f85-aecab0cd8210"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.7 [85.18, 90.18]</span></p>\n</td>\n</tr>", "ID": "db2413fe-1b68-4a5a-828a-af88649af02d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>\n</td>", "ID": "27cada4e-95bf-4bda-99ab-84797c23997a", "Styles": "width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "db2413fe-1b68-4a5a-828a-af88649af02d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span></p>", "ID": "a7796ad2-91b6-417c-a525-01b3efbb3806", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "27cada4e-95bf-4bda-99ab-84797c23997a"}, {"Element": "<span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI] </span>", "ID": "f78cb19d-811f-43d0-adc6-d969b7991fb1", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3   year event-free rate,% [95% CI] ", "ParentId": "a7796ad2-91b6-417c-a525-01b3efbb3806"}, {"Element": "<sup>2</sup>", "ID": "7c957df3-22ca-4114-b203-547924bd9322", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "f78cb19d-811f-43d0-adc6-d969b7991fb1"}, {"Element": "<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>\n</td>", "ID": "8c245b56-280c-40bb-942c-5beb06bd2c5d", "Styles": "width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "db2413fe-1b68-4a5a-828a-af88649af02d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>", "ID": "7b399132-90b9-47f1-8cef-a309ad448d4b", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c245b56-280c-40bb-942c-5beb06bd2c5d"}, {"Element": "<span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span>", "ID": "42a435ba-98c4-4163-9e2c-43ae6781581e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "76.9 [73.65, 80.14]", "ParentId": "7b399132-90b9-47f1-8cef-a309ad448d4b"}, {"Element": "<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.7 [85.18, 90.18]</span></p>\n</td>", "ID": "debdb97d-04f2-4a56-bcc6-037bb1e348dd", "Styles": "width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "db2413fe-1b68-4a5a-828a-af88649af02d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.7 [85.18, 90.18]</span></p>", "ID": "34b05c83-f094-47e3-bc75-68b5c54d9ae7", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "debdb97d-04f2-4a56-bcc6-037bb1e348dd"}, {"Element": "<span style=\"font-size:10.0pt\">87.7 [85.18, 90.18]</span>", "ID": "d82cbd14-c55d-4c2d-ba7f-eebf1e991847", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "87.7 [85.18, 90.18]", "ParentId": "34b05c83-f094-47e3-bc75-68b5c54d9ae7"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Disease-Free\n  Survival (DFS)<sup>3</sup> </span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "4b8b2c4f-19e1-43ef-9294-ab00977a8af4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Disease-Free\n  Survival (DFS)<sup>3</sup> </span></b></p>\n</td>", "ID": "3b0f3558-bb6a-41c6-9705-ce8b7046dc65", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "4b8b2c4f-19e1-43ef-9294-ab00977a8af4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Disease-Free\n  Survival (DFS)<sup>3</sup> </span></b></p>", "ID": "c6763a58-23e9-4d06-b18a-9b77585c2a32", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3b0f3558-bb6a-41c6-9705-ce8b7046dc65"}, {"Element": "<b><span style=\"font-size:10.0pt\">Disease-Free\n  Survival (DFS)<sup>3</sup> </span></b>", "ID": "64b3a950-879e-4aba-8d79-ceaa7a48d2b5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c6763a58-23e9-4d06-b18a-9b77585c2a32"}, {"Element": "<span style=\"font-size:10.0pt\">Disease-Free\n  Survival (DFS)<sup>3</sup> </span>", "ID": "7421265e-7306-47f4-a28a-f93ed3160616", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Disease-Free   Survival (DFS) ", "ParentId": "64b3a950-879e-4aba-8d79-ceaa7a48d2b5"}, {"Element": "<sup>3</sup>", "ID": "d2201126-4e8f-4319-bb4e-306a8fd7ab1d", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "7421265e-7306-47f4-a28a-f93ed3160616"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>\n</td>", "ID": "c00314e7-5d55-4f33-bd22-bc91a7c0e12c", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "4b8b2c4f-19e1-43ef-9294-ab00977a8af4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">\u00a0</span></b></p>", "ID": "6d3bac6a-8048-4d6a-9834-268653613a90", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c00314e7-5d55-4f33-bd22-bc91a7c0e12c"}, {"Element": "<b><span style=\"font-size:10.0pt\">\u00a0</span></b>", "ID": "b2cf811c-812c-4f29-b4de-bab9bdc2ce0d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6d3bac6a-8048-4d6a-9834-268653613a90"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a0</span>", "ID": "d853e4bc-7023-4fc2-a377-de87a708e35f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "b2cf811c-812c-4f29-b4de-bab9bdc2ce0d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">98 (13.2%)</span></p>\n</td>\n</tr>", "ID": "7c6ca4c8-edd0-488e-9780-ee4ad49219b0", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>", "ID": "52fcd50a-e4af-4b09-a2af-78d472da5304", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "7c6ca4c8-edd0-488e-9780-ee4ad49219b0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>", "ID": "93ffbe47-d717-4147-8f25-96c867011a05", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52fcd50a-e4af-4b09-a2af-78d472da5304"}, {"Element": "<span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span>", "ID": "2604281e-4d94-4963-af9a-ea45d91308d9", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Number   (%) of patients with event", "ParentId": "93ffbe47-d717-4147-8f25-96c867011a05"}, {"Element": "<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>\n</td>", "ID": "d59bcebf-8ddf-4f81-9ab2-5475127ab195", "Styles": "width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "7c6ca4c8-edd0-488e-9780-ee4ad49219b0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">167 (22.5%)</span></p>", "ID": "96de4381-7056-4507-8f0e-e1cc1d23ba8f", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d59bcebf-8ddf-4f81-9ab2-5475127ab195"}, {"Element": "<span style=\"font-size:10.0pt\">167 (22.5%)</span>", "ID": "a95d2647-8586-43cf-86c6-326e0257a696", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "167 (22.5%)", "ParentId": "96de4381-7056-4507-8f0e-e1cc1d23ba8f"}, {"Element": "<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">98 (13.2%)</span></p>\n</td>", "ID": "a3715d42-325d-44b7-8185-ac31f59e4aec", "Styles": "width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "7c6ca4c8-edd0-488e-9780-ee4ad49219b0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">98 (13.2%)</span></p>", "ID": "3ccb6b1a-04a6-405d-a5f7-88b5c93162d2", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a3715d42-325d-44b7-8185-ac31f59e4aec"}, {"Element": "<span style=\"font-size:10.0pt\">98 (13.2%)</span>", "ID": "93ab5277-6d19-4192-ac88-3364d814cab6", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "98 (13.2%)", "ParentId": "3ccb6b1a-04a6-405d-a5f7-88b5c93162d2"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.53 [0.41,\n  0.68]</span></p>\n</td>\n</tr>", "ID": "c76a9176-f4e5-4f6e-a06f-d94dbd122569", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>", "ID": "a3aa935f-75cf-4658-a7b0-c6884e799aa8", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c76a9176-f4e5-4f6e-a06f-d94dbd122569"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>", "ID": "dd8f5669-6df8-4a51-af83-7ed2717f08fb", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a3aa935f-75cf-4658-a7b0-c6884e799aa8"}, {"Element": "<span style=\"font-size:10.0pt\">HR\n  [95% CI]</span>", "ID": "8fccbd0a-b113-4054-a764-83bf87c5fd39", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "HR   [95% CI]", "ParentId": "dd8f5669-6df8-4a51-af83-7ed2717f08fb"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.53 [0.41,\n  0.68]</span></p>\n</td>", "ID": "e1267f47-cb76-45a5-b3ca-656e076350b8", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c76a9176-f4e5-4f6e-a06f-d94dbd122569"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">\u00a00.53 [0.41,\n  0.68]</span></p>", "ID": "cb24cb1b-d644-4fd1-95fc-241802b522e3", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e1267f47-cb76-45a5-b3ca-656e076350b8"}, {"Element": "<span style=\"font-size:10.0pt\">\u00a00.53 [0.41,\n  0.68]</span>", "ID": "bb7c9bd9-ed1b-4da9-91e0-cf034ab1891d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a00.53 [0.41,   0.68]", "ParentId": "cb24cb1b-d644-4fd1-95fc-241802b522e3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>\n</tr>", "ID": "cd38ca95-eccc-447c-8ecb-3a0683183497", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>", "ID": "2dd2ce6c-38ba-47af-b686-16839791030e", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "cd38ca95-eccc-447c-8ecb-3a0683183497"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>", "ID": "32db2c22-77e5-4888-844e-18bddc91d34e", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2dd2ce6c-38ba-47af-b686-16839791030e"}, {"Element": "<span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span>", "ID": "f481c3b0-918a-47da-941c-6d80db5ee87a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "p-value   (Log-Rank test, unstratified)", "ParentId": "32db2c22-77e5-4888-844e-18bddc91d34e"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>\n</td>", "ID": "e21a4e09-8b07-4316-87fe-4172ff6e5dc7", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "cd38ca95-eccc-447c-8ecb-3a0683183497"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">&lt;0.0001</span></p>", "ID": "ee45af75-6590-4a23-aebb-8c2c44521d63", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e21a4e09-8b07-4316-87fe-4172ff6e5dc7"}, {"Element": "<span style=\"font-size:10.0pt\">&lt;0.0001</span>", "ID": "9dc9c78a-a126-4eae-a62d-742b11965dd5", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "<0.0001", "ParentId": "ee45af75-6590-4a23-aebb-8c2c44521d63"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.41 [84.88, 89.93]</span></p>\n</td>\n</tr>", "ID": "99ff5cf4-466e-41aa-a086-5be4405db036", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>\n</td>", "ID": "febe7588-085f-4d72-9035-406657f87776", "Styles": "width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "99ff5cf4-466e-41aa-a086-5be4405db036"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>", "ID": "b1e5d95e-e191-4ecb-967f-9d3849690c5b", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "febe7588-085f-4d72-9035-406657f87776"}, {"Element": "<span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span>", "ID": "abd87ed5-8798-49ff-9631-798f6be7331a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3   year event-free rate,% [95% CI]", "ParentId": "b1e5d95e-e191-4ecb-967f-9d3849690c5b"}, {"Element": "<sup>2</sup>", "ID": "cb9ef814-2c83-4d1d-a8b0-464bfa5b51d5", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "abd87ed5-8798-49ff-9631-798f6be7331a"}, {"Element": "<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>\n</td>", "ID": "5fb8979a-7775-4d63-93dd-5edbcdd3de46", "Styles": "width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "99ff5cf4-466e-41aa-a086-5be4405db036"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span></p>", "ID": "4380ace7-efb7-4475-a000-1b7bf4448b09", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5fb8979a-7775-4d63-93dd-5edbcdd3de46"}, {"Element": "<span style=\"font-size:10.0pt\">76.9 [73.65, 80.14]</span>", "ID": "1e9ea8eb-7aff-4904-b4a7-20a1ec4493a3", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "76.9 [73.65, 80.14]", "ParentId": "4380ace7-efb7-4475-a000-1b7bf4448b09"}, {"Element": "<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.41 [84.88, 89.93]</span></p>\n</td>", "ID": "70f6b873-faa8-41af-987c-df9fdba38b33", "Styles": "width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "99ff5cf4-466e-41aa-a086-5be4405db036"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">87.41 [84.88, 89.93]</span></p>", "ID": "d877fe6f-73e5-4612-905c-5f7fb33d4b01", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "70f6b873-faa8-41af-987c-df9fdba38b33"}, {"Element": "<span style=\"font-size:10.0pt\">87.41 [84.88, 89.93]</span>", "ID": "6dfb02b2-f83e-42c8-8d56-99e3eb14e8ac", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "87.41 [84.88, 89.93]", "ParentId": "d877fe6f-73e5-4612-905c-5f7fb33d4b01"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Distant\n  recurrence-free interval (DRFI)<sup>3</sup></span></b></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>\n</td>\n</tr>", "ID": "c8f5eee7-9a6f-4bd8-ace3-41bce1c48735", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Distant\n  recurrence-free interval (DRFI)<sup>3</sup></span></b></p>\n</td>", "ID": "d9cdfe2a-007b-4023-846d-1666b3035cbc", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c8f5eee7-9a6f-4bd8-ace3-41bce1c48735"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><b><span style=\"font-size:10.0pt\">Distant\n  recurrence-free interval (DRFI)<sup>3</sup></span></b></p>", "ID": "fc9e0442-0095-455a-8b93-2a39d3cbf52a", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d9cdfe2a-007b-4023-846d-1666b3035cbc"}, {"Element": "<b><span style=\"font-size:10.0pt\">Distant\n  recurrence-free interval (DRFI)<sup>3</sup></span></b>", "ID": "8058b030-68e9-4d0f-8dbe-c4d7c79dd842", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fc9e0442-0095-455a-8b93-2a39d3cbf52a"}, {"Element": "<span style=\"font-size:10.0pt\">Distant\n  recurrence-free interval (DRFI)<sup>3</sup></span>", "ID": "ccb4acea-8f44-46a3-848e-f78d997c3acf", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Distant   recurrence-free interval (DRFI)", "ParentId": "8058b030-68e9-4d0f-8dbe-c4d7c79dd842"}, {"Element": "<sup>3</sup>", "ID": "770a07b8-f74a-441b-a41b-5deb35e999d1", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "ccb4acea-8f44-46a3-848e-f78d997c3acf"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>\n</td>", "ID": "ff817c89-a355-40ee-8e6a-6d8e8e42e807", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c8f5eee7-9a6f-4bd8-ace3-41bce1c48735"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span></p>", "ID": "9126a0ca-2c88-4447-98d8-050c52be05cd", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff817c89-a355-40ee-8e6a-6d8e8e42e807"}, {"Element": "<span style='font-size:8.0pt;font-family:\"CourierStd\",serif'>\u00a0</span>", "ID": "bfa421e6-2451-4a2a-a438-8346e2c96291", "Styles": "font-size:8.0pt;font-family:\"CourierStd\",serif", "Classes": "None", "Text": "\u00a0", "ParentId": "9126a0ca-2c88-4447-98d8-050c52be05cd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">121 (16.3%)</span></p>\n</td>\n<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">78 (10.5%)</span></p>\n</td>\n</tr>", "ID": "99accd34-9485-4618-b762-226d22740eb1", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>\n</td>", "ID": "bd995bb3-ec95-400b-9205-a3ced1615f71", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "99accd34-9485-4618-b762-226d22740eb1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span></p>", "ID": "cf9a47b2-74ab-4f9c-91fa-08756afc4eb8", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd995bb3-ec95-400b-9205-a3ced1615f71"}, {"Element": "<span style=\"font-size:10.0pt\">Number\n  (%) of patients with event</span>", "ID": "54e3bda6-9711-4e16-a70a-5272219f82cc", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Number   (%) of patients with event", "ParentId": "cf9a47b2-74ab-4f9c-91fa-08756afc4eb8"}, {"Element": "<td style=\"width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">121 (16.3%)</span></p>\n</td>", "ID": "f4300438-ea3b-43cd-ab0e-11b57cce4ebb", "Styles": "width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "99accd34-9485-4618-b762-226d22740eb1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">121 (16.3%)</span></p>", "ID": "43ad5bda-b770-4954-96d3-18ef81d470f5", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f4300438-ea3b-43cd-ab0e-11b57cce4ebb"}, {"Element": "<span style=\"font-size:10.0pt\">121 (16.3%)</span>", "ID": "c3c2f1ac-6aca-4a06-af99-90ee545d9e27", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "121 (16.3%)", "ParentId": "43ad5bda-b770-4954-96d3-18ef81d470f5"}, {"Element": "<td style=\"width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">78 (10.5%)</span></p>\n</td>", "ID": "f3c0b186-f1a3-47fd-a5b7-412871de50d2", "Styles": "width:106.35pt;border:none;border-right:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "99accd34-9485-4618-b762-226d22740eb1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">78 (10.5%)</span></p>", "ID": "0a8ed5ad-7313-4792-b799-c2ab1abf7175", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f3c0b186-f1a3-47fd-a5b7-412871de50d2"}, {"Element": "<span style=\"font-size:10.0pt\">78 (10.5%)</span>", "ID": "643553b7-b622-4b82-855d-3570503db154", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "78 (10.5%)", "ParentId": "0a8ed5ad-7313-4792-b799-c2ab1abf7175"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.60 [0.45, 0.79]</span><sup><span style=\"font-size:9.0pt\"> </span></sup></p>\n</td>\n</tr>", "ID": "a3f909dc-a4fd-4160-91e2-0bda238b0aeb", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>\n</td>", "ID": "04657c93-0c79-4826-8afd-0e1e72f31f46", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a3f909dc-a4fd-4160-91e2-0bda238b0aeb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">HR\n  [95% CI]</span></p>", "ID": "8bc4c25a-9b23-4a83-a57d-9c5cede643a7", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04657c93-0c79-4826-8afd-0e1e72f31f46"}, {"Element": "<span style=\"font-size:10.0pt\">HR\n  [95% CI]</span>", "ID": "26facba4-4a80-46d0-8109-95493156c1a0", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "HR   [95% CI]", "ParentId": "8bc4c25a-9b23-4a83-a57d-9c5cede643a7"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.60 [0.45, 0.79]</span><sup><span style=\"font-size:9.0pt\"> </span></sup></p>\n</td>", "ID": "82d162aa-f0b0-4594-adf2-13342a1865ad", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a3f909dc-a4fd-4160-91e2-0bda238b0aeb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.60 [0.45, 0.79]</span><sup><span style=\"font-size:9.0pt\"> </span></sup></p>", "ID": "3e959082-18b4-424d-b282-032634519bc9", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "82d162aa-f0b0-4594-adf2-13342a1865ad"}, {"Element": "<span style=\"font-size:10.0pt\">0.60 [0.45, 0.79]</span>", "ID": "cebea2f5-39ca-4174-8f85-c4f86554951b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.60 [0.45, 0.79]", "ParentId": "3e959082-18b4-424d-b282-032634519bc9"}, {"Element": "<sup><span style=\"font-size:9.0pt\"> </span></sup>", "ID": "c13fb458-05ec-4736-b92b-724154376377", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e959082-18b4-424d-b282-032634519bc9"}, {"Element": "<span style=\"font-size:9.0pt\"> </span>", "ID": "5b27ef0f-8a5c-4702-be56-fa28ecb33d3a", "Styles": "font-size:9.0pt", "Classes": "None", "Text": " ", "ParentId": "c13fb458-05ec-4736-b92b-724154376377"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0003</span></p>\n</td>\n</tr>", "ID": "e1bcfcbe-7491-484c-9299-641d0294174f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>\n</td>", "ID": "d93cc684-9881-47ef-89de-ff6cb53f353d", "Styles": "width:218.85pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "e1bcfcbe-7491-484c-9299-641d0294174f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span></p>", "ID": "652b19ed-1f70-4e31-98ad-7f6d5971ed07", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d93cc684-9881-47ef-89de-ff6cb53f353d"}, {"Element": "<span style=\"font-size:10.0pt\">p-value\n  (Log-Rank test, unstratified)</span>", "ID": "75d34201-767c-4e34-bcce-8939cf2348fc", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "p-value   (Log-Rank test, unstratified)", "ParentId": "652b19ed-1f70-4e31-98ad-7f6d5971ed07"}, {"Element": "<td colspan=\"2\" style=\"width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"292\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0003</span></p>\n</td>", "ID": "9d965e8f-7eef-4a54-bec4-71760c73e992", "Styles": "width:218.85pt;border:none;\n  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "e1bcfcbe-7491-484c-9299-641d0294174f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">0.0003</span></p>", "ID": "473b4f60-a411-4d28-8e09-570973b7d713", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d965e8f-7eef-4a54-bec4-71760c73e992"}, {"Element": "<span style=\"font-size:10.0pt\">0.0003</span>", "ID": "d02574c9-132d-4dcc-845c-8d6f29485aa0", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0003", "ParentId": "473b4f60-a411-4d28-8e09-570973b7d713"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>\n</td>\n<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">83.0 [80.10, 85.92 ]</span></p>\n</td>\n<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">89.7 [87.37, 92.01 ]</span></p>\n</td>\n</tr>", "ID": "8024a007-754f-478f-8bb1-d57a3c12caec", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "5b33625f-fd3b-42b7-8f85-52cf050fa782"}, {"Element": "<td style=\"width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"292\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>\n</td>", "ID": "9fd537c1-95df-43a7-b807-69607fd0512e", "Styles": "width:218.85pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8024a007-754f-478f-8bb1-d57a3c12caec"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid\"><span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span></p>", "ID": "6cc6f12d-efad-4ee7-89fa-2cc9d6a38ea8", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;\n  line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9fd537c1-95df-43a7-b807-69607fd0512e"}, {"Element": "<span style=\"font-size:10.0pt\">3\n  year event-free rate<sup>2</sup>,% [95% CI]</span>", "ID": "4f042cab-066e-4842-bacb-9012efa6067a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3   year event-free rate,% [95% CI]", "ParentId": "6cc6f12d-efad-4ee7-89fa-2cc9d6a38ea8"}, {"Element": "<sup>2</sup>", "ID": "3bbed803-867e-4e65-b0e1-ff813d91cf3c", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "4f042cab-066e-4842-bacb-9012efa6067a"}, {"Element": "<td style=\"width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"150\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">83.0 [80.10, 85.92 ]</span></p>\n</td>", "ID": "02376b53-1857-4577-9d65-8b831d478b3c", "Styles": "width:112.5pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8024a007-754f-478f-8bb1-d57a3c12caec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">83.0 [80.10, 85.92 ]</span></p>", "ID": "ff34e7b5-6308-4294-87d6-5899649fdbd4", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02376b53-1857-4577-9d65-8b831d478b3c"}, {"Element": "<span style=\"font-size:10.0pt\">83.0 [80.10, 85.92 ]</span>", "ID": "c133770b-811b-418f-a79d-f78e1866ea46", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "83.0 [80.10, 85.92 ]", "ParentId": "ff34e7b5-6308-4294-87d6-5899649fdbd4"}, {"Element": "<td style=\"width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"142\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">89.7 [87.37, 92.01 ]</span></p>\n</td>", "ID": "5bdeafb0-2eb3-4259-807d-25d3c5a91139", "Styles": "width:106.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8024a007-754f-478f-8bb1-d57a3c12caec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><span style=\"font-size:10.0pt\">89.7 [87.37, 92.01 ]</span></p>", "ID": "72267cbc-41a2-49ee-9782-9f01ef69d528", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5bdeafb0-2eb3-4259-807d-25d3c5a91139"}, {"Element": "<span style=\"font-size:10.0pt\">89.7 [87.37, 92.01 ]</span>", "ID": "6c1a2851-9617-4938-ae52-64ec0e3569c1", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "89.7 [87.37, 92.01 ]", "ParentId": "72267cbc-41a2-49ee-9782-9f01ef69d528"}, {"Element": "<p class=\"MsoNormal\"><b><span style=\"font-size:10.0pt\">Data from first interim\nanalysis 25 July 2018</span></b></p>", "ID": "4daa5d4a-87a0-4235-b2af-6c8744b5c65c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><span style=\"font-size:10.0pt\">Data from first interim\nanalysis 25 July 2018</span></b>", "ID": "d139294b-3249-4f3d-b829-6fcde67f4a43", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4daa5d4a-87a0-4235-b2af-6c8744b5c65c"}, {"Element": "<span style=\"font-size:10.0pt\">Data from first interim\nanalysis 25 July 2018</span>", "ID": "e9c6c7eb-8d41-47e1-b5cc-1c5925358ce3", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Data from first interim analysis 25 July 2018", "ParentId": "d139294b-3249-4f3d-b829-6fcde67f4a43"}, {"Element": "<p class=\"MsoNormal\"><b><span style=\"font-size:10.0pt\">Key to abbreviations\n(Table6): </span></b><span style=\"font-size:10.0pt\">HR: Hazard Ratio; CI:\nConfidence Intervals, </span></p>", "ID": "e4c9caf0-74fc-4224-9320-b75f2edb419a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><span style=\"font-size:10.0pt\">Key to abbreviations\n(Table6): </span></b>", "ID": "6b9b57e7-14a3-4011-8381-644123dc686f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e4c9caf0-74fc-4224-9320-b75f2edb419a"}, {"Element": "<span style=\"font-size:10.0pt\">Key to abbreviations\n(Table6): </span>", "ID": "4decc7ea-a556-4478-be7d-757aa3ff6a56", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Key to abbreviations (Table6): ", "ParentId": "6b9b57e7-14a3-4011-8381-644123dc686f"}, {"Element": "<span style=\"font-size:10.0pt\">HR: Hazard Ratio; CI:\nConfidence Intervals, </span>", "ID": "5a8c4082-4d1f-4c16-8a6c-b4d87692447a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "HR: Hazard Ratio; CI: Confidence Intervals, ", "ParentId": "e4c9caf0-74fc-4224-9320-b75f2edb419a"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\"><span style=\"font-size:10.0pt\">1. Hierarchical testing\napplied for IDFS and OS </span></p>", "ID": "22750365-7bbd-4b74-9260-a0e698b88b82", "Styles": "text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-size:10.0pt\">1. Hierarchical testing\napplied for IDFS and OS </span>", "ID": "d3dc82fa-1f61-4585-bc61-5861c24dbe47", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1. Hierarchical testing applied for IDFS and OS ", "ParentId": "22750365-7bbd-4b74-9260-a0e698b88b82"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\"><span style=\"font-size:10.0pt\">2. 3-year event-free rate\nand 5-year survival rate derived from Kaplan-Meier estimates</span></p>", "ID": "cde0d4c8-7a36-4d9b-8cf7-644095c8f3c5", "Styles": "text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-size:10.0pt\">2. 3-year event-free rate\nand 5-year survival rate derived from Kaplan-Meier estimates</span>", "ID": "12b5d1aa-3976-40e5-93df-03c0facb7d49", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "2. 3-year event-free rate and 5-year survival rate derived from Kaplan-Meier estimates", "ParentId": "cde0d4c8-7a36-4d9b-8cf7-644095c8f3c5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\"><span style=\"font-size:10.0pt\">3. These secondary\nendpoints were not adjusted for multiplicity</span><span style=\"font-size:10.0pt\">\n</span></p>", "ID": "b95bb8d3-aa23-43bc-b47c-f093975d488a", "Styles": "text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-size:10.0pt\">3. These secondary\nendpoints were not adjusted for multiplicity</span>", "ID": "98217ad9-dfea-4572-bb7a-1fa667d21784", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3. These secondary endpoints were not adjusted for multiplicity", "ParentId": "b95bb8d3-aa23-43bc-b47c-f093975d488a"}, {"Element": "<span style=\"font-size:10.0pt\">\n</span>", "ID": "0b78dd57-678e-4225-923b-2bbc9b03d104", "Styles": "font-size:10.0pt", "Classes": "None", "Text": " ", "ParentId": "b95bb8d3-aa23-43bc-b47c-f093975d488a"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\">\u00a0</p>", "ID": "180751ad-5ee5-49cf-9c7b-a42994db72ee", "Styles": "text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none\">\u00a0</p>", "ID": "d514a6f4-e94c-46b9-864c-7a3cd6474463", "Styles": "text-align:justify;text-justify:inter-ideograph;\ntext-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"FigureHolder\" style=\"text-align:justify;text-justify:inter-ideograph\"><b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Figure\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier\nCurve of Invasive Disease-Free Survival in KATHERINE</span></b></p>", "ID": "07cdbbb7-7b04-42ac-a2e4-7b48fe2fd03f", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['FigureHolder']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Figure\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier\nCurve of Invasive Disease-Free Survival in KATHERINE</span></b>", "ID": "62ea0c6f-dfb5-497d-bfa3-e4c6d1a3b76f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "07cdbbb7-7b04-42ac-a2e4-7b48fe2fd03f"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Figure\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier\nCurve of Invasive Disease-Free Survival in KATHERINE</span>", "ID": "041184bb-4521-4582-888e-dd8f7dde99b3", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "Figure\u00a01\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-Meier Curve of Invasive Disease-Free Survival in KATHERINE", "ParentId": "62ea0c6f-dfb5-497d-bfa3-e4c6d1a3b76f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><img border=\"0\" height=\"406\" id=\"Picture 3\" src=\"Kadcyla%20II-45%20EN%20PIclean_files/image001.gif\" width=\"605\"/></p>", "ID": "354420a1-bb4e-47aa-966b-a419f340630b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<img border=\"0\" height=\"406\" id=\"Picture 3\" src=\"Kadcyla%20II-45%20EN%20PIclean_files/image001.gif\" width=\"605\"/>", "ID": "f23c5340-b1e7-4a2b-9231-b4361b0ba9f5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "354420a1-bb4e-47aa-966b-a419f340630b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "6fd6298e-2009-4639-bfbb-796a8c7a36ca", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "9fc15de4-9cda-4cae-9e72-10e51e5e1df8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">In KATHERINE, consistent treatment benefit of trastuzumab\nemtansine for IDFS was seen in all the pre\u2011specified subgroups evaluated,\nsupporting the overall result. </p>", "ID": "14bd9679-01c9-42f1-badf-8b679646e40a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In KATHERINE, consistent treatment benefit of trastuzumab emtansine for IDFS was seen in all the pre\u2011specified subgroups evaluated, supporting the overall result. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "139c8deb-f4da-4815-b362-8003fcf0fd2a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;page-break-after:\navoid\"><i><u>Metastatic Breast Cancer</u></i></p>", "ID": "ea3aab09-8c25-4c35-aea1-4cadd1c422a2", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i><u>Metastatic Breast Cancer</u></i>", "ID": "e6fbe792-47d0-4149-9dfd-caab0854f873", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea3aab09-8c25-4c35-aea1-4cadd1c422a2"}, {"Element": "<u>Metastatic Breast Cancer</u>", "ID": "d310779f-7eb9-441b-80d7-246e70c8e7d0", "Styles": "None", "Classes": "None", "Text": "Metastatic Breast Cancer", "ParentId": "e6fbe792-47d0-4149-9dfd-caab0854f873"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>\u00a0</i></p>", "ID": "7ce8b063-8690-4d51-a21c-c906bf3d1de7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "bcf18ce1-175c-4581-8d65-ece2319d0a8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7ce8b063-8690-4d51-a21c-c906bf3d1de7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u>TDM4370g/BO21977(EMILIA)</u></i></p>", "ID": "8a53dbf8-3b6c-48c3-abf0-589607cf2f0e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i><u>TDM4370g/BO21977(EMILIA)</u></i>", "ID": "5bc3d4d9-d729-49bd-9764-a2c12bcb8fd8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8a53dbf8-3b6c-48c3-abf0-589607cf2f0e"}, {"Element": "<u>TDM4370g/BO21977(EMILIA)</u>", "ID": "bdf02a82-8986-4fea-a523-66c43eb7e41f", "Styles": "None", "Classes": "None", "Text": "TDM4370g/BO21977(EMILIA)", "ParentId": "5bc3d4d9-d729-49bd-9764-a2c12bcb8fd8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "a53844a1-48dd-40c7-9cb6-12a38765a7a9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "060efe5e-24ef-4403-afd3-d9784491082e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a53844a1-48dd-40c7-9cb6-12a38765a7a9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">A Phase\u00a0III, randomised,\nmulticentre, international, open\u2011label clinical study was conducted in\npatients with HER2\u2011positive unresectable locally advanced breast cancer\n(LABC) or MBC who had received prior taxane and trastuzumab\u2011based\ntherapy, including patients who received prior therapy with trastuzumab and a\ntaxane in the adjuvant setting and who relapsed during or within six months of\ncompleting adjuvant therapy. Only patients with Eastern Cooperative Oncology\nGroup (ECOG) Performance Status 0 or 1 were eligible.<i>\u00a0</i>Prior to\nenrolment, breast tumour samples were required to be centrally confirmed for\nHER2\u2011positive status defined as a score of 3\u00a0+ by IHC or gene\namplification by ISH. Baseline patient and tumour characteristics were well\nbalanced between treatment groups. Patients with treated brain metastases were\neligible for enrollment if they did not require therapy to control symptoms.\nFor patients randomised to trastuzumab emtansine, the median age was 53\u00a0years,\nmost patients were female (99.8%), the majority were Caucasian (72%), and 57%\nhad oestrogen\u2011receptor and/or progesterone\u2011receptor positive\ndisease. The study compared the safety and efficacy of trastuzumab emtansine\nwith that of lapatinib plus capecitabine. A total of 991\u00a0patients were\nrandomised to trastuzumab emtansine or lapatinib plus capecitabine as follows:</p>", "ID": "2ecb1f25-624e-43fd-8070-3c59cca48fe3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "A Phase\u00a0III, randomised, multicentre, international, open\u2011label clinical study was conducted in patients with HER2\u2011positive unresectable locally advanced breast cancer (LABC) or MBC who had received prior taxane and trastuzumab\u2011based therapy, including patients who received prior therapy with trastuzumab and a taxane in the adjuvant setting and who relapsed during or within six months of completing adjuvant therapy. Only patients with Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 were eligible.Prior to enrolment, breast tumour samples were required to be centrally confirmed for HER2\u2011positive status defined as a score of 3\u00a0+ by IHC or gene amplification by ISH. Baseline patient and tumour characteristics were well balanced between treatment groups. Patients with treated brain metastases were eligible for enrollment if they did not require therapy to control symptoms. For patients randomised to trastuzumab emtansine, the median age was 53\u00a0years, most patients were female (99.8%), the majority were Caucasian (72%), and 57% had oestrogen\u2011receptor and/or progesterone\u2011receptor positive disease. The study compared the safety and efficacy of trastuzumab emtansine with that of lapatinib plus capecitabine. A total of 991\u00a0patients were randomised to trastuzumab emtansine or lapatinib plus capecitabine as follows:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "0e14244a-b541-4ea9-b931-b881d3484750", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ecb1f25-624e-43fd-8070-3c59cca48fe3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "836d3938-7a29-4f32-80bc-5e0a5b2a5716", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Trastuzumab\nemtansine arm: trastuzumab emtansine 3.6\u00a0mg/kg intravenously over 30\u201190\u00a0minutes\non Day\u00a01 of a 21\u2011day cycle </p>", "ID": "848eeea9-4e04-441c-a3a0-48bc7c6d4070", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Trastuzumab emtansine arm: trastuzumab emtansine 3.6\u00a0mg/kg intravenously over 30\u201190\u00a0minutes on Day\u00a01 of a 21\u2011day cycle ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "e36d7151-0b0f-4c8a-9a14-a32ceb014104", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "848eeea9-4e04-441c-a3a0-48bc7c6d4070"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Control\narm (lapatinib plus capecitabine): lapatinib 1250\u00a0mg/day orally once per\nday of a 21\u2011day cycle plus capecitabine 1000\u00a0mg/m<sup>2</sup> orally\ntwice daily on Days\u00a01\u201114 of a 21\u2011day cycle</p>", "ID": "1de206ba-6d58-4406-89de-3b8a94a04f17", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Control arm (lapatinib plus capecitabine): lapatinib 1250\u00a0mg/day orally once per day of a 21\u2011day cycle plus capecitabine 1000\u00a0mg/m orally twice daily on Days\u00a01\u201114 of a 21\u2011day cycle", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "7f937c04-add3-4bfe-bafe-eb3f08cf326f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1de206ba-6d58-4406-89de-3b8a94a04f17"}, {"Element": "<sup>2</sup>", "ID": "ccfc66e5-31df-43b8-9124-2f7ac6601b80", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "1de206ba-6d58-4406-89de-3b8a94a04f17"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7e36f694-4335-48ff-93f8-aa9311e67b98", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The co\u2011primary efficacy\nendpoints of the study were progression\u2011free survival (PFS) as assessed\nby an independent review committee (IRC) and overall survival (OS)\n(see\u00a0Table\u00a07\u00a0and\u00a0Figures 2\u00a0to\u00a03). </p>", "ID": "498171e0-78a7-4dca-913b-573758c7f1e4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The co\u2011primary efficacy endpoints of the study were progression\u2011free survival (PFS) as assessed by an independent review committee (IRC) and overall survival (OS) (see\u00a0Table\u00a07\u00a0and\u00a0Figures 2\u00a0to\u00a03). ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "1a25e9d0-ec7c-422a-b970-99935c148d6f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Time to symptom\u00a0progression, as defined by a 5\u2011point\ndecrease in the score derived from the Trials Outcome Index\u2011Breast (TOI\u2011B)\nsubscale of the Functional Assessment of Cancer Therapy\u2011Breast Quality of\nLife (FACT\u2011B\u00a0QoL) questionnaire was also assessed during the\nclinical study. A change of 5\u00a0points in the TOI\u2011B is considered\nclinically significant. Kadcyla delayed patient-reported time to symptom progression\nfor 7.1 months compared with 4.6 months for the control arm (Hazard Ratio 0.796\n(0.667, 0.951); p-value 0.0121). The data are from an open-label study and no\nfirm conclusions can be drawn.</p>", "ID": "40d31b27-dffa-4042-b6d8-9bca70864a36", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Time to symptom\u00a0progression, as defined by a 5\u2011point decrease in the score derived from the Trials Outcome Index\u2011Breast (TOI\u2011B) subscale of the Functional Assessment of Cancer Therapy\u2011Breast Quality of Life (FACT\u2011B\u00a0QoL) questionnaire was also assessed during the clinical study. A change of 5\u00a0points in the TOI\u2011B is considered clinically significant. Kadcyla delayed patient-reported time to symptom progression for 7.1 months compared with 4.6 months for the control arm (Hazard Ratio 0.796 (0.667, 0.951); p-value 0.0121). The data are from an open-label study and no firm conclusions can be drawn.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "398470de-4995-4331-9160-ddc43358e1fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Table\u00a07\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof efficacy from study TDM4370g/BO21977 (EMILIA) </b></p>", "ID": "88031e53-ab4f-4f82-a797-2df6a4adf922", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Table\u00a07\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary\nof efficacy from study TDM4370g/BO21977 (EMILIA) </b>", "ID": "e98a8f9b-a6f0-4534-aeb0-bc77542c9c08", "Styles": "None", "Classes": "None", "Text": "Table\u00a07\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Summary of efficacy from study TDM4370g/BO21977 (EMILIA) ", "ParentId": "88031e53-ab4f-4f82-a797-2df6a4adf922"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "b5139006-e732-48fd-a602-62c62a28f11f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "b246ea2b-f661-4b5b-adfa-5cd4299bbf12", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b5139006-e732-48fd-a602-62c62a28f11f"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:2.85pt;border-collapse:collapse;border:none\" width=\"586\">\n<thead>\n<tr style=\"page-break-inside:avoid;height:14.5pt\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"252\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></b></p>\n</td>\n<td style=\"width:139.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Lapatinib\n   + Capecitabine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0496</span></b></p>\n</td>\n<td style=\"width:110.95pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab\n   emtansine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0495</span></b></p>\n</td>\n</tr>\n</thead>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" width=\"586\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Primary\n  endpoints</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>IRC-assessed\n  progression-free survival (PFS)</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">304 (61.3%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">265 (53.5%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.4</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.6</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.650</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.549, 0.771)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test, stratified*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;\u00a00.0001</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Overall\n  Survival (OS)** </b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients who died </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">182 (36.7%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">149 (30.1%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of survival (months)</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">25.1</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">30.9</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.682</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.548, 0.849)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:4.0pt\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:4.0pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:4.0pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0006</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" width=\"586\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Key\n  secondary endpoints</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Investigator-assessed\n  PFS</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">335 (67.5%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">287 (58.0%)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">5.8</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.4</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (95% CI)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.658 (0.560, 0.774)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;0.0001</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Objective\n  response rate (ORR)</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><i>\u00a0\u00a0\u00a0\n  </i></b>Patients with measurable disease</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">389</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">397</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.35pt;line-height:12.0pt;page-break-after:avoid\">Number\n  of patients with OR (%)</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120 (30.8%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173 (43.6%)</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Difference (95% CI)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.7% (6.0, 19.4)</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">p-value (Mantel-Haenszel chi-squared test*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0002</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Duration\n  of objective response (months)</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-indent:8.8pt;line-height:12.0pt;page-break-after:\n  avoid\">Number of patients with OR</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Median 95% CI</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.5 (5.5, 7.2) </p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.6 (8.4, 20.8)</p>\n</td>\n</tr>\n</table>", "ID": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8", "Styles": "margin-left:2.85pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                             ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<thead>\n<tr style=\"page-break-inside:avoid;height:14.5pt\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"252\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></b></p>\n</td>\n<td style=\"width:139.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Lapatinib\n   + Capecitabine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0496</span></b></p>\n</td>\n<td style=\"width:110.95pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab\n   emtansine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0495</span></b></p>\n</td>\n</tr>\n</thead>", "ID": "a642bbba-92ec-4f2d-b095-70bdc8991986", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<tr style=\"page-break-inside:avoid;height:14.5pt\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"252\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></b></p>\n</td>\n<td style=\"width:139.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Lapatinib\n   + Capecitabine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0496</span></b></p>\n</td>\n<td style=\"width:110.95pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab\n   emtansine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0495</span></b></p>\n</td>\n</tr>", "ID": "128c0cfe-00be-415c-b504-c5ed5e6a7c9d", "Styles": "page-break-inside:avoid;height:14.5pt", "Classes": "None", "Text": "    ", "ParentId": "a642bbba-92ec-4f2d-b095-70bdc8991986"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"252\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></b></p>\n</td>", "ID": "352dca92-045c-4c7b-837c-35bec3012f20", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n   padding:0in 2.85pt 0in 2.85pt;height:14.5pt", "Classes": "None", "Text": "  ", "ParentId": "128c0cfe-00be-415c-b504-c5ed5e6a7c9d"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></b></p>", "ID": "3dac1016-9f2d-40b2-8b32-78939e7b11aa", "Styles": "text-align:center;page-break-after:\n   avoid", "Classes": "['Default']", "Text": "", "ParentId": "352dca92-045c-4c7b-837c-35bec3012f20"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span></b>", "ID": "377c7079-e69d-4ca0-852d-e93adf1b8169", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3dac1016-9f2d-40b2-8b32-78939e7b11aa"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">\u00a0</span>", "ID": "1bcdc36a-2917-4b0c-a8f6-ffb7dd4ed08e", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "\u00a0", "ParentId": "377c7079-e69d-4ca0-852d-e93adf1b8169"}, {"Element": "<td style=\"width:139.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Lapatinib\n   + Capecitabine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0496</span></b></p>\n</td>", "ID": "1f5f449c-c691-496a-9d1f-b92610c63931", "Styles": "width:139.5pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt", "Classes": "None", "Text": "   ", "ParentId": "128c0cfe-00be-415c-b504-c5ed5e6a7c9d"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Lapatinib\n   + Capecitabine</span></b></p>", "ID": "80b9f2bf-d76a-4c0d-9d1d-4bb54f24f024", "Styles": "text-align:center;page-break-after:\n   avoid", "Classes": "['Default']", "Text": "", "ParentId": "1f5f449c-c691-496a-9d1f-b92610c63931"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Lapatinib\n   + Capecitabine</span></b>", "ID": "d7888835-3a62-4ddc-bb96-cd9859fce464", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "80b9f2bf-d76a-4c0d-9d1d-4bb54f24f024"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Lapatinib\n   + Capecitabine</span>", "ID": "42147eb5-79be-4a08-9d2d-794cdbfa5b31", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Lapatinib    + Capecitabine", "ParentId": "d7888835-3a62-4ddc-bb96-cd9859fce464"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0496</span></b></p>", "ID": "b041121c-407f-4b51-97a7-ddb016fa9a5b", "Styles": "text-align:center;page-break-after:\n   avoid", "Classes": "['Default']", "Text": "", "ParentId": "1f5f449c-c691-496a-9d1f-b92610c63931"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0496</span></b>", "ID": "bf6eb95c-ca8a-4b9d-b5b7-5b780159ccaf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b041121c-407f-4b51-97a7-ddb016fa9a5b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0496</span>", "ID": "7392dc97-ce1d-4765-a0d5-4c8ffdf6e6e0", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "n\u00a0=\u00a0496", "ParentId": "bf6eb95c-ca8a-4b9d-b5b7-5b780159ccaf"}, {"Element": "<td style=\"width:110.95pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab\n   emtansine</span></b></p>\n<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0495</span></b></p>\n</td>", "ID": "3275b645-60d2-4990-a4d6-4c15b5fe51b4", "Styles": "width:110.95pt;border:solid windowtext 1.0pt;\n   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt", "Classes": "None", "Text": "   ", "ParentId": "128c0cfe-00be-415c-b504-c5ed5e6a7c9d"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab\n   emtansine</span></b></p>", "ID": "4d50be27-de63-4c1e-8094-2188f788a11a", "Styles": "text-align:center;page-break-after:\n   avoid", "Classes": "['Default']", "Text": "", "ParentId": "3275b645-60d2-4990-a4d6-4c15b5fe51b4"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab\n   emtansine</span></b>", "ID": "553608e0-2fd4-4a3d-99e2-2308820ffe4d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4d50be27-de63-4c1e-8094-2188f788a11a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Trastuzumab\n   emtansine</span>", "ID": "fdafa271-2abc-4131-b8bd-4107b517137c", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "Trastuzumab    emtansine", "ParentId": "553608e0-2fd4-4a3d-99e2-2308820ffe4d"}, {"Element": "<p align=\"center\" class=\"Default\" style=\"text-align:center;page-break-after:\n   avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0495</span></b></p>", "ID": "4703bce4-1f2f-476f-9653-a721bca9b420", "Styles": "text-align:center;page-break-after:\n   avoid", "Classes": "['Default']", "Text": "", "ParentId": "3275b645-60d2-4990-a4d6-4c15b5fe51b4"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0495</span></b>", "ID": "7078f74e-2c2e-4672-9c1b-5e4e0b44d3e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4703bce4-1f2f-476f-9653-a721bca9b420"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">n\u00a0=\u00a0495</span>", "ID": "75f6ad25-98b0-4889-8d2f-4c55c5a43a3c", "Styles": "font-size:11.0pt;color:windowtext", "Classes": "None", "Text": "n\u00a0=\u00a0495", "ParentId": "7078f74e-2c2e-4672-9c1b-5e4e0b44d3e3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" width=\"586\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Primary\n  endpoints</b></p>\n</td>\n</tr>", "ID": "e17ed2b7-e19d-43dc-a7b7-1a3b154535fb", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td colspan=\"3\" style=\"width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" width=\"586\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Primary\n  endpoints</b></p>\n</td>", "ID": "1d21e486-6c24-4aad-bbe9-548ea5318476", "Styles": "width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "e17ed2b7-e19d-43dc-a7b7-1a3b154535fb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Primary\n  endpoints</b></p>", "ID": "32bf5070-a46f-4f2a-82ff-1d51f08f24b4", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1d21e486-6c24-4aad-bbe9-548ea5318476"}, {"Element": "<b>Primary\n  endpoints</b>", "ID": "c4f0ae8a-b07b-4978-afe6-7fd6fb57db2d", "Styles": "None", "Classes": "None", "Text": "Primary   endpoints", "ParentId": "32bf5070-a46f-4f2a-82ff-1d51f08f24b4"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>IRC-assessed\n  progression-free survival (PFS)</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>", "ID": "8a4b713b-6473-4588-bfcb-35b6a12f1641", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>IRC-assessed\n  progression-free survival (PFS)</b></p>\n</td>", "ID": "132a05dd-5450-4207-bc13-acdaf2a89364", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8a4b713b-6473-4588-bfcb-35b6a12f1641"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>IRC-assessed\n  progression-free survival (PFS)</b></p>", "ID": "9180204a-9653-4945-9081-74951276eacb", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "132a05dd-5450-4207-bc13-acdaf2a89364"}, {"Element": "<b>IRC-assessed\n  progression-free survival (PFS)</b>", "ID": "bb45d211-7800-4d20-8261-7f10033062a2", "Styles": "None", "Classes": "None", "Text": "IRC-assessed   progression-free survival (PFS)", "ParentId": "9180204a-9653-4945-9081-74951276eacb"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>", "ID": "f59f7551-a570-48f3-a88c-19b868944ab9", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8a4b713b-6473-4588-bfcb-35b6a12f1641"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "d804b18a-d952-44b9-b862-bfa148b3c235", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f59f7551-a570-48f3-a88c-19b868944ab9"}, {"Element": "<b>\u00a0</b>", "ID": "28fc1787-7b12-47a0-99ee-1ec0223d954c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d804b18a-d952-44b9-b862-bfa148b3c235"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">304 (61.3%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">265 (53.5%)</p>\n</td>\n</tr>", "ID": "bcf589f9-674d-4c73-96e0-fa25c637fb33", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>\n</td>", "ID": "48830ff9-2b07-4968-a659-270f81954494", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bcf589f9-674d-4c73-96e0-fa25c637fb33"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>", "ID": "05051641-b018-444a-a176-9d1d21210409", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Number   (%) of patients with event ", "ParentId": "48830ff9-2b07-4968-a659-270f81954494"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">304 (61.3%)</p>\n</td>", "ID": "d2a14ad1-e2e9-4b38-9462-359bf8e5bd39", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bcf589f9-674d-4c73-96e0-fa25c637fb33"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">304 (61.3%)</p>", "ID": "e03040ab-04f5-4fef-9ad6-5772de69592f", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "304 (61.3%)", "ParentId": "d2a14ad1-e2e9-4b38-9462-359bf8e5bd39"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">265 (53.5%)</p>\n</td>", "ID": "b51f88e0-1d90-4722-b9f6-d4429b26383a", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bcf589f9-674d-4c73-96e0-fa25c637fb33"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">265 (53.5%)</p>", "ID": "e6afadd9-c5be-46a7-8fba-80c7c2843a9d", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "265 (53.5%)", "ParentId": "b51f88e0-1d90-4722-b9f6-d4429b26383a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.4</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.6</p>\n</td>\n</tr>", "ID": "6628d353-e57e-4dab-a669-dca38f09be47", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>\n</td>", "ID": "1112a399-bcf4-475f-9685-531d5bccf62f", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6628d353-e57e-4dab-a669-dca38f09be47"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>", "ID": "bf10335b-4e79-4c8f-9cb2-814aa27ab3c3", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Median   duration of PFS (months) ", "ParentId": "1112a399-bcf4-475f-9685-531d5bccf62f"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.4</p>\n</td>", "ID": "9e5ae603-efbe-4660-821f-5a490a0deae3", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6628d353-e57e-4dab-a669-dca38f09be47"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.4</p>", "ID": "48baf5fb-69fe-4e38-b8a2-e9dcb6ed3a73", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "6.4", "ParentId": "9e5ae603-efbe-4660-821f-5a490a0deae3"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.6</p>\n</td>", "ID": "71662033-1253-49c0-b3a0-7e136f825e6e", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "6628d353-e57e-4dab-a669-dca38f09be47"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.6</p>", "ID": "3396d190-bea0-413b-a23b-c6a6ae58ffe3", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "9.6", "ParentId": "71662033-1253-49c0-b3a0-7e136f825e6e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.650</p>\n</td>\n</tr>", "ID": "9cb9b24f-1160-4574-b8d7-266ad48725c7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>\n</td>", "ID": "dace2103-31e2-4b0b-b09c-fafe4b8440f6", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "9cb9b24f-1160-4574-b8d7-266ad48725c7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>", "ID": "60ed9e0a-0d75-4a00-a8aa-6867aa9b34fb", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Hazard   ratio (stratified*)", "ParentId": "dace2103-31e2-4b0b-b09c-fafe4b8440f6"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.650</p>\n</td>", "ID": "b5052a9f-690e-4e2f-b965-51676aade1bc", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "9cb9b24f-1160-4574-b8d7-266ad48725c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.650</p>", "ID": "9bd54385-0950-4f54-9bc4-d94df1f31b42", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "0.650", "ParentId": "b5052a9f-690e-4e2f-b965-51676aade1bc"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.549, 0.771)</p>\n</td>\n</tr>", "ID": "ac242e95-d8af-4b64-9a6e-8ec22ff9fc3f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>\n</td>", "ID": "70f2201c-868a-4bc0-9ff4-33b43926defa", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "ac242e95-d8af-4b64-9a6e-8ec22ff9fc3f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>", "ID": "29529a9d-d4ef-45c7-a730-fa9ad6b7cf6f", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "95% CI   for Hazard ratio", "ParentId": "70f2201c-868a-4bc0-9ff4-33b43926defa"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.549, 0.771)</p>\n</td>", "ID": "ee628d8d-0326-4a0f-9d9a-c18242862a9b", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "ac242e95-d8af-4b64-9a6e-8ec22ff9fc3f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.549, 0.771)</p>", "ID": "6e985ade-8d5b-4fe0-b82a-372822037c95", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "(0.549, 0.771)", "ParentId": "ee628d8d-0326-4a0f-9d9a-c18242862a9b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test, stratified*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;\u00a00.0001</p>\n</td>\n</tr>", "ID": "10f29ca6-d47e-49b1-8ee7-d001e86b67e6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test, stratified*)</p>\n</td>", "ID": "735fce5a-bb4f-4364-8fa9-1bc89803712d", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "10f29ca6-d47e-49b1-8ee7-d001e86b67e6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test, stratified*)</p>", "ID": "bb9d1d44-0697-4280-992d-144df55d4fcd", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "p-value   (Log-rank test, stratified*)", "ParentId": "735fce5a-bb4f-4364-8fa9-1bc89803712d"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;\u00a00.0001</p>\n</td>", "ID": "439c72e2-adb7-4183-a15b-6227de9fb532", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "10f29ca6-d47e-49b1-8ee7-d001e86b67e6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;\u00a00.0001</p>", "ID": "cbf4df47-75fb-4922-a230-97cdf5c6bebd", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "<\u00a00.0001", "ParentId": "439c72e2-adb7-4183-a15b-6227de9fb532"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Overall\n  Survival (OS)** </b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>", "ID": "3fd5c18e-4415-45da-a0ed-c85e903eb3c1", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Overall\n  Survival (OS)** </b></p>\n</td>", "ID": "1b5fe354-8198-47fc-8698-fbda2ad91c32", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3fd5c18e-4415-45da-a0ed-c85e903eb3c1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Overall\n  Survival (OS)** </b></p>", "ID": "0cd8458e-b620-4c94-9064-3d14cdb0a43a", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1b5fe354-8198-47fc-8698-fbda2ad91c32"}, {"Element": "<b>Overall\n  Survival (OS)** </b>", "ID": "fee90f3e-d79e-45a9-aaf3-6541a64831c6", "Styles": "None", "Classes": "None", "Text": "Overall   Survival (OS)** ", "ParentId": "0cd8458e-b620-4c94-9064-3d14cdb0a43a"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>", "ID": "fc7186da-a64d-49bd-bcfe-b3c78b4e0a0c", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3fd5c18e-4415-45da-a0ed-c85e903eb3c1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "2826865a-2361-4109-87c4-c37d651010ef", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fc7186da-a64d-49bd-bcfe-b3c78b4e0a0c"}, {"Element": "<b>\u00a0</b>", "ID": "237a41d5-77b7-4eee-8f6a-efad1e41b391", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2826865a-2361-4109-87c4-c37d651010ef"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients who died </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">182 (36.7%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">149 (30.1%)</p>\n</td>\n</tr>", "ID": "0a38c8bb-cb79-4ed1-a6e1-519f6abfa33c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients who died </p>\n</td>", "ID": "95d86824-dbe2-45bb-9c46-ffd4fb7c23d0", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "0a38c8bb-cb79-4ed1-a6e1-519f6abfa33c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients who died </p>", "ID": "2ec4c2eb-ac06-4c69-91ae-5cb12bd29f02", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Number   (%) of patients who died ", "ParentId": "95d86824-dbe2-45bb-9c46-ffd4fb7c23d0"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">182 (36.7%)</p>\n</td>", "ID": "01c19fb4-24bf-4297-bfbb-76d51032c6ac", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "0a38c8bb-cb79-4ed1-a6e1-519f6abfa33c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">182 (36.7%)</p>", "ID": "8150e33d-6ee7-46fe-985f-76bda39a4197", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "182 (36.7%)", "ParentId": "01c19fb4-24bf-4297-bfbb-76d51032c6ac"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">149 (30.1%)</p>\n</td>", "ID": "660578a7-cb9e-4a66-9625-befc5d719698", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "0a38c8bb-cb79-4ed1-a6e1-519f6abfa33c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">149 (30.1%)</p>", "ID": "b4c1fc65-b00d-44d9-9609-9d2d143be016", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "149 (30.1%)", "ParentId": "660578a7-cb9e-4a66-9625-befc5d719698"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of survival (months)</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">25.1</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">30.9</p>\n</td>\n</tr>", "ID": "a3aa6fc3-7786-4f1f-a9b3-7bd8020bc4b8", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of survival (months)</p>\n</td>", "ID": "23833919-5f84-4345-b860-c5351883a12e", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a3aa6fc3-7786-4f1f-a9b3-7bd8020bc4b8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of survival (months)</p>", "ID": "e69711d1-dc94-45a6-a3e1-5f91a7b92dd8", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Median   duration of survival (months)", "ParentId": "23833919-5f84-4345-b860-c5351883a12e"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">25.1</p>\n</td>", "ID": "7563b7d6-226c-4a94-88f9-b6da16227b3c", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a3aa6fc3-7786-4f1f-a9b3-7bd8020bc4b8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">25.1</p>", "ID": "c689fd33-e0ba-498e-b788-0b341b130fbb", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "25.1", "ParentId": "7563b7d6-226c-4a94-88f9-b6da16227b3c"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">30.9</p>\n</td>", "ID": "950a9fe6-a941-4fec-90d5-4af6737c111d", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a3aa6fc3-7786-4f1f-a9b3-7bd8020bc4b8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">30.9</p>", "ID": "4897401a-763f-44cb-b3f1-16526af6b706", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "30.9", "ParentId": "950a9fe6-a941-4fec-90d5-4af6737c111d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.682</p>\n</td>\n</tr>", "ID": "771033fb-7048-4e17-9376-7e67410efba4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>\n</td>", "ID": "d6728e8c-dac6-4e87-9609-53220f589322", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "771033fb-7048-4e17-9376-7e67410efba4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (stratified*)</p>", "ID": "9bc709c3-5138-4b2a-a067-e2a137a45773", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Hazard   ratio (stratified*)", "ParentId": "d6728e8c-dac6-4e87-9609-53220f589322"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.682</p>\n</td>", "ID": "a6b7d1e3-eec3-4162-8a87-accec5ad909d", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "771033fb-7048-4e17-9376-7e67410efba4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.682</p>", "ID": "266d7332-f370-4f5b-b8eb-cc142e02329d", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "0.682", "ParentId": "a6b7d1e3-eec3-4162-8a87-accec5ad909d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.548, 0.849)</p>\n</td>\n</tr>", "ID": "7e9e992f-7dc1-457d-8c63-26b4a4ac5a71", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>\n</td>", "ID": "ef4df0a8-0571-4872-8d58-9e86f3da15c2", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "7e9e992f-7dc1-457d-8c63-26b4a4ac5a71"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">95% CI\n  for Hazard ratio</p>", "ID": "e29b1d93-fe57-4030-879c-61214e92dfea", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "95% CI   for Hazard ratio", "ParentId": "ef4df0a8-0571-4872-8d58-9e86f3da15c2"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.548, 0.849)</p>\n</td>", "ID": "b880913b-f992-44e3-9e4e-5bf2b6dfe38b", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "7e9e992f-7dc1-457d-8c63-26b4a4ac5a71"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">(0.548, 0.849)</p>", "ID": "1dc39f7d-b40c-42ac-adb9-896554fb2cbd", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "(0.548, 0.849)", "ParentId": "b880913b-f992-44e3-9e4e-5bf2b6dfe38b"}, {"Element": "<tr style=\"page-break-inside:avoid;height:4.0pt\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:4.0pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:4.0pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0006</p>\n</td>\n</tr>", "ID": "c7e6e55e-0145-43e1-b1b3-ea526c3fa0a2", "Styles": "page-break-inside:avoid;height:4.0pt", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:4.0pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>\n</td>", "ID": "555a11a4-caf0-4db3-bf3f-ee6a1c244436", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:4.0pt", "Classes": "None", "Text": "  ", "ParentId": "c7e6e55e-0145-43e1-b1b3-ea526c3fa0a2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>", "ID": "39425a99-cfcb-4d3d-aa11-d310cc0e9c6f", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "p-value   (Log-rank test*)", "ParentId": "555a11a4-caf0-4db3-bf3f-ee6a1c244436"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:4.0pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0006</p>\n</td>", "ID": "d602cdbf-3139-4802-b1be-35c4b09fcbb8", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt;height:4.0pt", "Classes": "None", "Text": "  ", "ParentId": "c7e6e55e-0145-43e1-b1b3-ea526c3fa0a2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0006</p>", "ID": "ab0db130-52bd-46d5-8f62-36f2becf898c", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "0.0006", "ParentId": "d602cdbf-3139-4802-b1be-35c4b09fcbb8"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" width=\"586\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Key\n  secondary endpoints</b></p>\n</td>\n</tr>", "ID": "1f8c9bde-03a0-421f-98ce-de599c2af584", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td colspan=\"3\" style=\"width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" width=\"586\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Key\n  secondary endpoints</b></p>\n</td>", "ID": "87e48524-fed4-4900-9c75-48edaf1242ac", "Styles": "width:439.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "1f8c9bde-03a0-421f-98ce-de599c2af584"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Key\n  secondary endpoints</b></p>", "ID": "c9d845ce-0dcb-45da-a8f4-9f58f9b8d335", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "87e48524-fed4-4900-9c75-48edaf1242ac"}, {"Element": "<b>Key\n  secondary endpoints</b>", "ID": "286b6e21-7847-48cd-bdfa-af4f821fdb48", "Styles": "None", "Classes": "None", "Text": "Key   secondary endpoints", "ParentId": "c9d845ce-0dcb-45da-a8f4-9f58f9b8d335"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Investigator-assessed\n  PFS</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>", "ID": "bbef6df6-10ae-4734-8e2a-f849ea02400a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Investigator-assessed\n  PFS</b></p>\n</td>", "ID": "b7516923-83d3-4173-a850-d881eafb7b26", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bbef6df6-10ae-4734-8e2a-f849ea02400a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Investigator-assessed\n  PFS</b></p>", "ID": "67e9105e-c4b9-402a-af02-0550a4999dcc", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b7516923-83d3-4173-a850-d881eafb7b26"}, {"Element": "<b>Investigator-assessed\n  PFS</b>", "ID": "a3494d28-9fe5-41cf-81f2-1e57a3a5ee40", "Styles": "None", "Classes": "None", "Text": "Investigator-assessed   PFS", "ParentId": "67e9105e-c4b9-402a-af02-0550a4999dcc"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>", "ID": "12186502-5324-44b6-9145-cd4f491ad674", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bbef6df6-10ae-4734-8e2a-f849ea02400a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "fef69eeb-4eb8-4dd8-82e8-79eeca13bfa6", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "12186502-5324-44b6-9145-cd4f491ad674"}, {"Element": "<b>\u00a0</b>", "ID": "d78ef99e-7d00-49c8-9668-c1d83da5105d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fef69eeb-4eb8-4dd8-82e8-79eeca13bfa6"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">335 (67.5%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">287 (58.0%)</p>\n</td>\n</tr>", "ID": "8d660efe-59ad-4b07-9b5b-c857448a00c6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>\n</td>", "ID": "66420a0b-1f79-4b78-b865-c26374b4bf4e", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8d660efe-59ad-4b07-9b5b-c857448a00c6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Number\n  (%) of patients with event </p>", "ID": "96e16275-141e-4268-8de1-3da6f5e686ce", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Number   (%) of patients with event ", "ParentId": "66420a0b-1f79-4b78-b865-c26374b4bf4e"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">335 (67.5%)</p>\n</td>", "ID": "1d37d60e-0cf9-4e4d-ac91-52b403dbeb8c", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8d660efe-59ad-4b07-9b5b-c857448a00c6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">335 (67.5%)</p>", "ID": "4a67ba34-afac-49b3-8fb3-e082313e7d90", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "335 (67.5%)", "ParentId": "1d37d60e-0cf9-4e4d-ac91-52b403dbeb8c"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">287 (58.0%)</p>\n</td>", "ID": "eb18b2b7-bf68-4ddf-ad26-681e0343cba2", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8d660efe-59ad-4b07-9b5b-c857448a00c6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">287 (58.0%)</p>", "ID": "f2c4acbd-424a-4ff1-becf-b1ab7227b475", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "287 (58.0%)", "ParentId": "eb18b2b7-bf68-4ddf-ad26-681e0343cba2"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">5.8</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.4</p>\n</td>\n</tr>", "ID": "d8681bb3-f218-4d09-814e-f506ac081c79", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>\n</td>", "ID": "476485f8-168a-4b1a-856d-c1ec58f78bc0", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d8681bb3-f218-4d09-814e-f506ac081c79"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Median\n  duration of PFS (months) </p>", "ID": "d100d4b8-1ac3-45a0-8855-422d2a796d7f", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Median   duration of PFS (months) ", "ParentId": "476485f8-168a-4b1a-856d-c1ec58f78bc0"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">5.8</p>\n</td>", "ID": "f4f6086d-947d-4a88-b1b3-8a7e79cc1231", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d8681bb3-f218-4d09-814e-f506ac081c79"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">5.8</p>", "ID": "9bc162d6-722c-4cf4-b50a-e45ce7a2c473", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "5.8", "ParentId": "f4f6086d-947d-4a88-b1b3-8a7e79cc1231"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.4</p>\n</td>", "ID": "fa9df5db-cede-4757-bfa2-8c4541032cbb", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d8681bb3-f218-4d09-814e-f506ac081c79"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">9.4</p>", "ID": "79defc5f-5188-4712-9729-536673c16fdb", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "9.4", "ParentId": "fa9df5db-cede-4757-bfa2-8c4541032cbb"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (95% CI)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.658 (0.560, 0.774)</p>\n</td>\n</tr>", "ID": "bf6215a5-8ef3-4d85-8227-a64ebec8dff5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (95% CI)</p>\n</td>", "ID": "5e0fdced-4926-4368-95dd-bf9bf3465acc", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bf6215a5-8ef3-4d85-8227-a64ebec8dff5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">Hazard\n  ratio (95% CI)</p>", "ID": "c0e3ec11-4e08-4821-a3f3-4853553c34b4", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Hazard   ratio (95% CI)", "ParentId": "5e0fdced-4926-4368-95dd-bf9bf3465acc"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.658 (0.560, 0.774)</p>\n</td>", "ID": "99f69dea-101d-4047-9653-8984535fe82f", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bf6215a5-8ef3-4d85-8227-a64ebec8dff5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.658 (0.560, 0.774)</p>", "ID": "fe5412e6-a6d6-42a4-ba50-d2422ba41d0b", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "0.658 (0.560, 0.774)", "ParentId": "99f69dea-101d-4047-9653-8984535fe82f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;0.0001</p>\n</td>\n</tr>", "ID": "0c767c7f-e8ef-4ef2-b1a3-95787339172e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>\n</td>", "ID": "346d5ac9-069c-4423-bbcd-f5b1f73a303a", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "0c767c7f-e8ef-4ef2-b1a3-95787339172e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid\">p-value\n  (Log-rank test*)</p>", "ID": "b6271046-1d87-4a8d-9d1f-989d208b8add", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "p-value   (Log-rank test*)", "ParentId": "346d5ac9-069c-4423-bbcd-f5b1f73a303a"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;0.0001</p>\n</td>", "ID": "610fcffb-9b5e-4393-a88b-0f3307b4483d", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "0c767c7f-e8ef-4ef2-b1a3-95787339172e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">&lt;0.0001</p>", "ID": "38d5dd50-a86f-403e-8450-c192e3f7780b", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "<0.0001", "ParentId": "610fcffb-9b5e-4393-a88b-0f3307b4483d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Objective\n  response rate (ORR)</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>", "ID": "94bdd4ed-ff2e-4bfc-8f38-4c623abccd28", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Objective\n  response rate (ORR)</b></p>\n</td>", "ID": "70eaba22-edcd-4845-a3b6-42791f5da0cd", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "94bdd4ed-ff2e-4bfc-8f38-4c623abccd28"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Objective\n  response rate (ORR)</b></p>", "ID": "da562c64-4ecd-42b6-be4d-7793bd083680", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "70eaba22-edcd-4845-a3b6-42791f5da0cd"}, {"Element": "<b>Objective\n  response rate (ORR)</b>", "ID": "24769f39-9a15-4144-a7fc-b8a998527495", "Styles": "None", "Classes": "None", "Text": "Objective   response rate (ORR)", "ParentId": "da562c64-4ecd-42b6-be4d-7793bd083680"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>", "ID": "1c8fafd1-06f5-4f05-9c16-5799049a174b", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "94bdd4ed-ff2e-4bfc-8f38-4c623abccd28"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "485894fe-111d-4ac9-8907-ebfa49abc97f", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1c8fafd1-06f5-4f05-9c16-5799049a174b"}, {"Element": "<b>\u00a0</b>", "ID": "f785f77c-74d1-4bfe-80ef-3c42241cc813", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "485894fe-111d-4ac9-8907-ebfa49abc97f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><i>\u00a0\u00a0\u00a0\n  </i></b>Patients with measurable disease</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">389</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">397</p>\n</td>\n</tr>", "ID": "34ab4e0a-d086-4465-a232-725514ab88fc", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><i>\u00a0\u00a0\u00a0\n  </i></b>Patients with measurable disease</p>\n</td>", "ID": "d6906f03-fbc2-466b-b7f5-5c0d4d9c56e1", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "34ab4e0a-d086-4465-a232-725514ab88fc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b><i>\u00a0\u00a0\u00a0\n  </i></b>Patients with measurable disease</p>", "ID": "d021cc2a-b127-4bfa-9035-5ad2127b65f7", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Patients with measurable disease", "ParentId": "d6906f03-fbc2-466b-b7f5-5c0d4d9c56e1"}, {"Element": "<b><i>\u00a0\u00a0\u00a0\n  </i></b>", "ID": "90e78b38-4a92-436f-8998-434adc3934c1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d021cc2a-b127-4bfa-9035-5ad2127b65f7"}, {"Element": "<i>\u00a0\u00a0\u00a0\n  </i>", "ID": "6d09d57c-6c04-47e0-9625-9b2f4649e8c4", "Styles": "None", "Classes": "None", "Text": "\u00a0\u00a0\u00a0   ", "ParentId": "90e78b38-4a92-436f-8998-434adc3934c1"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">389</p>\n</td>", "ID": "87d85ca4-d09a-45dd-892f-bd91487318d1", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "34ab4e0a-d086-4465-a232-725514ab88fc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">389</p>", "ID": "52e5bc6a-60fd-4741-9acf-f3d372b74e80", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "389", "ParentId": "87d85ca4-d09a-45dd-892f-bd91487318d1"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">397</p>\n</td>", "ID": "3788ec86-add0-4719-9a37-28ab9dae9285", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "34ab4e0a-d086-4465-a232-725514ab88fc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">397</p>", "ID": "fe8e50f9-117d-4f43-a935-ad790634b532", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "397", "ParentId": "3788ec86-add0-4719-9a37-28ab9dae9285"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.35pt;line-height:12.0pt;page-break-after:avoid\">Number\n  of patients with OR (%)</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120 (30.8%)</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173 (43.6%)</p>\n</td>\n</tr>", "ID": "37b801de-9a77-4eee-b3a5-91b1ccaa5cce", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.35pt;line-height:12.0pt;page-break-after:avoid\">Number\n  of patients with OR (%)</p>\n</td>", "ID": "1502db47-ec1e-4882-b548-9ec31fc41d92", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "37b801de-9a77-4eee-b3a5-91b1ccaa5cce"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.35pt;line-height:12.0pt;page-break-after:avoid\">Number\n  of patients with OR (%)</p>", "ID": "5500788a-2ddc-49cd-b7d4-c1ec28daad2c", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.35pt;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Number   of patients with OR (%)", "ParentId": "1502db47-ec1e-4882-b548-9ec31fc41d92"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120 (30.8%)</p>\n</td>", "ID": "b87dce04-bb65-4975-98d0-bf6541a7f338", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "37b801de-9a77-4eee-b3a5-91b1ccaa5cce"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120 (30.8%)</p>", "ID": "54b74ce6-92b0-4564-8e6d-06e15a6f57a2", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "120 (30.8%)", "ParentId": "b87dce04-bb65-4975-98d0-bf6541a7f338"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt\" valign=\"bottom\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173 (43.6%)</p>\n</td>", "ID": "75d02eac-bd18-4197-a77d-c505c717bd19", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "37b801de-9a77-4eee-b3a5-91b1ccaa5cce"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173 (43.6%)</p>", "ID": "cff0e83d-c39b-47d6-9a74-5407f2cf0d4f", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "173 (43.6%)", "ParentId": "75d02eac-bd18-4197-a77d-c505c717bd19"}, {"Element": "<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Difference (95% CI)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.7% (6.0, 19.4)</p>\n</td>\n</tr>", "ID": "9ac8618d-221c-4482-a8ee-231559373bec", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Difference (95% CI)</p>\n</td>", "ID": "d1e3787c-2456-4fdd-9858-52dd4210710e", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9ac8618d-221c-4482-a8ee-231559373bec"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Difference (95% CI)</p>", "ID": "89568b17-6194-4c27-8bd7-e942d759372e", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Difference (95% CI)", "ParentId": "d1e3787c-2456-4fdd-9858-52dd4210710e"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.7% (6.0, 19.4)</p>\n</td>", "ID": "1ea4afdd-6b67-45f6-96cd-672d7763ad3e", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9ac8618d-221c-4482-a8ee-231559373bec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.7% (6.0, 19.4)</p>", "ID": "00ba3a68-8b4a-4590-a679-2766ecee5e89", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "12.7% (6.0, 19.4)", "ParentId": "1ea4afdd-6b67-45f6-96cd-672d7763ad3e"}, {"Element": "<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">p-value (Mantel-Haenszel chi-squared test*)</p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0002</p>\n</td>\n</tr>", "ID": "6d95a737-3a4c-44f2-9e01-617e9a62c18c", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">p-value (Mantel-Haenszel chi-squared test*)</p>\n</td>", "ID": "0f8f3dc2-5876-4655-8224-85f9144b3c52", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6d95a737-3a4c-44f2-9e01-617e9a62c18c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">p-value (Mantel-Haenszel chi-squared test*)</p>", "ID": "6ad68ad9-f1d9-42a5-a5b5-536ecae18f5b", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "p-value (Mantel-Haenszel chi-squared test*)", "ParentId": "0f8f3dc2-5876-4655-8224-85f9144b3c52"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0002</p>\n</td>", "ID": "c8909873-0188-4bfe-91cc-e88a8dc9e14c", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6d95a737-3a4c-44f2-9e01-617e9a62c18c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">0.0002</p>", "ID": "f3c64a37-b90f-44d7-a875-62ca3239521a", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "0.0002", "ParentId": "c8909873-0188-4bfe-91cc-e88a8dc9e14c"}, {"Element": "<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Duration\n  of objective response (months)</b></p>\n</td>\n<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>\n</tr>", "ID": "26cf65e1-82a2-4822-a85a-a4425c9eb128", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Duration\n  of objective response (months)</b></p>\n</td>", "ID": "dd950fcf-f1a8-49ce-8b11-f3e29f64acdc", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "26cf65e1-82a2-4822-a85a-a4425c9eb128"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid\"><b>Duration\n  of objective response (months)</b></p>", "ID": "38fdcc5a-e09a-4fa8-98bc-a0d80428cdf6", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dd950fcf-f1a8-49ce-8b11-f3e29f64acdc"}, {"Element": "<b>Duration\n  of objective response (months)</b>", "ID": "c1c04d53-fb86-4fff-9e0a-530188463180", "Styles": "None", "Classes": "None", "Text": "Duration   of objective response (months)", "ParentId": "38fdcc5a-e09a-4fa8-98bc-a0d80428cdf6"}, {"Element": "<td colspan=\"2\" style=\"width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"334\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>\n</td>", "ID": "2d748d6d-f6f5-478a-8777-c46427292a5a", "Styles": "width:250.45pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "26cf65e1-82a2-4822-a85a-a4425c9eb128"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "886df356-d1df-4a36-b266-49a5ed0c8b40", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2d748d6d-f6f5-478a-8777-c46427292a5a"}, {"Element": "<b>\u00a0</b>", "ID": "7821eaec-5010-4419-9d38-06fe9a1f771d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "886df356-d1df-4a36-b266-49a5ed0c8b40"}, {"Element": "<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-indent:8.8pt;line-height:12.0pt;page-break-after:\n  avoid\">Number of patients with OR</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120</p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173</p>\n</td>\n</tr>", "ID": "3c12eaba-bea4-4dab-8272-1b31501545e7", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-indent:8.8pt;line-height:12.0pt;page-break-after:\n  avoid\">Number of patients with OR</p>\n</td>", "ID": "02c26796-aa59-432e-99e7-18e2ae06c579", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3c12eaba-bea4-4dab-8272-1b31501545e7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-indent:8.8pt;line-height:12.0pt;page-break-after:\n  avoid\">Number of patients with OR</p>", "ID": "87790814-b6c4-407e-a7ae-4a1091a4bdb6", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:0in;text-indent:8.8pt;line-height:12.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Number of patients with OR", "ParentId": "02c26796-aa59-432e-99e7-18e2ae06c579"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120</p>\n</td>", "ID": "6d08f994-b034-405e-bbf3-453e0ebd8fc5", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3c12eaba-bea4-4dab-8272-1b31501545e7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">120</p>", "ID": "82535671-5458-4c27-8077-63a449cab873", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "120", "ParentId": "6d08f994-b034-405e-bbf3-453e0ebd8fc5"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173</p>\n</td>", "ID": "6ad83477-59d2-4a16-915f-c3d8d82fb146", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3c12eaba-bea4-4dab-8272-1b31501545e7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">173</p>", "ID": "e6b1608d-ec98-4908-9c10-f53e4e2ef6c7", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "173", "ParentId": "6ad83477-59d2-4a16-915f-c3d8d82fb146"}, {"Element": "<tr>\n<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Median 95% CI</p>\n</td>\n<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.5 (5.5, 7.2) </p>\n</td>\n<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.6 (8.4, 20.8)</p>\n</td>\n</tr>", "ID": "6618c803-65ae-4779-b2d1-8db2cb873c0d", "Styles": "None", "Classes": "None", "Text": "    ", "ParentId": "90ccbae9-e0cf-40b9-b1bc-3831b20902d8"}, {"Element": "<td style=\"width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"252\">\n<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Median 95% CI</p>\n</td>", "ID": "d02afac8-4787-4bea-903a-ed8cda2dfb00", "Styles": "width:189.0pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6618c803-65ae-4779-b2d1-8db2cb873c0d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid\">Median 95% CI</p>", "ID": "f571cd66-dcc4-43f3-bc98-7bd95c8b0116", "Styles": "margin-top:2.5pt;margin-right:0in;margin-bottom:\n  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "Median 95% CI", "ParentId": "d02afac8-4787-4bea-903a-ed8cda2dfb00"}, {"Element": "<td style=\"width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"186\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.5 (5.5, 7.2) </p>\n</td>", "ID": "0015fc29-bc7e-44f5-aed9-effe54e8ed10", "Styles": "width:139.5pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6618c803-65ae-4779-b2d1-8db2cb873c0d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">6.5 (5.5, 7.2) </p>", "ID": "a7cccb60-ef99-4be4-b5e9-64321a5f4c46", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "6.5 (5.5, 7.2) ", "ParentId": "0015fc29-bc7e-44f5-aed9-effe54e8ed10"}, {"Element": "<td style=\"width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"148\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.6 (8.4, 20.8)</p>\n</td>", "ID": "d7d81208-97b6-4adf-994c-63218e43c8f9", "Styles": "width:110.95pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6618c803-65ae-4779-b2d1-8db2cb873c0d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid\">12.6 (8.4, 20.8)</p>", "ID": "dc5510a4-e0f9-49c3-9fbd-fb8d47c53800", "Styles": "margin-top:2.5pt;margin-right:0in;\n  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "12.6 (8.4, 20.8)", "ParentId": "d7d81208-97b6-4adf-994c-63218e43c8f9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:11.35pt;page-break-after:avoid\">OS:\noverall survival; PFS: progression-free survival; ORR: objective response rate;\nOR: objective response; IRC: independent review committee; HR: hazard ratios;\nCI: confidence interval</p>", "ID": "fa50ec08-8643-4862-8e9b-99ed586c7e27", "Styles": "margin-left:11.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "OS: overall survival; PFS: progression-free survival; ORR: objective response rate; OR: objective response; IRC: independent review committee; HR: hazard ratios; CI: confidence interval", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:11.35pt;text-indent:-7.1pt\">* Stratified\nby: world region (United States, Western Europe, other), number of prior\nchemotherapeutic regimens for locally advanced or metastatic disease (0-1 <i>vs.</i>\n&gt;\u00a01), and visceral <i>vs.</i> non-visceral disease.</p>", "ID": "4d5526af-6a9d-4b17-9d13-aca0eceb7fa4", "Styles": "margin-left:11.35pt;text-indent:-7.1pt", "Classes": "['MsoNormal']", "Text": "* Stratified by: world region (United States, Western Europe, other), number of prior chemotherapeutic regimens for locally advanced or metastatic disease (0-1  >\u00a01), and visceral  non-visceral disease.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>vs.</i>", "ID": "945232ad-f435-4e55-bb87-2ae17c71b640", "Styles": "None", "Classes": "None", "Text": "vs.", "ParentId": "4d5526af-6a9d-4b17-9d13-aca0eceb7fa4"}, {"Element": "<i>vs.</i>", "ID": "2d6d5e6f-6dee-492b-b7d9-85de5e7ad0d9", "Styles": "None", "Classes": "None", "Text": "vs.", "ParentId": "4d5526af-6a9d-4b17-9d13-aca0eceb7fa4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:11.35pt;text-indent:-11.35pt\">** The\ninterim analysis for OS was conducted when 331 events were observed. Since the\nefficacy boundary was crossed at this analysis, this is considered the\ndefinitive analysis.</p>", "ID": "82276afc-b957-4ef0-8ef4-83ad54720ead", "Styles": "margin-left:11.35pt;text-indent:-11.35pt", "Classes": "['MsoNormal']", "Text": "** The interim analysis for OS was conducted when 331 events were observed. Since the efficacy boundary was crossed at this analysis, this is considered the definitive analysis.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d237d9db-3015-4bc1-9de1-bf89ad49fb14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">A treatment benefit was seen in the subgroup of patients who\nhad relapsed within 6 months of completing adjuvant treatment and had not\nreceived any prior systemic anti-cancer therapy in the metastatic setting\n(n=118); hazard ratios for PFS and OS were 0.51 (95% CI: 0.30, 0.85) and 0.61\n(95% CI: 0.32, 1.16), respectively. The median PFS and OS for the trastuzumab\nemtansine group were 10.8 months and not reached,\u00a0respectively, compared\nwith 5.7 months and 27.9 months, respectively, for the lapatinib plus capecitabine\ngroup. </p>", "ID": "fe49f1db-567f-4d47-a4c4-abc66d0f288f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "A treatment benefit was seen in the subgroup of patients who had relapsed within 6 months of completing adjuvant treatment and had not received any prior systemic anti-cancer therapy in the metastatic setting (n=118); hazard ratios for PFS and OS were 0.51 (95% CI: 0.30, 0.85) and 0.61 (95% CI: 0.32, 1.16), respectively. The median PFS and OS for the trastuzumab emtansine group were 10.8 months and not reached,\u00a0respectively, compared with 5.7 months and 27.9 months, respectively, for the lapatinib plus capecitabine group. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "056c3ea1-6334-4fe3-93a8-10a21cbca81e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Figure\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-meier\ncurve of IRC-assessed progression-free survival</b></p>", "ID": "002336e4-934c-426a-a3f0-50d3b7e31d89", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Figure\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-meier\ncurve of IRC-assessed progression-free survival</b>", "ID": "2daf109f-53d8-47a1-a4b2-f7c318d42b89", "Styles": "None", "Classes": "None", "Text": "Figure\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-meier curve of IRC-assessed progression-free survival", "ParentId": "002336e4-934c-426a-a3f0-50d3b7e31d89"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "20edec7a-cb29-4e87-9286-c3b6cf7e1b95", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><img border=\"0\" height=\"385\" id=\"Picture 1\" src=\"Kadcyla%20II-45%20EN%20PIclean_files/image002.gif\" width=\"605\"/></p>", "ID": "0586ea8d-5bf1-43be-988e-75d2c27fa2ce", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<img border=\"0\" height=\"385\" id=\"Picture 1\" src=\"Kadcyla%20II-45%20EN%20PIclean_files/image002.gif\" width=\"605\"/>", "ID": "c2684aac-e5b6-4957-8c86-75ac16f5a56e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0586ea8d-5bf1-43be-988e-75d2c27fa2ce"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "90768480-b3d4-4d2f-8e63-43348013f24a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Figure\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-meier\ncurve of overall survival</b></p>", "ID": "b3317573-a034-4c92-aabd-6a1645743ce6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Figure\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-meier\ncurve of overall survival</b>", "ID": "c956d34d-5436-4f3f-bfc3-a7fac14b5fee", "Styles": "None", "Classes": "None", "Text": "Figure\u00a03\u00a0\u00a0\u00a0\u00a0\u00a0 Kaplan-meier curve of overall survival", "ParentId": "b3317573-a034-4c92-aabd-6a1645743ce6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "90b2bf1c-7e02-43a7-acac-5ec2596946e1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "b5554015-b973-41ef-a260-9eb38e9eac86", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "90b2bf1c-7e02-43a7-acac-5ec2596946e1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><img border=\"0\" height=\"387\" id=\"Picture 2\" src=\"Kadcyla%20II-45%20EN%20PIclean_files/image003.gif\" width=\"604\"/></p>", "ID": "278b28bd-eb29-4d1d-bb86-648eb2e56624", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<img border=\"0\" height=\"387\" id=\"Picture 2\" src=\"Kadcyla%20II-45%20EN%20PIclean_files/image003.gif\" width=\"604\"/>", "ID": "de650b12-d298-4f4d-b990-ab4eea63750a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "278b28bd-eb29-4d1d-bb86-648eb2e56624"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>", "ID": "2cfc6155-acef-45b1-8aea-76ea00f67d01", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">In study TDM4370g/BO21977, consistent treatment benefit of\ntrastuzumab emtansine was seen in the majority of pre\u2011specified subgroups\nevaluated, supporting the robustness of the overall result. In the subgroup of\npatients with hormone receptor-negative disease (n=426), the hazard ratios for\nPFS and OS were 0.56 (95% CI: 0.44, 0.72) and 0.75 (95% CI: 0.54, 1.03),\nrespectively.\u00a0 In the subgroup of patients with hormone receptor-positive\ndisease (n=545), the hazard ratios for PFS and OS were 0.72 (95% CI: 0.58,\n0.91) and 0.62 (95% CI: 0.46, 0.85), respectively.\u00a0 </p>", "ID": "b8b7e32d-8f91-42da-8e42-298ab1f59287", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In study TDM4370g/BO21977, consistent treatment benefit of trastuzumab emtansine was seen in the majority of pre\u2011specified subgroups evaluated, supporting the robustness of the overall result. In the subgroup of patients with hormone receptor-negative disease (n=426), the hazard ratios for PFS and OS were 0.56 (95% CI: 0.44, 0.72) and 0.75 (95% CI: 0.54, 1.03), respectively.\u00a0 In the subgroup of patients with hormone receptor-positive disease (n=545), the hazard ratios for PFS and OS were 0.72 (95% CI: 0.58, 0.91) and 0.62 (95% CI: 0.46, 0.85), respectively.\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "79508984-ef77-4b64-8529-0406dca42d25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">In the subgroup of patients with non-measurable disease\n(n=205), based on IRC assessments, the hazard ratios for PFS and OS were 0.91\n(95% CI: 0.59, 1.42) and 0.96 (95% CI: 0.54, 1.68), respectively. In patients\n\u2265 65 years old (n=138 across both treatment arms) the hazard ratios for\nprogression-free survival (PFS) and Overall Survival (OS) were 1.06 (95% CI:\n0.68, 1.66) and 1.05 (95% CI: 0.58, 1.91), respectively. In patients 65 to\n74\u00a0years old (n=113), based on IRC assessments, the hazard ratios for PFS\nand OS were 0.88 (95% CI: 0.53, 1.45) and 0.74 (95% CI: 0.37, 1.47),\nrespectively.\u00a0 For patients 75\u00a0years or above, based on IRC\nassessments, the hazard ratios for PFS and OS were 3.51 (95% CI: 1.22, 10.13)\nand 3.45 (95% CI: 0.94, 12.65), respectively. The subgroup of patients\n75\u00a0years or above did not demonstrate a benefit for PFS or OS, but was too\nsmall (n=25) to draw any definitive conclusions. </p>", "ID": "5c682ca1-dc53-4717-86db-d7f2b0ff7c1f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In the subgroup of patients with non-measurable disease (n=205), based on IRC assessments, the hazard ratios for PFS and OS were 0.91 (95% CI: 0.59, 1.42) and 0.96 (95% CI: 0.54, 1.68), respectively. In patients \u2265 65 years old (n=138 across both treatment arms) the hazard ratios for progression-free survival (PFS) and Overall Survival (OS) were 1.06 (95% CI: 0.68, 1.66) and 1.05 (95% CI: 0.58, 1.91), respectively. In patients 65 to 74\u00a0years old (n=113), based on IRC assessments, the hazard ratios for PFS and OS were 0.88 (95% CI: 0.53, 1.45) and 0.74 (95% CI: 0.37, 1.47), respectively.\u00a0 For patients 75\u00a0years or above, based on IRC assessments, the hazard ratios for PFS and OS were 3.51 (95% CI: 1.22, 10.13) and 3.45 (95% CI: 0.94, 12.65), respectively. The subgroup of patients 75\u00a0years or above did not demonstrate a benefit for PFS or OS, but was too small (n=25) to draw any definitive conclusions. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "88383ab2-7c37-4732-8d95-e0cb3d5a4fa2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">In the descriptive follow-up overall survival analysis, the\nhazard ratio was 0.75 (95% CI 0.64, 0.88). The median duration of overall\nsurvival was 29.9 months in the trastuzumab emtansine arm compared with 25.9\nmonths in the lapatinib plus capecitabine arm. At the time of the descriptive\nfollow-up overall survival analysis, a total of 27.4% of the patients had\ncrossed over from the lapatinib plus capecitabine arm to the trastuzumab\nemtansine arm. In a sensitivity analysis censoring patients at the time of\ncross-over, the hazard ratio was 0.69 (95% CI 0.59, 0.82). The results of this\ndescriptive follow-up analysis are consistent with the confirmatory OS analysis.</p>", "ID": "81f1c13e-ff50-48f8-be6a-fe4dc165ec8f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In the descriptive follow-up overall survival analysis, the hazard ratio was 0.75 (95% CI 0.64, 0.88). The median duration of overall survival was 29.9 months in the trastuzumab emtansine arm compared with 25.9 months in the lapatinib plus capecitabine arm. At the time of the descriptive follow-up overall survival analysis, a total of 27.4% of the patients had crossed over from the lapatinib plus capecitabine arm to the trastuzumab emtansine arm. In a sensitivity analysis censoring patients at the time of cross-over, the hazard ratio was 0.69 (95% CI 0.59, 0.82). The results of this descriptive follow-up analysis are consistent with the confirmatory OS analysis.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "a50d9043-865c-48e1-a120-e3f5327ef7c1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "bcbaded7-65d9-4cc1-819d-42186e6351c8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a50d9043-865c-48e1-a120-e3f5327ef7c1"}, {"Element": "<p class=\"MsoNormal\"><i><u>TDM4450g</u></i></p>", "ID": "adc755b3-dc79-41da-987a-f7d9ccea74f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i><u>TDM4450g</u></i>", "ID": "2d84aea6-ed99-405e-aa34-0196b6c177df", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "adc755b3-dc79-41da-987a-f7d9ccea74f4"}, {"Element": "<u>TDM4450g</u>", "ID": "cd9e8057-437f-43fe-89fc-1becd9e711e9", "Styles": "None", "Classes": "None", "Text": "TDM4450g", "ParentId": "2d84aea6-ed99-405e-aa34-0196b6c177df"}, {"Element": "<p class=\"MsoNormal\">A randomised, multicentre, open\u2011label phase\u00a0II\nstudy evaluated the effects of trastuzumab emtansine versus trastuzumab plus\ndocetaxel in patients with HER2\u2011positive MBC who had not received prior\nchemotherapy for metastatic disease. Patients were randomised to receive\ntrastuzumab emtansine 3.6\u00a0mg/kg intravenously every 3 weeks\n(n\u00a0=\u00a067) or trastuzumab\u00a08\u00a0mg/kg intravenous loading dose\nfollowed by 6\u00a0mg/kg intravenously every 3\u00a0weeks plus docetaxel 75\u2011100\u00a0mg/m<sup>2</sup>\nintravenously every 3\u00a0weeks (n\u00a0=\u00a070).</p>", "ID": "c6bcc66b-c26b-43ef-8e0f-e9578abc4af3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "A randomised, multicentre, open\u2011label phase\u00a0II study evaluated the effects of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with HER2\u2011positive MBC who had not received prior chemotherapy for metastatic disease. Patients were randomised to receive trastuzumab emtansine 3.6\u00a0mg/kg intravenously every 3 weeks (n\u00a0=\u00a067) or trastuzumab\u00a08\u00a0mg/kg intravenous loading dose followed by 6\u00a0mg/kg intravenously every 3\u00a0weeks plus docetaxel 75\u2011100\u00a0mg/m intravenously every 3\u00a0weeks (n\u00a0=\u00a070).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<sup>2</sup>", "ID": "3b6361bd-86d4-4134-8634-d7216d236d22", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "c6bcc66b-c26b-43ef-8e0f-e9578abc4af3"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "10f56ddf-595d-4e5f-9164-db8e0947da44", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The primary endpoint was investigator assessed Progression\u2011Free\nSurvival (PFS). The median PFS was 9.2\u00a0months in the trastuzumab plus\ndocetaxel arm and 14.2\u00a0months in the trastuzumab emtansine arm (hazard\nratio, 0.59; p\u00a0=\u00a00.035), with a median follow\u2011up of\napproximately 14\u00a0months in both arms. The objective response rate (ORR)\nwas 58.0% with trastuzumab plus docetaxel and 64.2% with trastuzumab emtansine.\nThe median duration of response was not reached with trastuzumab emtansine <i>vs.</i>\n9.5\u00a0months in the control arm.</p>", "ID": "8a6fda37-fbdb-4ade-9aae-ce281b936a4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The primary endpoint was investigator assessed Progression\u2011Free Survival (PFS). The median PFS was 9.2\u00a0months in the trastuzumab plus docetaxel arm and 14.2\u00a0months in the trastuzumab emtansine arm (hazard ratio, 0.59; p\u00a0=\u00a00.035), with a median follow\u2011up of approximately 14\u00a0months in both arms. The objective response rate (ORR) was 58.0% with trastuzumab plus docetaxel and 64.2% with trastuzumab emtansine. The median duration of response was not reached with trastuzumab emtansine  9.5\u00a0months in the control arm.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>vs.</i>", "ID": "d5a0309d-9b55-44c7-95e8-301430484380", "Styles": "None", "Classes": "None", "Text": "vs.", "ParentId": "8a6fda37-fbdb-4ade-9aae-ce281b936a4b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><b>\u00a0</b></p>", "ID": "f8de60e4-06f4-4eb4-899a-823fd8d4b0aa", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "7fe68efc-3f77-4b7e-82c0-aaf6e9b6ae50", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f8de60e4-06f4-4eb4-899a-823fd8d4b0aa"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><i><u>TDM4374g </u></i></p>", "ID": "0211cd70-ada5-4b2d-a007-a24d1835ecaf", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i><u>TDM4374g </u></i>", "ID": "512bbb74-0841-41dd-962a-fd58bfaea836", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0211cd70-ada5-4b2d-a007-a24d1835ecaf"}, {"Element": "<u>TDM4374g </u>", "ID": "c4a0de0b-8f98-4650-9c02-80527e4333aa", "Styles": "None", "Classes": "None", "Text": "TDM4374g ", "ParentId": "512bbb74-0841-41dd-962a-fd58bfaea836"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">A Phase\u00a0II, single\u2011arm,\nopen\u2011label study evaluated the effects of trastuzumab emtansine in\npatients with HER2\u2011positive incurable, LABC or MBC. All patients were\npreviously treated with HER2\u2011directed therapies (trastuzumab and\nlapatinib), and chemotherapy (anthracycline, taxane, and capecitabine) in the\nneoadjuvant, adjuvant, locally advanced, or metastatic setting. The median\nnumber of anti\u2011cancer agents that patients had received in any setting\nwas 8.5 (range, 5\u201119) and in the metastatic setting was 7.0 (range, 3\u201117),\nincluding all agents intended for the treatment of breast cancer. </p>", "ID": "1688e675-18fb-4162-917c-c0609dec1b63", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "A Phase\u00a0II, single\u2011arm, open\u2011label study evaluated the effects of trastuzumab emtansine in patients with HER2\u2011positive incurable, LABC or MBC. All patients were previously treated with HER2\u2011directed therapies (trastuzumab and lapatinib), and chemotherapy (anthracycline, taxane, and capecitabine) in the neoadjuvant, adjuvant, locally advanced, or metastatic setting. The median number of anti\u2011cancer agents that patients had received in any setting was 8.5 (range, 5\u201119) and in the metastatic setting was 7.0 (range, 3\u201117), including all agents intended for the treatment of breast cancer. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "60c40f34-233b-4b2b-a5f5-af00a3dcf0aa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Patients (n\u00a0=\u00a0110) received 3.6\u00a0mg/kg of\ntrastuzumab emtansine intravenously every 3\u00a0weeks until disease\nprogression or unacceptable toxicity. </p>", "ID": "e6c92056-bfe5-42ff-9cbd-2301c33e094d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Patients (n\u00a0=\u00a0110) received 3.6\u00a0mg/kg of trastuzumab emtansine intravenously every 3\u00a0weeks until disease progression or unacceptable toxicity. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "773edca1-eed9-460f-865b-ce462e0ddf14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The key efficacy analyses were ORR based on independent\nradiologic review and duration of objective response. The ORR was 32.7% (95%\nCI: 24.1,\u00a042.1), n\u00a0=\u00a036 responders, by both IRC and investigator\nreview. The median duration of response by IRC was not reached (95% CI,\n4.6\u00a0months to not estimable).</p>", "ID": "273b1b61-2f2c-43e4-a6dc-cbbee57f6acb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The key efficacy analyses were ORR based on independent radiologic review and duration of objective response. The ORR was 32.7% (95% CI: 24.1,\u00a042.1), n\u00a0=\u00a036 responders, by both IRC and investigator review. The median duration of response by IRC was not reached (95% CI, 4.6\u00a0months to not estimable).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "15ed5186-5e29-49b8-868d-ba51dbc95e68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "b03ba203-5a5e-469f-b9fb-bdbf60ec3c25", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "15ed5186-5e29-49b8-868d-ba51dbc95e68"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Paediatric population</u></p>", "ID": "26f17ffb-54ca-444e-b582-beb984b82f6b", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Paediatric population</u>", "ID": "176b871b-b802-4466-afff-e8ffe1c6b9cc", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "26f17ffb-54ca-444e-b582-beb984b82f6b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "2c19f6e8-fd39-45bb-906c-92fe94ed792d", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "866ab98c-68ff-40ed-95f5-c8b996a4aa91", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2c19f6e8-fd39-45bb-906c-92fe94ed792d"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "481f8f8d-715c-49f2-88ad-d975e8e7c581", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "866ab98c-68ff-40ed-95f5-c8b996a4aa91"}, {"Element": "<p class=\"MsoNormal\">The European Medicines Agency has waived the obligation to\nsubmit the results of studies with trastuzumab emtansine in all subsets of the\npaediatric population in breast cancer (see section\u00a04.2 for information on\npaediatric use).</p>", "ID": "5b74664e-0bac-4d32-9385-d5ea12f44dbc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The European Medicines Agency has waived the obligation to submit the results of studies with trastuzumab emtansine in all subsets of the paediatric population in breast cancer (see section\u00a04.2 for information on paediatric use).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3a68c5fb-fad5-4468-811f-dc5dfce2bc1b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</b></p>", "ID": "77245e31-a077-4680-b270-c6d71a739927", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</b>", "ID": "92f2e8f1-70ee-4235-bab0-d8b2c166a675", "Styles": "None", "Classes": "None", "Text": "5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties", "ParentId": "77245e31-a077-4680-b270-c6d71a739927"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\">\u00a0</p>", "ID": "77ea254c-b5f9-491c-b97c-bcdd0ff8f85f", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\">The population pharmacokinetic analysis suggested no\ndifference in trastuzumab emtansine exposure based on disease status (adjuvant\nvs. metastatic setting).</p>", "ID": "fbf8b10f-57c9-4937-8d48-2069290c4456", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The population pharmacokinetic analysis suggested no difference in trastuzumab emtansine exposure based on disease status (adjuvant vs. metastatic setting).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "f9977090-c108-4ec5-8b79-18dfa789d00c", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "2322d7a8-527b-448e-b619-33b87fb48661", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f9977090-c108-4ec5-8b79-18dfa789d00c"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "ef17c5f9-e71c-42da-80b1-d1b31389413d", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "2322d7a8-527b-448e-b619-33b87fb48661"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Absorption </u></p>", "ID": "685530b9-8c42-4b8a-9141-9516f6687c79", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Absorption </u>", "ID": "0f220de1-ea8e-4ee8-9a62-65570bb44436", "Styles": "None", "Classes": "None", "Text": "Absorption ", "ParentId": "685530b9-8c42-4b8a-9141-9516f6687c79"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\">Trastuzumab emtansine is administered intravenously.\nThere have been no studies performed with other routes of administration. </p>", "ID": "dd824002-c081-4b51-8c05-25f3e4249159", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine is administered intravenously. There have been no studies performed with other routes of administration. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "4a3d0cfe-748a-4daf-a971-4b58ea72ab54", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Distribution </u></p>", "ID": "f19ee87f-73a4-4b9d-bfe9-7d77b1b4811c", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Distribution </u>", "ID": "41104524-f764-4247-981a-2233a03c6074", "Styles": "None", "Classes": "None", "Text": "Distribution ", "ParentId": "f19ee87f-73a4-4b9d-bfe9-7d77b1b4811c"}, {"Element": "<p class=\"MsoNormal\">Patients in Study TDM4370g/BO21977 and Study BO29738 who\nreceived 3.6\u00a0mg/kg of trastuzumab emtansine intravenously every\n3\u00a0weeks had a mean Cycle 1 maximum serum concentration (C<sub>max</sub>)\nof trastuzumab emtansine of 83.4\u00a0(\u00b1\u00a016.5)\u00a0<span style=\"font-family:Symbol\">m</span>g/mL and 72.6 (\u00b1 24.3) <span style=\"font-family:Symbol\">m</span>g/mL, respectively. Based on population PK\nanalysis, following intravenous administration, the central volume of\ndistribution of trastuzumab emtansine was (3.13\u00a0L) and approximated that\nof plasma volume. </p>", "ID": "4e8fc923-b840-4171-a72e-ba45db31e132", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Patients in Study TDM4370g/BO21977 and Study BO29738 who received 3.6\u00a0mg/kg of trastuzumab emtansine intravenously every 3\u00a0weeks had a mean Cycle 1 maximum serum concentration (C) of trastuzumab emtansine of 83.4\u00a0(\u00b1\u00a016.5)\u00a0g/mL and 72.6 (\u00b1 24.3) g/mL, respectively. Based on population PK analysis, following intravenous administration, the central volume of distribution of trastuzumab emtansine was (3.13\u00a0L) and approximated that of plasma volume. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<sub>max</sub>", "ID": "d84c256e-41c7-434d-8a8b-71f5dbfa23b3", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "4e8fc923-b840-4171-a72e-ba45db31e132"}, {"Element": "<span style=\"font-family:Symbol\">m</span>", "ID": "ad434cbd-52a7-4713-a7d2-78fe42be3c06", "Styles": "font-family:Symbol", "Classes": "None", "Text": "m", "ParentId": "4e8fc923-b840-4171-a72e-ba45db31e132"}, {"Element": "<span style=\"font-family:Symbol\">m</span>", "ID": "0a0a2ab6-1602-4a76-8178-38b9b934448c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "m", "ParentId": "4e8fc923-b840-4171-a72e-ba45db31e132"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><i>\u00a0</i></p>", "ID": "4d1d07cb-9479-46ca-9e5e-830e7e3320fe", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "958192a8-e48b-4751-9b13-716375e14c0e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d1d07cb-9479-46ca-9e5e-830e7e3320fe"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span lang=\"DE\">Biotransformation (trastuzumab emtansine and DM1)</span></u></p>", "ID": "ae02c6a4-efe5-40be-acc8-2d22557f4633", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span lang=\"DE\">Biotransformation (trastuzumab emtansine and DM1)</span></u>", "ID": "2b493f53-7984-49af-8afc-9ccb5f40ce83", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ae02c6a4-efe5-40be-acc8-2d22557f4633"}, {"Element": "<span lang=\"DE\">Biotransformation (trastuzumab emtansine and DM1)</span>", "ID": "1aa5942c-7036-4bb0-a8cc-c4dcbc5d8c64", "Styles": "None", "Classes": "None", "Text": "Biotransformation (trastuzumab emtansine and DM1)", "ParentId": "2b493f53-7984-49af-8afc-9ccb5f40ce83"}, {"Element": "<p class=\"MsoNormal\">Trastuzumab emtansine is expected to undergo deconjugation\nand catabolism by means of proteolysis in cellular lysosomes. </p>", "ID": "8e697a6c-6b7e-416e-aaae-0564372051a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine is expected to undergo deconjugation and catabolism by means of proteolysis in cellular lysosomes. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "18fc1d8a-af93-4b1e-a523-db685ad24f6c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "9fe6d960-e7c0-486f-9f22-34cc56c9eae3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "18fc1d8a-af93-4b1e-a523-db685ad24f6c"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "50ba23d9-1579-42ce-88d7-9456af1cb688", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9fe6d960-e7c0-486f-9f22-34cc56c9eae3"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e2733bd2-69ec-4161-8126-e6538df53251", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "50ba23d9-1579-42ce-88d7-9456af1cb688"}, {"Element": "<p class=\"MsoNormal\"><i>In vitro</i> metabolism studies in human liver microsomes\nsuggest that DM1, a small molecule component of trastuzumab emtansine, is\nmetabolised mainly by CYP3A4 and to a lesser extent by CYP3A5. DM1 did not\ninhibit major CYP450 enzymes in vitro.\u00a0 In human plasma, trastuzumab\nemtansine catabolites MCC-DM1, Lys-MCC-DM1, and DM1 were detected at low levels.<i>\u00a0\nIn vitro,</i> DM1 was a substrate of P-glycoprotein (P-gp).</p>", "ID": "e88ae6f5-b16b-410e-baf2-738d02ca655a", "Styles": "None", "Classes": "['MsoNormal']", "Text": " metabolism studies in human liver microsomes suggest that DM1, a small molecule component of trastuzumab emtansine, is metabolised mainly by CYP3A4 and to a lesser extent by CYP3A5. DM1 did not inhibit major CYP450 enzymes in vitro.\u00a0 In human plasma, trastuzumab emtansine catabolites MCC-DM1, Lys-MCC-DM1, and DM1 were detected at low levels. DM1 was a substrate of P-glycoprotein (P-gp).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>In vitro</i>", "ID": "0be5a54d-7e87-42b7-810c-7c8aace54f27", "Styles": "None", "Classes": "None", "Text": "In vitro", "ParentId": "e88ae6f5-b16b-410e-baf2-738d02ca655a"}, {"Element": "<i>\u00a0\nIn vitro,</i>", "ID": "f83c6265-9630-409b-b8ee-b8db9b75113a", "Styles": "None", "Classes": "None", "Text": "\u00a0 In vitro,", "ParentId": "e88ae6f5-b16b-410e-baf2-738d02ca655a"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "05ca0343-dc03-4368-9afb-050244eef879", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Elimination</u></p>", "ID": "499f72c6-8970-4ae2-bad9-5b233b59084c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Elimination</u>", "ID": "b9c16604-b1e4-4708-9f4b-80f90f7448eb", "Styles": "None", "Classes": "None", "Text": "Elimination", "ParentId": "499f72c6-8970-4ae2-bad9-5b233b59084c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Based on population\npharmacokinetic (PK) analysis, following intravenous administration of\ntrastuzumab emtansine in patients with HER2\u2011positive metastatic breast\ncancer, the clearance of trastuzumab emtansine was 0.68\u00a0L/day and the\nelimination half\u2011life\u00a0(t<sub>1/2</sub>) was\napproximately\u00a04\u00a0days. No accumulation of trastuzumab emtansine was\nobserved after repeated dosing of intravenous infusion every\u00a03\u00a0weeks.</p>", "ID": "8858a2f7-5d5c-4bd5-991f-7c1cc96b6b7a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Based on population pharmacokinetic (PK) analysis, following intravenous administration of trastuzumab emtansine in patients with HER2\u2011positive metastatic breast cancer, the clearance of trastuzumab emtansine was 0.68\u00a0L/day and the elimination half\u2011life\u00a0(t) was approximately\u00a04\u00a0days. No accumulation of trastuzumab emtansine was observed after repeated dosing of intravenous infusion every\u00a03\u00a0weeks.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<sub>1/2</sub>", "ID": "77e63fa8-3f81-444f-a5e3-3080a5cd5f02", "Styles": "None", "Classes": "None", "Text": "1/2", "ParentId": "8858a2f7-5d5c-4bd5-991f-7c1cc96b6b7a"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "48450571-3bd7-4d6f-bda7-e7111b27a1a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Based on population PK analysis, body weight, albumin, sum\nof longest diameter of target lesions by Response Evaluation Criteria In Solid\nTumors<i> </i>(RECIST), HER2 shed extracellular domain (ECD), baseline\ntrastuzumab concentrations, and aspartate aminotransferase\u00a0(AST) were\nidentified as statistically significant covariates for trastuzumab emtansine PK\nparameters. However, the magnitude of effect of these covariates on trastuzumab\nemtansine exposure suggests that these covariates are unlikely to have any\nclinically meaningful effect on trastuzumab emtansine exposure. In addition,\nexploratory analysis showed that the impact of covariates (i.e., renal function,\nrace and age) on the pharmacokinetics of total trastuzumab and DM1 was limited\nand was not clinically relevant. In nonclinical studies, trastuzumab emtansine\ncatabolites including DM1, Lys\u2011MCC\u2011DM1, and MCC\u2011DM1 are\nmainly excreted in the bile with minimal elimination in urine.</p>", "ID": "c92e56e1-acc3-4c17-bd3f-20c872a05c27", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Based on population PK analysis, body weight, albumin, sum of longest diameter of target lesions by Response Evaluation Criteria In Solid Tumors(RECIST), HER2 shed extracellular domain (ECD), baseline trastuzumab concentrations, and aspartate aminotransferase\u00a0(AST) were identified as statistically significant covariates for trastuzumab emtansine PK parameters. However, the magnitude of effect of these covariates on trastuzumab emtansine exposure suggests that these covariates are unlikely to have any clinically meaningful effect on trastuzumab emtansine exposure. In addition, exploratory analysis showed that the impact of covariates (i.e., renal function, race and age) on the pharmacokinetics of total trastuzumab and DM1 was limited and was not clinically relevant. In nonclinical studies, trastuzumab emtansine catabolites including DM1, Lys\u2011MCC\u2011DM1, and MCC\u2011DM1 are mainly excreted in the bile with minimal elimination in urine.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i> </i>", "ID": "e792e574-4e4a-40ce-83ec-43c69d14e219", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "c92e56e1-acc3-4c17-bd3f-20c872a05c27"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "8045d63a-097d-4c62-a944-bb40e859f8c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "4a813809-3c30-4a13-a284-672d8beed122", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8045d63a-097d-4c62-a944-bb40e859f8c8"}, {"Element": "<p class=\"MsoNormal\"><u>Linearity/non-linearity</u></p>", "ID": "ef7a6ddb-a2ea-453f-8597-98b94f346fd3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Linearity/non-linearity</u>", "ID": "887b22f3-d434-420b-b405-fd6a5604ac4a", "Styles": "None", "Classes": "None", "Text": "Linearity/non-linearity", "ParentId": "ef7a6ddb-a2ea-453f-8597-98b94f346fd3"}, {"Element": "<p class=\"MsoNormal\">Trastuzumab emtansine when administered intravenously every\n3\u00a0weeks exhibited linear PK across doses ranging from 2.4 to\n4.8\u00a0mg/kg; patients who received doses less than or equal to\n1.2\u00a0mg/kg had faster clearance.</p>", "ID": "4c42c297-3617-4b9b-9168-0cad4278cf94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Trastuzumab emtansine when administered intravenously every 3\u00a0weeks exhibited linear PK across doses ranging from 2.4 to 4.8\u00a0mg/kg; patients who received doses less than or equal to 1.2\u00a0mg/kg had faster clearance.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "a49618e1-95da-4e05-b0ea-d77a9f1a2261", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "cc231583-0723-4856-825e-389b7f9ee693", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a49618e1-95da-4e05-b0ea-d77a9f1a2261"}, {"Element": "<p class=\"MsoNormal\"><u>Elderly patients\u00a0 </u></p>", "ID": "c9899ef8-a3ce-4576-bf6f-1dac807c9bd1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Elderly patients\u00a0 </u>", "ID": "b8c8531f-a432-4517-b99f-9a71a43f4247", "Styles": "None", "Classes": "None", "Text": "Elderly patients\u00a0 ", "ParentId": "c9899ef8-a3ce-4576-bf6f-1dac807c9bd1"}, {"Element": "<p class=\"MsoNormal\">The population PK analysis showed that age did not affect\nthe PK of trastuzumab emtansine. No significant difference was observed in the\nPK of trastuzumab emtansine among patients &lt;\u00a065 years\n(n\u00a0=\u00a0577), patients between 65\u201175 years (n\u00a0=\u00a078) and\npatients &gt;\u00a075\u00a0years (n\u00a0=\u00a016).</p>", "ID": "e0ff082b-7e1f-46c0-87dd-e8b46a3d9139", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The population PK analysis showed that age did not affect the PK of trastuzumab emtansine. No significant difference was observed in the PK of trastuzumab emtansine among patients <\u00a065 years (n\u00a0=\u00a0577), patients between 65\u201175 years (n\u00a0=\u00a078) and patients >\u00a075\u00a0years (n\u00a0=\u00a016).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "9109bd93-eb6b-4d81-83cb-7f1c0f8a04ca", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Renal impairment </u></p>", "ID": "494fb7b7-75d4-4b1d-ab0c-e8397baf43a3", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Renal impairment </u>", "ID": "8f91d0db-5c13-45ff-9389-f1b774ae6b49", "Styles": "None", "Classes": "None", "Text": "Renal impairment ", "ParentId": "494fb7b7-75d4-4b1d-ab0c-e8397baf43a3"}, {"Element": "<p class=\"MsoNormal\">No formal PK study has been conducted in patients with renal\nimpairment. The population PK analysis showed that creatinine clearance does\nnot affect the PK of trastuzumab emtansine. Pharmacokinetics of trastuzumab\nemtansine in patients with mild (creatinine clearance CLcr\u00a060 to\n89\u00a0mL/min,\u00a0n\u00a0=\u00a0254) or moderate (CLcr\u00a030 to\n59\u00a0mL/min,\u00a0n\u00a0=\u00a053) renal impairment were similar to those\nin patients with normal renal function (CLcr\u00a0<span style=\"font-family:\nSymbol\">\u00b3</span>\u00a090\u00a0mL/min,\u00a0n\u00a0=\u00a0361).\nPharmacokinetic data in patients with severe renal impairment (CLcr\u00a015 to\n29\u00a0mL/min) are limited (n\u00a0=\u00a01), therefore no dosage\nrecommendations can be made.</p>", "ID": "cfaf7a73-6d99-46d9-ab33-9fe23a9dd18a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No formal PK study has been conducted in patients with renal impairment. The population PK analysis showed that creatinine clearance does not affect the PK of trastuzumab emtansine. Pharmacokinetics of trastuzumab emtansine in patients with mild (creatinine clearance CLcr\u00a060 to 89\u00a0mL/min,\u00a0n\u00a0=\u00a0254) or moderate (CLcr\u00a030 to 59\u00a0mL/min,\u00a0n\u00a0=\u00a053) renal impairment were similar to those in patients with normal renal function (CLcr\u00a0\u00a090\u00a0mL/min,\u00a0n\u00a0=\u00a0361). Pharmacokinetic data in patients with severe renal impairment (CLcr\u00a015 to 29\u00a0mL/min) are limited (n\u00a0=\u00a01), therefore no dosage recommendations can be made.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:\nSymbol\">\u00b3</span>", "ID": "93a0688f-6293-4238-b6a6-a2e40d20ed03", "Styles": "font-family:\nSymbol", "Classes": "None", "Text": "\u00b3", "ParentId": "cfaf7a73-6d99-46d9-ab33-9fe23a9dd18a"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "ede5aaf8-e14a-4edd-9e81-5243441c9531", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "7a63115a-a592-4785-97a4-d87d7fc41aac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ede5aaf8-e14a-4edd-9e81-5243441c9531"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "2de9a51a-cf02-4243-a123-8dde8867cce9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7a63115a-a592-4785-97a4-d87d7fc41aac"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "58c30b2e-951f-4303-9d2b-a34c40d00b62", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "2de9a51a-cf02-4243-a123-8dde8867cce9"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u>Hepatic\nimpairment </u></p>", "ID": "6dfd38b1-b31a-44e0-b6b1-47b5a13df365", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Hepatic\nimpairment </u>", "ID": "d23e51ca-8b76-45d0-86b2-9980a89db6f6", "Styles": "None", "Classes": "None", "Text": "Hepatic impairment ", "ParentId": "6dfd38b1-b31a-44e0-b6b1-47b5a13df365"}, {"Element": "<p class=\"MsoNormal\">The liver is a primary organ for eliminating DM1 and\nDM1-containing catabolites. The pharmacokinetics of trastuzumab emtansine and\nDM1-containing catabolites were evaluated after the administration of 3.6 mg/kg\nof trastuzumab emtansine to metastatic HER2+ breast cancer patients with normal\nhepatic function (n=10), mild (Child-Pugh A; n=10) and moderate (Child-Pugh B;\nn=8) hepatic impairment. </p>", "ID": "899c3e78-8eef-40b6-abdf-23ac2a244f85", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The liver is a primary organ for eliminating DM1 and DM1-containing catabolites. The pharmacokinetics of trastuzumab emtansine and DM1-containing catabolites were evaluated after the administration of 3.6 mg/kg of trastuzumab emtansine to metastatic HER2+ breast cancer patients with normal hepatic function (n=10), mild (Child-Pugh A; n=10) and moderate (Child-Pugh B; n=8) hepatic impairment. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "580fcae4-fb9f-4232-9eb4-8f3ebd6ab77b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">- Plasma concentrations of DM1 and DM1-containing\ncatabolites (Lys-MCC-DM1 and MCC-DM1) were low and comparable between patients\nwith and without hepatic impairment.</p>", "ID": "7b0af177-a39a-4a8b-b624-300fb4ec245a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "- Plasma concentrations of DM1 and DM1-containing catabolites (Lys-MCC-DM1 and MCC-DM1) were low and comparable between patients with and without hepatic impairment.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f9057330-3cf6-4dc8-8b86-c288dedec5ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">- Systemic exposures (AUC) of trastuzumab emtansine at Cycle\n1 in patients with mild and moderate hepatic impairment were approximately 38%\nand 67% lower than that of patients with normal hepatic function, respectively.\nTrastuzumab emtansine exposure (AUC) at Cycle 3 after repeated dosing in\npatients with mild or moderate hepatic dysfunction was within the range\nobserved in patients with normal hepatic function.\u00a0 </p>", "ID": "dcb40975-c3cd-44c0-bf35-331b37237adc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "- Systemic exposures (AUC) of trastuzumab emtansine at Cycle 1 in patients with mild and moderate hepatic impairment were approximately 38% and 67% lower than that of patients with normal hepatic function, respectively. Trastuzumab emtansine exposure (AUC) at Cycle 3 after repeated dosing in patients with mild or moderate hepatic dysfunction was within the range observed in patients with normal hepatic function.\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a7ac5130-bde4-485a-a146-64beee38ac89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">No formal pharmacokinetic study has been conducted and no\npopulation PK data was collected in patients with severe hepatic impairment\n(Child-Pugh class C).</p>", "ID": "86de70c4-455b-47ba-a7a9-3aa90e10b0e3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No formal pharmacokinetic study has been conducted and no population PK data was collected in patients with severe hepatic impairment (Child-Pugh class C).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "4b7cb5b3-bb13-4c35-b0e0-e7335a12d283", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Other special populations</u></p>", "ID": "bd62a285-d565-4dfc-8cf1-1b45a67dd1b5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Other special populations</u>", "ID": "b1ec8a65-3a23-4804-bb76-ac1e78b47c10", "Styles": "None", "Classes": "None", "Text": "Other special populations", "ParentId": "bd62a285-d565-4dfc-8cf1-1b45a67dd1b5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">The population PK analysis\nshowed that race did not appear to influence the PK of trastuzumab emtansine.\nBecause most of the patients in trastuzumab emtansine clinical studies were\nfemales, the effect of gender on the PK of trastuzumab emtansine was not\nformally evaluated.</p>", "ID": "c4c73219-ce88-4fb8-a021-a676949b4b1b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "The population PK analysis showed that race did not appear to influence the PK of trastuzumab emtansine. Because most of the patients in trastuzumab emtansine clinical studies were females, the effect of gender on the PK of trastuzumab emtansine was not formally evaluated.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b4939d52-8364-4a0b-8ae3-a1594cb1370b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.3\u00a0\u00a0\u00a0\u00a0 Preclinical\nsafety data</b></p>", "ID": "7b33a4d0-8d23-4d24-b244-b86c3dabde04", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>5.3\u00a0\u00a0\u00a0\u00a0 Preclinical\nsafety data</b>", "ID": "6b61dc08-92b3-45f8-a964-a456ca73e5f3", "Styles": "None", "Classes": "None", "Text": "5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data", "ParentId": "7b33a4d0-8d23-4d24-b244-b86c3dabde04"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "e5c3adcb-e99f-4ffe-862e-a12414fb466c", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u>Animal\ntoxicology and/or pharmacology</u></p>", "ID": "136693ac-11d5-49d6-a3eb-38e918ef212c", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Animal\ntoxicology and/or pharmacology</u>", "ID": "bd8485f1-67a2-4135-b6c6-4d7d60f3beed", "Styles": "None", "Classes": "None", "Text": "Animal toxicology and/or pharmacology", "ParentId": "136693ac-11d5-49d6-a3eb-38e918ef212c"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "189a2938-c204-4a79-b969-3305a40e3535", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "6f912fce-4e82-435d-aedb-e2b30929a2d9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "189a2938-c204-4a79-b969-3305a40e3535"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b0a736eb-c546-47f9-a06f-553f20a19efc", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "6f912fce-4e82-435d-aedb-e2b30929a2d9"}, {"Element": "<p class=\"MsoNormal\">Administration of trastuzumab emtansine was well tolerated\nin rats and monkeys at doses up to 20 and 10\u00a0mg/kg, respectively,\ncorresponding to 2040\u00a0<span style=\"font-family:Symbol\">m</span>g DM1/m<sup>2</sup>\nin both species, which\u00a0is approximately equivalent to the clinical dose of\ntrastuzumab emtansine in patients.\u00a0 In the GLP toxicity studies, with the\nexception of irreversible peripheral axonal toxicity (observed only in monkeys\nat <span style=\"font-family:Symbol\">\u00b3</span>\u00a010 mg/kg) and\nreproductive organ toxicity (observed only in rats at 60\u00a0mg/kg), partially\nor completely reversible dose dependent toxicities were identified in both\nanimal models. Principal toxicities included liver (liver enzyme elevations) at\n<span style=\"font-family:Symbol\">\u00b3</span>\u00a020 mg/kg and <span style=\"font-family:Symbol\">\u00b3</span>\u00a010 mg/kg, bone marrow (reduced\nplatelet and white blood cell count)/hematologic at <span style=\"font-family:\nSymbol\">\u00b3</span>\u00a020 mg/kg and <span style=\"font-family:Symbol\">\u00b3</span>\u00a010\nmg/kg, and lymphoid organs at <span style=\"font-family:Symbol\">\u00b3</span>\u00a020\nmg/kg and\u00a0<span style=\"font-family:Symbol\">\u00b3</span>\u00a03\u00a0mg/kg,\u00a0\nin rat and monkey, respectively.</p>", "ID": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Administration of trastuzumab emtansine was well tolerated in rats and monkeys at doses up to 20 and 10\u00a0mg/kg, respectively, corresponding to 2040\u00a0g DM1/m in both species, which\u00a0is approximately equivalent to the clinical dose of trastuzumab emtansine in patients.\u00a0 In the GLP toxicity studies, with the exception of irreversible peripheral axonal toxicity (observed only in monkeys at \u00a010 mg/kg) and reproductive organ toxicity (observed only in rats at 60\u00a0mg/kg), partially or completely reversible dose dependent toxicities were identified in both animal models. Principal toxicities included liver (liver enzyme elevations) at \u00a020 mg/kg and \u00a010 mg/kg, bone marrow (reduced platelet and white blood cell count)/hematologic at \u00a020 mg/kg and \u00a010 mg/kg, and lymphoid organs at \u00a020 mg/kg and\u00a0\u00a03\u00a0mg/kg,\u00a0 in rat and monkey, respectively.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">m</span>", "ID": "a7498dc9-72d0-4e2f-be1c-0e7a6ff7706f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "m", "ParentId": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064"}, {"Element": "<sup>2</sup>", "ID": "76ec65b7-e36e-4b7a-9fa5-078c69350ba2", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "b2b13e6b-efaa-45a2-a134-e326938ab81f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "93689807-e174-4509-b6c8-b26e2adcddb5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "e4cc3252-1cc0-4a65-bda3-27784b398181", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064"}, {"Element": "<span style=\"font-family:\nSymbol\">\u00b3</span>", "ID": "66baba30-1886-43ef-b9e1-78919c21d5d8", "Styles": "font-family:\nSymbol", "Classes": "None", "Text": "\u00b3", "ParentId": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "4d6eb739-eeeb-405f-bf25-f2fe4d4080f2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "f4110626-93d5-46f3-bd6c-15fdf6d6c4a0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064"}, {"Element": "<span style=\"font-family:Symbol\">\u00b3</span>", "ID": "22cf10e8-d829-4af0-9ca5-4e903ac8d61b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b3", "ParentId": "e5570e0f-9aa4-4b24-bfcf-9b362f2c9064"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><i>\u00a0</i></p>", "ID": "3c4328a9-9048-4fe1-ad64-692a07128c14", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "9c68a358-d5bc-4e8a-9a41-1c0b69151e8f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3c4328a9-9048-4fe1-ad64-692a07128c14"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u>Mutagenicity</u></p>", "ID": "edcfc33a-aaaa-4fab-a22c-c6ff796ca7a5", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Mutagenicity</u>", "ID": "15f624c0-f9e9-4e80-891d-1bbf1c6c2b34", "Styles": "None", "Classes": "None", "Text": "Mutagenicity", "ParentId": "edcfc33a-aaaa-4fab-a22c-c6ff796ca7a5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "b8035960-632e-4d05-90d2-ad50ec007e37", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "6d9377ad-15b7-4a78-be82-bb604d0429e9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8035960-632e-4d05-90d2-ad50ec007e37"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "76e3a874-0dfd-4f77-9cbd-00345ee55139", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "6d9377ad-15b7-4a78-be82-bb604d0429e9"}, {"Element": "<p class=\"MsoNormal\">DM1 was aneugenic or clastogenic in an <i>in vivo</i>\nsingle-dose rat bone marrow micronucleus assay at exposures that were\ncomparable to mean maximum concentrations of DM1 measured in humans\nadministered trastuzumab emtansine. DM1 was not mutagenic in an <i>in vitro</i>\nbacterial reverse mutation (Ames) assay.\u00a0 </p>", "ID": "d51b127d-2b2e-44a9-88a9-f028eef10ea3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "DM1 was aneugenic or clastogenic in an  single-dose rat bone marrow micronucleus assay at exposures that were comparable to mean maximum concentrations of DM1 measured in humans administered trastuzumab emtansine. DM1 was not mutagenic in an  bacterial reverse mutation (Ames) assay.\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>in vivo</i>", "ID": "58dd6243-777f-4910-a87a-d6b1fff52cef", "Styles": "None", "Classes": "None", "Text": "in vivo", "ParentId": "d51b127d-2b2e-44a9-88a9-f028eef10ea3"}, {"Element": "<i>in vitro</i>", "ID": "84023ec0-d9e0-4b3b-ae88-7db8e3b5acee", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "d51b127d-2b2e-44a9-88a9-f028eef10ea3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "42557165-0620-433e-8c6b-21627959ed2c", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "1b7b17e3-e8f1-4fd9-899d-7fcb79ea38e4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "42557165-0620-433e-8c6b-21627959ed2c"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "a4f2ed97-2fdd-4ab9-83e3-ed5c38234929", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1b7b17e3-e8f1-4fd9-899d-7fcb79ea38e4"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "32bd45ff-51d6-403f-9c62-104f7485d640", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "a4f2ed97-2fdd-4ab9-83e3-ed5c38234929"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Impairment of fertility and teratogenicity</u></p>", "ID": "de7c039b-28ef-44ce-b858-b25acdf542bd", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Impairment of fertility and teratogenicity</u>", "ID": "71b5faf0-caed-4696-91a7-014428bdfa7f", "Styles": "None", "Classes": "None", "Text": "Impairment of fertility and teratogenicity", "ParentId": "de7c039b-28ef-44ce-b858-b25acdf542bd"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "edd4afac-cef0-4a09-ae1a-274e1b2649c6", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "5e800191-2e37-4ef1-b28c-23934a0166e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "edd4afac-cef0-4a09-ae1a-274e1b2649c6"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "774e63de-07f8-4ce2-8708-0d9e12016d33", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "5e800191-2e37-4ef1-b28c-23934a0166e5"}, {"Element": "<p class=\"MsoNormal\">No fertility studies in animals have been performed to\nevaluate the effect of trastuzumab emtansine. However, based on results from\ngeneral animal toxicity studies, adverse effects on fertility can be expected.</p>", "ID": "cf33a4a9-dec5-4c08-aef3-fec66713f0a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "No fertility studies in animals have been performed to evaluate the effect of trastuzumab emtansine. However, based on results from general animal toxicity studies, adverse effects on fertility can be expected.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "282d6767-e090-4613-b190-49aba5275d3c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Dedicated embryo\u2011foetal development studies have not\nbeen conducted in animals with trastuzumab emtansine. Developmental toxicity of\ntrastuzumab has been identified in the clinical setting although it was not\npredicted in the non\u2011clinical program. In addition, developmental\ntoxicity of maytansine has been identified in non\u2011clinical studies which\nsuggests that DM1, the microtubule\u2011inhibiting cytotoxic maytansinoid\ncomponent of trastuzumab emtansine, will be similarly teratogenic and\npotentially embryotoxic.</p>", "ID": "1424274c-5d5c-4d53-80f1-948a942ce454", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Dedicated embryo\u2011foetal development studies have not been conducted in animals with trastuzumab emtansine. Developmental toxicity of trastuzumab has been identified in the clinical setting although it was not predicted in the non\u2011clinical program. In addition, developmental toxicity of maytansine has been identified in non\u2011clinical studies which suggests that DM1, the microtubule\u2011inhibiting cytotoxic maytansinoid component of trastuzumab emtansine, will be similarly teratogenic and potentially embryotoxic.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "cae2ea99-82e2-497d-8685-1d33f3c7ed93", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "7d761550-ee19-422a-bdc5-2d4477b9d508", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</b></p>", "ID": "712bfe83-40e7-4943-a390-19f0124479ff", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</b>", "ID": "79652ae0-d877-4d6e-beea-08e74d3c56e9", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS", "ParentId": "712bfe83-40e7-4943-a390-19f0124479ff"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>\u00a0</b></p>", "ID": "403db9a9-57fc-45d7-bb25-776668d19f34", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "404d59c8-d233-442d-9653-b3f61ef35211", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "403db9a9-57fc-45d7-bb25-776668d19f34"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.1\u00a0\u00a0\u00a0\u00a0 List\nof excipients</b></p>", "ID": "a928445f-0ed2-4460-851b-f34d60fc9c51", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>6.1\u00a0\u00a0\u00a0\u00a0 List\nof excipients</b>", "ID": "bb8e7a38-59fc-4296-bc88-ace170e7ebd8", "Styles": "None", "Classes": "None", "Text": "6.1\u00a0\u00a0\u00a0\u00a0 List of excipients", "ParentId": "a928445f-0ed2-4460-851b-f34d60fc9c51"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "38127d5f-e493-46ff-9ec0-58bd84697bbf", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">Succinic\nacid</p>", "ID": "6732df1d-1b9b-4f54-a44a-8e612fac720b", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "Succinic acid", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">Sodium\nhydroxide</p>", "ID": "758475d0-f11d-4cc9-a51f-a91eef8cc97e", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "Sodium hydroxide", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">Sucrose</p>", "ID": "6a55705f-dc91-42d0-bd7e-71565144c45c", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "Sucrose", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">Polysorbate\u00a020</p>", "ID": "b3ebb4f0-bf9b-40e3-8b9d-17e9177c3aa8", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "Polysorbate\u00a020", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "51fac3ce-3a60-4ec1-af7e-1944a06810cd", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</b></p>", "ID": "866b1ce0-c139-466e-897d-b93c1a550725", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</b>", "ID": "a6612c08-10cd-4186-bf7b-b755aaa4c178", "Styles": "None", "Classes": "None", "Text": "6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities", "ParentId": "866b1ce0-c139-466e-897d-b93c1a550725"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "c828674b-1c3a-49f6-9dd3-74467f3242d8", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">This medicinal product must not be mixed or diluted with\nother medicinal products except those mentioned in section\u00a06.6.</p>", "ID": "4ba2b937-e7c3-481f-972e-3b018a2709d7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "This medicinal product must not be mixed or diluted with other medicinal products except those mentioned in section\u00a06.6.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d1d7a76b-d452-4a11-b038-fa2c94139e82", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Glucose\u00a0(5%) solution should not be used for\nreconstitution or dilution since it causes aggregation of the protein.</p>", "ID": "86f3905f-5a6f-41a7-86ec-fd1d57bc9e92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Glucose\u00a0(5%) solution should not be used for reconstitution or dilution since it causes aggregation of the protein.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8f9940fa-bfba-4657-a3fa-54c624653294", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</b></p>", "ID": "75aa85d8-7d5d-4d02-9b6e-d79c41a83e18", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</b>", "ID": "0b7332d7-3ee1-4118-a5ee-0d3dfe82f4af", "Styles": "None", "Classes": "None", "Text": "6.3\u00a0\u00a0\u00a0\u00a0 Shelf life", "ParentId": "75aa85d8-7d5d-4d02-9b6e-d79c41a83e18"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "f628e78a-620d-427e-ad24-2bd2fe5aca51", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Unopened vial</u></p>", "ID": "67eb9d91-c7b4-4bcc-b533-1df86b3b8320", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Unopened vial</u>", "ID": "bae598b0-621d-47b9-9b31-959bb198e805", "Styles": "None", "Classes": "None", "Text": "Unopened vial", "ParentId": "67eb9d91-c7b4-4bcc-b533-1df86b3b8320"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "f0f1bd97-5c33-4132-b0d0-9b35e24c3a55", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">3\u00a0years.</p>", "ID": "5a3b17a9-8a5b-451f-b209-9129ec0467b0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "3\u00a0years.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "bfcf9a4c-badf-4baa-9ff5-fc29bc33f23b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>Reconstituted solution</u></p>", "ID": "68a46ca8-9c66-4bb5-8fa2-2c367be08df4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Reconstituted solution</u>", "ID": "6449f007-7b97-4def-ad04-224f8a3c0384", "Styles": "None", "Classes": "None", "Text": "Reconstituted solution", "ParentId": "68a46ca8-9c66-4bb5-8fa2-2c367be08df4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u>\u00a0</u></p>", "ID": "8e47ec99-641e-4ca1-842a-21f693966982", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>\u00a0</u>", "ID": "bbbcb0e3-6d4f-465d-83e3-73f20fcf3292", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8e47ec99-641e-4ca1-842a-21f693966982"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Chemical and physical in\u2011use\nstability of the reconstituted solution has been demonstrated for up to\n24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C. From a microbiological point of\nview, the product should be used immediately. If not used immediately, the\nreconstituted vials can be stored for up to 24\u00a0hours at\n2\u00b0C\u00a0to\u00a08\u00b0C, provided it was reconstituted under controlled\nand validated aseptic conditions, and must be discarded thereafter.</p>", "ID": "b1381b53-6030-419c-834c-7d8016fea8f5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Chemical and physical in\u2011use stability of the reconstituted solution has been demonstrated for up to 24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C. From a microbiological point of view, the product should be used immediately. If not used immediately, the reconstituted vials can be stored for up to 24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C, provided it was reconstituted under controlled and validated aseptic conditions, and must be discarded thereafter.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "09c3c9b2-ffe9-4c01-af41-217de784d778", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><u>Diluted solution </u></p>", "ID": "c12971fb-922e-4682-a1bd-d16c8cdad6cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Diluted solution </u>", "ID": "eb60e70f-9dd3-4f66-b415-5615560e24ab", "Styles": "None", "Classes": "None", "Text": "Diluted solution ", "ParentId": "c12971fb-922e-4682-a1bd-d16c8cdad6cd"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "2217e71a-3bb1-43ef-b78f-f5219bd70232", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "1dc8f07c-0dd9-4dc2-a8f6-a89c7d93c3d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2217e71a-3bb1-43ef-b78f-f5219bd70232"}, {"Element": "<p class=\"MsoNormal\">The reconstituted Kadcyla solution diluted in infusion bags\ncontaining sodium chloride 9\u00a0mg/mL (0.9%) solution for infusion, or sodium\nchloride 4.5\u00a0mg/mL (0.45%) solution for infusion, is stable for up to\n24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C, provided it was prepared under\ncontrolled and validated aseptic conditions. Particulates may be observed on\nstorage if diluted in 0.9% sodium chloride (see\u00a0section\u00a06.6).</p>", "ID": "0807f62b-be73-4011-a98b-7957cfe81116", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The reconstituted Kadcyla solution diluted in infusion bags containing sodium chloride 9\u00a0mg/mL (0.9%) solution for infusion, or sodium chloride 4.5\u00a0mg/mL (0.45%) solution for infusion, is stable for up to 24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C, provided it was prepared under controlled and validated aseptic conditions. Particulates may be observed on storage if diluted in 0.9% sodium chloride (see\u00a0section\u00a06.6).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "234c5419-3672-42ef-a2a2-71edea4d29f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.4\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for storage</b></p>", "ID": "6953bc05-b424-4f4c-8bf7-d1cae97eeef5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>6.4\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for storage</b>", "ID": "567ee5ce-9202-43a2-a778-1c89743fdbf0", "Styles": "None", "Classes": "None", "Text": "6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage", "ParentId": "6953bc05-b424-4f4c-8bf7-d1cae97eeef5"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0a3ca177-8072-4470-b65c-fd1d97febd71", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Store in a refrigerator (2<span style=\"font-family:Symbol\">\u00b0</span>C\u00a0\u2013\u00a08<span style=\"font-family:Symbol\">\u00b0</span>C).</p>", "ID": "4d61e51c-4c26-4c38-95d8-aee3cd446ba2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Store in a refrigerator (2C\u00a0\u2013\u00a08C).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b0</span>", "ID": "54f20e34-34d2-4575-b1a1-40b9c69a45a5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b0", "ParentId": "4d61e51c-4c26-4c38-95d8-aee3cd446ba2"}, {"Element": "<span style=\"font-family:Symbol\">\u00b0</span>", "ID": "dbab3551-8830-450f-abd8-466225af9e29", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b0", "ParentId": "4d61e51c-4c26-4c38-95d8-aee3cd446ba2"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4015366b-b04d-4aef-b178-281cdc48b8cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">For storage conditions after reconstitution and dilution of\nthe medicinal product, see section\u00a06.3.</p>", "ID": "96137c39-a656-4562-937a-598df01f6125", "Styles": "None", "Classes": "['MsoNormal']", "Text": "For storage conditions after reconstitution and dilution of the medicinal product, see section\u00a06.3.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "64f26e09-1673-4cc5-aa59-db8ce6a5ac8b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.5\u00a0\u00a0\u00a0\u00a0 Nature\nand contents of container </b></p>", "ID": "9be102fe-6043-47a4-9b09-2c8a76538e3a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>6.5\u00a0\u00a0\u00a0\u00a0 Nature\nand contents of container </b>", "ID": "3ec6ced0-1bc3-4226-a446-cf7aed7e7659", "Styles": "None", "Classes": "None", "Text": "6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container ", "ParentId": "9be102fe-6043-47a4-9b09-2c8a76538e3a"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a7d8a51d-3465-4b4d-b1d5-44b8558cc0d6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><u>Kadcyla 100 mg powder for concentrate for solution for\ninfusion</u></p>", "ID": "6994b79f-76fa-44ed-9bed-08233dbe582c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Kadcyla 100 mg powder for concentrate for solution for\ninfusion</u>", "ID": "50ae85dc-7143-4ed8-8178-f951ab146642", "Styles": "None", "Classes": "None", "Text": "Kadcyla 100 mg powder for concentrate for solution for infusion", "ParentId": "6994b79f-76fa-44ed-9bed-08233dbe582c"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ab1a0efd-3da8-49e7-bfbd-aa9ff944a15c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla is provided in 15\u00a0mL (100 mg) Type 1 glass vial\nclosed with a grey-butyl rubber stopper coated with fluoro\u2011resin laminate,\nand sealed with an aluminium seal with a white plastic flip-off cap. </p>", "ID": "b5287143-1519-4d23-ad1f-dcd754592d56", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla is provided in 15\u00a0mL (100 mg) Type 1 glass vial closed with a grey-butyl rubber stopper coated with fluoro\u2011resin laminate, and sealed with an aluminium seal with a white plastic flip-off cap. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d07ccf2c-3677-4303-bfac-a34f70189aa0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Pack of 1\u00a0vial.</p>", "ID": "3c4c88dc-aaf3-42ef-adb6-35f983fb5d69", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Pack of 1\u00a0vial.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "52a3f8e0-5b7b-4d52-9753-3fe324e0bee7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><u>Kadcyla 160 mg powder for concentrate for solution for\ninfusion</u></p>", "ID": "cdba2649-505d-49b5-b2bf-bcc59a89d2bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Kadcyla 160 mg powder for concentrate for solution for\ninfusion</u>", "ID": "af0c2a28-1988-468c-b048-03740132be2f", "Styles": "None", "Classes": "None", "Text": "Kadcyla 160 mg powder for concentrate for solution for infusion", "ParentId": "cdba2649-505d-49b5-b2bf-bcc59a89d2bc"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "95b62741-04a4-4b57-80bd-04be343a8ab0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla is provided in 20 mL (160 mg) Type 1 glass vial\nclosed with a grey-butyl rubber stopper coated with fluoro resin laminate, and\nsealed with an aluminium seal with a purple plastic flip-off cap.</p>", "ID": "5bf551d1-f386-43a0-abc9-c17fdafa9d95", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla is provided in 20 mL (160 mg) Type 1 glass vial closed with a grey-butyl rubber stopper coated with fluoro resin laminate, and sealed with an aluminium seal with a purple plastic flip-off cap.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "77702075-00da-4c35-aa76-87b7fe8900de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Pack of 1 vial.</p>", "ID": "79e39784-8396-4ca6-93ef-b1f09f033e53", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Pack of 1 vial.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b95514db-f37d-47b0-9557-e0bd41f410a6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.6\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for disposal and other handling</b></p>", "ID": "fd5593b4-174f-4931-b94f-f945e949da84", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>6.6\u00a0\u00a0\u00a0\u00a0 Special\nprecautions for disposal and other handling</b>", "ID": "ba0f018c-2ba2-4b7c-b611-658d607a11d0", "Styles": "None", "Classes": "None", "Text": "6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal and other handling", "ParentId": "fd5593b4-174f-4931-b94f-f945e949da84"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "ce23bbd0-ffcf-4af6-8237-039c9aa9685e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "a00485b2-60be-442b-82b2-b7c7feed414f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce23bbd0-ffcf-4af6-8237-039c9aa9685e"}, {"Element": "<p class=\"MsoNormal\">Appropriate aseptic technique should be used. Appropriate\nprocedures for the preparation of chemotherapeutic medicinal products should be\nused.</p>", "ID": "17346a20-cdf6-4f72-a14e-d464659909a0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Appropriate aseptic technique should be used. Appropriate procedures for the preparation of chemotherapeutic medicinal products should be used.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ad6ab18a-c314-4cb2-ac98-d910f8369e5e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The reconstituted Kadcyla solution should be diluted in\npolyvinyl chloride (PVC) or latex\u2011free PVC\u2011free polyolefin infusion\nbags.</p>", "ID": "9e6b8ac8-4571-4609-b00e-aca815203b1e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The reconstituted Kadcyla solution should be diluted in polyvinyl chloride (PVC) or latex\u2011free PVC\u2011free polyolefin infusion bags.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "09b35481-86d8-4731-b837-90ac3c863b70", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The use of 0.20 or 0.22 micron in-line polyethersulfone\n(PES) filter is required for the infusion when the concentrate for infusion is\ndiluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. </p>", "ID": "583954de-3a15-48ee-9124-87ea97f83940", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The use of 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required for the infusion when the concentrate for infusion is diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "65f6764e-a475-4160-99b1-511b33b894af", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">In order to prevent medicinal product errors it is important\nto check the vial labels to ensure that the medicinal product being prepared is\nKadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).</p>", "ID": "a961f190-f0fe-423f-ba43-57b528656d6b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In order to prevent medicinal product errors it is important to check the vial labels to ensure that the medicinal product being prepared is Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\">\u00a0</p>", "ID": "95c6d5f5-ae7f-4f52-b317-643f48f9d25f", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u>Instructions for reconstitution</u></p>", "ID": "3b9a1706-ee1f-484c-a503-50897b7975b3", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Instructions for reconstitution</u>", "ID": "9e1ee56f-02c3-4912-ae2e-63e29fa7b99c", "Styles": "None", "Classes": "None", "Text": "Instructions for reconstitution", "ParentId": "3b9a1706-ee1f-484c-a503-50897b7975b3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "a1bd1d38-66f6-475d-a16e-074d62c2c265", "Styles": "text-align:justify;text-justify:inter-ideograph;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "b9c72b02-6acb-4a8a-92a7-e2b9bc6a73d1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a1bd1d38-66f6-475d-a16e-074d62c2c265"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "cfad5a7e-35ed-4274-8094-e4fb98ca74be", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "b9c72b02-6acb-4a8a-92a7-e2b9bc6a73d1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-align:justify;text-justify:\ninter-ideograph;text-indent:-17.85pt;page-break-after:avoid\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 100 mg trastuzumab\nemtansine vial: Using a sterile syringe, slowly inject 5\u00a0mL of sterile\nwater for injection into the vial. </p>", "ID": "5e9c46f2-2828-4e0d-8f7d-c8a6e615db34", "Styles": "margin-left:17.85pt;text-align:justify;text-justify:\ninter-ideograph;text-indent:-17.85pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 100 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 5\u00a0mL of sterile water for injection into the vial. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "e32a7689-342b-4e0b-949e-963ede1cbe19", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5e9c46f2-2828-4e0d-8f7d-c8a6e615db34"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-align:justify;text-justify:\ninter-ideograph;text-indent:-17.85pt;page-break-after:avoid\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 160 mg trastuzumab\nemtansine vial: Using a sterile syringe, slowly inject 8\u00a0mL of sterile\nwater for injection into the vial. </p>", "ID": "18a676c2-872e-492d-83a1-0cd5b15f7bb7", "Styles": "margin-left:17.85pt;text-align:justify;text-justify:\ninter-ideograph;text-indent:-17.85pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 160 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 8\u00a0mL of sterile water for injection into the vial. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "1e1c91b4-42b0-4252-812d-60cf85ba7d39", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "18a676c2-872e-492d-83a1-0cd5b15f7bb7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-align:justify;text-justify:\ninter-ideograph;text-indent:-17.85pt;page-break-after:avoid\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Swirl the vial\ngently until completely dissolved. Do not shake. </p>", "ID": "e1104c41-09db-4e18-b4c5-84aca045b05f", "Styles": "margin-left:17.85pt;text-align:justify;text-justify:\ninter-ideograph;text-indent:-17.85pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Swirl the vial gently until completely dissolved. Do not shake. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "b2ebd587-5eca-47c9-966c-ccfad6b9334e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e1104c41-09db-4e18-b4c5-84aca045b05f"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "083f7523-24f1-4b0e-8d76-6d8a5de056cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Reconstituted solution should be inspected visually for\nparticulate matter and discolouration prior to administration. The\nreconstituted solution should be free of visible particulates, clear to\nslightly opalescent. The colour of the reconstituted solution should be\ncolourless to pale brown. Do not use if the reconstituted solution contains\nvisible particulates, or is cloudy or discoloured.</p>", "ID": "71657acc-214a-4e84-9d24-0ea4596a5282", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Reconstituted solution should be inspected visually for particulate matter and discolouration prior to administration. The reconstituted solution should be free of visible particulates, clear to slightly opalescent. The colour of the reconstituted solution should be colourless to pale brown. Do not use if the reconstituted solution contains visible particulates, or is cloudy or discoloured.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "543c7182-bf4a-4a1b-a9dd-f52f4bfd13c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><u>Instructions for dilution</u></p>", "ID": "2e28eb68-fe6f-4099-9f4f-599f3d691196", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Instructions for dilution</u>", "ID": "38f6acca-9c9c-470a-89bb-40c9f207de48", "Styles": "None", "Classes": "None", "Text": "Instructions for dilution", "ParentId": "2e28eb68-fe6f-4099-9f4f-599f3d691196"}, {"Element": "<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "844aa071-b204-4620-a55c-bbac15c0d927", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "da302c82-b0e7-42a9-b512-911a55f83dfd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "844aa071-b204-4620-a55c-bbac15c0d927"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "04c07775-934f-40f6-9cbc-745c141e8d9c", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "da302c82-b0e7-42a9-b512-911a55f83dfd"}, {"Element": "<p class=\"MsoNormal\">Determine the volume of the reconstituted solution required\nbased on a dose of 3.6\u00a0mg trastuzumab emtansine/kg body weight (see\nsection\u00a04.2):</p>", "ID": "c87b84fc-3563-4601-9426-6e55dc0c1207", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Determine the volume of the reconstituted solution required based on a dose of 3.6\u00a0mg trastuzumab emtansine/kg body weight (see section\u00a04.2):", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ab583679-da90-4a28-986d-029419d53167", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Volume</b>\n(mL)\u00a0=\u00a0<i><u>Total dose to be administered</u></i><u> (<b>body weight</b>\n(kg) x <b>dose</b> (mg/kg))</u> </p>", "ID": "92735569-1704-4cb7-b19f-9f72c8b95a7a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": " (mL)\u00a0=\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Volume</b>", "ID": "cd71cb70-18ff-4e09-a038-d5baeb06f6bc", "Styles": "None", "Classes": "None", "Text": "Volume", "ParentId": "92735569-1704-4cb7-b19f-9f72c8b95a7a"}, {"Element": "<i><u>Total dose to be administered</u></i>", "ID": "8be24bc2-3a7a-42b8-a10b-70c474d00477", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "92735569-1704-4cb7-b19f-9f72c8b95a7a"}, {"Element": "<u>Total dose to be administered</u>", "ID": "cec60342-76e3-4b3c-a895-90bf10c9317a", "Styles": "None", "Classes": "None", "Text": "Total dose to be administered", "ParentId": "8be24bc2-3a7a-42b8-a10b-70c474d00477"}, {"Element": "<u> (<b>body weight</b>\n(kg) x <b>dose</b> (mg/kg))</u>", "ID": "16a4f5de-d9ba-4a9c-9beb-65418cc1cbf4", "Styles": "None", "Classes": "None", "Text": " ( (kg) x  (mg/kg))", "ParentId": "92735569-1704-4cb7-b19f-9f72c8b95a7a"}, {"Element": "<b>body weight</b>", "ID": "f30f711a-9ad5-412f-b751-1c0473bad2eb", "Styles": "None", "Classes": "None", "Text": "body weight", "ParentId": "16a4f5de-d9ba-4a9c-9beb-65418cc1cbf4"}, {"Element": "<b>dose</b>", "ID": "6a2c35f7-2841-478d-8aa3-83c520c832ab", "Styles": "None", "Classes": "None", "Text": "dose", "ParentId": "16a4f5de-d9ba-4a9c-9beb-65418cc1cbf4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n<b>20</b> (mg/mL, concentration of reconstituted solution)</p>", "ID": "75d14fa3-482d-4a42-8ff5-b1024c3b4dce", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  (mg/mL, concentration of reconstituted solution)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>20</b>", "ID": "d2fce221-a165-451a-aca0-287c044ee857", "Styles": "None", "Classes": "None", "Text": "20", "ParentId": "75d14fa3-482d-4a42-8ff5-b1024c3b4dce"}, {"Element": "<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "bff9d79f-13c1-4b20-b7b4-21b74078ac1c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "eccd2ab3-e592-4740-9428-b60d70d1a790", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bff9d79f-13c1-4b20-b7b4-21b74078ac1c"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "8d307599-e72a-4207-a74a-7a758fa6f681", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eccd2ab3-e592-4740-9428-b60d70d1a790"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "9eac63d3-aeca-4bb9-9ad4-339a38fa2fd5", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "8d307599-e72a-4207-a74a-7a758fa6f681"}, {"Element": "<p class=\"MsoNormal\">The appropriate amount of solution should be withdrawn from\nthe vial and added to an infusion bag containing 250\u00a0mL of sodium chloride\n4.5 mg/mL (0.45%) solution for infusion or sodium chloride 9\u00a0mg/mL (0.9%)\nsolution for infusion. Glucose\u00a0(5%) solution should not be used (see\nsection\u00a06.2). Sodium chloride 4.5 mg/mL (0.45%) solution for infusion may\nbe used without a polyethersulfone (PES) 0.20 or 0.22\u2011\u03bcm in\u2011line\nfilter. If sodium chloride 9 mg/mL (0.9%) solution for infusion is used for\ninfusion, a 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is\nrequired. Once the infusion is prepared it should be administered immediately.\nDo not freeze or shake the infusion during storage. </p>", "ID": "17ab2516-9360-4a37-be3f-f68c194bfbe7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The appropriate amount of solution should be withdrawn from the vial and added to an infusion bag containing 250\u00a0mL of sodium chloride 4.5 mg/mL (0.45%) solution for infusion or sodium chloride 9\u00a0mg/mL (0.9%) solution for infusion. Glucose\u00a0(5%) solution should not be used (see section\u00a06.2). Sodium chloride 4.5 mg/mL (0.45%) solution for infusion may be used without a polyethersulfone (PES) 0.20 or 0.22\u2011\u03bcm in\u2011line filter. If sodium chloride 9 mg/mL (0.9%) solution for infusion is used for infusion, a 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required. Once the infusion is prepared it should be administered immediately. Do not freeze or shake the infusion during storage. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "610e9a5d-26ca-4538-8f02-8af53db6f767", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "100064a2-fb80-4d5e-b4ed-d15cf668c25f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "610e9a5d-26ca-4538-8f02-8af53db6f767"}, {"Element": "<p class=\"MsoNormal\"><u>Disposal</u></p>", "ID": "43edfecc-29f0-4a75-b650-0488233dd3b7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Disposal</u>", "ID": "247b5eb2-3f8f-4b25-a45f-bc696c726c83", "Styles": "None", "Classes": "None", "Text": "Disposal", "ParentId": "43edfecc-29f0-4a75-b650-0488233dd3b7"}, {"Element": "<p class=\"MsoNormal\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "5d8adcd5-048d-4fde-ab0e-8196e916dc78", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "961d0e68-bfa6-42d8-8f0f-39dfee26f182", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5d8adcd5-048d-4fde-ab0e-8196e916dc78"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "dbf61cf9-d45c-4f9e-913d-ef67d3bef06f", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "961d0e68-bfa6-42d8-8f0f-39dfee26f182"}, {"Element": "<p class=\"MsoNormal\">The reconstituted product contains no preservative and is\nintended for single use only. Discard any unused portion.</p>", "ID": "16303a43-1b2b-4c92-a245-dc572799184c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The reconstituted product contains no preservative and is intended for single use only. Discard any unused portion.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e8c715dc-eb7e-4226-a275-ab1a909d3ba5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Any unused medicinal product or waste material should be\ndisposed of in accordance with local requirements.</p>", "ID": "458735d9-8725-4248-a37d-4a3c94dc3ed7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Any unused medicinal product or waste material should be disposed of in accordance with local requirements.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "59c14efe-bf47-4402-964c-9132e959a367", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "65add038-b677-452f-acd0-2a595452f814", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER</b></p>", "ID": "7ab5ad54-6192-455f-b75c-12ffc78aca49", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER</b>", "ID": "a2cb7972-4d5e-4cda-82c2-99be48917c02", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER", "ParentId": "7ab5ad54-6192-455f-b75c-12ffc78aca49"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "34aa4c17-266a-4d73-87d8-4252a977baa8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Roche Registration GmbH </p>", "ID": "7ba456c0-fed2-4f02-85c7-198f4ddbdc25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche Registration GmbH ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Emil-Barell-Strasse 1</span></p>", "ID": "4213dc9a-a120-490c-9524-0e11a1983e2e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Emil-Barell-Strasse 1</span>", "ID": "d8e052a1-d928-4c70-99f2-173a1cddabcd", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "4213dc9a-a120-490c-9524-0e11a1983e2e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">79639 Grenzach-Wyhlen</span></p>", "ID": "b01f949d-6dbb-4e89-aa59-5028a899966b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-CARRIBEAN\">79639 Grenzach-Wyhlen</span>", "ID": "16f05999-80f0-418e-99da-3d86adea92a5", "Styles": "None", "Classes": "None", "Text": "79639 Grenzach-Wyhlen", "ParentId": "b01f949d-6dbb-4e89-aa59-5028a899966b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Germany</span></p>", "ID": "00b6337a-9c60-43e1-80d9-646ae1f943d2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Germany</span>", "ID": "41e0e71f-a2af-414f-8f85-b4f3f318bbf0", "Styles": "None", "Classes": "None", "Text": "Germany", "ParentId": "00b6337a-9c60-43e1-80d9-646ae1f943d2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">\u00a0</span></p>", "ID": "36c9c0af-8dad-4559-9d40-9effafdbb252", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-CARRIBEAN\">\u00a0</span>", "ID": "a35c69e0-bc36-4456-b5dd-dfeabc1b71cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "36c9c0af-8dad-4559-9d40-9effafdbb252"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">\u00a0</span></p>", "ID": "47e61b21-e8d5-4064-9bb2-a21d95e8c000", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-CARRIBEAN\">\u00a0</span>", "ID": "1fde4574-7912-439a-b6c1-d6be35f6bd55", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "47e61b21-e8d5-4064-9bb2-a21d95e8c000"}, {"Element": "<p class=\"MsoNormal\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</b></p>", "ID": "c975d036-b8c5-48e0-92bb-dd2aa19b74a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</b>", "ID": "63dad75f-78b1-4fb1-ab4e-59598277b56e", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "c975d036-b8c5-48e0-92bb-dd2aa19b74a4"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "215f19fd-c656-4710-b5e2-dda833ea06ea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">EU/1/13/885/001</span></p>", "ID": "6b6bfef0-b5ea-4221-b058-2ed4d112db23", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"color:black\">EU/1/13/885/001</span>", "ID": "eeaebd38-5c63-4994-8d5a-e18f0b3a1314", "Styles": "color:black", "Classes": "None", "Text": "EU/1/13/885/001", "ParentId": "6b6bfef0-b5ea-4221-b058-2ed4d112db23"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">EU/1/13/885/002</span></p>", "ID": "13dea29a-4d87-44bc-8e97-1aea66461639", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"color:black\">EU/1/13/885/002</span>", "ID": "920e0b65-f4e2-4e82-ad8f-9a8bd6ea602c", "Styles": "color:black", "Classes": "None", "Text": "EU/1/13/885/002", "ParentId": "13dea29a-4d87-44bc-8e97-1aea66461639"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "17189c44-b152-4a91-aadf-20f8dc62b220", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0f97ca14-70b4-4111-b827-049af9f5a06f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>", "ID": "1f7dad66-3ac4-49c0-bcd1-67e4b9b9ddd8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE\nOF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b>", "ID": "cdbee7c4-80be-43c7-99e6-f1393ab2ba3b", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION", "ParentId": "1f7dad66-3ac4-49c0-bcd1-67e4b9b9ddd8"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "3d9f21c8-1e5b-4522-9939-3c7e2dff8f53", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "d2c04095-4a98-4c79-ba54-824c742cf7ac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3d9f21c8-1e5b-4522-9939-3c7e2dff8f53"}, {"Element": "<p class=\"MsoNormal\">Date of first authorisation: 15 November 2013</p>", "ID": "ae409d0e-d844-457a-b91c-fbef8a59f048", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Date of first authorisation: 15 November 2013", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Date of latest renewal: 17 September 2018</p>", "ID": "21dc070c-c656-48b3-b1e5-e5f8f241dbbe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Date of latest renewal: 17 September 2018", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "63acf4ab-2793-4f1b-8f92-fb1e4af2f3be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "9cd3b508-faec-4ab0-9266-525b79796bf3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "63acf4ab-2793-4f1b-8f92-fb1e4af2f3be"}, {"Element": "<p class=\"MsoNormal\"><i>\u00a0</i></p>", "ID": "ff2b8b66-a772-4ddf-96b5-03950b2ad14b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>\u00a0</i>", "ID": "fbed3224-3728-4a85-9975-b2e2c73bbdd6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ff2b8b66-a772-4ddf-96b5-03950b2ad14b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>10.\u00a0\u00a0\u00a0\u00a0 DATE\nOF REVISION OF THE TEXT</b></p>", "ID": "095cf1e5-0662-4808-a8ff-2685d0875f5c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>10.\u00a0\u00a0\u00a0\u00a0 DATE\nOF REVISION OF THE TEXT</b>", "ID": "e0aa5c9f-f6d5-40b0-9016-c5cd72308f9a", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT", "ParentId": "095cf1e5-0662-4808-a8ff-2685d0875f5c"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d2a8fc61-e98b-4e93-a2ce-7db94dee3c40", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\">Detailed information on this\nmedicinal product is available on the website of the European Medicines Agency <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a><span style=\"color:blue\">.</span></p>", "ID": "2ead2a19-1213-41b9-b83a-a6e084173532", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "Detailed information on this medicinal product is available on the website of the European Medicines Agency ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>", "ID": "6786949d-036c-4782-a942-c57ab9c87e38", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "2ead2a19-1213-41b9-b83a-a6e084173532"}, {"Element": "<span style=\"color:blue\">.</span>", "ID": "02b8e2d9-5528-4b2b-91eb-a7ad9182374d", "Styles": "color:blue", "Classes": "None", "Text": ".", "ParentId": "2ead2a19-1213-41b9-b83a-a6e084173532"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "268ff2f3-815e-43aa-b560-486db974dd26", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "27086d2f-31f9-4fdd-b116-f6f1032588b0", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "268ff2f3-815e-43aa-b560-486db974dd26"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6d9636a9-1d75-40e3-9300-7e0093362740", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2ef0cc71-c4a5-46e4-80a2-86a2e9f72722", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7e22d791-9348-4870-9809-4d91a60c8492", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "53e7fa69-92af-484c-8226-11878c85a333", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "59adacee-2828-44ae-8b31-592b8d5f0ba7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "946d670c-5552-4031-82cc-9b494d724487", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d3d1788b-8aea-4523-b00e-63dce9e246a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "fd7b8119-e68c-4360-bbce-ca36c0ef5f18", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "6d5a56f1-0e8c-4790-83ae-3eb185d5106c", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "04a09797-f2f2-4319-9694-1231730d033d", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "2308c069-5722-46a1-8c41-286e67ed0916", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "0075ec54-8e6c-4854-9ee1-a48abf9cc813", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "62b574f0-8720-43a7-a32d-d0339b17a3ed", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "cabd7510-f106-4efc-a0d7-c130abf997c2", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "ee38b787-e5e1-4c77-9be8-e2f32b3a656f", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "3404e7ef-7d80-4e95-9cac-ad1bede3435f", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "584fdb35-1a86-43f9-a685-858f93622bea", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "659f672e-a2d3-4544-8e6b-d848f4cb21f8", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "13116847-458e-4a97-baf0-1447cf5fdd5a", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "34884d4b-95cf-4923-bcce-cac7d18a78f2", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "f123bc97-6762-486e-8a50-19423fca0373", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "5e3547fc-4c5f-4a18-8a18-7cab0d2577b3", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "60144f9e-8d10-41f8-afe0-f2aa12596356", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:13.0pt\"><b>ANNEX\nII</b></p>", "ID": "9d5c2c11-9cc8-4b66-a287-b3c43abc13fb", "Styles": "text-align:center;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>ANNEX\nII</b>", "ID": "fcc6cb93-1f30-4859-a7f3-aa956aeb9234", "Styles": "None", "Classes": "None", "Text": "ANNEX II", "ParentId": "9d5c2c11-9cc8-4b66-a287-b3c43abc13fb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:13.0pt\">\u00a0</p>", "ID": "b227b83d-0fee-40d7-8489-61762dfcd3ea", "Styles": "margin-right:70.8pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:\n13.0pt\"><b>A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE\nBIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</b></p>", "ID": "2b7e8887-e5e1-4129-9ac7-4d8b59356ac6", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE\nBIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</b>", "ID": "98f0d699-8e69-4783-8079-a71b30a48c58", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE", "ParentId": "2b7e8887-e5e1-4129-9ac7-4d8b59356ac6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\n13.0pt\">\u00a0</p>", "ID": "cd860a5b-45c1-4e34-a119-5ca8d457a945", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt\"><b>B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS REGARDING SUPPLY AND USE</b></p>", "ID": "ba9112bd-effb-4380-ab3e-ea49bfd0480b", "Styles": "margin-top:0in;margin-right:70.9pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS REGARDING SUPPLY AND USE</b>", "ID": "5241c9da-5a97-4e8e-978e-da058a28e8b7", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "ba9112bd-effb-4380-ab3e-ea49bfd0480b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\n13.0pt\">\u00a0</p>", "ID": "682dafe8-36d5-4a37-b606-157616b88d0c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:77.95pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt\"><b>C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS\nOF THE MARKETING AUTHORISATION</b></p>", "ID": "af9d6c44-9066-45e5-a728-d50915cce784", "Styles": "margin-top:0in;margin-right:77.95pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS\nOF THE MARKETING AUTHORISATION</b>", "ID": "14143b51-39f7-4ba8-956e-d4548d1387ed", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "af9d6c44-9066-45e5-a728-d50915cce784"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:77.95pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt\"><b>\u00a0</b></p>", "ID": "911dad4e-3430-41d5-bb2b-b3de591d5687", "Styles": "margin-top:0in;margin-right:77.95pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "10c2716b-3db7-4377-8c76-9ce3e38f6ec6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "911dad4e-3430-41d5-bb2b-b3de591d5687"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:77.95pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt\"><b>D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </b><b>CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT\u00a0\n</b></p>", "ID": "2b18e52f-d476-48aa-9947-32c5d5036817", "Styles": "margin-top:0in;margin-right:77.95pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 </b>", "ID": "d828ff18-3c45-442a-822f-bc597019f89a", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2b18e52f-d476-48aa-9947-32c5d5036817"}, {"Element": "<b>CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT\u00a0\n</b>", "ID": "c3a1de68-c22e-475f-a6ef-ff844819e350", "Styles": "None", "Classes": "None", "Text": "CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT\u00a0 ", "ParentId": "2b18e52f-d476-48aa-9947-32c5d5036817"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:77.9pt;line-height:13.0pt\"><b>\u00a0</b></p>", "ID": "9448ec44-57cb-4c3b-aceb-2d688a7574e8", "Styles": "margin-right:77.9pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "710456f9-1f96-44f1-8b8f-bd975735c18b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9448ec44-57cb-4c3b-aceb-2d688a7574e8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:13.0pt\"><b>\u00a0</b></p>", "ID": "7b8cfec8-61e0-4ddd-8a2a-6d8c72d9bc7c", "Styles": "margin-right:70.8pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "1aea991c-8916-4384-8e1e-03127c6daed0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b8cfec8-61e0-4ddd-8a2a-6d8c72d9bc7c"}, {"Element": "<b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "2c636908-018a-4b6b-a676-700d00c62790", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "83e9a70a-1d76-4144-aaa1-aff359200579", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "2c636908-018a-4b6b-a676-700d00c62790"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "8a6da7c2-fc21-43b5-96c5-21314bdd559e", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "83e9a70a-1d76-4144-aaa1-aff359200579"}, {"Element": "<p class=\"AnnexHeading\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE\nBIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</p>", "ID": "31889c92-4954-4738-bc4b-566acac5d06a", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:13.0pt\">\u00a0</p>", "ID": "533592b7-6eec-4580-a4a0-a7c6220bd53e", "Styles": "margin-right:70.8pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><u>Name and address of the\nmanufacturer of the biological active substance</u></p>", "ID": "885c56e0-5234-4506-8b57-79ab9ed98a6a", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Name and address of the\nmanufacturer of the biological active substance</u>", "ID": "2f2a6c3b-232f-4376-aa2d-a4589f552171", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturer of the biological active substance", "ParentId": "885c56e0-5234-4506-8b57-79ab9ed98a6a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:13.0pt\">\u00a0</p>", "ID": "33b550f0-2b87-46f2-8dfd-9369dbbadd75", "Styles": "margin-right:70.8pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">Lonza Ltd.<br/>\nLonzastrasse<br/>\nCH-3930 Visp<br/>\nSwitzerland</p>", "ID": "86dda1f4-d81a-4b66-ad2f-b50544cde30d", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "Lonza Ltd. Lonzastrasse CH-3930 Visp Switzerland", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br/>", "ID": "8b33e470-6220-4957-8fd1-9a58ae0eff49", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "86dda1f4-d81a-4b66-ad2f-b50544cde30d"}, {"Element": "<br/>", "ID": "58eb85c7-7bcc-4d7e-bb52-8303c8a9b8c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "86dda1f4-d81a-4b66-ad2f-b50544cde30d"}, {"Element": "<br/>", "ID": "ddef7d21-05c5-4a6e-ba18-5e120632e9cd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "86dda1f4-d81a-4b66-ad2f-b50544cde30d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><b>\u00a0</b></p>", "ID": "3b531b8d-c6aa-43b9-a988-7c86f320db0d", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "41162fda-7624-49e5-851b-e7c8fe9e8220", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3b531b8d-c6aa-43b9-a988-7c86f320db0d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><u>Name and address of the\nmanufacturer responsible for batch release</u></p>", "ID": "4b1127a8-27af-490d-bee9-edf49757e408", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u>Name and address of the\nmanufacturer responsible for batch release</u>", "ID": "8ee0d868-f209-47b3-bfbe-3dfab2ca0c08", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturer responsible for batch release", "ParentId": "4b1127a8-27af-490d-bee9-edf49757e408"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "99b92dd5-a7df-42c2-8d24-f8ae445d0db8", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"DE\">Roche Pharma AG<br/>\nEmil-Barell-Strasse 1<br/>\nD-79639 Grenzach-Whylen<br/>\nGermany</span></p>", "ID": "eff69e94-9810-40a3-b886-812e0f7593bb", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE\">Roche Pharma AG<br/>\nEmil-Barell-Strasse 1<br/>\nD-79639 Grenzach-Whylen<br/>\nGermany</span>", "ID": "f3e2b6d3-d342-4ab7-8b62-469d3607f47a", "Styles": "None", "Classes": "None", "Text": "Roche Pharma AG Emil-Barell-Strasse 1 D-79639 Grenzach-Whylen Germany", "ParentId": "eff69e94-9810-40a3-b886-812e0f7593bb"}, {"Element": "<br/>", "ID": "9584b557-1acf-448d-b554-77434fde769f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f3e2b6d3-d342-4ab7-8b62-469d3607f47a"}, {"Element": "<br/>", "ID": "81c45543-79e5-4925-ad73-2feb9518619d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f3e2b6d3-d342-4ab7-8b62-469d3607f47a"}, {"Element": "<br/>", "ID": "8d5a815f-978e-4e58-aa77-5f3ce85f0311", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f3e2b6d3-d342-4ab7-8b62-469d3607f47a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><span lang=\"DE\">\u00a0</span></p>", "ID": "91d9b7f1-40e0-4751-bfef-d49990a1fd57", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "e6d04305-c465-460d-827d-3e35fcae198b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "91d9b7f1-40e0-4751-bfef-d49990a1fd57"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">The printed package leaflet of\nthe medicinal product must state the name and address of the manufacturer\nresponsible for the release of the concerned batch.</p>", "ID": "73eb2fc1-edaf-4ae1-a2b5-4aa008d995c2", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "c790ddcb-2f4b-4287-bcb1-85e6a8e882c5", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "21e2ac1d-3fd2-4ae6-a079-d9fc86d3f7c2", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"AnnexHeading\"><a name=\"OLE_LINK2\">B.</a>\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE </p>", "ID": "f95c8227-40f7-4ce6-82b8-00a45b5b3d8b", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<a name=\"OLE_LINK2\">B.</a>", "ID": "42f26169-4cf1-43f5-96f4-f0ee43576310", "Styles": "None", "Classes": "None", "Text": "B.", "ParentId": "f95c8227-40f7-4ce6-82b8-00a45b5b3d8b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "861f5579-58d8-41b6-8231-f15be5bf3ce7", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">Medicinal product subject to\nrestricted medical prescription (see Annex I: Summary of Product\nCharacteristics, section 4.2).</p>", "ID": "383cebf8-bc19-4801-a270-f9f7f759cfab", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\">\u00a0</p>", "ID": "d666feba-f00a-453e-8448-aba28a000f99", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><b>\u00a0</b></p>", "ID": "00a8a5b4-f0cc-45e0-b138-fc86bcf6c37f", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "7114d539-ebcc-4681-a64e-335c05372c51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00a8a5b4-f0cc-45e0-b138-fc86bcf6c37f"}, {"Element": "<p class=\"AnnexHeading\">C. \u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND\nREQUIREMENTS OF THE MARKETING AUTHORISATION</p>", "ID": "56851e59-fc02-4045-a8e9-3792a0359466", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "C. \u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "e586619d-fce7-4a53-ac3f-f413ee645619", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "06e4c315-5fe1-425a-9a32-818b3cba0d6d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e586619d-fce7-4a53-ac3f-f413ee645619"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "3a562277-562c-43e7-9fef-0f1d94bf2d06", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "06e4c315-5fe1-425a-9a32-818b3cba0d6d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b>Periodic\nSafety Update Reports</b></p>", "ID": "f17ee16e-af56-4716-be8c-1b5681885c3c", "Styles": "margin-left:.5in;text-indent:-.5in;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "15cb1261-6ced-403c-be42-92c266dff807", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f17ee16e-af56-4716-be8c-1b5681885c3c"}, {"Element": "<b>Periodic\nSafety Update Reports</b>", "ID": "39e88c9a-28a3-4110-8829-1ae687e95f32", "Styles": "None", "Classes": "None", "Text": "Periodic Safety Update Reports", "ParentId": "f17ee16e-af56-4716-be8c-1b5681885c3c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\">\u00a0</p>", "ID": "e770a58c-c582-49e7-a8da-d7107a94b5ac", "Styles": "margin-right:28.35pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\">The\nrequirements for submission of periodic safety update reports for this\nmedicinal product are set out in the list of Union reference dates (EURD list)\nprovided for under Article 107c(7) of Directive 2001/83/EC and any subsequent\nupdates published on the European medicines web-portal.</p>", "ID": "9f9dd2d8-f5bb-4832-8c7e-d1421e7ed539", "Styles": "margin-right:28.35pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "bd3b9487-f059-4273-bd28-319410e35eda", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "02237af9-c703-4611-b98c-cb1ae00deb15", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd3b9487-f059-4273-bd28-319410e35eda"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "ee52e4cc-bc3c-4bb3-8950-e3e28c2b858c", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "02237af9-c703-4611-b98c-cb1ae00deb15"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "70a6fa6a-b93f-4470-947b-6999903a1ee6", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "ef2367df-6f18-4c08-bff9-996f84502882", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "70a6fa6a-b93f-4470-947b-6999903a1ee6"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "cc6d729e-a315-4841-a732-e09c249e738d", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "ef2367df-6f18-4c08-bff9-996f84502882"}, {"Element": "<p class=\"AnnexHeading\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT\u00a0 </p>", "ID": "fac6e774-d281-45cd-930e-0d96488c0b2d", "Styles": "None", "Classes": "['AnnexHeading']", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\"><u><span style=\"text-decoration:none\">\u00a0</span></u></p>", "ID": "d873dcc0-3e26-4dc9-ac2c-58c701891574", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "4b3e6d7f-8695-4bb4-b2f0-c7c234cfc1f7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d873dcc0-3e26-4dc9-ac2c-58c701891574"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "4e898786-ed9b-42e3-97ef-653ecc431730", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "4b3e6d7f-8695-4bb4-b2f0-c7c234cfc1f7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b>Risk\nManagement Plan (RMP)</b></p>", "ID": "1756da82-57a9-4c3d-9e3a-2df9a270065a", "Styles": "margin-left:.5in;text-indent:-.5in;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "fe79ed29-71c2-49d0-93bf-d29915b3496c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1756da82-57a9-4c3d-9e3a-2df9a270065a"}, {"Element": "<b>Risk\nManagement Plan (RMP)</b>", "ID": "4dd528e3-28b5-4cb9-81bc-0b8dcf88dd7b", "Styles": "None", "Classes": "None", "Text": "Risk Management Plan (RMP)", "ParentId": "1756da82-57a9-4c3d-9e3a-2df9a270065a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.0pt\"><b>\u00a0</b></p>", "ID": "b150a854-5f62-4aed-9fcb-218ec3978743", "Styles": "margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "8444d129-2d27-4945-8886-4e5c78acb216", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b150a854-5f62-4aed-9fcb-218ec3978743"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:13.0pt\">The MAH\nshall perform the required pharmacovigilance activities and interventions\ndetailed in the agreed RMP presented in Module 1.8.2 of the Marketing\nAuthorisation and any agreed subsequent updates of the RMP.</p>", "ID": "6ac83da2-cf9c-4c9a-a3d4-ffed70276228", "Styles": "margin-right:28.35pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\">\u00a0</p>", "ID": "68a719fd-8116-4498-9b79-0ff3f1338a3b", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid\">An updated RMP should be submitted:</p>", "ID": "88a8a935-b442-4257-83c2-a5b1b4782b7d", "Styles": "margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "An updated RMP should be submitted:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt;line-height:\n13.0pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0 At the\nrequest of the European Medicines Agency;</p>", "ID": "4a930abf-1e10-4a74-b006-a7bad2b7afd5", "Styles": "margin-left:35.7pt;text-indent:-17.85pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0 At the request of the European Medicines Agency;", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f803fdb2-64ad-4783-99a5-209d9ece21e4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4a930abf-1e10-4a74-b006-a7bad2b7afd5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:35.7pt;text-indent:-17.85pt;line-height:\n13.0pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0 Whenever\nthe risk management system is modified, especially as the result of new information\nbeing received that may lead to a significant change to the benefit/risk\nprofile or as the result of an important (pharmacovigilance or risk\nminimisation) milestone being reached.</p>", "ID": "e203c4ac-b78b-4f1e-9c9e-d2f9ef0a5511", "Styles": "margin-left:35.7pt;text-indent:-17.85pt;line-height:\n13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0 Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "6003abf8-6c57-4b6d-b981-107fb0d45a3c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e203c4ac-b78b-4f1e-9c9e-d2f9ef0a5511"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\">\u00a0</p>", "ID": "edb189c2-e0c1-48c1-9eb4-6890e3637941", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:13.0pt;\npage-break-after:avoid\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b>Additional\nrisk minimisation measures </b></p>", "ID": "31c84a18-e44b-4dd7-8846-a58637667605", "Styles": "margin-left:.5in;text-indent:-.5in;line-height:13.0pt;\npage-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "2ac04c1b-0320-4d7a-ab29-6453d0d83ea4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "31c84a18-e44b-4dd7-8846-a58637667605"}, {"Element": "<b>Additional\nrisk minimisation measures </b>", "ID": "0e01ec75-6663-48af-8f25-950f9c195b26", "Styles": "None", "Classes": "None", "Text": "Additional risk minimisation measures ", "ParentId": "31c84a18-e44b-4dd7-8846-a58637667605"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid\">\u00a0</p>", "ID": "d490eab6-3f6d-471f-940f-071fbe23bb89", "Styles": "margin-right:-.05pt;line-height:13.0pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The MAH shall agree the content and format of the Kadcyla (trastuzumab\nemtansine) educational material and a communication plan with the National\nCompetent Authority in the Member State before Kadcyla (trastuzumab emtansine)\nis launched in each Member State.</p>", "ID": "1f42fe6b-4faf-4a76-a31f-517f7a41295f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The MAH shall agree the content and format of the Kadcyla (trastuzumab emtansine) educational material and a communication plan with the National Competent Authority in the Member State before Kadcyla (trastuzumab emtansine) is launched in each Member State.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6febbb12-5454-4c4a-8978-b1f13aaf8e24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The MAH shall ensure that in parallel to the launch of Kadcyla\n(trastuzumab emtansine), all health care professionals who may prescribe,\ndispense or administer Kadcyla (trastuzumab emtansine) and/or Herceptin (trastuzumab)\nare provided with a health care professional (HCP) educational pack.\u00a0 This\nHCP educational pack shall consist of the following:</p>", "ID": "7f5236c6-0cb8-415d-b232-ec927a5f77e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The MAH shall ensure that in parallel to the launch of Kadcyla (trastuzumab emtansine), all health care professionals who may prescribe, dispense or administer Kadcyla (trastuzumab emtansine) and/or Herceptin (trastuzumab) are provided with a health care professional (HCP) educational pack.\u00a0 This HCP educational pack shall consist of the following:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d457acd6-ae51-4c7a-a279-514ce8240b9c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:38.25pt;text-indent:-17.85pt;line-height:\n115%\"><span lang=\"ES\" style=\"line-height:115%;font-family:Symbol\">\u00b7</span><span style=\"line-height:115%\">\u00a0\u00a0\u00a0 </span><span style=\"line-height:\n115%\">Kadcyla (trastuzumab emtansine) SPC</span></p>", "ID": "d40636e5-ef67-4392-9a8e-aa1fc5cbbbc1", "Styles": "margin-left:38.25pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"line-height:115%;font-family:Symbol\">\u00b7</span>", "ID": "21c56b35-9022-4c5a-b32e-688d1e49b4da", "Styles": "line-height:115%;font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d40636e5-ef67-4392-9a8e-aa1fc5cbbbc1"}, {"Element": "<span style=\"line-height:115%\">\u00a0\u00a0\u00a0 </span>", "ID": "d09adfd2-be85-4000-8cce-0b57423b4620", "Styles": "line-height:115%", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "d40636e5-ef67-4392-9a8e-aa1fc5cbbbc1"}, {"Element": "<span style=\"line-height:\n115%\">Kadcyla (trastuzumab emtansine) SPC</span>", "ID": "d40e0853-3055-46d0-a29a-24d6710ac952", "Styles": "line-height:\n115%", "Classes": "None", "Text": "Kadcyla (trastuzumab emtansine) SPC", "ParentId": "d40636e5-ef67-4392-9a8e-aa1fc5cbbbc1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:38.25pt;text-indent:-17.85pt;line-height:\n115%\"><span lang=\"ES\" style=\"line-height:115%;font-family:Symbol\">\u00b7</span><span style=\"line-height:115%\">\u00a0\u00a0\u00a0 </span><span style=\"line-height:\n115%\">Health care professional information </span></p>", "ID": "a011c452-7635-4d9d-9a6f-9bad3f873e52", "Styles": "margin-left:38.25pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"line-height:115%;font-family:Symbol\">\u00b7</span>", "ID": "ca5256b6-e706-427f-9c0d-301c717ca437", "Styles": "line-height:115%;font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a011c452-7635-4d9d-9a6f-9bad3f873e52"}, {"Element": "<span style=\"line-height:115%\">\u00a0\u00a0\u00a0 </span>", "ID": "181ec2de-ebab-4063-b574-ec5383b1601b", "Styles": "line-height:115%", "Classes": "None", "Text": "\u00a0\u00a0\u00a0 ", "ParentId": "a011c452-7635-4d9d-9a6f-9bad3f873e52"}, {"Element": "<span style=\"line-height:\n115%\">Health care professional information </span>", "ID": "f2a684cc-ae48-4e7b-8770-81bfb0742161", "Styles": "line-height:\n115%", "Classes": "None", "Text": "Health care professional information ", "ParentId": "a011c452-7635-4d9d-9a6f-9bad3f873e52"}, {"Element": "<p class=\"MsoNormal\">The HCP information shall contain the following key\nmessages:</p>", "ID": "32f23042-2974-4fea-823c-b582a7a01bea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The HCP information shall contain the following key messages:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "56df111f-9b0f-43f5-b969-741f214225fe", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">1.\u00a0\u00a0 Kadcyla (</span><span style=\"line-height:115%\">trastuzumab emtansine)</span><span style=\"line-height:\n115%\"> and Herceptin (trastuzumab) are two very different products with\ndifferent active substances never to be used interchangeably.\u00a0 </span><span style=\"line-height:115%\">Kadcyla (trastuzumab emtansine)</span><span style=\"line-height:115%\"> is NOT a generic version of Herceptin (trastuzumab) and\nhas different properties, indications and dose.</span></p>", "ID": "d77bdb08-5043-4bf8-81aa-3d20b9fe815f", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">1.\u00a0\u00a0 Kadcyla (</span>", "ID": "a44fed84-7e22-4177-889a-be8b00dbf9db", "Styles": "line-height:115%", "Classes": "None", "Text": "1.\u00a0\u00a0 Kadcyla (", "ParentId": "d77bdb08-5043-4bf8-81aa-3d20b9fe815f"}, {"Element": "<span style=\"line-height:115%\">trastuzumab emtansine)</span>", "ID": "425ef33e-08cb-4ee2-b144-052951856b16", "Styles": "line-height:115%", "Classes": "None", "Text": "trastuzumab emtansine)", "ParentId": "d77bdb08-5043-4bf8-81aa-3d20b9fe815f"}, {"Element": "<span style=\"line-height:\n115%\"> and Herceptin (trastuzumab) are two very different products with\ndifferent active substances never to be used interchangeably.\u00a0 </span>", "ID": "53e1980f-3eea-4b13-8e2a-6162c74b1aa9", "Styles": "line-height:\n115%", "Classes": "None", "Text": " and Herceptin (trastuzumab) are two very different products with different active substances never to be used interchangeably.\u00a0 ", "ParentId": "d77bdb08-5043-4bf8-81aa-3d20b9fe815f"}, {"Element": "<span style=\"line-height:115%\">Kadcyla (trastuzumab emtansine)</span>", "ID": "246e4285-7585-462f-886b-b126059f1294", "Styles": "line-height:115%", "Classes": "None", "Text": "Kadcyla (trastuzumab emtansine)", "ParentId": "d77bdb08-5043-4bf8-81aa-3d20b9fe815f"}, {"Element": "<span style=\"line-height:115%\"> is NOT a generic version of Herceptin (trastuzumab) and\nhas different properties, indications and dose.</span>", "ID": "b65936d1-ea50-402c-81bd-ff9dbb40464d", "Styles": "line-height:115%", "Classes": "None", "Text": " is NOT a generic version of Herceptin (trastuzumab) and has different properties, indications and dose.", "ParentId": "d77bdb08-5043-4bf8-81aa-3d20b9fe815f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">2.\u00a0\u00a0 Trastuzumab emtansine is an\nantibody-drug conjugate containing humanized anti-HER2 IgG1 antibody\ntrastuzumab and DM1, a microtubule-inhibitory maytansinoid. </span></p>", "ID": "b774d871-1a89-4ab2-8bc0-2c8ae89d79f4", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">2.\u00a0\u00a0 Trastuzumab emtansine is an\nantibody-drug conjugate containing humanized anti-HER2 IgG1 antibody\ntrastuzumab and DM1, a microtubule-inhibitory maytansinoid. </span>", "ID": "b64ac96b-4ac3-460d-b9fb-2c21ee1316f1", "Styles": "line-height:115%", "Classes": "None", "Text": "2.\u00a0\u00a0 Trastuzumab emtansine is an antibody-drug conjugate containing humanized anti-HER2 IgG1 antibody trastuzumab and DM1, a microtubule-inhibitory maytansinoid. ", "ParentId": "b774d871-1a89-4ab2-8bc0-2c8ae89d79f4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">3.\u00a0\u00a0 Do not substitute or\ncombine trastuzumab emtansine with or for trastuzumab</span></p>", "ID": "23892f08-05cb-4ae4-a323-1f850f58c73f", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">3.\u00a0\u00a0 Do not substitute or\ncombine trastuzumab emtansine with or for trastuzumab</span>", "ID": "b7d4c3b4-1e00-4631-86fc-11647abb943e", "Styles": "line-height:115%", "Classes": "None", "Text": "3.\u00a0\u00a0 Do not substitute or combine trastuzumab emtansine with or for trastuzumab", "ParentId": "23892f08-05cb-4ae4-a323-1f850f58c73f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">4.\u00a0\u00a0 Do not administer trastuzumab\nemtansine in combination with chemotherapy</span></p>", "ID": "f6415dfc-43f0-46e1-822a-d4f09fef2705", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">4.\u00a0\u00a0 Do not administer trastuzumab\nemtansine in combination with chemotherapy</span>", "ID": "c46a7424-467e-40d9-bc8b-5da6e03da288", "Styles": "line-height:115%", "Classes": "None", "Text": "4.\u00a0\u00a0 Do not administer trastuzumab emtansine in combination with chemotherapy", "ParentId": "f6415dfc-43f0-46e1-822a-d4f09fef2705"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">5.\u00a0\u00a0 Do not administer </span><span style=\"line-height:115%\">trastuzumab emtansine</span><span style=\"line-height:\n115%\"> at doses greater than 3.6 mg/kg once every 3 weeks</span><span style=\"line-height:115%\"> </span></p>", "ID": "f1cef3ef-6275-4deb-b430-ccb0e4db2a4d", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">5.\u00a0\u00a0 Do not administer </span>", "ID": "50c123df-1cc1-4632-ba3c-bd2efae41154", "Styles": "line-height:115%", "Classes": "None", "Text": "5.\u00a0\u00a0 Do not administer ", "ParentId": "f1cef3ef-6275-4deb-b430-ccb0e4db2a4d"}, {"Element": "<span style=\"line-height:115%\">trastuzumab emtansine</span>", "ID": "dd390231-b15d-424f-b7ca-48d559a83c6a", "Styles": "line-height:115%", "Classes": "None", "Text": "trastuzumab emtansine", "ParentId": "f1cef3ef-6275-4deb-b430-ccb0e4db2a4d"}, {"Element": "<span style=\"line-height:\n115%\"> at doses greater than 3.6 mg/kg once every 3 weeks</span>", "ID": "88a2c8cb-84d6-4699-90f2-5f04fe01b6b5", "Styles": "line-height:\n115%", "Classes": "None", "Text": " at doses greater than 3.6 mg/kg once every 3 weeks", "ParentId": "f1cef3ef-6275-4deb-b430-ccb0e4db2a4d"}, {"Element": "<span style=\"line-height:115%\"> </span>", "ID": "10a9a959-d88c-4595-9fbc-7755ccd188b5", "Styles": "line-height:115%", "Classes": "None", "Text": " ", "ParentId": "f1cef3ef-6275-4deb-b430-ccb0e4db2a4d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">6.\u00a0\u00a0 If a prescription for\nKadcyla (trastuzumab emtansine) is written electronically, it is important to\nensure that the medicinal product prescribed is trastuzumab emtansine and not\ntrastuzumab. </span></p>", "ID": "4eeca532-3a1e-4853-b670-4d988b326943", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">6.\u00a0\u00a0 If a prescription for\nKadcyla (trastuzumab emtansine) is written electronically, it is important to\nensure that the medicinal product prescribed is trastuzumab emtansine and not\ntrastuzumab. </span>", "ID": "d32bae0e-26ca-4a57-b49f-fe1bd1065528", "Styles": "line-height:115%", "Classes": "None", "Text": "6.\u00a0\u00a0 If a prescription for Kadcyla (trastuzumab emtansine) is written electronically, it is important to ensure that the medicinal product prescribed is trastuzumab emtansine and not trastuzumab. ", "ParentId": "4eeca532-3a1e-4853-b670-4d988b326943"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">7.\u00a0\u00a0 Both the invented name\nKadcyla<b> </b>and its full non-proprietary name (trastuzumab emtansine) should\nbe used and confirmed when prescribing, preparing the infusion solution and administering\nKadcyla (trastuzumab emtansine) to patients. It must be verified that the\nnon-proprietary name is trastuzumab emtansine.</span></p>", "ID": "972b22a9-6cae-4ecb-8854-dddb14ccd27d", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">7.\u00a0\u00a0 Both the invented name\nKadcyla<b> </b>and its full non-proprietary name (trastuzumab emtansine) should\nbe used and confirmed when prescribing, preparing the infusion solution and administering\nKadcyla (trastuzumab emtansine) to patients. It must be verified that the\nnon-proprietary name is trastuzumab emtansine.</span>", "ID": "5782f905-e2db-4f04-a934-3ae5dd218cbf", "Styles": "line-height:115%", "Classes": "None", "Text": "7.\u00a0\u00a0 Both the invented name Kadcylaand its full non-proprietary name (trastuzumab emtansine) should be used and confirmed when prescribing, preparing the infusion solution and administering Kadcyla (trastuzumab emtansine) to patients. It must be verified that the non-proprietary name is trastuzumab emtansine.", "ParentId": "972b22a9-6cae-4ecb-8854-dddb14ccd27d"}, {"Element": "<b> </b>", "ID": "0627c45f-3963-41a6-88a6-c006125a0b43", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "5782f905-e2db-4f04-a934-3ae5dd218cbf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">8.\u00a0\u00a0 In order to prevent medicinal\nproduct errors it is important to review the Summary of Product Characteristics\nand to check the outer carton and vial labels to ensure that the medicinal\nproduct being prepared and administered is Kadcyla (trastuzumab emtansine) and\nnot trastuzumab. </span></p>", "ID": "6437fd22-0d6e-49d8-9d9a-8297ef0b0846", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">8.\u00a0\u00a0 In order to prevent medicinal\nproduct errors it is important to review the Summary of Product Characteristics\nand to check the outer carton and vial labels to ensure that the medicinal\nproduct being prepared and administered is Kadcyla (trastuzumab emtansine) and\nnot trastuzumab. </span>", "ID": "3248478c-28da-4a4e-b2f5-6b5dde0c49ec", "Styles": "line-height:115%", "Classes": "None", "Text": "8.\u00a0\u00a0 In order to prevent medicinal product errors it is important to review the Summary of Product Characteristics and to check the outer carton and vial labels to ensure that the medicinal product being prepared and administered is Kadcyla (trastuzumab emtansine) and not trastuzumab. ", "ParentId": "6437fd22-0d6e-49d8-9d9a-8297ef0b0846"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">9.\u00a0\u00a0 Description of the key\ndifferences between trastuzumab emtansine and trastuzumab in relation to\nindication, dose, administration and packaging differences. </span></p>", "ID": "c94be95d-fe61-4fb2-bd3e-ad2ef7b80c0e", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">9.\u00a0\u00a0 Description of the key\ndifferences between trastuzumab emtansine and trastuzumab in relation to\nindication, dose, administration and packaging differences. </span>", "ID": "9ab0bb44-fe5f-449e-a4d7-f5706ec93b48", "Styles": "line-height:115%", "Classes": "None", "Text": "9.\u00a0\u00a0 Description of the key differences between trastuzumab emtansine and trastuzumab in relation to indication, dose, administration and packaging differences. ", "ParentId": "c94be95d-fe61-4fb2-bd3e-ad2ef7b80c0e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%\"><span style=\"line-height:115%\">\u00a0</span></p>", "ID": "f907dd61-3f85-4f77-aa90-93a749fe67e5", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;line-height:\n115%", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"line-height:115%\">\u00a0</span>", "ID": "f0597e53-17fc-481e-8fbf-8cb45c75d221", "Styles": "line-height:115%", "Classes": "None", "Text": "\u00a0", "ParentId": "f907dd61-3f85-4f77-aa90-93a749fe67e5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>Obligation to conduct\npost-authorisation measures</b></p>", "ID": "6acd3091-2cd9-4677-9ae0-3a837a012199", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Obligation to conduct\npost-authorisation measures</b>", "ID": "fc0de86f-62af-40a8-a45c-9c12d66955cc", "Styles": "None", "Classes": "None", "Text": "Obligation to conduct post-authorisation measures", "ParentId": "6acd3091-2cd9-4677-9ae0-3a837a012199"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>", "ID": "d6685a08-778e-47dd-a8a7-fdb1601cc61c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">The MAH shall complete, within\nthe stated timeframe, the below measures:</p>", "ID": "48cd1b55-cc77-47d4-8b56-4e0c64cea723", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "The MAH shall complete, within the stated timeframe, the below measures:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">\u00a0</p>", "ID": "5216ba1b-d5e1-4040-8b38-e3a23a666a48", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:339.95pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"453\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Description</p>\n</td>\n<td style=\"width:113.15pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Due date</p>\n</td>\n</tr>\n<tr>\n<td style=\"width:339.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"453\">\n<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PAES:\n  In order to further investigate the efficacy of trastuzumab emtansine in the\n  adjuvant treatment of adult patients with HER2-positive early breast cancer\n  who have residual invasive disease, in the breast and/or lymph nodes, after\n  neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the\n  final analysis of OS from the phase 3, randomised, open-label study KATHERINE\n  (BO27938).</span></p>\n</td>\n<td style=\"width:113.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\">\n<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30\n  June 2024</span></p>\n</td>\n</tr>\n</table>", "ID": "f637f33d-7ecc-4fa4-ba99-c489447ae58f", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "   ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:339.95pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"453\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Description</p>\n</td>\n<td style=\"width:113.15pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Due date</p>\n</td>\n</tr>", "ID": "6a3d2159-2366-4cc5-8100-f240750299d0", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "f637f33d-7ecc-4fa4-ba99-c489447ae58f"}, {"Element": "<td style=\"width:339.95pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"453\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Description</p>\n</td>", "ID": "ab19fbfc-adf9-4c82-8e9e-40c3e6cfd3fa", "Styles": "width:339.95pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6a3d2159-2366-4cc5-8100-f240750299d0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">Description</p>", "ID": "b5ca9676-664b-490e-a444-10693c3adb24", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "Description", "ParentId": "ab19fbfc-adf9-4c82-8e9e-40c3e6cfd3fa"}, {"Element": "<td style=\"width:113.15pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\">\n<p class=\"MsoNormal\" style=\"text-autospace:none\">Due date</p>\n</td>", "ID": "be127790-bb2b-4ba0-8252-41f0354f8c13", "Styles": "width:113.15pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6a3d2159-2366-4cc5-8100-f240750299d0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">Due date</p>", "ID": "b60c735b-d158-4c1e-9181-2d922a66450a", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "Due date", "ParentId": "be127790-bb2b-4ba0-8252-41f0354f8c13"}, {"Element": "<tr>\n<td style=\"width:339.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"453\">\n<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PAES:\n  In order to further investigate the efficacy of trastuzumab emtansine in the\n  adjuvant treatment of adult patients with HER2-positive early breast cancer\n  who have residual invasive disease, in the breast and/or lymph nodes, after\n  neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the\n  final analysis of OS from the phase 3, randomised, open-label study KATHERINE\n  (BO27938).</span></p>\n</td>\n<td style=\"width:113.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\">\n<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30\n  June 2024</span></p>\n</td>\n</tr>", "ID": "a32625ea-3321-453d-b5fd-4b8d7400114f", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "f637f33d-7ecc-4fa4-ba99-c489447ae58f"}, {"Element": "<td style=\"width:339.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"453\">\n<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PAES:\n  In order to further investigate the efficacy of trastuzumab emtansine in the\n  adjuvant treatment of adult patients with HER2-positive early breast cancer\n  who have residual invasive disease, in the breast and/or lymph nodes, after\n  neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the\n  final analysis of OS from the phase 3, randomised, open-label study KATHERINE\n  (BO27938).</span></p>\n</td>", "ID": "c04f18f6-b60b-4745-b30c-0f16b4e1814f", "Styles": "width:339.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a32625ea-3321-453d-b5fd-4b8d7400114f"}, {"Element": "<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PAES:\n  In order to further investigate the efficacy of trastuzumab emtansine in the\n  adjuvant treatment of adult patients with HER2-positive early breast cancer\n  who have residual invasive disease, in the breast and/or lymph nodes, after\n  neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the\n  final analysis of OS from the phase 3, randomised, open-label study KATHERINE\n  (BO27938).</span></p>", "ID": "e254aad4-450e-4b4b-86ae-9d5a37c49ad6", "Styles": "None", "Classes": "['Paragraph']", "Text": "", "ParentId": "c04f18f6-b60b-4745-b30c-0f16b4e1814f"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PAES:\n  In order to further investigate the efficacy of trastuzumab emtansine in the\n  adjuvant treatment of adult patients with HER2-positive early breast cancer\n  who have residual invasive disease, in the breast and/or lymph nodes, after\n  neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the\n  final analysis of OS from the phase 3, randomised, open-label study KATHERINE\n  (BO27938).</span>", "ID": "6b361282-5b5b-42cd-8b60-f8d948f1c537", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "PAES:   In order to further investigate the efficacy of trastuzumab emtansine in the   adjuvant treatment of adult patients with HER2-positive early breast cancer   who have residual invasive disease, in the breast and/or lymph nodes, after   neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the   final analysis of OS from the phase 3, randomised, open-label study KATHERINE   (BO27938).", "ParentId": "e254aad4-450e-4b4b-86ae-9d5a37c49ad6"}, {"Element": "<td style=\"width:113.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"151\">\n<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30\n  June 2024</span></p>\n</td>", "ID": "568b34fe-4bc6-47c1-89e7-d897b3a322ef", "Styles": "width:113.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a32625ea-3321-453d-b5fd-4b8d7400114f"}, {"Element": "<p class=\"Paragraph\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30\n  June 2024</span></p>", "ID": "40dedbc7-8431-4eb3-b318-c31334ff5e4e", "Styles": "None", "Classes": "['Paragraph']", "Text": "", "ParentId": "568b34fe-4bc6-47c1-89e7-d897b3a322ef"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>30\n  June 2024</span>", "ID": "7314bff4-cc12-422c-9f61-f0ebcfd55990", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": "30   June 2024", "ParentId": "40dedbc7-8431-4eb3-b318-c31334ff5e4e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:13.0pt\">\u00a0</p>", "ID": "a06e5cb4-cb61-4d9d-980f-5becbd77df9f", "Styles": "margin-right:-.05pt;line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "0a65c4cf-20db-4988-8023-73d93bcb5904", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "a273c13a-f094-4d62-9642-e7ecbbf46bd0", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "0a65c4cf-20db-4988-8023-73d93bcb5904"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "0a9a50b8-b525-47e5-8198-ba295d6bb8dd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "1b0d3a8e-faea-45f5-a8eb-20c557f9ae82", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "96482f55-89f9-4b44-950b-3439ed7967f1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "e66d0bcc-d2ca-49c8-8ecc-a572123938e7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "f8df0e2b-0dcf-4636-b145-8ec99c245351", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "6160991f-d4e8-4a56-9978-48665fd44ed5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "591956da-bd19-4f01-8783-5820de9c2e66", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "a1cdf80b-cd73-4d92-baf2-2843da39a86a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "d16ff3ad-dcfe-4999-b0d3-8d79b1894674", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "b0bed95c-f6c8-4c8e-9ee1-1bfb3b1e46a2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ddbfab1a-a552-439e-b241-318793070f07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8cca9119-4ea0-4309-a260-d52de60fcc9f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6094d751-63c6-4f08-b936-b5646b20d0ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "697b2d0c-b2cf-46b0-9454-ac9f6e091f5b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a019130c-b50f-43c1-a222-0050c8ef189d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "69e56930-ca97-457b-955b-fd8a52d7d641", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "feedf4ad-4c8a-4619-9c1c-1f28140fb8ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "706cc919-90e2-48b0-b2c9-4cf4ff16fc42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "02ef21ea-47bf-4678-857d-992173adb666", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f113e557-6d67-4dbf-88c6-a1b79f2b5f7c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "41c586a2-aa98-43b6-9cb7-01cdb9dd1acd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e1bd47e2-632f-4e2f-8f24-f13bd7d6d038", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8a3b34db-aa34-46a8-8759-c24d36dc0875", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7573ae86-2d7a-4830-9d39-e28df1264004", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>ANNEX III</b></p>", "ID": "70c3de10-c307-47ec-af0e-28791040060c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>ANNEX III</b>", "ID": "634e46c7-7fc7-4187-8447-0426a79a91f4", "Styles": "None", "Classes": "None", "Text": "ANNEX III", "ParentId": "70c3de10-c307-47ec-af0e-28791040060c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "35d6faac-d58a-423c-975d-1857929b8c89", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "57ed576e-8a2a-4548-8ee7-6b9cb630f86e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35d6faac-d58a-423c-975d-1857929b8c89"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>LABELLING AND\nPACKAGE LEAFLET</b></p>", "ID": "670aae3d-991c-44a9-aac5-418df32e341e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>LABELLING AND\nPACKAGE LEAFLET</b>", "ID": "14ed524d-f04d-43ef-8092-3feb46634e26", "Styles": "None", "Classes": "None", "Text": "LABELLING AND PACKAGE LEAFLET", "ParentId": "670aae3d-991c-44a9-aac5-418df32e341e"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "15bff53f-09df-4878-9467-b72a40968176", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "8a59daf6-f0f0-4e63-ada3-a53566c3a482", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "69f2512e-6c5b-4b9b-99a9-30160ac14c70", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "8a59daf6-f0f0-4e63-ada3-a53566c3a482"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "068167b1-02b9-4f5c-8169-26785052fcd6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a0f2b4ed-4a9c-4299-981f-e2fe92e93446", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "44ee04ee-ac3c-4567-a445-9e44ac9e5aef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a5dd90a6-8b9a-48c5-b9c6-b5b88921fd72", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c30729f6-92f7-47d7-86a1-44fb8cc1f3d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "32705207-2c79-4446-bf3c-c35f82693463", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3a97955e-3464-427c-ba5a-215334339201", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "eefdf0bc-892c-4876-9f9e-a8f42fb601a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "05e7e97e-7c4b-4415-85b4-333029ab4f53", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e2f5e8c9-1a15-4632-8e8d-7fa7581df04e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d9b5bbb8-da5a-494b-a9da-036c81649efb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "efccde73-c16c-412d-89b6-9036e356329c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8f43c9bc-84b4-497a-a722-ef3d5f86609a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "74652f64-635b-4c47-a8d8-570af7e0884c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4cf9170d-a1a5-4384-aefd-f6728b821020", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a120a275-917e-4dce-878b-e40797039e31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f2fbbc4f-1098-4900-9698-71403a558513", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "61d5106c-ae21-4fa3-aec7-4aca7604b9d3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c2675905-3d14-4960-acf6-7b0f16b3bd26", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0ab55744-f64a-40b7-bd22-12bd69c0cdab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1842c178-57e6-4118-a4c5-12325223ea5d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8ff21799-b16b-444f-aa5c-2964f27e9044", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f3688d01-2da1-43af-bc62-a2f71ac98d83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "303d31e5-3639-41f7-a1c1-b267a21c51be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"Annex\">A. LABELLING</p>", "ID": "0a34765c-8305-485a-834d-e0b814272557", "Styles": "None", "Classes": "['Annex']", "Text": "A. LABELLING", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "71980587-cfaf-4773-baf7-e08f186be8ad", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "573aae66-53e8-4edb-95d6-b1ee460ced94", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "71980587-cfaf-4773-baf7-e08f186be8ad"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e5630b64-192d-402b-b3f1-2a1e99ec1916", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>CARTON </b></p>\n</td>\n</tr>\n</table>", "ID": "c13bae63-dff7-4eb6-8136-29abbffc8911", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>CARTON </b></p>\n</td>\n</tr>", "ID": "18b394be-421e-4e49-b7dc-7215923b05a0", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "c13bae63-dff7-4eb6-8136-29abbffc8911"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>CARTON </b></p>\n</td>", "ID": "0bb6294f-969d-413f-9d2a-696ff606dea0", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "18b394be-421e-4e49-b7dc-7215923b05a0"}, {"Element": "<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>", "ID": "dadd2236-eb36-42d3-8668-93ab14d7c859", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0bb6294f-969d-413f-9d2a-696ff606dea0"}, {"Element": "<b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b>", "ID": "4b41abe5-d5ab-438e-8d0e-607df799d6f1", "Styles": "None", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING", "ParentId": "dadd2236-eb36-42d3-8668-93ab14d7c859"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "e60fb775-2de9-4cf4-bbb6-3e82cf713daa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0bb6294f-969d-413f-9d2a-696ff606dea0"}, {"Element": "<b>\u00a0</b>", "ID": "d5567e84-07c1-4e39-9159-a130790ff3c4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e60fb775-2de9-4cf4-bbb6-3e82cf713daa"}, {"Element": "<p class=\"MsoNormal\"><b>CARTON </b></p>", "ID": "5a74f26f-b9e3-40b0-ac63-552b2aa01c54", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0bb6294f-969d-413f-9d2a-696ff606dea0"}, {"Element": "<b>CARTON </b>", "ID": "c50c6d7c-0f10-4254-9e71-cb805a54fd68", "Styles": "None", "Classes": "None", "Text": "CARTON ", "ParentId": "5a74f26f-b9e3-40b0-ac63-552b2aa01c54"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1b4499a1-031c-4228-a72a-2963d0bdbfb6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9ecadec2-5b31-4132-b6e1-9a6f29507f11", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>\n</td>\n</tr>\n</table>", "ID": "ae37a6b1-1e7f-492f-a770-5f9b35ee4b75", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>\n</td>\n</tr>", "ID": "cb36705e-75f7-4539-9523-215fae842785", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "ae37a6b1-1e7f-492f-a770-5f9b35ee4b75"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>\n</td>", "ID": "38b54c35-53d1-4c83-8cb8-18cd83e3672a", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb36705e-75f7-4539-9523-215fae842785"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>", "ID": "7a774bfd-33e2-4598-9749-b377748785b0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "38b54c35-53d1-4c83-8cb8-18cd83e3672a"}, {"Element": "<b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b>", "ID": "45e578b6-f2d1-447b-b0b3-63588e7844cf", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME   OF THE MEDICINAL PRODUCT", "ParentId": "7a774bfd-33e2-4598-9749-b377748785b0"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ad79be91-0c3f-4e2f-a52a-ee7e9842716b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla 100\u00a0mg powder for concentrate for solution for\ninfusion </p>", "ID": "8d06f5c9-9b65-4bd4-97de-7f3e4352f552", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla 100\u00a0mg powder for concentrate for solution for infusion ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">trastuzumab emtansine</p>", "ID": "4014f153-30d8-47f0-9ad0-fd511eee9423", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab emtansine", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5310d728-0d86-48b3-ae86-c88955cb2e9d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9925a241-722b-4c0e-b913-b071fd1d6115", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>\n</td>\n</tr>\n</table>", "ID": "3f845357-f23f-466e-86a0-40291324e057", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>\n</td>\n</tr>", "ID": "3c3f9980-ab53-4e60-8fcb-c4b4a38326e3", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "3f845357-f23f-466e-86a0-40291324e057"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>\n</td>", "ID": "806d6010-ad66-417e-8bd4-28e0e166bfe3", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3c3f9980-ab53-4e60-8fcb-c4b4a38326e3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>", "ID": "e879388c-9071-430f-99ea-97c5957a4657", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "806d6010-ad66-417e-8bd4-28e0e166bfe3"}, {"Element": "<b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b>", "ID": "5dd0b015-1887-4862-a544-a82c36edcdea", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT   OF ACTIVE SUBSTANCE(S)", "ParentId": "e879388c-9071-430f-99ea-97c5957a4657"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "42f7e905-500b-4554-80d8-d4d7c8673db6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">One vial of powder for concentrate for solution for infusion\ncontains 100 mg of trastuzumab emtansine. After reconstitution one vial of 5 mL\nsolution contains 20 mg/mL of trastuzumab emtansine.</p>", "ID": "a0ccd24e-4bbf-46f8-87c6-7be824a52fbe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "One vial of powder for concentrate for solution for infusion contains 100 mg of trastuzumab emtansine. After reconstitution one vial of 5 mL solution contains 20 mg/mL of trastuzumab emtansine.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b9bca5d4-ce18-4c04-9c15-718711d6428f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "30bcfb82-fdab-447d-a216-2d61659dcf85", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>\n</td>\n</tr>\n</table>", "ID": "d1572b96-e36c-45f5-a77b-6c3a26c25a7a", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>\n</td>\n</tr>", "ID": "f3ccd20d-e92a-4c29-aa88-1e022c74dccb", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "d1572b96-e36c-45f5-a77b-6c3a26c25a7a"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>\n</td>", "ID": "63150418-e846-4cdf-9333-de1958402cb6", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f3ccd20d-e92a-4c29-aa88-1e022c74dccb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>", "ID": "cd5a6a1f-e737-4fd3-933c-7a48b9360676", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63150418-e846-4cdf-9333-de1958402cb6"}, {"Element": "<b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b>", "ID": "5890e3b9-10e9-4e03-bd1f-b27658a98ad8", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST   OF EXCIPIENTS", "ParentId": "cd5a6a1f-e737-4fd3-933c-7a48b9360676"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2f987b1d-404f-4a3d-ae29-7e71e583cb68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Excipients:</p>", "ID": "b9ac74ec-b0b8-472e-bf55-8c4591ea1daa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Excipients:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Succinic acid, sodium hydroxide, sucrose, polysorbate\u00a020.</p>", "ID": "276d64c5-b9aa-4fb5-b353-be0ebb10ba10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Succinic acid, sodium hydroxide, sucrose, polysorbate\u00a020.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1cc8d6c4-e243-40ae-a174-41d046f0307c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4e9d27c1-f758-4e4f-94c0-b0e3bc115eac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>\n</td>\n</tr>\n</table>", "ID": "82ebfd53-351b-40af-8ea7-d290d04ad46d", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>\n</td>\n</tr>", "ID": "4913ac55-9343-48e5-8d1b-256ec4189c06", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "82ebfd53-351b-40af-8ea7-d290d04ad46d"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>\n</td>", "ID": "b6d0dc03-9a5d-47f4-b8f4-7cc56304bfdc", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4913ac55-9343-48e5-8d1b-256ec4189c06"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>", "ID": "26a9f61b-adcc-4a6c-a0c8-3a12fd866e6b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b6d0dc03-9a5d-47f4-b8f4-7cc56304bfdc"}, {"Element": "<b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b>", "ID": "8912df4c-6917-4d80-a6b9-a95a02845f80", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL   FORM AND CONTENTS", "ParentId": "26a9f61b-adcc-4a6c-a0c8-3a12fd866e6b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "147f9f51-c7ce-4fe1-bc77-416d27c0e8cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Powder for concentrate for solution for infusion</p>", "ID": "31a15fec-9cea-483c-9b2b-45d67ce9d832", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Powder for concentrate for solution for infusion", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">1 vial of 100\u00a0mg</p>", "ID": "c0db106b-cf5b-443b-9829-25e44a717ca8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "1 vial of 100\u00a0mg", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ec9bdf11-1d2b-42dd-92a8-b4af8640d9ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "33a6fe6b-ac1f-40e5-8d07-1f70239ce1b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>\n</td>\n</tr>\n</table>", "ID": "63dea1da-a0a0-4e8c-879c-3567a21181ee", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>\n</td>\n</tr>", "ID": "01efcdc3-75bc-4d98-8bdd-020edb0316e8", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "63dea1da-a0a0-4e8c-879c-3567a21181ee"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>\n</td>", "ID": "83e9b1b3-7f35-476f-bf3b-ecc132e25cf0", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "01efcdc3-75bc-4d98-8bdd-020edb0316e8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>", "ID": "47585e3b-d2f3-46da-a275-d52d62908564", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "83e9b1b3-7f35-476f-bf3b-ecc132e25cf0"}, {"Element": "<b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b>", "ID": "53600482-db8e-4819-aad3-35fc6d1d119a", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD   AND ROUTE(S) OF ADMINISTRATION", "ParentId": "47585e3b-d2f3-46da-a275-d52d62908564"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "3eac4332-3434-42ab-9541-9b777f524e7e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "04eec867-df02-45f0-807e-d89ca0ae9a5b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3eac4332-3434-42ab-9541-9b777f524e7e"}, {"Element": "<p class=\"MsoNormal\">For intravenous use after reconstitution and dilution</p>", "ID": "ee40e7a2-8149-4bf5-ab80-a078d9c7c920", "Styles": "None", "Classes": "['MsoNormal']", "Text": "For intravenous use after reconstitution and dilution", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Read the package leaflet before use</p>", "ID": "7afc3f98-7833-4912-9a3e-50ac6be42eae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Read the package leaflet before use", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ccb491ad-a4ce-4ef0-b088-7cd3b205d400", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9795769d-6c56-4345-af5e-90cfe828bd02", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>\n</td>\n</tr>\n</table>", "ID": "c00ff534-e711-488b-8c19-c7d3d3a925ea", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>\n</td>\n</tr>", "ID": "0bc2e25d-ad43-46ed-bbf2-a6cc9ffe6cce", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "c00ff534-e711-488b-8c19-c7d3d3a925ea"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>\n</td>", "ID": "499216ef-fd5e-457a-be4e-e57e3df640b6", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0bc2e25d-ad43-46ed-bbf2-a6cc9ffe6cce"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>", "ID": "b16379f0-d035-43d9-87f2-11b2edc61350", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "499216ef-fd5e-457a-be4e-e57e3df640b6"}, {"Element": "<b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b>", "ID": "58bec8b5-23ca-4c81-9520-e9a32dff0a37", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL   WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH   OF CHILDREN", "ParentId": "b16379f0-d035-43d9-87f2-11b2edc61350"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f8b61b5a-4857-44c2-99b1-0d53b566769b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Keep out of the sight and reach of children</p>", "ID": "308f4f08-39dc-4391-909b-a6fb5898e247", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Keep out of the sight and reach of children", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "cc97f77e-e341-42a1-9a3e-4587f97e7460", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a8369268-a325-4bae-bbb1-c7b9dd158d81", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>\n</td>\n</tr>\n</table>", "ID": "069cb2c6-8b37-4f66-9860-535ea166343b", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>\n</td>\n</tr>", "ID": "cb450fef-cc71-41f9-8184-aa0d57a932f6", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "069cb2c6-8b37-4f66-9860-535ea166343b"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>\n</td>", "ID": "5821b75d-677d-441e-835e-eed025760684", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb450fef-cc71-41f9-8184-aa0d57a932f6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>", "ID": "4bea0dcb-f613-42c2-a5da-60e08731e91e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5821b75d-677d-441e-835e-eed025760684"}, {"Element": "<b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b>", "ID": "27eece75-8be7-49e0-ad04-2b0c1559bfb9", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER   SPECIAL WARNING(S), IF NECESSARY", "ParentId": "4bea0dcb-f613-42c2-a5da-60e08731e91e"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "04d3561c-7da2-4ce0-9f30-486faf0636c0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Cytotoxic</p>", "ID": "3353df0d-636c-41fc-85e6-8cddea5660de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Cytotoxic", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c9828797-b72d-4e36-a731-6a072647423b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">To be administered under the supervision of a physician\nexperienced in the use of cytotoxic agents.</p>", "ID": "8be301a5-1d6b-4646-8cac-ce500bb98e16", "Styles": "None", "Classes": "['MsoNormal']", "Text": "To be administered under the supervision of a physician experienced in the use of cytotoxic agents.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c19e0bac-4c63-4356-a711-4af0e30729b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "56948985-6789-4979-b550-d4d533053a58", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>\n</td>\n</tr>\n</table>", "ID": "a3a3235c-ce38-4648-9469-098f51394f39", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>\n</td>\n</tr>", "ID": "fbf8e220-ac41-42f1-bec3-8c5053543b8c", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "a3a3235c-ce38-4648-9469-098f51394f39"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>\n</td>", "ID": "8c9a30b8-d520-46eb-a03d-9be7031225be", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fbf8e220-ac41-42f1-bec3-8c5053543b8c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>", "ID": "cd867131-dcb8-4dd0-9c14-7069587271de", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c9a30b8-d520-46eb-a03d-9be7031225be"}, {"Element": "<b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b>", "ID": "a506af1c-8cc4-45da-8067-8f9e0b2cf4fe", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY   DATE", "ParentId": "cd867131-dcb8-4dd0-9c14-7069587271de"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "19fa0f0a-2d6e-4023-aa21-bfc29c35fd9c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">EXP</p>", "ID": "4503233e-29a3-4e6f-b25b-5d7439c3da7d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "EXP", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "62d61565-df76-4cf8-b792-efec0997f1e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "81e33da9-8c45-497e-9afb-22dd34668f19", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>\n</td>\n</tr>\n</table>", "ID": "adf34c85-8db6-418b-a78b-b251e9645996", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>\n</td>\n</tr>", "ID": "5c1e41e3-6f6c-4aa8-a90b-6eba3fb3985e", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "adf34c85-8db6-418b-a78b-b251e9645996"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>\n</td>", "ID": "a6f81103-6e61-4b1b-9acb-58b9120c432d", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5c1e41e3-6f6c-4aa8-a90b-6eba3fb3985e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>", "ID": "77804169-b801-4606-9ffd-075679286553", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a6f81103-6e61-4b1b-9acb-58b9120c432d"}, {"Element": "<b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b>", "ID": "62bf6753-5278-47a8-bf46-5c9ad2dae684", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL   STORAGE CONDITIONS", "ParentId": "77804169-b801-4606-9ffd-075679286553"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "38224998-e36f-439c-946a-271ae79dce23", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Store in a refrigerator\n(2\u00baC \u2013 8\u00baC)</p>", "ID": "24ab67be-c78a-4880-9bdb-39d02f6cda97", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Store in a refrigerator (2\u00baC \u2013 8\u00baC)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "2896867a-3c50-471c-9ee0-2cd70e67558c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "fdf6356a-2830-43e6-b799-4d68f189271c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>\n</td>\n</tr>\n</table>", "ID": "c3a7cfc2-7c7a-4620-be84-47eb05e387ef", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>\n</td>\n</tr>", "ID": "43566d1e-7d82-4837-b797-52680ae1a08c", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "c3a7cfc2-7c7a-4620-be84-47eb05e387ef"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>\n</td>", "ID": "1dffeb86-d62a-4c42-90f0-3a0d95238787", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43566d1e-7d82-4837-b797-52680ae1a08c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>", "ID": "00070744-7247-4f20-ac59-0db656b17275", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1dffeb86-d62a-4c42-90f0-3a0d95238787"}, {"Element": "<b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b>", "ID": "42464580-a0f5-4368-af1d-17b55f7ccdec", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS   FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM   SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "00070744-7247-4f20-ac59-0db656b17275"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "80cf53f9-c235-4611-9a3e-7d4631e1459c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "483bfaab-6caf-4666-92bc-df502c7f1d32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>\n</td>\n</tr>\n</table>", "ID": "0bc101b5-3052-4fd7-8037-b902b4357ed4", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>\n</td>\n</tr>", "ID": "bf72a75c-cf78-4b4e-929b-e04d4c21be5f", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "0bc101b5-3052-4fd7-8037-b902b4357ed4"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>\n</td>", "ID": "899983f3-c71e-4381-9120-007a2321d8f4", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bf72a75c-cf78-4b4e-929b-e04d4c21be5f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>", "ID": "0bacb479-f2da-4ef1-a7ae-0b68daa06fac", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "899983f3-c71e-4381-9120-007a2321d8f4"}, {"Element": "<b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b>", "ID": "a4ee9ace-7e7d-43d9-916b-bd8cf75eed75", "Styles": "None", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0 NAME   AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "0bacb479-f2da-4ef1-a7ae-0b68daa06fac"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8c63fecb-d0dc-42e2-b4cb-8d7ca652aef8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>", "ID": "70f43e47-f2b5-472d-ad45-ce513cea0826", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">Roche Registration GmbH </span>", "ID": "f5f0a865-1e22-4d5a-985d-3b209182bacc", "Styles": "None", "Classes": "None", "Text": "Roche Registration GmbH ", "ParentId": "70f43e47-f2b5-472d-ad45-ce513cea0826"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>", "ID": "166c849f-74e6-418b-96a5-c5bb926d796e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">Emil-Barell-Strasse 1</span>", "ID": "3b6b0b1b-e122-4ebc-a22a-4df81fde2d8b", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "166c849f-74e6-418b-96a5-c5bb926d796e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">79639 Grenzach-Wyhlen</span></p>", "ID": "c6417460-1ecf-414c-9856-26cf94aaf7f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">79639 Grenzach-Wyhlen</span>", "ID": "76128602-e49f-4826-8ce9-b0e912ad59be", "Styles": "None", "Classes": "None", "Text": "79639 Grenzach-Wyhlen", "ParentId": "c6417460-1ecf-414c-9856-26cf94aaf7f2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Germany</span></p>", "ID": "64d82007-f054-4f0f-8bcf-cd1392fbb859", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">Germany</span>", "ID": "8a48bbfe-eb7a-4c4a-b11e-330b605a17a7", "Styles": "None", "Classes": "None", "Text": "Germany", "ParentId": "64d82007-f054-4f0f-8bcf-cd1392fbb859"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "5a9774ce-44d3-4cf9-9d55-04e5e8a9b296", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "75967c0c-2d4d-4874-ab0d-bbabdb58d486", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5a9774ce-44d3-4cf9-9d55-04e5e8a9b296"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "790c4140-66d2-4372-ae1e-aac7e7bdb7e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "ed429962-3e12-4749-b92b-dc8660a6f4dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "790c4140-66d2-4372-ae1e-aac7e7bdb7e5"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>\n</td>\n</tr>\n</table>", "ID": "f3dd3066-3004-4a66-811d-3c270a18bd66", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>\n</td>\n</tr>", "ID": "7b65e8ab-edf6-4d2f-a801-25f5dcfadb05", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "f3dd3066-3004-4a66-811d-3c270a18bd66"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>\n</td>", "ID": "b0058e54-ee4c-4e74-ae90-0b6dae51f5cc", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7b65e8ab-edf6-4d2f-a801-25f5dcfadb05"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>", "ID": "e9bb036f-b97e-4787-aa2f-d8885079e741", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0058e54-ee4c-4e74-ae90-0b6dae51f5cc"}, {"Element": "<b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b>", "ID": "50138a6e-a473-4cea-934f-a41d40c18bc0", "Styles": "None", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0 MARKETING   AUTHORISATION NUMBER(S)", "ParentId": "e9bb036f-b97e-4787-aa2f-d8885079e741"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2c565306-bd23-4d5d-9a76-cb3278e5b718", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">EU/1/13/885/001</span></p>", "ID": "75f16f90-b847-4676-bb49-004bf225cd05", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"color:black\">EU/1/13/885/001</span>", "ID": "085fef56-6c8b-4f06-ae9c-6a19f21c61f1", "Styles": "color:black", "Classes": "None", "Text": "EU/1/13/885/001", "ParentId": "75f16f90-b847-4676-bb49-004bf225cd05"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "732dd8eb-f8bc-4777-bab1-2a4523db45d9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "37ddfcbb-ee6b-4ae9-814a-e7e20a3191e8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>\n</td>\n</tr>\n</table>", "ID": "830764e7-6643-4ae0-ac9b-4015f50d3c1d", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>\n</td>\n</tr>", "ID": "b28adbfd-2318-465a-b192-ad7a0997dcfe", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "830764e7-6643-4ae0-ac9b-4015f50d3c1d"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>\n</td>", "ID": "00d73b8b-f1aa-43ea-bb87-8644cda38137", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b28adbfd-2318-465a-b192-ad7a0997dcfe"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>", "ID": "e247c0e3-02db-4a5a-898b-63f9ae4ca67c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "00d73b8b-f1aa-43ea-bb87-8644cda38137"}, {"Element": "<b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b>", "ID": "2860854a-c540-4a6c-94b1-4af1fdc434e1", "Styles": "None", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0 BATCH   NUMBER", "ParentId": "e247c0e3-02db-4a5a-898b-63f9ae4ca67c"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "31bf76f0-3e82-4d12-8215-f7bc54ae5625", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Batch</p>", "ID": "3d9f4978-2cd7-46a8-ba51-d93a773b760f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Batch", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7b20910b-ea07-4dda-aa59-adb2d416c17d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d9db44a4-48c0-4c91-9491-9e9604f1258a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>\n</td>\n</tr>\n</table>", "ID": "8e29ab8d-1321-4b6b-9ec9-68f5c345adc6", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>\n</td>\n</tr>", "ID": "00c18a40-6043-4586-931d-8c6a98fb2497", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8e29ab8d-1321-4b6b-9ec9-68f5c345adc6"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>\n</td>", "ID": "9c74778e-ddf1-4810-9828-3775993fcd20", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "00c18a40-6043-4586-931d-8c6a98fb2497"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>", "ID": "f29b3232-e059-448d-b789-c365dca9d554", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9c74778e-ddf1-4810-9828-3775993fcd20"}, {"Element": "<b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b>", "ID": "757ee6cb-ef21-4006-a788-04939983d948", "Styles": "None", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0 GENERAL   CLASSIFICATION FOR SUPPLY", "ParentId": "f29b3232-e059-448d-b789-c365dca9d554"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3cd4b51b-aa4b-4299-81a3-98560d60c556", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Medicinal product subject to medical prescription</p>", "ID": "02ded6dc-871e-4ca1-b475-1380a0920679", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Medicinal product subject to medical prescription", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8d93c3a9-446f-45b3-a1d0-b34ba508d494", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5b5ee01c-1b52-4ecb-b64a-71e102e9bc0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>\n</td>\n</tr>\n</table>", "ID": "d137fb29-0039-4643-9ad4-03a965660d9a", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>\n</td>\n</tr>", "ID": "311f2e39-2ac8-4d59-964a-d8c27ec2b38f", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "d137fb29-0039-4643-9ad4-03a965660d9a"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>\n</td>", "ID": "f25e4aaa-7665-4eea-98a7-3a240d8a95a7", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "311f2e39-2ac8-4d59-964a-d8c27ec2b38f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>", "ID": "bec803cb-a451-49ad-999f-bd8918e8be23", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f25e4aaa-7665-4eea-98a7-3a240d8a95a7"}, {"Element": "<b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b>", "ID": "09ae181c-2c57-44e6-9f00-97e583c6df33", "Styles": "None", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS   ON USE", "ParentId": "bec803cb-a451-49ad-999f-bd8918e8be23"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ded7cdd4-7d05-4b06-b4ec-f2190a1c6df9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1ab94d1b-c79d-4e00-8088-85b2730ed60a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b>16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</b></p>\n</div>", "ID": "c07360f0-b138-416a-869b-2cd9c2622e3b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b>16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</b></p>", "ID": "2d7e9bee-e4d7-43bc-a4db-52afc4579045", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c07360f0-b138-416a-869b-2cd9c2622e3b"}, {"Element": "<b>16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</b>", "ID": "2936fc5e-9fe4-4222-9ebf-367eb2d25b7e", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "2d7e9bee-e4d7-43bc-a4db-52afc4579045"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3c12ec2e-ae1c-4ff2-a4d2-f02b0cc81ad3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span style=\"background:lightgrey\">Justification for not\nincluding Braille accepted</span></p>", "ID": "9fced6dd-bdf5-4882-be47-788e1bf060b1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"background:lightgrey\">Justification for not\nincluding Braille accepted</span>", "ID": "0876042d-04e6-41c1-8664-61614d29ea68", "Styles": "background:lightgrey", "Classes": "None", "Text": "Justification for not including Braille accepted", "ParentId": "9fced6dd-bdf5-4882-be47-788e1bf060b1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "255d9fc0-0358-4f39-88d1-3bc94acd70b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d6ffa2ca-76c9-4112-8a9d-b4a7420e86ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>17.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b></p>\n</div>", "ID": "3d87ad92-9047-4e65-a02d-0f3fe97cfcdd", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>17.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b></p>", "ID": "c769a6f6-0664-41ea-af13-0b2650f8fa56", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3d87ad92-9047-4e65-a02d-0f3fe97cfcdd"}, {"Element": "<b>17.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b>", "ID": "30119b7b-0845-453a-b013-22266d2135a4", "Styles": "None", "Classes": "None", "Text": "17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE", "ParentId": "c769a6f6-0664-41ea-af13-0b2650f8fa56"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "584e122a-460a-4f3e-97ce-4d5270e2aa4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span style=\"background:lightgrey\">&lt;2D barcode carrying\nthe unique identifier included.&gt;</span></p>", "ID": "4199df3b-3fef-4b69-a1b6-a0aa1532737c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"background:lightgrey\">&lt;2D barcode carrying\nthe unique identifier included.&gt;</span>", "ID": "39b9dcbe-1ded-4cee-bd32-760dd9c8f4e3", "Styles": "background:lightgrey", "Classes": "None", "Text": "<2D barcode carrying the unique identifier included.>", "ParentId": "4199df3b-3fef-4b69-a1b6-a0aa1532737c"}, {"Element": "<p class=\"MsoNormal\"><span style=\"background:#CCCCCC\">\u00a0</span></p>", "ID": "80cefaed-eea8-4cd0-91b3-5e9cf01bdb8d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"background:#CCCCCC\">\u00a0</span>", "ID": "af41f2e7-9c90-4422-9a26-514859b9876c", "Styles": "background:#CCCCCC", "Classes": "None", "Text": "\u00a0", "ParentId": "80cefaed-eea8-4cd0-91b3-5e9cf01bdb8d"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6e7e7c62-9142-4fc7-863a-c6bb07282e58", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>18.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b></p>\n</div>", "ID": "b043016b-29a1-4dd5-87d3-0baa8904b3e9", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>18.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b></p>", "ID": "4037cb9e-56fc-4696-8635-0e3128e64bb6", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b043016b-29a1-4dd5-87d3-0baa8904b3e9"}, {"Element": "<b>18.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b>", "ID": "ba443989-d8a2-4399-903e-20da53a2370d", "Styles": "None", "Classes": "None", "Text": "18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA", "ParentId": "4037cb9e-56fc-4696-8635-0e3128e64bb6"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c9b03c47-0da6-4043-be4c-c1d773533d1a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">PC: </p>", "ID": "732ba9ea-7d52-4995-b7af-3bcd55f1a6e0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "PC: ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">SN: </p>", "ID": "b30827f6-60a5-4cf9-a3b2-42871b8ee280", "Styles": "None", "Classes": "['MsoNormal']", "Text": "SN: ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">NN: </p>", "ID": "766cf229-4d2c-4e86-ba4a-26ba2e728ac9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "NN: ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "b438bcfa-534d-417e-ad2a-58e5771884ac", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "54fbee36-7f00-4b2f-b57f-3e5877b25574", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "b438bcfa-534d-417e-ad2a-58e5771884ac"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9b031059-50a1-40a8-b199-5e3431e15875", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>MINIMUM PARTICULARS TO\nAPPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>VIAL LABEL</b></p>\n</div>", "ID": "57cc22d7-4e81-4f8a-9134-98b89f7c02b3", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>MINIMUM PARTICULARS TO\nAPPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>", "ID": "ef271e34-e14a-421c-8942-7d9b79fa2d90", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "57cc22d7-4e81-4f8a-9134-98b89f7c02b3"}, {"Element": "<b>MINIMUM PARTICULARS TO\nAPPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b>", "ID": "2a877f4f-ad0d-4c07-9c0c-1fb4def27d97", "Styles": "None", "Classes": "None", "Text": "MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS", "ParentId": "ef271e34-e14a-421c-8942-7d9b79fa2d90"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>\u00a0</b></p>", "ID": "5258798c-e457-4e57-b45f-1411f85d5a74", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "57cc22d7-4e81-4f8a-9134-98b89f7c02b3"}, {"Element": "<b>\u00a0</b>", "ID": "87d618ba-bbc8-44a2-9fd6-be071b246e84", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5258798c-e457-4e57-b45f-1411f85d5a74"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>VIAL LABEL</b></p>", "ID": "744bcc14-abb6-4c2d-b026-b89cba29e086", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "57cc22d7-4e81-4f8a-9134-98b89f7c02b3"}, {"Element": "<b>VIAL LABEL</b>", "ID": "de96d898-5930-4551-bfdc-ba4adf80118d", "Styles": "None", "Classes": "None", "Text": "VIAL LABEL", "ParentId": "744bcc14-abb6-4c2d-b026-b89cba29e086"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5766b2b2-ca98-42f2-b30b-aefac4ecc83d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6bbc387a-e854-4ceb-8f93-fd9c7fff6e63", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>\n</div>", "ID": "63eb0f24-9234-4d8e-a33c-0cdfb3ef57c6", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>", "ID": "493a5c10-6e2b-4a67-a1d7-fd1048639b6f", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63eb0f24-9234-4d8e-a33c-0cdfb3ef57c6"}, {"Element": "<b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b>", "ID": "03ccf4f7-2e50-489c-b32b-e5a98fa361d0", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION", "ParentId": "493a5c10-6e2b-4a67-a1d7-fd1048639b6f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>", "ID": "371e08f4-0087-4a86-886c-7166eb85dbc7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla 100\u00a0mg powder for concentrate for solution for\ninfusion</p>", "ID": "5dee99c4-edfa-461f-bca3-ae89c0309e87", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla 100\u00a0mg powder for concentrate for solution for infusion", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">trastuzumab emtansine</p>", "ID": "a43958e7-38e9-49b3-86aa-792aabbfdbbe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab emtansine", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Intravenous use</p>", "ID": "7c4a99b6-1b08-4c65-b05f-81da043802e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Intravenous use", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6911efd7-82de-4cdd-90ff-4538b03192e3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "549c9c3f-49df-4a95-8000-0c15ebbfeb24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</b></p>\n</div>", "ID": "f9013d08-7ed1-4b16-abf7-316aab6d853c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</b></p>", "ID": "3330ba1d-ab3e-46a5-b0ed-84d5011edb69", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f9013d08-7ed1-4b16-abf7-316aab6d853c"}, {"Element": "<b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</b>", "ID": "28d5dc2b-ed59-4ca8-bf1a-c2c737f01231", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION", "ParentId": "3330ba1d-ab3e-46a5-b0ed-84d5011edb69"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "95545e8f-43d6-4bac-8bd1-ce19a9cc2ad7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">For intravenous use after reconstitution and dilution</p>", "ID": "64762172-6a17-4316-96fe-ceaaafe061e7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "For intravenous use after reconstitution and dilution", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "04cc59e7-613c-412e-bd3c-66dff4eab74b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "cd172fb2-5276-4ea4-9298-00217ca7cf77", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</b></p>\n</div>", "ID": "001617b6-c181-4f55-beca-966325027d56", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</b></p>", "ID": "5f9c551b-d0da-47b4-84c5-913077d6d1b7", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "001617b6-c181-4f55-beca-966325027d56"}, {"Element": "<b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</b>", "ID": "2d419a9e-be9a-4d8d-987e-9e101e7b06ce", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "5f9c551b-d0da-47b4-84c5-913077d6d1b7"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7ee19b30-545b-4d0b-bb9c-ce0699399e25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">EXP</p>", "ID": "2c732170-8978-43a9-8efa-4297113052d1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "EXP", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4980f5ac-c392-46f7-a708-35cc78bf65d5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "50417bf0-18f8-4a1b-9232-a6b7df520833", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</b></p>\n</div>", "ID": "066ff83d-0279-4288-936b-ac770b5bb62d", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</b></p>", "ID": "1d03a028-6789-4d39-95f3-d9bcd4053506", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "066ff83d-0279-4288-936b-ac770b5bb62d"}, {"Element": "<b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</b>", "ID": "9ce54cc5-1441-4581-9dc7-c655efb07b7f", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "1d03a028-6789-4d39-95f3-d9bcd4053506"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "51173f98-8b34-4cb6-a43e-f4bc9e307a15", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">Lot</p>", "ID": "3d96b271-f048-4424-b229-cd95b7f8a39c", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "Lot", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "c6e8e651-9935-4702-b30f-1e36990c4542", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "0e582c93-2daa-459d-a1f7-cd295bfc8d77", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</b></p>\n</div>", "ID": "fcb19e93-bffc-4055-8c83-9f61ab8f9c94", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</b></p>", "ID": "0735c544-93ef-404a-9267-b428137f7786", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fcb19e93-bffc-4055-8c83-9f61ab8f9c94"}, {"Element": "<b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</b>", "ID": "b2eda874-834b-4a79-a783-2be17fa7cbe6", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT", "ParentId": "0735c544-93ef-404a-9267-b428137f7786"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "4b2af674-c757-48f9-a0cb-177c68bf00bf", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">100\u00a0mg</p>", "ID": "87ffb180-0a71-42ef-8148-51065dd2b895", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "100\u00a0mg", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "7fa925b1-d5e2-42ee-bd0c-062a6ef44a4a", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "dd6618e7-60aa-47b0-ac9a-e3b03ee2ce64", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</b></p>\n</div>", "ID": "96191fb9-8260-4bac-9b1d-b8c70568f2c7", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</b></p>", "ID": "542b22c0-f369-45d8-889c-324827198fbc", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "96191fb9-8260-4bac-9b1d-b8c70568f2c7"}, {"Element": "<b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</b>", "ID": "8cab3a49-ec2f-492e-84d7-87acfd45c7d9", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER", "ParentId": "542b22c0-f369-45d8-889c-324827198fbc"}, {"Element": "<p class=\"MsoNormal\" style=\"background:white\"><b>\u00a0</b></p>", "ID": "110e1b5c-ca52-4d53-ac58-b2bc2eebe6fd", "Styles": "background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "4336a7ad-ec8e-4a08-91f6-942daad37a6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "110e1b5c-ca52-4d53-ac58-b2bc2eebe6fd"}, {"Element": "<b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "41184b2f-1449-4011-8679-e399371e9edc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "f22c0f6e-1989-4475-958b-303fb0270371", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "41184b2f-1449-4011-8679-e399371e9edc"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "f7125d23-b613-4ccc-856a-16d9cdab483e", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "f22c0f6e-1989-4475-958b-303fb0270371"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">\u00a0</p>", "ID": "eda810be-959f-4350-8401-be5adbaff492", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>CARTON </b></p>\n</td>\n</tr>\n</table>", "ID": "aa4b70c9-e6d3-4c4a-bee5-adf5b0e49c87", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>CARTON </b></p>\n</td>\n</tr>", "ID": "ad3ae1e9-dff3-417f-9590-69a2bae9a708", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "aa4b70c9-e6d3-4c4a-bee5-adf5b0e49c87"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\"><b>CARTON </b></p>\n</td>", "ID": "a179d9a2-2b30-45f5-ad05-3635e76e1149", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "ad3ae1e9-dff3-417f-9590-69a2bae9a708"}, {"Element": "<p class=\"MsoNormal\"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>", "ID": "86a904bc-3943-425e-8307-3b2e2fca0b0b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a179d9a2-2b30-45f5-ad05-3635e76e1149"}, {"Element": "<b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b>", "ID": "4b329222-c165-4aa9-a516-17988525f4bf", "Styles": "None", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING", "ParentId": "86a904bc-3943-425e-8307-3b2e2fca0b0b"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "2be887e9-ceec-4af5-90f6-b23e8dfa840d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a179d9a2-2b30-45f5-ad05-3635e76e1149"}, {"Element": "<b>\u00a0</b>", "ID": "fc607317-d2d4-4ba5-9941-6d2564a864ed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2be887e9-ceec-4af5-90f6-b23e8dfa840d"}, {"Element": "<p class=\"MsoNormal\"><b>CARTON </b></p>", "ID": "d2739b89-e6e4-4921-bd2c-2b5ec53970be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a179d9a2-2b30-45f5-ad05-3635e76e1149"}, {"Element": "<b>CARTON </b>", "ID": "2a76f6a2-803a-4e36-bb3b-5b88abc53278", "Styles": "None", "Classes": "None", "Text": "CARTON ", "ParentId": "d2739b89-e6e4-4921-bd2c-2b5ec53970be"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "fc01c299-54ec-4b73-b63d-7e546dbbc1f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d87c98bd-b6a6-453d-bf82-23c8debd474d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>\n</td>\n</tr>\n</table>", "ID": "e73e2f80-6e80-49fe-8978-6d1592e657c1", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>\n</td>\n</tr>", "ID": "98a3da4e-d503-4887-a542-695d23e71f19", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e73e2f80-6e80-49fe-8978-6d1592e657c1"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>\n</td>", "ID": "9b67e6b1-72f7-451c-abf6-9282e9c10186", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "98a3da4e-d503-4887-a542-695d23e71f19"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b></p>", "ID": "788a6417-86b5-4f75-a8da-f8dd52081357", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b67e6b1-72f7-451c-abf6-9282e9c10186"}, {"Element": "<b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\n  OF THE MEDICINAL PRODUCT</b>", "ID": "aead4c48-a290-4192-bc59-091900108ab1", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME   OF THE MEDICINAL PRODUCT", "ParentId": "788a6417-86b5-4f75-a8da-f8dd52081357"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "13f8f621-af11-4e10-973f-6bf84c904775", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla 160\u00a0mg powder for concentrate for solution for\ninfusion </p>", "ID": "87b508a9-6776-4c5b-b577-da3a41ca786c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla 160\u00a0mg powder for concentrate for solution for infusion ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">trastuzumab emtansine</p>", "ID": "ec4062a1-961c-4e22-9ac4-462154da1c8f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab emtansine", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ef1e8538-1321-433f-84f5-c273a6c7f003", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3baef96d-5d61-4b2a-83d0-c478a6e9acdc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>\n</td>\n</tr>\n</table>", "ID": "b05a0abe-7b70-45f1-8d2a-8f23bd09bb29", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>\n</td>\n</tr>", "ID": "c47fa4e0-4099-4f28-a51a-3c6c3376901a", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "b05a0abe-7b70-45f1-8d2a-8f23bd09bb29"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>\n</td>", "ID": "7572f636-7a46-42fd-b0af-d0be8490d61f", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c47fa4e0-4099-4f28-a51a-3c6c3376901a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b></p>", "ID": "c569e493-9ebf-4970-afbf-deb44166ce26", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7572f636-7a46-42fd-b0af-d0be8490d61f"}, {"Element": "<b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\n  OF ACTIVE SUBSTANCE(S)</b>", "ID": "91d69a3a-8ed2-4a2c-86e9-4d158267457b", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT   OF ACTIVE SUBSTANCE(S)", "ParentId": "c569e493-9ebf-4970-afbf-deb44166ce26"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1993286a-295b-479f-b06b-b4624e9418d1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "70c5c579-ecc0-4c40-b0f3-b2939869ef2e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">One vial of powder for concentrate for solution for infusion\ncontains 160 mg of trastuzumab emtansine. After reconstitution one vial of 8 mL\nsolution contains 20 mg/mL of trastuzumab emtansine.</p>", "ID": "37e70e8b-4abf-4c0b-bc91-2cd7b016a2ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "One vial of powder for concentrate for solution for infusion contains 160 mg of trastuzumab emtansine. After reconstitution one vial of 8 mL solution contains 20 mg/mL of trastuzumab emtansine.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "91c12761-0cfc-4a2b-bbe1-d2aadcf6594d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e9b4cd2b-689d-4053-8f70-1670706d428c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>\n</td>\n</tr>\n</table>", "ID": "38b3f6c0-6e8c-40cc-a171-fa16aebd1a32", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>\n</td>\n</tr>", "ID": "8f129904-338c-484e-8ff1-452f6b19b220", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "38b3f6c0-6e8c-40cc-a171-fa16aebd1a32"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>\n</td>", "ID": "18ef0c3c-885a-474b-b6b7-65925c2f44bf", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f129904-338c-484e-8ff1-452f6b19b220"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b></p>", "ID": "c406d382-e33a-4095-8900-4da4c6d4e3b5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18ef0c3c-885a-474b-b6b7-65925c2f44bf"}, {"Element": "<b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\n  OF EXCIPIENTS</b>", "ID": "ac0711ac-af79-4111-90f5-7b6a0f20a6f8", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST   OF EXCIPIENTS", "ParentId": "c406d382-e33a-4095-8900-4da4c6d4e3b5"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5cfb224f-aa46-4edb-9a76-6af5d45f71f8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Excipients:</p>", "ID": "b63ded95-8e51-4400-a7ea-71bcc8f448c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Excipients:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Succinic acid, sodium hydroxide, sucrose, polysorbate 20.</p>", "ID": "0ec504a3-46a1-4ac6-9e5e-d5bcfec257ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Succinic acid, sodium hydroxide, sucrose, polysorbate 20.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d4de913f-dc47-42d2-b269-e5fde9725e9d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "464d55a9-2e81-4aa0-bee6-4ff644472e2b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>\n</td>\n</tr>\n</table>", "ID": "f2ef1d3c-2703-4b0d-9bb6-b5c4b5abc81a", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>\n</td>\n</tr>", "ID": "bb72dcad-d833-4d3b-b113-2a9165d7b5bf", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "f2ef1d3c-2703-4b0d-9bb6-b5c4b5abc81a"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>\n</td>", "ID": "45580e81-b3a2-48f5-876d-adf4afc48c87", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bb72dcad-d833-4d3b-b113-2a9165d7b5bf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b></p>", "ID": "2b491dc6-6a96-4ead-8dcd-dc57f02dcdb7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "45580e81-b3a2-48f5-876d-adf4afc48c87"}, {"Element": "<b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\n  FORM AND CONTENTS</b>", "ID": "cf6972a3-73bb-4b16-9a2b-a894dddfc72d", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL   FORM AND CONTENTS", "ParentId": "2b491dc6-6a96-4ead-8dcd-dc57f02dcdb7"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2a3a94a5-b33a-4acb-bebf-00d1ff7808ba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Powder for concentrate for solution for infusion</p>", "ID": "f49b4d39-5e6e-4f65-ae06-5b4bfcd948e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Powder for concentrate for solution for infusion", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">1 vial of 160\u00a0mg</p>", "ID": "ef1f7209-29a6-496e-86b5-14c47d55d89e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "1 vial of 160\u00a0mg", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ac62d060-b164-468d-9f1d-9e760a13f9c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9d44582c-ecbc-4f51-854d-af9648d8a4f8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>\n</td>\n</tr>\n</table>", "ID": "c22be4ac-0889-4a6d-9729-f752cb172dc4", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>\n</td>\n</tr>", "ID": "50ca887d-8fc3-48c6-87eb-df6e2de4e3e1", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "c22be4ac-0889-4a6d-9729-f752cb172dc4"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>\n</td>", "ID": "01c80158-9bd4-4ee4-8e23-04ea4372b549", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "50ca887d-8fc3-48c6-87eb-df6e2de4e3e1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b></p>", "ID": "b22299bc-19e0-4e4e-a4b0-0c2409b57618", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "01c80158-9bd4-4ee4-8e23-04ea4372b549"}, {"Element": "<b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\n  AND ROUTE(S) OF ADMINISTRATION</b>", "ID": "0f6faf37-d84e-45cc-b0df-883392692b78", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD   AND ROUTE(S) OF ADMINISTRATION", "ParentId": "b22299bc-19e0-4e4e-a4b0-0c2409b57618"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "a2bb1b9a-7d60-4e62-83db-9b2b13c6848e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "c46be72d-a4cf-4d82-a573-3d6edb117951", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a2bb1b9a-7d60-4e62-83db-9b2b13c6848e"}, {"Element": "<p class=\"MsoNormal\">For intravenous use after reconstitution and dilution</p>", "ID": "8408e030-d67f-4b2c-ab05-b002a104374d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "For intravenous use after reconstitution and dilution", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Read the package leaflet before use</p>", "ID": "9b3d37e4-88cf-4b36-8fea-a457d5771c40", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Read the package leaflet before use", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "21fad9df-698f-471d-9806-1f6f7de502bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3f00ccc2-128a-4984-bdd8-188a6b17a849", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>\n</td>\n</tr>\n</table>", "ID": "506b8923-b1e3-476f-a0db-fac4901d00a7", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>\n</td>\n</tr>", "ID": "6048dd32-ae05-40eb-9623-4fb840d08d22", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "506b8923-b1e3-476f-a0db-fac4901d00a7"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>\n</td>", "ID": "007eeea3-4123-45af-8ff0-5f39e81ef158", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6048dd32-ae05-40eb-9623-4fb840d08d22"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b></p>", "ID": "324f3d97-54eb-4803-a178-e2ffd8f889a1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "007eeea3-4123-45af-8ff0-5f39e81ef158"}, {"Element": "<b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH\n  OF CHILDREN</b>", "ID": "09c23de7-a3ee-4765-83cb-873cbddf622a", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL   WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH   OF CHILDREN", "ParentId": "324f3d97-54eb-4803-a178-e2ffd8f889a1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a63f2a27-e2bd-4c9d-8918-eab6cc57d9e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Keep out of the sight and reach of children</p>", "ID": "b3de0e84-4b3c-4d2f-855f-ffb4b622ae9a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Keep out of the sight and reach of children", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b1f567d3-a8c4-4742-ac99-a6cc60a20278", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4eed15a2-fda6-4054-9e85-535f14f25f30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>\n</td>\n</tr>\n</table>", "ID": "2c1bac68-fc16-4ee6-9fee-bff941ba60ee", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>\n</td>\n</tr>", "ID": "d2e20972-e872-45ef-b34a-6a4709ac040d", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "2c1bac68-fc16-4ee6-9fee-bff941ba60ee"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>\n</td>", "ID": "1822d254-b258-4fde-afb6-9152bb76fb1d", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d2e20972-e872-45ef-b34a-6a4709ac040d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b></p>", "ID": "90aa8c5e-9778-45c6-8ec8-a8ed5a15576d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1822d254-b258-4fde-afb6-9152bb76fb1d"}, {"Element": "<b>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\n  SPECIAL WARNING(S), IF NECESSARY</b>", "ID": "37693758-da08-4f95-bb17-44f581a93b6c", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER   SPECIAL WARNING(S), IF NECESSARY", "ParentId": "90aa8c5e-9778-45c6-8ec8-a8ed5a15576d"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "929154df-e1c2-44c3-96d5-1ed1c4b51acb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Cytotoxic</p>", "ID": "a7bdb1af-a5c7-4c64-ab24-fac8c694ea2c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Cytotoxic", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2351aadc-42c0-43d7-83f7-b447c58f73db", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">To be administered under the supervision of a physician\nexperienced in the use of cytotoxic agents.</p>", "ID": "17ca2a72-3416-4981-8fba-6e2a3ef6579c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "To be administered under the supervision of a physician experienced in the use of cytotoxic agents.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6e66dcdf-a1c1-4d67-afef-9ef35078d8ed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f33123d3-5226-4a0e-ba4e-0fcee15a4707", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>\n</td>\n</tr>\n</table>", "ID": "613cf39b-4b16-476b-a9e1-7edc4867d2ee", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>\n</td>\n</tr>", "ID": "82200147-7fe0-4378-abc7-9a16dd0b4d5d", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "613cf39b-4b16-476b-a9e1-7edc4867d2ee"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>\n</td>", "ID": "9d7633e8-6ee1-45e0-9f69-609d9ba645e1", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "82200147-7fe0-4378-abc7-9a16dd0b4d5d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b></p>", "ID": "c5dc2b0c-ae77-4d7b-8673-4d81dc056c48", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d7633e8-6ee1-45e0-9f69-609d9ba645e1"}, {"Element": "<b>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\n  DATE</b>", "ID": "8ac54709-3b05-45ce-9a5a-61667fbc45b3", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY   DATE", "ParentId": "c5dc2b0c-ae77-4d7b-8673-4d81dc056c48"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ac3b4e83-23ca-43ae-94bb-a99505c08a68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">EXP</p>", "ID": "936bfb14-8b3f-449e-8a58-177bb615ead1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "EXP", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e4624704-2813-4e7e-ae4e-dbef5082e444", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e331273d-eeb6-4ca7-9b68-07223e4fea00", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>\n</td>\n</tr>\n</table>", "ID": "e553ef67-2592-4ebb-8ab4-9c1db589ea64", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>\n</td>\n</tr>", "ID": "6a3d534a-3e68-40d7-89e6-53378d9c752c", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e553ef67-2592-4ebb-8ab4-9c1db589ea64"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>\n</td>", "ID": "3c53c817-5ff6-4c1a-b434-20f04c550c41", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6a3d534a-3e68-40d7-89e6-53378d9c752c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b></p>", "ID": "dd0e9f45-dbc2-4ff1-90cb-23404332fab0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3c53c817-5ff6-4c1a-b434-20f04c550c41"}, {"Element": "<b>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\n  STORAGE CONDITIONS</b>", "ID": "d0d1cb78-82bb-4d09-9819-63e48ce969ff", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL   STORAGE CONDITIONS", "ParentId": "dd0e9f45-dbc2-4ff1-90cb-23404332fab0"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9d7b51d3-bcca-46fd-9e54-03ae3b6b9a42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Store in a refrigerator (2\u00baC \u2013 8\u00baC)</p>", "ID": "254e0408-912a-4d89-8865-433dc7ba6e8a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Store in a refrigerator (2\u00baC \u2013 8\u00baC)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "96764520-86e6-4589-81c7-aefb2560b5d1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "640c6679-3e39-4b28-8190-d8a85c70c9fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>\n</td>\n</tr>\n</table>", "ID": "e9b31609-c565-4d4f-82fd-dda5f963837e", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>\n</td>\n</tr>", "ID": "764dc214-a071-41ae-a6aa-a261bed13a06", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "e9b31609-c565-4d4f-82fd-dda5f963837e"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>\n</td>", "ID": "a2137dab-8e64-4143-9a2d-f3f968dabf2d", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "764dc214-a071-41ae-a6aa-a261bed13a06"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid\"><b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>", "ID": "1d4c5b61-0cd8-4682-b593-dbc2e5a1e89d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\n  page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2137dab-8e64-4143-9a2d-f3f968dabf2d"}, {"Element": "<b>10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS\n  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM\n  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b>", "ID": "60a9336b-35f8-4b22-9f5c-435a4a4d8833", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS   FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM   SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "1d4c5b61-0cd8-4682-b593-dbc2e5a1e89d"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6ede850e-9e53-476f-8037-6451d5d11bfb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "dca17845-542a-4379-88a9-440f477d2b3b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>\n</td>\n</tr>\n</table>", "ID": "0cc966ad-e26b-4c8e-a429-5fd99f0aa0c6", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>\n</td>\n</tr>", "ID": "acf5ad8f-461c-4082-8f41-4c397d0d41ff", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "0cc966ad-e26b-4c8e-a429-5fd99f0aa0c6"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>\n</td>", "ID": "7cf42284-b199-4537-8ff0-c1d26930281d", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "acf5ad8f-461c-4082-8f41-4c397d0d41ff"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>", "ID": "6f0fae13-36ff-4d42-a6e3-5f31305a3837", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7cf42284-b199-4537-8ff0-c1d26930281d"}, {"Element": "<b>11.\u00a0\u00a0\u00a0\u00a0 NAME\n  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b>", "ID": "30781a4e-774a-4542-bf5c-a1ff022bc395", "Styles": "None", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0 NAME   AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "6f0fae13-36ff-4d42-a6e3-5f31305a3837"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "497dc82b-c02b-4843-afa9-b4e94d8b0f85", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Registration GmbH </span></p>", "ID": "703e3114-35b2-4874-8909-cff1c01a6fcc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">Roche Registration GmbH </span>", "ID": "90bd75df-23b4-4b79-99a2-9861a09e7334", "Styles": "None", "Classes": "None", "Text": "Roche Registration GmbH ", "ParentId": "703e3114-35b2-4874-8909-cff1c01a6fcc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>", "ID": "60552e1a-5c8e-41ae-8d4f-a410d731ba3a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">Emil-Barell-Strasse 1</span>", "ID": "add43747-231e-4176-bddb-803baa9a6a20", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "60552e1a-5c8e-41ae-8d4f-a410d731ba3a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">79639 Grenzach-Wyhlen</span></p>", "ID": "738c4a7b-788f-4f86-a46f-c537fec038b1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">79639 Grenzach-Wyhlen</span>", "ID": "febbf0ac-0f17-4f64-983c-bd860257bcb7", "Styles": "None", "Classes": "None", "Text": "79639 Grenzach-Wyhlen", "ParentId": "738c4a7b-788f-4f86-a46f-c537fec038b1"}, {"Element": "<p class=\"MsoNormal\">Germany</p>", "ID": "15ee7e5e-d0a9-4197-b0d2-86f6245d719a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Germany", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5c14aaa1-9fd5-4a71-bac6-45667430b223", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4f03aca8-eb35-49c6-92a9-998206952ff8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>\n</td>\n</tr>\n</table>", "ID": "3877958a-2884-4f81-b7cd-15cc39140055", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>\n</td>\n</tr>", "ID": "71cde639-1878-430e-af20-51790bbd571c", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "3877958a-2884-4f81-b7cd-15cc39140055"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>\n</td>", "ID": "45bd0eac-c984-4340-991d-bedf00578907", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "71cde639-1878-430e-af20-51790bbd571c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b></p>", "ID": "cfd7f2d3-9aaa-4e3e-a13a-a3beb9b93c71", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "45bd0eac-c984-4340-991d-bedf00578907"}, {"Element": "<b>12.\u00a0\u00a0\u00a0\u00a0 MARKETING\n  AUTHORISATION NUMBER(S)</b>", "ID": "b5326123-3c5d-4e1b-aeed-246e303548e9", "Styles": "None", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0 MARKETING   AUTHORISATION NUMBER(S)", "ParentId": "cfd7f2d3-9aaa-4e3e-a13a-a3beb9b93c71"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b0e550cc-b77e-4f9e-aaec-3668e3e11fc1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:black\">EU/1/13/885/002</span></p>", "ID": "4b634cbe-e633-4d8c-a09e-52d14172aa3b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"color:black\">EU/1/13/885/002</span>", "ID": "713e7549-7cc5-4c9f-9c11-ad8b17458f8b", "Styles": "color:black", "Classes": "None", "Text": "EU/1/13/885/002", "ParentId": "4b634cbe-e633-4d8c-a09e-52d14172aa3b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9c8e1af4-63fc-4df4-a8d5-00397cf14100", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "09b52332-ec7f-463f-b250-c9d39cb30962", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>\n</td>\n</tr>\n</table>", "ID": "b92c56af-e776-4121-ace2-5a5d28638ba1", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>\n</td>\n</tr>", "ID": "03c3d20f-f3ca-4094-b3a6-4a9ceabcd264", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "b92c56af-e776-4121-ace2-5a5d28638ba1"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>\n</td>", "ID": "7537aec8-48d0-485c-b2bb-18e84dc10bec", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "03c3d20f-f3ca-4094-b3a6-4a9ceabcd264"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b></p>", "ID": "29ae0c10-81a7-48d8-bf5a-e6e0dfca577c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7537aec8-48d0-485c-b2bb-18e84dc10bec"}, {"Element": "<b>13.\u00a0\u00a0\u00a0\u00a0 BATCH\n  NUMBER</b>", "ID": "ff7181dc-1858-4c3f-86c4-b6d42a6309b1", "Styles": "None", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0 BATCH   NUMBER", "ParentId": "29ae0c10-81a7-48d8-bf5a-e6e0dfca577c"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a367fa3c-7368-46b5-bb9c-e15ed8896f07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Batch</p>", "ID": "0b9939ab-8054-4980-89bb-675f1e458a5b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Batch", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "efa2eb3b-64b9-4e78-acec-ccc8ad4a15f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "133e891d-0e64-435f-b567-f5e414b4ab41", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>\n</td>\n</tr>\n</table>", "ID": "cee828d3-990e-4b3e-95b9-0636126bc61e", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>\n</td>\n</tr>", "ID": "b8af77d9-c9b7-4a87-8584-8add25e6090c", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "cee828d3-990e-4b3e-95b9-0636126bc61e"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>\n</td>", "ID": "5b9565cf-130f-46a3-b66c-8689a8af396c", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b8af77d9-c9b7-4a87-8584-8add25e6090c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b></p>", "ID": "b3865b60-0016-4394-99bc-344acb40db03", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5b9565cf-130f-46a3-b66c-8689a8af396c"}, {"Element": "<b>14.\u00a0\u00a0\u00a0\u00a0 GENERAL\n  CLASSIFICATION FOR SUPPLY</b>", "ID": "b2904ca2-6a20-4a74-8405-c39ed50f1bba", "Styles": "None", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0 GENERAL   CLASSIFICATION FOR SUPPLY", "ParentId": "b3865b60-0016-4394-99bc-344acb40db03"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e60bb51b-9189-4dd5-a600-be7f0aa6ac30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Medicinal product subject to medical prescription</p>", "ID": "f6d0d7f6-2dba-43a1-9c87-938bc26f18c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Medicinal product subject to medical prescription", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "61fd8d81-c7fb-43d2-a673-6aa42dd40858", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "76c71a13-8d4d-4012-b71b-1867ff8baf3a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>\n</td>\n</tr>\n</table>", "ID": "601f4000-1bfa-4a8e-93bc-26bdc282cc93", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr>\n<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>\n</td>\n</tr>", "ID": "453f2efc-5509-4a32-9c95-041ee12b1e39", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "601f4000-1bfa-4a8e-93bc-26bdc282cc93"}, {"Element": "<td style=\"width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>\n</td>", "ID": "a1055817-8764-4682-be17-4c800a432b91", "Styles": "width:464.35pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "453f2efc-5509-4a32-9c95-041ee12b1e39"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b></p>", "ID": "f70bbace-6cb2-4bda-a302-c6f58355cfe9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a1055817-8764-4682-be17-4c800a432b91"}, {"Element": "<b>15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\n  ON USE</b>", "ID": "ea7a2f3f-65df-45b9-975e-3a737bd384fe", "Styles": "None", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS   ON USE", "ParentId": "f70bbace-6cb2-4bda-a302-c6f58355cfe9"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1fc716cb-4bda-4f37-af41-dcb94640325d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c223478a-570a-45e8-85fe-b6c878cd8688", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b>16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</b></p>\n</div>", "ID": "e93bf6b9-d9ad-4ffc-ac84-a35d11d75007", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in\"><b>16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</b></p>", "ID": "dca95f76-b61d-4b8b-81a3-faed2c3cc0ce", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;border:none;\npadding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e93bf6b9-d9ad-4ffc-ac84-a35d11d75007"}, {"Element": "<b>16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</b>", "ID": "cf977fcf-ca9d-489f-9dbe-5ef5717c3a7f", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "dca95f76-b61d-4b8b-81a3-faed2c3cc0ce"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "19baf3fc-2871-4928-acff-bcf3e0ce8278", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span style=\"background:lightgrey\">Justification for not\nincluding Braille accepted</span></p>", "ID": "b04d56be-803f-46ad-a449-54fed06d9705", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"background:lightgrey\">Justification for not\nincluding Braille accepted</span>", "ID": "c8e87631-e884-4c4a-917b-30d238b0ccc0", "Styles": "background:lightgrey", "Classes": "None", "Text": "Justification for not including Braille accepted", "ParentId": "b04d56be-803f-46ad-a449-54fed06d9705"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b9a500e6-78d9-46f1-969a-bf5f4a7f2f63", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e7a4cfe3-fee0-402a-a957-3de2cfab8b76", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>17.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b></p>\n</div>", "ID": "219bf924-cda0-437e-aa66-3f335033c773", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>17.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b></p>", "ID": "071841dc-78ca-47ac-ab5c-c2dff3853a07", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "219bf924-cda0-437e-aa66-3f335033c773"}, {"Element": "<b>17.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER \u2013 2D BARCODE</b>", "ID": "65a370c9-9d20-43ab-bc9d-f1f1779c2e97", "Styles": "None", "Classes": "None", "Text": "17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE", "ParentId": "071841dc-78ca-47ac-ab5c-c2dff3853a07"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "da404b57-645e-4121-8edb-7fb5fb990ba7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><span style=\"background:lightgrey\">&lt;2D barcode carrying\nthe unique identifier included.&gt;</span></p>", "ID": "ce494169-bf65-465d-9bb9-9bba5c69026a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"background:lightgrey\">&lt;2D barcode carrying\nthe unique identifier included.&gt;</span>", "ID": "606d6eaf-c3d3-438a-9bcd-7076595a0830", "Styles": "background:lightgrey", "Classes": "None", "Text": "<2D barcode carrying the unique identifier included.>", "ParentId": "ce494169-bf65-465d-9bb9-9bba5c69026a"}, {"Element": "<p class=\"MsoNormal\"><span style=\"background:#CCCCCC\">\u00a0</span></p>", "ID": "fd9e076f-7367-4c6a-961a-d78470466400", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"background:#CCCCCC\">\u00a0</span>", "ID": "817000b9-e202-405d-ac20-1cf070794121", "Styles": "background:#CCCCCC", "Classes": "None", "Text": "\u00a0", "ParentId": "fd9e076f-7367-4c6a-961a-d78470466400"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e159a346-e494-4003-ab35-dc24c9249fdb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>18.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b></p>\n</div>", "ID": "cd01df6a-6463-45ca-b6b4-4c2fab892f49", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>18.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b></p>", "ID": "c22483e8-31b2-44d9-ab5e-2e7969c0f7e7", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cd01df6a-6463-45ca-b6b4-4c2fab892f49"}, {"Element": "<b>18.\u00a0\u00a0\u00a0\u00a0 UNIQUE\nIDENTIFIER - HUMAN READABLE DATA</b>", "ID": "fc11bc9d-6377-4608-a8f0-f979d4d87a5e", "Styles": "None", "Classes": "None", "Text": "18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA", "ParentId": "c22483e8-31b2-44d9-ab5e-2e7969c0f7e7"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "70e8b528-ce5b-48f3-97d7-5c31f22dc64d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">PC: </p>", "ID": "fa0f6be0-b1a8-4673-824f-984f76455143", "Styles": "None", "Classes": "['MsoNormal']", "Text": "PC: ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">SN: </p>", "ID": "fe70d8c7-f22c-49a8-95b1-195d34470316", "Styles": "None", "Classes": "['MsoNormal']", "Text": "SN: ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">NN: </p>", "ID": "65268055-d089-4e14-8810-1eabb37eccea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "NN: ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "1ec87a71-368c-4f3f-ad03-414997b8490c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "46b6813e-6b49-432a-a1e8-b944c407d1ac", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "1ec87a71-368c-4f3f-ad03-414997b8490c"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2e1db4c8-3115-4494-8525-1b54c6dc004b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>MINIMUM PARTICULARS TO\nAPPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>\u00a0</b></p>\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>VIAL LABEL</b></p>\n</div>", "ID": "b5092079-415a-486f-91a5-719e461903ca", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>MINIMUM PARTICULARS TO\nAPPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>", "ID": "7f780659-db7a-44dd-8d24-cfa5c468d71e", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b5092079-415a-486f-91a5-719e461903ca"}, {"Element": "<b>MINIMUM PARTICULARS TO\nAPPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b>", "ID": "1ac80823-c8e7-4878-aec9-61c7da64831a", "Styles": "None", "Classes": "None", "Text": "MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS", "ParentId": "7f780659-db7a-44dd-8d24-cfa5c468d71e"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>\u00a0</b></p>", "ID": "84ee8fdc-aec2-4f30-b6aa-440c81ee20fa", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b5092079-415a-486f-91a5-719e461903ca"}, {"Element": "<b>\u00a0</b>", "ID": "bedc95bb-edc7-43de-b103-18b9238432f2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "84ee8fdc-aec2-4f30-b6aa-440c81ee20fa"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>VIAL LABEL</b></p>", "ID": "8d690404-7d9f-415a-bc43-4dcbf59182d9", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b5092079-415a-486f-91a5-719e461903ca"}, {"Element": "<b>VIAL LABEL</b>", "ID": "d2d193ff-94a5-4a4f-99ff-55e1369d5495", "Styles": "None", "Classes": "None", "Text": "VIAL LABEL", "ParentId": "8d690404-7d9f-415a-bc43-4dcbf59182d9"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3ccfbfbb-4a80-457f-af80-dbf3d9c801a6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "27b04024-4f3e-4f81-91a4-de4694a85b3d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>\n</div>", "ID": "d815d3c6-0b09-4d59-9613-5db384fa7078", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>", "ID": "e5b5fbbf-8eb2-4bea-b716-e48db6302d19", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d815d3c6-0b09-4d59-9613-5db384fa7078"}, {"Element": "<b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b>", "ID": "b3aa09b5-14e9-41a8-9c5e-3de2ccc48ab7", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION", "ParentId": "e5b5fbbf-8eb2-4bea-b716-e48db6302d19"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>", "ID": "66d27286-ed9e-4534-a2f4-d32e6c6f3ff4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla 160\u00a0mg powder for concentrate for solution for\ninfusion</p>", "ID": "b4c9486b-7254-4054-a3da-7b63942cf630", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla 160\u00a0mg powder for concentrate for solution for infusion", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">trastuzumab emtansine</p>", "ID": "07f0fb3d-5908-42a7-acc5-1c12966da0c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "trastuzumab emtansine", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Intravenous use</p>", "ID": "a6ffebc2-1389-4cd4-b856-b7bd49c1bcaf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Intravenous use", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "5ab811f1-4083-4236-bd36-1142cb86ad0b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bfa6cdaa-0fa5-4a63-96c9-4ea179a8bb64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</b></p>\n</div>", "ID": "11057422-8b39-4cf1-b55d-7bebab88caaf", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</b></p>", "ID": "848c7da4-be0b-4aad-ac56-c95f4ced78ef", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "11057422-8b39-4cf1-b55d-7bebab88caaf"}, {"Element": "<b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nOF ADMINISTRATION</b>", "ID": "1c84ccc8-de20-4635-819b-a1f1e382d443", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION", "ParentId": "848c7da4-be0b-4aad-ac56-c95f4ced78ef"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d3f0c4d5-8b70-46ed-920a-cb891bb40610", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">For intravenous use after reconstitution and dilution</p>", "ID": "f9685b6f-d93c-4479-b448-1e827488218c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "For intravenous use after reconstitution and dilution", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "83d44a31-1482-435b-a1ec-bc48cae6d625", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "79922a3a-bbf1-481c-ae56-eb22d2f68d38", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</b></p>\n</div>", "ID": "c212c799-6a16-44a9-86d8-a36adce3cc7d", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</b></p>", "ID": "20174893-c81c-4706-bb33-df622a96769f", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c212c799-6a16-44a9-86d8-a36adce3cc7d"}, {"Element": "<b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</b>", "ID": "1bbb6073-e45d-4faa-9aad-65faf36c513e", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "20174893-c81c-4706-bb33-df622a96769f"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e317d84c-25cc-4b08-aaad-7e93f907960f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">EXP</p>", "ID": "31af3135-f3ea-49d4-8ffd-22a9ed756910", "Styles": "None", "Classes": "['MsoNormal']", "Text": "EXP", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b9e8587e-a2bd-4f5b-bbfc-c99bd1bed740", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9132dcb4-1247-45b1-bcde-46209966a871", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</b></p>\n</div>", "ID": "e2dbdccb-a6a4-4936-937f-a092faafcfad", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</b></p>", "ID": "e531e90d-18bd-4132-83c2-ef77c1f2195d", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e2dbdccb-a6a4-4936-937f-a092faafcfad"}, {"Element": "<b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</b>", "ID": "3765cb48-4f36-4aff-9095-68dcd880714e", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "e531e90d-18bd-4132-83c2-ef77c1f2195d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "be3b60a7-b3be-4c6d-b613-272307b0729f", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">Lot</p>", "ID": "41c11133-d6c0-45ba-a0db-51ff57a01eea", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "Lot", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "881dbf8b-57b3-46c9-a1b2-ee7f08fe792d", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "281a321b-fb54-44c2-ad24-27e7713d9b8c", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</b></p>\n</div>", "ID": "0a1db698-5e3b-49de-9c8e-ee2ed5287338", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</b></p>", "ID": "448e975a-5a14-488f-8c06-1c1e8d2721a9", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a1db698-5e3b-49de-9c8e-ee2ed5287338"}, {"Element": "<b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS\nBY WEIGHT, BY VOLUME OR BY UNIT</b>", "ID": "ae6926fc-9bab-4b19-b864-c53acacacdf0", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT", "ParentId": "448e975a-5a14-488f-8c06-1c1e8d2721a9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "dd0130de-2481-4a13-89d6-668a3aacd4b5", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">160\u00a0mg</p>", "ID": "06355b64-4c7c-43b6-947b-65274c0f14ad", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "160\u00a0mg", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "c8230669-0b11-4917-a46c-4b10440ec5fd", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:5.65pt\">\u00a0</p>", "ID": "f29548c5-ce5b-4429-8234-955b457e93a2", "Styles": "margin-right:5.65pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</b></p>\n</div>", "ID": "5164e9bf-c12a-4024-bb33-46e99ee636a0", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</b></p>", "ID": "8258a0f0-83e7-4ce1-9f23-b23fc6c121a3", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5164e9bf-c12a-4024-bb33-46e99ee636a0"}, {"Element": "<b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</b>", "ID": "ac569559-25ed-403c-b825-480c3629307b", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER", "ParentId": "8258a0f0-83e7-4ce1-9f23-b23fc6c121a3"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "11784b4a-d2a4-46be-8752-72a9dbb1216d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "0f31f269-54fb-4b93-9201-b23b6284442f", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "a61646ef-c932-49c7-b2e7-8c1de91e7f4a", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "0f31f269-54fb-4b93-9201-b23b6284442f"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1ded07c2-3b2e-433f-b54b-f05c8ed9b158", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c0ac39e0-6ed6-409d-94f2-6827c6932f39", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "51e5ca99-c76d-4372-9c51-d406f198f87e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1476863c-09ba-473c-a26b-f3dafb57adac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a61bd8f0-6736-4bad-be4f-049fa5e9f5ab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e809d0fb-1f5a-47aa-bfe9-14e19ca38a19", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0ef99107-af26-4671-a834-35fff0b06c9b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4ff94683-4ff0-44c4-956f-380fed907123", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d0893797-98b1-43fa-9db5-7997de17a22e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8dd213c8-85dd-4eec-9843-6bfc48a7dcdc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "44b122ba-3932-432f-8e0a-a93aab6b1b4d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ebd40ca4-621b-45ac-a754-f74d88061489", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8d813704-94d0-4d9c-b3d7-3d54360dc45c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f671cd46-4d88-4926-a06f-89cf73cc6517", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a46d3e6d-57c7-40a8-98c5-d38b99c76228", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "945ddf40-71b5-4e28-9ade-4709f0518675", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c84e22aa-0253-4eea-8e6a-361ceada5f5d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "88b1faea-1504-4d3a-9672-e7957e82e9cf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bf8eb7b3-95f9-4979-a26f-9c8e9d512f60", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c523434b-a253-4ea9-95a3-2792d2b02867", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a0552fb7-1f20-4e9f-bbbb-230b409201ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3b56d190-8aef-489c-bac3-685cc49bde27", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e56928a6-c380-40b8-9acb-8b431afbeb7c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "62c07b95-da36-47f7-8cf2-fbb0790af99a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"Annex\">B. PACKAGE LEAFLET</p>", "ID": "ab4f6f9b-80ce-4092-b9ef-3fea1c2ab8f5", "Styles": "None", "Classes": "['Annex']", "Text": "B. PACKAGE LEAFLET", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ef8dbc8f-e91f-48ff-8111-e4e8ee8ba3be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "3d415185-fed1-4988-9e4b-fd8ffddf002a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "962bc52a-7b14-489e-8b84-35973cf2c547", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "3d415185-fed1-4988-9e4b-fd8ffddf002a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Package leaflet:\nInformation for the user</b></p>", "ID": "71a7cdd2-d98a-47f4-8cc1-64b33638e08f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Package leaflet:\nInformation for the user</b>", "ID": "8722c7a1-581f-4988-a040-087b822a1d48", "Styles": "None", "Classes": "None", "Text": "Package leaflet: Information for the user", "ParentId": "71a7cdd2-d98a-47f4-8cc1-64b33638e08f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>\u00a0</b></p>", "ID": "151d1a69-d63b-4306-9a40-aa09b6418fe5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "42f644ab-e886-49a2-bec4-0cc1da0c7821", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "151d1a69-d63b-4306-9a40-aa09b6418fe5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Kadcyla100\u00a0mg\npowder for concentrate for solution for infusion</b></p>", "ID": "3adebd3a-62c1-4e97-b09f-512a00563598", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Kadcyla100\u00a0mg\npowder for concentrate for solution for infusion</b>", "ID": "c161f96e-63f2-4db7-833b-dc9cea719830", "Styles": "None", "Classes": "None", "Text": "Kadcyla100\u00a0mg powder for concentrate for solution for infusion", "ParentId": "3adebd3a-62c1-4e97-b09f-512a00563598"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b>Kadcyla\n160\u00a0mg powder for concentrate for solution for infusion</b></p>", "ID": "d8f96624-4e58-4542-a513-495634d1ed04", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Kadcyla\n160\u00a0mg powder for concentrate for solution for infusion</b>", "ID": "27f31537-c595-4afa-832d-69d24c841181", "Styles": "None", "Classes": "None", "Text": "Kadcyla 160\u00a0mg powder for concentrate for solution for infusion", "ParentId": "d8f96624-4e58-4542-a513-495634d1ed04"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\">trastuzumab emtansine</p>", "ID": "164cd2d3-a3f5-4908-ac2e-ed65fb67ef64", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "trastuzumab emtansine", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "4a4259db-8ceb-43fa-8941-8b89b993ea7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>Read all of this leaflet carefully before you start being\ngiven this medicine because it contains important information for you.</b></p>", "ID": "23169422-f7c7-48d8-a3c5-b46f5de296e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Read all of this leaflet carefully before you start being\ngiven this medicine because it contains important information for you.</b>", "ID": "39183cab-6e58-459b-a08d-350797b5aefa", "Styles": "None", "Classes": "None", "Text": "Read all of this leaflet carefully before you start being given this medicine because it contains important information for you.", "ParentId": "23169422-f7c7-48d8-a3c5-b46f5de296e1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Keep this\nleaflet. You may need to read it again.</p>", "ID": "fb36429a-7d16-4749-88c5-562039d8d858", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Keep this leaflet. You may need to read it again.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "541ce7ae-1a1f-40ae-ada8-cceb1b02dcba", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "fb36429a-7d16-4749-88c5-562039d8d858"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you\nhave any further questions, ask your doctor, pharmacist or nurse.</p>", "ID": "47fb88b6-8c52-43ce-bc29-c01d0d5ac1fa", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 If you have any further questions, ask your doctor, pharmacist or nurse.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "84653c2c-bf42-45d6-81f2-251f6e1fe04d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "47fb88b6-8c52-43ce-bc29-c01d0d5ac1fa"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you get\nany side effects, talk to your doctor, pharmacist or nurse. This includes any\npossible side effects not listed in this leaflet. See section 4.</p>", "ID": "b138b950-1c1c-48ee-a21c-46b0c7558956", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f3a365fa-200f-4680-ba85-f57c423baad5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b138b950-1c1c-48ee-a21c-46b0c7558956"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "90dccc18-9294-4379-a250-d9ece697771c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>What is in this leaflet</b></p>", "ID": "b66cab50-b481-4acf-9060-1a8a207da66e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>What is in this leaflet</b>", "ID": "fa9699d3-a88f-4fa0-b924-85d55ea8e8e8", "Styles": "None", "Classes": "None", "Text": "What is in this leaflet", "ParentId": "b66cab50-b481-4acf-9060-1a8a207da66e"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "b4f37629-c01b-44ad-a6a5-89a09ff7f17a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "4e5a1147-4c12-404e-ae7c-52892709ba66", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b4f37629-c01b-44ad-a6a5-89a09ff7f17a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">1.\u00a0\u00a0 What\nKadcyla is and what it is used for</p>", "ID": "45681e15-a6ff-46fc-8069-6ceeed1d80fe", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "1.\u00a0\u00a0 What Kadcyla is and what it is used for", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">2.\u00a0\u00a0 What\nyou need to know before you are given Kadcyla</p>", "ID": "2fb4e59c-5227-4f26-befd-42c85996dd6a", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "2.\u00a0\u00a0 What you need to know before you are given Kadcyla", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">3.\u00a0\u00a0 How\nyou are given Kadcyla </p>", "ID": "8c025688-7d0d-411b-8205-e15ec143255f", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "3.\u00a0\u00a0 How you are given Kadcyla ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">4.\u00a0\u00a0 Possible\nside effects</p>", "ID": "db11e671-b040-4cea-8ff2-c20baf121121", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "4.\u00a0\u00a0 Possible side effects", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">5.\u00a0\u00a0 How\nto store Kadcyla</p>", "ID": "9a601ed5-7685-4ef8-8754-dfa2fbea9919", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "5.\u00a0\u00a0 How to store Kadcyla", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\">6.\u00a0\u00a0 Contents\nof the pack and other information</p>", "ID": "c686fd97-adde-464a-9652-d177f162668b", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "6.\u00a0\u00a0 Contents of the pack and other information", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e39221b3-f182-4eb4-8bf0-4b80d5254311", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "791e6f3d-977e-47cd-a987-0391ed9f590d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Kadcyla is\nand what it is used for</b></p>", "ID": "ee258d82-f42c-4bcb-b86d-54fa483f57d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Kadcyla is\nand what it is used for</b>", "ID": "9796b371-b1a4-4b3e-98e1-d167eabe69d6", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Kadcyla is and what it is used for", "ParentId": "ee258d82-f42c-4bcb-b86d-54fa483f57d4"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "10e7ce17-94bd-4382-a956-3332b3b848ba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "155913e7-9edb-4754-ba67-02a4b6f6a56b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "10e7ce17-94bd-4382-a956-3332b3b848ba"}, {"Element": "<p class=\"MsoNormal\"><b>What Kadcyla is</b></p>", "ID": "94d1f1f5-199b-4910-ad99-21c7b62b53e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>What Kadcyla is</b>", "ID": "220b5f89-5930-4868-be4c-d7a1d41d11f3", "Styles": "None", "Classes": "None", "Text": "What Kadcyla is", "ParentId": "94d1f1f5-199b-4910-ad99-21c7b62b53e1"}, {"Element": "<p class=\"MsoNormal\">Kadcyla contains the active substance trastuzumab emtansine,\nwhich is made up of two parts that are linked together:</p>", "ID": "3422508c-32f0-483b-9ba9-c1ddcd9f1af3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla contains the active substance trastuzumab emtansine, which is made up of two parts that are linked together:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 trastuzumab\n- a monoclonal antibody that binds selectively to an antigen (a target protein)\ncalled human epidermal growth factor receptor 2 (HER2). HER2 is found in large\namounts on the surface of some cancer cells where it stimulates their growth.\nWhen trastuzumab binds to HER2 it can stop the cancer cells growth and cause\nthem to die.</p>", "ID": "def06070-9c82-46e4-b61d-3ad7d2405794", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 trastuzumab - a monoclonal antibody that binds selectively to an antigen (a target protein) called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When trastuzumab binds to HER2 it can stop the cancer cells growth and cause them to die.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "78766d98-65c2-45f8-bdca-123c42ea5895", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "def06070-9c82-46e4-b61d-3ad7d2405794"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 DM1\n\u2013 an anti-cancer substance that becomes active once Kadcyla enters the\ncancer cell. </p>", "ID": "fb7e24bd-4164-40ee-955c-07d72ebb824c", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 DM1 \u2013 an anti-cancer substance that becomes active once Kadcyla enters the cancer cell. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "775f283e-a654-4ff4-a3d0-276e716a7aea", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "fb7e24bd-4164-40ee-955c-07d72ebb824c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "0325adb3-2de9-4c2d-8269-f0433027ef35", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>What Kadcyla is used for</b></p>", "ID": "58b8bebc-8c10-44fc-a94d-30f3656a292a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>What Kadcyla is used for</b>", "ID": "f027bfef-c828-4e2d-8dc9-c4c538d448be", "Styles": "None", "Classes": "None", "Text": "What Kadcyla is used for", "ParentId": "58b8bebc-8c10-44fc-a94d-30f3656a292a"}, {"Element": "<p class=\"MsoNormal\">Kadcyla is used to treat breast cancer in adults when:</p>", "ID": "69731ac2-c415-4ab9-8b7b-61c5018b111e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla is used to treat breast cancer in adults when:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 the cancer\ncells have many HER2 proteins on them - your doctor will test your cancer cells\nfor this. </p>", "ID": "0651c710-3e60-499c-9ffa-6ce90f83932d", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 the cancer cells have many HER2 proteins on them - your doctor will test your cancer cells for this. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "1a4c12b9-71df-47ad-8323-d7b44fbd585e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0651c710-3e60-499c-9ffa-6ce90f83932d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 you have\nalready received the medicine trastuzumab and a medicine known as a taxane.</p>", "ID": "1b65bd77-b6de-40cd-bd0b-e45625962380", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 you have already received the medicine trastuzumab and a medicine known as a taxane.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "511c80d5-0633-4162-bef7-34269b934379", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1b65bd77-b6de-40cd-bd0b-e45625962380"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>the cancer has spread to areas near the breast or to other parts\nof your body (metastasized)</p>", "ID": "be9d2bee-2cdb-46bb-a853-4526cfe5f811", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoListParagraph']", "Text": "the cancer has spread to areas near the breast or to other parts of your body (metastasized)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "214a1c61-a370-4086-98d0-d95689451fb3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "be9d2bee-2cdb-46bb-a853-4526cfe5f811"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7b12168a-44c3-4900-b104-651c41ee79a1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "214a1c61-a370-4086-98d0-d95689451fb3"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>the cancer has not spread to other parts of the body and\ntreatment is going to be given after surgery (treatment after surgery is called\nadjuvant therapy).</p>", "ID": "5faa2092-ab14-4d18-a7da-64d1cc4d2c1a", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoListParagraph']", "Text": "the cancer has not spread to other parts of the body and treatment is going to be given after surgery (treatment after surgery is called adjuvant therapy).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "03428a4a-b773-429e-afad-01a2e2aab333", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5faa2092-ab14-4d18-a7da-64d1cc4d2c1a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "81e0c6dc-cc97-48d1-b789-282ad8b6ff9b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "03428a4a-b773-429e-afad-01a2e2aab333"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "42557699-42c3-4249-a466-06cc7ada7924", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "30531491-49a2-4f32-916b-627e0ad3fb56", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42557699-42c3-4249-a466-06cc7ada7924"}, {"Element": "<p class=\"MsoNormal\"><b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to\nknow before you are given Kadcyla</b></p>", "ID": "ba0c9efb-a15f-4c1d-999c-882c1a5ea15b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to\nknow before you are given Kadcyla</b>", "ID": "49d50f72-7802-4db7-a084-8b2dd7a95047", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you are given Kadcyla", "ParentId": "ba0c9efb-a15f-4c1d-999c-882c1a5ea15b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "bdd6a5c9-05e0-4fdd-9eb5-238f744271e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>You must not be given Kadcyla</b></p>", "ID": "41fcb9cb-14aa-4a6c-bc3e-e4f165164313", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>You must not be given Kadcyla</b>", "ID": "46c7162c-dc3d-4ec2-aa9c-cb4a00a63e9e", "Styles": "None", "Classes": "None", "Text": "You must not be given Kadcyla", "ParentId": "41fcb9cb-14aa-4a6c-bc3e-e4f165164313"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 if you are\nallergic to trastuzumab emtansine or any of the other ingredients of this\nmedicine (listed in section 6). </p>", "ID": "964dcc0a-a854-4304-94d8-d75fc67d92cf", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 if you are allergic to trastuzumab emtansine or any of the other ingredients of this medicine (listed in section 6). ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "3bc885ab-5eda-4e8e-8e8b-9bd1a3c1d5d2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "964dcc0a-a854-4304-94d8-d75fc67d92cf"}, {"Element": "<p class=\"MsoNormal\">You should not be given Kadcyla if the above applies to you.\nIf you are not sure, talk to your doctor or nurse before you are given Kadcyla.</p>", "ID": "1d3fd8b6-8598-4a98-be68-7c821fa8c099", "Styles": "None", "Classes": "['MsoNormal']", "Text": "You should not be given Kadcyla if the above applies to you. If you are not sure, talk to your doctor or nurse before you are given Kadcyla.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a8881f2f-0332-4cfc-b90d-c15d4fa6fd6c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Warnings and precautions</b></p>", "ID": "41e84b28-68d9-4f9d-8810-116761a3beb4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Warnings and precautions</b>", "ID": "4cbf6e39-b69f-4a0d-9596-60c4ba9c4062", "Styles": "None", "Classes": "None", "Text": "Warnings and precautions", "ParentId": "41e84b28-68d9-4f9d-8810-116761a3beb4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Talk to your doctor or nurse\nbefore you are given Kadcyla if:</p>", "ID": "e18fa2f2-fc3f-4a9d-810a-4e1f423628f4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Talk to your doctor or nurse before you are given Kadcyla if:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 you have\never had a serious infusion-related reaction from using trastuzumab characterised\nby symptoms such as flushing, chills, fever, shortness of breath, difficulty\nbreathing, rapid heartbeat or a drop in blood pressure.</p>", "ID": "f39ab79e-d89e-41c0-bdcd-b2dcab5840e9", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 you have ever had a serious infusion-related reaction from using trastuzumab characterised by symptoms such as flushing, chills, fever, shortness of breath, difficulty breathing, rapid heartbeat or a drop in blood pressure.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "be67dae8-25da-4962-b4e7-40d0cf9f2803", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f39ab79e-d89e-41c0-bdcd-b2dcab5840e9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 you are\nreceiving treatment with blood thinning medicines (e.g. warfarin, heparin).</p>", "ID": "1511de5c-b36a-412a-86d7-80dceabe1af1", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 you are receiving treatment with blood thinning medicines (e.g. warfarin, heparin).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9ec49ef8-3fff-45d5-a776-e1f4a88f1793", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1511de5c-b36a-412a-86d7-80dceabe1af1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 you have\nany history of liver problems. Your doctor will check your blood to test your\nliver function before and regularly during treatment</p>", "ID": "105adf0a-d1cc-45c6-97c0-2322ee5318d0", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 you have any history of liver problems. Your doctor will check your blood to test your liver function before and regularly during treatment", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "7b0906eb-0184-4d89-a1bc-6fd9ab60848b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "105adf0a-d1cc-45c6-97c0-2322ee5318d0"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9f4247bb-437b-43b3-8f97-506499255df0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">If any of the above apply to you (or you are not sure), talk\nto your doctor or pharmacist before you are given Kadcyla.</p>", "ID": "75721394-a88d-4563-bb93-fa79b1701355", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before you are given Kadcyla.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "97638748-680b-46e1-b267-361569edeb40", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>Look out for side effects</b></p>", "ID": "882d1ec4-1007-46c0-831a-21547acb94a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Look out for side effects</b>", "ID": "cf3fea31-1176-4feb-b8b6-06e53658ccd3", "Styles": "None", "Classes": "None", "Text": "Look out for side effects", "ParentId": "882d1ec4-1007-46c0-831a-21547acb94a4"}, {"Element": "<p class=\"MsoNormal\">Kadcyla can make some existing conditions worse, or cause\nside effects. See section\u00a04 for more details about what side effects to\nlook out for.</p>", "ID": "c96f78e3-6486-4888-a023-22831ed582c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla can make some existing conditions worse, or cause side effects. See section\u00a04 for more details about what side effects to look out for.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "f721e6cc-b6b2-48cf-8a08-7b32f15fc6bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "53cec4b9-e88d-4660-9e4c-34be1c6f3bff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f721e6cc-b6b2-48cf-8a08-7b32f15fc6bc"}, {"Element": "<p class=\"MsoNormal\"><b>Tell your doctor or nurse straight away if you notice any\nof the following serious side effects while you are given Kadcyla:</b></p>", "ID": "53c2c914-64fa-4c31-b3af-ce5adbcafdfe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Tell your doctor or nurse straight away if you notice any\nof the following serious side effects while you are given Kadcyla:</b>", "ID": "785bc6d3-4b91-405a-805e-883fa47e394b", "Styles": "None", "Classes": "None", "Text": "Tell your doctor or nurse straight away if you notice any of the following serious side effects while you are given Kadcyla:", "ParentId": "53c2c914-64fa-4c31-b3af-ce5adbcafdfe"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "fc77312b-7de1-4760-9575-e70bf96b3653", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Breathing\nproblems:</b> Kadcyla can cause serious breathing problems such as shortness of\nbreath (either at rest or while performing any type of activity) and\ncough.\u00a0 These may be signs of inflammation of your lung, which may be\nserious, and even fatal. If you develop lung disease your doctor may stop\ntreatment with this medicine.</p>", "ID": "1774e545-fc78-432d-9a11-6939fecd3391", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0  Kadcyla can cause serious breathing problems such as shortness of breath (either at rest or while performing any type of activity) and cough.\u00a0 These may be signs of inflammation of your lung, which may be serious, and even fatal. If you develop lung disease your doctor may stop treatment with this medicine.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "cd37e43e-8c1b-4b23-b7e5-d2dbebc4be63", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1774e545-fc78-432d-9a11-6939fecd3391"}, {"Element": "<b>Breathing\nproblems:</b>", "ID": "321b7a35-f1c5-45e6-a3f3-ba927a7596c8", "Styles": "None", "Classes": "None", "Text": "Breathing problems:", "ParentId": "1774e545-fc78-432d-9a11-6939fecd3391"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "6d56e656-8fbd-49de-b368-de8c054fb004", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Liver\nproblems: </b>Kadcyla can cause inflammation or damage to cells in the liver that\ncan stop the liver from functioning normally. Inflamed or injured liver cells\nmay leak higher than normal amounts of certain substances (liver enzymes) into\nthe bloodstream, resulting in elevated liver enzymes in blood tests. In most\ncases you will not have any symptoms. Some symptoms could be yellowing of your\nskin and whites of your eyes (jaundice). Your doctor will check your blood to\ntest your liver function before and regularly during treatment.</p>", "ID": "1278a82a-bf89-4347-8f47-13d3d78bff4b", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Kadcyla can cause inflammation or damage to cells in the liver that can stop the liver from functioning normally. Inflamed or injured liver cells may leak higher than normal amounts of certain substances (liver enzymes) into the bloodstream, resulting in elevated liver enzymes in blood tests. In most cases you will not have any symptoms. Some symptoms could be yellowing of your skin and whites of your eyes (jaundice). Your doctor will check your blood to test your liver function before and regularly during treatment.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "a94e6bad-3d58-4f35-bc38-0cf7087ac739", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1278a82a-bf89-4347-8f47-13d3d78bff4b"}, {"Element": "<b>Liver\nproblems: </b>", "ID": "bd1cf2ce-c8c2-4f43-8e96-5bc05fe97c71", "Styles": "None", "Classes": "None", "Text": "Liver problems: ", "ParentId": "1278a82a-bf89-4347-8f47-13d3d78bff4b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "597271c9-865c-402a-820f-25cee25cd7da", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">Another rare abnormality that can\noccur in the liver is a condition known as nodular regenerative hyperplasia\n(NRH). This abnormality causes the structure of the liver to change and can\nchange how the liver functions. Over time, this may lead to symptoms such as a\nbloated sensation or swelling of the abdomen due to fluid accumulation or\nbleeding from abnormal blood vessels in the gullet or rectum.</p>", "ID": "a246e213-38d3-4bf9-8bf6-f2efdb8a79e0", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "Another rare abnormality that can occur in the liver is a condition known as nodular regenerative hyperplasia (NRH). This abnormality causes the structure of the liver to change and can change how the liver functions. Over time, this may lead to symptoms such as a bloated sensation or swelling of the abdomen due to fluid accumulation or bleeding from abnormal blood vessels in the gullet or rectum.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "b4674274-a8e0-4c75-a04d-2fc206b302dd", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Heart\nproblems: </b>Kadcyla can weaken the heart muscle. When the heart muscle is\nweak, patients may develop symptoms such as shortness of breath at rest or when\nsleeping, chest pain, swollen legs or arms, and a sensation of rapid or\nirregular heartbeats. Your doctor will check your heart function before and\nregularly during treatment. You should tell your doctor immediately if you\nnotice any of the above symptoms.</p>", "ID": "f547a633-51e2-4d7b-854d-3852b07dd860", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Kadcyla can weaken the heart muscle. When the heart muscle is weak, patients may develop symptoms such as shortness of breath at rest or when sleeping, chest pain, swollen legs or arms, and a sensation of rapid or irregular heartbeats. Your doctor will check your heart function before and regularly during treatment. You should tell your doctor immediately if you notice any of the above symptoms.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "c182d7e4-f2e0-49f0-ae0a-d73b77453aa0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f547a633-51e2-4d7b-854d-3852b07dd860"}, {"Element": "<b>Heart\nproblems: </b>", "ID": "df4526a1-d980-4865-9dfb-843e7d37e670", "Styles": "None", "Classes": "None", "Text": "Heart problems: ", "ParentId": "f547a633-51e2-4d7b-854d-3852b07dd860"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "0f8d283b-0906-4e1b-b11d-35e4545cc710", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Infusion-related\nreactions or allergic reactions</b>: Kadcyla can cause flushing, shivering\nfits, fever, trouble breathing, low blood pressure, rapid heartbeat, sudden\nswelling of your face, tongue, or trouble swallowing during the infusion or\nafter the infusion on the first day of treatment. Your doctor or nurse will\ncheck to see whether you are having any of these side effects. If you develop a\nreaction, they will slow down or stop the infusion and may give you treatment\nto counteract the side effects. The infusion may be continued after the\nsymptoms improve.</p>", "ID": "76a520fc-0f00-4484-98c3-0e28f61b396d", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 : Kadcyla can cause flushing, shivering fits, fever, trouble breathing, low blood pressure, rapid heartbeat, sudden swelling of your face, tongue, or trouble swallowing during the infusion or after the infusion on the first day of treatment. Your doctor or nurse will check to see whether you are having any of these side effects. If you develop a reaction, they will slow down or stop the infusion and may give you treatment to counteract the side effects. The infusion may be continued after the symptoms improve.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "d7f9d184-2437-4f4f-9e33-3f187f059e2c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "76a520fc-0f00-4484-98c3-0e28f61b396d"}, {"Element": "<b>Infusion-related\nreactions or allergic reactions</b>", "ID": "c9173201-c388-4b2f-a237-bb1edccd5e36", "Styles": "None", "Classes": "None", "Text": "Infusion-related reactions or allergic reactions", "ParentId": "76a520fc-0f00-4484-98c3-0e28f61b396d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "37d63886-867d-4785-91fb-a5aabc7f89c5", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Bleeding\nproblems:</b> Kadcyla can lower the number of platelets in your blood.\nPlatelets help your blood to clot so you might get unexpected bruising or\nbleeding (such as nose bleeds, bleeding from gums). Your doctor will check your\nblood regularly for decreased platelets. You should tell your doctor\nimmediately if you notice any unexpected bruising or bleeding.</p>", "ID": "bc22baf9-d9d4-4789-aec4-d94db43b9ef0", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0  Kadcyla can lower the number of platelets in your blood. Platelets help your blood to clot so you might get unexpected bruising or bleeding (such as nose bleeds, bleeding from gums). Your doctor will check your blood regularly for decreased platelets. You should tell your doctor immediately if you notice any unexpected bruising or bleeding.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "b66e9168-05da-46dd-bfe2-b9ffb743f64b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bc22baf9-d9d4-4789-aec4-d94db43b9ef0"}, {"Element": "<b>Bleeding\nproblems:</b>", "ID": "f0615e24-c003-4a33-8e53-29a37e29bf6b", "Styles": "None", "Classes": "None", "Text": "Bleeding problems:", "ParentId": "bc22baf9-d9d4-4789-aec4-d94db43b9ef0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in\">\u00a0</p>", "ID": "22f6afc7-2300-4dba-b57b-27a3a5906844", "Styles": "margin-left:.25in", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 <b>Neurological\nproblems:</b> Kadcyla can damage nerves. You may experience tingling, pain,\nnumbness, itching, crawling sensation, pins and needles in your hands and feet.\nYour doctor will monitor you for signs and symptoms of neurological problems.<i>\n</i></p>", "ID": "0f8236cc-b47f-47d0-bc86-8729dc07ae1d", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0  Kadcyla can damage nerves. You may experience tingling, pain, numbness, itching, crawling sensation, pins and needles in your hands and feet. Your doctor will monitor you for signs and symptoms of neurological problems.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "55e39abf-e024-4595-842e-5696cecccd5d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0f8236cc-b47f-47d0-bc86-8729dc07ae1d"}, {"Element": "<b>Neurological\nproblems:</b>", "ID": "815f586f-859d-4516-b172-74ea221787ca", "Styles": "None", "Classes": "None", "Text": "Neurological problems:", "ParentId": "0f8236cc-b47f-47d0-bc86-8729dc07ae1d"}, {"Element": "<i>\n</i>", "ID": "b9d3e101-a40e-41a2-9a4f-0d83f7fa1478", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "0f8236cc-b47f-47d0-bc86-8729dc07ae1d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">\u00a0</p>", "ID": "52fe635b-caed-49ac-bbbf-21ea91a65157", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\">Tell your\ndoctor or nurse straight away if you notice any of the side effects above.</p>", "ID": "696e5a66-f107-4426-8005-b9cd846ea96f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "Tell your doctor or nurse straight away if you notice any of the side effects above.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "665f9ee5-8c00-4266-8f78-ea4c503a60fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "c91dce78-e814-4915-ae58-8ca9cacf17ec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "665f9ee5-8c00-4266-8f78-ea4c503a60fd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Children and adolescents</b></p>", "ID": "bae315b6-3a83-4895-ab9b-ea0c8e8e9541", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Children and adolescents</b>", "ID": "559c1649-427f-4c5a-9df8-1a37415c1ad1", "Styles": "None", "Classes": "None", "Text": "Children and adolescents", "ParentId": "bae315b6-3a83-4895-ab9b-ea0c8e8e9541"}, {"Element": "<p class=\"MsoNormal\">Kadcyla is not recommended for anyone under the age of\n18\u00a0years. This is because there is no information on how well it works in\nthis age group.</p>", "ID": "b92d330e-6356-43d3-a197-14eb0bfaa8ed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla is not recommended for anyone under the age of 18\u00a0years. This is because there is no information on how well it works in this age group.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "fe1de2d4-c219-47a9-8977-03cb728e648e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>Other medicines and Kadcyla</b></p>", "ID": "a752dfd7-3e4b-4c68-b296-a1883612fe78", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Other medicines and Kadcyla</b>", "ID": "cec0ac62-f4cd-44d5-b30f-a591284f5979", "Styles": "None", "Classes": "None", "Text": "Other medicines and Kadcyla", "ParentId": "a752dfd7-3e4b-4c68-b296-a1883612fe78"}, {"Element": "<p class=\"MsoNormal\">Tell your doctor or nurse if you are taking, have recently\ntaken or might take any other medicines. </p>", "ID": "58e1429e-fc54-47f4-bac2-1d84efc02333", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "25172c9e-1f63-4e2c-9b3e-702c1749eb99", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">In particular, tell your doctor or pharmacist if you are\ntaking:</p>", "ID": "fb22262a-3da0-4858-a6e9-5d48f0375514", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In particular, tell your doctor or pharmacist if you are taking:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 any\nmedicines to thin your blood such as warfarin or decrease the ability to form\nblood clot such as aspirin</p>", "ID": "b1c0b662-9dfb-4c86-8a8b-8a2253f1cd2e", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 any medicines to thin your blood such as warfarin or decrease the ability to form blood clot such as aspirin", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f5f0941c-05f1-449b-885c-a02d590c8987", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b1c0b662-9dfb-4c86-8a8b-8a2253f1cd2e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 medicines\nfor fungal infections called ketoconazole, itraconazole or voriconazole</p>", "ID": "150c03e7-fd15-4e0a-8a15-ce5d392b7806", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 medicines for fungal infections called ketoconazole, itraconazole or voriconazole", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "aa8b7323-38b1-4fa7-b153-75f933207428", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "150c03e7-fd15-4e0a-8a15-ce5d392b7806"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 antibiotics\nfor infections called clarithromycin or telithromycin</p>", "ID": "0a4df6aa-b643-4d3b-9bc4-441fb33be132", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 antibiotics for infections called clarithromycin or telithromycin", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "226ea108-4b5f-43a7-9317-a28f1568923a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0a4df6aa-b643-4d3b-9bc4-441fb33be132"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 medicines\nfor HIV called atazanavir, indinavir, nelfinavir, ritonavir or saquinavir.</p>", "ID": "5514211f-5112-44d0-bb38-9f871e80063c", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 medicines for HIV called atazanavir, indinavir, nelfinavir, ritonavir or saquinavir.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "1292875d-8c64-4209-91fa-1c0b8975f20d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5514211f-5112-44d0-bb38-9f871e80063c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 medicine\nfor depression called nefazodone</p>", "ID": "b657a122-b76c-4343-a46f-517e95f631b2", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 medicine for depression called nefazodone", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9621c2b7-1ffe-45cd-a18e-b9dec62e26dc", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b657a122-b76c-4343-a46f-517e95f631b2"}, {"Element": "<p class=\"MsoNormal\">If any of the above apply to you (or you are not sure), talk\nto your doctor or pharmacist before you are given Kadcyla.\u00a0 </p>", "ID": "412e83a5-7210-4c36-95ab-b6117dcaf1e7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before you are given Kadcyla.\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "0a1fc88e-32d2-43b4-9910-d9c278bc5ffb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "ec9a4fa7-9163-4c70-b9f9-2c122dc9bd33", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a1fc88e-32d2-43b4-9910-d9c278bc5ffb"}, {"Element": "<p class=\"MsoNormal\"><b>Pregnancy</b></p>", "ID": "97adf81d-3b56-4eeb-b07a-ffde324beaa2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Pregnancy</b>", "ID": "0c7bbecc-ba5e-4af3-9dda-0c962abb5f2f", "Styles": "None", "Classes": "None", "Text": "Pregnancy", "ParentId": "97adf81d-3b56-4eeb-b07a-ffde324beaa2"}, {"Element": "<p class=\"MsoNormal\">Kadcyla is not recommended if you are pregnant because this medicine\nmay cause harm to the unborn baby. </p>", "ID": "bf84f949-af95-464c-a72d-23f9f07fd0ae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla is not recommended if you are pregnant because this medicine may cause harm to the unborn baby. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Tell your\ndoctor before using Kadcyla if you are pregnant, think you may be pregnant or\nare planning to have a baby.</p>", "ID": "052d4528-8312-4fac-997b-43fcd0e25a21", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Tell your doctor before using Kadcyla if you are pregnant, think you may be pregnant or are planning to have a baby.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "c14e43bf-e7a6-455b-b1c3-8fb8d8bfb399", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "052d4528-8312-4fac-997b-43fcd0e25a21"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Use\neffective contraception to avoid becoming pregnant while you are being treated\nwith Kadcyla. Talk to your doctor about the best contraception for you.</p>", "ID": "ec925d42-ba29-4f18-ba62-4acd77cfc4cd", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Use effective contraception to avoid becoming pregnant while you are being treated with Kadcyla. Talk to your doctor about the best contraception for you.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "4ad64152-5fb6-47a6-84bf-87d12c3919e8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ec925d42-ba29-4f18-ba62-4acd77cfc4cd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 You should\ncontinue to take your contraception for at least 7 months after your last dose\nof Kadcyla. Talk to your doctor before stopping your contraception. </p>", "ID": "e1506d88-07c2-480c-afb6-bb279f43498f", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 You should continue to take your contraception for at least 7 months after your last dose of Kadcyla. Talk to your doctor before stopping your contraception. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9ee49282-2379-45d3-98b4-ab032daa98e0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e1506d88-07c2-480c-afb6-bb279f43498f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Male\npatients or their female partners should also use effective contraception. </p>", "ID": "b4b7c704-56b0-4d99-a6a7-104904b816e1", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Male patients or their female partners should also use effective contraception. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "169c1d46-dcd5-4bb9-810b-33dc89d5cd43", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b4b7c704-56b0-4d99-a6a7-104904b816e1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you do\nbecome pregnant during treatment with Kadcyla, tell your doctor straight away.</p>", "ID": "d91c66cb-197a-4e13-ab91-a11e1146a5a9", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 If you do become pregnant during treatment with Kadcyla, tell your doctor straight away.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "c2b060eb-633b-46ae-9968-bb72cd8aa3e2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d91c66cb-197a-4e13-ab91-a11e1146a5a9"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "ef50ad08-10f1-4067-ba6e-6410fbf15a21", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "d019c360-4f7f-4294-94a0-97da015fd139", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ef50ad08-10f1-4067-ba6e-6410fbf15a21"}, {"Element": "<p class=\"MsoNormal\"><b>Breast-feeding</b></p>", "ID": "ff63290b-a56a-446e-ad30-3a32d80cd537", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Breast-feeding</b>", "ID": "92e5918c-5ef6-4f6d-898a-ef5d29a62fd9", "Styles": "None", "Classes": "None", "Text": "Breast-feeding", "ParentId": "ff63290b-a56a-446e-ad30-3a32d80cd537"}, {"Element": "<p class=\"MsoNormal\">You should not breast-feed during treatment with Kadcyla.\nAlso you should not breast-feed for\u00a07 months after your last infusion of\nKadcyla. It is not known whether the ingredients in Kadcyla pass into\nbreast-milk. Talk to your doctor about this.</p>", "ID": "62065740-81e0-4573-b02b-ec653df9f021", "Styles": "None", "Classes": "['MsoNormal']", "Text": "You should not breast-feed during treatment with Kadcyla. Also you should not breast-feed for\u00a07 months after your last infusion of Kadcyla. It is not known whether the ingredients in Kadcyla pass into breast-milk. Talk to your doctor about this.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "297c7684-67aa-424d-a740-e4c740869939", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>Driving and using machines</b></p>", "ID": "11ca1ae4-5554-4cb9-9933-16714b0c5d8a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Driving and using machines</b>", "ID": "80787c02-1c61-4386-91b9-42af51658d5e", "Styles": "None", "Classes": "None", "Text": "Driving and using machines", "ParentId": "11ca1ae4-5554-4cb9-9933-16714b0c5d8a"}, {"Element": "<p class=\"MsoNormal\">It is not expected that Kadcyla will affect your ability to\ndrive, cycle, use tools or machines. If you experience flushing, shivering\nfits, fever, trouble breathing, low blood pressure or a rapid heartbeat\n(infusion-related reaction), blurred vision, tiredness, headache, or dizziness,\ndo not drive, cycle, use tools or machines until these reactions stop.</p>", "ID": "82b241c5-2bdd-4c7c-bffe-b3282fb38884", "Styles": "None", "Classes": "['MsoNormal']", "Text": "It is not expected that Kadcyla will affect your ability to drive, cycle, use tools or machines. If you experience flushing, shivering fits, fever, trouble breathing, low blood pressure or a rapid heartbeat (infusion-related reaction), blurred vision, tiredness, headache, or dizziness, do not drive, cycle, use tools or machines until these reactions stop.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "d705c0b3-7cd3-4b1b-9a79-f0dc1e074d9c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "4993e8cb-d9ca-4891-9904-c3e4f68cf62e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d705c0b3-7cd3-4b1b-9a79-f0dc1e074d9c"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "4aca05d3-bb7c-481f-8245-820cedc9efd0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4993e8cb-d9ca-4891-9904-c3e4f68cf62e"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "d8fa398c-8622-4ba6-a838-f2beb4590309", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "4aca05d3-bb7c-481f-8245-820cedc9efd0"}, {"Element": "<p class=\"MsoNormal\"><b>Important information about some of the ingredients of\nKadcyla</b></p>", "ID": "1081cda5-5375-4804-bb01-87c0b9275239", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Important information about some of the ingredients of\nKadcyla</b>", "ID": "347299b5-2411-407a-9d73-42eac2d3e6a6", "Styles": "None", "Classes": "None", "Text": "Important information about some of the ingredients of Kadcyla", "ParentId": "1081cda5-5375-4804-bb01-87c0b9275239"}, {"Element": "<p class=\"MsoNormal\">This medicine contains less than 1 mmol sodium (23 mg) per\ndose. It is essentially \u2018sodium- free\u2019.</p>", "ID": "ba712db5-002f-4531-9941-beb703d15d98", "Styles": "None", "Classes": "['MsoNormal']", "Text": "This medicine contains less than 1 mmol sodium (23 mg) per dose. It is essentially \u2018sodium- free\u2019.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "c99f2db4-ff51-4558-8f6a-8de0fd2ae1d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "cb3dcf4a-4d46-4f43-80ba-c74113dce96d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c99f2db4-ff51-4558-8f6a-8de0fd2ae1d8"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "56a1d67c-92cd-45eb-9540-190b78e6e99c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "a34b8f31-a0f3-4ed2-a3eb-73a0436ffd2b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "56a1d67c-92cd-45eb-9540-190b78e6e99c"}, {"Element": "<p class=\"MsoNormal\"><b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How you are given\nKadcyla</b></p>", "ID": "b08c8f67-edca-4084-913f-dc23856836a3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How you are given\nKadcyla</b>", "ID": "99fc9b23-974d-491d-9508-652e7459bf1e", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How you are given Kadcyla", "ParentId": "b08c8f67-edca-4084-913f-dc23856836a3"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "89ae1204-2314-4a75-bbef-ec75b9a1645b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\">Kadcyla\nwill be given to you by a doctor or nurse in a hospital or clinic:</p>", "ID": "26846fc8-3539-44f5-86ac-73627364a896", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Kadcyla will be given to you by a doctor or nurse in a hospital or clinic:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 It is\ngiven by a drip into a vein (intravenous infusion).</p>", "ID": "60a26e7b-0317-48c3-baf5-201d9eea5af7", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 It is given by a drip into a vein (intravenous infusion).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8191978f-3575-423f-8168-bd0f4249e70d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "60a26e7b-0317-48c3-baf5-201d9eea5af7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 You will\nbe given one infusion every\u00a03\u00a0weeks.</p>", "ID": "b2e4d238-367a-4945-ba27-0969dead13ba", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 You will be given one infusion every\u00a03\u00a0weeks.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "147fe4ad-5128-4ef9-862a-769570d385f2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b2e4d238-367a-4945-ba27-0969dead13ba"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "1321d74d-4c48-4dea-b004-5053ad6b6d47", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>How much you will be given</b></p>", "ID": "41ff2626-23aa-4721-889d-525318be4dff", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>How much you will be given</b>", "ID": "30128495-635b-4d2f-bd21-973fba87b5a0", "Styles": "None", "Classes": "None", "Text": "How much you will be given", "ParentId": "41ff2626-23aa-4721-889d-525318be4dff"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 You will\nbe given 3.6\u00a0mg of Kadcyla for every kilogram of your body weight. Your\ndoctor will calculate the correct dose for you.</p>", "ID": "21ca964d-aa60-4c5d-ad72-464c44fe61c8", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 You will be given 3.6\u00a0mg of Kadcyla for every kilogram of your body weight. Your doctor will calculate the correct dose for you.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "4b3f5b0c-0f61-4980-8ad2-8c2b89e107a2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "21ca964d-aa60-4c5d-ad72-464c44fe61c8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The first\ninfusion will be given to you over 90\u00a0minutes. You will be observed by a\ndoctor or nurse while it is being given and for at least 90\u00a0minutes\nfollowing the initial dose, in case you have any side effects. </p>", "ID": "5de7c076-87d8-4eb6-a0a0-4f87455abc4c", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 The first infusion will be given to you over 90\u00a0minutes. You will be observed by a doctor or nurse while it is being given and for at least 90\u00a0minutes following the initial dose, in case you have any side effects. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "19d6b215-cc10-47e4-85db-82dea49ac254", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5de7c076-87d8-4eb6-a0a0-4f87455abc4c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If the\nfirst infusion is well tolerated, the infusion on your next visit may be given\nover 30\u00a0minutes. You will be observed by a doctor or nurse while it is\nbeing given and for at least 30\u00a0minutes following the dose, in case you\nhave any side effects.</p>", "ID": "1616fb9d-ad25-4932-9d69-e2fa39f6b5e2", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 If the first infusion is well tolerated, the infusion on your next visit may be given over 30\u00a0minutes. You will be observed by a doctor or nurse while it is being given and for at least 30\u00a0minutes following the dose, in case you have any side effects.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "4577f240-999f-4061-be7f-656166790b9e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1616fb9d-ad25-4932-9d69-e2fa39f6b5e2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The total\nnumber of infusions that you will be given depends on how you respond to the\ntreatment and which indication is treated.</p>", "ID": "ed4b5f19-d797-480a-a368-b88f53ee5ce2", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 The total number of infusions that you will be given depends on how you respond to the treatment and which indication is treated.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "ed7fab35-4726-4216-bfcc-1995bba42cc0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ed4b5f19-d797-480a-a368-b88f53ee5ce2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 If you\nexperience side effects, your doctor may decide to continue your treatment but\nlower your dose, delay the next dose or stop the treatment.</p>", "ID": "6a84dc8a-b513-473a-863c-1ff5e3f1ac1f", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 If you experience side effects, your doctor may decide to continue your treatment but lower your dose, delay the next dose or stop the treatment.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "88fddb91-4b8e-4b9a-8e77-49faf8729cd5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6a84dc8a-b513-473a-863c-1ff5e3f1ac1f"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "659dc195-0e70-40ad-9a00-36bfea3717df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>If you miss a Kadcyla treatment</b></p>", "ID": "63c5fdd5-5b78-4357-851b-f8cfd507e740", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>If you miss a Kadcyla treatment</b>", "ID": "82f3a422-d83b-4ec7-953c-9b48baf3ef44", "Styles": "None", "Classes": "None", "Text": "If you miss a Kadcyla treatment", "ParentId": "63c5fdd5-5b78-4357-851b-f8cfd507e740"}, {"Element": "<p class=\"MsoNormal\">If you forget or miss your Kadcyla appointment, make another\nappointment as soon as possible. Do not wait until your next planned visit. </p>", "ID": "0537d9d2-2f1f-429c-a54b-8982ead7b758", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If you forget or miss your Kadcyla appointment, make another appointment as soon as possible. Do not wait until your next planned visit. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "70f7d5d0-b4d9-490b-9ffb-eea7f2407f2f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>If you stop Kadcyla treatment</b></p>", "ID": "e307ad9f-f646-4250-9c58-1f61ff29b288", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>If you stop Kadcyla treatment</b>", "ID": "240b022e-147b-4c68-b6ff-6b729c17699b", "Styles": "None", "Classes": "None", "Text": "If you stop Kadcyla treatment", "ParentId": "e307ad9f-f646-4250-9c58-1f61ff29b288"}, {"Element": "<p class=\"MsoNormal\">Do not stop treatment with this medicine without talking to\nyour doctor first.</p>", "ID": "84d412be-97eb-44d3-97a1-fda347bee62c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Do not stop treatment with this medicine without talking to your doctor first.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7192d317-991c-4396-84c7-724fc6bc9ef2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">If you have any further questions on the use of this\nmedicine, ask your doctor or nurse. </p>", "ID": "a6b3d7dd-8b8e-4c80-927b-4522cb3a4090", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If you have any further questions on the use of this medicine, ask your doctor or nurse. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "a5f2a8fa-4efa-4cd0-8afe-50857c636e4f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "ce31dd12-d27c-47df-9671-6deca848a89e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5f2a8fa-4efa-4cd0-8afe-50857c636e4f"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "c97320fd-b520-493f-9ddb-c042d0b49463", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "a6f31df7-ec17-4abd-8733-f894add7ebf6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c97320fd-b520-493f-9ddb-c042d0b49463"}, {"Element": "<p class=\"MsoNormal\"><b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</b></p>", "ID": "da15bd5f-02f0-43ab-92f1-78c7efe5a587", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</b>", "ID": "d853ca62-5d38-4cbf-b7b5-22da768faf96", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "da15bd5f-02f0-43ab-92f1-78c7efe5a587"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "07b4087b-10b1-460a-88d6-e34cde100fab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Like all medicines, this medicine can cause side effects,\nalthough not everybody gets them.</p>", "ID": "39c9461f-8c5f-4f81-88b9-1ef5bb72593c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Like all medicines, this medicine can cause side effects, although not everybody gets them.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "9eefc440-ba21-4f5f-b8b4-567af83b111b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>Tell your doctor or nurse straight away if you notice any\nof following serious side effects.</b></p>", "ID": "8a899288-45dd-4566-8e77-1d7de01ac8b5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Tell your doctor or nurse straight away if you notice any\nof following serious side effects.</b>", "ID": "786a6d7e-d85f-4051-97fe-b17bc25a51a2", "Styles": "None", "Classes": "None", "Text": "Tell your doctor or nurse straight away if you notice any of following serious side effects.", "ParentId": "8a899288-45dd-4566-8e77-1d7de01ac8b5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:6.0pt\"><b>Very common (may affect more\nthan 1 in 10 people):</b></p>", "ID": "079e80f0-0ca1-488a-99c6-4274c02a38f9", "Styles": "margin-top:6.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Very common (may affect more\nthan 1 in 10 people):</b>", "ID": "02cbbc57-ca5f-4c00-ba0a-273b19e27123", "Styles": "None", "Classes": "None", "Text": "Very common (may affect more than 1 in 10 people):", "ParentId": "079e80f0-0ca1-488a-99c6-4274c02a38f9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Kadcyla\nmay cause inflammation or damage to cells in the liver, resulting in elevated\nliver enzymes in blood tests. However, in most cases during Kadcyla treatment,\nliver enzyme levels are elevated mildly and temporarily, do not cause any\nsymptoms, and do not affect liver function.</p>", "ID": "f1a38ef5-f595-47fb-8d23-dab374b4bb46", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Kadcyla may cause inflammation or damage to cells in the liver, resulting in elevated liver enzymes in blood tests. However, in most cases during Kadcyla treatment, liver enzyme levels are elevated mildly and temporarily, do not cause any symptoms, and do not affect liver function.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f8a73415-2b4b-40ba-a8c6-724487129942", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f1a38ef5-f595-47fb-8d23-dab374b4bb46"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Unexpected\nbruising and bleeding (such as nose bleeds).</p>", "ID": "289cddaf-0693-45e3-955d-e500950b46ee", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Unexpected bruising and bleeding (such as nose bleeds).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "49923552-f899-4b7e-bb5d-fbda80038867", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "289cddaf-0693-45e3-955d-e500950b46ee"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Tingling,\npain, numbness, itching, crawling sensation, pins and needles in your hands and\nfeet. These symptoms may indicate nerve damage.</p>", "ID": "fe678ed1-6017-428f-98ca-2b47fd4a2e72", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Tingling, pain, numbness, itching, crawling sensation, pins and needles in your hands and feet. These symptoms may indicate nerve damage.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "072e128a-9ae9-46da-8d79-29db6e7f9325", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "fe678ed1-6017-428f-98ca-2b47fd4a2e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:6.0pt\"><b>Common (may affect up to 1 in 10\npeople):</b></p>", "ID": "b4554ef2-dd41-482a-a14a-84c646b3ef00", "Styles": "margin-top:6.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Common (may affect up to 1 in 10\npeople):</b>", "ID": "7f192bb3-5368-43b6-9bd0-4f6502e88e40", "Styles": "None", "Classes": "None", "Text": "Common (may affect up to 1 in 10 people):", "ParentId": "b4554ef2-dd41-482a-a14a-84c646b3ef00"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Flushing,\nshivering fits, fever, trouble breathing, low blood pressure or a rapid\nheartbeat during the infusion or up to 24 hours after the infusion \u2013\nthese are so-called infusion-related reactions. </p>", "ID": "b11e5ed3-23bd-4814-afe6-2b9e74bc71c9", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Flushing, shivering fits, fever, trouble breathing, low blood pressure or a rapid heartbeat during the infusion or up to 24 hours after the infusion \u2013 these are so-called infusion-related reactions. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "002f76e0-5d67-4dd8-a9c3-1c767ae00e99", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b11e5ed3-23bd-4814-afe6-2b9e74bc71c9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Heart\nproblems can occur. Most patients will not have symptoms from the heart\nproblems. If symptoms do occur, cough shortness of breath at rest or when\nsleeping flat, chest pain and swollen ankles or arms, a sensation of rapid or\nirregular heartbeats may be observed. </p>", "ID": "46b12c2d-07ab-4a73-9731-d60c5852e98a", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Heart problems can occur. Most patients will not have symptoms from the heart problems. If symptoms do occur, cough shortness of breath at rest or when sleeping flat, chest pain and swollen ankles or arms, a sensation of rapid or irregular heartbeats may be observed. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8bd5aafb-fa19-42ae-bc61-dd0c7cc4af07", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "46b12c2d-07ab-4a73-9731-d60c5852e98a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:6.0pt\"><b>Uncommon (may affect up to 1 in\n100 people):</b></p>", "ID": "6e7234c9-3f10-4d8e-9beb-ead1d1a48a33", "Styles": "margin-top:6.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Uncommon (may affect up to 1 in\n100 people):</b>", "ID": "ceec166e-9227-4b1d-aa1c-162945ee2ac3", "Styles": "None", "Classes": "None", "Text": "Uncommon (may affect up to 1 in 100 people):", "ParentId": "6e7234c9-3f10-4d8e-9beb-ead1d1a48a33"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Inflammation\nof your lungs can cause breathing problems such as shortness of breath (either\nat rest or while performing any type of activity), coughing or coughing spells\nwith a dry cough \u2013 these are signs of inflammation of your lung tissue.</p>", "ID": "b65d613e-9809-4129-861b-6904b5e8610c", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Inflammation of your lungs can cause breathing problems such as shortness of breath (either at rest or while performing any type of activity), coughing or coughing spells with a dry cough \u2013 these are signs of inflammation of your lung tissue.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "3dbcdda8-0b6d-4912-ab59-699ae6de546e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b65d613e-9809-4129-861b-6904b5e8610c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Your skin\nand whites of your eyes get yellow (jaundice) \u2013 these could be signs of\nsevere liver damage.</p>", "ID": "3c10697f-1d51-4789-b2cb-b477914ca12c", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Your skin and whites of your eyes get yellow (jaundice) \u2013 these could be signs of severe liver damage.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "6ed790e3-574c-4c98-97b8-42e84357486e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3c10697f-1d51-4789-b2cb-b477914ca12c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Allergic\nreactions can occur and most patients will have mild symptoms such as itching\nor tightness in the chest. In more severe cases, swelling of your face or\ntongue, trouble swallowing or difficulty breathing may occur. </p>", "ID": "f135ee06-b348-41c3-8f43-7c83b0b39ee1", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Allergic reactions can occur and most patients will have mild symptoms such as itching or tightness in the chest. In more severe cases, swelling of your face or tongue, trouble swallowing or difficulty breathing may occur. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "ce71ad92-9c79-45b8-a4a4-59cb77c39e2e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f135ee06-b348-41c3-8f43-7c83b0b39ee1"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c529ffd0-1152-4cf4-b202-c308f86610c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Tell your doctor or nurse straight away if you notice any of\nthe serious side effects above.</p>", "ID": "7ec2f1fb-71af-422a-ad5b-489f4166cab0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tell your doctor or nurse straight away if you notice any of the serious side effects above.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "9d3a2386-0591-4570-8c11-2d21e2570e51", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "f9ef0f57-afcc-4fc7-9cbf-f4cbeb48f786", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9d3a2386-0591-4570-8c11-2d21e2570e51"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Other side effects include</b></p>", "ID": "4df78493-379c-4591-9cbd-65b20d14d30e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Other side effects include</b>", "ID": "998c57d7-9976-45c4-93a9-58a8b57bdffa", "Styles": "None", "Classes": "None", "Text": "Other side effects include", "ParentId": "4df78493-379c-4591-9cbd-65b20d14d30e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "c1a63ad6-c571-43b7-8ce2-05d8a36759b5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "be26c0cb-1a82-4019-aec9-95bf37e49e6c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c1a63ad6-c571-43b7-8ce2-05d8a36759b5"}, {"Element": "<p class=\"MsoNormal\"><b>Very common:</b></p>", "ID": "c721f5e6-9d89-4cf5-b4eb-36a8d25965f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Very common:</b>", "ID": "1b9946ae-78fc-4a58-8ab8-67bc5cead858", "Styles": "None", "Classes": "None", "Text": "Very common:", "ParentId": "c721f5e6-9d89-4cf5-b4eb-36a8d25965f7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 decreased\nred blood cells (shown in a blood test)</p>", "ID": "a6fda298-765e-4615-9be3-8b4cae6709c7", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 decreased red blood cells (shown in a blood test)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "864a3df6-c4f4-413d-8b75-c69bf2e9a740", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a6fda298-765e-4615-9be3-8b4cae6709c7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 being sick\n(vomiting)</p>", "ID": "81dda0f4-6051-413d-8b54-a23b31ab8e67", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 being sick (vomiting)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "eda8b02c-040d-49e2-a08e-6a2609b5b798", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "81dda0f4-6051-413d-8b54-a23b31ab8e67"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 diarrhoea </p>", "ID": "5c1e486f-3557-4432-98ba-b2104ad5a2e3", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 diarrhoea ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "272fbb37-5acc-4ac2-aa63-938ce044ac09", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5c1e486f-3557-4432-98ba-b2104ad5a2e3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 dry mouth</p>", "ID": "e4762225-a425-4c49-a8cd-841ca0b9cb55", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 dry mouth", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "b267f983-0e60-404a-bf92-0cdacc6a6683", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e4762225-a425-4c49-a8cd-841ca0b9cb55"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 urinary\ntract infection</p>", "ID": "5bf53bfa-2d73-429d-82f5-dbe202ba2fe1", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 urinary tract infection", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f5205d6b-1068-4b68-9371-1f03675fdae9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5bf53bfa-2d73-429d-82f5-dbe202ba2fe1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 constipation</p>", "ID": "d6ffb201-410f-4f33-8465-10220e1e4e5b", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 constipation", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "763b04b6-54ea-4247-964a-28ea9b566fe5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d6ffb201-410f-4f33-8465-10220e1e4e5b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 stomach\nache</p>", "ID": "7689136c-82b2-47c0-b919-dedf25c08d57", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 stomach ache", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "a4d45a07-fd1d-4938-9ea9-14e94282ab20", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7689136c-82b2-47c0-b919-dedf25c08d57"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 cough</p>", "ID": "d5372840-bc9c-4ee3-b14c-335ac0e2c175", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 cough", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "6cd11bc4-e20f-4f3d-b604-10c9b849a6e5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d5372840-bc9c-4ee3-b14c-335ac0e2c175"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 shortness\nof breath</p>", "ID": "b87f297a-ed29-41d4-af98-20b9fccfad59", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 shortness of breath", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "df064082-142d-49f8-ace2-2ab83a554242", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b87f297a-ed29-41d4-af98-20b9fccfad59"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 inflammation\nof the mouth</p>", "ID": "59b4ee0d-47ce-4273-8c90-7312c0889dd1", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 inflammation of the mouth", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "84fbbd50-fca3-4552-be8d-105dbd278bb3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "59b4ee0d-47ce-4273-8c90-7312c0889dd1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 difficulty\nsleeping</p>", "ID": "db9fb17f-2d56-4f87-88a2-7e9137ff8b1b", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 difficulty sleeping", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "814598e9-88b4-48c5-b04e-26258cd598f8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "db9fb17f-2d56-4f87-88a2-7e9137ff8b1b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 muscle or joint\npain</p>", "ID": "59a2f4d4-134d-4b50-95c9-9de04b1b5576", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 muscle or joint pain", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "e21be98a-4236-4811-8dee-6b9b4d1657a7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "59a2f4d4-134d-4b50-95c9-9de04b1b5576"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 fever</p>", "ID": "d23815fe-bae0-4de4-abb0-d027711a0720", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 fever", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "fe2d37af-bbc0-462d-8596-7b5d2c88e39e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d23815fe-bae0-4de4-abb0-d027711a0720"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 headache</p>", "ID": "517e0f1f-eb94-49e6-8573-959a67a7dca6", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 headache", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "2676af23-79d1-49b0-b038-95cf0232f94d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "517e0f1f-eb94-49e6-8573-959a67a7dca6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 feeling\ntired</p>", "ID": "12c8ac30-41f9-4818-83f2-a58e1693d279", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 feeling tired", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "2368f0c9-73ea-40e1-983d-1bd006b93270", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "12c8ac30-41f9-4818-83f2-a58e1693d279"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 weakness</p>", "ID": "360dbd0c-7b13-4dc5-a17d-d35aec5e096d", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 weakness", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "cbdc667d-d959-4683-a736-22a9ad24d68e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "360dbd0c-7b13-4dc5-a17d-d35aec5e096d"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "d2d65fab-1834-4b0c-a18f-e54edae23082", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "af8690bc-f802-4ff8-ae4c-c743c183c862", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d2d65fab-1834-4b0c-a18f-e54edae23082"}, {"Element": "<p class=\"MsoNormal\"><b>Common</b><b>:</b></p>", "ID": "78d71652-caab-42a8-a225-d8633268856b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Common</b>", "ID": "995c8c63-8d09-4923-8bad-a2aa2542d81c", "Styles": "None", "Classes": "None", "Text": "Common", "ParentId": "78d71652-caab-42a8-a225-d8633268856b"}, {"Element": "<b>:</b>", "ID": "3e32560f-3be6-4a47-88dc-8ae1f4a14567", "Styles": "None", "Classes": "None", "Text": ":", "ParentId": "78d71652-caab-42a8-a225-d8633268856b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 chills or\nflu like symptoms </p>", "ID": "ac659360-3fe5-4dcd-a7c7-84c048fcf989", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 chills or flu like symptoms ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f567a964-554f-463d-8391-31c3bc5cf29d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ac659360-3fe5-4dcd-a7c7-84c048fcf989"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>decrease in your potassium levels (shown in a blood test)</p>", "ID": "70c2d78c-f853-4aee-866a-586ace08920a", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "decrease in your potassium levels (shown in a blood test)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b1d9cc7d-f9d9-4266-8a1c-93cb77b66f8b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "70c2d78c-f853-4aee-866a-586ace08920a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "393d838b-6710-4c9b-ba00-7c64bd649c11", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b1d9cc7d-f9d9-4266-8a1c-93cb77b66f8b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>skin rashes</p>", "ID": "a48f8303-b5af-4db9-a57a-ab5c1c8a0fe1", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "skin rashes", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "00be1993-adbe-4bb2-96c0-cc510a4b781f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a48f8303-b5af-4db9-a57a-ab5c1c8a0fe1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4181d450-51a2-4bed-bec6-0e4df3bbb9bc", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "00be1993-adbe-4bb2-96c0-cc510a4b781f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>decreased white blood cells (shown in a blood test)</p>", "ID": "74d8a7f4-59f6-45a3-8251-f0f26557048d", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "decreased white blood cells (shown in a blood test)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "bf74f5c8-18f5-4dfb-a9e3-0fed9bd92b5b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "74d8a7f4-59f6-45a3-8251-f0f26557048d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "92358d43-d9b6-4f3c-ba07-e201caa14ee8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bf74f5c8-18f5-4dfb-a9e3-0fed9bd92b5b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 dry eyes,\nwatery eyes or blurred vision</p>", "ID": "127e22cd-d246-432a-9081-95f2fd5c5ef0", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 dry eyes, watery eyes or blurred vision", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "ea4f72cc-8263-4a39-b785-b2d91d020351", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "127e22cd-d246-432a-9081-95f2fd5c5ef0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 eye\nredness or infection</p>", "ID": "7111af82-2731-422f-a982-122747de2f5c", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 eye redness or infection", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "ed3c8421-9a92-49f1-b5e0-2c5c66de29fb", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7111af82-2731-422f-a982-122747de2f5c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 indigestion</p>", "ID": "73fb31bd-b51b-4861-bd30-549ae6e1298c", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 indigestion", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "79528ace-af3c-4315-ad95-f1e37333dce2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "73fb31bd-b51b-4861-bd30-549ae6e1298c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 swelling\nof legs and/or arms</p>", "ID": "8a585d3d-370c-4c6c-8945-a264f73520df", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 swelling of legs and/or arms", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9ee5e4dd-79db-4540-994f-6c76c59dd5ff", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8a585d3d-370c-4c6c-8945-a264f73520df"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 bleeding\nfrom the gums</p>", "ID": "e6a1e263-2287-4a41-8d5b-b4bc356ea5b7", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 bleeding from the gums", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "174ab369-fa6e-4238-8555-f7e953094790", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e6a1e263-2287-4a41-8d5b-b4bc356ea5b7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 increase\nin blood pressure </p>", "ID": "3f12b7eb-538c-4e11-be6f-a0d83a8c0bd2", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 increase in blood pressure ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "0f608ee3-f97b-4125-ab7d-a5d9275ee119", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3f12b7eb-538c-4e11-be6f-a0d83a8c0bd2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 feeling\ndizzy</p>", "ID": "1d753ca8-b0ea-4d28-bc6b-5a8d009dacb9", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 feeling dizzy", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "d36714c5-0d85-4fe2-8b05-a4ce17a1c7a6", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1d753ca8-b0ea-4d28-bc6b-5a8d009dacb9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 taste\ndisturbances</p>", "ID": "63bb98fb-ef75-4640-89b3-302259a2651e", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 taste disturbances", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "badbb473-2b05-4272-807f-576a0542f370", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "63bb98fb-ef75-4640-89b3-302259a2651e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 itching</p>", "ID": "1c73df0f-fd67-4b9c-9da7-cf4d2ccbe961", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 itching", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "211b5638-e355-4157-9b4f-04a177b24d0f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1c73df0f-fd67-4b9c-9da7-cf4d2ccbe961"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 difficulty\nin remembering</p>", "ID": "0d56aa54-5d98-4e9b-af21-3b619fa1f74f", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 difficulty in remembering", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "a49feaa3-d7fb-43ca-8adf-b2df617fded8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0d56aa54-5d98-4e9b-af21-3b619fa1f74f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 hair loss</p>", "ID": "37f13dd4-1c23-4026-b7c2-0c122c13b26d", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 hair loss", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "4d8bddd2-c0cf-49ed-9b09-b83105eb8c82", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "37f13dd4-1c23-4026-b7c2-0c122c13b26d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 hand-and-foot\nskin reaction (Palmar-plantar erythrodysaesthesia syndrome)</p>", "ID": "c113a37c-38fe-45ee-b86c-2bd327111963", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 hand-and-foot skin reaction (Palmar-plantar erythrodysaesthesia syndrome)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "280ff9a7-2958-40f7-b28d-781838d6480f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c113a37c-38fe-45ee-b86c-2bd327111963"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 nail\ndisorder</p>", "ID": "cdef0c5d-79cf-4dbe-945d-e55b6b17fcab", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 nail disorder", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "8175b7df-e9a6-49e3-b3e3-327a610ae9ea", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "cdef0c5d-79cf-4dbe-945d-e55b6b17fcab"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>\u00a0</b></p>", "ID": "ee1c753b-b7e1-4c44-ba65-1fd9d9138741", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "2eb0c854-8d01-430d-bccd-35491743679a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ee1c753b-b7e1-4c44-ba65-1fd9d9138741"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Uncommon:</b></p>", "ID": "28f65390-2094-4a45-8daa-76632410f4b0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Uncommon:</b>", "ID": "22bc2518-2e24-4646-aada-fb8863aefbdb", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "28f65390-2094-4a45-8daa-76632410f4b0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Another\nabnormality that can be caused by Kadcyla is a condition known as nodular\nregenerative hyperplasia of the liver. This abnormality causes the structure of\nthe liver to change. Patients develop multiple nodules in the liver that can\nchange how the liver functions. Over time, this may lead to symptoms such as a\nbloated sensation or swelling of the abdomen due to fluid accumulation or\nbleeding from abnormal blood vessels in the gullet or rectum.</p>", "ID": "4be00f70-cc1c-43d7-a1e5-a8c2bc28a8e5", "Styles": "margin-left:28.1pt;text-indent:-28.1pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Another abnormality that can be caused by Kadcyla is a condition known as nodular regenerative hyperplasia of the liver. This abnormality causes the structure of the liver to change. Patients develop multiple nodules in the liver that can change how the liver functions. Over time, this may lead to symptoms such as a bloated sensation or swelling of the abdomen due to fluid accumulation or bleeding from abnormal blood vessels in the gullet or rectum.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "89abdafc-261c-47de-a486-8c61255f96a2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4be00f70-cc1c-43d7-a1e5-a8c2bc28a8e5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If\nthe Kadcyla infusion solution leaks into the area around the infusion site you\nmay develop tenderness or redness of your skin, or swelling at the infusion\nsite. </p>", "ID": "79becb34-7b4d-4680-ac60-3256dea7b8e5", "Styles": "margin-left:28.1pt;text-indent:-28.1pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If the Kadcyla infusion solution leaks into the area around the infusion site you may develop tenderness or redness of your skin, or swelling at the infusion site. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "4f1b7e87-c3dc-460c-a860-78b97f73b318", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "79becb34-7b4d-4680-ac60-3256dea7b8e5"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "ddc740e4-21ed-4e50-8995-55c71436c28e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">If you get any of the side effects after your treatment with\nKadcyla has stopped, talk to your doctor or nurse and tell them that you have\nbeen treated with Kadcyla.</p>", "ID": "138a1d1e-31e1-45b4-b590-1e14a38a4bd7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If you get any of the side effects after your treatment with Kadcyla has stopped, talk to your doctor or nurse and tell them that you have been treated with Kadcyla.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "691ce55a-8aa6-41b7-a26c-7e3992055dec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>Reporting of side effects</b></p>", "ID": "6fb5e1bf-1257-4333-b40c-34e6fcb24fa4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Reporting of side effects</b>", "ID": "b4dd210d-363e-403d-96f1-0d50dc8913bf", "Styles": "None", "Classes": "None", "Text": "Reporting of side effects", "ParentId": "6fb5e1bf-1257-4333-b40c-34e6fcb24fa4"}, {"Element": "<p class=\"MsoNormal\">If you get any side effects, talk to your doctor or nurse.\nThis includes any possible side effects not listed in this leaflet. </p>", "ID": "69573935-a3b5-48fb-9e54-dee439021f97", "Styles": "None", "Classes": "['MsoNormal']", "Text": "If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "419d6ecc-1726-4711-a23e-9cdfe2a6d78c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">You can also report side effects directly via <span style=\"background:lightgrey\">the national reporting system listed in </span><a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span style=\"background:lightgrey\">Appendix V</span></a><span style=\"color:#3366FF\">.</span>\nBy reporting side effects you can help provide more information on the safety\nof this medicine.</p>", "ID": "0ac9f641-05aa-4581-a27f-75170a929107", "Styles": "None", "Classes": "['MsoNormal']", "Text": "You can also report side effects directly via  By reporting side effects you can help provide more information on the safety of this medicine.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"background:lightgrey\">the national reporting system listed in </span>", "ID": "0d4fff54-d933-4993-864a-ef753d8320df", "Styles": "background:lightgrey", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "0ac9f641-05aa-4581-a27f-75170a929107"}, {"Element": "<a href=\"https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc\"><span style=\"background:lightgrey\">Appendix V</span></a>", "ID": "b66ef8c4-f826-481e-adeb-e6088f382b0e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0ac9f641-05aa-4581-a27f-75170a929107"}, {"Element": "<span style=\"background:lightgrey\">Appendix V</span>", "ID": "cc54dae6-0e10-4e68-943a-bb034da2e130", "Styles": "background:lightgrey", "Classes": "None", "Text": "Appendix V", "ParentId": "b66ef8c4-f826-481e-adeb-e6088f382b0e"}, {"Element": "<span style=\"color:#3366FF\">.</span>", "ID": "5858bb1f-d259-4b3b-91a1-5b6ec6724994", "Styles": "color:#3366FF", "Classes": "None", "Text": ".", "ParentId": "0ac9f641-05aa-4581-a27f-75170a929107"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "551d4a80-dfa0-460b-ad2a-ffeaff4ce5f9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "7995cf5a-5c0c-4048-85da-7bcd264ef9cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "551d4a80-dfa0-460b-ad2a-ffeaff4ce5f9"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "d3ec2d85-aae6-40c1-86f8-6ac5dd64facf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "21bb9e9f-3861-405a-b6b3-b722405557ca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d3ec2d85-aae6-40c1-86f8-6ac5dd64facf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Kadcyla</b></p>", "ID": "0e0878a3-1aff-44db-898a-cb5b80e6ba1c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Kadcyla</b>", "ID": "588b949c-1eca-4b41-9970-f7496135b6d3", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Kadcyla", "ParentId": "0e0878a3-1aff-44db-898a-cb5b80e6ba1c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "0dc6f36b-10d5-4f02-a959-fd99188fa313", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Kadcyla will be stored by the\nhealth professionals at the hospital or clinic.</p>", "ID": "fcba39ea-98d0-48a7-b144-c4276ac1f71f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "Kadcyla will be stored by the health professionals at the hospital or clinic.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "3ccc20f7-e027-4398-b5c2-ff757b15a1ad", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep\nthis medicine out of the sight and reach of children.</p>", "ID": "3859c919-643c-45c2-aa3c-9475ac6e9d1f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this medicine out of the sight and reach of children.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "0893c26e-a6f2-4578-965d-55f6a7547689", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3859c919-643c-45c2-aa3c-9475ac6e9d1f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do\nnot use this medicine after the expiry date which is stated on the outer carton\nand vial after EXP. The expiry date refers to the last day of that month.</p>", "ID": "cc3afb52-2bd5-4752-83c4-d16b43e6523e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not use this medicine after the expiry date which is stated on the outer carton and vial after EXP. The expiry date refers to the last day of that month.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "77d8d59f-9b0e-4e44-81cf-fb8c0e78737b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "cc3afb52-2bd5-4752-83c4-d16b43e6523e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Store\nin a refrigerator at (2\u00b0C \u2011 8\u00b0C). Do not freeze.</p>", "ID": "7f0662fd-646d-46ba-b2eb-168d38e89618", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Store in a refrigerator at (2\u00b0C \u2011 8\u00b0C). Do not freeze.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "655e7b71-f321-47af-9e33-a97f3e709cc2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7f0662fd-646d-46ba-b2eb-168d38e89618"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 When\nprepared as a solution for infusion Kadcyla is stable for up to 24 hours at\n2\u00b0C\u00a0to\u00a08\u00b0C, and must be discarded thereafter. </p>", "ID": "4c0af003-abbb-435b-b38c-0c79ab989cf0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 When prepared as a solution for infusion Kadcyla is stable for up to 24 hours at 2\u00b0C\u00a0to\u00a08\u00b0C, and must be discarded thereafter. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "539bfa2f-86d6-40d2-945a-e156fecc5521", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4c0af003-abbb-435b-b38c-0c79ab989cf0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do\nnot throw away any medicines via wastewater or household waste. Ask your\npharmacist how to dispose of medicines you no longer use. These measures will\nhelp to protect the environment.</p>", "ID": "00f08179-b122-4548-a9d4-fa2bb30589e5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "9afa4506-503a-4266-8784-f8fc4e4ce655", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "00f08179-b122-4548-a9d4-fa2bb30589e5"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "8d2f3177-475c-4ac6-940e-0f582fc8867e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "2c8742b3-16cc-4dad-b567-a0a6e4241618", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the\npack and other information</b></p>", "ID": "fe10b5a2-7e59-464b-9527-0821675aab75", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the\npack and other information</b>", "ID": "0a263bb3-390d-4772-9acd-07b265359bc9", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "fe10b5a2-7e59-464b-9527-0821675aab75"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "00207fe6-22f6-4e9f-822c-8947b8f5010d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "03777852-b60e-4958-93b9-609c9c771e2b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00207fe6-22f6-4e9f-822c-8947b8f5010d"}, {"Element": "<p class=\"MsoNormal\"><b>What Kadcyla contains</b></p>", "ID": "fe9a8dd9-d3b2-4f73-8353-11d45bb4149f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>What Kadcyla contains</b>", "ID": "d609f291-d551-4206-8f99-baab9336f69e", "Styles": "None", "Classes": "None", "Text": "What Kadcyla contains", "ParentId": "fe9a8dd9-d3b2-4f73-8353-11d45bb4149f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The active\nsubstance is trastuzumab emtansine. </p>", "ID": "08e22033-d1f1-49a9-ba3a-4268d56ce657", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 The active substance is trastuzumab emtansine. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "e875914c-f39e-4125-b464-1c1e1c853079", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "08e22033-d1f1-49a9-ba3a-4268d56ce657"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0  Kadcyla\n100mg: One vial of powder for concentrate for solution for infusion contains\n100 mg of trastuzumab emtansine. After reconstitution one vial of 5 mL solution\ncontains 20 mg/mL of trastuzumab emtansine.</p>", "ID": "6548ceb4-40f3-47b3-8b19-f09a6c9b62ed", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0  Kadcyla 100mg: One vial of powder for concentrate for solution for infusion contains 100 mg of trastuzumab emtansine. After reconstitution one vial of 5 mL solution contains 20 mg/mL of trastuzumab emtansine.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "3f1139ec-28f0-498e-9723-00bb09beb629", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6548ceb4-40f3-47b3-8b19-f09a6c9b62ed"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Kadcyla\n160mg: One vial of powder for concentrate for solution for infusion contains\n160 mg of trastuzumab emtansine. After reconstitution one vial of 8 mL solution\ncontains 20 mg/mL of trastuzumab emtansine.</p>", "ID": "c4b53094-4040-43a9-80dd-944fd3b0c417", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Kadcyla 160mg: One vial of powder for concentrate for solution for infusion contains 160 mg of trastuzumab emtansine. After reconstitution one vial of 8 mL solution contains 20 mg/mL of trastuzumab emtansine.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "5b36a18e-6027-43fb-8e00-05c12d989bb6", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c4b53094-4040-43a9-80dd-944fd3b0c417"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 The other\ningredients are succinic acid, sodium hydroxide (see section 2 under\n\u2018Important information about some of the ingredients of Kadcyla\u2019),\nsucrose, and polysorbate\u00a020.</p>", "ID": "11b1188d-f384-4f8f-9e73-d242aff10cb7", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 The other ingredients are succinic acid, sodium hydroxide (see section 2 under \u2018Important information about some of the ingredients of Kadcyla\u2019), sucrose, and polysorbate\u00a020.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "66c2d1a0-9460-4026-a0a2-6228ea076dec", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "11b1188d-f384-4f8f-9e73-d242aff10cb7"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "bea2ef0c-9478-48d3-8cab-05f8b3fbb65e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "dd66d1e3-2cbe-47a7-ba2b-98e1a15e9c16", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bea2ef0c-9478-48d3-8cab-05f8b3fbb65e"}, {"Element": "<p class=\"MsoNormal\"><b>What Kadcyla looks like and contents of the pack</b></p>", "ID": "7861c0ed-65d9-48f4-8167-4ce02598f610", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>What Kadcyla looks like and contents of the pack</b>", "ID": "79e38936-9a6e-41b9-8431-b294f2e64215", "Styles": "None", "Classes": "None", "Text": "What Kadcyla looks like and contents of the pack", "ParentId": "7861c0ed-65d9-48f4-8167-4ce02598f610"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Kadcyla is\na white to off-white lyophilised powder for concentrate for solution for\ninfusion supplied in glass vials. </p>", "ID": "5c33c2a3-7cfe-4b55-bb7e-3e0cf8fafef2", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Kadcyla is a white to off-white lyophilised powder for concentrate for solution for infusion supplied in glass vials. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "f4433cd6-c967-475b-9c92-0acc834623c2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5c33c2a3-7cfe-4b55-bb7e-3e0cf8fafef2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:17.85pt;text-indent:-17.85pt\"><span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0 Kadcyla is\navailable in packs containing 1 vial.</p>", "ID": "16f7cf38-dcc2-4c1b-b5ad-19ac4f7335bf", "Styles": "margin-left:17.85pt;text-indent:-17.85pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0 Kadcyla is available in packs containing 1 vial.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"ES\" style=\"font-family:Symbol\">\u00b7</span>", "ID": "894d035e-7f48-429e-8aad-924194be1971", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "16f7cf38-dcc2-4c1b-b5ad-19ac4f7335bf"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c102b0ee-18ec-4d15-a6c1-42a18b875838", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><b>Marketing Authorisation Holder</b></p>", "ID": "f132b9c0-d5ff-454d-b31e-69e935a09382", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Marketing Authorisation Holder</b>", "ID": "9c0c3842-4623-4bc2-88d8-ab7607ea9791", "Styles": "None", "Classes": "None", "Text": "Marketing Authorisation Holder", "ParentId": "f132b9c0-d5ff-454d-b31e-69e935a09382"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Roche Registration GmbH </span></p>", "ID": "5727627a-3836-4f8f-9378-798dc2de866d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Roche Registration GmbH </span>", "ID": "052bfb67-fd51-4018-bd5c-999416e3d771", "Styles": "None", "Classes": "None", "Text": "Roche Registration GmbH ", "ParentId": "5727627a-3836-4f8f-9378-798dc2de866d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">Emil-Barell-Strasse 1</span></p>", "ID": "bee59f9b-60bf-4ccb-ae24-faeefa7d2d77", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-CARRIBEAN\">Emil-Barell-Strasse 1</span>", "ID": "f1e0f199-2f56-4714-a843-99f2359b59ac", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "bee59f9b-60bf-4ccb-ae24-faeefa7d2d77"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">79639 Grenzach-Wyhlen</span></p>", "ID": "e798e3b1-55c2-4b53-9230-7bba2c8f4e18", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-CARRIBEAN\">79639 Grenzach-Wyhlen</span>", "ID": "ee123d03-767d-4349-8e02-b76c9c4f7c4b", "Styles": "None", "Classes": "None", "Text": "79639 Grenzach-Wyhlen", "ParentId": "e798e3b1-55c2-4b53-9230-7bba2c8f4e18"}, {"Element": "<p class=\"MsoNormal\">Germany</p>", "ID": "5d0922d7-a2b9-4714-8172-4a845badfcc6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Germany", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7c485953-3c51-4e25-8c47-ee60ad17962f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Manufacturer</b></p>", "ID": "ad222202-9379-4566-9261-89cc3eec4174", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Manufacturer</b>", "ID": "49d9133c-e1b7-4012-82f3-5618d3309ecc", "Styles": "None", "Classes": "None", "Text": "Manufacturer", "ParentId": "ad222202-9379-4566-9261-89cc3eec4174"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE-CH\">Roche Pharma\nAG</span></p>", "ID": "379acc85-fd30-40bd-b8fd-9cb52832ba88", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">Roche Pharma\nAG</span>", "ID": "0da97107-3788-4d36-8f3b-d69bf4e34e95", "Styles": "None", "Classes": "None", "Text": "Roche Pharma AG", "ParentId": "379acc85-fd30-40bd-b8fd-9cb52832ba88"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Emil-Barell-Strasse 1</span></p>", "ID": "fc7b22c7-e9ed-4630-af26-7e94ce916296", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"DE-CH\">Emil-Barell-Strasse 1</span>", "ID": "bb1023e4-cd1e-4115-8291-ea63799da1f2", "Styles": "None", "Classes": "None", "Text": "Emil-Barell-Strasse 1", "ParentId": "fc7b22c7-e9ed-4630-af26-7e94ce916296"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-CARRIBEAN\">D-79639 Grenzach-Wyhlen</span></p>", "ID": "a7c6c151-628d-4873-b2a2-1687a8b746dc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span lang=\"EN-CARRIBEAN\">D-79639 Grenzach-Wyhlen</span>", "ID": "4a9da1ee-dc3f-4857-8341-313095216923", "Styles": "None", "Classes": "None", "Text": "D-79639 Grenzach-Wyhlen", "ParentId": "a7c6c151-628d-4873-b2a2-1687a8b746dc"}, {"Element": "<p class=\"MsoNormal\">Germany</p>", "ID": "3fefd582-3341-4370-a9a3-8ed1991bf640", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Germany", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "311721b4-da84-4d07-ba78-c9e39f4af97c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">For any information about\nthis medicine, please contact the local representative of the Marketing\nAuthorisation Holder:</p>", "ID": "823eed00-d110-474d-8b08-5bd7030ad0ee", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0</p>", "ID": "63986511-5559-4b9b-b3a6-749cdca15af2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"FR\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</b></p>\n<p class=\"MsoNormal\">\u0420\u043e\u0448 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</p>\n<p class=\"MsoNormal\">\u0422\u0435\u043b<span lang=\"FR\">: +359 2\u00a0818 44 44</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +370 5 2546799</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +36 - 23 446 800</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Danmark</b></p>\n<p class=\"MsoNormal\">Roche a/s</p>\n<p class=\"MsoNormal\">Tlf: +45 - 36 39 99 99</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Malta</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">(See Ireland)</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\">Tel: +31 (<span style=\"layout-grid-mode:line\">0) 348\n  438050</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span style=\"layout-grid-mode:line\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Roche Norge AS</span></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Tlf: +47 - 22 78 90 00</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</b></p>\n<p class=\"MsoNormal\">Roche (Hellas) A.E. </p>\n<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +30 210 61 66 100</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\">Tel: +34 - 91 324 81 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Polska</b></p>\n<p class=\"MsoNormal\">Roche Polska Sp.z o.o.</p>\n<p class=\"MsoNormal\">Tel: +48 - 22 345 18 88</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>France</b></p>\n<p class=\"MsoNormal\">Roche</p>\n<p class=\"MsoNormal\">T\u00e9l: +33\u00a0(0)1 47 61 40 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica,\n  Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel:\u00a0 +385 1 4722 333</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\">Tel: +40 21 206 47 01</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Ireland</b></p>\n<p class=\"MsoNormal\">Roche Products (Ireland) Ltd.</p>\n<p class=\"MsoNormal\">Tel: +353 (0) 1 469 0700</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Slovenija</b></p>\n<p class=\"MsoNormal\">Roche farmacevtska dru\u017eba d.o.o.</p>\n<p class=\"MsoNormal\">Tel: +386 - 1 360 26 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi<span style=\"layout-grid-mode:\n  line\">: +354 540 8000</span></span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\">Tel: +421 - 2 52638201</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>\n<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Sverige</b></p>\n<p class=\"MsoNormal\">Roche AB</p>\n<p class=\"MsoNormal\">Tel: +46 (0) 8 726 1200</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>United Kingdom</b></p>\n<p class=\"MsoNormal\">Roche Products Ltd.</p>\n<p class=\"MsoNormal\">Tel: +44 (0) 1707 366000</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>\n</table>", "ID": "88d4729a-0bd5-4eb5-8bd4-9698c3068809", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "               ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"FR\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</b></p>\n<p class=\"MsoNormal\">\u0420\u043e\u0448 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</p>\n<p class=\"MsoNormal\">\u0422\u0435\u043b<span lang=\"FR\">: +359 2\u00a0818 44 44</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +370 5 2546799</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "65d7a07d-bfde-4436-acbc-56d9dcef6b83", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"FR\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</b></p>\n<p class=\"MsoNormal\">\u0420\u043e\u0448 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</p>\n<p class=\"MsoNormal\">\u0422\u0435\u043b<span lang=\"FR\">: +359 2\u00a0818 44 44</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>\n</td>", "ID": "bdb9c5e5-b69f-4260-84ad-404f7ea08fd8", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "         ", "ParentId": "65d7a07d-bfde-4436-acbc-56d9dcef6b83"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b></p>", "ID": "7ba42b2f-15b4-44d9-a6db-2d04bff48d70", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdb9c5e5-b69f-4260-84ad-404f7ea08fd8"}, {"Element": "<b><span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span></b>", "ID": "b51ae866-6980-4b02-8dfc-4fce883e5605", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7ba42b2f-15b4-44d9-a6db-2d04bff48d70"}, {"Element": "<span lang=\"FR-CH\">Belgi\u00eb/Belgique/Belgien</span>", "ID": "2544abdf-9164-498c-b7e3-52da13d1494e", "Styles": "None", "Classes": "None", "Text": "Belgi\u00eb/Belgique/Belgien", "ParentId": "b51ae866-6980-4b02-8dfc-4fce883e5605"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR-CH\">N.V. Roche S.A.</span></p>", "ID": "51b0af7f-dca3-4c3d-80c8-e6ac3a31ec9f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdb9c5e5-b69f-4260-84ad-404f7ea08fd8"}, {"Element": "<span lang=\"FR-CH\">N.V. Roche S.A.</span>", "ID": "605188b7-8d08-4926-a1d6-d598b65a662d", "Styles": "None", "Classes": "None", "Text": "N.V. Roche S.A.", "ParentId": "51b0af7f-dca3-4c3d-80c8-e6ac3a31ec9f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span></p>", "ID": "80a7be6c-04e0-42a9-b14d-0e4c9c3cbc41", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdb9c5e5-b69f-4260-84ad-404f7ea08fd8"}, {"Element": "<span lang=\"FR\">T\u00e9l/Tel: +32 (0) 2 525 82 11</span>", "ID": "ba8966b7-d4c7-4494-8296-1e41f53829b6", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel: +32 (0) 2 525 82 11", "ParentId": "80a7be6c-04e0-42a9-b14d-0e4c9c3cbc41"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"FR\">\u00a0</span></b></p>", "ID": "fae02872-3e97-47b1-a6f7-316e00913e28", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdb9c5e5-b69f-4260-84ad-404f7ea08fd8"}, {"Element": "<b><span lang=\"FR\">\u00a0</span></b>", "ID": "6157603b-7fc0-4a81-8bdf-40d43d648fc3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fae02872-3e97-47b1-a6f7-316e00913e28"}, {"Element": "<span lang=\"FR\">\u00a0</span>", "ID": "85d2d539-69ad-47b0-b330-dc260315718a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6157603b-7fc0-4a81-8bdf-40d43d648fc3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b>\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</b></p>", "ID": "d9e0d5a0-371f-44a9-b841-dc394e5eecf0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdb9c5e5-b69f-4260-84ad-404f7ea08fd8"}, {"Element": "<b>\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</b>", "ID": "f30f531d-6c8b-4740-8bc7-6ca17e5ae91e", "Styles": "None", "Classes": "None", "Text": "\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f", "ParentId": "d9e0d5a0-371f-44a9-b841-dc394e5eecf0"}, {"Element": "<p class=\"MsoNormal\">\u0420\u043e\u0448 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</p>", "ID": "426e2f0d-7aa1-47b5-8b1d-c0ae4a8bf466", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u0420\u043e\u0448 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f   \u0415\u041e\u041e\u0414", "ParentId": "bdb9c5e5-b69f-4260-84ad-404f7ea08fd8"}, {"Element": "<p class=\"MsoNormal\">\u0422\u0435\u043b<span lang=\"FR\">: +359 2\u00a0818 44 44</span></p>", "ID": "615e21d7-84ab-43d5-bcf2-51c3c948af16", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u0422\u0435\u043b", "ParentId": "bdb9c5e5-b69f-4260-84ad-404f7ea08fd8"}, {"Element": "<span lang=\"FR\">: +359 2\u00a0818 44 44</span>", "ID": "362d4663-c1cc-42a7-a56f-84d1a4e40bd9", "Styles": "None", "Classes": "None", "Text": ": +359 2\u00a0818 44 44", "ParentId": "615e21d7-84ab-43d5-bcf2-51c3c948af16"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"FR\">\u00a0</span></b></p>", "ID": "bb489115-4b7c-4157-a740-ea294d2d9e73", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdb9c5e5-b69f-4260-84ad-404f7ea08fd8"}, {"Element": "<b><span lang=\"FR\">\u00a0</span></b>", "ID": "7424cf47-9c4f-44d5-a4b8-f8c5bb74fdf0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bb489115-4b7c-4157-a740-ea294d2d9e73"}, {"Element": "<span lang=\"FR\">\u00a0</span>", "ID": "416b3806-13be-4c0e-91c6-4f8088c158b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7424cf47-9c4f-44d5-a4b8-f8c5bb74fdf0"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Lietuva</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">UAB \u201cRoche Lietuva\u201d</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +370 5 2546799</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>\n</td>", "ID": "da1c3f33-379e-43c6-ba6a-f2990f4e5b5f", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "        ", "ParentId": "65d7a07d-bfde-4436-acbc-56d9dcef6b83"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">Lietuva</span></b></p>", "ID": "9912fc29-a759-4352-a2df-991b2005a822", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da1c3f33-379e-43c6-ba6a-f2990f4e5b5f"}, {"Element": "<b><span lang=\"DE\">Lietuva</span></b>", "ID": "6af19097-0344-49c5-9658-8364bbd673cc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9912fc29-a759-4352-a2df-991b2005a822"}, {"Element": "<span lang=\"DE\">Lietuva</span>", "ID": "f0c370bc-6789-40da-869c-a4d1431048c5", "Styles": "None", "Classes": "None", "Text": "Lietuva", "ParentId": "6af19097-0344-49c5-9658-8364bbd673cc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">UAB \u201cRoche Lietuva\u201d</span></p>", "ID": "80189894-ffce-4856-8ee0-ca17cd11365a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da1c3f33-379e-43c6-ba6a-f2990f4e5b5f"}, {"Element": "<span lang=\"DE\">UAB \u201cRoche Lietuva\u201d</span>", "ID": "5b7f5d90-45e2-4b77-8271-de6a5f59af39", "Styles": "None", "Classes": "None", "Text": "UAB \u201cRoche Lietuva\u201d", "ParentId": "80189894-ffce-4856-8ee0-ca17cd11365a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +370 5 2546799</span></p>", "ID": "a9b71e55-c69f-4e3d-a74a-096b5b6ae495", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da1c3f33-379e-43c6-ba6a-f2990f4e5b5f"}, {"Element": "<span lang=\"DE\">Tel: +370 5 2546799</span>", "ID": "dc6b85f3-035b-43da-b98e-ae42e1afd958", "Styles": "None", "Classes": "None", "Text": "Tel: +370 5 2546799", "ParentId": "a9b71e55-c69f-4e3d-a74a-096b5b6ae495"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>", "ID": "ac14851e-ed09-484d-b707-96c2735b73c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da1c3f33-379e-43c6-ba6a-f2990f4e5b5f"}, {"Element": "<b><span lang=\"DE-CH\">\u00a0</span></b>", "ID": "fecf6f55-a01b-4e16-87bf-e51f38bf3d19", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ac14851e-ed09-484d-b707-96c2735b73c9"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "d811953c-c11c-4174-8438-2d969aa56e74", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fecf6f55-a01b-4e16-87bf-e51f38bf3d19"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b></p>", "ID": "5f8e88a8-788a-42bc-9951-2fd9fd1052ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da1c3f33-379e-43c6-ba6a-f2990f4e5b5f"}, {"Element": "<b><span lang=\"DE-CH\">Luxembourg/Luxemburg</span></b>", "ID": "b92e2019-8fba-4942-95a5-c745441b88f8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5f8e88a8-788a-42bc-9951-2fd9fd1052ac"}, {"Element": "<span lang=\"DE-CH\">Luxembourg/Luxemburg</span>", "ID": "2af11d47-6ae9-4d1d-98be-224bdc3d74e4", "Styles": "None", "Classes": "None", "Text": "Luxembourg/Luxemburg", "ParentId": "b92e2019-8fba-4942-95a5-c745441b88f8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span></p>", "ID": "081528b8-e5bf-4551-96dc-a39ab4eb0322", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da1c3f33-379e-43c6-ba6a-f2990f4e5b5f"}, {"Element": "<span lang=\"DE-CH\">(Voir/siehe Belgique/Belgien)</span>", "ID": "c5cc1f5d-b1fd-4243-9ec7-837f1f887b2f", "Styles": "None", "Classes": "None", "Text": "(Voir/siehe Belgique/Belgien)", "ParentId": "081528b8-e5bf-4551-96dc-a39ab4eb0322"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00a0</span></b></p>", "ID": "671f071d-3fde-4565-a817-0935e488c554", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da1c3f33-379e-43c6-ba6a-f2990f4e5b5f"}, {"Element": "<b><span lang=\"DE-CH\">\u00a0</span></b>", "ID": "2e1c021a-b351-436c-b570-c7646bf95011", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "671f071d-3fde-4565-a817-0935e488c554"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "88c93c32-22e0-4301-885a-dfd402ba539e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2e1c021a-b351-436c-b570-c7646bf95011"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +36 - 23 446 800</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>", "ID": "55114a70-0a4f-489c-b65a-5fb910662c36", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 - 2 20382111</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "df3701cb-4ba1-4f58-956f-fa0ec4742b06", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "55114a70-0a4f-489c-b65a-5fb910662c36"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b></p>", "ID": "b7dce55e-892a-45cd-b3c5-ab294e09bfd1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "df3701cb-4ba1-4f58-956f-fa0ec4742b06"}, {"Element": "<b><span lang=\"DE-CH\">\u010cesk\u00e1 republika</span></b>", "ID": "d5e5f0d3-7fac-4d0a-94c1-544ddce6ffd3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7dce55e-892a-45cd-b3c5-ab294e09bfd1"}, {"Element": "<span lang=\"DE-CH\">\u010cesk\u00e1 republika</span>", "ID": "2a17e48c-f8ba-4d82-9b69-6bb7b5c7d5e2", "Styles": "None", "Classes": "None", "Text": "\u010cesk\u00e1 republika", "ParentId": "d5e5f0d3-7fac-4d0a-94c1-544ddce6ffd3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche s. r. o.</span></p>", "ID": "ef03d0bf-9929-4b6a-86f4-194722281a27", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "df3701cb-4ba1-4f58-956f-fa0ec4742b06"}, {"Element": "<span lang=\"DE-CH\">Roche s. r. o.</span>", "ID": "eba9bf90-a1e9-4a53-98c4-158134ee60d7", "Styles": "None", "Classes": "None", "Text": "Roche s. r. o.", "ParentId": "ef03d0bf-9929-4b6a-86f4-194722281a27"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +420 - 2 20382111</span></p>", "ID": "ed76c976-0028-44cf-8665-756efddf8895", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "df3701cb-4ba1-4f58-956f-fa0ec4742b06"}, {"Element": "<span lang=\"DE-CH\">Tel: +420 - 2 20382111</span>", "ID": "b38ab573-8182-45d1-9d45-a8043aef872c", "Styles": "None", "Classes": "None", "Text": "Tel: +420 - 2 20382111", "ParentId": "ed76c976-0028-44cf-8665-756efddf8895"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "b208c5d2-7a93-4040-ae8c-935887a3372c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "df3701cb-4ba1-4f58-956f-fa0ec4742b06"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "2e13a7cd-65b3-4655-9319-8a3d7fe8c740", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b208c5d2-7a93-4040-ae8c-935887a3372c"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche (Magyarorsz\u00e1g) Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +36 - 23 446 800</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "8290db4e-b180-426d-8dbe-30491068cf12", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "55114a70-0a4f-489c-b65a-5fb910662c36"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Magyarorsz\u00e1g</span></b></p>", "ID": "270eb676-f436-4459-8043-8c764b6d1d5d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8290db4e-b180-426d-8dbe-30491068cf12"}, {"Element": "<b><span lang=\"DE-CH\">Magyarorsz\u00e1g</span></b>", "ID": "90294267-8a9e-4958-8c92-3f36d00e4b41", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "270eb676-f436-4459-8043-8c764b6d1d5d"}, {"Element": "<span lang=\"DE-CH\">Magyarorsz\u00e1g</span>", "ID": "4afe4d75-fd58-4ec8-b937-4e9c7ade31e4", "Styles": "None", "Classes": "None", "Text": "Magyarorsz\u00e1g", "ParentId": "90294267-8a9e-4958-8c92-3f36d00e4b41"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche (Magyarorsz\u00e1g) Kft.</span></p>", "ID": "12cf8950-fe27-43e3-af06-ba3516551d45", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8290db4e-b180-426d-8dbe-30491068cf12"}, {"Element": "<span lang=\"DE-CH\">Roche (Magyarorsz\u00e1g) Kft.</span>", "ID": "cf1220d7-4c5e-4d60-a111-3681386ddbad", "Styles": "None", "Classes": "None", "Text": "Roche (Magyarorsz\u00e1g) Kft.", "ParentId": "12cf8950-fe27-43e3-af06-ba3516551d45"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +36 - 23 446 800</span></p>", "ID": "364ca81b-ecd4-4e01-9d68-20139f3a994c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8290db4e-b180-426d-8dbe-30491068cf12"}, {"Element": "<span lang=\"DE-CH\">Tel: +36 - 23 446 800</span>", "ID": "109c2df9-a4d6-4f73-b9fe-b93c86239da0", "Styles": "None", "Classes": "None", "Text": "Tel: +36 - 23 446 800", "ParentId": "364ca81b-ecd4-4e01-9d68-20139f3a994c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "54398dc8-098e-475b-98e0-80f11712f224", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8290db4e-b180-426d-8dbe-30491068cf12"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "27c3b29f-475d-42d3-a8b9-29ffb9e1290a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "54398dc8-098e-475b-98e0-80f11712f224"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Danmark</b></p>\n<p class=\"MsoNormal\">Roche a/s</p>\n<p class=\"MsoNormal\">Tlf: +45 - 36 39 99 99</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Malta</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">(See Ireland)</p>\n</td>\n</tr>", "ID": "3e80716b-9894-4fd4-9cd7-47bcd9f124c5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Danmark</b></p>\n<p class=\"MsoNormal\">Roche a/s</p>\n<p class=\"MsoNormal\">Tlf: +45 - 36 39 99 99</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "44c6b3d0-fcf3-40dd-a42c-9023828bb082", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "3e80716b-9894-4fd4-9cd7-47bcd9f124c5"}, {"Element": "<p class=\"MsoNormal\"><b>Danmark</b></p>", "ID": "a775ccf5-d72a-4be4-a002-91d03c810987", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "44c6b3d0-fcf3-40dd-a42c-9023828bb082"}, {"Element": "<b>Danmark</b>", "ID": "151e6b1c-5f29-47fd-9fda-c09bdf48422d", "Styles": "None", "Classes": "None", "Text": "Danmark", "ParentId": "a775ccf5-d72a-4be4-a002-91d03c810987"}, {"Element": "<p class=\"MsoNormal\">Roche a/s</p>", "ID": "ed3fb01e-2b04-418d-86d7-63f495ca6614", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche a/s", "ParentId": "44c6b3d0-fcf3-40dd-a42c-9023828bb082"}, {"Element": "<p class=\"MsoNormal\">Tlf: +45 - 36 39 99 99</p>", "ID": "bc6d639b-aae5-4cc5-ba0e-c8d804e8339d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tlf: +45 - 36 39 99 99", "ParentId": "44c6b3d0-fcf3-40dd-a42c-9023828bb082"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "21a7cd26-6efe-4ae9-af13-f56d223a831a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "44c6b3d0-fcf3-40dd-a42c-9023828bb082"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Malta</b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\">(See Ireland)</p>\n</td>", "ID": "dc040268-6d65-4976-9bbc-1d2c7f3064a9", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "3e80716b-9894-4fd4-9cd7-47bcd9f124c5"}, {"Element": "<p class=\"MsoNormal\"><b>Malta</b></p>", "ID": "f4ee8036-fc0d-40cd-baf1-4f67614542ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dc040268-6d65-4976-9bbc-1d2c7f3064a9"}, {"Element": "<b>Malta</b>", "ID": "061769c3-4cea-41c4-8662-190232220d22", "Styles": "None", "Classes": "None", "Text": "Malta", "ParentId": "f4ee8036-fc0d-40cd-baf1-4f67614542ef"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">(See Ireland)</p>", "ID": "cceec6db-8e95-47df-9b2d-1930ecd9f456", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "(See Ireland)", "ParentId": "dc040268-6d65-4976-9bbc-1d2c7f3064a9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\">Tel: +31 (<span style=\"layout-grid-mode:line\">0) 348\n  438050</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "b12fa278-ef81-47d0-86b1-80b3998e9af6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>\n</td>", "ID": "547e6ef6-cc4d-4489-b40b-3c56b453069e", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "b12fa278-ef81-47d0-86b1-80b3998e9af6"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Deutschland</span></b></p>", "ID": "ee100164-b513-409f-9726-8345d0504bac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "547e6ef6-cc4d-4489-b40b-3c56b453069e"}, {"Element": "<b><span lang=\"DE-CH\">Deutschland</span></b>", "ID": "6b58f2f0-f51a-4130-bb43-b9a5e6a1a6e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ee100164-b513-409f-9726-8345d0504bac"}, {"Element": "<span lang=\"DE-CH\">Deutschland</span>", "ID": "f9c93eb1-4db4-4b79-9150-330cad55ca31", "Styles": "None", "Classes": "None", "Text": "Deutschland", "ParentId": "6b58f2f0-f51a-4130-bb43-b9a5e6a1a6e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Pharma AG</span></p>", "ID": "201d4df2-8af1-46db-b70d-d290b26cb59c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "547e6ef6-cc4d-4489-b40b-3c56b453069e"}, {"Element": "<span lang=\"DE-CH\">Roche Pharma AG</span>", "ID": "92872aa7-16ca-4293-a66a-5e4d5095d017", "Styles": "None", "Classes": "None", "Text": "Roche Pharma AG", "ParentId": "201d4df2-8af1-46db-b70d-d290b26cb59c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span></p>", "ID": "896cb3f7-642b-42e5-b4ba-ff0d1990b92b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "547e6ef6-cc4d-4489-b40b-3c56b453069e"}, {"Element": "<span lang=\"DE-CH\">Tel: +49 (0) 7624 140</span>", "ID": "bc4aa59e-1726-4107-a4a8-1a518aec7080", "Styles": "None", "Classes": "None", "Text": "Tel: +49 (0) 7624 140", "ParentId": "896cb3f7-642b-42e5-b4ba-ff0d1990b92b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00a0</span></b></p>", "ID": "6b185cb4-469d-4448-b2df-c66b81a58828", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "547e6ef6-cc4d-4489-b40b-3c56b453069e"}, {"Element": "<b><span lang=\"DE\">\u00a0</span></b>", "ID": "b147d1e6-8eae-4519-878e-f68eb3c62072", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b185cb4-469d-4448-b2df-c66b81a58828"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "2dbc05a8-1eec-4eb0-91bd-f812c942ae81", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b147d1e6-8eae-4519-878e-f68eb3c62072"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>\n<p class=\"MsoNormal\">Tel: +31 (<span style=\"layout-grid-mode:line\">0) 348\n  438050</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "9db35952-fb15-4cd0-a199-7a5a98566a8e", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "b12fa278-ef81-47d0-86b1-80b3998e9af6"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Nederland</span></b></p>", "ID": "e84b6e2c-73a5-434c-b063-7fc8081b6059", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9db35952-fb15-4cd0-a199-7a5a98566a8e"}, {"Element": "<b><span lang=\"DE-CH\">Nederland</span></b>", "ID": "b348168b-e4aa-4b41-beed-ba0be4198de5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e84b6e2c-73a5-434c-b063-7fc8081b6059"}, {"Element": "<span lang=\"DE-CH\">Nederland</span>", "ID": "50d505dc-772a-4efb-86d9-c1943b3cbb63", "Styles": "None", "Classes": "None", "Text": "Nederland", "ParentId": "b348168b-e4aa-4b41-beed-ba0be4198de5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Nederland B.V.</span></p>", "ID": "4c73b48e-688e-4330-864b-dede5093e5c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9db35952-fb15-4cd0-a199-7a5a98566a8e"}, {"Element": "<span lang=\"DE-CH\">Roche Nederland B.V.</span>", "ID": "21070b8f-4d9d-4b10-9b41-17f017f9cbad", "Styles": "None", "Classes": "None", "Text": "Roche Nederland B.V.", "ParentId": "4c73b48e-688e-4330-864b-dede5093e5c3"}, {"Element": "<p class=\"MsoNormal\">Tel: +31 (<span style=\"layout-grid-mode:line\">0) 348\n  438050</span></p>", "ID": "d0051bef-b2e3-48fe-84ed-09e8a66d5a07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +31 (", "ParentId": "9db35952-fb15-4cd0-a199-7a5a98566a8e"}, {"Element": "<span style=\"layout-grid-mode:line\">0) 348\n  438050</span>", "ID": "13d808ca-0b34-4957-85d2-1c4203c5b833", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "0) 348   438050", "ParentId": "d0051bef-b2e3-48fe-84ed-09e8a66d5a07"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "30fa169e-3c80-449c-99be-400894857198", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "9db35952-fb15-4cd0-a199-7a5a98566a8e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span style=\"layout-grid-mode:line\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Roche Norge AS</span></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Tlf: +47 - 22 78 90 00</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "f06a9d13-8469-4e8e-9dfb-801c159c875e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>", "ID": "26467655-351e-4abe-bca5-315ca604c19f", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "f06a9d13-8469-4e8e-9dfb-801c159c875e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Eesti</span></b></p>", "ID": "afd83c43-ac38-466d-9878-8bd46630e41c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26467655-351e-4abe-bca5-315ca604c19f"}, {"Element": "<b><span lang=\"IT\">Eesti</span></b>", "ID": "9573bb45-8eef-4a43-9c7a-3c16c707a567", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "afd83c43-ac38-466d-9878-8bd46630e41c"}, {"Element": "<span lang=\"IT\">Eesti</span>", "ID": "14cb4499-c81a-4255-a022-8e90cc891b6e", "Styles": "None", "Classes": "None", "Text": "Eesti", "ParentId": "9573bb45-8eef-4a43-9c7a-3c16c707a567"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche Eesti O\u00dc</span></p>", "ID": "c9beb61e-328c-466e-971c-729e7e63faf0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26467655-351e-4abe-bca5-315ca604c19f"}, {"Element": "<span lang=\"IT\">Roche Eesti O\u00dc</span>", "ID": "e6b80623-9654-45f0-977f-97b247087ca3", "Styles": "None", "Classes": "None", "Text": "Roche Eesti O\u00dc", "ParentId": "c9beb61e-328c-466e-971c-729e7e63faf0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Tel: + 372 - 6 177 380</span></p>", "ID": "57603a83-b78b-4085-8363-7250b261c570", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26467655-351e-4abe-bca5-315ca604c19f"}, {"Element": "<span lang=\"IT\">Tel: + 372 - 6 177 380</span>", "ID": "d530dc39-964b-4c84-87d6-ab4978650f76", "Styles": "None", "Classes": "None", "Text": "Tel: + 372 - 6 177 380", "ParentId": "57603a83-b78b-4085-8363-7250b261c570"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>", "ID": "9e903119-9444-41c1-8f94-9ab95fddb8e7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26467655-351e-4abe-bca5-315ca604c19f"}, {"Element": "<b><span lang=\"IT\">\u00a0</span></b>", "ID": "d582e538-9b56-4c75-afd3-d6a01e470f60", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9e903119-9444-41c1-8f94-9ab95fddb8e7"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "ed45f6ba-01ba-410f-8e6d-d2f8a4870c4a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d582e538-9b56-4c75-afd3-d6a01e470f60"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span style=\"layout-grid-mode:line\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Roche Norge AS</span></p>\n<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Tlf: +47 - 22 78 90 00</span></p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "75fe9628-2334-44ce-8218-38fc11456f2e", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "f06a9d13-8469-4e8e-9dfb-801c159c875e"}, {"Element": "<p class=\"MsoNormal\"><b><span style=\"layout-grid-mode:line\">Norge</span></b></p>", "ID": "5e15de7d-72ff-4460-b87e-47f5dbaf1fcf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "75fe9628-2334-44ce-8218-38fc11456f2e"}, {"Element": "<b><span style=\"layout-grid-mode:line\">Norge</span></b>", "ID": "530d4723-db72-49b1-b93d-6a67eb68d572", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5e15de7d-72ff-4460-b87e-47f5dbaf1fcf"}, {"Element": "<span style=\"layout-grid-mode:line\">Norge</span>", "ID": "298e9040-686e-443b-a63c-d99e4c3155fe", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Norge", "ParentId": "530d4723-db72-49b1-b93d-6a67eb68d572"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Roche Norge AS</span></p>", "ID": "7c280c81-4443-4bf3-8c2f-80d17ea50749", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "75fe9628-2334-44ce-8218-38fc11456f2e"}, {"Element": "<span style=\"layout-grid-mode:line\">Roche Norge AS</span>", "ID": "72a37972-acb5-4736-9b61-219c017dc1ed", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Roche Norge AS", "ParentId": "7c280c81-4443-4bf3-8c2f-80d17ea50749"}, {"Element": "<p class=\"MsoNormal\"><span style=\"layout-grid-mode:line\">Tlf: +47 - 22 78 90 00</span></p>", "ID": "b464df71-d4fe-46d4-b779-704c6d2cf6af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "75fe9628-2334-44ce-8218-38fc11456f2e"}, {"Element": "<span style=\"layout-grid-mode:line\">Tlf: +47 - 22 78 90 00</span>", "ID": "0418f063-f2ae-4006-8b14-697ec2f50e50", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Tlf: +47 - 22 78 90 00", "ParentId": "b464df71-d4fe-46d4-b779-704c6d2cf6af"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f17a9910-e7a8-4534-a826-7b4bed456c8a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "75fe9628-2334-44ce-8218-38fc11456f2e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</b></p>\n<p class=\"MsoNormal\">Roche (Hellas) A.E. </p>\n<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +30 210 61 66 100</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>", "ID": "a8d34113-f66f-46ee-b7af-446c8ce6c2ad", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</b></p>\n<p class=\"MsoNormal\">Roche (Hellas) A.E. </p>\n<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +30 210 61 66 100</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "04eb6e64-ad01-4463-93f2-124bb2de8490", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "a8d34113-f66f-46ee-b7af-446c8ce6c2ad"}, {"Element": "<p class=\"MsoNormal\"><b>\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</b></p>", "ID": "6e995b14-4ada-47da-8056-b3afa4db4de2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04eb6e64-ad01-4463-93f2-124bb2de8490"}, {"Element": "<b>\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</b>", "ID": "8fdfc01a-fae8-42f7-a7d8-f4c80d948ef0", "Styles": "None", "Classes": "None", "Text": "\u0395\u03bb\u03bb\u03ac\u03b4\u03b1", "ParentId": "6e995b14-4ada-47da-8056-b3afa4db4de2"}, {"Element": "<p class=\"MsoNormal\">Roche (Hellas) A.E. </p>", "ID": "5cf539dc-a29b-4aff-a418-502eea3b6b14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche (Hellas) A.E. ", "ParentId": "04eb6e64-ad01-4463-93f2-124bb2de8490"}, {"Element": "<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +30 210 61 66 100</p>", "ID": "3b19d15f-e56c-4a46-82ea-495180f44ba9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u03a4\u03b7\u03bb: +30 210 61 66 100", "ParentId": "04eb6e64-ad01-4463-93f2-124bb2de8490"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a46fdc4c-200f-499d-82cf-9bc39ff56fe6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "04eb6e64-ad01-4463-93f2-124bb2de8490"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "08a35b1b-088f-44ef-b9bc-c72c3a0d1c55", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "a8d34113-f66f-46ee-b7af-446c8ce6c2ad"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">\u00d6sterreich</span></b></p>", "ID": "925b2f45-0795-4828-84e6-dc7891e577ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "08a35b1b-088f-44ef-b9bc-c72c3a0d1c55"}, {"Element": "<b><span lang=\"DE-CH\">\u00d6sterreich</span></b>", "ID": "bb3147c3-e60b-4301-a243-919f231cbb6c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "925b2f45-0795-4828-84e6-dc7891e577ec"}, {"Element": "<span lang=\"DE-CH\">\u00d6sterreich</span>", "ID": "eb3c5bc2-0d5f-4ebf-92bb-070919a1eeb6", "Styles": "None", "Classes": "None", "Text": "\u00d6sterreich", "ParentId": "bb3147c3-e60b-4301-a243-919f231cbb6c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Austria GmbH</span></p>", "ID": "96e2c2cd-0e68-4605-80a4-03daa0880b17", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "08a35b1b-088f-44ef-b9bc-c72c3a0d1c55"}, {"Element": "<span lang=\"DE-CH\">Roche Austria GmbH</span>", "ID": "9bf8d1f1-46d8-446f-b1ba-0c6d2f841d15", "Styles": "None", "Classes": "None", "Text": "Roche Austria GmbH", "ParentId": "96e2c2cd-0e68-4605-80a4-03daa0880b17"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span></p>", "ID": "599fa5df-b204-4b7e-a3f8-f88af7fd57e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "08a35b1b-088f-44ef-b9bc-c72c3a0d1c55"}, {"Element": "<span lang=\"DE-CH\">Tel: +43 (0) 1 27739</span>", "ID": "ce29591d-3819-4f79-887e-64c5db201650", "Styles": "None", "Classes": "None", "Text": "Tel: +43 (0) 1 27739", "ParentId": "599fa5df-b204-4b7e-a3f8-f88af7fd57e6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "a26428f2-97f8-400a-ba72-29269f592a83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "08a35b1b-088f-44ef-b9bc-c72c3a0d1c55"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "0229787d-f1f8-4ddc-9b70-ec3ceefa2fa0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a26428f2-97f8-400a-ba72-29269f592a83"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\">Tel: +34 - 91 324 81 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Polska</b></p>\n<p class=\"MsoNormal\">Roche Polska Sp.z o.o.</p>\n<p class=\"MsoNormal\">Tel: +48 - 22 345 18 88</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "e0922878-3a1b-4b96-80a2-1df2cba1da93", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>\n<p class=\"MsoNormal\">Tel: +34 - 91 324 81 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "abf45b55-d9ee-46ad-8fab-2e13eb389ada", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e0922878-3a1b-4b96-80a2-1df2cba1da93"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>", "ID": "98aa7d67-64f0-49ce-8fce-0f248e96d634", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "abf45b55-d9ee-46ad-8fab-2e13eb389ada"}, {"Element": "<b><span lang=\"ES\">Espa\u00f1a</span></b>", "ID": "f8fc2ccc-c68b-4660-9a86-f5323a1a4dcb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98aa7d67-64f0-49ce-8fce-0f248e96d634"}, {"Element": "<span lang=\"ES\">Espa\u00f1a</span>", "ID": "40da1005-885d-4eb8-9bd0-2f31a499e3ae", "Styles": "None", "Classes": "None", "Text": "Espa\u00f1a", "ParentId": "f8fc2ccc-c68b-4660-9a86-f5323a1a4dcb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">Roche Farma S.A.</span></p>", "ID": "3a0317dc-a613-4b0f-bd9d-649768d842b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "abf45b55-d9ee-46ad-8fab-2e13eb389ada"}, {"Element": "<span lang=\"ES\">Roche Farma S.A.</span>", "ID": "454bf45f-13cd-48a0-a25e-226ff173a92e", "Styles": "None", "Classes": "None", "Text": "Roche Farma S.A.", "ParentId": "3a0317dc-a613-4b0f-bd9d-649768d842b3"}, {"Element": "<p class=\"MsoNormal\">Tel: +34 - 91 324 81 00</p>", "ID": "f42b9c0c-35f9-431e-bd92-88a5c35320e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +34 - 91 324 81 00", "ParentId": "abf45b55-d9ee-46ad-8fab-2e13eb389ada"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "05e9d962-3e62-4a59-8f25-5f60edda6d8a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "abf45b55-d9ee-46ad-8fab-2e13eb389ada"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Polska</b></p>\n<p class=\"MsoNormal\">Roche Polska Sp.z o.o.</p>\n<p class=\"MsoNormal\">Tel: +48 - 22 345 18 88</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "d4b88ad7-2ea8-41f9-9157-2c65eff3b54b", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "e0922878-3a1b-4b96-80a2-1df2cba1da93"}, {"Element": "<p class=\"MsoNormal\"><b>Polska</b></p>", "ID": "8ab4d0c1-1075-483b-918a-3243c2a02905", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d4b88ad7-2ea8-41f9-9157-2c65eff3b54b"}, {"Element": "<b>Polska</b>", "ID": "be4bc6f7-2e10-4b6c-bc81-934432c09318", "Styles": "None", "Classes": "None", "Text": "Polska", "ParentId": "8ab4d0c1-1075-483b-918a-3243c2a02905"}, {"Element": "<p class=\"MsoNormal\">Roche Polska Sp.z o.o.</p>", "ID": "dd04cf1a-6f82-4ec1-a8b6-b9ebf935e085", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche Polska Sp.z o.o.", "ParentId": "d4b88ad7-2ea8-41f9-9157-2c65eff3b54b"}, {"Element": "<p class=\"MsoNormal\">Tel: +48 - 22 345 18 88</p>", "ID": "5a0bb6b1-f8fa-45a4-a3ac-9eceb1e6632f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +48 - 22 345 18 88", "ParentId": "d4b88ad7-2ea8-41f9-9157-2c65eff3b54b"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3f95735c-b40e-49fd-a1ed-c816563b886c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d4b88ad7-2ea8-41f9-9157-2c65eff3b54b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>France</b></p>\n<p class=\"MsoNormal\">Roche</p>\n<p class=\"MsoNormal\">T\u00e9l: +33\u00a0(0)1 47 61 40 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica,\n  Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>\n</tr>", "ID": "20ec60d6-5bdc-409c-b4b9-5c656438344c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>France</b></p>\n<p class=\"MsoNormal\">Roche</p>\n<p class=\"MsoNormal\">T\u00e9l: +33\u00a0(0)1 47 61 40 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "ef1aa265-5ace-45c5-95fa-c34a0e969e0e", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "20ec60d6-5bdc-409c-b4b9-5c656438344c"}, {"Element": "<p class=\"MsoNormal\"><b>France</b></p>", "ID": "b63fc320-41d3-4332-b081-1fd16bafb73c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ef1aa265-5ace-45c5-95fa-c34a0e969e0e"}, {"Element": "<b>France</b>", "ID": "6a30a148-b40f-4350-ba89-b3f0a8c18e1e", "Styles": "None", "Classes": "None", "Text": "France", "ParentId": "b63fc320-41d3-4332-b081-1fd16bafb73c"}, {"Element": "<p class=\"MsoNormal\">Roche</p>", "ID": "cc46978d-b546-4cac-8816-c32094250132", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche", "ParentId": "ef1aa265-5ace-45c5-95fa-c34a0e969e0e"}, {"Element": "<p class=\"MsoNormal\">T\u00e9l: +33\u00a0(0)1 47 61 40 00</p>", "ID": "c8d6dd01-0888-40b1-8898-81d770e1d3f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "T\u00e9l: +33\u00a0(0)1 47 61 40 00", "ParentId": "ef1aa265-5ace-45c5-95fa-c34a0e969e0e"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0528dd06-7de2-4b70-bd3b-427e7b0b6f39", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "ef1aa265-5ace-45c5-95fa-c34a0e969e0e"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica,\n  Lda</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>\n</td>", "ID": "e98dc80e-76f8-4463-a173-3c73e8d324d6", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "20ec60d6-5bdc-409c-b4b9-5c656438344c"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>", "ID": "fa4e4c2d-8e96-4614-a0dc-6746476d2427", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e98dc80e-76f8-4463-a173-3c73e8d324d6"}, {"Element": "<b><span lang=\"PT-BR\">Portugal</span></b>", "ID": "42bc1f22-5c61-4a75-ae34-57be08611130", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fa4e4c2d-8e96-4614-a0dc-6746476d2427"}, {"Element": "<span lang=\"PT-BR\">Portugal</span>", "ID": "6c774980-4178-46fd-9bac-1dbe30f479ac", "Styles": "None", "Classes": "None", "Text": "Portugal", "ParentId": "42bc1f22-5c61-4a75-ae34-57be08611130"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica,\n  Lda</span></p>", "ID": "77ef7c67-5d9c-4b1c-89e2-a29de2024dfc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e98dc80e-76f8-4463-a173-3c73e8d324d6"}, {"Element": "<span lang=\"PT-BR\">Roche Farmac\u00eautica Qu\u00edmica,\n  Lda</span>", "ID": "16bf2d01-1c0c-4712-b295-c9536f476966", "Styles": "None", "Classes": "None", "Text": "Roche Farmac\u00eautica Qu\u00edmica,   Lda", "ParentId": "77ef7c67-5d9c-4b1c-89e2-a29de2024dfc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span></p>", "ID": "85feb3ea-d68a-4973-84fc-adc73f3e3ae0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e98dc80e-76f8-4463-a173-3c73e8d324d6"}, {"Element": "<span lang=\"PT-BR\">Tel: +351 - 21 425 70 00</span>", "ID": "8bcab283-d1ac-44a8-9411-1b6f2cd7a7da", "Styles": "None", "Classes": "None", "Text": "Tel: +351 - 21 425 70 00", "ParentId": "85feb3ea-d68a-4973-84fc-adc73f3e3ae0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">\u00a0</span></p>", "ID": "dd7bb02f-48cf-43f0-ac49-afbdbbde3f68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e98dc80e-76f8-4463-a173-3c73e8d324d6"}, {"Element": "<span lang=\"PT-BR\">\u00a0</span>", "ID": "f3c5195a-4eee-4ac7-ac4e-92defbb362c4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dd7bb02f-48cf-43f0-ac49-afbdbbde3f68"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel:\u00a0 +385 1 4722 333</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\">Tel: +40 21 206 47 01</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "7090aa7f-6f78-42cd-8fc9-e3485208f0d9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel:\u00a0 +385 1 4722 333</span></p>\n</td>", "ID": "3002ec05-2351-4fbf-a695-84bf740be4ca", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "7090aa7f-6f78-42cd-8fc9-e3485208f0d9"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Hrvatska</span></b></p>", "ID": "868eb973-5d9f-4225-8972-85c9386252e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3002ec05-2351-4fbf-a695-84bf740be4ca"}, {"Element": "<b><span lang=\"DE-CH\">Hrvatska</span></b>", "ID": "0246caf7-8b7e-4f83-b869-27f042095328", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "868eb973-5d9f-4225-8972-85c9386252e6"}, {"Element": "<span lang=\"DE-CH\">Hrvatska</span>", "ID": "3a709b2c-7897-42da-8764-29b785b0decc", "Styles": "None", "Classes": "None", "Text": "Hrvatska", "ParentId": "0246caf7-8b7e-4f83-b869-27f042095328"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche d.o.o</span></p>", "ID": "0faab2bc-115a-4824-a021-3596fb81e485", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3002ec05-2351-4fbf-a695-84bf740be4ca"}, {"Element": "<span lang=\"DE-CH\">Roche d.o.o</span>", "ID": "a5d2d1a5-2a2f-4164-8719-131961db0994", "Styles": "None", "Classes": "None", "Text": "Roche d.o.o", "ParentId": "0faab2bc-115a-4824-a021-3596fb81e485"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel:\u00a0 +385 1 4722 333</span></p>", "ID": "969a137f-78f1-4f7c-acb1-7bc09454bd63", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3002ec05-2351-4fbf-a695-84bf740be4ca"}, {"Element": "<span lang=\"DE-CH\">Tel:\u00a0 +385 1 4722 333</span>", "ID": "10d56d9a-af78-4a3b-bcf9-4da439617b9d", "Styles": "None", "Classes": "None", "Text": "Tel:\u00a0 +385 1 4722 333", "ParentId": "969a137f-78f1-4f7c-acb1-7bc09454bd63"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>\n<p class=\"MsoNormal\">Tel: +40 21 206 47 01</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "97f10203-807c-4c56-9182-0422493b4d93", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "7090aa7f-6f78-42cd-8fc9-e3485208f0d9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:13.0pt\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>", "ID": "b7d0b745-dd89-4d4c-9ea2-f1cf582900d0", "Styles": "line-height:13.0pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "97f10203-807c-4c56-9182-0422493b4d93"}, {"Element": "<b><span lang=\"IT\">Rom\u00e2nia</span></b>", "ID": "4bb8aba8-9f2a-4fbd-94b2-395ec25fe14a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7d0b745-dd89-4d4c-9ea2-f1cf582900d0"}, {"Element": "<span lang=\"IT\">Rom\u00e2nia</span>", "ID": "6ad913c0-210f-4cd0-b17a-6311f55546d6", "Styles": "None", "Classes": "None", "Text": "Rom\u00e2nia", "ParentId": "4bb8aba8-9f2a-4fbd-94b2-395ec25fe14a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span></p>", "ID": "5daea6b5-3f69-45b3-a5c4-aabcd331779e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "97f10203-807c-4c56-9182-0422493b4d93"}, {"Element": "<span lang=\"IT\">Roche Rom\u00e2nia S.R.L.</span>", "ID": "89a2e49e-9bcd-416b-ac69-92d7b3166743", "Styles": "None", "Classes": "None", "Text": "Roche Rom\u00e2nia S.R.L.", "ParentId": "5daea6b5-3f69-45b3-a5c4-aabcd331779e"}, {"Element": "<p class=\"MsoNormal\">Tel: +40 21 206 47 01</p>", "ID": "4b02c0ed-442d-4207-8bc7-b5f77ff3bf79", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +40 21 206 47 01", "ParentId": "97f10203-807c-4c56-9182-0422493b4d93"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d548c324-5c83-4393-8f5b-f73d42cbf616", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "97f10203-807c-4c56-9182-0422493b4d93"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Ireland</b></p>\n<p class=\"MsoNormal\">Roche Products (Ireland) Ltd.</p>\n<p class=\"MsoNormal\">Tel: +353 (0) 1 469 0700</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Slovenija</b></p>\n<p class=\"MsoNormal\">Roche farmacevtska dru\u017eba d.o.o.</p>\n<p class=\"MsoNormal\">Tel: +386 - 1 360 26 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "180883f2-c403-4124-ac47-da11d819ffdf", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Ireland</b></p>\n<p class=\"MsoNormal\">Roche Products (Ireland) Ltd.</p>\n<p class=\"MsoNormal\">Tel: +353 (0) 1 469 0700</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "58cbd461-5070-499c-acad-de1c916b90d9", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "180883f2-c403-4124-ac47-da11d819ffdf"}, {"Element": "<p class=\"MsoNormal\"><b>Ireland</b></p>", "ID": "fdd4bee9-3f90-4f33-96b4-c193be96b2ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "58cbd461-5070-499c-acad-de1c916b90d9"}, {"Element": "<b>Ireland</b>", "ID": "8cca9bee-e9a8-4dd7-83c6-b142abd9409b", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "fdd4bee9-3f90-4f33-96b4-c193be96b2ec"}, {"Element": "<p class=\"MsoNormal\">Roche Products (Ireland) Ltd.</p>", "ID": "4bc723fe-f798-4561-85c5-fb4840f9a98d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche Products (Ireland) Ltd.", "ParentId": "58cbd461-5070-499c-acad-de1c916b90d9"}, {"Element": "<p class=\"MsoNormal\">Tel: +353 (0) 1 469 0700</p>", "ID": "d44ca901-8edd-476f-88bb-6b8ed43bd689", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +353 (0) 1 469 0700", "ParentId": "58cbd461-5070-499c-acad-de1c916b90d9"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e78dc663-8c35-4e2d-89cb-1c82a029a751", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "58cbd461-5070-499c-acad-de1c916b90d9"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Slovenija</b></p>\n<p class=\"MsoNormal\">Roche farmacevtska dru\u017eba d.o.o.</p>\n<p class=\"MsoNormal\">Tel: +386 - 1 360 26 00</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "b79808a6-cbf5-47d1-9364-352fa8fa0669", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "180883f2-c403-4124-ac47-da11d819ffdf"}, {"Element": "<p class=\"MsoNormal\"><b>Slovenija</b></p>", "ID": "cd48d93d-509a-4de2-bdf1-4d834a1148e9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b79808a6-cbf5-47d1-9364-352fa8fa0669"}, {"Element": "<b>Slovenija</b>", "ID": "6c2dbb96-43cd-4c4f-807e-208f072c8489", "Styles": "None", "Classes": "None", "Text": "Slovenija", "ParentId": "cd48d93d-509a-4de2-bdf1-4d834a1148e9"}, {"Element": "<p class=\"MsoNormal\">Roche farmacevtska dru\u017eba d.o.o.</p>", "ID": "ede0bde9-a828-4e88-b2e2-2e96d1ccdd02", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche farmacevtska dru\u017eba d.o.o.", "ParentId": "b79808a6-cbf5-47d1-9364-352fa8fa0669"}, {"Element": "<p class=\"MsoNormal\">Tel: +386 - 1 360 26 00</p>", "ID": "fb602dab-bd88-4f4a-920b-c015abf7b606", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +386 - 1 360 26 00", "ParentId": "b79808a6-cbf5-47d1-9364-352fa8fa0669"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "42139aee-fc2f-4fc2-9be6-795fe8fc5ee1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "b79808a6-cbf5-47d1-9364-352fa8fa0669"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi<span style=\"layout-grid-mode:\n  line\">: +354 540 8000</span></span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\">Tel: +421 - 2 52638201</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n</td>\n</tr>", "ID": "9e4462cc-e600-4b17-a48c-37460b780f46", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>\n<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi<span style=\"layout-grid-mode:\n  line\">: +354 540 8000</span></span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>\n</td>", "ID": "edacbf91-4d31-422f-9b5b-5c0e26a1af91", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "9e4462cc-e600-4b17-a48c-37460b780f46"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b></p>", "ID": "acf1ed5b-97ba-4eca-b7b6-ce007cfe4846", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "edacbf91-4d31-422f-9b5b-5c0e26a1af91"}, {"Element": "<b><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span></b>", "ID": "be919a14-0bca-4461-aa2d-645443be3150", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "acf1ed5b-97ba-4eca-b7b6-ce007cfe4846"}, {"Element": "<span lang=\"PT-BR\" style=\"layout-grid-mode:line\">\u00cdsland\n  </span>", "ID": "5783452a-7531-4ea8-ab99-ddefe568a921", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00cdsland   ", "ParentId": "be919a14-0bca-4461-aa2d-645443be3150"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span></p>", "ID": "82f6d2f4-8534-4432-8d69-fb9e4fc804a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "edacbf91-4d31-422f-9b5b-5c0e26a1af91"}, {"Element": "<span lang=\"PT-BR\" style=\"layout-grid-mode:line\">Roche a/s</span>", "ID": "f9dc65a4-6f76-4796-b4b8-5947aced7ed1", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Roche a/s", "ParentId": "82f6d2f4-8534-4432-8d69-fb9e4fc804a4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">c/o Icepharma hf</span></p>", "ID": "82ea1333-f267-44c3-a8dc-34248d84919e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "edacbf91-4d31-422f-9b5b-5c0e26a1af91"}, {"Element": "<span lang=\"PT-BR\">c/o Icepharma hf</span>", "ID": "9d987be2-39f0-49a5-80ce-f56032a3f773", "Styles": "None", "Classes": "None", "Text": "c/o Icepharma hf", "ParentId": "82ea1333-f267-44c3-a8dc-34248d84919e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT-BR\">S\u00edmi<span style=\"layout-grid-mode:\n  line\">: +354 540 8000</span></span></p>", "ID": "a70fa6d1-bfc6-4dbc-8d5d-a444f6a8b4b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "edacbf91-4d31-422f-9b5b-5c0e26a1af91"}, {"Element": "<span lang=\"PT-BR\">S\u00edmi<span style=\"layout-grid-mode:\n  line\">: +354 540 8000</span></span>", "ID": "f3c4a797-7a16-42de-bfc8-ac81e9295f32", "Styles": "None", "Classes": "None", "Text": "S\u00edmi", "ParentId": "a70fa6d1-bfc6-4dbc-8d5d-a444f6a8b4b8"}, {"Element": "<span style=\"layout-grid-mode:\n  line\">: +354 540 8000</span>", "ID": "32f65d7b-f181-4373-a324-b769bb18806c", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": ": +354 540 8000", "ParentId": "f3c4a797-7a16-42de-bfc8-ac81e9295f32"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"PT-BR\">\u00a0</span></b></p>", "ID": "bc0690d6-6260-4bec-84eb-4bd2a22ff94f", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "edacbf91-4d31-422f-9b5b-5c0e26a1af91"}, {"Element": "<b><span lang=\"PT-BR\">\u00a0</span></b>", "ID": "36ca1993-f9f8-488d-baef-a059539fc409", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bc0690d6-6260-4bec-84eb-4bd2a22ff94f"}, {"Element": "<span lang=\"PT-BR\">\u00a0</span>", "ID": "b2a14eed-1ed3-4a54-8632-ef99ea63eb1a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "36ca1993-f9f8-488d-baef-a059539fc409"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Slovensk\u00e1 republika </span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Slovensko, s.r.o.</span></p>\n<p class=\"MsoNormal\">Tel: +421 - 2 52638201</p>\n<p class=\"MsoNormal\"><b>\u00a0</b></p>\n</td>", "ID": "07e671d0-a8a4-489c-a261-bda3d208e331", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "9e4462cc-e600-4b17-a48c-37460b780f46"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Slovensk\u00e1 republika </span></b></p>", "ID": "4ade4d0a-2927-41df-9851-e2e94229ed34", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "07e671d0-a8a4-489c-a261-bda3d208e331"}, {"Element": "<b><span lang=\"IT\">Slovensk\u00e1 republika </span></b>", "ID": "95d3d127-d48f-4263-a821-692796a0aac7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4ade4d0a-2927-41df-9851-e2e94229ed34"}, {"Element": "<span lang=\"IT\">Slovensk\u00e1 republika </span>", "ID": "a349c5af-e5f3-4338-a559-5a280e6e9a0a", "Styles": "None", "Classes": "None", "Text": "Slovensk\u00e1 republika ", "ParentId": "95d3d127-d48f-4263-a821-692796a0aac7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche Slovensko, s.r.o.</span></p>", "ID": "790a3f81-8c31-4fbf-8dfd-001f262b711f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "07e671d0-a8a4-489c-a261-bda3d208e331"}, {"Element": "<span lang=\"IT\">Roche Slovensko, s.r.o.</span>", "ID": "3d9f04ec-8d6c-4268-aa92-d4364c0b5e3b", "Styles": "None", "Classes": "None", "Text": "Roche Slovensko, s.r.o.", "ParentId": "790a3f81-8c31-4fbf-8dfd-001f262b711f"}, {"Element": "<p class=\"MsoNormal\">Tel: +421 - 2 52638201</p>", "ID": "8a252f97-b54a-4fa4-b204-dbce03778488", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +421 - 2 52638201", "ParentId": "07e671d0-a8a4-489c-a261-bda3d208e331"}, {"Element": "<p class=\"MsoNormal\"><b>\u00a0</b></p>", "ID": "58bbf144-4985-400d-9caf-0f37a80fac0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "07e671d0-a8a4-489c-a261-bda3d208e331"}, {"Element": "<b>\u00a0</b>", "ID": "30555b9e-0aa1-463f-8945-6437bcc7c5d1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "58bbf144-4985-400d-9caf-0f37a80fac0c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>\n</tr>", "ID": "740a4a27-b176-4dff-bcd4-c2824511bde3", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>\n</td>", "ID": "5ebc9002-211d-437a-9ad2-247de3c50bf6", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "740a4a27-b176-4dff-bcd4-c2824511bde3"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Italia</span></b></p>", "ID": "ab9cb702-1197-488a-92f0-4d49cabbbb4e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ebc9002-211d-437a-9ad2-247de3c50bf6"}, {"Element": "<b><span lang=\"IT\">Italia</span></b>", "ID": "f93328dc-7d91-4ff4-8421-4f5723351f92", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ab9cb702-1197-488a-92f0-4d49cabbbb4e"}, {"Element": "<span lang=\"IT\">Italia</span>", "ID": "b51056e6-58cc-4e81-8efa-e465bac1447c", "Styles": "None", "Classes": "None", "Text": "Italia", "ParentId": "f93328dc-7d91-4ff4-8421-4f5723351f92"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche S.p.A.</span></p>", "ID": "64409d12-70b4-409b-94b2-bfe21ee0445a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ebc9002-211d-437a-9ad2-247de3c50bf6"}, {"Element": "<span lang=\"IT\">Roche S.p.A.</span>", "ID": "60a0188e-2860-4f9c-a8c3-2d759e74eedd", "Styles": "None", "Classes": "None", "Text": "Roche S.p.A.", "ParentId": "64409d12-70b4-409b-94b2-bfe21ee0445a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Tel: +39 - 039 2471</span></p>", "ID": "de99ca97-7269-47f0-8c73-a5bc004af3de", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ebc9002-211d-437a-9ad2-247de3c50bf6"}, {"Element": "<span lang=\"DE-CH\">Tel: +39 - 039 2471</span>", "ID": "3abd47e7-06d8-4c92-af28-b3bc87deacbf", "Styles": "None", "Classes": "None", "Text": "Tel: +39 - 039 2471", "ParentId": "de99ca97-7269-47f0-8c73-a5bc004af3de"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>\n</td>", "ID": "f695f758-1cb9-4d5e-82e3-b6cbd37e7c11", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "740a4a27-b176-4dff-bcd4-c2824511bde3"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">Suomi/Finland</span></b></p>", "ID": "a1f060ff-925f-4e22-bdf5-d8616fd8428a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f695f758-1cb9-4d5e-82e3-b6cbd37e7c11"}, {"Element": "<b><span lang=\"DE-CH\">Suomi/Finland</span></b>", "ID": "c57f2239-4fbf-443c-9861-3c16b5a6c245", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a1f060ff-925f-4e22-bdf5-d8616fd8428a"}, {"Element": "<span lang=\"DE-CH\">Suomi/Finland</span>", "ID": "f48a211c-6f02-47e5-84af-019becbf09fe", "Styles": "None", "Classes": "None", "Text": "Suomi/Finland", "ParentId": "c57f2239-4fbf-443c-9861-3c16b5a6c245"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span></p>", "ID": "5e1e3cfa-4ac9-4cc7-95b1-ff2189d94248", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f695f758-1cb9-4d5e-82e3-b6cbd37e7c11"}, {"Element": "<span lang=\"DE-CH\">Roche Oy<span style=\"layout-grid-mode:\n  line\"> </span></span>", "ID": "c8d43983-f89a-4784-8ee2-2821d71b6461", "Styles": "None", "Classes": "None", "Text": "Roche Oy", "ParentId": "5e1e3cfa-4ac9-4cc7-95b1-ff2189d94248"}, {"Element": "<span style=\"layout-grid-mode:\n  line\"> </span>", "ID": "1681edb2-792e-4d45-a6aa-b2bde6e8a9da", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": " ", "ParentId": "c8d43983-f89a-4784-8ee2-2821d71b6461"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span></p>", "ID": "3e3e4e71-4fa1-4a96-9a41-33a1617771d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f695f758-1cb9-4d5e-82e3-b6cbd37e7c11"}, {"Element": "<span lang=\"DE-CH\">Puh/Tel: +358 (0) 10 554 500</span>", "ID": "ddaea720-192a-43aa-a1f8-c588b1dfa35e", "Styles": "None", "Classes": "None", "Text": "Puh/Tel: +358 (0) 10 554 500", "ParentId": "3e3e4e71-4fa1-4a96-9a41-33a1617771d4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE-CH\">\u00a0</span></p>", "ID": "e27ae277-5230-4586-8024-be735489f3d6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f695f758-1cb9-4d5e-82e3-b6cbd37e7c11"}, {"Element": "<span lang=\"DE-CH\">\u00a0</span>", "ID": "ba4d1939-13d1-498c-99e4-b43cc2609fbd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e27ae277-5230-4586-8024-be735489f3d6"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>\n<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Sverige</b></p>\n<p class=\"MsoNormal\">Roche AB</p>\n<p class=\"MsoNormal\">Tel: +46 (0) 8 726 1200</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "7143a7e8-0e62-42d0-992a-44e5145e26c4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\"> </span></p>\n<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>\n<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "3ff15c7d-a391-4284-933d-2f3ce74b4960", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "7143a7e8-0e62-42d0-992a-44e5145e26c4"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE-CH\">K</span></b><b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b><span lang=\"EL\"> </span></p>", "ID": "adebda1f-1f2c-4ca3-ab49-52dce625eda7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ff15c7d-a391-4284-933d-2f3ce74b4960"}, {"Element": "<b><span lang=\"DE-CH\">K</span></b>", "ID": "7ab94f6f-c77c-4840-aae0-c3afa360f9ea", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "adebda1f-1f2c-4ca3-ab49-52dce625eda7"}, {"Element": "<span lang=\"DE-CH\">K</span>", "ID": "6b2175fc-35f7-4159-857d-a2a07454d0ba", "Styles": "None", "Classes": "None", "Text": "K", "ParentId": "7ab94f6f-c77c-4840-aae0-c3afa360f9ea"}, {"Element": "<b><span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span></b>", "ID": "610e41c4-a1c6-4a0c-aabe-b1c982a124f3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "adebda1f-1f2c-4ca3-ab49-52dce625eda7"}, {"Element": "<span lang=\"EL\">\u03cd\u03c0\u03c1\u03bf\u03c2</span>", "ID": "8afa4113-a895-4a5a-9959-3b74d6b661ea", "Styles": "None", "Classes": "None", "Text": "\u03cd\u03c0\u03c1\u03bf\u03c2", "ParentId": "610e41c4-a1c6-4a0c-aabe-b1c982a124f3"}, {"Element": "<span lang=\"EL\"> </span>", "ID": "41557f68-ae8f-4603-ac62-8a284d94874c", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "adebda1f-1f2c-4ca3-ab49-52dce625eda7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span></p>", "ID": "d563aa1d-8bd5-48f8-9e2d-97336b222f21", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ff15c7d-a391-4284-933d-2f3ce74b4960"}, {"Element": "<span lang=\"EL\">\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2\n  &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.</span>", "ID": "fc38324f-5b51-42bb-9d9d-013ba2cd8241", "Styles": "None", "Classes": "None", "Text": "\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2   & \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.", "ParentId": "d563aa1d-8bd5-48f8-9e2d-97336b222f21"}, {"Element": "<p class=\"MsoNormal\">\u03a4\u03b7\u03bb: +357 - 22 76 62 76</p>", "ID": "d697c78d-4153-4571-b5aa-ad31c295536b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u03a4\u03b7\u03bb: +357 - 22 76 62 76", "ParentId": "3ff15c7d-a391-4284-933d-2f3ce74b4960"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0141dfeb-7a4a-47b4-b79e-d854ee82d286", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "3ff15c7d-a391-4284-933d-2f3ce74b4960"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>Sverige</b></p>\n<p class=\"MsoNormal\">Roche AB</p>\n<p class=\"MsoNormal\">Tel: +46 (0) 8 726 1200</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "ff264e5f-6c14-4eb7-9a61-c71b1512be6f", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "7143a7e8-0e62-42d0-992a-44e5145e26c4"}, {"Element": "<p class=\"MsoNormal\"><b>Sverige</b></p>", "ID": "bb0da2dc-7c6f-4bab-b9e0-004002925872", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff264e5f-6c14-4eb7-9a61-c71b1512be6f"}, {"Element": "<b>Sverige</b>", "ID": "38fc9449-54a1-42da-8d07-59f8ae1b80a7", "Styles": "None", "Classes": "None", "Text": "Sverige", "ParentId": "bb0da2dc-7c6f-4bab-b9e0-004002925872"}, {"Element": "<p class=\"MsoNormal\">Roche AB</p>", "ID": "5cdd74d0-2196-4caf-9dab-41c7a6cd28df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche AB", "ParentId": "ff264e5f-6c14-4eb7-9a61-c71b1512be6f"}, {"Element": "<p class=\"MsoNormal\">Tel: +46 (0) 8 726 1200</p>", "ID": "598f85e5-87e1-4800-96f4-650afbfd4941", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +46 (0) 8 726 1200", "ParentId": "ff264e5f-6c14-4eb7-9a61-c71b1512be6f"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "c1be6845-3560-4fa9-98d8-6106b4fcb685", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "ff264e5f-6c14-4eb7-9a61-c71b1512be6f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>\n<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>United Kingdom</b></p>\n<p class=\"MsoNormal\">Roche Products Ltd.</p>\n<p class=\"MsoNormal\">Tel: +44 (0) 1707 366000</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>\n</tr>", "ID": "58285363-2688-4a57-abcf-7acc741ba591", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "88d4729a-0bd5-4eb5-8bd4-9698c3068809"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>\n</td>", "ID": "215676b3-8af7-4d9c-9282-2c4fb4ad82a9", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "58285363-2688-4a57-abcf-7acc741ba591"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Latvija</span></b></p>", "ID": "dac34017-a0a7-4e25-a2f8-3c06a50dc172", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "215676b3-8af7-4d9c-9282-2c4fb4ad82a9"}, {"Element": "<b><span lang=\"IT\">Latvija</span></b>", "ID": "32780eb5-c106-4d87-a735-9866ca926aa6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dac34017-a0a7-4e25-a2f8-3c06a50dc172"}, {"Element": "<span lang=\"IT\">Latvija</span>", "ID": "42fab559-0f40-473f-b918-28fc388fd1c8", "Styles": "None", "Classes": "None", "Text": "Latvija", "ParentId": "32780eb5-c106-4d87-a735-9866ca926aa6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Roche Latvija SIA</span></p>", "ID": "069f4436-8759-4fb8-b361-37bd2cc319f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "215676b3-8af7-4d9c-9282-2c4fb4ad82a9"}, {"Element": "<span lang=\"IT\">Roche Latvija SIA</span>", "ID": "07d28c11-a32c-4efa-81f5-48ceafba3e61", "Styles": "None", "Classes": "None", "Text": "Roche Latvija SIA", "ParentId": "069f4436-8759-4fb8-b361-37bd2cc319f2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 - 6 7039831</span></p>", "ID": "d888f4b2-9018-4feb-89fa-1fa9f3827975", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "215676b3-8af7-4d9c-9282-2c4fb4ad82a9"}, {"Element": "<span lang=\"IT\">Tel: +371 - 6 7039831</span>", "ID": "a0adadf5-d5c3-4e42-9619-9a7c63071d58", "Styles": "None", "Classes": "None", "Text": "Tel: +371 - 6 7039831", "ParentId": "d888f4b2-9018-4feb-89fa-1fa9f3827975"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">\u00a0</span></b></p>", "ID": "76988972-15bb-466b-b211-bd65e51daea3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "215676b3-8af7-4d9c-9282-2c4fb4ad82a9"}, {"Element": "<b><span lang=\"IT\">\u00a0</span></b>", "ID": "0a9734be-c8a0-4bcb-8fc1-eda71fa5539a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "76988972-15bb-466b-b211-bd65e51daea3"}, {"Element": "<span lang=\"IT\">\u00a0</span>", "ID": "134e77df-ee60-49d9-ae4a-738da43f3bc1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a9734be-c8a0-4bcb-8fc1-eda71fa5539a"}, {"Element": "<td style=\"width:229.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"306\">\n<p class=\"MsoNormal\"><b>United Kingdom</b></p>\n<p class=\"MsoNormal\">Roche Products Ltd.</p>\n<p class=\"MsoNormal\">Tel: +44 (0) 1707 366000</p>\n<p class=\"MsoNormal\">\u00a0</p>\n</td>", "ID": "3154a091-b73b-4187-baeb-908b6c81308e", "Styles": "width:229.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "58285363-2688-4a57-abcf-7acc741ba591"}, {"Element": "<p class=\"MsoNormal\"><b>United Kingdom</b></p>", "ID": "dbe4e2e5-489d-4452-8ac5-e0559c32b4f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3154a091-b73b-4187-baeb-908b6c81308e"}, {"Element": "<b>United Kingdom</b>", "ID": "d1a02b36-d6fb-4e9e-8f5a-870be44f6e2f", "Styles": "None", "Classes": "None", "Text": "United Kingdom", "ParentId": "dbe4e2e5-489d-4452-8ac5-e0559c32b4f2"}, {"Element": "<p class=\"MsoNormal\">Roche Products Ltd.</p>", "ID": "73e7d6b6-1af7-4eee-b219-62333bb806e7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Roche Products Ltd.", "ParentId": "3154a091-b73b-4187-baeb-908b6c81308e"}, {"Element": "<p class=\"MsoNormal\">Tel: +44 (0) 1707 366000</p>", "ID": "82ba813e-219d-4e19-baf9-49d46a53e6dc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Tel: +44 (0) 1707 366000", "ParentId": "3154a091-b73b-4187-baeb-908b6c81308e"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "7b076043-c76f-4499-9d37-aa9f100fa30a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "3154a091-b73b-4187-baeb-908b6c81308e"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "0b42df1d-c5d0-4c0b-9549-6f9803924829", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>This leaflet was last\nrevised in </b></p>", "ID": "432dd4ba-0431-4e67-80d3-446e8e430439", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>This leaflet was last\nrevised in </b>", "ID": "d460fce5-0892-4bab-afa5-98a15cb9c33b", "Styles": "None", "Classes": "None", "Text": "This leaflet was last revised in ", "ParentId": "432dd4ba-0431-4e67-80d3-446e8e430439"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\">\u00a0</p>", "ID": "7db44e1e-ccda-4c13-a097-5ecc00135e2e", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b>Other\nsources of information</b></p>", "ID": "38ca478d-14a6-4881-a721-94233ff9d21c", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Other\nsources of information</b>", "ID": "1c9fd6c6-7447-41d7-b7a0-d4cfd54c0518", "Styles": "None", "Classes": "None", "Text": "Other sources of information", "ParentId": "38ca478d-14a6-4881-a721-94233ff9d21c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\">\u00a0</p>", "ID": "962a084a-f08d-4cf5-8064-abf46b0f3ca9", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\">Detailed information on this\nmedicine is available on the European Medicines Agency web site: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a><span style=\"color:blue\">.</span> </p>", "ID": "51dd4192-9ab6-4c33-a867-41a0f7c2f337", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "Detailed information on this medicine is available on the European Medicines Agency web site:  ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>", "ID": "2af25dd4-0f5c-4d36-9dd2-d9960d6167a0", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "51dd4192-9ab6-4c33-a867-41a0f7c2f337"}, {"Element": "<span style=\"color:blue\">.</span>", "ID": "f096fc1e-c3ee-4fa6-87a2-1be2fff78e92", "Styles": "color:blue", "Classes": "None", "Text": ".", "ParentId": "51dd4192-9ab6-4c33-a867-41a0f7c2f337"}, {"Element": "<b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "f0e48309-4304-4408-8760-b3f3e5656475", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "30035dd2-438d-4fdf-a08c-c86102d26ea3", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "f0e48309-4304-4408-8760-b3f3e5656475"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "da1f9b4c-e52a-4a8e-96e4-b5806f5b9a6e", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "30035dd2-438d-4fdf-a08c-c86102d26ea3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b>\u00a0</b></p>", "ID": "0f15a865-c511-418f-ba99-c2bba8a22ef3", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>\u00a0</b>", "ID": "6d3e3162-6322-45de-a9ea-ad6e7b0f45bc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f15a865-c511-418f-ba99-c2bba8a22ef3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><b>The\nfollowing information is intended for medical or healthcare professionals only:\n</b></p>", "ID": "471cadc4-1f85-46df-91a9-da44e2aa69d5", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>The\nfollowing information is intended for medical or healthcare professionals only:\n</b>", "ID": "de73eac5-8e5e-448f-a986-970533f52e16", "Styles": "None", "Classes": "None", "Text": "The following information is intended for medical or healthcare professionals only: ", "ParentId": "471cadc4-1f85-46df-91a9-da44e2aa69d5"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "3e24ac20-543c-4c3c-a5c2-4d53424d7193", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">In order to prevent medicinal product errors it is important\nto check the vial labels to ensure that the medicinal product being prepared is\nKadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).</p>", "ID": "54a37482-a412-46ad-8d93-68fd6e7d29fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "In order to prevent medicinal product errors it is important to check the vial labels to ensure that the medicinal product being prepared is Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "6324525e-6ab1-4802-9204-8d47ff9f0c62", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Kadcyla must be reconstituted and diluted by a healthcare\nprofessional and administered as an intravenous infusion. It must not be\nadministered as an intravenous push or bolus.</p>", "ID": "067400fa-36d0-4ad1-bfa6-d03f2fcfd6cf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Kadcyla must be reconstituted and diluted by a healthcare professional and administered as an intravenous infusion. It must not be administered as an intravenous push or bolus.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "15e72ea1-2cbb-49a0-9c43-77d7359e511a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Always keep this medicine in the closed original pack at a\ntemperature of 2\u00baC \u2013 8 \u00baC in a refrigerator. A vial of Kadcyla\nreconstituted with water for injections (not supplied) is stable for 24 hours\nat </p>", "ID": "486e3d1c-79fc-4c29-a061-25a081ac4ec2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Always keep this medicine in the closed original pack at a temperature of 2\u00baC \u2013 8 \u00baC in a refrigerator. A vial of Kadcyla reconstituted with water for injections (not supplied) is stable for 24 hours at ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">2\u00baC \u2013 8 \u00baC after reconstitution and must not\nbe frozen. </p>", "ID": "941ec6cd-6ec4-48c9-97ad-d6b35c71eb45", "Styles": "None", "Classes": "['MsoNormal']", "Text": "2\u00baC \u2013 8 \u00baC after reconstitution and must not be frozen. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "63ad093e-184c-4aec-b19a-0a3c18762dfe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Appropriate aseptic technique should be used. Appropriate\nprocedures for the preparation of chemotherapeutic medicinal products should be\nused. </p>", "ID": "51938fc0-8e28-4750-bf58-964f1066e9fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Appropriate aseptic technique should be used. Appropriate procedures for the preparation of chemotherapeutic medicinal products should be used. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "a6b1ad05-2061-461a-b56a-8f13f8d6fbae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The reconstituted Kadcyla solution should be diluted in\npolyvinyl chloride (PVC) or latex\u2011free PVC\u2011free polyolefin infusion\nbags.</p>", "ID": "2cab047b-7788-49d5-90f5-721046280a94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The reconstituted Kadcyla solution should be diluted in polyvinyl chloride (PVC) or latex\u2011free PVC\u2011free polyolefin infusion bags.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "112fd180-f240-4e9b-8d8b-c3a1490adb32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">The use of 0.20 or 0.22 micron in-line polyethersulfone\n(PES) filter is required for the infusion when the concentrate for infusion is\ndiluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. </p>", "ID": "aac1d94d-bd59-43d0-a8a4-f0f75ea46618", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The use of 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required for the infusion when the concentrate for infusion is diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "e1a0dd51-deb9-4dd5-97b1-7748b90011ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>Instructions for reconstitution</i></p>", "ID": "b7e2088f-63a9-41c3-9e99-bd00be385f92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Instructions for reconstitution</i>", "ID": "e5e26d21-f51a-46dc-9aa4-346949181290", "Styles": "None", "Classes": "None", "Text": "Instructions for reconstitution", "ParentId": "b7e2088f-63a9-41c3-9e99-bd00be385f92"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:22.5pt;text-indent:-22.5pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 <u>Kadcyla\n100mg</u>: using a sterile syringe, slowly inject 5\u00a0mL of sterile water\nfor injection into the 100\u00a0mg trastuzumab emtansine vial. </p>", "ID": "dacbe693-059e-4a2a-89b2-4b16a0af4636", "Styles": "margin-left:22.5pt;text-indent:-22.5pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 : using a sterile syringe, slowly inject 5\u00a0mL of sterile water for injection into the 100\u00a0mg trastuzumab emtansine vial. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "b133e24c-2d5b-43ef-971b-ce59e234a1ac", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "dacbe693-059e-4a2a-89b2-4b16a0af4636"}, {"Element": "<u>Kadcyla\n100mg</u>", "ID": "8f725ce0-4aec-402c-82ec-343afbe526ba", "Styles": "None", "Classes": "None", "Text": "Kadcyla 100mg", "ParentId": "dacbe693-059e-4a2a-89b2-4b16a0af4636"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:22.5pt;text-indent:-22.5pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 <u>Kadcyla\n160mg</u>: using a sterile syringe, slowly inject 8\u00a0mL of sterile water\nfor injection into the 160 mg trastuzumab emtansine vial.</p>", "ID": "a32e6274-1023-402d-8b60-e33d3bac0b98", "Styles": "margin-left:22.5pt;text-indent:-22.5pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 : using a sterile syringe, slowly inject 8\u00a0mL of sterile water for injection into the 160 mg trastuzumab emtansine vial.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "cadce0a6-b933-4e80-a72b-1fd96ac38c8a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a32e6274-1023-402d-8b60-e33d3bac0b98"}, {"Element": "<u>Kadcyla\n160mg</u>", "ID": "97729803-e547-4176-8b41-cc5166c52ca8", "Styles": "None", "Classes": "None", "Text": "Kadcyla 160mg", "ParentId": "a32e6274-1023-402d-8b60-e33d3bac0b98"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:22.5pt;text-indent:-22.5pt\"><span style=\"font-family:Symbol\">\u00b7</span>\u00a0\u00a0\u00a0\u00a0\u00a0 Swirl\nthe vial gently until completely dissolved. Do not shake. </p>", "ID": "2c950856-3a92-4472-9bb9-6930272c54ed", "Styles": "margin-left:22.5pt;text-indent:-22.5pt", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0 Swirl the vial gently until completely dissolved. Do not shake. ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7</span>", "ID": "2c9d0771-a648-411c-a76c-8512af519d46", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2c950856-3a92-4472-9bb9-6930272c54ed"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "f0169dd7-ea33-421f-8dec-bde88c6e2c6e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Reconstituted solution should be inspected visually for\nparticulate matter and discolouration prior to administration. The\nreconstituted solution should be free of visible particulates, clear to\nslightly opalescent. The colour of the reconstituted solution should be\ncolourless to pale brown. Do not use if reconstituted solution is cloudy or\ndiscoloured.</p>", "ID": "d0f399ef-224d-4821-9935-55bad9dfb882", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Reconstituted solution should be inspected visually for particulate matter and discolouration prior to administration. The reconstituted solution should be free of visible particulates, clear to slightly opalescent. The colour of the reconstituted solution should be colourless to pale brown. Do not use if reconstituted solution is cloudy or discoloured.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "b5c9d336-3f3a-432f-8cc7-f28f0658a76b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">Discard any unused portion. The reconstituted product contains\nno preservative and is intended for single use only.</p>", "ID": "dba97b30-dd7a-4fd9-b7f3-1edadf4de593", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Discard any unused portion. The reconstituted product contains no preservative and is intended for single use only.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "d5ce712a-21a7-46a3-9a1e-a90307f51ba4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\"><i>Instructions for dilution</i></p>", "ID": "4ea0c0e5-18f2-47eb-945e-5053574fcbfc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<i>Instructions for dilution</i>", "ID": "cf911d64-7b99-4a66-9a35-3a9c4d73e2d4", "Styles": "None", "Classes": "None", "Text": "Instructions for dilution", "ParentId": "4ea0c0e5-18f2-47eb-945e-5053574fcbfc"}, {"Element": "<p class=\"MsoNormal\">Determine the volume of the reconstituted solution required\nbased on a dose of 3.6\u00a0mg trastuzumab emtansine/kg body weight:</p>", "ID": "172f6ffe-8b3a-4cad-b914-b2487f63c4ae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "Determine the volume of the reconstituted solution required based on a dose of 3.6\u00a0mg trastuzumab emtansine/kg body weight:", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\">\u00a0</p>", "ID": "be673715-a0a1-4f50-936b-3643e1920820", "Styles": "None", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b>Volume</b>\n(mL)\u00a0=\u00a0<i><u>Total dose to be administered</u></i><u> =(<b>body\nweight</b> (kg) x <b>dose</b> (mg/kg))</u> </p>", "ID": "f87b5991-71d1-4dc9-9cd2-42f9698e26d0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": " (mL)\u00a0=\u00a0 ", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>Volume</b>", "ID": "938283ec-d5a1-471d-9ff6-d023b912d4ef", "Styles": "None", "Classes": "None", "Text": "Volume", "ParentId": "f87b5991-71d1-4dc9-9cd2-42f9698e26d0"}, {"Element": "<i><u>Total dose to be administered</u></i>", "ID": "b9b78c97-ce7d-4c6a-bb7c-d3e888672d6a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f87b5991-71d1-4dc9-9cd2-42f9698e26d0"}, {"Element": "<u>Total dose to be administered</u>", "ID": "2d289431-5bf5-49e7-a422-8919331e4240", "Styles": "None", "Classes": "None", "Text": "Total dose to be administered", "ParentId": "b9b78c97-ce7d-4c6a-bb7c-d3e888672d6a"}, {"Element": "<u> =(<b>body\nweight</b> (kg) x <b>dose</b> (mg/kg))</u>", "ID": "c060ddf3-7a74-46b1-80e3-38eaba1714c6", "Styles": "None", "Classes": "None", "Text": " =( (kg) x  (mg/kg))", "ParentId": "f87b5991-71d1-4dc9-9cd2-42f9698e26d0"}, {"Element": "<b>body\nweight</b>", "ID": "19f84b70-eb77-4024-bb24-1007c9e3e22d", "Styles": "None", "Classes": "None", "Text": "body weight", "ParentId": "c060ddf3-7a74-46b1-80e3-38eaba1714c6"}, {"Element": "<b>dose</b>", "ID": "a124f166-ea5b-4094-a18a-3ac795e31ccc", "Styles": "None", "Classes": "None", "Text": "dose", "ParentId": "c060ddf3-7a74-46b1-80e3-38eaba1714c6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n<b>20</b> (mg/mL, concentration of reconstituted solution)</p>", "ID": "0c1141f4-4c41-4d05-93e3-f6f0bb584296", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  (mg/mL, concentration of reconstituted solution)", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b>20</b>", "ID": "f273cbdf-e8f7-40c0-9480-8c6841063650", "Styles": "None", "Classes": "None", "Text": "20", "ParentId": "0c1141f4-4c41-4d05-93e3-f6f0bb584296"}, {"Element": "<p class=\"MsoNormal\"><b><u><span style=\"text-decoration:none\">\u00a0</span></u></b></p>", "ID": "e06dcc85-a009-4b88-9222-e2ff20f39ded", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<b><u><span style=\"text-decoration:none\">\u00a0</span></u></b>", "ID": "3ed5c1e1-318f-417a-acdd-92cb94eca7e0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e06dcc85-a009-4b88-9222-e2ff20f39ded"}, {"Element": "<u><span style=\"text-decoration:none\">\u00a0</span></u>", "ID": "047d60b8-cb7f-4ef8-a037-3df73eececdf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3ed5c1e1-318f-417a-acdd-92cb94eca7e0"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "937e7c6f-95ff-42c1-9eac-b741b8080fa3", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "047d60b8-cb7f-4ef8-a037-3df73eececdf"}, {"Element": "<p class=\"MsoNormal\">The appropriate amount of solution should be withdrawn from\nthe vial and added to an infusion bag containing 250\u00a0mL of sodium chloride\n4.5 mg/mL (0.45%) solution for infusion or sodium chloride 9\u00a0mg/mL (0.9%)\nsolution for infusion. Glucose\u00a0(5%) solution should not be used Sodium\nchloride 4.5\u00a0mg/mL (0.45%) solution for infusion may be used without a\npolyethersulfone (PES) 0.20 or 0.22\u2011\u03bcm in\u2011line filter. If\nsodium chloride 9 mg/mL (0.9%) solution for infusion is used for infusion, a\n0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required. Once the\ninfusion is prepared it should be administered immediately. Do not freeze or\nshake the infusion during storage. If diluted aseptically, it may be stored for\nup to 24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C.</p>", "ID": "38eca2b5-93fc-4b32-bca5-bc07ea1b888e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "The appropriate amount of solution should be withdrawn from the vial and added to an infusion bag containing 250\u00a0mL of sodium chloride 4.5 mg/mL (0.45%) solution for infusion or sodium chloride 9\u00a0mg/mL (0.9%) solution for infusion. Glucose\u00a0(5%) solution should not be used Sodium chloride 4.5\u00a0mg/mL (0.45%) solution for infusion may be used without a polyethersulfone (PES) 0.20 or 0.22\u2011\u03bcm in\u2011line filter. If sodium chloride 9 mg/mL (0.9%) solution for infusion is used for infusion, a 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required. Once the infusion is prepared it should be administered immediately. Do not freeze or shake the infusion during storage. If diluted aseptically, it may be stored for up to 24\u00a0hours at 2\u00b0C\u00a0to\u00a08\u00b0C.", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\">\u00a0</p>", "ID": "93de767d-186f-429b-ada1-8a721c4c238e", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Text": "\u00a0", "ParentId": "d38ed4b3-383b-4546-9be2-af8a0800ef72"}]}